{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Vantage keyword analysis"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "An analysis to identify the most import/common keywords and bi-grams in Vantage articles between Nov 2019 and Oct 2020."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "#import story contents\n",
    "pvdata = pd.read_csv(r'C:\\Users\\EdwinE\\.spyder-py3\\Vantage article analysis\\pageviews.csv')   \n",
    "output = pd.read_csv(r'C:\\Users\\EdwinE\\.spyder-py3\\Vantage article analysis\\sentimentoutput.csv')\n",
    "#merge pageviews with text data\n",
    "alldata = output.merge(pvdata,on='URL')\n",
    "alldata = alldata.drop(['Unnamed: 0'], axis =1)\n",
    "alldata['Pageviews'] = alldata['Pageviews'].replace({',':''},regex=True).apply(pd.to_numeric,1)\n",
    "output=alldata\n",
    "output = output.dropna()\n",
    "#have to drop medtech as they have different lingo\n",
    "nomedtech = output[~output['tags'].str.contains(\"Medtech\")]\n",
    "nomedtech = nomedtech.reset_index(drop = True)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Obviously, the text needs some working before anything useful can be gained from it. So let's process the data."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package stopwords to\n",
      "[nltk_data]     C:\\Users\\EdwinE\\AppData\\Roaming\\nltk_data...\n",
      "[nltk_data]   Package stopwords is already up-to-date!\n",
      "[nltk_data] Downloading package wordnet to\n",
      "[nltk_data]     C:\\Users\\EdwinE\\AppData\\Roaming\\nltk_data...\n",
      "[nltk_data]   Package wordnet is already up-to-date!\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "the     10484\n",
      "of       5825\n",
      "to       5375\n",
      "a        5174\n",
      "in       4928\n",
      "and      3981\n",
      "is       3459\n",
      "that     2596\n",
      "for      2269\n",
      "with     1971\n",
      "dtype: int64\n",
      "the              10484\n",
      "of                5825\n",
      "to                5375\n",
      "a                 5174\n",
      "in                4928\n",
      "                 ...  \n",
      "signalled            1\n",
      "dish                 1\n",
      "Acing                1\n",
      "questionable;        1\n",
      "elsewhere,           1\n",
      "Length: 24439, dtype: int64\n"
     ]
    }
   ],
   "source": [
    "# Import libraries for text preprocessing\n",
    "import re\n",
    "import nltk\n",
    "\n",
    "# You only need to download these resources once. After you run this \n",
    "# the first time--or if you know you already have these installed--\n",
    "# you can comment these two lines out (with a #)\n",
    "nltk.download('stopwords')\n",
    "nltk.download('wordnet')\n",
    "\n",
    "from nltk.corpus import stopwords\n",
    "from nltk.stem.porter import PorterStemmer\n",
    "from nltk.tokenize import RegexpTokenizer\n",
    "from nltk.stem.wordnet import WordNetLemmatizer\n",
    "\n",
    "textcol= nomedtech['text']\n",
    "##most and least common words pre-processing\n",
    "#Top 10\n",
    "freq = pd.Series(' '.join(map(str, nomedtech['text'])).split()).value_counts()[:10]\n",
    "print(freq)\n",
    "#bottom 10\n",
    "freq1 = pd.Series(' '.join(map(str, nomedtech['text'])).split()).value_counts()[:-10]\n",
    "print(freq1)\n",
    "# Create a list of stop words from nltk\n",
    "stop_words = set(stopwords.words(\"english\"))\n",
    "stop_words.add('also')\n",
    "stop_words.add('could')\n",
    "\n",
    "# Pre-process dataset to get a cleaned and normalised text corpus\n",
    "corpus = []\n",
    "nomedtech['word_count'] = nomedtech['text'].apply(lambda x: len(str(x).split(\" \")))\n",
    "ds_count = len(nomedtech.word_count)\n",
    "\n",
    "for i in range(0, ds_count):\n",
    "    # Remove punctuation\n",
    "    text = re.sub('[^a-zA-Z]', ' ', str(nomedtech['text'][i]))\n",
    "    \n",
    "    # Convert to lowercase\n",
    "    text = text.lower()\n",
    "    \n",
    "    # Remove tags\n",
    "    text=re.sub(\"&lt;/?.*?&gt;\",\" &lt;&gt; \",text)\n",
    "    \n",
    "    # Remove special characters and digits\n",
    "    text=re.sub(\"(\\\\d|\\\\W)+\",\" \",text)\n",
    "    \n",
    "    # Convert to list from string\n",
    "    text = text.split()\n",
    "    \n",
    "    # Stemming\n",
    "    ps=PorterStemmer()\n",
    "    \n",
    "    # Lemmatisation\n",
    "    lem = WordNetLemmatizer()\n",
    "    text = [lem.lemmatize(word) for word in text if not word in  \n",
    "            stop_words] \n",
    "    text = \" \".join(text)\n",
    "    corpus.append(text)\n",
    "\n",
    "\n",
    "# Tokenize the text and build a vocabulary of known words\n",
    "from sklearn.feature_extraction.text import CountVectorizer\n",
    "import re\n",
    "cv=CountVectorizer(max_df=0.8,stop_words=stop_words, max_features=10000, ngram_range=(1,3))\n",
    "X=cv.fit_transform(corpus)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "    Keyword  Frequency\n",
      "0     trial       1138\n",
      "1      year        979\n",
      "2      data        976\n",
      "3   company        966\n",
      "4     study        956\n",
      "5   patient        943\n",
      "6     phase        667\n",
      "7   project        559\n",
      "8      drug        543\n",
      "9       two        536\n",
      "10    first        529\n",
      "11      one        500\n",
      "12   market        483\n",
      "13       bn        455\n",
      "14   cancer        431\n",
      "15    might        423\n",
      "16    month        407\n",
      "17    covid        404\n",
      "18   result        387\n",
      "19    group        385\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Text(0, 0, 'trial'),\n",
       " Text(0, 0, 'year'),\n",
       " Text(0, 0, 'data'),\n",
       " Text(0, 0, 'company'),\n",
       " Text(0, 0, 'study'),\n",
       " Text(0, 0, 'patient'),\n",
       " Text(0, 0, 'phase'),\n",
       " Text(0, 0, 'project'),\n",
       " Text(0, 0, 'drug'),\n",
       " Text(0, 0, 'two'),\n",
       " Text(0, 0, 'first'),\n",
       " Text(0, 0, 'one'),\n",
       " Text(0, 0, 'market'),\n",
       " Text(0, 0, 'bn'),\n",
       " Text(0, 0, 'cancer'),\n",
       " Text(0, 0, 'might'),\n",
       " Text(0, 0, 'month'),\n",
       " Text(0, 0, 'covid'),\n",
       " Text(0, 0, 'result'),\n",
       " Text(0, 0, 'group')]"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 936x576 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# View most frequently occuring keywords\n",
    "def get_top_n_words(corpus, n=None):\n",
    "    vec = CountVectorizer().fit(corpus)\n",
    "    bag_of_words = vec.transform(corpus)\n",
    "    sum_words = bag_of_words.sum(axis=0) \n",
    "    words_freq = [(word, sum_words[0, idx]) for word, idx in      \n",
    "                   vec.vocabulary_.items()]\n",
    "    words_freq =sorted(words_freq, key = lambda x: x[1], \n",
    "                       reverse=True)\n",
    "    return words_freq[:n]\n",
    "\n",
    "# Convert most freq words to dataframe for plotting bar plot, save as CSV\n",
    "top_words = get_top_n_words(corpus, n=20)\n",
    "top_df = pd.DataFrame(top_words)\n",
    "top_df.columns=[\"Keyword\", \"Frequency\"]\n",
    "print(top_df)\n",
    "\n",
    "# Barplot of most freq words\n",
    "import seaborn as sns\n",
    "sns.set(rc={'figure.figsize':(13,8)})\n",
    "g = sns.barplot(x=\"Keyword\", y=\"Frequency\", data=top_df, palette=\"Blues_d\")\n",
    "g.set_xticklabels(g.get_xticklabels(), rotation=45)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                     Bi-gram  Frequency\n",
      "0                   phase ii        267\n",
      "1                  phase iii        251\n",
      "2           primary endpoint        164\n",
      "3                  last year        164\n",
      "4                 first line        108\n",
      "5                 market cap         97\n",
      "6                  next year         88\n",
      "7             clinical trial         85\n",
      "8               gene therapy         85\n",
      "9              covid vaccine         84\n",
      "10             adverse event         83\n",
      "11            versus placebo         82\n",
      "12                  merck co         82\n",
      "13  according evaluatepharma         78\n",
      "14               share price         75\n",
      "15             bristol myers         75\n",
      "16              myers squibb         71\n",
      "17                 iii trial         70\n",
      "18             response rate         70\n",
      "19                big pharma         67\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Text(0, 0, 'phase ii'),\n",
       " Text(0, 0, 'phase iii'),\n",
       " Text(0, 0, 'primary endpoint'),\n",
       " Text(0, 0, 'last year'),\n",
       " Text(0, 0, 'first line'),\n",
       " Text(0, 0, 'market cap'),\n",
       " Text(0, 0, 'next year'),\n",
       " Text(0, 0, 'clinical trial'),\n",
       " Text(0, 0, 'gene therapy'),\n",
       " Text(0, 0, 'covid vaccine'),\n",
       " Text(0, 0, 'adverse event'),\n",
       " Text(0, 0, 'versus placebo'),\n",
       " Text(0, 0, 'merck co'),\n",
       " Text(0, 0, 'according evaluatepharma'),\n",
       " Text(0, 0, 'share price'),\n",
       " Text(0, 0, 'bristol myers'),\n",
       " Text(0, 0, 'myers squibb'),\n",
       " Text(0, 0, 'iii trial'),\n",
       " Text(0, 0, 'response rate'),\n",
       " Text(0, 0, 'big pharma')]"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 936x576 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Most frequently occuring bigrams\n",
    "def get_top_n2_words(corpus, n=None):\n",
    "    vec1 = CountVectorizer(ngram_range=(2,2),  \n",
    "            max_features=2000).fit(corpus)\n",
    "    bag_of_words = vec1.transform(corpus)\n",
    "    sum_words = bag_of_words.sum(axis=0) \n",
    "    words_freq = [(word, sum_words[0, idx]) for word, idx in     \n",
    "                  vec1.vocabulary_.items()]\n",
    "    words_freq =sorted(words_freq, key = lambda x: x[1], \n",
    "                reverse=True)\n",
    "    return words_freq[:n]\n",
    "\n",
    "# Convert most freq bigrams to dataframe for plotting bar plot, save as CSV\n",
    "top2_words = get_top_n2_words(corpus, n=20)\n",
    "top2_df = pd.DataFrame(top2_words)\n",
    "top2_df.columns=[\"Bi-gram\", \"Frequency\"]\n",
    "print(top2_df)\n",
    "\n",
    "import seaborn as sns\n",
    "sns.set(rc={'figure.figsize':(13,8)})\n",
    "h=sns.barplot(x=\"Bi-gram\", y=\"Frequency\", data=top2_df, palette=\"Blues_d\")\n",
    "h.set_xticklabels(h.get_xticklabels(), rotation=75)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Most frequently occuring Tri-grams\n",
    "def get_top_n3_words(corpus, n=None):\n",
    "    vec1 = CountVectorizer(ngram_range=(3,3), \n",
    "           max_features=2000).fit(corpus)\n",
    "    bag_of_words = vec1.transform(corpus)\n",
    "    sum_words = bag_of_words.sum(axis=0) \n",
    "    words_freq = [(word, sum_words[0, idx]) for word, idx in     \n",
    "                  vec1.vocabulary_.items()]\n",
    "    words_freq =sorted(words_freq, key = lambda x: x[1], \n",
    "                reverse=True)\n",
    "    return words_freq[:n]\n",
    "\n",
    "# Convert most freq trigrams to dataframe for plotting bar plot, save as CSV\n",
    "top3_words = get_top_n3_words(corpus, n=20)\n",
    "top3_df = pd.DataFrame(top3_words)\n",
    "top3_df.columns=[\"Tri-gram\", \"Frequency\"]\n",
    "print(top3_df)\n",
    "\n",
    "import seaborn as sns\n",
    "sns.set(rc={'figure.figsize':(13,8)})\n",
    "j=sns.barplot(x=\"Tri-gram\", y=\"Frequency\", data=top3_df, palette=\"Blues_d\")\n",
    "j.set_xticklabels(j.get_xticklabels(), rotation=75)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Abstract:\n",
      "easy dismiss many publicity seeking announcement related covid past two week beyond hype active progress made last several potential treatment led gilead remdesivir clinic mrna vaccine moderna week dosed first study subject first antibody therapeutic still planning stage interesting theory developing around il inhibition something resulted role proposed roche actemra sanofi regeneron kevzara excitement il already seen tiziana jump bandwagon tiziana take deep breath target covid march spurred addition actemra rheumatoid arthritis drug chinese guideline basis covid patient respond infection overproducing il two day ago sanofi regeneron said starting phase ii iii trial anti il mab kevzara clearly side effect drug kevzara acetmra carry black box warning risk serious infection patient pulmonary disease need closely monitored another emergency measure saw china add favipiravir covid treatment programme flu drug sold japan taisho fujifilm avigan discontinued virtually everywhere else toxicity profile likely limit use covid first line attack far antiviral go greatest hope west come gilead remdesivir two pivotal study read may one enrols moderately ill subject patient severe covid several intriguing study recently gone clinicaltrials gov registry neurorx plan test aviptadil largely discontinued antihypertensive covid related respiratory distress academic group studying chloroquine covid prevention cozaar soliris biocryst evaluating galidesvir evercore isi josh shimmer highlighted potential lopinavir rotinavir see sort antiviral first line attack new coronavirus amid hype however noteworthy johnson johnson moved issue statement cautioning evidence hiv antiviral prezista effect covid perhaps excitement reserved vaccine though work far relatively early vaccine development according trial registry company announcement one moderna mrna clinical study sponsored company niaid later line attack antibody none entered clinic yet regeneron thought analyst able move quickly area provided fertile ground deal making vir collaborating biogen lilly abcellera instance business development aplenty covid vaccine biontech recently tying pfizer fosun mrna project bnt german group standing around idly clinical trial pfizer deal begin next month\n",
      "\n",
      "Keywords:\n",
      "covid 0.261\n",
      "line attack 0.195\n",
      "kevzara 0.176\n",
      "il 0.173\n",
      "attack 0.157\n",
      "antiviral 0.137\n",
      "vaccine 0.131\n",
      "registry 0.13\n",
      "first line attack 0.13\n",
      "tiziana 0.125\n",
      "regeneron 0.12\n",
      "mrna 0.117\n",
      "excitement 0.111\n",
      "actemra 0.111\n",
      "hype 0.109\n",
      "gilead remdesivir 0.109\n",
      "sanofi regeneron 0.107\n",
      "announcement 0.095\n",
      "remdesivir 0.094\n",
      "discontinued 0.087\n",
      "infection 0.078\n",
      "johnson 0.076\n",
      "moderna 0.076\n",
      "clinic 0.076\n",
      "line 0.071\n",
      "\n",
      "Abstract:\n",
      "paid careful attention roche full year financial presentation yesterday noticed company moving anti tigit antibody tiragolumab pivotal first line small cell lung cancer study combination tecentriq term roche ambition however tip iceberg speaking vantage yesterday swiss group revealed disclosed trial skyscraper one fewer eight pivotal tiragolumab study get way nothing else revealed competitive reason merck co rival tigit combo phase ii ido il tigit suddenly emerged industry next big immuno oncology bet course quest mechanism boost pd l blockade going year without much success yervoy still checkpoint blocker approved anti pd l drug incyte epacadostat nektar bempegaldesleukin mark ido il respectively two biggest disappointment search far earlier development targeting immune checkpoint tim lag ox failed deliver knockout data roche hope tiragolumab come anything lead renewed interest biotech including arcus beigene compugen early stage tigit blocker pipeline clear work tigit ramped behind scene recently two week ago without slightest fanfare merck co two begun keynote phase ii study company anti tigit project mk combination keytruda chemo first line nsclc merck reported partial response rate earlier keytruda combo study though mk monotherapy efficacy negligible sitc search immuno oncology combo continues november beyond data scarce oncomed merged mereo reported zero remission study etigilimab given lack published data immediately clear driven roche enthusiasm though group likely internal champion tigit genentech vice president oncology research ira mellman spoken tigit one several target capable synergising pd l blockade neither known sclc roche first targeted indication tecentriq secured first line sclc label back impower study threat atrazeneca imfinzi look like might amount much surprise tumour keytruda work january still numerous indication pursued perhaps sclc happens one start first roche revealed design skyscraper information available study registered clinicaltrials gov first subject dosed next week roche told vantage virtually every checkpoint blockade approach pd l underwhelmed clear company giving next generation mechanism yet next move merck others keenly awaited expanded version earlier story\n",
      "\n",
      "Keywords:\n",
      "tigit 0.418\n",
      "sclc 0.187\n",
      "roche 0.181\n",
      "tiragolumab 0.169\n",
      "pd 0.135\n",
      "blockade 0.129\n",
      "skyscraper 0.125\n",
      "checkpoint 0.124\n",
      "search 0.112\n",
      "merck 0.111\n",
      "anti tigit 0.107\n",
      "study 0.106\n",
      "pd blockade 0.105\n",
      "mk 0.105\n",
      "keytruda 0.104\n",
      "combo 0.099\n",
      "first 0.098\n",
      "first line 0.097\n",
      "blocker 0.097\n",
      "revealed 0.097\n",
      "oncology 0.093\n",
      "next 0.091\n",
      "immuno oncology 0.09\n",
      "immuno 0.09\n",
      "il 0.083\n",
      "\n",
      "Abstract:\n",
      "keytruda domination anti pd l market sometimes seems comprehensive surprising see flunk clinical trial yesterday happened keynote study failing show overall survival benefit first line small cell lung cancer setback seems particularly galling two competitor desperate pursuit keytruda roche tecentriq astrazeneca imfinzi already succeeded tumour type disparity already seen one bank turn scientific paper answer citing retrospective analysis published jama leerink argued tumour characterised poor pd l expression le fit patient sclc one evidence pd l inhibitor like tecentriq imfinzi work better pd targeting drug like keytruda yesterday disclosure keytruda failed keynote earlier failure bristol myers squibb opdivo checkmate appear back hypothesis le sophisticated view hold pd drug overall better pd l though massively skewed timing study readout ecentriq already approved first line sclc basis impower trial last year imfinzi matched result caspian study world lung astra achievement sclc unlikely game changer september anti pd l drug showed month median overall survival yielding around reduction risk death versus chemo alone keynote absolute survival benefit disclosed merck said relative reduction risk death insufficient hit statistical significance statistical benefit progression free survival keynote co primary endpoint unlikely enough approval given availability tecentriq imfinzi caspian result merck stock morning irrespective first line failure keytruda retains third line sclc label backing remission rate seen keynote study front line development likely little relevance pharmamar zepsyre recently filed second line sclc licensed jazz hard gauge much keytruda lose sale evaluatepharma sale indication consensus forecast show revenue coming sclc clear much comprises first line use keytruda next significant test keynote readout first line triple negative breast cancer\n",
      "\n",
      "Keywords:\n",
      "sclc 0.363\n",
      "keynote 0.239\n",
      "keytruda 0.236\n",
      "pd 0.229\n",
      "line sclc 0.181\n",
      "line 0.176\n",
      "imfinzi 0.17\n",
      "first line 0.157\n",
      "survival 0.12\n",
      "tecentriq 0.116\n",
      "caspian 0.116\n",
      "pd drug 0.109\n",
      "reduction risk death 0.106\n",
      "risk death 0.099\n",
      "keynote study 0.096\n",
      "survival benefit 0.092\n",
      "reduction risk 0.088\n",
      "overall 0.086\n",
      "anti pd 0.084\n",
      "first 0.079\n",
      "overall survival 0.077\n",
      "benefit 0.072\n",
      "statistical 0.071\n",
      "lung 0.069\n",
      "death versus chemo 0.064\n",
      "\n",
      "Abstract:\n",
      "lot time resource thrown developing treatment covid government around world pledging spend whatever take find treatment much initial expense fall biopharma company however estimate much investigation might cost vantage extracted estimate evaluatepharma vision looked historic precedent development vaccine antiviral previous pandemic phase iii trial gilead remdesivir likely expensive venture right u biotech indicated initial data emerge end march readout represents world nearest term chance finding treatment sometimes deadly respiratory symptom caused particular coronavirus according evaluatepharma vision r cost module trial probably cost gilead around run estimate phase iii trial run china included much lower figure reflect fact substantially cheaper run study region description cost calculated gilead afford course remdesivir prove effective commercial return likely huge notwithstanding company claiming effort rooted commercial roche booked cumulative sale bn tamiflu since launched annual sale peaked bn figure exclude sale booked company make previous vantage analysis looking historic sale flu antiviral show much drug brought developer previous pandemic antiviral demand spike see biocryst jump aboard march evaluatepharma vision r cost model estimate cost individual clinical programme using real world data company disclosed product level spend clinical trial patient number combined create cost per patient benchmark technology therapy type utilising matching algorithm benchmark applied commercially relevant clinical trial estimate cost aggregated product estimate cost development product\n",
      "\n",
      "Keywords:\n",
      "cost 0.316\n",
      "estimate 0.253\n",
      "estimate cost 0.168\n",
      "evaluatepharma vision 0.164\n",
      "vision 0.154\n",
      "antiviral 0.135\n",
      "previous pandemic 0.135\n",
      "historic 0.123\n",
      "vision cost 0.115\n",
      "evaluatepharma vision cost 0.115\n",
      "previous 0.112\n",
      "run 0.102\n",
      "world 0.101\n",
      "sale 0.094\n",
      "gilead 0.092\n",
      "remdesivir 0.092\n",
      "spend 0.09\n",
      "benchmark 0.09\n",
      "much 0.086\n",
      "product 0.078\n",
      "figure 0.075\n",
      "commercial 0.074\n",
      "phase iii trial 0.071\n",
      "trial 0.071\n",
      "initial 0.07\n",
      "\n",
      "Abstract:\n",
      "sanofi already shaky ground dengue fever vaccine dengvaxia product look likely relegated sideline thanks impressive data pivotal tide trial takeda rival candidate tak dengvaxia approved u fda may child previously infected virus following concern safety dengue na subject notably well looking good overall population tak showed sign efficacy previously uninfected people help takeda project get broader label still finding dengue na seronegative population exploratory far takeda wait data confirm tak efficacy takeda vaccine showed much better performance strain virus others although data exploratory turning tide result first part patient tide study published yesterday nejm previously takeda said trial met primary endpoint serious safety concern study enrolled healthy child aged asia latin america received either two dos tak placebo three month apart primary endpoint prevention dengue caused four different serotypes virus known denv tak overall efficacy higher pooled efficacy rate seen across dengvaxia two phase iii trial figure dengvaxia skewed lack efficacy seronegative people excluding population dengvaxia efficacy according u label putting line tak however dengvaxia ineffective seronegative population actually harmful mass immunisation programme philippine uncovered link vaccine severe disease seen previously uninfected child went contract dengue sanofi dengue setback benefit takeda march tak edge safety analysis thrown nothing worry far secondary endpoint tide vaccine performance according baseline infection status part one study found efficacy around seronegative group exploratory finding present need confirmed second part trial involves another six month follow another secondary endpoint formally assessed part two tak performance different dengue serotypes exploratory analysis part one vaccine best strain known denv modest efficacy serotypes handful case infection denv serotype data inconclusive indication conclusive vaccine might effective denv strain people seronegative baseline picture soon become clearer takeda plan present data tak american society tropical medicine hygiene held maryland november including formal assessment secondary endpoint commercial prospect vaccine dengue endemic poorer country might another matter takeda prove tak worth seronegative subject vaccine presumably potential traveller dengue afflicted region would open broader market tak forecast bring according evaluatepharma sellside consensus making takeda valuable pipeline asset whether live expectation one unanswered question around vaccine evidence far better chance making mark dengvaxia\n",
      "\n",
      "Keywords:\n",
      "dengue 0.415\n",
      "tak 0.395\n",
      "dengvaxia 0.323\n",
      "seronegative 0.259\n",
      "takeda 0.257\n",
      "vaccine 0.185\n",
      "denv 0.184\n",
      "tide 0.164\n",
      "serotypes 0.129\n",
      "exploratory 0.12\n",
      "efficacy 0.119\n",
      "strain 0.118\n",
      "child 0.101\n",
      "part 0.099\n",
      "previously 0.094\n",
      "na 0.086\n",
      "virus 0.08\n",
      "part one 0.079\n",
      "population 0.078\n",
      "secondary endpoint 0.077\n",
      "performance 0.076\n",
      "endpoint 0.075\n",
      "people 0.074\n",
      "secondary 0.064\n",
      "broader 0.058\n",
      "\n",
      "Abstract:\n",
      "article updated clarify mechanism eusa pharma sylvant addition last week roche anti il receptor antibody actemra chinese guideline treating patient covid prompted tiziana life science speed development similarly acting tzls use group stock london aim far today somewhat overenthusiastic one thing tzls still preclinical another approved anti il r mabs carry black box warning risk serious infection patient pulmonary disease planning give anti il r covid patient bold move actemra long approved rheumatoid arthritis reportedly used patient severe covid infection china lowering body temperature within one day one discharged hospital within fortnight approach seems prompted suggestion covid patient might respond infection overproducing inflammatory cytokine il phenomenon called cytokine storm actemra approved fda treat cytokine release syndrome caused car treatment rationale provided research published march indicating viral load associated elevated il level severely ill covid patient researcher wrote il considered therapeutic target critically ill patient excessive inflammatory response according wsj regeneron sanofi repurposing anti il r kevzara new virus partner intend start clinical trial mab widely approved rheumatoid arthritis cytokine release syndrome severe covid soon possible one approved product act pathway eusa pharma sylvant product chimeric monoclonal antibody bind il company state distinct different mechanism action anti il receptor antibody sylvant appear investigation coronavirus according label sylvant given patient severe infection tizzy advantage approved product opposed novel drug development gilead remdesivir used label relatively easily production distribution ramped relatively quickly getting away poor safety profile stopped tiziana course safety profile tzls like efficacy covid anything else unknown yet given human neither advantage approved product yet evidence dozen il r clinical preclinical development aimed covid perhaps group see nicely tiziana done market today might make announcement still giving untried drug severely ill patient many elderly comorbidities taking big risk would true even molecule belong class known potentially dangerous patient lung infection\n",
      "\n",
      "Keywords:\n",
      "il 0.353\n",
      "sylvant 0.223\n",
      "anti il 0.213\n",
      "tzls 0.179\n",
      "covid 0.17\n",
      "infection 0.16\n",
      "cytokine 0.153\n",
      "tiziana 0.153\n",
      "approved product 0.153\n",
      "approved 0.145\n",
      "covid patient 0.136\n",
      "actemra 0.136\n",
      "ill 0.133\n",
      "patient 0.131\n",
      "pharma sylvant 0.111\n",
      "il receptor 0.111\n",
      "eusa pharma sylvant 0.111\n",
      "eusa pharma 0.111\n",
      "eusa 0.111\n",
      "anti 0.107\n",
      "ill patient 0.106\n",
      "severely ill 0.102\n",
      "patient severe 0.098\n",
      "severely 0.093\n",
      "release syndrome 0.093\n",
      "\n",
      "Abstract:\n",
      "every public health emergency present opportunity bioharma justify existence springing action develop vaccine diagnostics treatment time use mention disease way drive share price tap investor money regard current outbreak coronavirus covid stuck script several vaccine antiviral poised enter clinic every bona fide effort numerous hanger rough calculation vantage reveals outbreak helped several small midcap biotech put combined bn market valuation case several huge gainer fact little show beyond hype press release small cap jumping coronavirus bandwagon include faron aim immunotech novavax cerus immunoprecise antibody tonix vantage analysed stock market movement january february biopharma company made public announcement coronavirus though first covid case reported last december week january became apparent global health emergency offing perhaps prominent work develop treatment involves gilead rose yesterday starting phase iii covid trial nucleotide analogue remdesvir though iv route drug far optimal view baird brian skorney gilead far plausible coronavirus stock achieve anything besides overpriced follow offering financial bet even made back health crisis retail investor website recently ran article entitled initial coronoavirus trading plan seems distasteful still without hard cash little real work would likely get done treat emergency among biggest example hype stand novavax biotech burned bn investor cash marketed product show instead using press release like sars rsv bird flu prelude cash call yesterday announced plan develop covid vaccine faron surged mere mention failed lead traumakine interferon beta biological first line defence viral infection tonix yesterday trumpeted vaccine collaboration stock surged relevant period owing separate trial failure many stock cap movement exaggerated fact concern micro cap company taken together increase valuation considerable diagnostics predictably diagnostics group recorded largest share price gain novacyt co diagnostics dragging penny stock territory novacyt february launched world first ce marked test covid virus co diagnostics followed ce marked diagnostic week later today followed fund raising earlier pharmamar announced developing coronavirus test actuality three pipped roche full year result meeting january said already introduced commercial yet approved coronavirus assay elsewhere investor piling moderna though analyst remain sceptical whether mrna approach resist virus mutation vir biotechnology claim working anti covid mabs dismissed baird nowhere close effective therapeutic reality real progress virus much likely made big company academic centre established infectious disease expertise corporate world includes merck co notable developing ebola vaccine get market johnson johnson owns vaccine business crucell pharma giant sanofi glaxosmithkline company size use trader hoping ride speculative surge chasing corona trade remember small cap immune crashing back earth drama\n",
      "\n",
      "Keywords:\n",
      "diagnostics 0.215\n",
      "coronavirus 0.183\n",
      "vaccine 0.182\n",
      "covid 0.145\n",
      "novacyt 0.127\n",
      "health emergency 0.127\n",
      "emergency 0.126\n",
      "tonix 0.121\n",
      "co diagnostics 0.121\n",
      "baird 0.121\n",
      "virus 0.118\n",
      "stock 0.116\n",
      "cap 0.116\n",
      "health 0.112\n",
      "develop 0.11\n",
      "movement 0.106\n",
      "january 0.104\n",
      "small cap 0.103\n",
      "outbreak 0.101\n",
      "hype 0.101\n",
      "mention 0.099\n",
      "novavax 0.094\n",
      "marked 0.091\n",
      "cash 0.09\n",
      "surged 0.085\n",
      "\n",
      "Abstract:\n",
      "lilly confirmed last week huge hope experimental diabetes project tirzepatide patient cardiovascular outcome trial cvot start later year pitting dual gip glp agonist trulicity similarly acting agent company best selling drug executive wrong describe move bold though trulicity losing patent protection presumably feel risk worth taking new trial represents massive financial commitment evaluatepharma vision r cost model estimate trulicity cvot expensive ever run glp agonist tirzepatide though set new record trulicity rewind trial cost lilly almost bn run estimated glp agonist cvots rewind longest undertaken although almost patient enrolment similar outcome study conducted novo nordisk rybelsus victoza glaxosmithkline tanzeum shorter smaller cvots bring average table detail laid lilly last week indicate tirzepatide test cardiovascular safety come cheap called surpass cvot study recruit patient type diabetes confirmed atherosclerotic cardiovascular disease primary endpoint time first occurrence composite endpoint cv death myocardial infarction stroke ass non inferiority superiority tirzepatide versus trulicity lilly estimate study take four year complete trial alone double number patient company plan test tirzepatide however look clinical programme already running show company ambition project lie beyond diabetes impressive weight loss seen phase ii patient fuelling hope obesity mid stage programme underway nash thought hitting gip add effectiveness glp agonism though come cost tirzepatide weak spot likely tolerability high rate nausea vomiting diarrhoea reported earlier trial lilly belief managed dose titration long run proposed week highest dose tested limit project appeal surpass programme start read towards end year real potential tirzepatide hard estimate held sellside back consensus forecast indicate launch swift ramp sale bn surely represents best case scenario though committing billion project lilly must expecting nothing le evaluatepharma vision r cost model estimate cost individual clinical programme using real world data company disclosed product level spend clinical trial patient number combined create cost per patient benchmark technology therapy type utilising matching algorithm benchmark applied commercially relevant clinical trial estimate cost aggregated product estimate cost development product\n",
      "\n",
      "Keywords:\n",
      "tirzepatide 0.337\n",
      "trulicity 0.264\n",
      "cost 0.22\n",
      "estimate 0.198\n",
      "glp 0.161\n",
      "lilly 0.156\n",
      "estimate cost 0.132\n",
      "glp agonist 0.129\n",
      "indicate 0.1\n",
      "gip 0.1\n",
      "agonist 0.097\n",
      "programme 0.095\n",
      "vision cost model 0.093\n",
      "diabetes 0.093\n",
      "vision cost 0.09\n",
      "model estimate 0.09\n",
      "evaluatepharma vision cost 0.09\n",
      "cost model estimate 0.09\n",
      "cost model 0.09\n",
      "patient 0.087\n",
      "evaluatepharma vision 0.086\n",
      "cardiovascular 0.086\n",
      "vision 0.081\n",
      "run 0.08\n",
      "trial 0.078\n",
      "\n",
      "Abstract:\n",
      "biotech follower yesterday unveiling presentation upcoming ash conference notable prompting deflation bubble around next generation btk inhibitor arqule sunesis fell heavily constellation unexpected winner early data bet inhibitor first line myelofibrosis course meeting year last big medical showdown crucial bigger company though might reflected stock movement instance liso cel registrational study hugely relevant contingent value right cvr payable bristol myers squibb takeout celgene one event cvr payout depends u approval liso cel jcar lymphoma end celgene vowed file car project fda end year ash allow investor first look transcend nhl study hinge year death prior infusion manufacturing failure excluded liso cel ash abstract reveals orr broadly line gilead novartis marketed car therapy yescarta kymriah car therapy available however key doubt whether fda even approve third without significantly stronger data key focus thus fall safety liso cel look good rate serious cytokine release syndrome instance four treatment related death doubt draw attention last significant update one bcma among celgene asset investor paying attention anti bcma bispecific cc might impressed first clinical data due ash meeting feature different bcma targeting asset crowding space already led discontinuation autolus auto instance closely watched glaxosmithkline belantamab mafodotin whose dreamm study submitted ash late breaker bluebird bcma presence centre underwhelming update bb lead asset ide cel bb form another part celgene cvr pivotal karmma study make ash expected instead unveiled press release transcend nhl orr mpfs mth mo mth manu failure treatment related death absence data sent two non covalent btk inhibitor player yesterday sunesis fell news vecabrutinib yet generate single remission investor must hope ash abstract placeholder data meeting arqule failed convince arq lilly provided first early sign activity redx originated loxo derived asset loxo closely watched ash relevant btk inhibitor actually astrazeneca calquence whose first line elevate tn trial mark serious challenge abbvie imbruvica first line cll away oncology bluebird feature courtesy lentiglobin data hgb sickle cell trial main point sanofi sangamo st look like threat least yet ash presentation another sickle cell challenger vertex crispr ctx present clinical data fate therapeutic stem cell derived nk cell therapy ft ft disappointment sending originator stock yesterday early winner ash constellation thinly traded biotech floated year ago lead asset cpi impressed ash abstract covering bet inhibitor detail combination incyte jakafi untreated myelofibrosis concern four subject given least four treatment cycle true four exceeded threshold spleen volume reduction total symptom score improvement day nextcure surged perhaps constellation stock increase another indication biotech investor thirst glimmer efficacy however early might ash conference take place orlando florida december\n",
      "\n",
      "Keywords:\n",
      "ash 0.39\n",
      "cel 0.189\n",
      "liso cel 0.177\n",
      "liso 0.177\n",
      "bcma 0.157\n",
      "ash abstract 0.138\n",
      "cvr 0.123\n",
      "celgene 0.12\n",
      "btk inhibitor 0.117\n",
      "btk 0.117\n",
      "transcend nhl 0.1\n",
      "transcend 0.1\n",
      "sunesis 0.1\n",
      "four treatment 0.1\n",
      "abstract 0.099\n",
      "nhl 0.096\n",
      "inhibitor 0.09\n",
      "asset 0.09\n",
      "treatment related death 0.089\n",
      "related death 0.089\n",
      "bb 0.089\n",
      "arqule 0.089\n",
      "car 0.088\n",
      "instance 0.087\n",
      "ash conference 0.086\n",
      "\n",
      "Abstract:\n",
      "unveiling presentation title first instalment year aacr meeting revealed two surprise absence keenly awaited clinical data roche anti tigit mab tiragolumab presence trio study ox immuno oncology target earlier fallen favour latter feature first human data one glaxosmithkline major oncology hope bispecific alligator bioscience well early data moderna ox l producing mrna project plenty novel target whet investor appetite absence tigit major disappointment investor tigit focused biotech including arcus compugen iteos keenly awaiting early tiragolumab data evidence back roche decision launch phase ii iii programme comprises three skyscraper study subject tiragolumab nearest rival merck co subsequently put competitor mk four new trial however aacr nothing tiragolumab presentation obviously highlighting tigit targeting project story published roche told vantage tiragolumab data presentation planned aacr ii june instalment aacr started friday covid pandemic caused organiser turn meeting two virtual event first next monday tuesday feature clinical presentation aacr say wanted get timely manner meeting abstract title made available aacr ii separate three day virtual meeting june abstract go live may among novel approach featuring clinical presentation aacr anti lif mab northern biologics optioned celgene whose future bristol myers squibb uncertain anti cldn conjugate abbvie immutep soluble lag protein focus ox come surprise already written approach esmo meeting pfizer pf astrazeneca medi showed disappointing remission rate monotherapies among preclinical presentation serd theme get airing data astrazeneca roche kras via poster novartis shp inhibitor pair boehringer ingelheim asset targeting kras so kras data interest mirati slumped yesterday short report kerrisdale capital term share price appreciation aacr already produced one winner iovance multi billion dollar valuation put another april title til study revealed durable complete response nsclc inference least two cr trial recruited subject meant rate least however nothing known remission evaluated occurred durable indeed since single arm study combine tils opdivo il two chemotherapy seems difficult put benefit specifically iovance tils instead intriguing cell therapy presentation aacr might first human data gracell allogeneic anti cd car project gc little known gracell chinese company founded former chief executive controversial company cellular biomedicine group raised series b round claim one day car manufacturing process among technical question clear gc target cell leukaemia might avoid fratricide problem perhaps revealed next week aacr take place virtual format april full abstract text wil go live april\n",
      "\n",
      "Keywords:\n",
      "aacr 0.414\n",
      "tiragolumab 0.228\n",
      "presentation 0.205\n",
      "presentation aacr 0.171\n",
      "tigit 0.169\n",
      "ox 0.152\n",
      "title 0.141\n",
      "kras 0.118\n",
      "meeting 0.117\n",
      "instalment 0.106\n",
      "gracell 0.106\n",
      "gc 0.106\n",
      "clinical presentation 0.106\n",
      "abstract 0.104\n",
      "go live 0.101\n",
      "virtual 0.098\n",
      "tils 0.097\n",
      "iovance 0.094\n",
      "first human data 0.091\n",
      "durable 0.091\n",
      "data 0.09\n",
      "roche 0.084\n",
      "first human 0.083\n",
      "anti 0.082\n",
      "april 0.081\n",
      "\n",
      "Abstract:\n",
      "recent move sanofi roche advance respective selective oestrogen receptor degrader pivotal testing moved analyst take second look mechanism action perhaps boldest view articulated yesterday jefferies called least bn market opportunity quite turnaround mechanism action roche disastrous takeover seragon set make somewhat mediocre addition breast cancer armamentarium emboldened developer notion efficacious drug orally bioavailable real game changer selective oestrogen receptor degrader serd story actually begun fulvestrant astrazeneca faslodex launched whose sale breached bn mark last full year patent expired thought faslodex poor bioavailability intramuscular delivery held drug back spawning search effective oral negative er positive niche drug target breast cancer typically negative driven oestrogen receptor signalling faslodex second line label failure aromatase inhibitor theory binding oestrogen receptor change activity first generation selective oestrogen receptor modulators included tamoxifen blanket effect receptor signalling cue serds degrading receptor eliminate effect entirely structurally serds comprise molecular scaffold hit receptor ligand binding pocket plus long side chain known degron cause receptor degradation developer varying makeup pursuit ideal characteristic though course pivotal data ultimate test jefferies caution mechanism thrust spotlight recently sanofi new chief executive naming company offering sar one group top six growth driver sanofi new broom clean house december second line phase ii trial yield data end year allow filing roche meanwhile last month revealed rg entering phase iii study yet posted clinicaltrials gov swiss firm say test serd first line combination cdk inhibition two earlier generation serds roche acquired along seragon ditched time ago group reckons found secret sauce rg call best class oral asset improved efficacy vivo versus serds year early data come pfizer zentalis zn c g therapeutic rintodestrant according company potential best class serd start phase ii expansion study combination pfizer cdk inhibitor ibrance joker pack perhaps radius elacestrant entered phase iii emerald study showing impressive remission rate subject failed median three prior therapy however last november radius decided focus endocrine disease explore strategic option oncology emerald set complete enrolment later year company plan investment\n",
      "\n",
      "Keywords:\n",
      "oestrogen receptor 0.313\n",
      "oestrogen 0.278\n",
      "receptor 0.263\n",
      "serds 0.25\n",
      "selective oestrogen receptor 0.188\n",
      "selective oestrogen 0.188\n",
      "faslodex 0.188\n",
      "serd 0.176\n",
      "selective 0.146\n",
      "degrader 0.117\n",
      "sanofi new 0.111\n",
      "signalling 0.1\n",
      "cdk 0.1\n",
      "roche 0.092\n",
      "rg 0.089\n",
      "mechanism action 0.088\n",
      "jefferies 0.088\n",
      "best class 0.088\n",
      "sanofi 0.086\n",
      "mechanism 0.084\n",
      "binding 0.083\n",
      "generation 0.076\n",
      "second line 0.071\n",
      "breast cancer 0.07\n",
      "breast 0.069\n",
      "\n",
      "Abstract:\n",
      "effort develop treatment covid continue probably possible declare pandemic truly effective vaccine exists numerous company active vantage analysis reveals nearly project special interest among mrna vaccine seized early lead courtesy moderna though johnson johnson promise develop adenovirus vector based approach non profit basis might promise however despite understandable enthusiasm road vaccine approved long treacherous need build sufficient manufacturing infrastructure one aspect slow process vaccine sufficient efficacy developed take find product right mix safety ability generate antibody offer sufficient protection recent article coalition epidemic preparedness innovation cepi nejm pointed industry ability respond quickly need pandemic flu vaccine said sars followed similar path additionally covid rna virus industry vaccine effort type pathogen notably rsv underwhelmed early attention might surprise coronavirus pandemic moderna mrna rather traditional vaccine approach seized early attention one key advantage rna dna vaccine use synthetic process require culture fermentation offering much faster manufacturing moderna claim mrna vaccine better mimicking natural infection highlight agility manufacturing system production phase ii trial begin month ultimately allow million dos made pfizer deal biontech hope enter clinic another mrna vaccine month told vantage working record pace development process generally take year working partner government agency find opportunity save time wherever unique antigen mechanistically prophylactic vaccine work exposing immune system antigen unique virus question seeking prime immune system quick generation large amount antibody event actual infection mrna vaccine instance comprises mrna code expression protein antigen different vaccine different property term whether generate humoral b cell antibody versus cellular effector cell immunity site elicited beyond modality vaccine approach us whether adjuvanting needed potentiate immune response key consideration clearly choice antigen far popular approach target epitope covid spike protein structure found surface virus ideally antibody raised bind virus immediately stop infection host cell vaccine target far undisclosed epitope protein cepi outlined carrying multiple activity simultaneously rather linearly curtail development time pandemic j j say accelerated timeline see lead vaccine ready emergency use would represent extraordinarily fast turnaround even vaccine sort might needed even sooner thus even suboptimal vaccine moderate efficacy merely reduce severity covid infection might viable way protecting people next winter approach think hard imagine fully returning pre covid life effective vaccine population infected therapy turn nearly severe case nothing annual flu say dan chen chief medical officer igm bioscience coronavirus expert virtue phd thesis require global government follow funding promise nejm paper author caution sars zika epidemic ended vaccine development complete point federal funding dried developer left nursing loss biopharma obviously want play role pandemic acutely aware often vaccine development represents economic black hole story corrects earlier mistake table\n",
      "\n",
      "Keywords:\n",
      "vaccine 0.521\n",
      "mrna 0.177\n",
      "mrna vaccine 0.145\n",
      "antigen 0.143\n",
      "virus 0.129\n",
      "infection 0.119\n",
      "sufficient 0.115\n",
      "pandemic 0.111\n",
      "approach 0.105\n",
      "process 0.103\n",
      "covid 0.099\n",
      "vaccine approach 0.099\n",
      "seized 0.095\n",
      "system 0.093\n",
      "epitope 0.092\n",
      "epidemic 0.092\n",
      "cepi 0.092\n",
      "sars 0.089\n",
      "immune 0.089\n",
      "moderna 0.086\n",
      "manufacturing 0.086\n",
      "protein 0.085\n",
      "promise 0.085\n",
      "antibody 0.082\n",
      "nejm 0.081\n",
      "\n",
      "Abstract:\n",
      "vaccine antiviral approach tackling covid pandemic time antibody take turn spotlight week lilly seized lead space starting first clinical trial antibody designed treat novel coronavirus ly cov derived deal abcellera target covid spike protein meaning unlike project aiming reduce infection complication take direct aim virus present clinical stage antibody covid retain monopoly long spike protein targeting approach similar several lilly competitor protein present virus surface virus us dock ace receptor target cell allowing internalised infect next project clinic mechanism come vir partnership glaxosmithkline far identified two lead mabs keenly awaited multi antibody cocktail regeneron project way astrazeneca studied patient within next month hope antibody prevent virus docking hit another part lead antibody mediated destruction last two noteworthy based part plasma derived patient recovered covid infection approach might surmised provide broader range target might provide efficient way targeting virus hitting spike protein spike protein used target industry vaccine approach seeking prime immune system indeed regeneron suggested regn cov prophylactic role biologicals already clinical development mabs cytokine gm csf angiopoietin considered aim treat effect covid cytokine elevation respiratory complication rather virus design though many project target common additional variability antibody structure instance based igg tie atreca beigene igm bioscience looking derived igm iga company argue binding domain hence greater binding power igg separate tie vir xencor look develop mabs engineered fc domain give extended half life similar thinking lie behind called darpins development molecular partner bispecific approach fusion protein instance si f development systimmune private u group focusing mabs bispecifics antibody dug conjugate combine two protein mimicking ace aiming take relevant binding site covid prevent interaction endogenous ace receptor many company making claim superiority respective approach course based animal vitro data comparison possible first clinical trial read lilly clinical study primarily testing safety pharmacokinetics pharmacodynamics design competitor trial watched interest article updated reflect celltrion choice ct p lead\n",
      "\n",
      "Keywords:\n",
      "protein 0.244\n",
      "virus 0.237\n",
      "spike protein 0.207\n",
      "antibody 0.2\n",
      "ace 0.182\n",
      "spike 0.18\n",
      "mabs 0.177\n",
      "approach 0.154\n",
      "covid 0.146\n",
      "binding 0.135\n",
      "derived 0.125\n",
      "target 0.122\n",
      "igm 0.116\n",
      "igg 0.116\n",
      "complication 0.109\n",
      "domain 0.104\n",
      "lead 0.102\n",
      "prevent 0.101\n",
      "clinical 0.096\n",
      "lilly 0.094\n",
      "first clinical 0.093\n",
      "aiming 0.093\n",
      "vir 0.091\n",
      "cov 0.089\n",
      "cytokine 0.088\n",
      "\n",
      "Abstract:\n",
      "glaxosmithkline failed secure late breaker belantamab mafodotin month ash conference investor today found likely reason data simply good enough result dreamm trial underwhelm versus earlier exploratory dreamm study fell well short rival multiple myeloma agent similar mechanism action inhibiting bcma antigen approach already hugely crowded yet undeterred glaxo today vowed complete regulatory filing belantamab belantamab antibody drug conjugate earlier yielded overall remission rate dreamm study subject failed least three prior line therapy ash saw multitude presentation rival bcma player yielding orr ash car bispecific antibody threat real december bad worse today however thing got even worse glaxo dreamm study belantamab filed yielded orr including rate complete remission group said bad enough serious instance keratopathy toxicity involving change eye corneal epithelium seen dreamm subject johnson johnson cartitude trial jnj instance detail keratopathy side effect gone badly wrong glaxo immediate finger blame pointed fact dreamm subject failed anti cd mab like darzalex represents particularly hard treat group today data suggest patient belantamab simply work well view confirmed thorough reading earlier dreamm data included darzalex progressed naive subject alike reveals important dichotomy previously treated cd mab orr belantamab yielded result illustrate glaxo j j orr result cartitude achieved despite fact study enrolees triple refractory meaning failed cd mab jnj car therapy look like efficacious anti bcma asset industry pipeline outside cell therapy direct threat glaxo bristol myers squibb anti bcma bispecific mab cc yielded orr study subject darzalex refractory making big surprise ash immediate competition glaxo come elsewhere bluebird bristol intend imminently file anti bcma car ide cel strength karmma study whose subject cd refractory evaluatepharma reveals bcma targeting industry project phase ii recent analysis bcma space bernstein identified car project six bispecifics two antibody drug conjugate two asset say glaxo work cut would putting mildly\n",
      "\n",
      "Keywords:\n",
      "dreamm 0.353\n",
      "bcma 0.301\n",
      "belantamab 0.284\n",
      "glaxo 0.277\n",
      "orr 0.157\n",
      "dreamm study 0.151\n",
      "ash 0.143\n",
      "darzalex 0.138\n",
      "anti bcma 0.135\n",
      "car 0.129\n",
      "cd 0.125\n",
      "yielded 0.124\n",
      "cd mab 0.122\n",
      "mab 0.112\n",
      "subject 0.109\n",
      "refractory 0.108\n",
      "cartitude 0.097\n",
      "yielded orr 0.092\n",
      "subject failed 0.088\n",
      "jnj 0.088\n",
      "failed 0.087\n",
      "study subject 0.086\n",
      "anti 0.085\n",
      "immediate 0.079\n",
      "bad 0.077\n",
      "\n",
      "Abstract:\n",
      "since taking rein pfizer beginning albert bourla overseen demergers company consumer healthcare division established medicine business yesterday annual result chief executive distanced pharma giant another old pfizer trope mr bourla ruled acquisition cost synergy main driver essentially suggests megamergers table past different pfizer deal constantly declining revenue even financial engineering said capital directed pipeline instead pledged spending bn share repurchase buyback planned year preserve firepower deal making investor expect evidence deployment coming month mr bourla said pfizer sight phase ii phase iii ready asset mitigate company next round painful patent expiry commence around apparent hoarding capital many suspecting company planning larger typical bolt deal though course close market project come cheap true far harder drive earnings growth via successful development valuable new drug using cash buy back stock exactly many large drug maker come rely form financial engineering disparaged mr bourla keep investor happy biotech big buck buyback begin burn november spending money wisely hard part drop pfizer share yesterday suggests shareholder entirely board mr bourla quickly come pressure revert former tactic business development fails pan mr bourla argues shedding legacy product left pfizer competitive growth profile among big pharma peer might true prospect largely driven drug already market yesterday annual result presentation talked pipeline progress expect year reality highlighted little speak company gene therapy project major interest though largely investor smaller player either competing collaborating pharma giant real doubt whether pfizer leading position candidate sellside yet pencil number revealing mr bourla directs firepower new project technology pledge put new gene therapy project clinic every year made yesterday though update limited vague timeline commitment new data pfizer duchenne muscular dystrophy therapy pf announced investor day march executive hinted advising interested party take front row seat company flagged abrocitinib according sellside consensus forecast pfizer biggest pipeline hope much depends approaching jade compare study pit project dupixent atopic dermatitis disappoints company need fresh blood laid bare absence sale forecast r project highlighted yesterday show much still prove important commercially speaking update year pfizer already marketed drug ibrance readout delayed slightly perhaps worry study double addressable patient blockbuster breast cancer pill anchor study meanwhile move pfizer newly acquired braftovi mektovi combination valuable front line setting certain colorectal cancer patient underline exactly cash earmarked year pfizer repositioned newly focused innovator readout flagged yesterday presumably represent biggest news existing pipeline capable generating next month mr bourla better get spending\n",
      "\n",
      "Keywords:\n",
      "mr bourla 0.389\n",
      "bourla 0.38\n",
      "pfizer 0.279\n",
      "mr 0.198\n",
      "spending 0.117\n",
      "yesterday 0.115\n",
      "financial engineering 0.104\n",
      "buyback 0.104\n",
      "gene therapy project 0.099\n",
      "pipeline 0.095\n",
      "year pfizer 0.095\n",
      "therapy project 0.095\n",
      "engineering 0.095\n",
      "annual result 0.095\n",
      "firepower 0.087\n",
      "newly 0.085\n",
      "project 0.077\n",
      "pharma giant 0.076\n",
      "capital 0.076\n",
      "giant 0.071\n",
      "exactly 0.07\n",
      "valuable 0.069\n",
      "new 0.067\n",
      "financial 0.067\n",
      "highlighted 0.065\n",
      "\n",
      "Abstract:\n",
      "time dust settle year ash might best remembered conference bispecific antibody threat car became real case point multiple myeloma targeting bcma long hotbed car activity duelling anti bcma car therapy continued battle ash yesterday regeneron became latest group suggest bispecific mab least good came day bristol myers squibb cell engager cc virtually unknown asset first knocked hole car approach cc data look even impressive ash abstract suggested particular highest cc dose mg appears active many anti bcma car t overall response rate rate complete remission true numerous caveat importantly mg dataset comprises nine subject clearly difference baseline patient characteristic comparing across multiple study cannot denied car competitor reckoned advanced car therapy space bluebird bristol ide cel yielded orr cr rate respectively highest dose pivotal karmma study patient characteristic cc population failed median five prior therapy triple refractory disease karmma subject failed least three therapy line triple refractory perhaps impressive aspect cc result none subject given highest dose progressed seven month responding vital consideration time patient relapse becoming big problem bcma targeted car car suddenly look vulnerable regeneron another beneficiary company yesterday reported first clinical data regn take anti bcma cell engager approach regn differs structurally cc latter two bcma binding domain instance principle behind ash poster yesterday revealed four response one complete first seven regn treated subject dose escalation still ongoing dose limiting toxicity yet reached remarkably population failed median seven line systemic therapy debit side one partial remitters relapsed seven week though three response ongoing one week counting comparison glaxosmithkline bcma targeting antibody drug conjugate belantamab mafodotin whose dreamm study yielded orr belantamab pivotal dreamm trial known read positively apparently submitted ash late breaker ultimately make year conference like car different cell engager like cc bind target antigen one end interacts cell thus bringing latter close proximity target tumour cell effect similar car approach achieved antibody possible convenience advantage immune system stimulating strategy safety important consideration cc trial one patient died cytokine release syndrome similar single death karmma cartitude study separate anti bcma car johnson johnson jnj investor want know weekend shift bcma tectonic plate might play virtue celgene acquisition bristol look pole position boasting cc addition several car asset prioritises cc ide cel obviously latter originator bluebird lose threat jnj cell therapy including poseida roche consistently refused buy car ground impractical expensive see major vindication saturday roche fired shot across bow shape mosunetuzumab bispecific mab showed activity patient relapsed car mean end cell therapy expectation reset\n",
      "\n",
      "Keywords:\n",
      "car 0.387\n",
      "cc 0.369\n",
      "bcma 0.31\n",
      "anti bcma 0.144\n",
      "ash 0.143\n",
      "cell 0.127\n",
      "engager 0.126\n",
      "cell engager 0.126\n",
      "bcma car 0.117\n",
      "anti bcma car 0.117\n",
      "karmma 0.114\n",
      "regn 0.106\n",
      "therapy 0.096\n",
      "seven 0.092\n",
      "failed median 0.088\n",
      "car approach 0.088\n",
      "triple refractory 0.084\n",
      "dose 0.084\n",
      "bispecific 0.082\n",
      "highest 0.082\n",
      "dreamm 0.081\n",
      "bispecific mab 0.078\n",
      "patient characteristic 0.076\n",
      "belantamab 0.076\n",
      "yielded orr 0.074\n",
      "\n",
      "Abstract:\n",
      "three day moderna generated investor frenzy dribbling report neutralising antibody eight volunteer given covid vaccine astrazeneca come swinging message big pharma group anything better astra today revealed help develop produce coronavirus vaccine secured bn u government double granted moderna development programme promise unveil data shortly study volunteer threaten upstage moderna effort far vaccine astra involved cov chimp adenovirus vector based project development uk university oxford astra joined effort last month scale distribution deal call project azd speedy work today development another example speed industry effort tackle new coronavirus azd clinical trial began last month yet expected yield result shortly though admittedly astra say whether data subject available still positive strong phase iii study planned manufacturing capacity secured enable shipping september part moderna unveiled positive though preliminary finding handful volunteer niaid trial mrna vaccine mrna moderna reminds market biotech dual purpose may biotech group starting phase ii volunteer imminently yet finalise design phase iii test subsequently moderna came fire piecemeal way revealed finding press release stat point impossible put company finding context verify claim mrna elicited neutralising antibody level equivalent convalescent serum given wide variability patient recovered covid scale project moderna year agreement lonza target eventual production billion dos year long dose g astra seems want least match saying first agreement least million dos concluded manufacturing capacity secured one billion dos far thorny issue hand however vague moderna claim company seems convinced many potentially efficacious product oxford vaccine meanwhile come fire lack activity rhesus monkey study astra keen reverse perception report first human data separate controversy moderna secured u government agency barda yet still able tap investor bn today astra revealed bn barda funding uk group come similar criticism moderna certainly valid ask u throwing taxpayer money hugely well financed sometimes profitable corporate entity astra hinted quid pro quo saying covid vaccine would widely accessible around world equitable manner neither moderna tackled directly thorny issue vaccine would priced whether soon would profitable\n",
      "\n",
      "Keywords:\n",
      "moderna 0.378\n",
      "astra 0.277\n",
      "vaccine 0.208\n",
      "volunteer 0.173\n",
      "secured 0.173\n",
      "vaccine would 0.118\n",
      "fire 0.118\n",
      "profitable 0.11\n",
      "mrna 0.106\n",
      "manufacturing capacity 0.104\n",
      "barda 0.104\n",
      "effort 0.103\n",
      "neutralising antibody 0.097\n",
      "finding 0.097\n",
      "neutralising 0.095\n",
      "capacity 0.093\n",
      "revealed 0.092\n",
      "oxford 0.089\n",
      "azd 0.088\n",
      "dos 0.088\n",
      "agreement 0.085\n",
      "government 0.082\n",
      "billion 0.081\n",
      "shortly 0.08\n",
      "uk 0.073\n",
      "\n",
      "Abstract:\n",
      "race develop vaccine covid moderna biontech pfizer rival project shown impressive ability generate neutralising antibody far little said ability stimulate cell today changed astrazeneca azd join leader first clinical data published lancet included finding ability generate cell response biontech pfizer preprint separate trial bnt b vaccine detailed perhaps impressive cell response far hypothesised prevent severe covid infection generate long lasting effect might necessary vaccine stimulate cellular well humoural antibody based immunity key part immune response ultimately lead destruction pathogen antibody astrazeneca today reported data part patient population want enrol astra oxford university trial far enrolled subject lancet paper key finding relate neutralising antibody level available showed detectable neutralising antibody response single azd dose became booster author wrote neutralising antibody key interfere virus ability infect cell cell response data meanwhile available subject response induced peaking day maintained two month injection astra said statement however lancet paper low detail revealed boost cellular response observed following second dose moreover nothing said whether cd helper cd killer cell response disappoint investor enthused uk press report friday stressed stimulation killer cell bnt b biontech pfizer bnt b biontech pfizer mrna moderna part biontech pfizer pre empted lancet publication publication another scientific paper pre print time relating german trial mrna vaccine project bnt b specifically highlighting effect cd cell trial enrolled subject across four g dose level tested cellular response company said mounted called functional cd cell response comparable memory response observed cmv ebv influenza virus cellular response covid receptor binding domain implying precise response antigen bnt b encodes dose response relationship author argued positive implying response mounted even low dose moderna mrna rival mrna shown effect cell study published nejm last week seen somewhat modest mrna encodes binding domain entire spike protein response said specific first bnt b study reported u trial evaluable volunteer shown strong neutralising antibody response nothing said cell covid vaccine remain hot spite inovio july doubt investor continue pick apart data coming day covid tectonic plate shifted biontech morning rose astra unmoved moderna lost\n",
      "\n",
      "Keywords:\n",
      "response 0.292\n",
      "cell 0.219\n",
      "bnt 0.209\n",
      "cell response 0.203\n",
      "neutralising antibody 0.189\n",
      "neutralising 0.186\n",
      "biontech 0.178\n",
      "biontech pfizer 0.174\n",
      "lancet 0.172\n",
      "cellular 0.162\n",
      "cellular response 0.156\n",
      "mrna 0.138\n",
      "antibody 0.134\n",
      "vaccine 0.116\n",
      "ability 0.113\n",
      "cd 0.11\n",
      "paper 0.11\n",
      "pfizer 0.109\n",
      "moderna 0.107\n",
      "stimulate 0.097\n",
      "lancet paper 0.097\n",
      "antibody response 0.097\n",
      "ability generate 0.097\n",
      "covid 0.093\n",
      "response observed 0.093\n",
      "\n",
      "Abstract:\n",
      "biogen aducanumab filing setting stage u fda showdown set year alzheimer disease danish diabetes specialist novo nordisk soon chance join party courtesy investigator sponsored study testing hypothesis neurodegeneration linked low insulin insulin resistance thus glp analogue diabetes drug like novo victoza improve cognitive function however outlandish sound novo share hit time high last week least one source put alzheimer wednesday danish newspaper b rsen floated idea victoza promise alzheimer lay behind spike citing analyst berenberg suggested positive data unleash hidden potential note bernstein following day asked alzheimer type diabetes posited role glp drug insulin signalling theory claim simply put diabetes associated dementia impaired insulin signalling suggested common mechanistic link correlation blood glucose level rate cognitive decline seen even without clinical diabetes suggested type diabetes almost double risk developing alzheimer associated accelerated cognitive decline people mild cognitive impairment others suggested insulin play role beyond glucose metabolism involved memory learning one paper describes function insulin receptor brain say defect receptor identified neuron alzheimer brain course correlation equal causation sceptical pharma sector remained sideline indeed striking number clinical trial testing hypothesis counted finger one hand none corporate pharma company sponsor change elad trial victoza run imperial college london generates promising data quarter enrolment target subject mild alzheimer dementia study far biggest date look diabetes drug cognitive impairment double blind placebo controlled design relatively long month treatment period primary endpoint measure rate glucose metabolism brain seeking stronger sign promise look secondary measure investigating various scale measuring cognition including ada cdr sum box adcs adl beyond vitro preclinical data little hard evidence suggest positive outcome clinical trial type approach generate data conducted university aarhus showed six month treatment victoza associated increase glucose metabolism versus placebo though effect statistically significant two academic study completed recently one victoza another astrazeneca bydureon data published beyond elad one trial ongoing u study non diabetic testing whether boehringer ingelheim lilly jardiance elevates level ketone body effect brain metabolism measured magnetic resonance clinical evidence backing aducanumab scant yet drug increasingly seen likely approval alzheimer year expect novo analyst seize hint victoza efficacy elad\n",
      "\n",
      "Keywords:\n",
      "victoza 0.292\n",
      "alzheimer 0.282\n",
      "insulin 0.273\n",
      "cognitive 0.222\n",
      "diabetes 0.219\n",
      "metabolism 0.188\n",
      "glucose 0.188\n",
      "glucose metabolism 0.171\n",
      "brain 0.16\n",
      "elad 0.16\n",
      "novo 0.138\n",
      "suggested 0.124\n",
      "cognitive impairment 0.106\n",
      "month treatment 0.101\n",
      "impairment 0.097\n",
      "correlation 0.097\n",
      "cognitive decline 0.097\n",
      "signalling 0.091\n",
      "dementia 0.087\n",
      "associated 0.086\n",
      "beyond 0.085\n",
      "diabetes drug 0.085\n",
      "danish 0.085\n",
      "glp 0.081\n",
      "type diabetes 0.079\n",
      "\n",
      "Abstract:\n",
      "bluebird missing deadline getting registrational karmma dataset ash conference way left clear johnson johnson seize early spotlight today ash presentation first human data j j anti bcma car project jnj shown staggering remission rate bluebird bristol myers squibb unveil karmma data yesterday press release result certainly seem good enough secure approval ide cel bb late line multiple myeloma relapse remain elephant room care taken attempting cross study comparison owing differing patient characteristic karmma instance treated subject failed least three therapy line triple refractory key efficacy data overall response rate including complete remission look reasonable compared orr cr rate seen earlier study bb subject failed average seven prior therapy however worry relapse remission karmma lasted month average median progression free survival month backdrop threat j j jnj already highly competitive field suddenly become real ash today j j said cartitude trial jnj far treated subject triple refractory penta refractory patient responded jnj amazing showing complete remission better follower j j thus breathe sigh relief company licensed jnj bispecific car two different epitope bcma protein nanjing legend subsidiary china genscript biotech front legend data since drawn criticism ash legend mystery car raise question december cartitude presenting author dr deepu madduri mount sinai medical center suggested preferential expansion cd central memory cell one reason behind jnj impressive efficacy said real test durability early day subject progression free median six month follow go unnoticed cartitude karmma featured report patient death owing cytokine release syndrome might surprising given prevailing view car related side effect largely controllable interesting aside legend still running chinese study legend update result ash monday continues call project lcar b identical jnj though j j previously told vantage us different manufacturing scale process separate car asset multiple myeloma unveiled ash today another chinese group cellyan therapeutic target bcma cd yielded orr cr multiple myeloma subject failed two nine prior therapy response ongoing week said huazhong university science technology dr heng mei however given differing standard treatment prospective western partner project would well advised run confirmatory study u j j jnj contingent value leave bluebird bristol investor ide cel important consideration one three element contingent value right bristol issued bought celgene bluebird original partner cvr triggered among thing ide cel approved u march strength karmma certainly look achievable filing based dataset look likely go ahead imminently broader question big ide cel turn unfortunately bluebird karmma provides little solace potent though short lived therapy offer little hope expanding ide cel earlier line therapy bb bluebird played potentially improved version ide cel actually look little better according ash abstract attention turn bristol bispecific anti bcma mab cc whose first clinical data presented ash today impressed ide cel kicked bcma revolution multiple meyloma time year instalment ash might look remarkably vulnerable\n",
      "\n",
      "Keywords:\n",
      "jnj 0.272\n",
      "karmma 0.256\n",
      "ash 0.249\n",
      "ide cel 0.238\n",
      "ide 0.238\n",
      "cel 0.225\n",
      "legend 0.195\n",
      "bluebird 0.184\n",
      "bcma 0.167\n",
      "ash today 0.128\n",
      "car 0.125\n",
      "cartitude 0.113\n",
      "bb 0.113\n",
      "subject failed 0.102\n",
      "myeloma 0.091\n",
      "multiple myeloma 0.091\n",
      "remission 0.089\n",
      "multiple 0.088\n",
      "refractory 0.084\n",
      "triple refractory 0.081\n",
      "bluebird bristol 0.078\n",
      "bristol 0.077\n",
      "treated subject 0.073\n",
      "orr cr 0.073\n",
      "prior therapy 0.071\n",
      "\n",
      "Abstract:\n",
      "rigorous study sanofi regeron repurposed rheumatoid arthritis drug kevzara found anti il antibody little use outside critically ill covid patient dashing hope big impact mechanism finding reminds investor danger jumping encouraging result small trial experimental intervention enthusiasm continues boost share price mesoblast notable beneficiary last day company australia listed share doubled data coronavirus subject treated allogeneic cell therapy evaluate vantage tracking notable covid announcement clear pandemic news flow showing sign slowing clinical data emerges biopharma myriad attempt identify potential treatment risk drug development must forgotten kevzara result show small study prompted chinese add roche actemra treatment guideline covid initiation bigger trial il antibody one theory driving work coronavirus infection prompt surge cytokine il blocker damp making sense covid treatment approach march seems utility lie critically ill patient meaning requiring mechanical ventilation high flow oxygenation sanofi regneron said today ongoing phase ii iii trial would continue subject interim analysis found little benefit le severe patient readout expected june plus phase iii critical patient cohort give clearer picture role last week announcement mesoblast hand show little clarity remestemcel l utility data gathered allogeneic cell therapy compassionate use programme u surface seems encouraging nine patient treated came ventilator impossible say whether remestemcel l anything lack control group one issue patient receiving several intervention mesoblast description moderate severe ards puzzling given ventilation tends reserved critical patient mention made randomised phase ii iii due start though company long history disappointing make many investor wary much data emerge covid pipeline far compassionate use programme mesoblast certainly alone benefiting press releasing early finding israeli microcap redhill biopharma trading higher morning saying sphingosine kinase inhibitor opaganib produced measurable improvement six subject treated pharming received boost last week reporting improvement five patient given ruconest failed respond standard care rigorously gathered result available right investor chasing pandemic play little else go worth remembering even best intention ind hand small company simply cash capacity run large confirmatory trial certainly short time frame bigger developer restrained astrazeneca example announced last week start patient study farxiga see diabetes medicine reduce risk complication death high risk covid patient smaller biotech really need industry academic partner help fund run bigger study necessary pharming example university hospital basel board run patient study ruconest covid mesoblast partnering arm nih u neither study seems started travail gilead remdesivir show even researched probably best funded project nothing certain rigorous data emerge\n",
      "\n",
      "Keywords:\n",
      "mesoblast 0.278\n",
      "covid 0.156\n",
      "patient 0.151\n",
      "ventilation 0.117\n",
      "ruconest 0.117\n",
      "remestemcel 0.117\n",
      "pharming 0.117\n",
      "il antibody 0.111\n",
      "critically ill 0.111\n",
      "critically 0.111\n",
      "compassionate use 0.111\n",
      "il 0.111\n",
      "bigger 0.108\n",
      "gathered 0.107\n",
      "compassionate 0.107\n",
      "allogeneic cell therapy 0.107\n",
      "allogeneic cell 0.107\n",
      "intervention 0.103\n",
      "last week 0.1\n",
      "subject treated 0.1\n",
      "rigorous 0.1\n",
      "kevzara 0.1\n",
      "data emerge 0.097\n",
      "little 0.096\n",
      "covid patient 0.095\n",
      "\n",
      "Abstract:\n",
      "secured u approval breast cancer four month early enhertu already showing promise elsewhere today topline data registrational study suggest astrazeneca daiichi sankyo anti antibody drug conjugate used late line gastric cancer targeting agent including roche kadcyla failed enhertu give analyst pleasant surprise especially inroad made earlier line therapy however sting tail enhertu toxicity especially interstitial lung disease emerged side effect watch enhertu destiny breast study secured approval last month subject suffered side effect leading four treatment related death sabcs astrazeneca daiichi join resistance december least interstitial lung disease related death seen among positive subject destiny gastric trial read today though toxicity related pneumonitis seen case mild one grade two grade event optimism said seems plenty room optimism especially destiny gastric enhertu improved overall survival well overall remission primary endpoint versus physician choice enter study subject positive failed least two treatment positive gastric cancer patient herceptin plus chemo first line standard care option limited relapse lilly cyramza instance second line label comer first line patient got chemo herceptin logically remains second line option however enhertu real triumph shown activity failure herceptin one assumption patient fails roche mab would longer respond another directed drug like destiny breast enhertu disproved theory astra daiichi argue enhertu high intensity payload cell membrane permeability might enable target tumour express relatively low level far theory playing moreover enhertu look especially promising light failure anti therapy recently roche kadcyla failed gatsby trial second line positive gastric cancer earlier novartis tykerb flunked tytan trial similar population asian subject roche perjeta studied front line neoadjuvant positive gastro oesophageal adenocarcinoma astra daiichi investor want know big opportunity become evaluatepharma sellside consensus see enhertu sale bn coming gastric cancer enhertu next gastric cancer test second line study ending october astra told vantage planning gastric cancer trial stressed educating doctor patient early identification intervention management interstitial lung disease pneumonitis front line label represents best case scenario surely require head head beat herceptin mention allaying fear lung disease\n",
      "\n",
      "Keywords:\n",
      "enhertu 0.447\n",
      "gastric 0.325\n",
      "gastric cancer 0.244\n",
      "herceptin 0.172\n",
      "line 0.169\n",
      "destiny 0.167\n",
      "lung disease 0.159\n",
      "daiichi 0.149\n",
      "interstitial lung disease 0.129\n",
      "interstitial lung 0.129\n",
      "interstitial 0.129\n",
      "cancer 0.127\n",
      "second line 0.119\n",
      "especially 0.116\n",
      "lung 0.105\n",
      "secured approval 0.098\n",
      "roche kadcyla 0.098\n",
      "kadcyla 0.093\n",
      "destiny breast 0.093\n",
      "astra daiichi 0.093\n",
      "positive 0.091\n",
      "astrazeneca daiichi 0.089\n",
      "breast 0.087\n",
      "related death 0.086\n",
      "optimism 0.083\n",
      "\n",
      "Abstract:\n",
      "knock effect covid spread far wide one aspect biopharma investor must consider risk ongoing trial might delayed even abandoned yesterday lexicon provided case point cancelling two zynquista study recently completed enrolment nearly type diabetic true coronavirus pandemic one reason cited likely lexicon largely wanted end uncertainty accept partner fund trial completion would found vantage identified pivotal study due end year subject might suffer similar fate among feature project pfizer clostridium difficile vaccine candidate pf whose clover study subject enrolled biggest analysis separate pf trial seeking recruit feature among top five study reading year yet enrol fully threat huge amount clinical work threat analysis sought identify biopharma advanced valuable crop r asset pinpoint study invested term time money vantage searched specifically pivotal stage project yet receive u approval trial primary completion date according clinicaltrials gov topline analysis reveals trial still recruiting another active fully enrolled comprising subject respectively remarkably look like least five near term blockbuster threat lilly tirzepatide reata bardoxolone immunomedics sacituzumab govitecan bristol myers squibb tyk inhibitor galapagos filgotinib exposure bristol especially striking four tyk study due completed year plus another four ozanimod latter project feature contingent value right issued celgene acquisition stat news pointed fda review delay mean cvr never pay numerous way covid situation hit clinical trial big risk patient lost follow early analysis possible would require protocol change database locked problem le severe actual analysis delayed cro already outside pivotal setting many first quarter expected clinical readout doubt provention bio iveric bio arrowhead three company recently said would pause study recruitment pending clinical readout make across line march lexicon case pointlessness scored soloist trial halted yesterday perhaps foregone conclusion zynquista awaiting approval type diabetes type setting scored soloist meant opened really big market however lexicon lost sanofi partner completing two trial relied finding new licensee something pandemic situation imposing severe restriction meeting movement people must seen impossible fortunate sponsor u fda taken lead problem trial delay spelling willingness consider protocol amendment design change alternative method study subject assessment small mercy something\n",
      "\n",
      "Keywords:\n",
      "lexicon 0.254\n",
      "feature 0.139\n",
      "soloist 0.139\n",
      "scored soloist 0.139\n",
      "trial 0.132\n",
      "study 0.128\n",
      "tyk 0.127\n",
      "analysis 0.126\n",
      "threat 0.117\n",
      "protocol 0.111\n",
      "pf 0.111\n",
      "study subject 0.108\n",
      "study due 0.103\n",
      "fully 0.095\n",
      "type 0.095\n",
      "completion 0.094\n",
      "clinical readout 0.094\n",
      "delayed 0.093\n",
      "consider 0.093\n",
      "situation 0.092\n",
      "scored 0.092\n",
      "subject 0.091\n",
      "bio 0.086\n",
      "lost 0.085\n",
      "clinical 0.083\n",
      "\n",
      "Abstract:\n",
      "decade drug development parkinson disease yielded little beyond levodopa used control movement disorder symptomatic condition therapy capable halting reversing patient neurodegeneration come light several mid stage trial set read year ought show new mechanism might stand chance halting progression parkinson chief among mechanism synuclein hypothesis imminent phase ii data rival inhibitor protein developed roche biogen ought show whether theory leg basis hypothesis several mutation synuclein protein cause autosomal dominant form parkinson others increase syn expression linked higher normal risk disorder spherical aggregated form protein lewy body hallmark parkinsonian neuropathology wage syn first data two part pasadena trial prothena anti syn mab prx licensed roche pasadena first part test high dose mg patient bodyweight kg mg weigh le low dose mg placebo end part one year patient placebo group randomised either high low dose prx another year primary endpoint change baseline patient score movement disorder society unified parkinson disease rating scale md updrs one year part one data come year prothena said last week phase ii spark trial biogen biib perhaps le useful proof syn concept spark similar size design pasadena testing three dos mab versus placebo interim readout one year endpoint look patient outcome instead primary measure rate adverse event secondary geared towards pharmacodynamic effect biib dopaminergic nerve well pharmacokinetics immunogenicity data safety possibly pharmacodynamics expected second half tiny phase ii trial even tinier extension study cerebral dopamine neurotrophic factor formulation development herantis pharma ought yield data year according finnish group cdnf protects neuron degeneration restores function already degenerating neuron function several way company contends one inhibiting formation synuclein oligomers play syn theory despite small size trial assessing whole suite endpoint initial trial primary endpoint extension according clinicaltrials gov value conclusion wrought small trial open question data expected first quarter swimming upstream data anavex anavex called blarcamesine expected mid year project sigma receptor ligand anavex say act upstream target activating neuroprotective signal help neuron return homeostasis company exploratory phase ii data suggesting project improve cognition alzheimer patient far human data parkinson phase ii parkinson trial ass effect two dos computer based cognition test well molecule safety versus placebo big cap pharma trying new attack sanofi gz aka venglustat development several rare disorder associated mutation glycosphingolipid metabolic pathway move pd trial enrolled parkinson disease patient mutation gba gene mutation one common genetic risk factor parkinson patient carry variant making common mutation synuclein gene patient gba mutation tend experience motor symptom deficit cognitive decline rapidly others move pd pretty solid endpoint change baseline md updrs part ii iii score two month one year almost unimaginably unlikely event move pd roche prothena pasadena trial hit sanofi project reach wider population following analysis exclude investigator initiated trial due report exclude gene therapy parkinson covered separately several novel mechanism evaluated phase study though naturally yield definitive conclusion disease modifying nature therapy two anti synuclein mabs phase takeda astrazeneca tak lundbeck lu af neither expected post data clinical benefit denali therapeutic two shot goal leucine rich repeat kinase inhibitor dnl dnl lrrk regulator lysosomal function impaired parkinson disease contributing formation lewy body neurodegeneration trial read month ago dnl meeting biomarker goal generally well tolerated lower dose tested dnl well tolerated dos trial met safety biomarker goal dnl phase b trial expanded study higher dos coming month denali intends choose either dnl dnl take phase ii iii trial parkinson fb target c abl south korean group st biotherapeutics claim play role driving synuclein pathogenesis parkinson compound thought first c abl inhibitor advance clinical trial single multiple ascending dose study report year trial pasadena move pd one watch since reveal effect differing mechanism development parkinson alzheimer plenty cns disorder extent difficulty showing definite effect disease progression matched vastness reward gained success difficulty reflected consensus forecast compiled evaluatepharma one project sale number attached prx forecast sell\n",
      "\n",
      "Keywords:\n",
      "parkinson 0.367\n",
      "dnl 0.259\n",
      "synuclein 0.202\n",
      "syn 0.197\n",
      "pasadena 0.185\n",
      "move pd 0.158\n",
      "trial 0.133\n",
      "mutation 0.13\n",
      "parkinson disease 0.12\n",
      "prx 0.118\n",
      "one year 0.111\n",
      "prothena 0.111\n",
      "anavex 0.105\n",
      "ought 0.098\n",
      "disorder 0.098\n",
      "neuron 0.092\n",
      "ii 0.088\n",
      "phase 0.087\n",
      "part 0.085\n",
      "one 0.081\n",
      "data 0.078\n",
      "patient 0.078\n",
      "phase ii 0.076\n",
      "pd 0.076\n",
      "several 0.074\n",
      "\n",
      "Abstract:\n",
      "presentation title upcoming esmo congress made available judging late breaking abstract meeting look another one heavy focus big pharma immunotherapy among late breaker two tumour type stand particular focus front line gastric cancer merck co bristol myers squibb square triple negative breast cancer interest follower roche immunomedics common medical meeting esmo take place virtual format congress start september keen analysing data submitted still wait text late breaking presentation go live two embargo lift pm eastern next thursday friday central european time friday saturday respectively however title least give good idea look gastric oesophageal gastroesophageal junction cancer focus presidential session monday september fewer four late breaking study profiled concerning keytruda opdivo either first line adjuvant setting keytruda anti pd l mab gastric gastroesophageal junction cancer label third line last month bristol said opdivo became first drug show first line survival benefit courtesy checkmate study week later keytruda scored keynote trial feature esmo allow interesting comparison merck bristol chase front line market tnbc meanwhile roche tecentriq star impassion neoadjuvant study toplined positive pd l positive patient comer alike course tecentriq already front line tnbc label pd l expressers basis abraxane combo impassion study esmo post mortem failed impassion trial interest wanting understand abraxane combo worked non encapsulated paclitaxel interesting impassion highlighted late breaker two failed trial keytruda keynote urothelial cancer novartis combi study spartalizumab plus tafinlar mekinist braf positive melanoma similarly feature late breaking presentation presumably esmo continues trying counter excessively positive data reporting biotech biotech investor keenly follow presentation immunomedics ascent trial late line tnbc basis trodelvy approved super quick time late breaker presented saturday afternoon biotech relevant late breaker include seattle genetics tisotumab vedotin scored june late line cervical cancer remission rate investor try gauge whether enough regulatory filing keen tease benefit specifically third line patient agenus apparently beneficiary unexpected late breaker featuring take pd ctla combo balstilimab plus zalifrelimab group come extremely late game combo tested cervical cancer keytruda monotherapy already available prepping esmo discussion healthcare specialist biotech investor brad loncar free listen esmo congress take place virtual format september story presentation beyond late breaker published separately\n",
      "\n",
      "Keywords:\n",
      "late 0.277\n",
      "late breaker 0.221\n",
      "breaker 0.218\n",
      "esmo 0.204\n",
      "impassion 0.19\n",
      "late breaking 0.163\n",
      "line 0.156\n",
      "breaking 0.153\n",
      "presentation 0.138\n",
      "tnbc 0.132\n",
      "keytruda 0.132\n",
      "cancer 0.13\n",
      "gastric 0.125\n",
      "congress 0.117\n",
      "pd 0.103\n",
      "combo 0.101\n",
      "junction 0.1\n",
      "gastroesophageal junction 0.1\n",
      "gastroesophageal 0.1\n",
      "virtual format 0.095\n",
      "take place virtual 0.095\n",
      "place virtual format 0.095\n",
      "place virtual 0.095\n",
      "esmo congress 0.095\n",
      "abraxane 0.091\n",
      "\n",
      "Abstract:\n",
      "took arbutus moderna almost hour comment publicly relevance thursday legal bust saw former prevail patent ruling threaten latter covid vaccine neither company look covered glory entry curevac fray complicates thing still arbutus admitted actually signed away much relevant right two year ago stock lost moderna meanwhile claimed tech fact covered arbutus patent case initiate legal action arbutus begin curevac clear german group revealed hand filing u sec proposed flotation document curevac spelled reliance lipid nanoparticle lnp technology developed acuitas private canadian company link alnylam way tie pay annual maintenance fee acuitas centre dispute moderna arbutus source lnps used biontech pfizer remarkable upshot three major mrna covid vaccine competitor might way rely lnp technology question longstanding aggression moderna say challenged three relevant arbutus patent response longstanding aggressive posture taken arbutus claim lnp technology advanced beyond arbutus patent describe perhaps implying largely engineered mrna approach past two year arbutus statement meanwhile come surprise investor paying close attention sake clarity arbutus might legal decision spell interest patent question u spun right lnp technology relate hepatitis b genevant venture vivek ramaswamy holding company roivant science covid vaccine battle got interesting july back one thinking covid arbutus key focus hepatitis b venture owned roivant arbutus investor get worse genevant subsequently issued convertible debt paid new equity arbutus shareholder significantly diluted arbutus say however entitled low single digit royalty sale product derived patent held genevant\n",
      "\n",
      "Keywords:\n",
      "arbutus 0.681\n",
      "lnp technology 0.22\n",
      "lnp 0.22\n",
      "patent 0.194\n",
      "legal 0.165\n",
      "genevant 0.165\n",
      "arbutus patent 0.165\n",
      "curevac 0.129\n",
      "moderna 0.122\n",
      "acuitas 0.11\n",
      "technology 0.104\n",
      "covid vaccine 0.095\n",
      "roivant 0.094\n",
      "covered 0.09\n",
      "covid 0.084\n",
      "hepatitis 0.081\n",
      "vaccine 0.079\n",
      "venture 0.076\n",
      "two year 0.064\n",
      "mrna 0.063\n",
      "relevant 0.062\n",
      "past two year 0.052\n",
      "diluted 0.052\n",
      "complicates 0.052\n",
      "close attention 0.052\n",
      "\n",
      "Abstract:\n",
      "mirikizumab would launched late late entrant crowded psoriasis market perhaps explains lilly simultaneously pushing ahead phase iii trial anti il mab ulcerative colitis crohn disease clinical programme phenomenally expensive project still somewhat radar evaluatepharma vision r cost model estimate total clinical development mirikizumab cost lilly bn including almost year insignificant investment become third il market psoriasis suggesting gi disorder might lilly see real opportunity still psoriasis market overlooked upcoming data phase iii trial give sense well mirikizumab might competition oasis study expected report spring enrolled nearly patient moderate severe plaque psoriasis pitting mirikizumab novartis cosentyx first phase iii study project indication evaluating active control primary endpoint assessed four month treatment percentage patient two point improvement baseline static physician global assessment pga proportion achieving pasi improvement baseline psoriasis area severity index cosentyx anti il forecast become psoriasis market leader according evaluatepharma sellside consensus abbvie skyrizi really one beat il antibody significantly improved treatment outcome skin disease skyrizi viewed effective pasi course tougher bar hit pasi mirikizumab aiming oasis oasis study completed last year us pasi co primary lilly yet report data trial lilly spokesperson told vantage oasis data released within next couple month another piece puzzle revelation three week ago skyrizi trounced cosentyx head head phase iii trial abbvie mab scored pasi rate four month compared cosentyx one year primary endpoint pasi difference starker skyrizi versus cosentyx skyrizi showed superiority cosentyx trial secondary endpoint including pasi pasi pga clear almost clear current consensus forecast mirikizumab peg sale would make ninth biggest psoriasis seller year lilly blockbuster anti il taltz number seven bigger opportunity developer hope il agent hold big potential autoimmune bowel disorder major clinical programme way first mirikizumab phase iii trial ulcerative colitis lucent yield data towards end year far ahead tremfya whose quasar phase ii iii uc study report late skyrizi however threat phase ii iii study abbvie product due conclude september neck neck lucent followed phase iii yield data skyrizi suggesting similar timeline mirikizumab stelara hit il well il approved condition last october back clinical remission rate unifi trial hope pure il best class proved psoriasis lucent skyrizi trial first big test hypothesis mirikizumab focus remains psoriasis market home six blockbuster already lilly must hoping timing advantage skyrizi challenge ulcerative colitis inconsiderable either evaluatepharma vision r cost model estimate cost individual clinical programme using real world data company disclosed product level spend clinical trial patient number combined create cost per patient benchmark technology therapy type utilising matching algorithm benchmark applied commercially relevant clinical trial estimate cost aggregated product estimate cost development product article updated include comment form lilly\n",
      "\n",
      "Keywords:\n",
      "mirikizumab 0.322\n",
      "skyrizi 0.309\n",
      "pasi 0.275\n",
      "psoriasis 0.269\n",
      "il 0.214\n",
      "cosentyx 0.193\n",
      "psoriasis market 0.161\n",
      "oasis 0.15\n",
      "lilly 0.149\n",
      "cost 0.137\n",
      "lucent 0.121\n",
      "iii 0.099\n",
      "estimate 0.094\n",
      "estimate cost 0.094\n",
      "ulcerative colitis 0.092\n",
      "ulcerative 0.092\n",
      "colitis 0.092\n",
      "anti il 0.086\n",
      "phase iii trial 0.08\n",
      "trial 0.079\n",
      "clinical 0.079\n",
      "phase 0.079\n",
      "phase iii 0.077\n",
      "iii trial 0.077\n",
      "improvement baseline 0.075\n",
      "\n",
      "Abstract:\n",
      "surely measure cancer vaccine abysmal track record mere overall response rate enough spotlight oncology conference step forward ro personalised neoantigen vaccine development roche biontech first human data unveiled year second virtual aacr meeting however despite highlighted pre meeting press conference result phase multi tumour study shown ro plus tecentriq modest activity heavily pretreated dose escalation patient population admitted dr juanita lopez royal marsden nh foundation trust investor come away wanting seen better dr lopez insisted trial least one important aspect saying thing excited managed show majority patient able elicit specific immune response typical immune response fail initiated evidenced immune cell seen within tumour trial tecentriq combo cohort neoantigen specific cell response induced vaccine observed subject ro monotherapy cohort detailed separate aacr presentation cell response observed peripheral blood patient sufficient however dr lopez accepted may sufficient ro monotherapy yielded one complete response evaluable subject combo tecentriq eight partial one complete remission evaluable patient one reason poor efficacy suggested dr lopez subject heavily pretreated median three prior therapy clear many subject might responded tecentriq alone dr lopez would indulge cross trial comparison patient entering combo cohort failed immunotherapy would say percentage nine responder dr lopez detail two remission one partial one complete initial dose escalation first checkpoint experienced pd l high second neither data presented tuesday ro known code rg bnt first project emerge deal roche biontech struck back course biontech floated able bask current bn valuation largely result effort develop mrna vaccine covid two clinical trial ro way phase dose escalation study unveiled aacr phase ii trial called imcode combination merck co keytruda front line melanoma started year ago company plan two randomised study resected lung colorectal tumour conceptually ro anything simple manufactured per patient basis patient tumour analysed sequenced identify neoantigens corresponding mrna generated encapsulated liposome injected aim eliciting immune response promising evidence mechanistic rationale approach shown unless cell response translate clinical remission cancer vaccine future\n",
      "\n",
      "Keywords:\n",
      "lopez 0.353\n",
      "ro 0.33\n",
      "dr lopez 0.295\n",
      "dr 0.207\n",
      "response 0.156\n",
      "one complete 0.151\n",
      "cell response 0.138\n",
      "tecentriq 0.134\n",
      "vaccine 0.132\n",
      "escalation 0.132\n",
      "dose escalation 0.132\n",
      "aacr 0.129\n",
      "immune 0.125\n",
      "immune response 0.122\n",
      "cancer vaccine 0.105\n",
      "tumour 0.101\n",
      "biontech 0.101\n",
      "patient 0.091\n",
      "cell 0.09\n",
      "remission 0.086\n",
      "observed 0.086\n",
      "heavily pretreated 0.086\n",
      "combo 0.083\n",
      "pretreated 0.083\n",
      "evaluable 0.083\n",
      "\n",
      "Abstract:\n",
      "careful wish moderna fired first salvo arbutus two year ago seeking assert position lipid nanoparticle lnp technology event come worse yesterday u court deemed key arbutus patent stand sending tiny biotech stock remarkably moderna issued formal statement ruling presumably wanting give away anything possible implication lnp tech thought underlie mrna work including high profile covid vaccine project mrna moderna evidently want spell ruling concern third three arbutus patent moderna challenged inter partes review moderna prevailed first got mixed verdict second regarding third concerning u patent judge yesterday ruled moderna shown preponderance evidence claim patent unpatentable course appeal last two ruling virtually assured though moderna yet reveal hand stressed final outcome unlikely see moderna prevented marketing lnp based product worst moderna might agree pay arbutus royalty course long lnp tech arbutus claim indeed implicated moderna mrna work clinicaltrials gov entry moderna phase covid vaccine trial state mrna novel lnp encapsulated mrna based vaccine moreover infringement would depend mrna actually getting market based clinical data generated far moderna project lag biontech pfizer mrna rival bnt b novavax keep investor waiting july investor price extra risk yesterday moderna stock lost equivalent bn market cap complicated farrago came complicated markman advisor new york based patent consultancy pointed moderna initially licensed lnps acuitas small canadian firm acquired arbutus acuitas right sublicense became subject separate arbutus litigation settled february effect acuitas limited four specific viral target moderna thus appeared frozen started challenging validity arbutus lnp patent twist acuitas source lnps biontech pfizer use bnt b arrangement appears routed deal biontech genevant venture founded jointly april arbutus vivek ramaswamy holding company roivant science disparity arbutus moderna david versus goliath battle underestimated moderna bn market cap arbutus valuation stand puny even including yesterday surge u corporate law size financial firepower count lot nevertheless mark sudden turnaround arbutus fortune group formerly known tekmira best known hepatitis b failure stake second clinical stage covid vaccine\n",
      "\n",
      "Keywords:\n",
      "arbutus 0.52\n",
      "moderna 0.46\n",
      "lnp 0.294\n",
      "acuitas 0.196\n",
      "mrna 0.195\n",
      "patent 0.173\n",
      "ruling 0.134\n",
      "arbutus patent 0.098\n",
      "vaccine 0.094\n",
      "biontech 0.09\n",
      "covid vaccine 0.084\n",
      "complicated 0.084\n",
      "tech 0.076\n",
      "based 0.076\n",
      "yesterday 0.072\n",
      "bnt 0.07\n",
      "biontech pfizer 0.07\n",
      "bn market cap 0.067\n",
      "bn market 0.064\n",
      "covid 0.056\n",
      "stand 0.054\n",
      "claim 0.051\n",
      "lnp technology 0.049\n",
      "genevant 0.049\n",
      "market cap 0.048\n",
      "\n",
      "Abstract:\n",
      "last night asco abstract dump revealed several result interest company pursuing first line non small cell lung cancer keenly awaited cityscape trial anti tigit mab tiragolumab instance show roche investing heavily project though real world relevance seems marginal roche important thing find way catching merck co keytruda similar consideration bristol myers squibb unveiled checkmate la study meant support approval opdivo plus yervoy chemo merck catching study stage iii nsclc show keytruda astrazeneca imfinzi sight tigit became closely watched immuno oncology target roche began wide ranging clinical programme tiragolumab year asco data supporting scant cityscape phase ii trial robust design tiragolumab plus tecentriq versus tecentriq alone good news roche addition tigit blockade pd l show additive effect term response rate median progression free survival bad strongly driven highest pd l expressers combo number look good tecentriq alone performs particularly badly first point particularly relevant pd l low subject efficacy pd l blockade need boosting yet tigit blockade appears add nothing providing clue cityscape enrolled pd l expressers roche phase iii tigit trial skyscraper enrols subject plus side tigit blockade appears add toxicity tecentriq plus tiragolumab combo look better keytruda already approved first line nsclc use arcus biotech tigit player traded strongly tandem roche tigit plan opened morning bristol case opdivo due double u fda verdict use st line nsclc first tomorrow yervoy combo based controversially overhauled checkmate trial august basis checkmate la study combining opdivo yervoy chemotherapy asco abstract reveals first efficacy data second trial since said succeeded last october improving overall survival indeed triple combo reduced risk death versus chemo alone p interim analysis reveals longer follow show improving picture median o versus month hazard ratio look promising approval like roche tigit hardly challenge keytruda whose chemo combo study keynote yielded reduction risk death versus chemo alone toxicity burden considerable checkmate la patient combo experienced grade toxicity versus control stage iii separate nsclc setting pre metastatic stage iii disease astra imfinzi carving niche thanks approval based pacific trial notwithstanding doubt benefit pd l non expressers threat checkpoint blocker looming asco reveals first data merck keynote trial keytruda regimen yielded remission rate six month o pacific imfinzi showed six month o orr important point keynote keytruda given chemoradiation whereas pacific enrolled subject already given chemoradiation progressed thus potential keytruda establish niche setting imfinzi approved keytruda already first line stage iii nsclc label courtesy keynote trial pd l patient candidate chemoradiation course keynote uncontrolled study cityscape checkmate la analysis comparison across different study possibly recruited differing patient population doubt data scrutinised asco being asco virtual conference take place may\n",
      "\n",
      "Keywords:\n",
      "tigit 0.312\n",
      "keytruda 0.185\n",
      "cityscape 0.174\n",
      "stage iii 0.166\n",
      "pd 0.157\n",
      "checkmate la 0.154\n",
      "asco 0.15\n",
      "tiragolumab 0.149\n",
      "la 0.145\n",
      "chemoradiation 0.14\n",
      "checkmate 0.138\n",
      "keynote 0.137\n",
      "nsclc 0.133\n",
      "combo 0.132\n",
      "tigit blockade 0.131\n",
      "roche 0.12\n",
      "pacific 0.119\n",
      "imfinzi 0.117\n",
      "blockade 0.114\n",
      "chemo 0.107\n",
      "tecentriq 0.106\n",
      "expressers 0.104\n",
      "yervoy 0.088\n",
      "death versus chemo 0.087\n",
      "alone 0.087\n",
      "\n",
      "Abstract:\n",
      "atara got bogged delay lead project tab cel transformation car company cell therapy approach progressive multiple sclerosis took something back seat work continues recent result backed selection dose enough efficacy take forward data presented virtual european academy neurology week late breaking abstract went live friday multiple sclerosis might secondary consideration investor lost faith atara stock run week last week ean abstract drop latest result relate ata allogeneic cell therapy atara pining multiple sclerosis hope group autologous m project ata deprioritised dose finding part ata phase trial yielded data first time high dose million cell month two six subject cohort showed clinical improvement defined expanded disability status scale eds unveiled ean poster reveals better transformational showing improvement suggests patient experiencing slowing disease especially important progressive m still relatively intractable though roche ocrevus making important inroad treatment halting disease transformational reversing disease even better aj joshi atara head clinical development told evaluate vantage across subject four cohort two deterioration eds score rest either improved stable atara told investor call today ata comprises donor cell sensitised epstein barr virus ebv antigen hla typed matched recipient atara argues recognise eliminate ebv infected b cell involvement ebv m put forward dr michael pender university queensland australia first clinical safety data ata released year ago last september ectrims meeting atara presented six month efficacy result first two cohort showing first hint activity ean finding updated showing one eds improvement five million cell cohort none subject given million cell cohort study million cell far two six subject showing eds improvement however six month yet confirmed month reading based modified score composite measure including eds atara decided take cohort dose next randomised placebo controlled stage study mr joshi said trial adaptive design retained possibility adding cohort dose subsequent data suggested benefit ready make switch toxicity signal said mr joshi next stage atara ata trial see initial subject recruited time next year month readout looking various measure addition eds including lumbar puncture data result ata study announced three participant experienced clinical improvement measured decreased eds score mr joshi stressed le robust investigator initiated trial comprised initial six month reading whether autologous therapy like ata future separate question allogeneic clearly way go large space like m said mr joshi updated version story first appeared friday\n",
      "\n",
      "Keywords:\n",
      "atara 0.417\n",
      "ata 0.371\n",
      "eds 0.325\n",
      "joshi 0.232\n",
      "mr joshi 0.185\n",
      "million cell 0.185\n",
      "cell 0.142\n",
      "ean 0.139\n",
      "ebv 0.13\n",
      "cohort 0.127\n",
      "million 0.114\n",
      "improvement 0.105\n",
      "six 0.101\n",
      "multiple sclerosis 0.095\n",
      "mr 0.094\n",
      "sclerosis 0.089\n",
      "showing 0.088\n",
      "cohort dose 0.087\n",
      "two six 0.083\n",
      "dose 0.082\n",
      "six month 0.079\n",
      "six subject 0.077\n",
      "said mr 0.077\n",
      "clinical improvement 0.077\n",
      "score 0.076\n",
      "\n",
      "Abstract:\n",
      "many european investor begin looking beyond advanced project like car therapy cell engaging antibody modality instead focus simple naked antibody tafasitamab anti cd mab engineered fc fragment represents morphosys attempt taking project way market asset hefty expectation behind evaluatepharma sellside consensus seeing sale track filed year lead indication diffuse large b cell lymphoma combination revlimid ongoing study key unlocking full potential study b mind compare morphosys project head head rituxan cohort getting bendamustine backbone november morphosys closed sellside celebrated fact b mind passed interim futility analysis rolling filing meanwhile rolling u bla initiated le important setting morphosys yet announce whether filing completed aim end basis filing l mind mind study former single arm trial testing tafasitamab plus revlimid latter separate test designed solely act l mind synthetic control use synthetic control unusual way getting around fact efficacy term morphosys currently armed single cohort trial regulator view awaited company argues worked hard ensure mind comprises comparable patient cohort simply way present l mind result light favourable tafasitamab possibly important point concern use revlimid combination drug revlimid main use multiple myeloma drug approved mantle cell lymphoma follicular lymphoma combination rituxan year mean standard care bottom line therefore tafasitamab secure initial approval basis l mind use might amount much term sale b mind important optimistic ever morphosys successfully win approval tafasitamab execute robust commercial launch proceed extend tafasitamab label additional indication gushed berenberg analyst recently however simple importantly performing futility analysis data monitoring board recommended enrolment b mind increased subject rarely good sign suggesting benefit marginal rendering trial underpowered original design moreover second change proposed b mind earlier year morphosys implemented additional biomarker based co primary analysis trial specific biomarker agreed regulator low baseline nk cell count peripheral blood interpreted sign tafasitamab struggling show effect comer population morphosys giving two shot goal perhaps resulted b mind lacking power analysis recruitment increased either way investor clear game plan tafasitamab much morphosys bn valuation riding\n",
      "\n",
      "Keywords:\n",
      "mind 0.492\n",
      "morphosys 0.423\n",
      "tafasitamab 0.392\n",
      "revlimid 0.168\n",
      "lymphoma 0.1\n",
      "synthetic 0.098\n",
      "futility analysis 0.094\n",
      "rolling 0.091\n",
      "cell lymphoma 0.091\n",
      "simple 0.088\n",
      "futility 0.088\n",
      "cell 0.084\n",
      "way 0.08\n",
      "rituxan 0.077\n",
      "use 0.076\n",
      "analysis 0.075\n",
      "filing 0.07\n",
      "biomarker 0.069\n",
      "combination 0.067\n",
      "cohort 0.065\n",
      "increased 0.063\n",
      "important 0.061\n",
      "getting 0.058\n",
      "additional 0.058\n",
      "basis 0.056\n",
      "\n",
      "Abstract:\n",
      "domination cancer research disease well appreciated new analysis deal money deployed show extent biopharma preoccupation almost half cash spent drug developer company acquisition licensing deal directed oncology past five year sum around bn total deployed according vantage analysis evaluatepharma data excludes deal targeting several therapy area like celgene real figure likely larger cardiovascular space seen second biggest spend though two substantial deal skew figure johnson johnson bn takeout actelion novartis recent move medicine company almost bn transaction left analysis pure therapy area play course removing increase cancer proportional take analysis constructed transaction clear primary therapy focus front fee paid used rather total deal value give complete look sector spending vantage counted licensing deal though disclosed front value assigned based therapy focus lead project important remember cancer cardiovascular field vast compared area like dermatology sensory organ expected attract larger sum money still working infectious disease example would argue distribution wealth always followed need dip sum spent oncology project surged last year deal making activity drug maker overall dimming since biotech boom previously described vantage licensing deal alike trend partly driven easy access financing lessened need smaller developer sell time however cancer share cash deployed hovered around chart show surging last year driven multi billion takeout array bn loxo bn arqule bn area stand include cardiovascular peak representing deal mentioned previously neurology seen big transaction area includes central nervous system related indication like psychiatry dementia peak driven novartis acquisition avexis similar story emerges looking count deal happening first proportional basis actual number outside ever dominant cancer space interesting see biopharma interest neurology remained constant around deal announced since notable considering exit several big pharma group space miscellaneous group seen emerging chart contains lot rare disease project easily fit traditional therapy area looking actual number deal dip activity across therapy area since evident field seem registered bigger underlying decline identified however infectious disease stand nine deal last year commercial difficulty antibiotic maker encountering perhaps one explanation whether huge investment cancer worth commercially driven commensurate improvement patient life question entirely course ability company charge premium price therapy big pull factor real progress made certain area field like immuno oncology advanced many hoped analysis suggest sector remains fully committed oncology though clear considerably le competitive sector found updated story corrected include several deal missing previous analysis\n",
      "\n",
      "Keywords:\n",
      "deal 0.314\n",
      "area 0.271\n",
      "therapy area 0.191\n",
      "deployed 0.154\n",
      "licensing deal 0.135\n",
      "cancer 0.133\n",
      "driven 0.131\n",
      "analysis 0.13\n",
      "therapy 0.13\n",
      "licensing 0.12\n",
      "sum 0.119\n",
      "transaction 0.116\n",
      "actual number 0.114\n",
      "field 0.113\n",
      "oncology 0.113\n",
      "neurology 0.106\n",
      "bn 0.101\n",
      "infectious disease 0.1\n",
      "dip 0.1\n",
      "cardiovascular 0.097\n",
      "sector 0.095\n",
      "infectious 0.093\n",
      "spent 0.089\n",
      "actual 0.087\n",
      "space 0.082\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Abstract:\n",
      "clinical development tackling covid pandemic moved pace first biopharma project recently entered trial already first clinical data albeit academic centre emerged true result concerning flu antiviral avigan anti hiv combination kaletra antimalarial plaquenil highly equivocal come range caveat represent first hint covid tackled dampen severity disease serve important guide industry already evident existing antiviral might form first line attack people infected covid even activity limited blunting course disease covid treatment plan slowly emerges march first clinical data gilead remdesivir due may keenly awaited interest grown around avigan taisho fujifilm drug available treating flu japan since added china emergency covid treatment programme yesterday chinese authority published first evidence avigan efficacy coronavirus face data positive avigan treated patient clearing virus four day versus day given lopinavir however subject enrolled randomised fashion got additional background therapy none seem severely ill setting front line treatment target intriguingly china claiming serious adverse event seen avigan known carry numerous toxicity indeed development outside japan largely discontinued like avigan remdesivir rna polymerase inhibitor read across gilead trial failure success yesterday first clinical data concerning abbvie anti hiv combo kaletra covid published nejm academic team several chinese centre author clear study failed showing benefit kaletra versus standard care time clinical improvement however evercore isi umer raffat disagreed pointing subject treatment initiated relatively quickly patient given kaletra within day symptom onset mortality versus standard care subset comprised subject set another benchmark remdesivir trial finally professor didier raoult ihu diterran e infection marseille reported data via youtube video covid subject given malaria drug plaquenil claimed six day subject tested positive covid versus separate group untreated patient caveat unpublished result trial without formal control cohort choloroquine non hydroxylated version plaquenil active ingredient separately subject covid prevention study uk university oxford trial initiation study listed past day include massachusetts general covid prevention trial using inhaled nitric oxide idea mooted mallinckrodt week ago private company pulmotect started prevention study using inhaled pul appears tlr agonist january pulmotect claimed seen positive preclinical signal roche moved begin phase iii study actemra covid patient cautioning little evidence backing il inhibition coronavirus sanofi regeneron separately begun trial similarly acting kevzara\n",
      "\n",
      "Keywords:\n",
      "avigan 0.34\n",
      "covid 0.25\n",
      "kaletra 0.238\n",
      "plaquenil 0.17\n",
      "first clinical data 0.139\n",
      "prevention 0.134\n",
      "first clinical 0.13\n",
      "remdesivir 0.123\n",
      "subject 0.117\n",
      "day 0.115\n",
      "prevention study 0.113\n",
      "versus standard care 0.109\n",
      "versus standard 0.109\n",
      "clinical data 0.105\n",
      "first 0.104\n",
      "inhaled 0.102\n",
      "covid treatment 0.102\n",
      "hiv 0.095\n",
      "japan 0.09\n",
      "clinical 0.089\n",
      "trial 0.088\n",
      "flu 0.087\n",
      "centre 0.087\n",
      "versus 0.083\n",
      "separately 0.083\n",
      "\n",
      "Abstract:\n",
      "newron pivotal star study testing sarizotan rett syndrome always high risk bet company lacked human data project starting trial star duly missed primary endpoint newron share tanked today company scrapped whole rett programme blow therapy area approved product candidate gw pharma acadia anavex next line like sarizotan focus treating symptom rather disorder underlying cause rett syndrome almost exclusively affect girl caused mutation x chromosome mecp gene encodes protein involved development central nervous system especially synaptic circuit maturation following apparently normal development first six month life patient experience decline hand use communication many recurrent seizure well variety motor problem including increased muscle tone abnormal movement behind sarizotan development pipeline anavex therapy anavex small molecule activator sigma receptor data six adult patient open label portion phase ii study showed improvement score rett syndrome behaviour questionnaire rsbq clinical global impression improvement cgi scale seven week data placebo controlled part trial patient ought provide compelling evidence expected second half year second phase ii study called avatar conducted australia report year phase ii iii paediatric excellence study due report clinic gw attention rett syndrome understandable company cannabinoid epidiolex already market rare childhood epilepsy condition dravet lennox gastaut filed tuberous sclerosis complex drug able reduce frequency seizure epilepsy condition sale forecast reach bn according consensus evaluatepharma tiny portion expected rett syndrome phase iii rett study arch recruiting patient aged two two dos epidiolex tested versus placebo week improvement rsbq cgi score primary endpoint study primary completion date august next year acadia trofinetide analogue neuropeptide igf company say reduce neuroinflammation support synaptic function phase iii lavender study week placebo controlled trial us rsbq cgi score primary endpoint trial started last november aimed recruit patient aged five march company announced new patient would enrolled due covid pandemic previously enrolled patient continue study although clear large cohort result expected next year disease modifying approach using gene therapy ultimate treatment goal retts still way sarepta therapeutic teamed stridebio end last year stride leading early r four cns target including one rett syndrome ind novartis gene therapy avxs gained avexis acquisition expected\n",
      "\n",
      "Keywords:\n",
      "rett 0.435\n",
      "rett syndrome 0.327\n",
      "syndrome 0.182\n",
      "cgi 0.155\n",
      "anavex 0.155\n",
      "newron 0.109\n",
      "score primary endpoint 0.104\n",
      "score primary 0.104\n",
      "study 0.1\n",
      "patient aged 0.096\n",
      "score 0.096\n",
      "seizure 0.093\n",
      "star 0.091\n",
      "epidiolex 0.091\n",
      "patient 0.09\n",
      "gw 0.089\n",
      "epilepsy 0.087\n",
      "gene 0.083\n",
      "portion 0.08\n",
      "aged 0.08\n",
      "improvement 0.079\n",
      "expected 0.077\n",
      "primary 0.073\n",
      "placebo controlled 0.073\n",
      "phase 0.071\n",
      "\n",
      "Abstract:\n",
      "pricing biopharma rather opaque business covid pandemic public perception count lot perhaps mind astrazeneca today disclosed first time covid vaccine azd might cost dollar per dose revelation made group second quarter medium call morning threatens serious embarrassment two astra coronavirus vaccine rival pfizer suggested price vaccine moderna appears going higher still rumoured per dose per course mrna stressed moderna number official come anonymous source speaking uk financial time deflect attention moderna group whose covid vaccine effort attracted u taxpayer funding addition huge amount raised investor astra pfizer benefited project warp speed partnership u department health human service fda nih barda department defense tune bn nearly bn respectively important distinction pfizer get money vaccine successful funding essentially pre order wrapped agreement buy hundred million dos fda approval astra stressing pandemic unique global problem put duty biopharma strong implication come obligation price responsibly today call astra chief executive pascal soriot repeated group pledge supply adz cost long pandemic persisted pam cheng astra vice president operation fleshed promise stating cost good perspective able manufacture dollar per dose part pfizer recently announced cost bnt b potential covid vaccine joint development biontech covid vaccine move pivotal development july yesterday earnings call albert bourla pfizer chief executive said based volume people order order le price would higher order little bit lower important point group keeping eye margin want bnt b profitable manufacturing key element price equation whether assumes profit breakeven much vaccine cost make moderna pfizer mrna vaccine touted manufacturing advantage vaccine commercially available yet play astra today said fortunate azd traditional adenovirus vaccine made proven platform keeping cost implication price mr soriot appeared take swipe mrna vaccine stored much lower temperature azd vaccine work safe keep degree imagine practical distribute america africa said fierce pr battle biopharma role tackling coronavirus pandemic astra look moved noticeably ahead moderna story amended correct mistake regarding warp speed funding biontech pfizer\n",
      "\n",
      "Keywords:\n",
      "vaccine 0.377\n",
      "astra 0.237\n",
      "order 0.203\n",
      "cost 0.19\n",
      "pfizer 0.19\n",
      "per dose 0.182\n",
      "moderna 0.168\n",
      "covid vaccine 0.139\n",
      "per 0.135\n",
      "azd 0.129\n",
      "soriot 0.122\n",
      "department 0.122\n",
      "price 0.118\n",
      "funding 0.117\n",
      "covid 0.116\n",
      "warp speed 0.107\n",
      "warp 0.107\n",
      "mrna 0.104\n",
      "pandemic 0.104\n",
      "keeping 0.097\n",
      "implication 0.087\n",
      "bnt 0.087\n",
      "mrna vaccine 0.085\n",
      "dollar 0.085\n",
      "biopharma 0.084\n",
      "\n",
      "Abstract:\n",
      "annual asco meeting prove volatile time drug stock despite cancer conference going virtual year still look likely deliver healthy flow market moving news abstract made public yesterday early beneficiary included allogene provided first look data shelf car project immunogen got boost encouraging result lead antibody drug conjugate downside however cytomx arvinas macrogenics fell heavily early trade pullback macrogenics almost inevitable company market cap tripled last week surprisingly detailed update trial would present macrogenics scoop asco bounce may later cut data due conference compared released abstract much remains learned two project feature remain early course toxicity particular key focus even dip morning macrogenics share remain two year high arvinas fell heavily data probably held mgc macrogenics anti b h bispecific prostate cancer arv mechanistically different described protein degrader androgen receptor psa response two patient seems underwhelming abstract detail two serious adverse event including case renal failure appears linked statin use drop morning cytomx look one biggest casualty company presentation three project asco disappointment around lack efficacy data highest profile one might playing part abstract bm ctla probody partnered bristol myers squibb contains toxicity data number project attempting improve known toxicity ctla inhibition show asco including bispecifics xencor alphamab share latter climbed hong kong today two cytomx abstract concern earlier stage wholly owned conjugate response rate appear underwhelming ocular toxicity confirmed signal watch cx company probody technology still largely unvalidated investor must hope full presentation reverse pre asco pessimism biggest pre asco bounce appears go allogene opened higher encouraging data lead car project allo lymphoma enjoying bounce immunogen present data antibody drug conjugate folate receptor alpha fr orr patient high fr expression look encouraging presentation attracting interest include amgen latest data kras project amg colorectal cancer orr look improved slightly presented esmo climbing although limited response tumour beyond colorectal lung cancer provide ammunition believe potential overblown elsewhere new data project recently acquired big pharma pull crowd gilead provide update magrolimab paid bn number point improvement update ash merck co provides first new data mk cost bn via peloton takeover hif inhibitor achieved response rate rare form renal cell carcinoma much headline grabbing data saved conference late breaking abstract text still wrap much still come asco investor plenty chew meantime look late breaker found asco start take shape asco virtual conference take place may\n",
      "\n",
      "Keywords:\n",
      "asco 0.302\n",
      "macrogenics 0.232\n",
      "abstract 0.229\n",
      "cytomx 0.16\n",
      "bounce 0.16\n",
      "data 0.136\n",
      "immunogen 0.117\n",
      "fr 0.117\n",
      "toxicity 0.112\n",
      "probody 0.111\n",
      "asco bounce 0.111\n",
      "allogene 0.111\n",
      "conjugate 0.108\n",
      "conference 0.104\n",
      "encouraging 0.104\n",
      "project 0.102\n",
      "update 0.1\n",
      "presentation 0.097\n",
      "look 0.093\n",
      "new data 0.091\n",
      "car project 0.091\n",
      "underwhelming 0.088\n",
      "cancer 0.087\n",
      "colorectal 0.084\n",
      "response 0.083\n",
      "\n",
      "Abstract:\n",
      "though august might normally classed quiet month sector time around hold valuable u approval decision five project due assessed blockbuster potential forecast bn according evaluatepharma consensus valuable novartis inclisiran pdufa date disclosed guided second half year project small interfering rna designed target pcsk lower ldl cholesterol inclisiran look effective marketed anti pcsk mabs amgen astellas repatha sanofi regeneron praluent mabs however proved disappointing commercially carried huge sale forecast since slashed inclisiran main advantage seems convenience injected twice yearly versus every two week monthly mabs still remains risky commercially key factor novartis price money another expected big money spinner due decision biomarin valrox haemophilia gene therapy ahead rival durability lingering red flag four year data showed treated patient clotting factor continued fade time valrox look approvable room improvement pfizer sangamo offering giroctocogene fitelparvovec produced encouraging albeit early result far prove durable biomarin fight hand three day later august fda discus roche risdiplam spinal muscular atrophy smn splicing modifier filed use infant type disease patient two year old le severe disease known type risdiplam shown encouraging efficacy clean safety profile oral agent threatens biogen spinraza delivered intrathecally sellside agrees risdiplam forecast look set overtake spinraza according evaluatepharma toxicity issue glaxosmithkline belantamab mafodotin anti bcma antibody drug conjugate received positive adcom vote multiple myeloma earlier month despite underwhelming efficacy serious ocular toxicity approved label include black box warning risk mitigation programme implemented whether patient willing accept side effect profile key forecast met another project adverse event implication gilead galapagos filgotinib filed use rheumatoid arthritis jak inhibitor called jyseleca received eu backing last week mg mg dos several question remain fda decision expected second half year black box warning likely thrombosis case abbvie rinvoq approved arthritis last year second worry fda take conservative approach approve lower dose adverse event appear dose dependent lastly potential warning risk testicular toxicity signal picked animal model specific case clinical trial two safety study called manta manta ray conducted expected read early next year stifel think unlikely fda need safety data approving filgotinib ra possibility agency add toxicity wording label study read leading slow early uptake study report fda seems largely track approval decision little sign covid pandemic abating real impact timeline become significant coming month go go pandemic loom fda timeline july table list first time supplementary fda approval due august consensus forecast evaluatepharma\n",
      "\n",
      "Keywords:\n",
      "risdiplam 0.173\n",
      "fda 0.151\n",
      "inclisiran 0.148\n",
      "mabs 0.12\n",
      "spinraza 0.115\n",
      "forecast 0.111\n",
      "toxicity 0.11\n",
      "warning risk 0.109\n",
      "manta 0.109\n",
      "august 0.107\n",
      "decision 0.107\n",
      "warning 0.105\n",
      "valrox 0.098\n",
      "pcsk 0.098\n",
      "second half year 0.092\n",
      "biomarin 0.088\n",
      "approval decision 0.085\n",
      "filgotinib 0.082\n",
      "box warning 0.081\n",
      "black box warning 0.081\n",
      "half year 0.08\n",
      "black box 0.08\n",
      "arthritis 0.079\n",
      "valuable 0.076\n",
      "box 0.076\n",
      "\n",
      "Abstract:\n",
      "sideways shift obesity logical move diabetes company particularly substantial glp agonist franchise proven metabolic impact novo nordisk biggest player led drive push drug weight loss space company ambition extend beyond mechanism coming month several mid stage project slated yield data variously promise suppress appetite increase energy expenditure novo belief combination approach ultimately needed match sort reduction achieved bariatric surgery biggest pending readout pivotal step programme semaglutide company newest glp agonist well form backbone treatment regimen phase ii trial suggest semaglutide produce double level weight loss seen liraglutide novo older glp agonist marketed obesity saxenda saxenda associated weight loss bariatric surgery shown help patient lose body weight three year despite bestowing appears marginal benefit saxenda launched share global obesity market end novo claim product generated revenue last year company aim double obesity sale target much easily hit semaglutide raise game data four late stage study step program expected around middle year novo indicated coronavirus pandemic changed timeline noting recently significant delay expected trial already close finalisation pivotal programme test weekly subcutaneous injection mg semaglutide previously phase ii study mg daily dose semaglutide produced weight loss one year effect show sign plateauing common adverse event dose related gastrointestinal symptom primarily nausea something watch higher dose used step program bernstein analyst written greater weight loss would ideal phase iii study assume novo use priority review voucher get semaglutide market soon possible saxenda patent expires semaglutide life expectation provide big improvement currently available therapy however novo ultimately want able offer result closer seen bariatric surgery despite successful result complex intervention carry risk tends restricted severly obese patient getting weight loss involve adding another mechanism although course prove monotherapy first one company biggest hope involves targeting amylin long acting human amylin analogue phase demonstrated around weight loss eight week phase ii dose ranging study expected report first half year saxenda used active comparator group little luck targeting amylin including amylin pharmaceutical pramlintide whose development obesity discontinued previously novo chief science officer mads krogsgaard thomsen told evaluate vantage novo made improvement help avoid nausea seen pramlintide real potential mechanism revealed trial combine semaglutide regimen generate weight loss least according mr thomsen phase combination study due report second half year semaglutide serve appetite suppressor novo two phase candidate la gdf pyy boosting energy expenditure side coin novo glp glucagon targeting doublet triplet add gip agonist come still early project entirely clear whether novo say much result ongoing trial probably considered material group whole progression larger study might best indication signal seen semaglutide different story course step readout one biggest event novo horizon sellside already high hope product projected become market leader obesity according evaluatepharma\n",
      "\n",
      "Keywords:\n",
      "novo 0.352\n",
      "semaglutide 0.341\n",
      "weight loss 0.295\n",
      "weight 0.266\n",
      "obesity 0.2\n",
      "saxenda 0.199\n",
      "loss 0.188\n",
      "amylin 0.159\n",
      "glp 0.128\n",
      "bariatric surgery 0.126\n",
      "bariatric 0.126\n",
      "step 0.103\n",
      "agonist 0.103\n",
      "glp agonist 0.102\n",
      "surgery 0.098\n",
      "thomsen 0.084\n",
      "targeting amylin 0.084\n",
      "pramlintide 0.084\n",
      "expenditure 0.084\n",
      "phase 0.077\n",
      "program 0.076\n",
      "energy 0.076\n",
      "biggest 0.071\n",
      "nausea 0.065\n",
      "appetite 0.064\n",
      "\n",
      "Abstract:\n",
      "urogen first u approval week treatment rare form urothelial cancer executive forgiven feeling pang regret timing small developer face making debut incredibly tough market largely locked coronavirus pandemic urogen preparing virtual launch insists still carried successfully jelmyto arrive june company certainly alone braving uncertain territory evaluate vantage identified product launched past couple month sellside belief hold significant revenue potential sale risk none escape disruption though pandemic hurt launch others jelmyto example treat low grade upper tract urothelial cancer orphan disease afflicts patient year targeted marketing campaign specialist urogen doubt already sight probably still impact treatment cancer life threatening illness continuing throughout pandemic another advantage sort company focus however cancellation medical conference big blow hoping roll medicine captive physician audience treating rare disease certainly shield bluebird bio released beta thalassemia gene therapy germany january said earlier month expected first patient dosed later year warned pandemic would hinder ability launch european market feeling pain launch targeting primary care market thought particularly vulnerable global shutdown aside widespread disruption healthcare system sale team physically unable reach front line physician category biohaven look particularly exposed company launched migraine treatment nurtec odt march presumably marketing team grounded esperion cholesterol lowering drug nexletol arrived u pharmacy shelf end last month company resorted setting telephone line email address asking physician get touch question aimmune peanut allergy treatment another march debut hindrance uptake palforzia need administered office allergist like biohaven esperion aimmune due report first quarter earnings may point lockdown ramification launch revealed investor braced disappointing number hope result reflect delay rather permanent commercial setback big drug developer affected bristol myers squibb receiving approval new multiple sclerosis treatment zeposia march said would hold launch bristol motivation presumably give product entering highly competitive market best start possible smaller company however typically invested heavily ahead launch le willing able simply hit pause button closer eye cash flow difficult time note projected sale according evaluatepharma consensus urogen jelmyto fall outside threshold selected cut analysis depth look covid pandemic impacting biopharma medtech sector check free report\n",
      "\n",
      "Keywords:\n",
      "launch 0.275\n",
      "urogen 0.273\n",
      "pandemic 0.153\n",
      "debut 0.136\n",
      "physician 0.135\n",
      "feeling 0.131\n",
      "esperion 0.131\n",
      "aimmune 0.119\n",
      "disruption 0.117\n",
      "treatment 0.116\n",
      "urothelial cancer 0.112\n",
      "urothelial 0.112\n",
      "biohaven 0.112\n",
      "team 0.108\n",
      "marketing 0.106\n",
      "march 0.097\n",
      "launched 0.093\n",
      "cancer 0.08\n",
      "market 0.076\n",
      "hold 0.076\n",
      "sale 0.075\n",
      "company 0.075\n",
      "presumably 0.073\n",
      "certainly 0.073\n",
      "rare 0.073\n"
     ]
    }
   ],
   "source": [
    "#Get TF-IDF (term frequency/inverse document frequency) -- \n",
    "# TF-IDF lists word frequency scores that highlight words that \n",
    "# are more important to the context rather than those that \n",
    "# appear frequently across documents\n",
    "topstories = nomedtech.nlargest(40,'Pageviews')\n",
    "topstories = topstories.reset_index()\n",
    "topstories['dist'] = 397-topstories['index']\n",
    "keyword=[]\n",
    "keyvalue=[]\n",
    "\n",
    "from sklearn.feature_extraction.text import TfidfTransformer \n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "tfidf_transformer=TfidfTransformer(smooth_idf=True,use_idf=True)\n",
    "tfidf_transformer.fit(X)\n",
    "    # Get feature names\n",
    "feature_names=cv.get_feature_names()\n",
    " \n",
    "# Fetch document for which keywords needs to be extracted\n",
    "\n",
    "\n",
    "for x in topstories['dist']:\n",
    "    doc=corpus[ds_count-x]\n",
    "     \n",
    "    # Generate tf-idf for the given document\n",
    "    tf_idf_vector=tfidf_transformer.transform(cv.transform([doc]))\n",
    "    \n",
    "    \n",
    "    # Sort tf_idf in descending order\n",
    "    from scipy.sparse import coo_matrix\n",
    "    def sort_coo(coo_matrix):\n",
    "        tuples = zip(coo_matrix.col, coo_matrix.data)\n",
    "        return sorted(tuples, key=lambda x: (x[1], x[0]), reverse=True)\n",
    "     \n",
    "    def extract_topn_from_vector(feature_names, sorted_items, topn=25):\n",
    "        \n",
    "        # Use only topn items from vector\n",
    "        sorted_items = sorted_items[:topn]\n",
    "        score_vals = []\n",
    "        feature_vals = []\n",
    "        \n",
    "        # Word index and corresponding tf-idf score\n",
    "        for idx, score in sorted_items:\n",
    "            \n",
    "            # Keep track of feature name and its corresponding score\n",
    "            score_vals.append(round(score, 3))\n",
    "            feature_vals.append(feature_names[idx])\n",
    "     \n",
    "        # Create tuples of feature,score\n",
    "        # Results = zip(feature_vals,score_vals)\n",
    "        results= {}\n",
    "        for idx in range(len(feature_vals)):\n",
    "            results[feature_vals[idx]]=score_vals[idx]\n",
    "        return results\n",
    "    \n",
    "    # Sort the tf-idf vectors by descending order of scores\n",
    "    sorted_items=sort_coo(tf_idf_vector.tocoo())\n",
    "    \n",
    "    # Extract only the top n; n here is 25\n",
    "    keywords=extract_topn_from_vector(feature_names,sorted_items,25)\n",
    "     \n",
    "    # Print the results, save as CSV\n",
    "    print(\"\\nAbstract:\")\n",
    "    print(doc)\n",
    "    print(\"\\nKeywords:\")\n",
    "    for k in keywords:\n",
    "        print(k,keywords[k])\n",
    "        keyword.append(k)\n",
    "        keyvalue.append(keywords[k])\n",
    "        \n",
    "\n",
    "##count repeated keywords      \n",
    "from collections import Counter  \n",
    "kwcount = Counter(keyword)\n",
    "kwcounts=pd.DataFrame.from_dict(kwcount, orient='index').reset_index()\n",
    "kwcounts.columns = ['word','count']\n",
    "kwcounts = kwcounts.sort_values(by=['count'])\n",
    "kwcount20=kwcounts.tail(20)\n",
    "bgcount = kwcounts[kwcounts['word'].str.contains(r' ', na=True)]\n",
    "\n",
    "sns.set(rc={'figure.figsize':(13,8)})\n",
    "j=sns.barplot(x=\"word\", y=\"count\", data=kwcount20, palette=\"Blues_d\")\n",
    "j.set_xticklabels(j.get_xticklabels(), rotation=75)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Abstract:\n",
      "aptinyx share price doubled pre market trading reported phase ii data nmda receptor modulator nyx patient post traumatic stress disorder closer examination data included press release however reveals readout clear investor might hope component primary endpoint reached significance even dos stage trial aptinyx determined head pivotal trial group contention data validate nmda receptor modulation platform look little optimistic aptinyx needed pretty unequivocal hit phase ii study wanted restore confidence novel approach hitting nmda target knocked badly failure similarly acting nyx diabetic peripheral neuropathy start last year appear obtained one phase ii ptsd study sequential parallel comparison design method developed reduce high placebo response often seen cns drug study conducted two placebo controlled stage respond placebo first stage removed final analysis given placebo stage one respond randomised drug placebo data patient considered analysis stage two aptinyx trial result two stage separately pooled together presented primary endpoint improvement clinician administered ptsd scale dsm cap total score well various subscores statistical power seemingly split several cut data total cap measure neither stage one stage two patient met significance versus placebo either nyx dos tested mg daily neither pooled population subscore concerning negative cognition mood squeaked significance versus placebo p mg dose stage one patient analysed stage two patient might expected respond better phase one better drug placebo pooled data missed significance subscore better finding came cap arousal reactivity score evaluates symptom including hypervigilance aggression reckless self destructive behaviour pooled data stage one two met significance dos stage one mg dose hit significance stage two mg dose\n",
      "\n",
      "Keywords:\n",
      "stage one 0.322\n",
      "stage 0.297\n",
      "stage two 0.258\n",
      "aptinyx 0.241\n",
      "significance 0.206\n",
      "pooled 0.196\n",
      "nyx 0.193\n",
      "placebo 0.185\n",
      "nmda 0.165\n",
      "respond 0.128\n",
      "mg dose 0.126\n",
      "pooled data 0.121\n",
      "nmda receptor 0.121\n",
      "drug placebo 0.121\n",
      "mg 0.118\n",
      "two patient 0.106\n",
      "significance versus placebo 0.103\n",
      "significance versus 0.103\n",
      "one 0.103\n",
      "two 0.098\n",
      "\n",
      "Abstract:\n",
      "vertex bn market capitalisation big correction last week showed investor optimism outstrip even usually bullish expectation sellside biopharma sector riding high hard find example frothy valuation even share price collapse last week vertex still look keenly valued market according evaluate vantage analysis jittery biotech investor might reassured know big biotech peer look expensive exception beigene among mid sized biotech different story alnylam acceleron looking particularly vulnerable setback look valuation disconnect investor equity analyst evaluate vantage compared market cap biotech net present value asset computed evaluate omnium sellside forecast separate analysis carried big group defined company worth bn coming player valuation bn biopharma company whose current valuation inflated involvement development covid vaccine therapy excluded generic speciality player chart show vertex clear outlier big biotech cohort market cap double total npv marketed r asset clinical setback lay bare vertex weakness october beigene far behind chinese group seen market cap double since time last year inked big deal amgen although beigene developing covid antibody candidate company core focus remains cancer hope focused btk inhibitor brukinsa anti pd mab tislelizumab course market cap reflect much future value revenue stream particularly come larger established company manufacturing capability proven r competence given vertex track record dominating cystic fibrosis perhaps argued deserved premium valuation according chart investor far le optimistic big biotech amgen example faced call buy new growth setback heart failure project omecamtiv mecarbil earlier month gilead sentiment doldrums look like mirror image vertex former stock sitting five year low following fda rejection filgotinib fear might overpaid immunomedics worth noting sellside forecast tend optimistic side particularly relevant smaller drug developer whose valuation rest solely potential pipeline chart show market cap many coming biotech exceeded npvs asset many coming player big gap npv market cap developmental stage group much hyped space mirati ridden high hope kras inhibition next big thing cancer case point big takeover premium already look priced arrowhead subject high investor expectation time hinging group rnai platform big test coming shortly full phase ii data aro aat due aasld meeting november always high risk high reward bet made biotech certain investor always willing chase market become huge matter hyped crispr therapeutic good example group bn market cap incredible company asset early stage trial crispr ca gene editing turn clinical utility possibility endless course huge valuation disconnect exist marketed product although arguably deserved leading position rnai alnylam earned premium launch onpattro givlaari belt meanwhile acceleron reblozyl licensed bristol myers squibb via celgene decent launch group recently scored mid stage win january wholly owned pulmonary arterial hypertension asset sotatercept neurocrine ingrezza horizon tepezza overseen successful solo launch although company need keep momentum given biotech enjoying bull run surprising many valuation look high vertex collapse last week suggests market remains sensitive disappointment perhaps warning investor company disconnect wide\n",
      "\n",
      "Keywords:\n",
      "vertex 0.275\n",
      "valuation 0.184\n",
      "biotech 0.178\n",
      "market cap 0.171\n",
      "cap 0.161\n",
      "big 0.159\n",
      "market 0.147\n",
      "disconnect 0.144\n",
      "big biotech 0.123\n",
      "beigene 0.118\n",
      "high 0.104\n",
      "chart 0.101\n",
      "valuation disconnect 0.101\n",
      "market cap double 0.101\n",
      "cap double 0.101\n",
      "investor 0.098\n",
      "collapse 0.096\n",
      "acceleron 0.096\n",
      "premium 0.095\n",
      "coming 0.093\n",
      "\n",
      "Abstract:\n",
      "huge sum money flowing drug development resulting surge valuation meant one thing industry buyer soaring price tag average takeout premium biopharma deal year sitting record tipped triple figure evaluate vantage analysis find uncertainty wrought global pandemic seemingly failed transfer power back acquirer desirable asset look set remain strong position largely cash easy raise public private investor alike leaving seller little incentive negotiate anything gold plated term meanwhile many large drug developer need pipeline infusion perfect storm mean fiercely competitive area ever higher premium paid chart calculates target average share price day deal announced includes deal worth excludes mega merger concern acquisition pure play drug developer sanofi move principia leaked exactly day transaction officially announced causing principia stock jump year average premium would triple figure boosting year average takeover nestle alexion aimmune portola respectively deal rank among five richest across year analysis biggest premium paid period actually tobira allergan bought bn day premium however excluded outlier tobira suffered big clinical setback allergan swooped actually bought historically depressed price despite high premium applies vitae aimmune portola buyout triggered substantial erosion value synthorx spark takeover presumably competitive process worth pointing gilead bn move immunomedics year struck premium extremely rare see premium move triple figure transaction size another example big deal struck huge premium alexion bn takeout synageva premium however acquisition since much derided synageva lead drug kanuma fell well short alexion blockbuster hope gilead hope big splurge turn better use cash final analysis interesting show despite climbing premium average size biopharma deal gone direction median basis actually got smaller cut data performed cohort transaction yet course takeout immunomedics myokardia show buyer prepared pay big buck big premium seems likely many desirable asset simply expensive consider right long run benefit one whether buying selling\n",
      "\n",
      "Keywords:\n",
      "premium 0.493\n",
      "triple figure 0.21\n",
      "average 0.191\n",
      "alexion 0.164\n",
      "deal 0.147\n",
      "desirable 0.131\n",
      "transaction 0.127\n",
      "year average 0.125\n",
      "portola 0.125\n",
      "biopharma deal 0.125\n",
      "triple 0.12\n",
      "takeout 0.117\n",
      "principia 0.116\n",
      "figure 0.109\n",
      "actually 0.109\n",
      "aimmune 0.109\n",
      "big 0.104\n",
      "immunomedics 0.097\n",
      "allergan 0.093\n",
      "move 0.089\n",
      "\n",
      "Abstract:\n",
      "even though galapagos glpg radar asset barely featured sellside model failure knee osteoarthritis yesterday laid company low galapagos stock came morning likely reflecting broad loss sentiment setback phase ii rocella study glpg failed beat placebo either primary secondary week endpoint erode trust galapagos pipeline last year got bn windfall gilead since filgotinib received u complete response letter delay approval rheumatoid arthritis even approved delay hand abbvie earlier pulled deal filgotinib valuable extra time build market share competitor rinvoq though another galapagos asset gilead right ziritaxestat scored early clinical win scleroderma last year gilead yet see direct benefit bn bet adamts glpg inhibitor adamts zinc metalloendopeptidase implicated osteoarthritis via degradation aggrecan structural cartilage proteoglycan industry pipeline reveals similarly acting asset however mechanism used merck kgaa day ago licensed novartis front galapagos gilead collaboration big hope rest mysterious toledo programme nothing known novel inflammatory target project act though patent filing suggest might sik kinase apparently multiple asset taken forward disclosed progress made thus last year galapagos started phase trial glpg first toledo compound data revealed asset quietly discontinued according galapagos latest investor update subsequently glpg compound acting two toledo family member taken phase ii first data expected end meanwhile several proof concept study launched gilead option ex european right completion phase ii analyst expect galapagos reveal toledo project october investor gilead pay close attention\n",
      "\n",
      "Keywords:\n",
      "galapagos 0.422\n",
      "glpg 0.379\n",
      "toledo 0.324\n",
      "gilead 0.208\n",
      "asset 0.135\n",
      "compound 0.112\n",
      "filgotinib 0.108\n",
      "acting 0.1\n",
      "last year 0.088\n",
      "delay 0.082\n",
      "taken 0.081\n",
      "phase 0.079\n",
      "phase ii 0.078\n",
      "ii 0.077\n",
      "zinc 0.076\n",
      "taken phase 0.072\n",
      "structural 0.072\n",
      "received complete response 0.072\n",
      "received complete 0.072\n",
      "knee 0.072\n",
      "\n",
      "Abstract:\n",
      "society immunotherapy cancer added extra frisson annual meeting inadvertently revealing full abstract website yesterday four week embargo supposed lifted mistake soon rectified investor took screenshots acted information resulting replimune surging iovance another early riser common replimune put data public domain sitc mistake noticed others uncertainty continue market aware presentation title investor quick mark argue situation untenable replimune iovance full disclosure seems fairest course action hand company abstract contain positive data interest get zero response case incyte instance sitc abstract brief moment available revealed zero response patient given oral small molecule pd l inhibitor incb despite cell activation sign pd pd l interaction blockade incyte fell replimune surge triggered three response six subject given oncolytic virus project rp monotherapy oncolytic virus cumbersome poor track record largely limited niche use melanoma remaining utility combination explains excitement around replimune still rp ordinary oncolytic virus additionally express anti ctla molecule separate replimune virus rp subject another sitc presentation time combination opdivo iovance closed yesterday sitc abstract revealed remission rate til project ln combination keytruda head neck cancer might validate tils another tumour type fact patient checkpoint inhibitor naive lack keytruda control limit relevance like iovance xencor published entire text sitc abstract u regulatory filing sitc snafu concerned pd ctla bispecific xmab included orr expansion dose subject prior checkpoint inhibitor exposure however two treatment related death among patient dosed among multitude early clinical result investor note large number bispecifics might interest oddity pharma microbiome regulator mrx ict antibody activating gamma delta cell development private french company imcheck however chaotic situation investor already know data presentation others look set continue formal abstract unveiling november unless course sitc decides damage already done warrant full disclosure\n",
      "\n",
      "Keywords:\n",
      "replimune 0.354\n",
      "sitc 0.345\n",
      "abstract 0.232\n",
      "iovance 0.208\n",
      "sitc abstract 0.189\n",
      "oncolytic virus 0.189\n",
      "oncolytic 0.177\n",
      "rp 0.169\n",
      "virus 0.147\n",
      "pd 0.122\n",
      "zero response 0.118\n",
      "full disclosure 0.118\n",
      "mistake 0.108\n",
      "incyte 0.101\n",
      "presentation 0.098\n",
      "zero 0.092\n",
      "disclosure 0.09\n",
      "checkpoint inhibitor 0.09\n",
      "ctla 0.08\n",
      "situation 0.078\n",
      "\n",
      "Abstract:\n",
      "vertex bn loss market cap morning failure mid stage rare disease asset look face little dramatic project vx alpha antitrypsin deficiency aatd hardly expected big seller market reaction asset discontinuation much sentiment seems investor finally beginning wake fact vertex little beyond marketed cystic fibrosis drug save admittedly interesting highly risky pipeline project vertex valuation today sat bn look bloated company enjoyed substantial premium helped reputation cystic fibrosis powerhouse net present value company asset according evaluate omnium bn bn accounted cf franchise like many big biotech vertex need expand beyond core franchise might need small early stage deal historically stuck indeed pipeline project attracted sale forecast discontinued vx ctx ex vivo gene editing asset developed crispr therapeutic sickle cell disease beta thalassaemia huge disconnect vertex enjoyed halo effect dominance cystic fibrosis argued even though handful clinical programme understanding biology meant high probability success always seemed flimsy basis massive premium leerink analyst noted investor likely question whether heralded vertex research capability really validated beyond cystic fibrosis light vx failure company facing call buy something fast despite impressive cash reserve big deal never group style true acquisition aurora set vertex path becoming dominant force cf today notable purchase since semma therapeutic developer stem cell therapy type diabetes vertex spends nearly bn semma unproven diabetes cell tech september project remains preclinical according vertex website vertex largely preferred strike research collaboration intriguing crispr therapeutic company investigating gene editing various disorder ctx first emerge however crispr semma look like risky bet well outside vertex core expertise small molecule still small molecule help vx vertex said yesterday elevated liver enzyme seen several subject patient phase ii trial along poor drug exposure suggests company unable find therapeutic window project vertex discontinued vx still another structurally distinct small molecule development aatd vx phase ii data due first half next year analyst already written chance management clarified dose level tested second aatd programme activity liver tox compare vx leerink wrote saying whole programme would fade obscurity pressure vertex desperation never make good buyer particularly valuation currently high side wonder investor heading door picking right acquisition target huge challenge vertex little track record point\n",
      "\n",
      "Keywords:\n",
      "vertex 0.56\n",
      "vx 0.335\n",
      "cystic fibrosis 0.16\n",
      "cystic 0.16\n",
      "semma 0.154\n",
      "aatd 0.154\n",
      "fibrosis 0.125\n",
      "crispr 0.12\n",
      "small molecule 0.1\n",
      "crispr therapeutic 0.091\n",
      "cf 0.091\n",
      "gene editing 0.088\n",
      "ctx 0.088\n",
      "molecule 0.084\n",
      "therapeutic 0.082\n",
      "pipeline project 0.08\n",
      "enjoyed 0.08\n",
      "core 0.08\n",
      "editing 0.078\n",
      "beyond 0.077\n",
      "\n",
      "Abstract:\n",
      "vertex might dominant force cystic fibrosis still small subset patient company drug effective company developing inhaled rna targeting project including ionis arrowhead translate bio hoping reach patient vertex cannot potentially promising phase data ionis ionis enac rx reported yesterday suggest project one watch though full result due later month needed gauge asset chance properly meanwhile phase ii trial arrowhead translate candidate set read next year cf caused mutation cftr gene turn lead defective missing cftr protein vital chloride transport result poor flow salt water cell organ including lung build thick sticky mucus vertex made stride cftr modulators even advanced drug triplet trikafta treat population hope new therapy effective remaining cf patient called nonsense mutation essentially lead functional cftr protein produced project including developed arrowhead ionis act synergistically cftr modulators asset designed reduce activity epithelial sodium channel enac lung ctfr dysfunction cause increased enac activity thought contribute airway dehydration ionis using antisense oligonucleotide arrowhead employing rna interference notably vertex already tried inhibit enac small molecule licensed parion science lead project vx fell short clinical trial vertex returned right smaller group beginning year according arrowhead development inhaled small molecule enac inhibitor limited target renal toxicity short duration action lung august company started phase ii study candidate aro enac healthy volunteer cf patient primary endpoint safety trial evaluate various exploratory efficacy endpoint cf patient including change lung clearance index forced expiratory volume ionis advance ionis slightly ahead reported phase data yesterday ionis enac rx however much go company said healthy volunteer given mg mean reduction enac mrna expression statistically significant p company noted mouse model enac mrna reduction led improvement cf lung disease data human matter investor watching full presentation result due north american cystic fibrosis conference taking place virtually october stifel analyst raised several key question including whether toxicity issue arose whether reduction enac expression measured via bronchial cell brushing representative happening across lung project utility lung disease like copd indeed ionis already planning phase ii trial translating mrna translate bio meanwhile hope lead project mrt used cf patient regardless mutation taking different approach asset designed deliver mrna encoding fully functional ctfr protein lung group reported interim result single ascending dose portion phase ii trial cf patient last year data multiple ascending dose portion due trial stopped earlier year owing covid pandemic enrolment dosing resumed last month translate yet provided updated timeline data translate lead mrna player cf couple project preclinical development notably vertex moderna extended research collaboration cf september given vertex success larger cf market might soon count company completely\n",
      "\n",
      "Keywords:\n",
      "enac 0.427\n",
      "cf 0.38\n",
      "ionis 0.286\n",
      "vertex 0.218\n",
      "cftr 0.213\n",
      "cf patient 0.213\n",
      "lung 0.172\n",
      "translate 0.153\n",
      "arrowhead 0.153\n",
      "mrna 0.113\n",
      "lead 0.08\n",
      "including 0.077\n",
      "project including 0.076\n",
      "modulators 0.076\n",
      "translate bio 0.073\n",
      "ascending dose 0.073\n",
      "ascending 0.07\n",
      "mutation 0.07\n",
      "project 0.069\n",
      "inhaled 0.068\n",
      "\n",
      "Abstract:\n",
      "yesterday revelation yet another covid clinical trial halt time lilly antibody ly trigger speculation caused problem molecule presented relatively clean profile revealed however likeliest explanation patient heterogeneity trial question well fact study concerned different population still worth noting advanced player taken differing approach developing antibody covid much remains undisclosed precise construct development preclinical paper shed light one obvious difference antibody contain modification tail called fc region others natural antibody fc region bind desired antigen rather interacts receptor activate immune system recruit cell release cytotoxic molecule engineered mabs modified fc region increase decrease half life modulate immune response ly lilly mab whose activ study halted full antibody unmodified fc region one line speculation therefore whether influence immune system might contributed deleterious effect however far early sort conjecture known u niaid sponsored study halted recommendation safety monitoring board enrolling planned subject imbalance clinical status seen ly placebo recipient nothing known nature importantly however activ recruit patient hospitalised acute medical care study yield data including ly blaze trial test regeneron regn cov combo concerned mild covid lilly speculates patient severest symptom might benefit antibody note antiviral might play ly separately studied combination another lilly mab ly interestingly latter fc null meaning elicits fc mediated effect exerting activity solely competitively blocking receptor binding domain covid meanwhile regn cov comprises two mabs fully functioning fc region safety profile raised concern albeit non hospitalised patient indeed preclinical study compared full version mabs antigen binding fragment former exhibited better activity latter led author state bivalent binding meaning desired antigen via fc region cause cross linking might augment efficacy another combo another approach interested antibody design note separate combo astrazeneca azd last week entered phase iii made two mabs modified fc region increase half life reduce fc binding doubt speculation approach best safest continue seems apparent matter much pressure developer bring coronavirus pandemic control fast system exists ensure safety corner cut tripped two covid vaccine antibody necessarily bad news\n",
      "\n",
      "Keywords:\n",
      "fc 0.439\n",
      "fc region 0.394\n",
      "region 0.277\n",
      "ly 0.271\n",
      "antibody 0.166\n",
      "binding 0.149\n",
      "mabs 0.147\n",
      "speculation 0.132\n",
      "antigen 0.108\n",
      "lilly 0.104\n",
      "covid 0.1\n",
      "desired 0.1\n",
      "regn cov 0.096\n",
      "system 0.095\n",
      "half life 0.093\n",
      "modified 0.09\n",
      "hospitalised 0.09\n",
      "immune 0.09\n",
      "recruit 0.086\n",
      "regn 0.084\n",
      "\n",
      "Abstract:\n",
      "covid vaccine candidate developed astrazeneca johnson johnson couple thing common linked safety scare use adenoviral vector far little known adverse event caused j j pause covid vaccine trial including phase iii ensemble study turn similar neurological issue caused astra u trial put hold would big problem adenovirus approach fortunately handful covid vaccine candidate development use adenoviral vector apart j j ad cov astra azd cansino biologics ad ncov reithera grad cov entered clinical trial analysis evaluate vantage reveals addition oral adenovirus based vaccine vaxart went phase today sputnik v vaccine approved russia although phase ii data available based two adenoviral vector type type many unknown take time ascertain whether issue ad cov indeed adenoviral vaccine broadly j j found event sunday evening mathai mammen head r j j janssen unit said company third quarter earnings call today company informed study data safety monitoring board immediately quickly posted statement website monday explained stressed study remains blinded j j know whether event occurred vaccine placebo arm asked event neurological nod suspected case transverse myelitis caused astra trial halt mr mammen answered company know little point added j j committed transparency intends provide update detail emerge would take day minimum information evaluated mr mammen declined answer question many patient dosed ensemble far cannot many study began late september maintained j j plan complete enrolment two three month remains track warning sign however sign far adenoviral vaccine augur well neurological event led halt study j j ebola vaccine us adenovirus vector covid vaccine candidate still programme resumed ebola vaccine approved eu july j j keen stress difference clinical trial halt pause statement former requirement fda latter still investor public large doubt watching see pause becomes something serious notably astra restarted study azd uk brazil africa u study still hold approach face latest news look like positive advanced covid vaccine developer pfizer biontech moderna put ahead closest rival project mrna vaccine might play way public confidence vaccine already shaky another adverse event even different platform add overall vaccine hesitancy people might particularly reluctant receive vaccine using novel technology mrna receive emergency use authorisation long term follow large number patient concern potential toxicity new platform unlikely assuaged winner might end company testing traditional approach like recombinant protein vaccine advanced novavax nvx cov began patient phase iii uk trial september meanwhile sanofi glaxosmithkline candidate phase ii company expect data december positive push phase iii later month hope able submit vaccine approval first half story updated include detail vaxart oral adenovirus vaccine\n",
      "\n",
      "Keywords:\n",
      "vaccine 0.469\n",
      "adenoviral 0.258\n",
      "adenovirus 0.161\n",
      "vector 0.155\n",
      "adenoviral vector 0.155\n",
      "covid vaccine 0.148\n",
      "cov 0.144\n",
      "neurological 0.129\n",
      "covid vaccine candidate 0.129\n",
      "pause 0.126\n",
      "halt 0.126\n",
      "ad 0.123\n",
      "vaccine candidate 0.121\n",
      "event 0.116\n",
      "astra 0.115\n",
      "candidate 0.102\n",
      "covid 0.098\n",
      "ebola vaccine 0.094\n",
      "ad cov 0.094\n",
      "caused 0.085\n",
      "\n",
      "Abstract:\n",
      "intercept last week added woe sharp eyed investor noticed modified boilerplate language company quarterly filing implied toxicity problem ocaliva revelation missed sellside knocked company already battered stock price last week without information precise toxicity u fda apparently looking since may impossible quantify possible problem safety database advera health analytics shed important light matter meanwhile major biotech boom intercept stand year group big knockback course occurred june fda handed ocaliva complete response letter nash apparently citing concern activity based surrogate histopathologic endpoint might outweigh potential risk dream intercept june deeper problem already risk hepatobiliary event known casting doubt whether ocaliva label would extended narrow approved use primary biliary cholangitis pbc broad indication like nash however latest problem suggested problem deeper still last week q filing intercept slipped fact fda begun evaluate newly identified safety signal regarding liver disease ocaliva potential risk remarkably review begun may mentioned publicly advera get data fda faers adverse event reporting system adjusts number factor add context remove duplication show several active liver toxicity signal already cited ocaliva label include liver failure portal hypertension derived adverse event reporting market use ocaliva pbc term frequency event relevant metric risk odds ratio ror ror score indicates higher expected reporting rate given adverse event widely accepted benchmark regarding level triggering safety signal many industry assume result warrant attention advera say one caveat issue related underlying disease since pbc affect liver higher ror le likely seems would explain away adverse event seen whatever reason intercept mentioning fda review last week fact started may fit chronologically nash adcom postponement investor want know whether new toxicity signal behind june crl whether presage restriction ocaliva approved pbc indication label already black boxed warning bigger opportunity nash risk sellside remains incredibly bullish consensus bn according evaluatepharma even mounting evidence drug going anywhere fast\n",
      "\n",
      "Keywords:\n",
      "ocaliva 0.363\n",
      "pbc 0.243\n",
      "intercept 0.238\n",
      "advera 0.2\n",
      "problem 0.167\n",
      "nash 0.165\n",
      "last week 0.153\n",
      "reporting 0.15\n",
      "event 0.15\n",
      "liver 0.148\n",
      "signal 0.142\n",
      "adverse event 0.132\n",
      "toxicity 0.128\n",
      "adverse 0.128\n",
      "potential risk 0.127\n",
      "fda 0.125\n",
      "risk 0.119\n",
      "toxicity signal 0.118\n",
      "regarding 0.118\n",
      "safety signal 0.114\n",
      "\n",
      "Abstract:\n",
      "tough couple year thing finally looking alkermes group soon get u approval big pipeline hope antipsychotic alks advisory committee meeting held friday anything go making alks commercial success look like trickier prospect sellside forecasting sale according evaluatepharma consensus expectation vary widely leerink pencilling peak sale versus mizuho bullish set analyst admit project tough sell alkermes meanwhile confident alks commercial chance although spokesperson declined give estimate peak sale panel meeting blair jackson company senior vice president corporate planning told evaluate vantage project approved drive lot growth business clear group two year ago saw failure ultimate fda rejection depression project alks need fresh blood sale alkermes marketed addiction drug vivitrol slowed clinical pipeline look thin least alks look odds approval schizophrenia bipolar disorder project combination antipsychotic olanzapine opioid antagonist samidorphan rationale combo would effective olanzapine avoiding weight gain problem older antipsychotic alks qualified success patient receiving drug gain weight much olanzapine weighty issue shrink alkermes disappear november still friday panellist voted samidorphan meaningfully mitigates olanzapine associated weight gain safety question big question around alks safety specifically issue using opioid antagonist psychiatric patient population abuse opioids relatively high fda concerned samidorphan might spur withdrawal patient physically dependent opioids lead overdose patient trying overcome opioid blocking effect risk samidorphan might cancel painkilling effect opioids medically necessary worry look unlikely hold back approval alks panel voted safety profile alks adequately characterised alkermes avoid rem programme panel coming labelling would enough mitigate risk relating samidorphan although panellist argued approval bipolar disorder asking data path largely cleared fda nod however getting market might easy part shifting patient generic antipsychotic branded product tough especially given alks decent stellar weight gain profile quote stifel analyst similar vein mizuho noted patient would likely need try multiple generic product given alks perhaps concern help explain gaining premarket trading alkermes share price soon open morning thin pipeline still group little else pick slack right alkermes pipeline feature il targeting project alks posted intriguing result recent esmo meeting il proven tough nut crack even company succeeded shift focus oncology time soon mr jackson told vantage instead group look partner least alks programme remaining heavily involved asset development said alkermes pipeline asset preclinical hdac inhibitor gained via last year purchase rodin therapeutic alkermes reckons utility neurodegenerative disease well cancer early day project foreseeable future company hope rest making mark alks\n",
      "\n",
      "Keywords:\n",
      "alks 0.567\n",
      "alkermes 0.364\n",
      "samidorphan 0.245\n",
      "olanzapine 0.196\n",
      "antipsychotic 0.184\n",
      "tough 0.138\n",
      "weight gain 0.131\n",
      "weight 0.13\n",
      "opioid 0.126\n",
      "pipeline 0.105\n",
      "gain 0.101\n",
      "panel 0.095\n",
      "voted 0.087\n",
      "panellist 0.087\n",
      "bipolar 0.087\n",
      "thin 0.081\n",
      "mizuho 0.072\n",
      "project 0.068\n",
      "peak sale 0.066\n",
      "soon 0.065\n",
      "\n",
      "Abstract:\n",
      "surprising fact day gilead stock worth le beginning year share third april reflecting hope company covid antiviral veklury fleeting nature gain provides cautionary tale investor continue chase promise pandemic treatment search next weapon virus continues enthusiasm among shareholder drug developer vast majority best performing biopharma stock nine month mark involved covid research big pharma eli lilly lonza regeneron big cap moderna biontech among smaller rank really one storyline biopharma right data confirming veklury far magic bullet arguably help keep investor interested come next rest sector still gilead probably excused disappointment lack recognition seems getting bn revenue veklury drug forecast bring end swift recovery certain famous patient put antibody approach covid firmly spotlight hope therapy make big impact course disease lifted eli lilly regeneron leading developer frontrunners pandemic research need little introduction particularly vaccine player astrazeneca novavax moderna biontech supply deal moderna mrna vaccine boosted lonza major manufacturer biopharmaceutical material somewhat surprisingly inovio remains one successful small cap despite vaccine hope largely evaporating two korean company make grade seen retail investor pile announcing covid research project jump year immunomedics included among small cap riser however thanks gilead bn buyout bid given reach pandemic stock rising reason really stand vertex horizon benefitting strong position rare disease former enjoys monopoly cystic fibrosis latest offering trikafta flying shelf meanwhile horizon experiencing hugely successful launch thyroid eye disease drug tepezza ongoing strong sale gout drug krystexxa among nano cap seres helped put microbiome player map year hit phase iii c difficile project year glacial progress adaptimmune finally got investor interested data asco providing something trigger course never good news biopharma world always biggest fall suffered smallest player pipeline setback took nextcure urogen dbv look unlikely see peanut allergy treatment get market amarin patent woe well known galapagos suffered fda rejection filgotinib another reason gilead fall grace year investor seem unconvinced sumitomo decision last year hand bn roivant solve patent worry share japanese company decline since among larger company bayer continues grapple expensive fallout monsanto acquisition merck novartis considered among exposed pandemic fallout term hit drug sale finally glaxosmithkline particularly poor year despite covid effort shape antibody deal vir several collaboration vaccine adjuvant concern pharma giant might cut dividend weighing heavily stock\n",
      "\n",
      "Keywords:\n",
      "among 0.204\n",
      "veklury 0.197\n",
      "vaccine 0.132\n",
      "covid 0.131\n",
      "lonza 0.131\n",
      "fallout 0.131\n",
      "gilead 0.126\n",
      "cap 0.126\n",
      "moderna biontech 0.122\n",
      "eli lilly 0.122\n",
      "eli 0.122\n",
      "pandemic 0.118\n",
      "research 0.115\n",
      "moderna 0.114\n",
      "small cap 0.112\n",
      "stock 0.101\n",
      "player 0.099\n",
      "investor 0.096\n",
      "suffered 0.096\n",
      "biopharma 0.096\n",
      "\n",
      "Abstract:\n",
      "normally meeting clinical trial primary efficacy endpoint considered win amgen cytokinetics heart failure project omecamtiv mecarbil investor virtually wrote yesterday seeing long awaited result galactic hf trial pivotal study important endpoint term real world relevance cardiovascular death secondary outcome measure missed cytokinetics lost yesterday disappointment laying bare amgen poor pipeline big biotech stock came key secondary endpoint missed galactic hf primary measure composite death heart failure event showed underwhelming result risk reduction versus standard care p seriously underperformed astrazeneca farxiga scored farxiga shown pure mortality benefit tune risk reduction suggests omecamtiv commercial future case amgen need take hard look pipeline apart omecamtiv biosimilars significant developmental asset kras inhibitor sotorasib tezepelumab anti tslp mab respiratory indication monday amgen issued peculiar statement saying sotorasib phase ii effect nsclc consistent previously reported phase data revealing result hinted early regulatory filing perhaps amgen trying distract attention upcoming omecamtiv bombshell case kras bubble fast deflating astrazeneca partnered tezepelumab meanwhile face key binary outcome event result phase iii navigator study severe non eosinophilic asthma due year excluding biosimilars tezepelumab amgen biggest pipeline hope term forecast sale reason caution omecamtiv amgen cytokinetics said full data galactic hf would presented late breaker american heart association meeting november said nothing filing plan commenting result provided insight targeting cardiac muscle contractility omecamtiv asset cardiac myosin activator binding aiming recruit cardiac myosin head interact actin systole long history clinical development many year amgen cytokinetics tie date back january time phase asset changed hand front plus cytokinetics equity subgroup leerink analyst speculated one possibility would look subgroup benefit galactic hf mean getting omecamtiv approved unlikely work unless demonstrated prospectively new study course action seems unlikely pursuing indication heart failure preserved ejection fraction cannot denied study overpowered galactic hf recruited subject yield mediocre result disappointing great news biotech follower point amgen desperate need fill pipeline sign buy project true biotech asset acquisition licensing extremely expensive present amgen ran alternative time ago\n",
      "\n",
      "Keywords:\n",
      "omecamtiv 0.353\n",
      "amgen 0.347\n",
      "galactic hf 0.283\n",
      "galactic 0.283\n",
      "cytokinetics 0.265\n",
      "hf 0.221\n",
      "tezepelumab 0.159\n",
      "heart 0.129\n",
      "heart failure 0.116\n",
      "cardiac 0.112\n",
      "cardiac myosin 0.101\n",
      "pipeline 0.097\n",
      "myosin 0.097\n",
      "sotorasib 0.094\n",
      "biosimilars 0.088\n",
      "result 0.087\n",
      "farxiga 0.083\n",
      "risk reduction 0.081\n",
      "kras 0.078\n",
      "asset 0.076\n",
      "\n",
      "Abstract:\n",
      "checkpoint blockade yet establish perioperative cancer setting bristol myers squibb invested heavily opdivo investor yesterday rewarded group handsomely said first time checkpoint mab beaten chemo neoadjuvant treatment lung cancer despite bristol revealing actual data trial question checkmate stock closed equivalent amazing bn valuation increase evaluatepharma sellside consensus seeing opdivo sale falling year victory adjuvant neoadjuvant setting needed competition far behind setting nsclc important first line use bristol famously lost apparent upper hand merck co keytruda able catch since keytruda go drug unresectable nsclc perioperative use threatens shake thing instance anti pd l drug establish neoadjuvant adjuvant setting eliminate scope subsequent checkpoint blockade analogous bet astrazeneca making postoperative pre metastatic stage iii nsclc imfinzi approved thanks pacific trial checkmate first neoadjuvant nsclc study read first proper control checkmate opdivo given chemo neoadjuvant treatment meaning surgery result term pathological complete response time surgery disease free survival six year compared versus chemo alone yesterday bristol said first co primary endpoint hit without giving number said nothing second clearly take considerably time generate data third cohort testing opdivo plus yervoy scrapped two year ago justify investor enthusiasm evercore isi umer raffat pointed disease free survival endpoint important speculated approval pcr alone possible moreover entirely clear big opportunity nsclc present drug therapy time surgery neoadjuvant chemo mean standard practice several competitor trial perioperative nsclc reading soon imminent one astrazeneca aegean merck keynote pearl roche impower however last two adjuvant study drug given time surgery merck roche neoadjuvant study read later overall neo adjuvant setting remain wild card immunotherapy bristol alike company invested heavily betting turn opdivo around drug sold almost bn last year revenue projected fall bn evaluatepharma sellside consensus suggests investor must hope checkmate result hold scrutiny sign success come\n",
      "\n",
      "Keywords:\n",
      "neoadjuvant 0.366\n",
      "nsclc 0.229\n",
      "surgery 0.195\n",
      "perioperative 0.188\n",
      "adjuvant 0.18\n",
      "opdivo 0.177\n",
      "checkmate 0.159\n",
      "chemo 0.154\n",
      "bristol 0.141\n",
      "setting 0.127\n",
      "said first 0.119\n",
      "checkpoint 0.118\n",
      "disease free survival 0.111\n",
      "disease free 0.111\n",
      "adjuvant setting 0.107\n",
      "establish 0.105\n",
      "checkpoint blockade 0.096\n",
      "study read 0.094\n",
      "invested 0.093\n",
      "time 0.091\n",
      "\n",
      "Abstract:\n",
      "huge pool capital available u long provided pull european drug developer good reason decent biotech company based say london copenhagen decides list locally fortune capped possibly share price performance biotech ipo euronext starkly different company crossed atlantic list according evaluate vantage analysis course exception handful flotation successful european drug developer local market message investor seems pretty clear back new issue continent caution come surprise involved research stage biopharma europe course secret u much welcoming high risk company acceptance translates substantial benefit financial otherwise ultimately u market support much higher valuation disparate exchange spread across europe large base specialist investor concentrated single stock exchange nasdaq considered major advantage u euronext probably closest equivalent europe nasdaq although term ipo volume two barely comparable since euronext hosted flotation research stage drug developer nasdaq europe based company chose list u instead several exchange host biotech ipo europe including nasdaq various nordic market well london stock exchange small company market aim six swiss exchange analysis vantage captured float across exchange europe taking total number biotech ipo period europe chart map share price performance year ipo split exchange region company based float end last month analysis restricted involved specifically drug development medtech digital health excluded example remembered number company group varies widely european company listing nasdaq euronext counted low single digit year nasdaq quietest year still saw ipo thus small number european company major caveat drawing conclusion relative performance obvious poorly euronext listing appear biotech listed exchange european company travelled u float fared better performance across european exchange scrape positive territory year except somewhat surprisingly chicken egg analysis seems support view investing biotech ipo europe much riskier business u structural reason play many european company list small free float share example low liquidity cause problem another possibility considered whether company list europe poorer prospect counter argument restricted access financing lot capping potential european biotech sector equivalent chicken egg question cut data suggests european company list u performance dissimilar domestic firm financial climate young drug developer arguably best year europe company like morphosys genmab argenx show continent produce highly desirable start ups investor partner quality european science question company took decade get today newly listed biotech europe work lot harder prove worth debuting u market little wonder many fleeing nasdaq window remains open\n",
      "\n",
      "Keywords:\n",
      "europe 0.332\n",
      "exchange 0.306\n",
      "european 0.289\n",
      "european company 0.246\n",
      "euronext 0.246\n",
      "nasdaq 0.202\n",
      "ipo 0.186\n",
      "list 0.168\n",
      "biotech ipo 0.154\n",
      "biotech 0.145\n",
      "company 0.144\n",
      "company list 0.138\n",
      "performance 0.135\n",
      "float 0.127\n",
      "drug developer 0.116\n",
      "developer 0.087\n",
      "share price performance 0.084\n",
      "price performance 0.084\n",
      "egg 0.084\n",
      "company based 0.084\n",
      "\n",
      "Abstract:\n",
      "yesterday lilly struck blow covid antibody rival regeneron promising result ly cov plus ly cov doublet based admittedly sparse data far lilly combo look edge regeneron antibody combo however long regeneron back front foot announcing filed u emergency use authorisation regn plus regn regeneron need make head start filing manufacturing plus direct endorsement president trump prevail battle anti covid antibody true lilly announced eua submission yesterday ly cov alone combo set filed eua november based data two different cohort blaze study combo look lot efficacious term reducing viral load\n",
      "\n",
      "Keywords:\n",
      "ly cov 0.306\n",
      "ly 0.287\n",
      "regeneron 0.261\n",
      "cov 0.233\n",
      "combo 0.225\n",
      "combo look 0.224\n",
      "eua 0.197\n",
      "covid antibody 0.191\n",
      "regn 0.178\n",
      "lilly 0.166\n",
      "plus 0.15\n",
      "antibody 0.132\n",
      "filed 0.117\n",
      "regn regeneron 0.106\n",
      "promising result 0.106\n",
      "need make 0.106\n",
      "look lot 0.106\n",
      "blaze 0.106\n",
      "back front 0.106\n",
      "anti covid antibody 0.106\n",
      "\n",
      "Abstract:\n",
      "spiralling cost asset seems put many would biopharma buyer big acquisition gilead whose bn purchase immunomedics prevented third quarter complete disaster deal banker without immunomedics takeout total spent last quarter look pedestrian least compared previous year sign activity picking see bristol myers squibb bn purchase myokardia week price target still high buyer either need pay substantial premium keep powder dry even gilead immunomedics deal last three month show increase spending company takeout versus first two quarter coronavirus pandemic blamed depressing something certainly looked true early stage outbreak however immunomedics myokardia deal suggest covid longer used excuse holding back transaction perhaps knock effect pandemic bigger factor spotlight biopharma persuaded investor pile pushing valuation many area testing level biopharma takeover show quantity quality july pipeline always need filled company desperate growth might take hit well purchasing immunomedics gilead put hand pocket several time year including shelling nearly bn forty seven big biotech shown afraid accused overpaying case point bn acquisition kite pharma least deal still getting done number transaction sealed third quarter climbed slightly previous two reinforcing idea activity might picking well takeover analysis includes minority majority stake purchase acquisition business unit option aggregated deal number concern deal dedicated drug maker diagnostics medtech transaction excluded dip valuation would probably required really get biopharma scene going present market cooled slightly nasdaq biotech index mere start year depending u election play bigger change sentiment horizon\n",
      "\n",
      "Keywords:\n",
      "immunomedics 0.293\n",
      "deal 0.178\n",
      "purchase 0.165\n",
      "transaction 0.154\n",
      "biopharma 0.147\n",
      "picking 0.14\n",
      "myokardia 0.136\n",
      "bn purchase 0.132\n",
      "quarter 0.127\n",
      "acquisition 0.116\n",
      "gilead 0.109\n",
      "buyer 0.106\n",
      "third quarter 0.103\n",
      "bigger 0.097\n",
      "takeout 0.094\n",
      "slightly 0.094\n",
      "bn 0.089\n",
      "takeover 0.089\n",
      "previous 0.088\n",
      "substantial premium 0.075\n",
      "\n",
      "Abstract:\n",
      "covid pandemic opened another regulatory divergence u fda opposite number eu u possible approval covid vaccine take increasingly political dimension european medicine agency already quietly begun rolling review two vaccine one astrazeneca azd project whose clinical trial halted unexplained illness might taken signal eu regulator favourably disposed towards quick green light though surely step far suggest first vaccine might approved eu u still worth asking question already ema shown willing move quickly pandemic using rolling review process equivalent commonly used u rolling submission special regulatory tool used speed assessment public health emergency gilead covid antiviral veklury instance received conditional eu approval july day start rolling review u drug got emergency use authorisation may day rolling bla initiated three month rolling process completed fastest course filing assessed merit fda look moved faster ema however covid vaccine maker started u regulatory process yet eu regulator already assessing two vaccine yesterday saying biontech pfizer bnt b rolling review comprises first batch preclinical data conclusion reached safety efficacy ema cautioned week ago agency put motion first rolling review pertaining preclinical study azd clinical trial azd halted september subject unexplained illness dosing uk site resumed shortly afterwards astra made formal comment rolling review process biontech formal submission finalised following rolling review pending demonstration vaccine efficacy safety confirmation submitted data adequate german group stated yesterday read potentially looser stance versus u fda time communicating company want see median least two month safety observation trial participant part emergency use application issue taken huge importance president donald trump clearly fearing would preclude vaccine approval november u election fda reiterated stance yesterday appendix upcoming vaccine advisory panel drawing instant ire president trump last month ft pharma biotech summit stephane bancel chief executive moderna developing mrna denied political interference saying nobody asked u go faster go slower said manufacturing constraint meant vaccine unlikely made available week potential emergency use authorisation fda requesting extensive manufacturing information least month submission emergency application together requirement adcom vaccine show fda stamping authority combined review time several week make pre election approval look like pipe dream emergency use approval take longer many investor expecting leerink analyst wrote today investor might rethink timeline u eu alike\n",
      "\n",
      "Keywords:\n",
      "rolling 0.426\n",
      "rolling review 0.361\n",
      "vaccine 0.23\n",
      "review 0.218\n",
      "eu 0.201\n",
      "emergency 0.191\n",
      "emergency use 0.142\n",
      "process 0.128\n",
      "ema 0.124\n",
      "fda 0.109\n",
      "submission 0.107\n",
      "azd 0.102\n",
      "unexplained 0.096\n",
      "political 0.092\n",
      "illness 0.092\n",
      "two vaccine 0.088\n",
      "review process 0.088\n",
      "stance 0.083\n",
      "approval 0.081\n",
      "use authorisation 0.075\n",
      "\n",
      "Abstract:\n",
      "venture feeding frenzy young biopharma group dissipating maybe bn raised past three month smallest quarterly sum year typical year figure easily set record course far normal pandemic persuaded investor throw huge amount money sector already pretty well financing front result venture cash raised first nine month full year record bar one year young drug developer banked bn venture funding year tally already bn final quarter would tank pretty spectacularly miss setting new record sign suggest might happen ipo market going full throttle equity market remain strong world still embroiled fighting pandemic arguably biggest event year sector u presidential election looming major upheaval week ahead cannot ruled dip mega round raising explains retraction seen last quarter three month company managed snag amount largest raise achieved kronos bio contrast second quarter contained five round raised first quarter saw three company tip threshold still average amount raised financing year still tracking well historical level another metric look likely see new record analysis track company involved research stage drug development excludes sector including medtech diagnostics digital health example important question frequency mega round dipped last quarter simply matter timing would take couple large financing close day different quarter make big difference something else play however many big financing called crossover round designed bring big public market specialist investor deep pocket ahead ipo perhaps foreshadows something retraction biotech flotation coming month understandable management team might decide listing period u politics easily make stock market volatile indeed rush float raise money via route ahead u election well help explain bumper number seen ipo venture market far year another aspect consider rise spacs special purpose acquisition company offer private group alternative route market eliminating need crossover round many persuaded biotech start ups advantage yet implausible fairly widely consideration biotech test third way market september end day venture world look buoyant many segment biopharma right reason next quarter might see another slowdown even happens look certain go record breaker\n",
      "\n",
      "Keywords:\n",
      "round 0.249\n",
      "venture 0.224\n",
      "quarter 0.182\n",
      "financing 0.177\n",
      "record 0.176\n",
      "raised 0.135\n",
      "new record 0.13\n",
      "crossover round 0.13\n",
      "market 0.121\n",
      "mega round 0.119\n",
      "last quarter 0.115\n",
      "ipo 0.113\n",
      "persuaded 0.112\n",
      "crossover 0.112\n",
      "ahead 0.105\n",
      "mega 0.104\n",
      "sector 0.103\n",
      "amount 0.102\n",
      "route 0.102\n",
      "election 0.096\n",
      "\n",
      "Abstract:\n",
      "past performance indicator future performance go adage throwing money biotech ipo year hope hold true median return one past five year flotation negative looking particularly disappointing year considered successful period biotech ipo almost three quarter biopharma company floated currently trading underwater new issue meanwhile performing strongly although course early day company investor would well forget real nature drug development nature high risk high reward reward far analysis tracked performance development stage drug developer listed nasdaq new york stock exchange end june year bought premium float price another either taken discount share price collapsed became reverse merger target considerably languish zombie company presumably awaiting fate worse almost fifth new issue still trading lost least three quarter listing price chart describes performance year new issue least remain trading end september takeout reverse merger target removed notable case detailed research stage drug developer make analysis sector like medtech digital health excluded performance class similarly dire yet financing climate different year average biotech ipo raised setting record decade bn raised total however something desert biotech banking bn via ipo average flotation raising mere course graph snapshot time performance change investor stock stick around find story end however ipo still trading loser outnumber winner float price end september versus still spectacular gain among riser company seen share price least double investor might argue need pick one two big winner shareholder myokardia float still holding today would certainly agree company already best performing new issue analysis today bn takeout bristol myers squibb premium listing price rank biggest return bristol bet big myokardia october chart show ipo mostly remain water however worth remembering new issue coming market valuation seen year ever average raise first half year came longer unusual see company floating bn higher market cap another huge quarter biotech flotation october strong demand thing biotech supporting valuation market deteriorate quickly investor win big takeover must happen premium many newly minted frequently early stage public company premium look already baked\n",
      "\n",
      "Keywords:\n",
      "new issue 0.247\n",
      "performance 0.214\n",
      "ipo 0.211\n",
      "premium 0.152\n",
      "biotech ipo 0.152\n",
      "biotech 0.143\n",
      "price 0.142\n",
      "trading 0.139\n",
      "issue 0.139\n",
      "flotation 0.127\n",
      "float 0.125\n",
      "three quarter 0.122\n",
      "still trading 0.122\n",
      "merger target 0.122\n",
      "listing price 0.122\n",
      "new 0.118\n",
      "float price 0.116\n",
      "stage drug developer 0.111\n",
      "stage drug 0.107\n",
      "reverse merger 0.107\n",
      "\n",
      "Abstract:\n",
      "myokardia mavacamten undoubtedly yielded impressive data lead indication obstructive hypertrophic cardiomyopathy whether enough justify bn bristol myers squibb dropped company today another matter mavacamten use patient heart failure preserved ejection fraction hfpef bristol exec said today however admitted early day evaluatepharma sellside consensus put project sale nearly bn giving net present value around bn justified bristol chief executive giovanni caforio insisted conference call today mavacamten promise obstructive hypertrophic cardiomyopathy hcm alone justified acquisition myokardia calling indication multibillion opportunity hcm affect around one people making common genetic cardiovascular disease around two third obstructive form around symptomatic population bristol initially targeting number around patient apiece u europe mavacamten cardiac myosin inhibitor look likely get approved based explorer hcm study result presented recent esc congress esc myokardia odds first approval heart muscle disease august bristol plan file mavacamten breakthrough status u first quarter project get go ahead bristol market currently specific therapy approved hcm competition way behind celltrion cytokinetics rival cardiac myosin inhibitor shape ct g ck phase phase ii respectively eliquis footstep bristol know cardiovascular arena company plan use playbook employed anticoagulant eliquis best selling drug ahead opdivo company need something replace blood thinner set go patent might cling exclusivity little longer recent court ruling mavacamten bristol initially intends target around specialist centre treat around hcm patient gradually expand include broader cardiology setting primary care provider today call several analyst noted heart failure therapy often suffered slow ramp sale bristol exec said strong story tell payer healthcare provider regarding mavacamten however declined give clue pricing saying early discus bristol ability charge rare disease rate take hit project approved hcm widespread disease like hfpef immediate next step project non obstructive hcm completed phase ii trial maverick hcm non obstructive form account remaining third hcm patient bristol highlighted asset myokardia clinical pipeline danicamtiv myk next generation cardiac myosin inhibitor designed reduced pharmacokinetic variability still main draw bristol undoubtedly mavacamten mr caforio would say whether bidding process myokardia competitive investor hope bristol pressured overpaying meanwhile myokardia backer delighted seeing company bought premium share price friday whopping premium listing price\n",
      "\n",
      "Keywords:\n",
      "hcm 0.403\n",
      "mavacamten 0.359\n",
      "bristol 0.275\n",
      "myokardia 0.242\n",
      "obstructive 0.215\n",
      "myosin inhibitor 0.141\n",
      "cardiac myosin inhibitor 0.141\n",
      "cardiac myosin 0.134\n",
      "myosin 0.129\n",
      "around 0.121\n",
      "cardiac 0.1\n",
      "provider 0.094\n",
      "obstructive form 0.094\n",
      "hfpef 0.094\n",
      "hcm patient 0.094\n",
      "hypertrophic cardiomyopathy 0.09\n",
      "hypertrophic 0.09\n",
      "eliquis 0.09\n",
      "heart 0.086\n",
      "justified 0.086\n",
      "\n",
      "Abstract:\n",
      "clear biotech investor exuberance already turned outstanding year flotation share price performance perhaps le well appreciated scope provided financial engineering affording company investment banking advisor two shot making money latest example came courtesy bridgebio pharma today decided buy back eidos already floated minority interest two year ago follows illumina move spend bn reacquiring grail ionis buying back akcea spun five year previously course move often driven u turn management thinking ionis instance buying back stake akcea several year subsidiary bought back fully boardroom clearout ionis give lesson financial engineering march first today move bridgebio come earlier attempt reaquire eidos terminated last year initially comprised bridgebio share eidos share despite sweetened twice final offer bridgebio share plus option receive part cash party agree suitable price seem found one bridgebio share equivalent today alternatively cash maximum total eidos ended last week per share today shot bridgebio offer price eidos get stage company primarily focused transthyretin amyloid cardiomyopathy project ag raised june ipo valuation bridgebio move today reached market cap bn largely promise ag time minority stake floated bridgebio still privately held year later listed stock becoming biggest biotech ipo brought independent valuation one way understand bridgebio action eidos see stock market vehicle parent company used asset owned independently valued seems highly unlikely bridgebio would achieved recognition ag asset internally held might struggled close big ipo true criticised letting go stake pay reacquire crucially whole time eidos stock surging implied value majority stake bridgebio still owned without bridgebio lift finger added cost investment banking fee pale insignificance time cash raised cheaply asset already mostly tripled value parent company investor subsidiary advisor win meantime bridgebio two bite valuation cherry independent eidos second time eidos majority owner risk around ag pivotal study design need compete pfizer become problem another day\n",
      "\n",
      "Keywords:\n",
      "bridgebio 0.608\n",
      "eidos 0.45\n",
      "ag 0.187\n",
      "bridgebio share 0.15\n",
      "stake 0.113\n",
      "ionis 0.112\n",
      "share 0.096\n",
      "parent company 0.094\n",
      "financial engineering 0.094\n",
      "akcea 0.094\n",
      "investment banking 0.089\n",
      "subsidiary 0.085\n",
      "parent 0.085\n",
      "engineering 0.085\n",
      "move 0.085\n",
      "advisor 0.083\n",
      "ipo 0.081\n",
      "minority 0.08\n",
      "banking 0.078\n",
      "today 0.077\n",
      "\n",
      "Abstract:\n",
      "heading last quarter year number valuable u drug approval decision pending including kala eysuvis whose fate decided end october another strong year novel drug approval making september perhaps important event due month panel meeting october discus general development covid vaccine though expected cover one particular project provide additional insight fda expectation requirement vaccine readout ongoing phase iii study due coming month j j novavax push covid vaccine candidate late stage testing september approval decision though eysuvis critical kala since dry eye asset group biggest growth driver despite kala run three clinical study getting result needed approval likely green light status covid pandemic permitting kala plan double sale force rep biggest hurdle meeting sellside expectation according evaluatepharma consensus sale forecast reach bn making eysuvis biggest selling dry eye therapy year generic steroid version allergan artificial tear treatment restasis major obstacle eysuvis npv bn given kala market cap investor apparently share sellside enthusiasm cocktail hour regeneron meanwhile awaiting decision ebola project regn eb three antibody cocktail developed using similar technology company covid asset regn cov encouraging data released week regeneron join lilly validating covid antibody approach september study run niaid testing four different ebola therapy showed regn eb superior zmapp triple mab used control reducing mortality ebola regn eb showed mortality rate versus gilead veklury regn eb achieved faster viral clearance zmapp veklury notably study tested mab called ansuvimab single treatment showed similar efficacy regeneron therapy ansuvimab developed ridgeback biotherapeutics filed u decision expected early next year money drain notable supplemental decision due fourth quarter astrazeneca brilinta stroke sale blood thinner long disappointed patent expiry astra need wring product decision based thales study brilinta plus aspirin showed statistically significant clinically meaningful reduction primary endpoint composite risk stroke death day however benefit came expense increased bleeding rate including fatal haemorrhage jefferies analyst note sanofi plavix remain favoured given lower bleeding risk astra invested huge sum label extension brilinta far managed add two study substantial parthenon programme label cost astrazeneca building brilinta january table list first time supplementary u approval well panel meeting due october consensus forecast evaluatepharma\n",
      "\n",
      "Keywords:\n",
      "kala 0.253\n",
      "regn eb 0.245\n",
      "eb 0.229\n",
      "brilinta 0.229\n",
      "regn 0.228\n",
      "eysuvis 0.202\n",
      "decision 0.16\n",
      "ebola 0.14\n",
      "covid 0.109\n",
      "veklury 0.109\n",
      "panel meeting 0.101\n",
      "cocktail 0.101\n",
      "october 0.101\n",
      "regeneron 0.1\n",
      "dry eye 0.098\n",
      "approval 0.096\n",
      "dry 0.096\n",
      "stroke 0.091\n",
      "drug approval 0.091\n",
      "bleeding 0.089\n",
      "\n",
      "Abstract:\n",
      "impressed biotech ipo second quarter blown away came next number new listing amount raised broke record third quarter according evaluatepharma setting scene year hard forget surging demand thing biotech mean financing climate surely good anyone remember though implication equally buoyant valuation positive company understandably raising money tune bn past three month almost equalling total banked ipo entire course number new arrival make past three month biggest quarter since measure last biotech ipo boom year respective young biotech made debut flotation far seems unlikely tally beaten really remarkable part story amount money raised moment evaluate vantage tracking ipo since analysis restricted research stage drug developer omitting medtech diagnostics digital health example past two quarter easily surpassed period highest risk end biopharma sector year first quarter held record bn raised third quarter almost double figure average ipo raise year tracking substantially higher previous year total breached three figure first time average raise topping year massive offering commonplace course year flotation raised raised two raised sort sum unheard even last year latest gluttonous valuation achieved relay therapeutic debuted july market cap bn raising stock promptly doubled focus cancer novel small molecule drug discovery technology described motion based drug design one project made phase far big thing apparently expected relay analysis help explain huge sum coming ipo average priced initial range proposed equity market buying private investor keep delivering company make mistake demand driving valuation looking ever divorced reality high risk drug development\n",
      "\n",
      "Keywords:\n",
      "ipo 0.275\n",
      "raised 0.247\n",
      "quarter 0.19\n",
      "past three month 0.151\n",
      "number new 0.145\n",
      "average 0.139\n",
      "biotech ipo 0.132\n",
      "past three 0.129\n",
      "biotech 0.125\n",
      "tracking 0.124\n",
      "past 0.117\n",
      "flotation 0.11\n",
      "valuation 0.108\n",
      "sum 0.105\n",
      "raising 0.105\n",
      "demand 0.105\n",
      "third quarter 0.103\n",
      "three month 0.096\n",
      "figure 0.088\n",
      "thing 0.086\n",
      "\n",
      "Abstract:\n",
      "failure vital head head study selecta sobi gout project sel another lesson biotech something obvious go phase iii without first clearly showing scientific business rationale make sobi swedish orphan biovitrum particular look rather rash sobi licensed sel front four month ago perhaps sobi say took risky punt price break bank company decided initiate pivotal study last month harder fathom sel fact raised pretty substantial doubt well yesterday failure beat krystexxa head head back phase ii trial failed fewer half patient able maintain serum uric acid level despite complex treatment cycle selecta feel pain gout november failure demonstrate suitable dosing schedule rung alarm bell meantime separate phase ii trial compare took major importance pitted sel head head krystexxa horizon therapeutic recently anointed gout market leader go compare compare flopped yesterday company said sel failed beat krystexxa lowering serum uric acid mg dl least time month three six combined compare primary endpoint numerical benefit versus come close hitting statistical significance p mizuho analyst said setback would significantly reduce sel u commercial opportunity stifel wrote client reason buy selecta share morning fell evidently selecta sobi plea look per protocol assessment subject rather enrolled patient fell deaf ear company argued covid pandemic caused protocol deviation intent treat population per protocol analysis came closer meeting statistical significance p group claimed win three month point considered though resulting p value nominal since primary analysis failed anything however three month effect harks back earlier phase ii flop sel inability maintain long term serum uric acid level krystexxa comprises pegloticase recombinant uricase sel combine therapeutic uricase enzyme pegsiticase pegadricase immune tolerance technology former due sell according evaluatepharma sellside consensus yesterday failure latter carried forecast annabel samimy stifel analyst covering horizon wrote competitive threat krystexxa removed selecta sobi said would explore impact covid full compare dataset hand insisted numerical finding supported sel pivotal programme comprising two trial dissolve ii expected generate topline result second half pivotal study pit sel placebo hope success relatively high indeed sel might well approvable without demonstrated advantage established market leader mountain climb\n",
      "\n",
      "Keywords:\n",
      "sel 0.534\n",
      "sobi 0.272\n",
      "selecta 0.243\n",
      "krystexxa 0.227\n",
      "compare 0.148\n",
      "uric acid 0.146\n",
      "uric 0.146\n",
      "serum uric acid 0.146\n",
      "serum uric 0.146\n",
      "selecta sobi 0.146\n",
      "head 0.137\n",
      "gout 0.136\n",
      "serum 0.12\n",
      "protocol 0.108\n",
      "acid 0.095\n",
      "per protocol 0.091\n",
      "head head 0.09\n",
      "maintain 0.08\n",
      "failure 0.074\n",
      "market leader 0.068\n",
      "\n",
      "Abstract:\n",
      "lifesci acquisition corp became latest special purpose acquisition company spac find merger target week vincera pharma private cancer focused start take lifesci nasdaq listing become publicly traded company bank purpose spacs offer private firm alternative route market surge creation recent trend biopharma world performance company listed via mechanism decidedly mixed however vincera progress watched interest spacs delivered deal early tell whether vehicle delivering promise evaluate vantage identified five drug company arrived market via spac vincera one gained value since immunovant considered something poster child field success probably responsible persuading lot investor take punt type investment huge sum money flowing biotech right spacs formed growing enthusiasm year tenzing acquisition corp tenzing vincera spac called blank cheque company shell raise money ipo cash specifically earmarked purchase private business evaluate vantage scoured sec filing found spacs listed year explicit focus drug development compare two previous three year given vehicle disclose sector fishing likely many considering biopharma opportunity active field believe probably many biotech spacs right competing private company good company negotiate valuation term multiple spacs andrew mcdonald chief executive lifesci acquisition corp founding partner banking advisory group lifesci partner told vantage interview presumably mean spacs might settle poorer term originally hoped obvious implication return road investor told vantage several spacs known deal fall another sign competitive financing climate right advantage still mr mcdonald belief spacs stay offer private company economically attractive route market two obvious advantage time cost company get market week via spac compared month via traditional ipo avoid investment banking fee still insider ability retain larger share company real value lie proponent spac model argue largely spac remove need crossover round typically large private financing done ahead ipo bringing sector specialist bank public market fund deep pocket strong reputation however company original investor see holding diluted crossover round ipo mr mcdonald said spac transaction follow financing event structured lot flexibility said vincera deal example stockholder issued even share newly traded company road certain milestone hit according another investor much demand spacs driven company happy level dilution crossover stage irony many investor spacs private equity venture financing firm fund crossover round financing plentiful biopharma right make sense investor pursue ipo spacs alike though mr mcdonald argues latter clear advantage bank go fund say float thing talk prospectus spac superior investor go data room go much deeper due diligence said like get money back whether ipo spac make better return key question spacs need find immunovants persuade doubter company seem unlikely flock great number spacs although offer surely many math company dead set traditional crossover ipo really want validation blue chip bulge bracket investment bank bring going convince go spac route mr mcdonald say change company like vincera going keep ipo cousin month ahead\n",
      "\n",
      "Keywords:\n",
      "spacs 0.511\n",
      "spac 0.39\n",
      "vincera 0.234\n",
      "mcdonald 0.195\n",
      "ipo 0.169\n",
      "crossover 0.156\n",
      "mr mcdonald 0.156\n",
      "lifesci 0.156\n",
      "private 0.146\n",
      "financing 0.124\n",
      "company 0.122\n",
      "crossover round 0.109\n",
      "corp 0.109\n",
      "acquisition corp 0.109\n",
      "bank 0.094\n",
      "via 0.089\n",
      "route 0.085\n",
      "round 0.084\n",
      "mr 0.079\n",
      "offer private 0.073\n",
      "\n",
      "Abstract:\n",
      "easy find flaw first clinical result regeneron anti covid antibody cocktail disclosed market close yesterday pandemic time detail almost irrelevant matter data validate antibody approach key question whether might enough secure u emergency use authorisation given project including convalescent plasma received eua much weaker data answer might yes though regeneron keeping option open analyst call last night group said begun sharing result regulator would used inform next step today stock opened investor unsure evercore isi analyst hinted sale bn year long covid lingers followed possibility delivery national stockpile descriptive analysis snippet data regeneron hope generate first several trial cocktail regn plus regn regeneron curiously called descriptive analysis came phase ii iii trial non hospitalised patient covid data comprised first patient enrolled across two dose group placebo blinded study recruitment target perhaps important finding covid viral load reduced patient highest load baseline central part regeneron thesis infection patient mount effective immune response high viral load low load already generated antiviral antibody thus company emboldened surmise patient greatest need one benefited called finding incredible correlation next question identify patient high viral load regeneron called major societal imperative regeneron already partnered one company working diagnostic purpose roche one possibility thus use diagnostic therapeutic concert formal primary endpoint regeneron trial study five three relating safety one concerning viral load reduction one regarding cutting covid related medical visit treatment related adverse event infusion related hypersensitivity reaction occurred rarely fairly evenly across three cohort though regeneron highlighted viral load reduction even attributing p value high dose dos combined seronegative patient careful call statistically significant small patient number interim analysis must minimal alpha assigned regeneron correctly called p value nominal confounding finding included lack numerical dose response relationship according jefferies regeneron debating whether continue low dose absolute viral load reduction look modest though evercore stressed covid acute infection drop seen still meaningful clinically medical visit numerical reduction cocktail versus placebo visit total way discerning relevance target two antibody regeneron cocktail hit different epitope receptor binding domain covid spike protein lilly targeting different spike protein epitope two mabs ly cov ly cov reported first data former lilly lead covid antibody charge september overall said datasets finding promising mean emphatic help shift spotlight vaccine treatment though course necessary combat pandemic vaccine development proceeding apace curevac today starting phase ii trial cvncov moderna data trial mrna old adult published nejm meanwhile inovio controversial project ino monday put u clinical hold next data point watch regeneron study hospitalised patient already sign good group say patient tend much higher viral load ambulatory subject course eua granted soon might become academic\n",
      "\n",
      "Keywords:\n",
      "load 0.356\n",
      "regeneron 0.35\n",
      "viral load 0.285\n",
      "viral 0.225\n",
      "cocktail 0.163\n",
      "viral load reduction 0.148\n",
      "load reduction 0.148\n",
      "covid 0.141\n",
      "visit 0.122\n",
      "patient 0.109\n",
      "finding 0.096\n",
      "antibody 0.091\n",
      "called 0.089\n",
      "hospitalised patient 0.088\n",
      "ly cov 0.084\n",
      "eua 0.082\n",
      "epitope 0.082\n",
      "reduction 0.08\n",
      "ly 0.079\n",
      "hospitalised 0.079\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Abstract:\n",
      "delving key catalyst due big pharma biotech company evaluate vantage look smallest player market cap bn novel approach oncology one focus underserved neurological condition rett angelman syndrome another area interest notably almost half company list gone public past two year upcoming clinical readout provide investor initial glimpse whether money well spent one company replimune completed ipo towards end year investor see early data two oncolytic immunotherapy rp company lead project version hsv type engineered replicate tumour rp armed two gene one encoding fusogenic protein enhance cell death encoding gm csf cytokine believed aid immune activation rp derivative rp express anti ctla antibody like molecule updated result due phase ii study testing rp opdivo earlier data skin cancer expansion cohort encouraging albeit small number patient relatively short follow objective response rate seen cutaneous squamous cell carcinoma comprising four complete two partial response orr occurred anti pd refractory cutaneous melanoma rp initial data expected phase study solid tumour testing compound single agent combination opdivo another early stage oncology player due report data tcr therapeutic floated last year raising tcr cell receptor fusion construct truc technology claimns incorporates feature car tcr cell therapy tc company advanced project target mesothelin positive solid tumour dose escalation update phase study due interim data previously reported five patient showed tumour regression including two partial response one confirmed tc meanwhile target cd positive b cell haematological malignancy initial data expected study including adult indolent non hodgkin lymphoma area car therapy currently commercialised rare disease neurology look area interest smallest player rett syndrome rare neurological disorder almost exclusively affect girl target anavex therapy anavex result two phase ii study small molecule activator sigma receptor one taking place u australia due report earlier data open label portion u study showed improvement score rett syndrome behaviour questionnaire clinical global impression improvement scale seven week six adult patient upcoming data patient placebo controlled part trial approved product rett failure newron pivotal study may left thin pipeline avanex one advanced still standing ultimate treatment goal would disease modifying approach still way novartis gene therapy avxs expected start trial anavex tested parkinson disease dementia patient study measuring two different dos versus placebo primary secondary endpoint ass cognition parkinsonian motor symptom sleep function week study another condition lack treatment option angelman syndrome complex genetic disorder primarily affect nervous system advanced clinical candidate ovid ov known gaboxadol primary endpoint pivotal neptune study ov cgi clinical global impression improvement score week study powered show point improvement baseline aggregate measure score despite meeting cgi endpoint phase ii star trial ov failed show benefit huge list measure although detailed younger patient responded better star study enrolment included aged neptune enrolled patient year old therapy development angelman include roche rg recently started phase genetx ultragenyx gtx phase ii data expected next year trying target underlying genetic cause disease following table note additional fourth quarter event smallest company includes consensus forecast evaluatepharma evaluate vantage separately assessed expected catalyst larger drug maker biotech company market cap bn\n",
      "\n",
      "Keywords:\n",
      "rp 0.257\n",
      "rett 0.18\n",
      "angelman 0.135\n",
      "tcr 0.129\n",
      "ov 0.129\n",
      "anavex 0.129\n",
      "study 0.124\n",
      "smallest 0.11\n",
      "syndrome 0.1\n",
      "data expected 0.093\n",
      "cell 0.092\n",
      "rett syndrome 0.09\n",
      "improvement score 0.09\n",
      "impression improvement 0.09\n",
      "global impression improvement 0.09\n",
      "clinical global impression 0.09\n",
      "clinical global 0.09\n",
      "angelman syndrome 0.09\n",
      "improvement 0.087\n",
      "data 0.086\n",
      "\n",
      "Abstract:\n",
      "oncology readout dominate big pharma player focus biotech varied evaluate vantage look important event due company market cap bn ash conference december focus haematological malignancy early data forma kura trillium expected arena report atopic dermatitis result rhythm hope expand use obesity project various genetic form disorder madrigal meanwhile hope tackle fatty liver disease madrigal data open label arm phase iii maestro nafld trial around patient given mg resmetirom daily week result expected non invasive test including mri pdff fibrosis biomarkers liver enzyme atherogenic lipid lipoprotein resmetirom thyroid hormone receptor agonist mechanism investigated viking therapeutic benchmark madigal upcoming data albeit week viking vk showed median change baseline liver fat content across three treatment arm versus placebo phase iia nafld study madrigal upcoming resmetirom result read registrational maestro nash study data due second half next year owing enrolment delay due covid bigger indication rhythm setmelanotide melanocortin agonist already filed two rare genetic obesity indication pro opiomelanocortin deficiency obesity leptin receptor deficiency obesity u action date november broaden project reach data expected towards end year early alstrom syndrome bardet biedl syndrome two rare genetic disorder sufferer experience insatiable hunger known hyperphagia severe obesity beginning early life stifel analyst note bardet biedl main value driver patient globally pivotal trial patient primary endpoint proportion patient achieve reduction baseline body weight week treatment week double blind placebo controlled period followed week open label stage phase ii open label basket study mean change body weight baseline month seven bardet biedl patient common adverse event injection site reaction first fourth quarter arena etrasimod yield data first foray dermatology phase iib advise study atopic dermatitis sufferer test two dos week treatment period followed four week observation primary endpoint ass percent change eczema area security index easi baseline week secondary measure include easi looking competition sanofi regeneron market leader dupixent shown placebo adjusted week easi abbvie jak inhibitor rinvoq meanwhile shown result higher dose phase iii etrasimod p receptor modulator like bristol zeposia approved relapsing remitting multiple sclerosis late stage trial ulcerative colitis crohn disease however look development atopic dermatitis etrasimod lead valuable indication ulcerative colitis investor wait end next year data two phase iii study conference data forma therapeutic managed ipo june phase data expected ash ascending dos sickle cell disease project ft eha back june single mg dose ft showed median mmhg reduction point sickling three subject hour trial enrols healthy volunteer placebo cohort grade adverse event seen palpitation occur one sickle cell disease patient eight hour single dose something watch upcoming data ft pyruvate kinase r pkr activator much like agio mitapivat multiple ascending dose data latter due ash result toplined earlier eha focus previously disclosed vaso occlusive crisis possibly related treatment mitapivat although early call winner leerink analyst believe ft become best class pkr drug thanks longer half life potentially allowing daily dosing target aromatase impact evident mitapivant preclinically following table note additional fourth quarter event biotech includes consensus forecast evaluatepharma analysis covering company market cap bn follow\n",
      "\n",
      "Keywords:\n",
      "obesity 0.178\n",
      "ft 0.146\n",
      "resmetirom 0.144\n",
      "etrasimod 0.144\n",
      "biedl 0.144\n",
      "bardet biedl 0.144\n",
      "bardet 0.144\n",
      "madrigal 0.135\n",
      "week 0.129\n",
      "easi 0.128\n",
      "atopic dermatitis 0.107\n",
      "atopic 0.107\n",
      "dermatitis 0.105\n",
      "data 0.105\n",
      "baseline 0.094\n",
      "open label 0.092\n",
      "genetic 0.091\n",
      "rhythm 0.09\n",
      "period followed 0.09\n",
      "mitapivat 0.09\n",
      "\n",
      "Abstract:\n",
      "long term result ascendis pharma make case transcon pth become new treatment adult hypoparathyroidism pressure danish group move quickly take advantage fortuitous window opportunity previous hormone replacement therapy disease takeda natpara injectable parathyroid hormone pth pulled u market last year owing manufacturing contamination ascendis hope regulatory following wind allows begin u pivotal trial immediately something would help back bn market cap fair valuation factor advanced growth hormone project scored important pivotal trial win last year transcon pth result thus add evidence backing ascendis technology lie behind asset logic behind transcon pth clever delivery long acting prodrug pth hypoparathyroidism patient produce insufficient amount aim overcome natpara problem variable pth level natpara associated calcium imbalance carried black box warning osteosarcoma ascendis earlier reported positive data controlled portion transcon pth phase ii trial longer term result moved amend u ind allow phase iii begin soon possible latest result relate open label six month extension mid stage study extension opened participant across various dose control arm elected take part subject declined reason unrelated safety efficacy transcon pth four week controlled phase subject across three dos met primary endpoint seeing normalised serum urine excreted calcium coming vitamin reducing calcium intake mg day le comparison placebo recipient met endpoint time data got better least ignore several additional missing patient subject across four cohort available data six month met composite primary efficacy measure later time point missing patient ascendis said three subject urine sample prepared properly another two received laboratory remaining four omitted subject excluded missing day urine sampling window four fact vitamin mg calcium supplement ascendis said three normalised serum urine calcium open label extension data support planned pivotal study six month primary endpoint composite measure differ slightly phase ii comprising serum calcium normalisation plus vitamin independence mg calcium supplementation urinary calcium normalisation secondary measure phase iii plan randomise subject middle phase ii dose transcon pth g day placebo analyst call today ascendis said depending various assumption evaluable phase ii subject would met phase iii endpoint planned study extremely well powered success stated evaluatepharma sellside consensus see transcon pth generating sale though lag bn expected transcon growth hormone forecast new data show ascendis one trick pony\n",
      "\n",
      "Keywords:\n",
      "pth 0.415\n",
      "transcon 0.332\n",
      "ascendis 0.332\n",
      "calcium 0.303\n",
      "transcon pth 0.291\n",
      "urine 0.158\n",
      "natpara 0.133\n",
      "ascendis said 0.133\n",
      "hormone 0.121\n",
      "vitamin 0.118\n",
      "serum 0.11\n",
      "subject 0.095\n",
      "missing 0.094\n",
      "met 0.092\n",
      "extension 0.092\n",
      "phase 0.087\n",
      "subject across 0.083\n",
      "hypoparathyroidism 0.083\n",
      "growth hormone 0.079\n",
      "six month 0.076\n",
      "\n",
      "Abstract:\n",
      "heading towards end year dominated covid evaluate vantage delved data release expected big pharma fourth quarter excluding readout expected coronavirus therapy vaccine oncology look dominate astrazeneca gilead takeda glaxosmithkline due unveil important update elsewhere alzheimer come play roche bristol myers squibb pfizer tyk inhibitor development psoriasis first data pending first look lilly gip glp agonist tirzepatide emerge astrazeneca immunotherapy imfinzi well established stage iii nsclc chemoradiotherapy crt data expected pacific earlier setting imfinzi given crt versus crt alone primary endpoint pfs hope pacific help defend competitor aiming beat efficacy achievable imfinzi crt well targeting earlier population data asco merck co keytruda showed remission rate six month overall survival keynote study keytruda given crt though uncontrolled study data expected imfinzi first line liver cancer himalaya trial test imfinzi monotherapy two combination anti ctla agent tremelimumab nexavar primary outcome overall survival readout draw comparison imbrave led approval roche tecentriq plus avastin first line treatment reduced risk death p cut risk disease worsening death p versus nexavar jefferies analyst note imfinzi monotherapy beat nexavar difficult beat tecentriq combination result prior failure imfinzi plus tremelimumab various cancer setting mean expectation low astra combination elsewhere cancer takeda pevonedistat first class nedd activating enzyme nae inhibitor yield phase iii data soon aim improve chemotherapy drug vidaza pevonedistat given combination versus vidaza alone panther study patient high risk myelodysplastic syndrome md chronic myelomonocytic leukaemia low blast aml primary endpoint event free survival o secondary measure phase ii data reported year asco showed benefit particularly patient high risk md subgroup term event free survival primary endpoint result month versus month intent treat population difference event free survival statistically significant gilead anti cd mab magrolimab shown impressive response data md phase ib study md project advanced indication phase iii enhance trial way dlbcl data expected fourth quarter result likely ash conference december come phase ii study testing magrolimab combination rituxan magrolimab gained gilead bn acquisition forty seven two month deal gilead bought stake arcus bioscience gain access biotech cancer pipeline data expected next quarter arc phase ii study pd l positive nsclc patient trial three arm monotherapy checkpoint inhibitor zimberelimab zimberelimab plus anti tigit mab ab lastly plus ab adenosine b receptor antagonist arcus intends disclose data half patient approximately arm tigit mechanism generated interest merck roche latter advanced candidate tiragolumab benchmark arcus upcoming data roche cityscape trial showed highest overall remission rate pd l high patient combination tecentriq versus tecentriq clinical benefit pd l low patient arcus deal gilead gained immediate right zimberelimab arc data prove competitive mizuho analyst see gilead exercising opt right ab broader development strategy following shortly oncology aside several readout due roche beta amyloid mabs alzheimer last week company anti tau mab semorinemab failed phase ii elsewhere two tyk inhibitor generate data bristol myers squibb leading pack pfizer following psoriasis check table full list upcoming catalyst consensus forecast evaluatepharma look catalyst biotech smallest company published ph v soc data aha nov\n",
      "\n",
      "Keywords:\n",
      "crt 0.242\n",
      "imfinzi 0.212\n",
      "data 0.144\n",
      "md 0.144\n",
      "arcus 0.144\n",
      "zimberelimab 0.136\n",
      "event free survival 0.136\n",
      "event free 0.136\n",
      "nexavar 0.129\n",
      "gilead 0.125\n",
      "data expected 0.125\n",
      "combination 0.118\n",
      "magrolimab 0.116\n",
      "ab 0.113\n",
      "tecentriq 0.11\n",
      "survival 0.107\n",
      "expected 0.097\n",
      "elsewhere 0.09\n",
      "roche 0.089\n",
      "patient high risk 0.086\n",
      "\n",
      "Abstract:\n",
      "venture fund might awash cash still want exit takeout remains favoured route long might investor need wait founding start answer median almost nine year according evaluate vantage crunch number figure shifted little since ipo another story however median time float founding currently sitting little five year two year faster speed market fuelled rising demand biotech stock public investor turn produced record ipo number recently strong equity market helped course biotech finding even favour throughout pandemic venture firm wasting time listing portfolio company enthusiastic participation crossover fund recent year playing role investor help load balance sheet start ups making attractive public investor still growing trend early company many year away clinical testing managing command huge valuation potential investor burned surely growing series new issue go nowhere nothing long term health biotech ipo market egregious example recently include passage bio listed february little two year founded gene therapy researcher managed raise valuation despite nothing clinic gene editing company beam therapeutic waited slightly respectable three year founding float company preclinical yet valued almost bn post money raising ipo time buy acquirer seem le willing take punt fledgling firm least one interpretation takeout time data shown drift downwards analysis look company founded still venture investor would prefer see takeout time get shorter worth remembering past couple year biopharma market active many would liked perhaps maintaining median takeout time considered achievement analysis show buyer prepared take risk relatively young start ups year around half vc backed buyout year old around length typical venture fund always outlier course quickest include celgene purchase delinia atlas sofinnova put young biotech time takeout front le two year delinia founded flexus established raised much bristol myers squibb agreed pay front takeover venture fund dine sort transaction year although remain exception rather rule\n",
      "\n",
      "Keywords:\n",
      "venture 0.256\n",
      "venture fund 0.224\n",
      "takeout 0.221\n",
      "founding 0.213\n",
      "fund 0.184\n",
      "founded 0.182\n",
      "ipo 0.173\n",
      "time 0.151\n",
      "two year 0.13\n",
      "investor 0.125\n",
      "start ups 0.122\n",
      "biotech 0.117\n",
      "median 0.113\n",
      "growing 0.11\n",
      "young 0.109\n",
      "ups 0.107\n",
      "float 0.103\n",
      "little 0.093\n",
      "firm 0.092\n",
      "start 0.089\n",
      "\n",
      "Abstract:\n",
      "race bring covid vaccine market heated entry two candidate phase iii week johnson johnson ad cov known jnj novavax nvx cov four five late stage contender published trial protocol becoming clearer vaccine need show first report biontech pfizer bnt b initial data expected end october result might come even sooner one analytics firm airfinity calculated first interim analysis vaccine phase iii study triggered event come early september moderna far behind group said first result vaccine mrna available november fda requested median least two month safety observation trial participant part application emergency use leerink analyst wrote recently might put paid hope vaccine becoming available u election november one shot johnson johnson jnj went patient pivotal trial week might logistical edge late stage vaccine requires one injection j j planning uk trial two dose schedule furthermore jnj incorporates tried tested technology us adenovirus part j j ebola vaccine regimen received eu approval july novavax testing familiar approach nvx cov recombinant protein vaccine type widespread use today next advanced recombinant protein covid candidate sanofi glaxosmithkline expected start pivotal testing december nvx cov look convenient term storage requirement kept c jnj stable two year c least three month c storage requirement mrna candidate much onerous per protocol phase iii contender bar novavax published trial protocol novavax said coming day patient uk pivotal trial announced yesterday given investor unique chance peer working study difference particularly way covid infection defined make cross trial comparison even trickier usual data emerge example j j evaluating moderate severe disease primary endpoint developer include mild disease meanwhile novavax study two co primary endpoint one looking moderate severe disease evaluating symptomatic covid infection way covid defined varies pfizer trial least stringent definition patient report one list symptom moderna astra j j study require one major symptom difficulty breathing two symptom chill headache another big difference number event needed first interim analysis astra strictest requiring event trigger first look might give greater confidence interim analysis according leerink higher bar mean interim data likely similar primary endpoint analysis trial whose interim cut come earlier astra uncertainty however recruitment u trial astrazeneca azd yet restarted following halt caused case transverse myelitis uk curiously uk study resumed well trial brazil africa astra head biopharmaceuticals r sir mene pangalos recently told leerink analyst company interim data uk brazil phase iii trial end year however unclear whether fda would even consider reviewing package u data still immature according leerink astra final stage submitting document fda hope resume study soon time agency might hand full first mrna vaccine data sep sep source eric topol twitter clinicaltrials gov trial protocol story updated include link j j ph preprint data novavax ph study eduract number\n",
      "\n",
      "Keywords:\n",
      "novavax 0.224\n",
      "vaccine 0.217\n",
      "interim 0.178\n",
      "trial protocol 0.162\n",
      "protocol 0.161\n",
      "jnj 0.161\n",
      "uk 0.147\n",
      "cov 0.14\n",
      "astra 0.14\n",
      "trial 0.139\n",
      "nvx cov 0.126\n",
      "nvx 0.126\n",
      "interim analysis 0.114\n",
      "johnson 0.112\n",
      "leerink 0.109\n",
      "storage 0.101\n",
      "covid 0.096\n",
      "brazil 0.096\n",
      "way covid 0.092\n",
      "recombinant protein 0.092\n",
      "\n",
      "Abstract:\n",
      "handful unexpected knockbacks fda year biopharma follower wondering whether u regulator sharpened teeth raw number seem support idea novel agent received green light far four fewer last year total hopeful awaiting decision year end according evaluate vantage calculation approval round would set something record still outcome high profile application likely considered barometer regulatory climate rather whatever final tally come fda plenty big call still make example novartis hear approval lipid lowering agent inclisiran towards end year group paid bn project developer medicine company month ago given another expensive buyout continues cause headache scandal prone avexis novartis bought bn swiss firm want give investor reason question nous impressive ldl cholesterol lowering seems give inclisiran good shot approval however rnai technology agent work novel cardiovascular outcome study orion due read fda choose take cautious stance roxadustat another big project decision emerge towards end year novel anaemia therapy first type cross fda path advisory committee called read good sign supporter developer astrazeneca fibrogen however project avoided controversy green light far assured kala look like safer bet dry eye project eysuvis escape notice fda company run three phase iii trial getting result wanted persistence pay kala march bristol myers squibb former celgene shareholder nervous month ahead approval liso cel december must occur contingent payment pledged time celgene takeout made another component contingent value right ide cel received refusal file letter earlier year new pdufa date march four day cvr deadline regulatory risk exists product course matter easy path market appears course whether agent manage meet sale forecast separate equally important question sellside consensus number frequently considered ambitious rate complete response letter watched carefully coming week previous analysis evaluate vantage found little evidence uptick regulatory red light string high profile knockbacks including rejection gilead galapagos filgotinib biomarin valrox gene therapy prompted question tightening regulatory climate big year regulatory knockbacks september improbable project review year end pas muster unlikely year approval tally novel agent drop dramatically outcome application detailed real interest however fda really become le friendly biopharma would really something worry\n",
      "\n",
      "Keywords:\n",
      "knockbacks 0.196\n",
      "regulatory 0.16\n",
      "fda 0.147\n",
      "agent 0.147\n",
      "novel 0.135\n",
      "regulatory climate 0.131\n",
      "novel agent 0.131\n",
      "kala 0.115\n",
      "inclisiran 0.112\n",
      "high profile 0.112\n",
      "light 0.11\n",
      "approval 0.11\n",
      "tally 0.106\n",
      "climate 0.106\n",
      "towards end year 0.104\n",
      "outcome 0.101\n",
      "year end 0.1\n",
      "cel 0.098\n",
      "lowering 0.097\n",
      "contingent 0.095\n",
      "\n",
      "Abstract:\n",
      "pre conference deal ultimately responsible substantial share price gain notched two biggest winner esmo immunomedics seattle genetics data presented cancer meeting help explain group attracted attention first place notable stock market move include exelixis bounce checkmate er data put cabometyx back game first line renal cancer advance cardiff oncology mersana stand among small cap pieris clear loser biotech probably conclude esmo positive force sector year perhaps expected considering demand biopharma stock remains buoyant notwithstanding something pullback week find biggest move among esmo presenting stock evaluate vantage tracked share price gain loss close september ahead release abstract close september final day conference leader gilead takeout immunomedics announced middle period triggering latter surge esmo saw full result ascent trial doubt helped persuade gilead pull trigger deal gilead cancer ambition stretch bn september study tested trodelvy metastatic triple negative breast cancer despite already received median four line therapy patient given trop targeting antibody drug conjugate experienced month overall survival advantage given single agent chemo hr p data bladder cancer le encouraging trophy u trial trodelvy overall response came patient progressed chemotherapy checkpoint inhibitor seattle astellas rival adc padcev approved setting orr putting boot partner announced early termination efficacy confirmatory ev study esmo got way seattle received esmo boost presentation full result innovatv trial tisotumab vedotin separate adc project advanced metastatic cervical cancer orr among patient median overall survival month persuaded company partner genmab seek accelerated approval esmo period saw substantial deal seattle collaboration merck co two separate asset including adc ladiratuzumab vedotin little surprise seattle emerged esmo victor seattle benefit merck long shot september extent adcs show period certainly confirms technology finally come age whether esmo data immunomedics justifies price tag gilead agreed another question entirely others receiving esmo boost included exelixis bristol myers squibb look clawed back position first line renal cancer combination respective drug cabometyx opdivo bristol share actually fell esmo period though harder discern impact conference big pharma stock lilly look benefited prime spot sunday presidential session monarche study found verzenio reduced risk cancer recurrence high risk early stage breast cancer patient new market cdk inhibitor one pfizer ruled failed pallas trial setting featured esmo among small cap cardiff oncology rose mounting hope onvansertib tangentially competes kras space plk inhibitor target kras directly plk described master regulator mitosis synthetic lethality kras mutated colorectal cancer esmo saw efficacy data nine patient four partial response four stable disease one proceeding curative surgery followed evidence disease company valuation ballooned tenfold since initial data aacr earlier year first piqued interest company since changed name trovagene kras cooling leading kras contender amgen failed ignite much new excitement among investor sotorasib however despite data published new england journal medicine mersana provided news adc front response rate xmt similar reported asco earlier year albeit patient remarkable run company market cap sits staggering bn leaving little room disappointment blueprint rise largely non esmo data ayvakit systemic mastocytosis however company attract attention preclinical data describes fourth generation egfr inhibitor blu designed block several resistance mechanism including used tumour use evade tagrisso astrazeneca leading egfr tki project due go clinic next year blueprint work egfr lung cancer likely become major focus coming year several company continue work project hope improve response rate lung cancer niche j j bispecific approach show esmo although work early elsewhere innovative chinese company continue become visible global cancer conference innovent beigene receiving esmo period share price boost presenting several new datasets beigene particular attracted attention combo trial pd l pd inhibitor data urothelial cancer contained intriguing hint efficacy although yet clear whether company push approach finally pieris appears biggest casualty esmo phase data bb bispecific pr disappointed despite company best effort talk result orr reached pr monotherapy project combined roche tecentriq pr hold pieris carry study requested fda perhaps investor see little reason carry\n",
      "\n",
      "Keywords:\n",
      "esmo 0.404\n",
      "cancer 0.212\n",
      "seattle 0.17\n",
      "kras 0.151\n",
      "adc 0.136\n",
      "esmo period 0.131\n",
      "period 0.118\n",
      "pieris 0.112\n",
      "pr 0.108\n",
      "among 0.101\n",
      "egfr 0.097\n",
      "data 0.095\n",
      "immunomedics 0.09\n",
      "september 0.082\n",
      "esmo data 0.078\n",
      "company continue 0.078\n",
      "attracted attention 0.078\n",
      "company 0.077\n",
      "gilead 0.075\n",
      "mersana 0.075\n",
      "\n",
      "Abstract:\n",
      "september esmo mover antibody drug conjugate dominate news flow notable progress antibody drug conjugate seattle genetics immunomedics drove biggest esmo share price move september j j go broke lung cancer bispecific company egfr cmet targeted bispecific generated early encouraging signal lung cancer however j j face stiff competition alkermes succeed nektar failed early sign suggest alkermes might found therapeutic window il targeting agent alks september encouraging sign checkpoint bispecifics promising early data pd x ctla bispecifics macrogenics akeso add weight approach september double win complicates gastric cancer picture bristol myers squibb merck co hail front line success histology biomarker status remain live issue doctor backing beigene unusual combo approach company one studied combining pd pd l blockade approach still need scientific validation modest early activity jounce competitor european unimpressed lynparza prostate performance september lilly latecomer score early breast cancer verzenio look set move valuable adjuvant setting pfizer miss ibrance laid bare kras cool long awaited update amgen kras inhibitor show waning single agent efficacy situation apparently pre empted mirati pfizer next gen lung cancer drug impress september agenus see light end tunnel last benefit balstilimab cervical cancer irrespective pd l expression give agenus shot u approval opdivo cabometyx back game full data checkmate er trial suggest new combo match merck co keytruda plus inlyta first line renal cancer september ipatasertib akts miss roche akt inhibitor advanced breast cancer leaf question population combination mediola make case triplet therapy ovarian cancer private group claim early impressive pancreatic win september mersana hold steady ovarian cancer expectation grow data xmt durability still key question september kidney cancer showdown get star billing preview late breaking immunotherapy preview\n",
      "\n",
      "Keywords:\n",
      "september 0.312\n",
      "cancer 0.283\n",
      "pd 0.143\n",
      "early 0.136\n",
      "agenus 0.132\n",
      "lung cancer 0.126\n",
      "preview 0.123\n",
      "alkermes 0.123\n",
      "lung 0.112\n",
      "ovarian cancer 0.106\n",
      "miss 0.106\n",
      "ovarian 0.103\n",
      "kras 0.103\n",
      "bispecifics 0.101\n",
      "drug conjugate 0.088\n",
      "antibody drug conjugate 0.088\n",
      "antibody drug 0.088\n",
      "bispecific 0.086\n",
      "conjugate 0.085\n",
      "approach 0.084\n",
      "\n",
      "Abstract:\n",
      "repeated failure anti amyloid drug targeting tau protein next big idea alzheimer disease setback one tau first big test suggests progress mechanism might come easier news failure roche ac immune anti tau mab semorinemab set nerve jangling like biogen lilly stalwart amyloid year heavily invested tau detail available semorinemab flop host company developing tau targeting agent wait see glimmer hope found among wreckage roche ac immune saying phase ii tauriel trial prodromal mild alzheimer meet primary endpoint change clinical dementia rating sum box score semorinemab showing benefit placebo company disclose p value study missed two secondary endpoint ada cog adcs adl data presented ctad meeting november according leerink analyst attendee particularly keen see tau biomarker data semorinemab shown effective clearing tau explain failure meaning tau hypothesis might still play tau caution even turn case reason cautious late stage anti tau project advanced taurx pharmaceutical lmtx already failed twice phase iii axon neuroscience aadvac failed show benefit clinical efficacy endpoint phase ii trial furthermore abbvie biogen anti tau mabs abbv e gosuranemab failed last year progressive supranuclear palsy like alzheimer characterised build tau brain question mark whether antibody effective therapy given target extracellular tau pathologic tau largely accumulates within neuron however extracellular tau role spread pathologic tau neuron ac immune taking different approach two anti tau project vaccine aci developed collaboration j j lilly partnered aci small molecule designed able pas cell membrane inhibit intracellular tau aggregate semorinemab dead yet phase ii lauriet study moderate alzheimer ongoing however hope low reflected fact ac immune lost nearly half value yesterday\n",
      "\n",
      "Keywords:\n",
      "tau 0.751\n",
      "semorinemab 0.217\n",
      "ac immune 0.183\n",
      "ac 0.174\n",
      "anti tau 0.167\n",
      "alzheimer 0.121\n",
      "immune 0.104\n",
      "roche ac immune 0.091\n",
      "roche ac 0.091\n",
      "pathologic 0.091\n",
      "extracellular 0.091\n",
      "aci 0.091\n",
      "anti 0.088\n",
      "neuron 0.076\n",
      "amyloid 0.074\n",
      "biogen 0.059\n",
      "failure 0.056\n",
      "effective 0.055\n",
      "failed 0.054\n",
      "phase 0.048\n",
      "\n",
      "Abstract:\n",
      "third generation kinase inhibitor dramatically improved response rate egfr mutated non small cell lung cancer relapse still happen targeting resistance pathway thus major avenue research early data novel bispecific johnson johnson presented esmo year hinted promising new approach amivantamab said target egfr cmet receptor attempt improve response rate even j j trialling top novel third generation egfr targeting tki lazertinib seeing response rate previously untreated egfr positive metastatic patient company decided pit combination widely viewed best class agent astrazeneca tagrisso phase iii trial pivotal mariposa trial poised start enrolling shortly surely make break move j j strategy three arm study allow head head comparison combination single agent lazertinib versus tagrisso brave step considering agent demonstrated survival benefit want able add value already available rather focusing tagrisso failure said dr joaqu n casariego head oncology j j janssen unit europe interview evaluate vantage weakness mariposa trial combination arm open label opposed blinded tki arm presumably difficulty giving sham intravenous therapy notably j j selecting patient cmet mutation egfr cmet known driver nsclc tumour specifically variant known exon deletion thought account cancer involved relapse via cmet amplification develop resistance mechanism egfr inhibitor focusing carrier egfr mutation tagrisso record ultimately j j need beat esmo first amivantamab lazertinib data revealed hinting combination achieve chrysalis study generated competitive response rate among tki refractory patient one complete response median follow four month even impressively patient received prior treatment disease responded partial response median follow seven month\n",
      "\n",
      "Keywords:\n",
      "egfr 0.391\n",
      "cmet 0.281\n",
      "lazertinib 0.225\n",
      "tagrisso 0.224\n",
      "tki 0.201\n",
      "response rate 0.152\n",
      "response 0.149\n",
      "third generation 0.141\n",
      "egfr cmet 0.141\n",
      "median follow 0.134\n",
      "combination 0.121\n",
      "head 0.106\n",
      "rate 0.105\n",
      "arm 0.102\n",
      "relapse 0.102\n",
      "focusing 0.102\n",
      "resistance 0.099\n",
      "agent 0.095\n",
      "generation 0.091\n",
      "mutation 0.083\n",
      "\n",
      "Abstract:\n",
      "disappointing result nektar therapeutic bempegaldesleukin made targeting il look like dead end alkermes reckons managed design molecule get around toxicity limited use older agent data presented esmo meeting suggest group might something particularly promising sign came form two partial response alks monotherapy melanoma agent le convincing renal cancer small number patient trialled far mean caution still warranted efficacy le tox stimulating il activates immune system long pursued cancer target indeed novartis recombinant il proleukin approved since albeit strenuous safety warning toxicity arises il stimulation cause surge cytokine vascular leak syndrome dr ulka vaishampayan university michigan presented alks data esmo explained majority toxicity come binding il alpha receptor told evaluate vantage alks novel fusion protein preferentially bind intermediate affinity il receptor avoids alpha receptor bypass issue alkermes belief\n",
      "\n",
      "Keywords:\n",
      "il 0.413\n",
      "alks 0.288\n",
      "alkermes 0.192\n",
      "receptor 0.163\n",
      "toxicity 0.157\n",
      "alpha 0.156\n",
      "esmo 0.127\n",
      "il receptor 0.109\n",
      "affinity 0.109\n",
      "vascular leak syndrome 0.103\n",
      "vascular leak 0.103\n",
      "two partial response 0.103\n",
      "surge cytokine 0.103\n",
      "like dead 0.103\n",
      "leak syndrome 0.103\n",
      "group might 0.103\n",
      "get around 0.103\n",
      "fusion protein 0.103\n",
      "disappointing result 0.103\n",
      "avoids 0.103\n",
      "\n",
      "Abstract:\n",
      "hitting pd l ctla proven efficacy bristol myers squibb shown opdivo plus yervoy toxicity associated latter target capped potential combination several company trying hit target bispecific antibody hope showing similar antitumour activity better safety early data presented virtual esmo meeting macrogenics akeso go way validating approach small patient number still unanswered question macrogenics mgd particular linked high toxicity sign akeso ak look promising mesothelioma promise data ak came mesothelioma particularly hard treat cancer esmo heard detail overall response rate immunotherapy na mesothelioma patient private chinese group phase study trial found rate treatment related grade adverse event lower seen opdivo yervoy checkmate mesothelioma study ak treated patient discontinued due treatment related adverse event compared opdivo yervoy checkmate ak specifically designed safer opdivo yervoy bind tumour infiltrating lymphocyte expressing pd ctla effect stay localised tumour microenvironment according professor michael millward university western australia presented data esmo drawing broad conclusion safety might premature mizuho analyst noted later emergence side effect uncommon checkpoint inhibitor professor millward concluded ak warrant study mesothelioma adding combination chemo first line disease particularly attractive notably akeso already testing ak combination chemo first line gastric cancer macrogenics look sweet spot macrogenics meanwhile reported orr heavily pretreated patient phase basket study mgd including one complete response encouragingly project showed activity tumour type typically responsive checkpoint inhibitor including microsatellite stable colorectal cancer metastatic castration resistant prostate cancer overall side effect profile looked similar opdivo yervoy patient mgd experiencing grade greater treatment emergent adverse event however half came highest dose group mg kg macrogenics dropping mg kg taken forward macrogenics hope found sweet spot reason optimism four response came mg kg mg kg group excluding dos lower mg kg analysis gave impressive orr group course need replicate phase ii latest data read across xencor rival bispecific xmab far yielded one complete response melanoma patient reported year asco mizuho analyst set response rate checkpoint experienced patient bar xmab beat company report data phase duet trial due within next month meanwhile astrazeneca pushed ahead contender medi several early stage trial way astra turn bispecifics solve treme problem february way go ascertain whether bispecifics edge opdivo plus yervoy even similar efficacy safety profile lead competitive product given likely cost convenience advantage single agent\n",
      "\n",
      "Keywords:\n",
      "ak 0.31\n",
      "mesothelioma 0.241\n",
      "macrogenics 0.23\n",
      "mg kg 0.207\n",
      "yervoy 0.194\n",
      "kg 0.185\n",
      "opdivo 0.164\n",
      "opdivo yervoy 0.161\n",
      "mgd 0.138\n",
      "akeso 0.138\n",
      "mg 0.118\n",
      "sweet spot 0.097\n",
      "combination chemo 0.097\n",
      "xmab 0.092\n",
      "sweet 0.092\n",
      "one complete response 0.092\n",
      "checkpoint 0.091\n",
      "one complete 0.088\n",
      "chemo first line 0.088\n",
      "chemo first 0.088\n",
      "\n",
      "Abstract:\n",
      "illumina decision spend billion reacquiring grail liquid biopsy developer spun nearly five year ago somewhat puzzling grail pan cancer test galleri still year market grail expected money pit time yet firm current arrangement generally regarded working pretty well illumina owns around grail sell sequencing instrument reagent take royalty sale sell sequencer consumables liquid biopsy developer grail back board illumina competing customer webcast today illumina management brushed concern aside saying modelling suggested bringing grail back inside would bring money direct revenue hope royalty stream liquid biopsy market top bn reacquiring grail would expand illumina addressable market bn executive claimed certainly reason buy rather ipo two week ago grail filed nasdaq listing considering recent post float share price jump healthcare sector strength market illumina might felt hand somewhat forced even today move stand contrast illumina general behaviour company great track record commercialising actual diagnostics focussing instead making selling machine company next gen sequencing based test run illumina worked reduce stake grail past couple year spin raised pile venture cash current equity stake amount buy rest grail pay bn share bn balance sheet cash plus debt equity bn deal far largest acquisition ever done playing galleri however illumina hook substantial r investment far guaranteed outcome grail look likely incur operating expense probably even next year clinical trial cost rise pre commercialisation expense peak pathfinder trial enrolling patient intended evaluate galleri ability aid cancer diagnosis used clinical practice subject cancer diagnosis enrolment trial include cohort greater risk developing cancer ex smoker genetic predisposition disease trial succeed demonstrating place galleri clinical practice launch next year clia waiver lab developed test might welcomed doctor pathfinder study illumina take galleri assay development grail three clinical trial ongoing total current programme signed subject top illumina fork sale force look obtaining regulatory approval currently pencilled lurks another problem guardant roche selling test year obtained regulatory nod vital convincing oncologist test worth last month illumina third market solid three year illumina expects eps dilution first year deal close second half according leerink analyst translates roughly additional operating expense acquiring customer unprecedented move illumina though previous time january bought foetal chromosome testing company verinata spent though illumina grail sole supplier sequencing tech spin major customer management saying today top company illumina sell customer cancer blood testing space far delighted buy competitor still dominance illumina alternative provider turn illumina customer miffed investor rumour deal prompted illumina haemorrhage bn market cap last week stock opened lower today perhaps shareholder wondering stake might pacbio merger come\n",
      "\n",
      "Keywords:\n",
      "illumina 0.667\n",
      "grail 0.456\n",
      "galleri 0.188\n",
      "customer 0.175\n",
      "liquid biopsy 0.105\n",
      "liquid 0.105\n",
      "sequencing 0.096\n",
      "expense 0.08\n",
      "test 0.079\n",
      "biopsy 0.076\n",
      "reacquiring grail 0.07\n",
      "reacquiring 0.07\n",
      "cancer 0.065\n",
      "sell 0.065\n",
      "spin 0.064\n",
      "stake 0.064\n",
      "buy 0.061\n",
      "diagnosis 0.06\n",
      "bn 0.059\n",
      "clinical practice 0.058\n",
      "\n",
      "Abstract:\n",
      "given chequered history checkpoint blockade gastric oesophageal cancer come surprise one two anti pd antibody shown first line benefit quick succession claimed two esmo late breaker monday chemo combo checkmate keynote trial study lead author claimed respective agent bristol myers squibb opdivo merck co keytruda first line standard devil detail cannot denied two trial yielded positive survival result versus chemo alone toplined august bristol said opdivo become first pd inhibitor achieve outcome adenocarcinoma keytruda repeat trick patient regardless histology context needed esmo press briefing discussant dr salah al batran nordwest krankenhaus frankfurt spelled trial differing recruitment criterion primarily seeking show effect pd l expressers checkmate keynote subsequently showed apparent benefit comer dr al batran slammed author claim checkpoint blockade standard first line patient regardless pd l expression said first wanted see efficacy pd l low subject pd l non expressers given pd l high patient likely driving overall benefit told press briefing responsive group high expressers used inflate result comer nevertheless accepted trial practice changing outcome certainly unexpected given recent history keytruda approved third line gastric gastroesophageal junction gej adenocarcinoma patient expressing pd l based small keynote trial potentially confirmatory second line study keynote failed first line keynote trial inconclusive followed second line u approval pd l expressing oesophageal carcinoma squamous histology strength keynote require confirmatory trial eu filing use pulled regulator cited unanswered question opdivo meanwhile approved year second line biomarker independent oesophageal cancer squamous histology back attraction trial complex picture latest data add picture checkmate keynote enrolled oesophageal gej cancer subject including gastric cancer fact included mixed histology except adenocarcinoma stipulation oesophageal tumour gej cancer pose sufficient complexity doctor parsing benefit pd l expression cloud picture fact study primarily focused pd l expressers show company hedged bet fact esmo presentation highlighted benefit comer thus dr markus moehler mainz university hospital presenting checkmate data able boast highly significant clear overall survival benefit patient irrespective pd l expression meanwhile median o pd l expressers co primary endpoint amounted reduction risk death dana farber cancer institute dr peter enzinger one author keynote presentation focused comer median o pfs hit statistical significance p showing reduction risk death reduction risk progression keynote complex statistical design powering initially split o squamous oesophageal cancer pd l expressers pfs squamous oesophageal subject sequential analysis going comer irrespective histology tumour subtype biomarker status final broad population setting keytruda plus chemo new standard care dr enzinger claimed bristol merck interest seek broadest label possible whether fda mandate biomarker approach question\n",
      "\n",
      "Keywords:\n",
      "pd 0.309\n",
      "oesophageal 0.265\n",
      "keynote 0.242\n",
      "expressers 0.205\n",
      "histology 0.189\n",
      "squamous 0.157\n",
      "comer 0.142\n",
      "pd expressers 0.14\n",
      "oesophageal cancer 0.137\n",
      "gej 0.137\n",
      "checkmate keynote 0.137\n",
      "dr 0.134\n",
      "line 0.119\n",
      "adenocarcinoma 0.117\n",
      "cancer 0.111\n",
      "keynote trial 0.11\n",
      "checkmate 0.109\n",
      "pd expression 0.107\n",
      "gastric 0.107\n",
      "benefit 0.097\n",
      "\n",
      "Abstract:\n",
      "logic combining pd inhibitor one blocking ligand pd l beigene think based small low profile study presented weekend esmo conference though limited precedent industry player suggests jury still astrazeneca thought run human study combo anti pd element medi discontinued bristol myers squibb anti pd l bm immunotherapy company picked either one target esmo expert offer little insight combo mechanistic rationale stopped beigene concluding phase dose escalation confirmation phase ii combo tislelizumab anti pd sell china baizean bgb anti pd l data second line urothelial cancer cohort solid tumour study presented esmo catalan institute oncology dr juan martin liberal headline efficacy number showed beigene combo yield confirmed remission rate among subject including two partial two complete response among six pd l expressers median duration response single arm study month lack control mean investor look cautiously across rival trial comparison orr range merck kgaa pfizer bavencio roche tecentriq much larger trial including orr among pd l high subject given tecentriq rightfully given small beigene study dr martin liberal enthusiasm stopped cautious conclusion data provided insight pd pd l combo study discussant university copenhagen dr ulrik lassen praised remission rate pd l high patient however dr lassen offered little way mechanistic rationale discussing logic behind combining pd l ctla lag inhibition pd known bind pd l well pd l hint one approach might better rather backing combination previous study found little positive bristol thought canned bm without studying opdivo combo astra run trial medi plus imfinzi hypothesised offered potential complete pd pd l axis inhibition however data last updated esmo last year bear among renal cell carcinoma subject two complete four partial response two latter unconfirmed difference pd l expressing non expressing subject patient dropped adverse event combo versus monotherapy cohort caveat small patient number beigene study saw increase severe treatment related adverse event monotherapy dose escalation dose expansion combo part follower space one asset watch lilly ly anti pd x pd l bispecific antibody phase study year clinical data seem presented yet preclinical paper published month cancer immunology research suggested ly demonstrated enhanced immunomodulatory property human data ly update beigene combo strategy keenly awaited\n",
      "\n",
      "Keywords:\n",
      "pd 0.535\n",
      "beigene 0.243\n",
      "combo 0.235\n",
      "anti pd 0.172\n",
      "pd pd 0.133\n",
      "ly 0.133\n",
      "dr 0.13\n",
      "esmo 0.121\n",
      "study 0.108\n",
      "among 0.103\n",
      "anti 0.1\n",
      "mechanistic rationale 0.099\n",
      "combining pd 0.099\n",
      "medi 0.092\n",
      "logic 0.092\n",
      "expressing 0.092\n",
      "offered 0.089\n",
      "mechanistic 0.089\n",
      "study presented 0.087\n",
      "bm 0.084\n",
      "\n",
      "Abstract:\n",
      "editorial new england journal medicine hailing druggability last kras alter fact investor expectation likely dashed commentary relates latest update amgen study sotorasib simultaneously published nejm presented esmo today offer little fresh hope follower space still unclear whether kras blocker significant activity beyond lung cancer durable effect acknowledge limited single agent efficacy two kras player mirati boehringer ingelheim moved put respective asset combo study tie announced thursday mechanistically intriguing see mitati mrtx like sotorasib kras g c selective inhibitor combined boehringer bi so pan kras inhibitor said block kras independent mutation type so helper protein turn kras state seems questionable whether additionally blocking specific sub mutation improve efficacy broadly acting agent nevertheless boehringer say one several combination exploring bi optimise activity broad population monotherapy last year triple eortc nci aacr meeting mirati reported mrtx monotherapy data subject amounting remission rate nsclc colorectal appendiceal tumour pretty much mirror amgen seeing sotorasib though larger dataset previous update asco sotorasib codebreak study comprised evaluable subject given target mg daily dose esmo today little get enthusiastic among additional nsclc subject given target dose one partial remission orr fall meanwhile colorectal cancer dataset doubled subject two pr remission rate creep additional isolated response seen pancreatic endometrial cancer melanoma adding appendiceal tumour pr already reported study author wrote response rate among nsclc subject particularly promising undoubtedly note waning sotorasib efficacy dataset grown lack durability patient highlighted previously remains issue median response duration month across responder patient disease progression shortly initial remission rapid progression might suggest high degree tumour heterogeneity early adaptation treatment reported preclinical study precursor inhibitor wrote nejm editorial hail study encouraging showing first step drugging undruggable clinical inhibition previously untouchable target possible mirati instance valued bn might hoping much\n",
      "\n",
      "Keywords:\n",
      "kras 0.363\n",
      "sotorasib 0.31\n",
      "mirati 0.168\n",
      "boehringer 0.168\n",
      "remission 0.147\n",
      "given target 0.14\n",
      "bi 0.134\n",
      "nsclc 0.128\n",
      "mrtx 0.128\n",
      "pr 0.124\n",
      "dataset 0.124\n",
      "nsclc subject 0.12\n",
      "subject 0.115\n",
      "subject given 0.109\n",
      "nejm 0.109\n",
      "colorectal 0.101\n",
      "reported 0.098\n",
      "study 0.097\n",
      "tumour 0.097\n",
      "wrote 0.094\n",
      "\n",
      "Abstract:\n",
      "importance picking right population demonstrated virtual esmo conference today saw presentation two adjuvant breast cancer trial competing cdk inhibitor lilly verzenio pfizer ibrance result dramatically different former showing reduction recurrence cancer latter showing absolutely nothing already known former monarche trial succeeded latter pallas study failed reviewing physician concluded monarche focus patient high risk relapse likely explained divergent finding staggering ibrance patient discontinuing treatment early pallas adverse event causing almost two third drop out seems little pfizer salvage monarche pallas studied early stage patient common form breast cancer hormone receptor positive negative surgery chemo radiotherapy hormone adjuvant therapy dosed decade cure patient however relapse preventing delaying disease recurrence adding cdk inhibitor adjuvant endocrine therapy aim trial monarche used clinical pathological risk factor lymph node involvement tumour size guide enrolment pallas meanwhile simply stated woman must stage ii iii cancer study tested verzenio ibrance dosed two year top standard adjuvant endocrine therapy used invasive disease free survival idf primary endpoint monarche produced early clear separation curve virtually difference seen pallas\n",
      "\n",
      "Keywords:\n",
      "monarche 0.399\n",
      "pallas 0.384\n",
      "adjuvant 0.24\n",
      "ibrance 0.2\n",
      "endocrine therapy 0.168\n",
      "endocrine 0.153\n",
      "recurrence 0.148\n",
      "cdk inhibitor 0.148\n",
      "verzenio 0.144\n",
      "cdk 0.144\n",
      "cancer 0.125\n",
      "relapse 0.122\n",
      "hormone 0.122\n",
      "breast cancer 0.1\n",
      "breast 0.1\n",
      "dosed 0.099\n",
      "former 0.087\n",
      "showing 0.086\n",
      "early 0.082\n",
      "patient high risk 0.08\n",
      "\n",
      "Abstract:\n",
      "fast moving battle control first line renal cancer seen opdivo cabometyx edged rival pd l kinase inhibitor combination two back game message full data checkmate er study presented today esmo congress ironically exelixis ipsen cabometyx bristol myers squibb opdivo earlier fierce rival latter combination yervoy joining force seem least matched common enemy threatened consign second line setting checkmate er data toplined april nothing beyond hazard ratio survival known esmo data showed median progression free survival opdivo plus cabometyx er primary endpoint month versus sutent control cross trial basis active arm numerical benefit look line month pfs keytruda plus inlyta scored keynote study beat setting benefit dash hope numerically superior median number impressive hazard ratio seen er accounted sutent relative underperformance versus keynote like keynote indeed merck kgaa pfizer javelin renal trial overall survival yet reach median hazard ratio show er competitive merck co study one question latest data leave merck kgaa pfizer bavencio plus inlyta combo first immunotherapy kinase inhibitor combination yield knockout result first line renal cancer look eclipsed though median overall survival reached upper bound confidence interval nevertheless checkmate er lead author dana farber cancer institute dr toni choueiri refused rule duelling first line combination comparing across trial hard sure going see phase iii trial compare combination told esmo press conference however accepted combo choose billion dollar question varying length patient follow currently make comparison unfair one way level field would put study side side similar median follow discussant dr dominik berthold lausanne university hospital said opdivo plus cabometyx drawback agent mechanism action first class keytruda bavencio inlyta combo approved u first line moreover cabometyx already first second line label opdivo monotherapy approved second line opdivo plus yervoy available first line based checkmate study caused controversy esmo three year ago opdivo cabometyx combo filed u fda last month still need learn patient population may benefit er combination said dr berthold cabometyx quite unique kinase inhibitor may target bone metastasis better inlyta example unanswered question include quality life across various study long term treatment discontinuation still choice good patient doctor alike much probably nice problem referring multiple first line renal cancer study upstaging one another dr choueiri said past three four year drinking hose\n",
      "\n",
      "Keywords:\n",
      "cabometyx 0.292\n",
      "er 0.285\n",
      "opdivo 0.198\n",
      "inlyta 0.177\n",
      "line 0.173\n",
      "first line 0.148\n",
      "first line renal 0.132\n",
      "combination 0.13\n",
      "line renal cancer 0.129\n",
      "line renal 0.129\n",
      "checkmate er 0.129\n",
      "renal 0.128\n",
      "checkmate 0.127\n",
      "median 0.127\n",
      "dr 0.125\n",
      "renal cancer 0.119\n",
      "esmo 0.117\n",
      "first 0.112\n",
      "plus 0.112\n",
      "opdivo plus 0.111\n",
      "\n",
      "Abstract:\n",
      "took year bn shareholder cash immuno oncology laggard agenus yesterday started process filing one asset rolling filing completed balstilimab become seventh pd l blocker approved u second cervical cancer fact indication poorly served immunotherapy likely drove agenus strategy esmo conference yesterday heard data backing approval case among checkpoint blocker merck co keytruda cervical cancer label cross trial basis balstilimab look decent shot approval esmo data suggest balstilimab key advantage activity patient test positive pd l rolling bla seek comer label keytruda meanwhile approved patient shown express pd l vital detail cohort e merck drug keynote study showed overall remission rate pd l expressers crucially remission seen subject express pd l balstilimab monotherapy trial presented esmo yesterday showed orr second line refractory subject among pd l negative three response giving orr said ohio state university dr david malley stressed u fda decides drug approval based individual project merit rather comparing available therapy comparison keynote would highly relevant came persuading doctor seeking establish market share balstilimab esmo heard separate agenus cervical cancer study combined balstilimab anti ctla mab zalifrelimab showed activity pd l negative higher orr second line comer monotherapy trial dr malley pointed activity study seen irrespective tumour histology though higher squamous cell cancer adenocarcinoma combo later anti pd monotherapy agenus pursue u approval likely seeking approval two agent neither available would present regulatory problem might case agenus see zalifrelimab additive benefit sufficiently convincing setting question added toxicity known problem drug hitting ctla indeed immune related adverse event occurred higher rate combo versus monotherapy trial though patient number probably small make accurate comparison versus bristol myers squibb notoriously toxic yervoy balstilimab secure approval data alone enough dislodge keytruda agenus need strong marketing partner deal gilead appears cover either pd ctla asset\n",
      "\n",
      "Keywords:\n",
      "balstilimab 0.415\n",
      "agenus 0.355\n",
      "pd 0.289\n",
      "cervical cancer 0.156\n",
      "cervical 0.156\n",
      "esmo 0.145\n",
      "monotherapy 0.138\n",
      "ctla 0.127\n",
      "approval 0.125\n",
      "rolling 0.11\n",
      "orr 0.106\n",
      "heard 0.104\n",
      "express 0.099\n",
      "keytruda 0.099\n",
      "cancer 0.092\n",
      "blocker 0.092\n",
      "activity 0.087\n",
      "seeking 0.084\n",
      "comer 0.082\n",
      "higher 0.079\n",
      "\n",
      "Abstract:\n",
      "first data pivotal ipatunity trial roche ipatasertib show failure least show pleasingly symmetrical one presented esmo virtual meeting show progression free survival response rate response duration exactly treatment placebo arm failure something surprise given antigen profile trial participant prior success similar population albeit different disease overall survival follow ongoing future ipatasertib advanced breast cancer depend trial combination endocrine blockade cohort b ipatunity consisted patient whose advanced breast cancer hr positive negative pik ca akt pten altered suitable chemotherapy two third received ipatasertib plus paclitaxel control group got paclitaxel plus placebo data presented dr nick turner royal marsden nh foundation trust london show near identical pfs curve two cohort hazard ratio showing zero reduction risk progression roche project pi k akt inhibitor like ipatasertib might expected work patient whose tumour pik ca akt pten altered pten phosphatase tensin homologue deleted chromosome ten negative regulator proto oncogenic pi k akt pathway ipatential first line prostate cancer show benefit ipatasertib pten altered subject comer ipatasertib curate egg june study subject presidential session esmo sunday breast cancer ipatasertib shown promise different group patient whose tumour pten low jefferies analyst point phase ii lotus study triple negative breast cancer placebo adjusted overall survival benefit larger patient pten low tumour pik ca akt pten altered tumour subgroup larger trial rigorous analysis food thought future readout another question whether combining additional mechanism ipatasertib might yield better result dr turner pointed phase ii faktion trial astrazeneca otsuka akt inhibitor capivasertib oestrogen antagonist fulvestrant combination yielded significantly longer pfs versus placebo fulvestrant dr turner suggested endocrine blockade may critical activity akt inhibitor hr positive setting ipatunity study adding ipatersertib fulvestrant ibrance way report couple year still two cohort ipatunity come cohort compare two regimen triple negative disease analysed independently cohort c seek signal efficacy evaluate safety combination ipatasertib paclitaxel tecentriq pik ca akt pten non altered patient maybe disinter valuable data maybe cohort b overall survival analysis come positive though seems unlikely case pfs primary endpoint moreover positive showing balance additional adverse event seen ipatasertib added paclitaxel including notably higher rate nausea diarrhoea ipatasertib forecast top bn worldwide sale according evaluatepharma consensus jefferies analyst give probability launch\n",
      "\n",
      "Keywords:\n",
      "ipatasertib 0.408\n",
      "pten 0.312\n",
      "akt 0.297\n",
      "altered 0.185\n",
      "pik ca akt 0.167\n",
      "pik ca 0.167\n",
      "pik 0.167\n",
      "ca akt pten 0.167\n",
      "ca akt 0.167\n",
      "akt pten 0.167\n",
      "pten altered 0.156\n",
      "ipatunity 0.156\n",
      "ca 0.156\n",
      "paclitaxel 0.148\n",
      "fulvestrant 0.111\n",
      "akt inhibitor 0.111\n",
      "patient whose 0.107\n",
      "cohort 0.098\n",
      "breast cancer 0.093\n",
      "breast 0.092\n",
      "\n",
      "Abstract:\n",
      "string high profile fda rejection recently prompted biopharma follower wonder whether u drug regulator finally showing teeth period perceived leniency idea supported raw number however counting complete response letter complicated fact many large private company disclose received certainly time mean attempt track rate knockbacks likely underestimation evaluate vantage uncovered crls issued end august figure look weighty examining rate past couple year analysis us evaluatepharma calendar event draw publicly available press release sec filing annual report mean retrospectively announced caught number certainly go year end course mallinckrodt terlipressin knocked back week chart suggest tracking higher previous year given tally already approaching level however crunch number reveals past four year august tended see crls sent remainder conforms trend annual crl count year actually ballpark previous couple year analysis weakened patchy disclosure august flurry seems supported event year gilead galapagos filgotinib biomarin valrox gene therapy dbv peanut allergy therapy biggest project receive rejection last month first two particular garnering much attention fennec announced knockback cancer therapy august four crls actually make last month average comparison period previous year high profile setback year include collapse intercept hope break nash crl merck co seemingly unstoppable checkpoint inhibitor keytruda still nature rejection prompted speculation tightening regulatory climate apparent flurry filgotinib widely expected sail chance valrox held higher green light considered likely outcome decline standard application might explain surprising knock back however turn would surely fuelled collective belief regulatory bar lowered many would welcome stricter standard true investor benefited period permissiveness fda future big approval decision monitored closely sign shift regulatory climate\n",
      "\n",
      "Keywords:\n",
      "crls 0.227\n",
      "august 0.197\n",
      "rejection 0.194\n",
      "regulatory climate 0.159\n",
      "year analysis 0.151\n",
      "previous year 0.145\n",
      "supported 0.14\n",
      "period 0.138\n",
      "valrox 0.136\n",
      "high profile 0.136\n",
      "previous 0.132\n",
      "flurry 0.132\n",
      "climate 0.129\n",
      "crl 0.126\n",
      "regulatory 0.116\n",
      "filgotinib 0.114\n",
      "couple year 0.109\n",
      "prompted 0.108\n",
      "couple 0.094\n",
      "annual 0.091\n",
      "\n",
      "Abstract:\n",
      "waiting definitive data durability mersana therapeutic antibody drug conjugate xmt wait bit longer group reported updated result ovarian cancer cohort phase trial esmo today number look similar presented asco earlier year albeit patient mersana stock doubled asco data jumped another third week record high giving company bn valuation still durability remains key question xmt mersana expect answer end year known mean duration response reached seven patient deemed higher expressers napi b xmt target conference call today mersana chief executive anna protopapas declined disclose duration response far overall ovarian cancer cohort saying number small say much call lead investigator dr erika hamilton sarah cannon research institute played importance duration response single arm study claiming u fda would focus response rate however provide bar xmt would need cross year end update saying reach least four month dor good place late line might seem like much xmt tested late line setting patient failed four previous therapy platinum resistant current standard care population single agent chemotherapy prognosis good response rate median progression free survival three four month median overall survival le one year dr hamilton noted response rate would clinically meaningful xmt exceeded today update detailed orr evaluable patient ovarian cancer cohort study enrolled patient total\n",
      "\n",
      "Keywords:\n",
      "xmt 0.42\n",
      "mersana 0.28\n",
      "cancer cohort 0.21\n",
      "duration response 0.192\n",
      "ovarian cancer 0.176\n",
      "ovarian 0.17\n",
      "response 0.162\n",
      "duration 0.16\n",
      "response rate 0.124\n",
      "late line 0.115\n",
      "four month 0.115\n",
      "durability 0.105\n",
      "cohort 0.096\n",
      "dr 0.096\n",
      "patient 0.09\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "four 0.09\n",
      "asco 0.088\n",
      "update 0.087\n",
      "saying 0.086\n",
      "rate 0.086\n",
      "\n",
      "Abstract:\n",
      "pfizer sangamo long positioned haemophilia gene candidate giroctocogene fitelparvovec best class new long term data suggest efficacy might waning difficult draw firm conclusion latest result encompass five patient something doubt watched upcoming phase iii trial particularly question durability tripped biomarin rival gene therapy roctavian new data giroctocogene fitelparvovec previously known sb came pfizer r yesterday chart show factor viii level year five patient phase ii alta trial receiving highest dose x vg kg\n",
      "\n",
      "Keywords:\n",
      "giroctocogene fitelparvovec 0.29\n",
      "giroctocogene 0.29\n",
      "fitelparvovec 0.29\n",
      "five patient 0.269\n",
      "gene 0.154\n",
      "viii 0.145\n",
      "factor viii 0.145\n",
      "vg kg 0.139\n",
      "vg 0.139\n",
      "pfizer sangamo 0.139\n",
      "five 0.138\n",
      "pfizer 0.136\n",
      "positioned 0.135\n",
      "waning 0.131\n",
      "latest result 0.131\n",
      "sangamo 0.127\n",
      "patient phase ii 0.127\n",
      "haemophilia gene 0.127\n",
      "sb 0.124\n",
      "chart show 0.121\n",
      "\n",
      "Abstract:\n",
      "recently covid vaccine grabbing headline monoclonal antibody might provide nearer term weapon pandemic making quiet progress today lilly reported first data clinical trial antibody result ly cov looked promising mean emphatic data needed approach deemed success still several candidate already phase iii definitive answer might available soon blazing trail ly cov one late stage candidate phase iii trial blaze evaluating utility preventing covid nursing home resident staff however earlier stage trial yielded interim data today blaze patient mild moderate covid phase ii study tested three dos ly cov mg mg mg versus placebo mg dose met primary endpoint change baseline viral load day lack dose response troubling noted patient placebo group showed near complete viral clearance day lilly noted seen better clearance ly cov three day without giving detail lilly claimed benefit another prespecified endpoint covid related hospitalisation emergency room visit occurred pooled ly cov patient versus placebo group relative risk reduction however small number patient hospitalised five ly cov nine placebo group lilly say whether difference statistically significant company said intends quickly publish data peer reviewed journal question might soon answered might become apparent soon whether lilly apply emergency use authorisation back blaze result might misguided move given mixed data far desperation covid therapy seen project granted euas much flimsier evidence regeneron coming lilly might want get jump regeneron advanced rival latter testing regn cov cocktail two antibody regn regn phase ii iii study ambulatory hospitalised covid patient well phase iii prevention trial preliminary data expected later summer company said meanwhile big player recently taken antibody candidate clinic glaxosmithkline vir biotechnology dosed first patient phase ii iii comet ice trial vir august data expected end year last month astrazeneca started phase trial azd another two antibody cocktail lilly combining ly cov another antibody ly cov another part blaze study table show good progress since evaluate vantage last analysis least among front runner anti covid antibody move quickly clinic june hopefully next set result give clearer picture eventual role antibody fight covid\n",
      "\n",
      "Keywords:\n",
      "ly cov 0.38\n",
      "ly 0.356\n",
      "cov 0.326\n",
      "blaze 0.198\n",
      "lilly 0.18\n",
      "antibody 0.164\n",
      "covid 0.158\n",
      "regn 0.124\n",
      "placebo group 0.122\n",
      "mg 0.102\n",
      "phase 0.095\n",
      "two antibody 0.095\n",
      "cocktail 0.092\n",
      "hospitalised 0.089\n",
      "clearance 0.087\n",
      "iii 0.085\n",
      "placebo 0.08\n",
      "might 0.079\n",
      "data 0.077\n",
      "candidate 0.077\n",
      "\n",
      "Abstract:\n",
      "marinus pharmaceutical might missed big prize sole project ganaxolone year gaba modulator crashed post partum depression group decision switch focus rare epilepsy look like good move company stock climbed albeit low base news pivotal trial success cdkl deficiency disorder cdd several red flag including low placebo response missed secondary endpoint regulator might least want confirmatory trial giving ganaxolone green light marinus meanwhile optimistic chance getting quick approval strength marigold trial result plan file oral ganaxolone u fda mid europe ema third quarter next year group hope doubt fuelled fact approved drug cdd genetic disorder characterised severe epilepsy developmental delay affect around patient apiece u europe marinus estimate market might huge still make difference company size marinus leerink analyst estimate cdd patient receive ganaxolone per year would make peak sale opportunity perhaps importantly marigold data bode well ganaxolone chance rare epilepsy developed including tuberous sclerosis gw pharmaceutical epidiolex recently approved approval cdd net marius priority review voucher although value provide useful source fund marigold bloom marigold primary endpoint change day seizure frequency hit ganaxolone showing median reduction versus reduction placebo statistically significant p value however ganaxolone flattered low placebo response marinus expecting reduction placebo group another reason caution marigold meet predefined secondary endpoint company chief medical officer joe hulihan said conference call discus data study powered primary endpoint rather secondary marinus claimed trial meet significance exploratory secondary endpoint including caregiver global impression change seizure intensity duration however exploratory endpoint cannot definition statistically significant overall issue might scupper ganaxolone chance disease unmet need high patient marigold median seizure per month baseline failed average seven anti epilepsy drug however fda might require marinus carry another pivotal trial reata pharmaceutical recently hit request omaveloxolone developing friedreich ataxia rare neurological disease approved therapy success rare epilepsy would make stronger story least marinus prospect look lot rosier last year\n",
      "\n",
      "Keywords:\n",
      "marinus 0.416\n",
      "ganaxolone 0.416\n",
      "marigold 0.333\n",
      "cdd 0.222\n",
      "epilepsy 0.207\n",
      "rare epilepsy 0.148\n",
      "seizure 0.133\n",
      "endpoint 0.109\n",
      "rare 0.106\n",
      "secondary 0.102\n",
      "pharmaceutical 0.099\n",
      "secondary endpoint 0.092\n",
      "would make 0.089\n",
      "placebo response 0.083\n",
      "placebo 0.08\n",
      "chance 0.073\n",
      "exploratory 0.072\n",
      "low 0.07\n",
      "europe 0.068\n",
      "reduction 0.067\n",
      "\n",
      "Abstract:\n",
      "biopharma world trying figure gilead got bn immunomedics yesterday merck co seattle genetics unleashed next question sector pharma giant seen smaller developer liv targeting antibody drug conjugate ladiratuzumab vedotin limited data released past year underwhelmed clinical trial started back understandably adc largely ignored financial community yet merck plan pump bn seattle corner project potentially hook much progress dependent milestone bn table true term fraction gilead handing trodelvy immunomedics sole asset another adc gilead cancer ambition stretch bn september look deal struck conjugate past year confirms considered prized asset merck certainly afford potential combine asset keytruda appears main draw specifically triple negative breast cancer although merck might seen signal promise tumour type seattle reported data two two study ladiratuzumab vedotin single agent tnbc trial back ongoing phase ii trial combination keytruda first line metastatic disease latter interim data sabcs last december showed overall response rate among patient regardless pd l status although majority partial response time result stand chemotherapy generally achieves orr according leerink analyst tecentriq achieved response rate pd l patient combination abraxane result roche drug approval still track record checkpoint inhibitor cancer type described mixed roche merck notching win loss assumption must therefore merck seen later cut various seattle data warrant pushing particularly patient low pd l expression call yesterday seattle executive spoke working weekly dosing regimen optimise safety efficacy pd l combination although declined say data might released pivotal trial might commence leerink analyst wrote today early data combining seattle vedotin payload keytruda yielded promising signal believe first real test approach come readout phase iii trial another seattle adc adectris trialled combination opdivo hodgkin lymphoma trial checkmate yield data next year confirmation metastatic breast cancer express liv however tumour type ovarian prostate express marker lesser extent merck presumably party data separate ongoing solid tumour study got way late however seattle executive yesterday promised optimised data several tumour type future term deal see partner sharing profit cost equally suggestion second generation liv targeting adcs horizon front merck bought another revenue term right commercialise tukysa targeting kinase inhibitor asia middle east global location merck move much liv target seem feature company pipeline according search evaluatepharma database make ladiratuzumab vedotin unique opportunity raise question others managed get anything clinic high expression breast cancer would seem attractive target pursue much data needed explain merck move meantime perhaps deal see others finally take liv seriously\n",
      "\n",
      "Keywords:\n",
      "seattle 0.31\n",
      "liv 0.298\n",
      "merck 0.235\n",
      "vedotin 0.197\n",
      "ladiratuzumab vedotin 0.167\n",
      "ladiratuzumab 0.167\n",
      "adc 0.139\n",
      "tumour type 0.121\n",
      "data 0.118\n",
      "pd 0.115\n",
      "cancer 0.103\n",
      "tumour 0.103\n",
      "type 0.101\n",
      "breast cancer 0.1\n",
      "breast 0.099\n",
      "deal see 0.098\n",
      "combination 0.096\n",
      "past year 0.089\n",
      "express 0.089\n",
      "keytruda 0.088\n",
      "\n",
      "Abstract:\n",
      "remaining doubt gilead intent become oncology player blown away last night group bn purchase immunomedics immediate question whether gilead overpaid although seattle genetics might wondering one got away seattle tried license immunomedics antibody drug conjugate sacituzumab govitecan approved trodelvy mere three year ago thwarted activist investor venbio immunomedics decision go alone appears justified seattle unlikely sore today announced substantial tie merck co immunomedics certainly waiting long time moment company founded back investor kept faith several setback including complete response letter celebrating big payday per share purchase price represents premium friday close stock beginning year gilead obviously troubled manufacturing issue spurred crl coin overused biopharma phrase belief found pipeline product trodelvy group work cut justify price tag evaluatepharma npv derived sellside consensus sale number put trodelvy net present value bn deal largest biopharma year far well biggest gilead history start gilead need expand trodelvy trop targeting adc beyond current use late line triple negative breast cancer received accelerated approval april group gunning earlier line therapy tnbc well new tumour type including bladder non small cell lung cancer indication strategy might pan upcoming esmo meeting virtual conference see full data ascent trodelvy confirmatory tnbc trial perhaps even eagerly awaited updated result pivotal trophy u trial urothelial cancer merdad parsey gilead chief medical officer pointed really promising data bladder cancer conference call yesterday discus deal result need improved interim analysis trophy u presented esmo last year found overall response rate short orr seen seattle genetics adc padcev metastatic urothelial cancer however mr parsey yesterday highlighted trodelvy better tolerability profile maybe gilead plan position immunomedics agent safer alternative combo year esmo feature data trodelvy combination possibly parp checkpoint inhibitor adc trialled alongside like clovis rubraca roche tecentriq future investor watching data tropic trial hr positive negative metastatic breast cancer due next year decent data aforementioned trial help gilead stay ahead astrazeneca recently licensed another trop targeting adc d daiichi sankyo another astra daiichi tie put trop focus july stable drug linker lower drug antibody ratio mean le toxicity d although project phase becomes apparent whether indeed case gilead need several opportunity come deal trodelvy immunomedics pipeline list one clinical asset adc targeting ceacam immu progress past year presumably abandoned seems likely competitive bidding process drove immunomedics price leerink analyst claimed least four company involved negotiation maybe merck one given deal seattle today gilead shown shy paying top dollar although group chief executive dan day insisted yesterday medium sized deal group still firepower bolt ons time tell acquiring immunomedics masterstroke along line pharmasset dud like kite\n",
      "\n",
      "Keywords:\n",
      "trodelvy 0.367\n",
      "immunomedics 0.307\n",
      "gilead 0.238\n",
      "adc 0.216\n",
      "seattle 0.181\n",
      "trop 0.148\n",
      "cancer 0.116\n",
      "trophy 0.104\n",
      "trop targeting 0.104\n",
      "deal 0.097\n",
      "tnbc 0.092\n",
      "esmo 0.091\n",
      "maybe 0.089\n",
      "bladder 0.089\n",
      "urothelial cancer 0.081\n",
      "urothelial 0.081\n",
      "daiichi 0.079\n",
      "seattle genetics 0.075\n",
      "although 0.074\n",
      "genetics 0.073\n",
      "\n",
      "Abstract:\n",
      "year esmo meeting starting virtual format week show whether bristol myers squibb exelixis chance competing keytruda attempt muscle established territory front line renal cancer come courtesy checkmate er study full data secured star billing presidential session saturday though meeting tends offer slim picking biotech investor presentation trial featuring novel oncology mechanism combination ignored either title available abstract present text poster presentation go live pm eastern time sunday monday central european time rest presentation including late breaker made available two embargo lift pm eastern next thursday friday checkmate er pitting opdivo plus cabometyx front line renal cancer vital represents bristol exelixis bid remain relevant setting renal cancer thought opdivo important use combination inlyta bavencio especially keytruda pose serious threat opdivo cabometyx initial competitor based checkmate cabosun trial space moved quickly er nod fact checkpoint blockade plus kinase inhibition dominant force front line disease er hazard ratio toplined absolute median number progression free overall survival well patient demographic key focus esmo study interest competitor read across include amgen sotorasib though nsclc followed mirati shareholder fan kras targeting merck co anti tigit mab vibostolimab interest investor arcus recently floated iteos despite roche merck massive investment tigit mechanism approach look like potential part pd l combo judging roche early data mainly pd l high subject opportunity merck others differentiate clear somewhat radar trial mediola study astrazeneca lynparza combined imfinzi avastin non brca mutated ovarian cancer help investor handicap large clinical programme testing lynparza combination keytruda especially keylynk trial similar setting novel mechanism far novel mechanism go merck anti immunoglobulin like transcript project mk alkermes attempt utilising il via alks mersana napi b antibody drug conjugate xmt attract attention mersana surged may early xmt data lot live beyond exelixis ipsen involvement checkmate er biotech investor might look pd ctla bispecific approach macrogenics akeso feature oral esmo presentation servier low key pd asset combined lag tim blockade get similar billing however perhaps intriguing abstract come beigene combining pd pd l blockade trial urothelial cancer patient debate better approach whether combined really tested whether early study capable demonstrating additive effect separate question course prepping esmo discussion healthcare specialist biotech investor brad loncar free listen esmo congress take place virtual format september story late breaking abstract published separately\n",
      "\n",
      "Keywords:\n",
      "er 0.229\n",
      "pd 0.174\n",
      "esmo 0.164\n",
      "checkmate er 0.145\n",
      "checkmate 0.143\n",
      "exelixis 0.141\n",
      "renal cancer 0.134\n",
      "biotech investor 0.134\n",
      "presentation 0.124\n",
      "pm eastern 0.113\n",
      "pm 0.113\n",
      "billing 0.113\n",
      "blockade 0.11\n",
      "abstract 0.11\n",
      "mechanism 0.108\n",
      "renal 0.108\n",
      "virtual format 0.107\n",
      "eastern 0.107\n",
      "cancer 0.104\n",
      "xmt 0.103\n",
      "\n",
      "Abstract:\n",
      "presentation title upcoming esmo congress made available judging late breaking abstract meeting look another one heavy focus big pharma immunotherapy among late breaker two tumour type stand particular focus front line gastric cancer merck co bristol myers squibb square triple negative breast cancer interest follower roche immunomedics common medical meeting esmo take place virtual format congress start september keen analysing data submitted still wait text late breaking presentation go live two embargo lift pm eastern next thursday friday central european time friday saturday respectively however title least give good idea look gastric oesophageal gastroesophageal junction cancer focus presidential session monday september fewer four late breaking study profiled concerning keytruda opdivo either first line adjuvant setting keytruda anti pd l mab gastric gastroesophageal junction cancer label third line last month bristol said opdivo became first drug show first line survival benefit courtesy checkmate study week later keytruda scored keynote trial feature esmo allow interesting comparison merck bristol chase front line market tnbc meanwhile roche tecentriq star impassion neoadjuvant study toplined positive pd l positive patient comer alike course tecentriq already front line tnbc label pd l expressers basis abraxane combo impassion study esmo post mortem failed impassion trial interest wanting understand abraxane combo worked non encapsulated paclitaxel interesting impassion highlighted late breaker two failed trial keytruda keynote urothelial cancer novartis combi study spartalizumab plus tafinlar mekinist braf positive melanoma similarly feature late breaking presentation presumably esmo continues trying counter excessively positive data reporting biotech biotech investor keenly follow presentation immunomedics ascent trial late line tnbc basis trodelvy approved super quick time late breaker presented saturday afternoon biotech relevant late breaker include seattle genetics tisotumab vedotin scored june late line cervical cancer remission rate investor try gauge whether enough regulatory filing keen tease benefit specifically third line patient agenus apparently beneficiary unexpected late breaker featuring take pd ctla combo balstilimab plus zalifrelimab group come extremely late game combo tested cervical cancer keytruda monotherapy already available prepping esmo discussion healthcare specialist biotech investor brad loncar free listen esmo congress take place virtual format september story presentation beyond late breaker published separately\n",
      "\n",
      "Keywords:\n",
      "late 0.277\n",
      "late breaker 0.221\n",
      "breaker 0.218\n",
      "esmo 0.204\n",
      "impassion 0.19\n",
      "late breaking 0.163\n",
      "line 0.156\n",
      "breaking 0.153\n",
      "presentation 0.138\n",
      "tnbc 0.132\n",
      "keytruda 0.132\n",
      "cancer 0.13\n",
      "gastric 0.125\n",
      "congress 0.117\n",
      "pd 0.103\n",
      "combo 0.101\n",
      "junction 0.1\n",
      "gastroesophageal junction 0.1\n",
      "gastroesophageal 0.1\n",
      "virtual format 0.095\n",
      "\n",
      "Abstract:\n",
      "last year novo nordisk said hoped double obesity sale target already look beatable impressive data semaglutide prompted analyst raise forecast danish group obesity franchise hopeful sign next generation combination project currently sellside consensus compiled evaluatepharma see novo exceeding goal would equate sale bn far company cautious raising expectation novo chief science officer mads krogsgaard thomsen tell evaluate vantage analyst might right track never said double said double say got better data step programme semaglutide combo predicted might achieve target earlier thought key bullish expectation semaglutide active ingredient novo latest glp agonist drug already marketed diabetes name ozempic rybelsus lower dos obesity sema look odds approval obesity back impressive data step programme novo targeting weight loss least non placebo adjusted basis step trial found loss company plan file sema new indication end analyst expectation sema obesity rising since first step trial read may evaluatepharma consensus show present sellside expects sema overtake novo existing obesity drug saxenda saxenda particularly effective leading around weight loss still managed generate sale last year sema represents step efficacy novo hope even better group long time ambition find drug generate weight loss line achieved bariatric surgery least novo big thinking obesity pay april danish company belief might possible latest obesity hopeful combination sema amylin analogue others little luck targeting amylin mr thomsen previously told evaluate vantage novo made improvement help avoid nausea seen amylin pharmaceutical pramlintide example phase ii data combo released august showed weight loss sema combo week\n",
      "\n",
      "Keywords:\n",
      "sema 0.39\n",
      "obesity 0.372\n",
      "novo 0.341\n",
      "weight loss 0.207\n",
      "step 0.18\n",
      "amylin 0.167\n",
      "weight 0.165\n",
      "loss 0.164\n",
      "semaglutide 0.143\n",
      "thomsen 0.117\n",
      "step programme 0.111\n",
      "saxenda 0.111\n",
      "hopeful 0.107\n",
      "double 0.098\n",
      "impressive data 0.098\n",
      "danish 0.093\n",
      "expectation 0.092\n",
      "combo 0.088\n",
      "generate 0.069\n",
      "sale 0.061\n",
      "\n",
      "Abstract:\n",
      "pausing astrazeneca phase iii trial covid vaccine candidate timely reminder project rushed market detail available nature adverse event seen study azd news put safety squarely back focus recent talk emergency approval based preliminary data hard say yet whether hold knock effect covid vaccine developer johnson johnson cansino like astra using adenoviral vector vaccine face particularly nervous wait question answer right known u phase iii trial azd put hold unnamed adverse event seen trial participant uk possibly phase ii iii study reported stat later new york time reported event might transverse myelitis inflammation spinal cord triggered viral infection astrazeneca would confirm whether transverse myelitis seen saying standard review process triggered voluntarily paused vaccination allow review safety data independent committee company described routine action astra share london stock exchange fell much largely recovered end day still many unanswered question urgent event transverse myelitis related azd first time study azd put hold another trial paused july participant developed transverse myelitis according volunteer information sheet later deemed unrelated vaccine although two similar event would raise alarm bell come pas even event turn something le serious transverse myelitis even unrelated vaccine astra still facing delay week month comb safety database leerink analyst estimated adenovirus anxiety worst confirmed might time j j cansino start worrying azd us chimp adenoviral vector express coronavirus spike protein j j china cansino use human adenovirus deliver spike protein currently marketed vaccine employ chimp adenoviral vector although j j recently got eu approval ebola vaccine us adenovirus vector covid vaccine candidate another ebola vaccine merck co ervebo us different viral vector vesicular stomatitis virus approved u hold least little read developer advanced covid vaccine candidate biontech pfizer moderna project use different approach mrna however mrna unproven technology news underscore need cautious project tested relatively people far true developing conventional recombinant protein based vaccine novavax sanofi glaxosmithkline former said plan start uk phase iii trial third quarter project latter two group set go pivotal development december however covid vaccine developer see sale affected vaccine hesitance general population product get market already concern rushing vaccine development make people wary getting coronavirus shot help fan anti vaccine sentiment safety scare would add even nothing worrying found might make volunteer afraid enrol latter issue trouble biontech pfizer moderna recruited phase iii study impressive speed almost reached target perhaps biggest surprise many patient receiving novel vaccine big safety scare one story corrected include detail j j ebola vaccine\n",
      "\n",
      "Keywords:\n",
      "vaccine 0.38\n",
      "transverse myelitis 0.222\n",
      "transverse 0.222\n",
      "myelitis 0.222\n",
      "vector 0.176\n",
      "azd 0.165\n",
      "adenoviral vector 0.14\n",
      "adenoviral 0.14\n",
      "covid vaccine 0.134\n",
      "ebola vaccine 0.128\n",
      "cansino 0.128\n",
      "covid vaccine candidate 0.117\n",
      "ebola 0.114\n",
      "vaccine candidate 0.109\n",
      "adenovirus 0.109\n",
      "event 0.105\n",
      "hold 0.099\n",
      "pfizer moderna 0.094\n",
      "biontech pfizer moderna 0.094\n",
      "us 0.092\n",
      "\n",
      "Abstract:\n",
      "albireo mirum vying get first bile acid transporter inhibitor market albireo scored point rival data odevixibat rare paediatric liver disorder progressive familial intrahepatic cholestasis pfic mirum know need lead bile acid transporter maralixibat project pivotal march trial pfic set complete december however mirum targeting narrower patient population evaluatepharma sellside consensus currently expects odevixibat lead bile acid inhibitor early trade share astrazeneca spinoff albireo initial fall mirum rallied climbed couple percent albireo look like cleared path odevixibat approval pfic life threatening disorder characterised build bile liver currently approved drug treatment pfic surgical option include partial external biliary diversion liver transplant pruritis itching one troublesome symptom pfic one co primary endpoint albireo patient phase iii study pedfic co primary bile acid response study met endpoint high degree statistical significance pruritis improvement defined one point greater reduction point scale\n",
      "\n",
      "Keywords:\n",
      "pfic 0.368\n",
      "albireo 0.368\n",
      "bile 0.325\n",
      "mirum 0.315\n",
      "bile acid 0.295\n",
      "odevixibat 0.221\n",
      "acid 0.205\n",
      "transporter 0.147\n",
      "pruritis 0.147\n",
      "bile acid transporter 0.147\n",
      "acid transporter 0.147\n",
      "liver 0.123\n",
      "co primary 0.099\n",
      "currently 0.082\n",
      "point 0.081\n",
      "disorder 0.078\n",
      "vying 0.07\n",
      "study met 0.07\n",
      "reduction point 0.07\n",
      "percent 0.07\n",
      "\n",
      "Abstract:\n",
      "two pivotal trial merck chronic cough project gefapixant top lined success march full data p x receptor inhibitor efficacy look quite impressive drug reduced coughing much le dramatic extent seen phase ii probably soon write gefapixant chance approval data coupled drug poor side effect profile limit potential market according full data cough trial presented virtual congress european respiratory society higher gefapixant dose mg twice daily demonstrated statistically significant reduction hour cough frequency versus placebo cough respectively reduction calculated using complex formula disappointing compared achieved earlier trial phase ii mg dose gefapixant achieved placebo adjusted reduction hour cough frequency week noted relative reduction calculation figure made explicit approval industry watcher note cough reduction gefapixant look pretty similar achieved failed phase ii trial bellus rival cough therapy blu mg twice daily dose reduced awake cough frequency slightly different measure hour cough frequency endpoint used merck bellus choke chronic cough july today bellus outlined plan phase iib trial focusing particularly badly affected patient phase iii data gefapixant underwhelming patient improvement course trial considered mean reduction baseline cough frequency mg dose cough cough however placebo treated patient saw reduction baseline cough respectively concerning fact efficacy seems waning time patient cough received drug six month twice long cough achieved smaller effect tolerability aspect gefapixant notorious unpleasant side effect alteration loss taste cough respectively patient experienced taste related adverse event subject respectively discontinued therapy adverse event data filed regulator merck said unmet need refractory unexplained chronic cough approval might possible higher dose hit study endpoint difficulty come convincing doctor mild treatment effect worth side effect gefapixant currently forecast sell according sellside consensus evaluatepharma figure might trimmed perhaps point merck investor start wondering company bothering\n",
      "\n",
      "Keywords:\n",
      "cough 0.656\n",
      "gefapixant 0.311\n",
      "cough frequency 0.194\n",
      "frequency 0.148\n",
      "hour cough frequency 0.137\n",
      "cough respectively 0.137\n",
      "reduction 0.129\n",
      "hour cough 0.128\n",
      "bellus 0.117\n",
      "chronic cough 0.113\n",
      "achieved 0.095\n",
      "hour 0.093\n",
      "respectively 0.089\n",
      "mg 0.083\n",
      "dose 0.08\n",
      "effect 0.08\n",
      "twice 0.078\n",
      "taste 0.078\n",
      "chronic 0.076\n",
      "twice daily 0.073\n",
      "\n",
      "Abstract:\n",
      "approval viela bio uplizna earlier year represented swift progress company founded marked another successful transition market astrazeneca spinout three company pharma giant actively set independent path another seen drug approved third late stage trial company albireo entasis track record arguably make astra one successful big pharma company come building new home unwanted asset evaluate vantage review activity find merck kgaa far enthusiastic spinner forged nine young start ups last decade though still around today back merck kgaa biotech unit merck serono pledged seed number company dramatically cutting back reshaping r operation geneva lead string spinouts including asceneuron calypso biotech ionctura remain early stage company tocopherx appears longer exist although prexton first spun acquired lundbeck front defining spinout become slightly complicated emergence motivated venture firm actively seek unwanted project set build company around decade ago activity much driven parent pharma company provided asset frequently staff although external partner generally brought provide financing example bing yao chief executive viela head respiratory inflammation autoimmunity astrazeneca medimmune unit striking head start alongside several astra staffer external investor initially injected astra retained large stake similar model used spinouts albireo entasis compare start like impact biomedicine set around fedratinib asset abandoned sanofi company explicitly set buy jak inhibitor pharma giant aided large part medicxi venture firm big proponent called asset centric investment model sanofi retained stake impact formation company driven party external pharma giant grey area course certain extent come semantics take corvidia therapeutic example recently bought novo nordisk front company founded venture firm sofinnova apple tree funded licensing deal astrazeneca project earmarked selling true corvidia took several former astra employee however pharma giant consider corvidia spinout strict definition term track record overview focus spinouts far determined driven parent company focus set large drug developer concern spinouts research stage company separation business unit product already market vantage search evaluatepharma database found company set independent path formed past decade spun global drug maker nine remain private moved stock market seven either bankrupt longer appear active ten acquired nine seen product win approval around quarter company managed cross regulatory finish line pretty impressive given many set early project perhaps though surprising motivated parent unlikely spend time money set new company unless see real potential still necessarily mean investor rush back big pharma spinouts nine got market real commercial success story notable spinouts listed even several taken year deliver achievement venture firm flush cash plenty buyer big pharma cast offs huge developer doubt content complex time consuming activity driven externally\n",
      "\n",
      "Keywords:\n",
      "spinouts 0.344\n",
      "venture firm 0.204\n",
      "set 0.186\n",
      "company 0.179\n",
      "pharma 0.174\n",
      "pharma giant 0.156\n",
      "external 0.153\n",
      "corvidia 0.153\n",
      "venture 0.147\n",
      "spinout 0.147\n",
      "parent 0.147\n",
      "giant 0.146\n",
      "firm 0.132\n",
      "nine 0.13\n",
      "astra 0.119\n",
      "driven 0.118\n",
      "unit 0.117\n",
      "decade 0.108\n",
      "viela 0.107\n",
      "albireo 0.107\n",
      "\n",
      "Abstract:\n",
      "safety concern long haunted akebia oral anaemia project vadadustat yesterday fear materialised pill demonstrated worse cardiac safety epo agent aranesp two crucial chronic kidney disease study finding wreck vadadustat chance approval clearly disaster akebia lost three quarter market cap assumption vadadustat even manage limp onto market fibrogen already considered leader field developer advanced hif ph inhibitor roxadustat removal close rival prove advantageous company stock fell yesterday suggesting situation simple true fibrogen share initially rise vadadustat news closed wider market retreated reason caution optimism term plus point fact fibrogen market along marketing partner astellas astrazeneca certainly big one glaxosmithkline hif ph inhibitor daprodustat pivotal development result unlikely emerge contender going two distinct market dialysis dependent patient yet progress dialysis epo widely used treat anaemia first group known cardiac risk class mean receive latter setting patient generally le sick pivotal programme fibrogen demonstrated roxadustat non inferior placebo efficacy mean haemoglobin change cardiac safety group company certainly without critic many concerned roxadustat stand regulatory scrutiny point adcom called ahead december pdufa date read positive sign akebia meanwhile shown vadadusat non inferior aranesp ckd patient dialysis inno vate study secure approval indication company contends problem lie non dialysis patient pro tect trial vadadustat pitted aranesp former proving non inferior primary efficacy endpoint mean change haemoglobin primary safety endpoint time first major adverse cardiac event hazard ratio failed cross non inferiority margin suggests patient vadadustat arm greater risk dying suffering heart attack stroke taking aranesp given margin prospectively agreed fda seems implausible approval considered patient approval dialysis dependent patient surely threatened however akebia still broad label sight full data four trial pivotal programme presented american society nephrology annual meeting october totality data path forward emerge executive insist conference call regional patient characteristic hinted explain different safety finding pro tect inno vate inno vate enrolment skewed u akebia executive said seems blame might laid foot different standard care part world see data together agree path forward chief executive john butler said straightforward path forward believe support approval dialysis non dialysis patient akebia argument thus seems somewhat contradictory claiming indication distinct time approval gained totality data meeting fda planned later year regulator decide whether hold water class effect implication fibrogen still hard gauge vadadustat aside far assured roxadustat get clean broad label company vadadustat would fail roxadustat seemed succeed becomes crucial question different molecule course answer simple fibrogen bull long argued roxadustat better designed dosed trial design another factor roxadustat pitted placebo vadadusat versus active agent argued fibrogen favour surely harder demonstrate non inferior safety sugar pill fda verdict roxadustat emerges impossible rule fear class effect reflected label understandable view pro tect finding increasing chance outcome\n",
      "\n",
      "Keywords:\n",
      "vadadustat 0.325\n",
      "roxadustat 0.292\n",
      "dialysis 0.273\n",
      "fibrogen 0.263\n",
      "akebia 0.243\n",
      "aranesp 0.171\n",
      "non inferior 0.156\n",
      "inferior 0.151\n",
      "inno vate 0.137\n",
      "non 0.13\n",
      "tect 0.128\n",
      "pro tect 0.128\n",
      "cardiac 0.12\n",
      "pro 0.11\n",
      "path forward 0.107\n",
      "safety 0.093\n",
      "patient 0.091\n",
      "approval 0.086\n",
      "totality data 0.085\n",
      "non dialysis 0.085\n",
      "\n",
      "Abstract:\n",
      "move gilead abbvie reckons got differentiated cd targeting agent abbvie stand pay lot le lemzoparlimab licensed chinese group mab biopharma today bn gilead shelled forty seven march abbvie still need prove lemzoparlimab indeed contender full phase data coming soon closely watched two big deal year quite turnaround cd mechanism looked moribund celgene termination anti cd mab cc others space far left cold trillium hope renewed interest bag partner buyer simply best mab claim lemzoparlimab known tjc different rest minimises binding red blood cell company say caused adverse event like anaemia older cd antibody chinese group claim project demonstrated differentiated profile phase u trial patient solid tumour lymphoma full data presented sitc meeting november mab executive said conference call today abbvie obviously saw enough pique interest deal mab heavily back end loaded group pay front license lemzoparlimab outside china due project hit certain clinical regulatory milestone another milestone dependent sale bn biodollars biggest outlicensing deal china based biotech company mab exec said call still pale comparison bn gilead paid forty seven cd worth bn gilead march might come abbvie first dibs two lemzoparlimab based bispecific antibody currently preclinical development mab reckons utility solid tumour hope start clinical trial next year potential combine lemzoparlimab abbvie agent mab exec highlighted venclexta lemzoparlimab one potential combo competition gilead magrolimab poised start phase iii putting ahead sizeable pack includes trillium another group touted potential acquisition target trillium stock sank today perhaps missed getting acquired pharma interest cd resurgent deal coming buyer plenty asset choose\n",
      "\n",
      "Keywords:\n",
      "lemzoparlimab 0.476\n",
      "mab 0.259\n",
      "cd 0.215\n",
      "abbvie 0.196\n",
      "bn gilead 0.191\n",
      "trillium 0.168\n",
      "gilead 0.146\n",
      "differentiated 0.127\n",
      "chinese group 0.112\n",
      "exec 0.097\n",
      "deal 0.095\n",
      "forty seven 0.094\n",
      "forty 0.094\n",
      "reckons 0.092\n",
      "solid tumour 0.09\n",
      "interest 0.088\n",
      "chinese 0.087\n",
      "buyer 0.085\n",
      "solid 0.084\n",
      "milestone 0.083\n",
      "\n",
      "Abstract:\n",
      "end year amgen see data three key late stage programme sotorasib nsclc omecamtiv heart failure asthma project tezepelumab astrazeneca see share profit tezepelumab valuable pipeline project amgen blockbuster number expected evaluatepharma consensus suggests tezepelumab evaluated phase iii navigator study severe asthma market crowded biologicals amgen astra targeting specific type disease non eosinophilic treatment option novel monoclonal antibody chequered past recently failed phase ii trial atopic dermatitis flunking indication might bode well asthma trial given disease similar mechanism however amgen maintained second quarter earnings call result atopic dermatitis limited read navigator company added best insight tezepelumab might perform asthma would come large phase ii asthma study trial pathway success tested tezepelumab add corticosteroid labas found reduction annual asthma exacerbation three dos subcutaneous tezepelumab significant versus placebo reduction similar patient baseline eosinophil count l eosinophilia high level white blood cell present approximately severe asthma case monoclonal antibody including sanofi dupixent expected market leader astra fasenra glaxosmithkline nucala primarily target eosinophilic phenotype non eosinophilic disease common poorly understood amgen astra hope find place tezepelumab demonstrating efficacy severe uncontrolled asthma irrespective baseline eosinophil count navigator trial patient severe disease inadequately controlled despite treatment inhaled corticosteroid plus one additional asthma controller medicine primary endpoint annualised asthma exacerbation rate safety closely watched given tezepelumab novel agent target thymic stromal lymphopoietin tslp il like cytokine concern inhibiting action tslp raise risk infection cytokine thought play role host defence infection pathway safety data looked relatively clean though three serious drug related adverse event result impaired host defence pneumonia stroke patient guillain barr syndrome another anti tslp mab development novartis inhaled csj due start phase ii soon gsk roche project early development seem abandoned according evaluatepharma data astra lead development tezepelumab project one five antibody covered deal astra struck amgen back front astra see share profit tezepelumab forecast become amgen fourth biggest growth driver according evaluatepharma sellside consensus setback would leave rather large hole company pipeline\n",
      "\n",
      "Keywords:\n",
      "tezepelumab 0.496\n",
      "asthma 0.453\n",
      "amgen 0.227\n",
      "astra 0.165\n",
      "tslp 0.149\n",
      "eosinophilic 0.141\n",
      "navigator 0.136\n",
      "severe 0.104\n",
      "severe asthma 0.099\n",
      "eosinophil count 0.099\n",
      "eosinophil 0.099\n",
      "exacerbation 0.094\n",
      "defence 0.094\n",
      "monoclonal antibody 0.091\n",
      "monoclonal 0.091\n",
      "inhaled 0.085\n",
      "atopic dermatitis 0.079\n",
      "atopic 0.079\n",
      "dermatitis 0.077\n",
      "host 0.073\n",
      "\n",
      "Abstract:\n",
      "astrazeneca think found new standard care chronic kidney disease shape diabetes drug farxiga drug appears perform well better patient without type diabetes condition impressive result dapa ckd trial presented european society cardiology congress yesterday give astra shot market comprising million patient many early stage ckd patient showing symptom finding tricky dapa ckd conducted diabetic non diabetic patient ckd known hit since stopped overwhelming efficacy march farxiga tie fourth string bow march esc heard yesterday study found reduction primary endpoint composite worsening renal function renal cardiovascular death farxiga versus placebo patient taking sglt inhibitor relative reduction cause death\n",
      "\n",
      "Keywords:\n",
      "ckd 0.401\n",
      "farxiga 0.257\n",
      "dapa ckd 0.209\n",
      "dapa 0.183\n",
      "diabetic 0.168\n",
      "renal 0.14\n",
      "patient 0.129\n",
      "diabetes 0.129\n",
      "death 0.109\n",
      "versus placebo patient 0.104\n",
      "patient many 0.104\n",
      "diabetic non diabetic 0.104\n",
      "diabetic non 0.104\n",
      "ckd patient 0.104\n",
      "string bow 0.1\n",
      "society cardiology 0.1\n",
      "reduction primary endpoint 0.1\n",
      "reduction primary 0.1\n",
      "overwhelming 0.1\n",
      "found reduction 0.1\n",
      "\n",
      "Abstract:\n",
      "pivotal explorer hcm trial myokardia mavacamten top lined success may magnitude benefit placebo patient hypertrophic cardiomyopathy revealed twice many responder treatment group placebo arm myokardia well track submit nda beginning next year question investor whether data good enough approval hook partner perhaps buyer hypertrophic cardiomyopathy common genetic cardiovascular disease affecting one people severe case experience progressive thickening heart muscle consequent angina heart failure arrhythmia syncope sudden cardiac death therapy specifically hcm exist symptom managed generic drug including beta blocker blood thinner novartis heart failure therapy entresto used label cardiac myosin inhibitor mavacamten become first therapy treat underlying cause disorder explorer hcm set mavacamten placebo patient symptomatic obstructive hcm patient received initial mg dose per day two opportunity week adjust dose mg mg based drug plasma concentration measure heart health data presented virtual meeting european society cardiology today showed patient randomised mavacamten responded compared placebo recipient highly statistically significant finding patient deemed responded met various measure cardiac function listed secondary endpoint met statistical significance explorer hcm threw safety concern either rate treatment emergent adverse event serious cardiac adverse event similar two arm rate serious adverse event numerically higher placebo presenting data professor iacopo olivotto careggi university hospital florence said explorer hcm result provide evidence support mavacamten first potential disease specific targeted treatment obstructive hcm fda without approved therapy available comparison tricky predict mavacamten chance regulatory success possible drug help patient considered good enough possibility seems fairly remote mavacamten breakthrough status suggesting fda board trial design hcm clear unmet need mavacamten advanced project development hcm way ongoing academic phase ii trial silicofcm comparing entresto lifestyle management perhaps novartis glom onto result seek label expansion hcm pharma giant said nothing case phase iii trial would presumably necessary otherwise celltrion ct g patient phase trial versus placebo primary outcome measure adverse event rate day administration data come early fda play ball myokardia hcm niche time analyst forecasting blockbuster sale bn according sellside consensus compiled evaluatepharma myokardia might able attract partner company partnered lianbio china since myokardia partnership sanofi ended january right u europe grab buyer group stock doubled price top line hit revealed myokardia market cap excess bn opportunity bigger player bag bargain might passed\n",
      "\n",
      "Keywords:\n",
      "hcm 0.493\n",
      "mavacamten 0.359\n",
      "myokardia 0.242\n",
      "explorer hcm 0.179\n",
      "explorer 0.179\n",
      "cardiac 0.133\n",
      "heart 0.115\n",
      "placebo 0.109\n",
      "obstructive hcm 0.094\n",
      "adverse event 0.093\n",
      "adverse 0.091\n",
      "hypertrophic cardiomyopathy 0.09\n",
      "hypertrophic 0.09\n",
      "obstructive 0.086\n",
      "cardiomyopathy 0.086\n",
      "entresto 0.083\n",
      "patient 0.078\n",
      "placebo patient 0.077\n",
      "responded 0.072\n",
      "good enough 0.071\n",
      "\n",
      "Abstract:\n",
      "year ago astrazeneca reported impressive data diabetes drug farxiga heart failure patient without diabetes year european society cardiology meeting lilly boehringer ingelheim shown almost identical effect rival sglt inhibitor jardiance true emperor reduced study jardiance enrolled sicker patient population dapa hf trial farxiga heart failure benefit starting look like class effect sglt jardiance maker want regain ground astra saw farxiga approved heart failure reduced ejection fraction may however astra long make mark cardiologist notoriously conservative perhaps jardiance suffer much fast follower royal rumble based evidence far much differentiate two agent emperor reduced showed reduction composite primary endpoint cardiovascular death hospitalisation jardiance versus placebo finding published new england journal medicine almost carbon copy result reported dapa hf last year esc farxiga look dapa outside diabetes september however difference trial population come play study enrolled patient ejection fraction le emperor reduced author noted study included patient markedly reduced ejection fraction le demonstrating emperor reduced population severe incidence primary outcome around higher versus dapa hf investigator added driven hospitalisation notwithstanding plenty parallel trial study overall benefit driven impact hospitalisation rather cardiovascular death however marked emperor reduced risk hospitalisation lower jardiance versus placebo risk cv death reduced contrast dapa hf found reduction risk cv death reduction risk worsening hf farxiga trial showed similar benefit diabetic non diabetic emperor reduced diabetic saw reduction risk primary endpoint non diabetic reduction around half patient emperor reduced diabetic similar proportion seen dapa hf safety looked clean trial reassuringly increase number lower limb amputation jardiance emperor reduced side effect closely watched since linked johnson johnson sglt invokana convincing cardiologist spokesperson boehringer told vantage jardiance might filed hf end year look like biggest difficulty getting jardiance approved hf convincing cardiologist use drug lead investigator emperor reduced dr milton packer baylor university alluded esc press conference friday saying hundred thousand hf patient benefit sglt depends whether physician paying attention said many doctor treating hf still using state art year ago added sglt become standard care hf reduced ejection fraction alongside drug like beta blocker spokesperson astra told vantage soon comment farxiga sale hf presumably soon clue drug uptake new indication press event friday astra head biopharmaceuticals r sir mene pangalos played prospect big battle farxiga jardiance saying company first foremost want grow sglt class whole might take tide turn evidence widespread use mounting\n",
      "\n",
      "Keywords:\n",
      "hf 0.362\n",
      "jardiance 0.31\n",
      "emperor reduced 0.31\n",
      "emperor 0.31\n",
      "reduced 0.281\n",
      "farxiga 0.197\n",
      "dapa 0.181\n",
      "sglt 0.173\n",
      "dapa hf 0.16\n",
      "diabetic 0.138\n",
      "ejection fraction 0.118\n",
      "ejection 0.118\n",
      "hospitalisation 0.115\n",
      "cardiologist 0.109\n",
      "fraction 0.105\n",
      "reduced ejection fraction 0.093\n",
      "reduced ejection 0.093\n",
      "astra 0.08\n",
      "heart failure 0.079\n",
      "reduction 0.078\n",
      "\n",
      "Abstract:\n",
      "hectic august saw fda dish unexpected complete response letter biomarin gilead galapagos september looking quieter scheduled pdufa decision first bristol acute myeloid leukaemia treatment cc oral formulation chemotherapy drug azacitidine aml market look crowded still high unmet need maintenance therapy cc find place data phase iii quazar aml trial released ash last year showed highly significant month median overall survival advantage cc placebo study first line aml maintenance meaning therapy given patient still complete response receiving induction chemo approval looking likely safety acceptable serious adverse event seen patient cc placebo arm respectively bristol need good news aml company targeted drug idhifa recently failed extend survival relapsed refractory aml used alongside best supportive care panel throw question two project awaiting decision september mesoblast ryoncil mallinckrodt terlipressin already subject panel meeting positive case latter one vote terlipressin developed treatment hepatorenal syndrome type type progressive kidney failure seen people severe liver damage often caused cirrhosis panel questioned terlipressin efficacy phase iii confirm trial prevailed surrogate endpoint death treatment placebo arm panel worried toxicity terlipressin particular concern respiratory failure sepsis high unmet need vulnerable patient population sway regulator adequate rem program implemented however getting terlipressin approved least mallinckrodt concern bankruptcy might soon card company tied liability u opioid crisis bn debt meanwhile mesoblast ryoncil stem cell derived therapy filed steroid refractory acute graft versus host disease sr agvhd child younger australian company rollercoaster august share initially lost panel briefing document questioning ryoncil data manufacturing stock regained panel voted nine one favour turnaround likely fact therapy approved u patient sr agvhd incyte jakafi market older patient scan clinicaltrials gov show study ongoing child aged day year testing jakafi combination steroid acute disease knock back positive ad coms rare fda baring teeth late aforementioned surprise crls nervous wait mallinckrodt mesoblast table list first time supplementary fda approval due september consensus forecast evaluatepharma\n",
      "\n",
      "Keywords:\n",
      "terlipressin 0.319\n",
      "aml 0.266\n",
      "panel 0.263\n",
      "cc 0.213\n",
      "mesoblast 0.182\n",
      "mallinckrodt 0.175\n",
      "jakafi 0.122\n",
      "acute 0.121\n",
      "unmet need 0.102\n",
      "unmet 0.102\n",
      "placebo arm 0.102\n",
      "steroid 0.1\n",
      "child 0.1\n",
      "september 0.096\n",
      "maintenance 0.09\n",
      "refractory 0.084\n",
      "therapy 0.079\n",
      "august 0.079\n",
      "patient 0.075\n",
      "complete response 0.074\n",
      "\n",
      "Abstract:\n",
      "arbutus might seem strange choice partner assembly bioscience company already struggling keep bigger player hepatitis b space recent update ab former rnai based hep b candidate poorly received perhaps assembly little choice rnai project already tied existing deal big pharma agreement two company announced yesterday see assembly lead core inhibitor abi h tested combination ab nucleotide reverse transcriptase inhibitor nrti latter standard care disease news timed coincide easl medical conference several update rnai contender due show standard arbutus assembly need strive data emerging vir biotechnology particular interest vir sirna currently earmarked triple combination study j j working arrowhead roche dicerna paired speculation vir assembly struck deal vir appears efficiently knocking hbsag known surface antigen believed closely watched biomarker need suppressed functional cure achieved ongoing phase ii trial patient found mg dose group achieved maximal reduction hbsag week mean reduction log baseline mean reduction log maintained week cohort easl hear seems encouraging update four week cut data released april vir bid enter hepatitis b race april easl get look johnson johnson rnai contender licensed arrowhead trial conducted combination nrti therapy across three dos jnj patient sustained hbsag reduction log approximately nine month last dose suggesting impressive durability data triple combination study add core inhibitor eagerly awaited wake data patient presented aasld last year longer larger reef trial started last year safety focus elsewhere early data novel antisense project show arbutus assembly glaxosmithkline ionis presentation gsk update previous aasld result patient across patient six hbsag reduction log still one patient trial suffered liver enzyme elevation classified serious adverse event although self resolved safety closely scrutinised full detail project emerge liver enzyme elevation seen arbutus march remain focus assembly partnership progress glaxo confident enough push company said today phase iib programme get way end year interesting see combination push forward assembly arbutus meanwhile said phase iii triple combination trial start next year around virologically suppressed patient need speed competitive space understandable assembly still fighting concern core inhibitor underwhelming aasld presentation showed subject treated abi h managed achieve greater log decrease hbsag easl update promise show much assembly tried argue hbsag le important measure core inhibitor true project managed impressively quash marker infection viral dna rna mizuho analyst recommend buying assembly share point making direct comparison agent entirely fair due different dos combination used certainly true four week mark abi h hbsag log reduction ballpark seen project similar timeframe argue data due next year assembly looking happens patient viral load treatment reduced remains critical milestone company aasld assembly asks investor keep faith november assembly arbutus arguably trailing much bigger rival highly competitive hepatitis b space remains seen whether nascent partnership improve either company chance\n",
      "\n",
      "Keywords:\n",
      "assembly 0.545\n",
      "hbsag 0.249\n",
      "log 0.206\n",
      "arbutus 0.206\n",
      "reduction log 0.156\n",
      "core inhibitor 0.156\n",
      "easl 0.142\n",
      "aasld 0.142\n",
      "vir 0.139\n",
      "core 0.13\n",
      "combination 0.118\n",
      "triple combination 0.117\n",
      "abi 0.117\n",
      "rnai 0.113\n",
      "update 0.111\n",
      "reduction 0.101\n",
      "hepatitis 0.086\n",
      "hbsag reduction log 0.078\n",
      "hbsag reduction 0.078\n",
      "patient 0.073\n",
      "\n",
      "Abstract:\n",
      "moderna first data drop covid vaccine mrna criticised including older subject one need protection coronavirus result released wednesday showed promising immune response older age group alongside acceptable safety profile moderna vaccine logistical edge pfizer biontech rival mrna candidate bnt b mrna stored higher temperature biontech pfizer project making convenient real world use course factor come play company must show vaccine safe efficacious sign far mrna promising meeting cdc advisory committee immunization practice acip heard result yesterday phase niaid sponsored trial vaccine yielded initial data july moderna covid vaccine show promise july first release included data patient aged younger yesterday moderna presented result patient apiece two cohort aged aged receiving two g dos mrna dose moderna taken phase iii patient older age category showed neutralising antibody level similar previously reported younger cohort antibody thought indicator vaccine ability provide protection coronavirus\n",
      "\n",
      "Keywords:\n",
      "vaccine 0.275\n",
      "mrna 0.273\n",
      "moderna 0.265\n",
      "aged 0.213\n",
      "protection coronavirus 0.192\n",
      "older 0.186\n",
      "younger 0.165\n",
      "age 0.15\n",
      "protection 0.142\n",
      "biontech 0.117\n",
      "july 0.115\n",
      "covid vaccine 0.11\n",
      "promising 0.109\n",
      "coronavirus 0.092\n",
      "wednesday 0.091\n",
      "vaccine show 0.091\n",
      "temperature 0.091\n",
      "taken phase 0.091\n",
      "sponsored trial 0.091\n",
      "showed neutralising antibody 0.091\n",
      "\n",
      "Abstract:\n",
      "rare childhood epilepsy space new contender back positive phase ii data ovid therapeutic takeda novel cholesterol hydroxylase inhibitor soticlestat soon go late stage testing win emphatic elektra study showed benefit soticlestat dravet syndrome project look fallen short efficacy bar set zogenix fintepla soticlestat stumbled lennox gastaut syndrome lgs ovid evaluating next step ovid stock climbed much premarket trading ended yesterday perhaps doubt hit home might helped company wasted time announcing fundraising elektra shine ovid doubt following old biotech mantra raising money rather need given elekta face success trial enrolled dravet lgs patient received either soticlestat placebo eight week dose optimisation period followed week maintenance period primary endpoint median change baseline seizure frequency across epilepsy type maintenance phase elekta hit endpoint showing reduction seizure soticlestat treated patient versus increase placebo group statistically significant p value however delving different epilepsy subtypes paint different picture dravet lgs soticlestat showed benefit dravet ovid plan move phase iii however look placebo adjusted number suggests soticlestat efficacy fall short seen higher dose zogenix fintepla approved dravet june least ovid takeda project look better gw pharmaceutical epidiolex number represent absolute difference response rate treatment placebo arm obviously caution applies making cross trial comparison one major difference trial variable response seen placebo notably phase iii trial fintepla found reduction seizure frequency placebo group conversely elekta soticlestat flattered low placebo response ovid executive admitted conference call yesterday increase seizure placebo arm surprised expecting reduction seizure placebo line trial rare epilepsy spell trouble phase iii typical placebo response seen even soticlestat continues fall short fintepla still place especially given fintepla cardiovascular side effect soticlestat adverse event profile looked fairly clean common side effect lethargy constipation raise possibility soticlestat different mechanism action used combination agent rare epilepsy patient often treated multiple drug enrolees elektra four concomitant medication including epidiolex fintepla included drug approved time trial recruiting ovid exec said lgs loss soticlestat chance lgs look doubtful patient elekta showed reduction drop seizure week versus reduction placebo arm statistically significant p ovid exec said encouraged trend lgs pointing heterogeneous disease noting certain patient appeared better others epidiolex approved lgs fintepla behind zogenix reported phase iii win february ovid chief medical officer amit rakhit concluded still possibility move forward lgs company want make sure good handle data announces plan soticlestat forecast bring according evaluatepharma fintepla epidolex expected make bn year\n",
      "\n",
      "Keywords:\n",
      "soticlestat 0.514\n",
      "ovid 0.338\n",
      "lgs 0.316\n",
      "fintepla 0.261\n",
      "seizure 0.19\n",
      "dravet 0.158\n",
      "elekta 0.158\n",
      "placebo 0.156\n",
      "epilepsy 0.147\n",
      "elektra 0.119\n",
      "reduction seizure 0.111\n",
      "zogenix 0.098\n",
      "epidiolex 0.092\n",
      "placebo arm 0.088\n",
      "reduction 0.08\n",
      "zogenix fintepla 0.07\n",
      "rare epilepsy 0.07\n",
      "project look 0.07\n",
      "showed benefit 0.068\n",
      "seizure frequency 0.068\n",
      "\n",
      "Abstract:\n",
      "reversing proteostasis yumanity therapeutic made much two company shared interest protein misfolding reality look like neurodegeneration player wanted public shell call home one question yumanity positioning group forefront revolution neurodegenerative disease drum interest ipo true investor might put notoriously difficult field neuro player denali managed rake cash similarly early stage despite yumanity hubris one project clinic ytx phase parkinson disease initial patient data due second quarter next year project designed inhibit enzyme stearoyl coa desaturase scd thereby protecting neuron toxic effect pathogenic synuclein misfolded version protein seen parkinson various company evaluating anti synuclein mabs none developing scd inhibitor disease according evaluatepharma indeed yumanity project take aim novel target company describes approach applying oncology r principle neurodegeneration looking easily druggable target within network better known trickier hit target conference call yesterday cancer analogy given yumanity chief executive richard peter development mtor inhibitor get around difficulty hitting ra gene mr peter boasted yumanity prolific drug discovery engine fact uncovered novel target however detail scant group next advanced project ytx another scd inhibitor\n",
      "\n",
      "Keywords:\n",
      "yumanity 0.57\n",
      "scd 0.285\n",
      "synuclein 0.162\n",
      "novel target 0.162\n",
      "peter 0.157\n",
      "neurodegeneration 0.157\n",
      "target 0.136\n",
      "parkinson 0.136\n",
      "protein 0.097\n",
      "inhibitor 0.096\n",
      "novel 0.092\n",
      "project 0.088\n",
      "player 0.085\n",
      "shell 0.085\n",
      "richard 0.085\n",
      "revolution 0.085\n",
      "protecting 0.085\n",
      "principle 0.085\n",
      "next advanced 0.085\n",
      "hit target 0.085\n",
      "\n",
      "Abstract:\n",
      "roche novartis endeavoured show durability impressive response rate generated braf mek inhibitor melanoma improved adding pd blockade former look succeeded rival countryman failed combi trial used novartis unapproved pd agent spartalizumab top tafinlar mekinist meet primary endpoint company quietly announced late last friday supposed spartalizumab route market clearly disappointing however closer look roche data setting suggests novartis trial might missed much roche imspire combi study similar design size recruiting untreated metastatic braf positive melanoma patient pitting triple combination pd blockade braf mek inhibition doublet kinase inhibitor therapy roche approval tecentriq back imspire trial june tested anti pd l asset tecentriq top cotellic zelboraf full data detailed aacr year pivotal study used investigator assessed pfs primary endpoint however imspire underwent independent review revealingly reading data failed find statistically significant difference study arm result confirm clear win adding tecentriq setting overall survival remains important readout longer duration response triplet therapy certainly encouraging survival benefit would give finding boost novartis setback leaf roche clear run space implication failure yet prove uncomfortable novartis yet release data combi interesting see close trial came succeeding difference study need scrutinised subtle shift design recruitment played role different outcome roche novartis hope push forward melanoma august cross trial comparison kinase inhibitor backbone used notable hint better underlying efficacy roche doublet certain measure although important overall survival reading tafinlar mekinist seem triumph whatever reason combi failure novartis left even behind competitive anti pd l space huge commercial success anticipated latecomer course internal anti pd agent long considered strategically important combination reason agent number early study experimental mechanism next important readout another later line melanoma study possibly course worst case scenario considered spartalizumab dud company finally approach regulator approval failed phase iii bag might make uncomfortable question story corrected state tecentriq received full approval advanced melanoma accelerated approval\n",
      "\n",
      "Keywords:\n",
      "combi 0.266\n",
      "novartis 0.239\n",
      "melanoma 0.235\n",
      "pd 0.206\n",
      "spartalizumab 0.19\n",
      "braf 0.19\n",
      "roche 0.183\n",
      "tecentriq 0.162\n",
      "tafinlar mekinist 0.133\n",
      "tafinlar 0.133\n",
      "mek 0.133\n",
      "anti pd 0.132\n",
      "uncomfortable 0.127\n",
      "pd agent 0.127\n",
      "mekinist 0.127\n",
      "difference study 0.127\n",
      "pd blockade 0.106\n",
      "doublet 0.106\n",
      "important 0.105\n",
      "survival 0.094\n",
      "\n",
      "Abstract:\n",
      "last night announcement u fda granted emergency use authorisation convalescent plasma covid caused shockwaves inaccurate claim fda made data used support plasma use timing announcement day president trump criticised fda raise question agency credibility reality fast tracking plasma already used covid unlikely make huge difference term usage although make recruiting robust study harder much worrying precedent eua set covid vaccine development safety worry coronavirus vaccine get rushed onto market similar way would prompt even fiercer backlash scientific community main concern small study used basis eua might uncover safety signal would detected larger trial trivial consideration vaccine destined million people worldwide many already harbour worry coronavirus vaccine developed quickly potentially cost safety hint vaccine might available early winter realistic still optimistic scenario available vaccine winter still fast enough financial time reported last night fda considering eua astrazeneca university oxford covid vaccine candidate azd ahead u presidential election november astra made clear nothing idea spokesperson telling vantage company discussed emergency use authorisation u government would premature speculate possibility spokesperson added company anticipate phase ii iii efficacy data later year azd currently patient phase iii study although ft reported eua based patient uk trial yield result sooner interesting timing ft report came day president trump accused deep state whoever fda making difficult drug company test vaccine therapeutic claimed agency hoping delay project presidential election tweet came day eua convalescent plasma announced press conference president trump yesterday timing plasma eua undoubtedly odd week ago go ahead reportedly put hold nih official raised concern data move criticised president yesterday announcement little clear confusion data question president trump fda commissioner stephen hahn claimed convalescent plasma shown reduce mortality study carried mayo clinic crucially randomised placebo controlled trial far carried convalescent plasma us plasma donor recovered covid main data far come preprint observational trial based mayo clinic expanded access programme reported seven day mortality rate patient treated plasma within three day covid diagnosis versus patient treated four day diagnosis unclear figure came fda spokesperson highlighted reduction mortality patient treated high titre versus low titre plasma subgroup analysis subgroup analysis using arbitrary titre cutoff making relevance highly questionable leading widespread condemnation agency perhaps would outrage convalescent plasma decision looked apolitical make sense standard lower euas full approval former designed fast track project intended emergency nothing little else available however latest decision make harder generate definitive evidence convalescent plasma benefit lack given stymie recruitment randomised trial u uk recovery trial uncovered dexamethasone benefit provide answer treated first patient convalescent plasma arm june cohort enrolled patient far data expected late spokesperson told vantage although depends scale epidemic uk coming month ultimately eua might make little difference uptake convalescent plasma already used treat around u patient case limited availability donor way fda announcement made way agency doubled questionable data raise serious doubt whether rigorous standard upheld covid vaccine decision story updated include detail recovery trial enrolment timing\n",
      "\n",
      "Keywords:\n",
      "plasma 0.458\n",
      "convalescent plasma 0.314\n",
      "convalescent 0.287\n",
      "eua 0.242\n",
      "vaccine 0.169\n",
      "president 0.14\n",
      "spokesperson 0.139\n",
      "president trump 0.134\n",
      "trump 0.12\n",
      "timing 0.118\n",
      "fda 0.118\n",
      "titre 0.112\n",
      "announcement 0.109\n",
      "agency 0.106\n",
      "covid 0.105\n",
      "day 0.091\n",
      "mortality 0.084\n",
      "treated 0.084\n",
      "patient treated 0.083\n",
      "emergency 0.078\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Abstract:\n",
      "latest scientific paper preprint typical way covid vaccine data released shed light biontech pfizer decision take bnt b phase iii thing already moved investor focus next trigger fast moving field including pivotal data astrazeneca azd first phase result crop relative laggard including curevac glaxosmithkline johnson johnson last notable week raising target enrolment proposed phase iii study massive volunteer ensemble pivotal trial j j ad cov previously thought starting september clinicaltrials gov entry revealed double enrolment target across hospital u south america south africa philippine ukraine start date september phase iii study astra azd way four day ago high risk individual formal primary completion date december analyst believe initial result first data pivotal covid vaccine study come sooner perhaps october meanwhile fourth quarter see pivotal data moderna mrna biontech pfizer bnt b well perhaps novavax nvx cov though like ad cov last begin phase iii next month nvx cov recently generated first clinical result confirming place covid vaccine race obviously metric investor looking phase iii effective vaccine actually offering protection infection impossible gauge phase data looked neutralising antibody generation cell stimulation measure may may translate real protective effect case point biontech pfizer bnt comprises four separate vaccine bnt b first generate clinical data bnt b went phase iii company explaining b code full protein shown better tolerability b code receptor binding domain generating similar neutralising antibody titre yesterday backed scientific preprint result small head head trial two project described little le injection site pain fewer side effect like chill fatigue b versus b immunogenicity meanwhile broadly similar beyond pivotal front runner early trial covid vaccine swiftly getting way one closely watched curevac cvncov swiftly moved phase ii fourth quarter yield data phase trial volunteer important asset given curevac recent nasdaq flotation swiftly brought fourfold share price increase bn valuation curevac yesterday said held exploratory talk provide eu million dos mrna vaccine though reveal possible price many investor watching gam covid vac adenovirus vaccine developed gamaleya research institute completed two phase study wonder become intriguing asset human data yet released remarkably received regulatory approval russia day ago\n",
      "\n",
      "Keywords:\n",
      "vaccine 0.233\n",
      "bnt 0.218\n",
      "curevac 0.19\n",
      "phase 0.175\n",
      "cov 0.169\n",
      "swiftly 0.142\n",
      "covid vaccine 0.14\n",
      "biontech pfizer 0.131\n",
      "phase iii 0.125\n",
      "iii 0.12\n",
      "covid 0.116\n",
      "pivotal 0.113\n",
      "biontech 0.111\n",
      "ad cov 0.111\n",
      "preprint 0.104\n",
      "data 0.103\n",
      "south 0.102\n",
      "pfizer bnt 0.102\n",
      "nvx cov 0.102\n",
      "nvx 0.102\n",
      "\n",
      "Abstract:\n",
      "biomarin market cap lost bn yesterday u rejection haemophilia gene therapy project valoctocogene roxaparvovec valrox number huge coming close bullish analyst say entire asset worth higher calculation valrox entire npv based consensus sale forecast obvious reading market entirely written valrox true buyside assumption likely even overblown serf cautionary tale enthusiast competing gene therapy roche pfizer sangamo think carefully celebrating win problem valrox waning efficacy rumbling time biomarin hope long term valrox data stem bleeding may gene therapy player making case premium pricing per valrox dose mooted logic would destroyed therapy done procedure biomarin claim u fda moved goalpost demanding long term data approving valrox aka roctavian central point yesterday complete response letter ring hollow question competitor whether must brace similar regulatory demand investor would apparently rather think worry sangamo whose haemophilia gene therapy sb partnered pfizer closed yesterday biomarin key rival roche spark derived rg uniqure amt recently discontinued competitive reason true none competitor suffered waning efficacy similar valrox none reported comprehensive dataset far biomarin since clear whether patient even dosed gene therapy never mind cost smart investor think carefully risk house card worth investigating expectation priced potential gene therapy like valrox seems many analyst model little house card take valrox consensus sale estimate yesterday setback evaluatepharma consensus six bank provided recent forecast saw valrox revenue peaking bn plugging number cashflow model discounting cost capital yield npv bn number wildly kilter yesterday bn market cap decline high would assumption justify loss value one bullish bank put peak sale estimate leerink one point suggested valrox would sell bn later reined bn shown model generated evaluate vantage replicate scenario even peak sale estimate bn yield npv bn yesterday leerink cut valuation biomarin bn bn saying without valrox group worth bn implication valrox worth somewhere bn bn hard get revenue forecast back yesterday investor said either valrox zero expectation even higher bullish sellside analyst\n",
      "\n",
      "Keywords:\n",
      "valrox 0.658\n",
      "biomarin 0.235\n",
      "bn 0.186\n",
      "gene therapy 0.175\n",
      "gene 0.155\n",
      "yesterday 0.132\n",
      "npv 0.112\n",
      "bullish 0.112\n",
      "therapy 0.111\n",
      "worth 0.1\n",
      "carefully 0.097\n",
      "think 0.096\n",
      "model 0.096\n",
      "estimate 0.096\n",
      "waning 0.088\n",
      "haemophilia gene therapy 0.088\n",
      "sangamo 0.085\n",
      "haemophilia gene 0.085\n",
      "npv bn 0.083\n",
      "consensus sale 0.083\n",
      "\n",
      "Abstract:\n",
      "turning point cheerleader happy yesterday update repotrectinib company ro ntrk targeted project sits hugely attractive targeted oncology space response rate continue look competitive versus roche pfizer asset recent talk u regulator laid clear path filing two crucial component still missing story evidence repotrectinib greater durability aforementioned rival partner deep pocket generating former likely lead latter course likelihood chain event unfolding remains hard call company bn valuation suggests investor see bright future share company tripled since floated april given huge sum paid targeted oncology asset perhaps enthusiasm reasonable think bn lilly paid loxo bn pfizer paid ariad fact remains repotrectinib face entrenched competition niche ultimately gunning kinase inhibitor hit ro ntrk though former greater interest mutation drive around non small cell lung cancer ntrk accounting pfizer xalkori roche rozlytrek approved ro positive patient although nothing available big proportion patient develop resistance mutation repotrectinib specifically designed overcome tumour evasion tactic offer option patient fail xalkori rozlytrek turning point want shot first line market well important repotrectinib emerge durable measure soon make call range duration presented yesterday front line patient ongoing trident study certainly encouraging phase portion trial generated response lasted month albeit different dose carried forward need confirming larger group however response rate repotrectinib look good result generated patient leerink analyst point recent cut rozlytrek data revealed european medicine registry drug orr slipped u label seems highly likely repotrectinib data trend downwards safety something watch high rate dizziness worrying issue data needed differentiation prove crucial approval finding partner surely essential two big pharma player already market assuming response rate patient relapsed xalkori rozlytrek hold repotrectinib look like emerging important new option clear company ambition along investor expectation stretch beyond opportunity call yesterday executive said information recruitment filing timeline would given early next year pandemic make trial recruitment difficult adding fda requires month follow file treatment naive patient six month pretreated cohort acknowledged hope accelerated approval based interim look data rozlytrek beaten surely applies repotrectinib wider commercial potential par efficacy simply cut\n",
      "\n",
      "Keywords:\n",
      "repotrectinib 0.528\n",
      "rozlytrek 0.314\n",
      "xalkori 0.176\n",
      "ntrk 0.176\n",
      "ro 0.151\n",
      "targeted 0.114\n",
      "targeted oncology 0.112\n",
      "turning point 0.107\n",
      "paid 0.101\n",
      "patient 0.097\n",
      "response rate 0.095\n",
      "turning 0.09\n",
      "rate 0.088\n",
      "response 0.083\n",
      "recruitment 0.082\n",
      "pfizer 0.079\n",
      "call 0.075\n",
      "crucial 0.072\n",
      "greater 0.07\n",
      "surely 0.069\n",
      "\n",
      "Abstract:\n",
      "galapagos looked like dealmaking genius partnered repartnered filgotinib market close yesterday reality bit jak inhibitor handed u complete response letter delay approval rheumatoid arthritis unexpected setback caused toxicity concern come rude awakening long seen filgotinib safest jak compound growing concern filgotinib late market entry already caused project forecast whittled away consensus data evaluatepharma reveal little wonder share galapagos gilead filgotinib licensed came morning tune respectively filgotinib key part company growth plan npv accounting respective two group market cap according evaluatepharma calculation sellside consensus number instead abbvie today look like business development genius abbvie five year ago controversially given right opt filgotinib preferring instead focus jak inhibitor launched last year rinvoq abbvie filgotinib becomes go tinib september december gilead picked filgotinib front plus equity investment obligation junior party fund phase iii cost gave galapagos even better deal would abbvie rinvoq win today rinvoq winning race rheumatoid arthritis market share among jak least notwithstanding toxicity problem launched label warning thrombosis similar older jak inhibitor xeljanz olumiant market coming first count lot scathing note client morning wolfe research tim anderson wrote even yesterday setback filgotinib going struggle commercially late entrant crowded category dominated deep pocketed big pharma company know space much better gilead growing concern reflected historic sellside consensus compiled evaluatepharma show u sale forecast fallen bn two year ago today task competing become even harder complete response letter cite possible impact filgotinib mg dose sperm parameter fda want see data manta manta ray trial due deciding approvability manta manta ray initiated investigate possibility filgotinib testicular toxicity issue came year ago rat study anyone wondering whether problem end would well consider fda decided approving mg dose however uncompetitive efficacy might fact agency hint broader concern might filgotinib risk benefit profile outside u news gilead galapagos better filgotinib look soon approved japan eu despite rumour contrary chmp delivered positive opinion last month u filgotinib gilead sole responsibility clearly big money pressing need filgotinib get market quickly gilead filed priority review voucher bought ultragenyx enabled fda say four month sooner might otherwise done\n",
      "\n",
      "Keywords:\n",
      "filgotinib 0.587\n",
      "manta 0.208\n",
      "jak 0.196\n",
      "galapagos 0.152\n",
      "gilead 0.15\n",
      "rinvoq 0.125\n",
      "jak inhibitor 0.121\n",
      "abbvie 0.112\n",
      "ray 0.104\n",
      "manta ray 0.104\n",
      "manta manta ray 0.104\n",
      "manta manta 0.104\n",
      "concern 0.092\n",
      "market 0.087\n",
      "year ago 0.087\n",
      "growing 0.081\n",
      "rheumatoid arthritis 0.079\n",
      "rheumatoid 0.079\n",
      "toxicity 0.079\n",
      "mg dose 0.076\n",
      "\n",
      "Abstract:\n",
      "substantial potential seen project target neonatal fc receptor fcrn triggered much dealmaking past year johnson johnson bn takeout momentum represents biggest play date j j getting whole momentum deal mostly nipocalimab delivered impressive proof concept data earlier year well trigger talk premium look generous intense competition asset already sellside asking whether enough seal deal momentum share opened touch j j agreed pay suggesting market see another bidder entering hard believe already competitive sale process momentum banker surely busy shopping company around truist analyst formerly suntrust robinson asked morning whether j j may underplayed worth noting defending price target considerably higher bank takeover battle rare particularly wake agreed bid one true unencumbered anti fcrn asset target attracted much attention broad applicability across range autoimmune disease many treatment option inhibiting fcrn project thought able control recycling igg reduce activation complement believed drive many condition efgartigimod advanced asset biopharma anti fcrn pipeline market cap bn fiercely independent chief executive however argenx would probably prove pricey buyer large mid cap ucb planning go alone though rozanolixizumab considered weakest project alexion snapped syntimmune back look like good value front deal affibody candidate ended bust earlier year momentum gone leaf immunovant share duly jumped morning data due day imvt become even interesting interestingly argenx share opened higher morning big pharma endorsement presumably outweighed threat another deep pocketed competitor alongside alexion arriving scene fitting end j j plan nipocalimab eagerly awaited press release contained detail mentioned huge swathe disease area might investigated maternal foetal disorder neuro inflammatory disorder rheumatology dermatology autoimmune haematology course momentum nipocalimab hypersialylated igg deliver result idiopathic thrombocytopenic purpura shortly decision couple year ago exit biosimilars look well judged spending year trying get copaxone generic glatopa market momentum threw towel copycat business late defeat arguably impenetrable u biologicals market failing long term investor happy dismiss history today stock never closed year market acquisition rank largest biopharma buyout far year knocking gilead bn takeout fortyseven top spot fact deal getting done despite pandemic far please sector follower\n",
      "\n",
      "Keywords:\n",
      "momentum 0.407\n",
      "fcrn 0.261\n",
      "nipocalimab 0.214\n",
      "igg 0.13\n",
      "share opened 0.126\n",
      "argenx 0.126\n",
      "alexion 0.119\n",
      "bn takeout 0.116\n",
      "agreed 0.111\n",
      "morning 0.108\n",
      "deal 0.107\n",
      "autoimmune 0.104\n",
      "market 0.095\n",
      "opened 0.095\n",
      "earlier year 0.093\n",
      "takeout 0.085\n",
      "target 0.082\n",
      "getting 0.08\n",
      "johnson 0.079\n",
      "asset 0.077\n",
      "\n",
      "Abstract:\n",
      "bn market cap float last friday curevac ranked sixth highly valued biotech arrive nasdaq door recent year impressive statistic pale comparison stock performance since ipo mere two trading day surge first day trading made curevac best performing biopharma ipo measure past five year evaluate vantage calculation another jump yesterday mean group valuation swelled almost fivefold bn whether company worth big question even believer german developer mrna technology must finding increasingly hard justify number curevac performance largely thanks timing course coming market covid vaccine move clinic pandemic related research triggered substantial investor interest numerous company though notable curevac post money market cap current valuation two mrna researcher moderna biontech moderna biontech sit record book two biopharma biggest ipo sport vastly inflated market cap term vaccine development curevac slightly behind though reality remains almost impossible know vaccine project ultimately successful indeed demand might look like uncertainty make valuation many pandemic play feel overblown curevac come another warning relatively small free float long term shareholder dievini hopp owning listed company german government glaxosmithkline hold stake result deal curevac vaccine would typically make investor wary yet stock performance since float suggests banker underwriting offer seriously undervalued company raised curevac money group banked around ipo dievini hopp purchased stock private placement time private financing round closed july perhaps made raising fund unnecessary interesting see quickly curevac decides capitalise buoyant stock price biontech tapped market four month ipo raising money remains something mantra biotech executive top pop biggest first day share price jump since assuming curevac valuation hold bank conducted ipo work hard justify chasm group float price stock closed yesterday analyst start covering company coming month unlikely fresh data back share price according curevac prospectus phase data trial healthy volunteer expected fourth quarter week company listed another study time dose finding phase ii clinicaltrials gov testing g g dos notably appears dropped lower g g dosage studied ongoing phase phase iii trial slated start year end moderna biontech already pivotal study way former company remains well ahead valuation term two german developer market cap aligned given covid hype propelling biopharma right entirely unpredictable market would judge curevac worth something similar setback prove painful investor still buying level\n",
      "\n",
      "Keywords:\n",
      "curevac 0.526\n",
      "ipo 0.195\n",
      "float 0.154\n",
      "moderna biontech 0.149\n",
      "biontech 0.137\n",
      "valuation 0.128\n",
      "german 0.123\n",
      "first day 0.112\n",
      "market cap 0.109\n",
      "vaccine 0.107\n",
      "hopp 0.107\n",
      "market 0.104\n",
      "stock 0.103\n",
      "cap 0.102\n",
      "performance 0.099\n",
      "moderna 0.093\n",
      "price 0.087\n",
      "money 0.085\n",
      "justify 0.084\n",
      "company 0.082\n",
      "\n",
      "Abstract:\n",
      "yesterday move bristol myers squibb license dragonfly radar il asset remind investor still mileage cytokine therapy despite touted year cytokine ultimately ending disappointment field torch bearer back nektar il project bempegaldesleukin manage middling efficacy pivot study notwithstanding bn bet bristol interest cytokine beyond il il one bristol join company including astrazeneca moderna like il il cytokine broadly speaking stimulates growth activity cell like il developing therapy approach dogged complexity around toxicity associated broad immune system activation well relatively short half life data far mixed industry player remained interested toxic approach one obvious reason anticancer immunotherapy tends work hot immunogenic tumour pro inflammatory cytokine thought capable turning cold tumour hot theory expand us anti pd mab like opdivo explains bristol continued fascination cytokine despite pivot disappointment company year doubled bempegaldesleukin harnessing power work reducing toxicity il meanwhile focused local intratumoural delivery controlling situ expression targeting cytokine tumour microenvironment bristol deal dragonfly paying near term front concern df monovalent il fc fusion protein aim extend il half life look industry pipeline show array project similarly seek harness therapeutic power cytokine minimising shortcoming include gene therapy well another fusion protein perhaps closely watched asset astrazeneca moderna medi comprises il encoding mrna encapsulated lipid nanoparticles delivered intratumoural injection phase study combination imfinzi started last year immunotherapy combination include merck kgaa fusion protein bavencio combo study javelin il bristol armored car project jcar combine il secretion targeting muc antigen ziopharm ad rts hil studied libtayo though development year without scoring notable success ad rts hil slow progress remind investor il disappointment notably oncosec tavo like bempegaldesleukin failed turn cold melanoma hot disappointing io combo trial like nektar project remains development regulon lipovil avrobio avr onc discontinued recombinant human il lilly got along bn purchase armo bioscience armo lead cytokine il project pegilodecakin appears going nowhere interestingly yesterday bristol already deal dragonfly via tie signed legacy company celgene covering right develop cell therapy based nk cell judging dragonfly pipeline long way private biotech primary focus indeed dragonfly barely mentioned existence df emerged stealth mode asset represents bristol latest attempt deliver cytokine promise\n",
      "\n",
      "Keywords:\n",
      "il 0.514\n",
      "cytokine 0.348\n",
      "dragonfly 0.271\n",
      "bristol 0.182\n",
      "fusion protein 0.145\n",
      "fusion 0.139\n",
      "bempegaldesleukin 0.134\n",
      "hot 0.116\n",
      "remind investor 0.101\n",
      "like il 0.101\n",
      "astrazeneca moderna 0.101\n",
      "armo 0.101\n",
      "remind 0.097\n",
      "il project 0.097\n",
      "il il 0.097\n",
      "disappointment 0.093\n",
      "half life 0.09\n",
      "protein 0.083\n",
      "nektar 0.083\n",
      "ad 0.081\n",
      "\n",
      "Abstract:\n",
      "rumour true sanofi bought partner principia biopharma bn french group undoubtedly need new avenue growth question whether wise deal big one sanofi paid top dollar already right principia key asset oral btk inhibitor sar developed multiple sclerosis well potentially saving milestone payment sanofi said part rationale eliminate future royalty based evaluatepharma consensus sale forecast estimated royalty rate come around devil detail question data far sar come phase ii trial relapsing m multiple sclerosis win make principia short squirm february sanofi reported highest dose sar mg reduced gd enhancing hyperintense lesion versus placebo use surrogate endpoint rather harder outcome like relapse raised alarm bell complex trial design along small patient number make much harder handicap future success june sanofi enrolled first patient pivotal study comparing sar aubagio relapsing m part four trial programme sar unique selling point ability penetrate brain sanofi hope evaluate project cns disease beyond conference call today discus deal john reed sanofi global head r declined say indication might disagree analyst suggested sar utility parkinson amyotrophic lateral sclerosis big one alzheimer buying principia full give french group two btk inhibitor rilzabrutinib oral project late stage development autoimmune disease pemphigus immune thrombocytopenia prn topical agent phase rilzabrutinib chance hard call particularly phase ii trial include control group royalty sar main attraction sanofi main motivation avoiding royalty look paid handsomely privilege least based current sale consensus licensing deal project detail tiered royalty mid teen assuming would average around using discount rate total royalty launch sale peak would come even adding potential milestone saved price sanofi paid look rich course better expected sale sar would cast deal better light must sanofi banking particularly expand project use outside m company indeed looking alzheimer golden ticket although would long shot given others track record disorder right appears principia got better end deal group stock already doubled since july rumour acquisition emerged another morning principia hand doubt strengthened sanofi need build pipeline fast fact french group ready cash deploy disposing stake regeneron jefferies analyst estimate sanofi another bn bn spend something lift valuation several biotech\n",
      "\n",
      "Keywords:\n",
      "sar 0.419\n",
      "sanofi 0.338\n",
      "principia 0.303\n",
      "royalty 0.222\n",
      "french group 0.152\n",
      "french 0.127\n",
      "sclerosis 0.118\n",
      "sanofi paid 0.115\n",
      "deal 0.107\n",
      "paid 0.099\n",
      "relapsing 0.096\n",
      "rumour 0.093\n",
      "btk inhibitor 0.089\n",
      "btk 0.089\n",
      "multiple sclerosis 0.083\n",
      "sale 0.08\n",
      "group 0.079\n",
      "alzheimer 0.076\n",
      "milestone 0.075\n",
      "harder 0.073\n",
      "\n",
      "Abstract:\n",
      "shortly new car therapy player hong kong stock exchange chaired none han bishop chief exec sold juno celgene jw therapeutic started joint venture juno wuxi apptec soon floated right regulatory document show remarkably given china burgeoning cell therapy sector jw become one handful business publicly traded proposed ipo serve reminder draw mr bishop behind u cell therapy company sana biotechnology lyell immunopharma sana lyell already caused head turn completing monster private financing round series c money lyell march initial raise sana closed second quarter amount came spite group relative secrecy precisely working redacted still clear much jw want raise ipo given much prospectus including number share issued price range redacted pretty standard hong kong exchange listing however much already known company founded venture juno wuxi aim license cell therapy candidate juno pipeline local development backed wuxi local knowledge alliance juno look east april two year later jw raised series brought new investor jw ipo document reveals company car pipeline indeed derived juno asset additional manufacturing tweak supplemented deal eureka lyell acepodia instance anti bcma asset jwcar us construct juno originated jcarh orva cel deal remains place jw continue licensing juno cell therapy project even though ownership business moved via celgene bristol myers squibb jw prospectus reveals much potential competition china company leading project group working locally anti cd anti bcma car example competitor space remind investor much cell therapy work ongoing china however jw rival including carsgen precision biotech huadao car juventas privately owned pure play cell therapy company hong kong listing appears immunotech biopharma shanghai fosun innovent listed locally car work derives tie ups others cellular biomedicine group legend biotech opted u flotation nasdaq yet evident whether jw achieve valuation rival legend keeping mr bishop name prominent bound remain important strategy towards achieving goal\n",
      "\n",
      "Keywords:\n",
      "jw 0.492\n",
      "juno 0.35\n",
      "lyell 0.204\n",
      "cell therapy 0.196\n",
      "wuxi 0.153\n",
      "sana 0.153\n",
      "bishop 0.153\n",
      "car 0.149\n",
      "kong 0.146\n",
      "hong kong 0.146\n",
      "hong 0.146\n",
      "cell 0.126\n",
      "therapy 0.111\n",
      "mr bishop 0.102\n",
      "prospectus 0.097\n",
      "locally 0.097\n",
      "local 0.097\n",
      "legend 0.093\n",
      "cell therapy company 0.093\n",
      "china 0.089\n",
      "\n",
      "Abstract:\n",
      "past couple year tyk inhibition emerged important novel mechanism watch autoimmune disease company made biggest bet bristol myers squibb year deliver first pivotal data advanced tyk inhibitor bm measure bristol confidence bm clinical programme aim enrol subject phase iii study across several indication advanced use psoriasis subject two pivotal trial ending year bristol promise initial result first late underpinning confidence basically one dataset result phase ii psoriasis trial released late suggested bm convenience relatively clean safety profile pde inhibitor otezla higher efficacy otezla course celgene psoriasis blockbuster bristol divested amgen satisfy u regulatory condition celgene acquisition concern otezla bm together constitute monopoly fact bristol sold former latter huge vote confidence tyk idea behind bm efficacy line biologicals like abbvie humira novartis cosentyx oral convenience otezla pfizer xeljanz jak inhibitor oral former suffers relatively lower efficacy broad jak inhibition associated side effect including infection year jp morgan conference bristol said bm potentially best class oral drug potential biological like efficacy convenient administration putting money mouth phase iii poetyk pso study test bm head head otezla measure co primary endpoint number patient achieving pasi score spga score week enrolment complete apparent delay due covid bristol expects data reported end year first study said second quarter call phase ii highest bm dose saw patient score pasi week cross study basis looked strikingly better otezla controlled head head setting blinded multicentre phase iii trial mean margin superiority unlikely expectation set nevertheless bristol report phase ii result bm psoriatic arthritis medical meeting data received say support beginning phase iii mid stage study result lupus ulcerative colitis term event still clear whether specific tyk inhibition deliver optimal efficacy safety whether mechanism combined jak related bristol nearest competitor theravance j j tyk jak inhibitor td though phase ii iii trial ulcerative colitis biggest threat meanwhile probably come pfizer brepocitinib tyk jak inhibitor pf pure anti tyk phase ii latter face key catalyst psoriasis study due read second half clearly pfizer give xeljanz franchise without long fight size threat bristol become apparent soon enough\n",
      "\n",
      "Keywords:\n",
      "bm 0.382\n",
      "tyk 0.333\n",
      "otezla 0.313\n",
      "bristol 0.234\n",
      "jak 0.186\n",
      "psoriasis 0.166\n",
      "phase 0.123\n",
      "jak inhibitor 0.115\n",
      "head 0.105\n",
      "confidence 0.103\n",
      "xeljanz 0.095\n",
      "pasi 0.095\n",
      "inhibitor 0.093\n",
      "score 0.092\n",
      "inhibition 0.091\n",
      "efficacy 0.09\n",
      "phase ii 0.09\n",
      "oral 0.089\n",
      "ii 0.089\n",
      "iii 0.085\n",
      "\n",
      "Abstract:\n",
      "u approval nippon shinyaku viltepso give duchenne muscular dystrophy patient right kind mutation second therapeutic option exon skipper direct competition sarepta vyondys look clinical data dystrophin production suggests viltepso edge willing accept weight study patient eight received approved dose viltepso trial make data vyondys approved patient look like model rigour larger study looking measure motor performance work data appear seems likely pricing japanese group yet announce dictate product sell best phase ii trial two rival therapy approved looked efficacy measure production dystrophin protein patent muscle surrogate muscle function u trial viltepso brought level dystrophin eight patient given mg kg normal week treatment point increase baseline vyondys manage improvement le one percentage point twice long treatment period comparing data across trial fraught difficulty especially true patient population minuscule task facing paediatrician harder data arrive confirmatory trial ongoing drug racer enrol patient amenable exon skipping treated viltepso placebo week primary endpoint time stand test essence trial vyondys rather larger patient placebo controlled portion open label part primary endpoint six minute walk test week essence expected read racer data coming two year later controversy u approval viltepso strength tiny patient number perhaps surprising controversy vyondys green light sarepta product waved fda four month rejected decision approve fiercely disputed within agency internal fda document reveal familiar story sarepta january sellside see viltepso outselling vyondys soon according consensus forecast evaluatepharma sarepta probably view equanimity projection duchenne gene therapy srp outpacing exon skipper might winner disorder long term anyway\n",
      "\n",
      "Keywords:\n",
      "viltepso 0.483\n",
      "vyondys 0.387\n",
      "sarepta 0.215\n",
      "dystrophin 0.207\n",
      "exon 0.145\n",
      "skipper 0.129\n",
      "exon skipper 0.129\n",
      "essence 0.123\n",
      "patient 0.122\n",
      "controversy 0.108\n",
      "duchenne 0.101\n",
      "muscle 0.092\n",
      "production 0.088\n",
      "data 0.082\n",
      "trial 0.082\n",
      "eight 0.078\n",
      "approved 0.072\n",
      "larger 0.072\n",
      "srp 0.065\n",
      "week 0.062\n",
      "\n",
      "Abstract:\n",
      "biotech double clinical failure belt near zero cash balance fear probably another company nearby think represent attractive bargain basement acquisition opportunity today lesson genkyotex despite knee managed get taken calliditas swedish group formerly known pharmalink true genkyotex buyout valuation unlikely break bank relevant question whether pipeline worth anything genkyotex latest setback occurred last year lead effectively sole asset nadph oxidase inhibitor gkt setanaxib flunked mid stage trial primary biliary cholangitis go back project coded gkt failed first attempted indication diabetic nephropathy gkt failure hit primary endpoint pbc followed analysis measure whereupon genkyotex hailed success high dose subgroup patient shown reduction liver stiffness measure comer one secondary endpoint weak basis genkyotex decided pressing phase iii warranted rose tinted glass might save genkyotex may course lack money prevented genkyotex completed right issue earlier year mid cash balance stood statistically significant step forward calliditas today bought genkyotex second reinvention claiming phase ii clinical trial setanaxib demonstrated evidence anti fibrotic activity well statistically significant impact fatigue latter listed among study endpoint likely derived post hoc analysis case supposed positive effect relates subgroup primary failure numerical benefit considered exploratory best today deal calliditas first acquire genkyotex stake pay cash followed tender offer remainder relevant question whether calliditas might acquired genkyotex le waited go insolvency picked asset liquidator calliditas brushed setanaxib pbc failure saying project tested unusual endpoint said nadph oxidase nox inhibition represented promising way blocking inflammatory fibrotic pathway beyond pbc swedish group inflammatory disease focus see potential primary sclerosing cholangitis kidney disease idiopathic pulmonary fibrosis failing diabetic nephropathy failing pbc genkyotex gained stock market listing via reverse takeover french company genticel time cited several first class nox inhibitor fibrosis inflammatory pain least one gkt longer appears pipeline beyond gkt claim undisclosed preclinical nox inhibitor since stock lost value even accounting today takeover fuelled rise calliditas bailout come cold comfort many investor\n",
      "\n",
      "Keywords:\n",
      "genkyotex 0.59\n",
      "calliditas 0.322\n",
      "gkt 0.268\n",
      "pbc 0.183\n",
      "setanaxib 0.161\n",
      "nox 0.161\n",
      "inflammatory 0.109\n",
      "swedish 0.1\n",
      "oxidase 0.1\n",
      "fibrotic 0.1\n",
      "relevant question 0.095\n",
      "nephropathy 0.095\n",
      "cash balance 0.092\n",
      "cholangitis 0.084\n",
      "failure 0.082\n",
      "diabetic 0.077\n",
      "balance 0.074\n",
      "failing 0.073\n",
      "cash 0.071\n",
      "endpoint 0.07\n",
      "\n",
      "Abstract:\n",
      "report death contingent value right biopharma appear greatly exaggerated including cvrs deal fell favour sanofi notorious takeover genzyme security seems back vogue analysis evaluate vantage reveals fund invested celgene instance currently grappling increasing likelihood cvr attached company acquisition bristol myers squibb might pay week brought news another transaction included cvr element ligand took pfenex price hinge undisclosed regulatory milestone achieved end right receive cash equivalent per pfenex share structured cvr yet clear whether cvr like bristol publicly tradable valuation disconnect tradable cvrs typically written deal bridge valuation gap seller want receive buyer willing pay think company worth fine pay event bull case scenario playing basic logic underlying cvrs probably coincidence security become popular bull market disconnect buyer seller peak vantage analysis seems bear treading water several year issuance cvrs along biopharma deal surged middle quarter ended cvr number accelerated meanwhile last month nasdaq biotech index gained exceed high hit mid true absolute number relatively small pattern hard ignore sanofi genzyme deal annual number deal cvr attached remained single digit transaction signed first half already seen nine cvr containing transaction excludes ligand pfenex third quarter deal one question buyer still accept cvr part acquisition especially genzyme holder ended sue sanofi recover believed due cvr relating multiple sclerosis drug lemtrada value sanofi genzyme security rest law court january celgene cvr appears skewed bristol favour acquirer control relevant milestone might occur caveat fiduciary duty respect interest security holder buy cvr time despite cvrs popular financial instrument biopharma investment banker thankful asset price departing ever reality still exists way get deal across finish line\n",
      "\n",
      "Keywords:\n",
      "cvr 0.541\n",
      "cvrs 0.302\n",
      "genzyme 0.258\n",
      "security 0.221\n",
      "deal 0.158\n",
      "buyer 0.121\n",
      "sanofi 0.119\n",
      "transaction 0.117\n",
      "disconnect 0.115\n",
      "pay 0.104\n",
      "popular 0.101\n",
      "attached 0.101\n",
      "holder 0.098\n",
      "seller 0.096\n",
      "ligand 0.096\n",
      "favour 0.088\n",
      "biopharma 0.084\n",
      "bull 0.083\n",
      "bristol 0.081\n",
      "ended 0.08\n",
      "\n",
      "Abstract:\n",
      "last week moderna said small deal done covid vaccine mrna came per shot markedly higher major candidate said bulk sale might allow offer vaccine lower price true word yesterday million dose commitment u government see vaccine priced around per dose investor thrilled moderna opened later trading price per dose ignores moderna already received u taxpayer funding group received warp speed programme factored u government actually paying closer per shot tranche dos delivered according leerink analyst u government agreement moderna includes incentive payment timely delivery portion agreed price risk mrna fail secure emergency use authorisation bla approval end january eua certainly possible within time frame given flexibility u global regulatory body concerning covid vaccine candidate risk come trial delayed interim phase iii data expected later year disappoint still least started phase testing moderna appears closer goal u authorisation approval called top six candidate u government placed dose order phase iii trial two others biontech pfizer astrazeneca oxford university imminent following early data novavax nvx cov last week project slated enter phase iii september novavax claim place covid vaccine race august two vaccine johnson johnson glaxosmithkline sanofi even generated phase data yet per dose warp speed funding included moderna vaccine still one expensive option contract u arranged pfizer biontech two candidate bnt b appears promising peg nearly per shot vaccine development glaxo sanofi come warp speed funding included calculation far best value option current showing astrazeneca may uk group agreed provide million dos azd exchange bn warp speed funding advanced trial scaled manufacturing work per shot line company pricing announcement july astra shake thing covid pricing disclosure july best rest beyond top six several vaccine development one moved step arcturus therapeutic dosed first cohort phase ii trial arct formerly designated lunar cov trial conducted singapore comprises two part phase escalating dos administered single injection three cohort made adult year old based safety immunogenicity cell response seen group dose regimen chosen phase ii section include subject aged study yield data fourth quarter arcturus seems trailing handful potential vaccine least merck co iavi v project outside top six known received funding barda modest race u market going contested fiercely global race however already russia country ministry health saying yesterday approved vaccine developed gamaleya research institute epidemiology microbiology moscow testing people called sputnik v vaccine initially given small number vulnerable people widespread use banned presumably larger trial conducted meantime phase iii trial involving people begin month russia united arab emirate saudi arabia brazil mexico mass production vaccine begin september mass production different meaning russia versus u sputnik v manufacturer zelenograd based binnopharm say make million dos per year information available kind governmental funding project received\n",
      "\n",
      "Keywords:\n",
      "vaccine 0.304\n",
      "per 0.218\n",
      "per shot 0.209\n",
      "funding 0.188\n",
      "warp speed 0.173\n",
      "warp 0.173\n",
      "moderna 0.162\n",
      "top six 0.147\n",
      "per dose 0.147\n",
      "russia 0.14\n",
      "warp speed funding 0.134\n",
      "speed funding 0.134\n",
      "speed 0.13\n",
      "government 0.13\n",
      "shot 0.12\n",
      "phase 0.115\n",
      "dose 0.111\n",
      "received 0.1\n",
      "candidate 0.096\n",
      "million 0.096\n",
      "\n",
      "Abstract:\n",
      "failure four year ago seres bacterial formulation ser threatened end mounting exuberance microbiome therapeutic company pressed phase iii trial unexpected success yesterday reawaken field certainly reawakened seres share price crashed disappointment drifting next year stock yesterday surged value seres bn quite turnaround seres gunning quick u regulatory filing hope result first ever marketed microbiome therapeutic development curious number reason obvious biotech insist initiating pivotal development despite unconvincing negative mid stage data usually suffer punishing phase iii failure second company backup compound ser unlike ser synthetically designed thought far promising event ser flunked phase clostridium difficile infection trial two year ago ended abandoned leaving remaining investor attention ser enough approval yesterday seres said ser pivotal study c difficile called ecospor iii met primary endpoint reducing recurrence infection eight week percentage point versus placebo overall risk recurrence cut p value despite tested one sided level look impressive importantly fda apparently told seres single study would suffice approval long upper bound hazard ratio range fell value come seres initiated ecospor iii reviewing ser might failed phase ii possible reason ranged manufacturing problem clinical site variability even mix trial sample ultimately ecospor iii tested fold higher ser dose used phase ii ser oral formulation purified donor stool derived firmicute bacteria spore designed germinate repopulate microbiome inhibit germination growth c difficile seres say convenient le risky better characterised faecal transplant though head head trial prove safety seres investor sitting fourfold gain aware stumbling block one subject exposed ser phase iii dose seres safety database patient short group hope requirement met post marketing commitment worst dose analyse extra subject open label phase approval another seres funding requirement second quarter cash enough last year competition among numerous industry project aim restore patient microbiome health ferring rbx development c difficile whose pivotal trial read imminently ferring acquired takeover rebiotix something soon look like smart move\n",
      "\n",
      "Keywords:\n",
      "seres 0.543\n",
      "ser 0.528\n",
      "microbiome 0.188\n",
      "difficile 0.188\n",
      "ecospor iii 0.158\n",
      "ecospor 0.158\n",
      "iii 0.097\n",
      "phase 0.09\n",
      "recurrence 0.087\n",
      "requirement 0.079\n",
      "formulation 0.068\n",
      "value 0.064\n",
      "infection 0.057\n",
      "dose 0.056\n",
      "pivotal 0.055\n",
      "met 0.055\n",
      "yesterday 0.055\n",
      "designed 0.054\n",
      "year ago 0.052\n",
      "trial 0.052\n",
      "\n",
      "Abstract:\n",
      "last year esmo meeting set expectation bristol myers squibb mesothelioma study checkmate result presented saturday session virtual world lung congress disappoint first line trial position opdivo plus yervoy become new standard care said netherlands cancer institute dr paul baa presenting data disease mostly produced disappointment checkmate one large industry sponsored mesothelioma trial ongoing read positively highly encouraging however statistically significant overall survival benefit seen across comer trial clearly driven patient non epithelioid disease performed badly chemo control university leicester dr dean fennell discussing world lung data said viewed opdivo plus yervoy new standard non epithelioid mesothelioma primary comer endpoint checkmate saw reduction risk death favouring opdivo plus yervoy p month median o combo absolute benefit similar epithelioid non epithelioid tumour chemo control fared much worse latter histology former resulting difference appeared strongly significant non epithelioid subject month median survival benefit favouring immunotherapy combo hazard ratio dichotomy expected dr baa said checkmate stratified subject ensure even split epithelioid non epithelioid histology two cohort central relevance bristol combo mesothelioma toxicity given rate serious treatment related adverse event double seen chemo alone resulting benefit much favour opdivo plus yervoy non epithelioid histology epithelioid patient risk benefit finely balanced said dr fennell indeed possibly tilt slightly favour chemotherapy told world lung histology thus key factor designing future clinical trial non epithelioid mesothelioma exhibit epithelial mesenchymal transition said dr fennell result certain protein expressed lead increased resistance chemo immunotherapy last year esmo separate issue discussed namely mesothelioma patient extremely poor prognosis imbalance hyperprogressors undermine clinical trial time positive data uncontrolled map trial relapsed subject raised hope success checkmate filing strategy bristol say discus latest data global health authority giving away nothing timing breadth regulatory filing might seek said would make sense file combo comer give company broadest label still keeping possibility histology based approval u fda deemed data warranted dr baa heralded checkmate first randomised trial dual immunotherapy first line mesothelioma given platinum doublet chemo first line standard care yield five year survival importance even borderline readout underestimated however dr fennell pointed avastin five year ago reduced risk death given top alimta cisplatin first line map trial despite roche drug approved mesothelioma separate academic sponsored front line trial beat meso combination tecentriq bristol combo comer discussant would go suggesting immunotherapy might combined chemo relevant across histology\n",
      "\n",
      "Keywords:\n",
      "epithelioid 0.402\n",
      "mesothelioma 0.321\n",
      "non epithelioid 0.301\n",
      "histology 0.213\n",
      "dr 0.176\n",
      "fennell 0.172\n",
      "checkmate 0.153\n",
      "chemo 0.148\n",
      "dr fennell 0.129\n",
      "baa 0.129\n",
      "non 0.122\n",
      "plus yervoy 0.121\n",
      "opdivo plus yervoy 0.121\n",
      "opdivo plus 0.119\n",
      "world lung 0.115\n",
      "yervoy 0.108\n",
      "comer 0.106\n",
      "immunotherapy 0.102\n",
      "combo 0.101\n",
      "opdivo 0.091\n",
      "\n",
      "Abstract:\n",
      "alzheimer project aducanumab biogen nearing knife edge decision change fortune markedly away life death event however normal business operating biotech company go paying upfront denali therapeutic yesterday exchange right phase stage parkinson disease therapy handful project biogen forged one biggest licensing deal year partner co develop co promote various project right varying different territory well upfront fee agreement see biogen take stake denali equity investment around per share come premium denali closing price wednesday back end denali line another bn milestone well royalty chief among molecule biogen licensed dnl enter late stage testing next year one trial enrol parkinson patient kinase activating mutation leucine rich repeat kinase lrrk gene patient sporadic disease lrrk regulator lysosomal function mutation gene cause parkinson well lysosomal dysfunction contributes neurodegeneration denali say lrrk inhibitor slow progression parkinson suggestion halt reverse disease biogen stranger lrrk targeting drug collaborating ionis pharmaceutical development biib antisense oligonucleotide targeting gene phase multiple ascending intrathecal dosing trial reason began last year parkinson subject without verified lrrk mutation data expected biomarker data dnl advanced much generated limited biomarker data phase ib january denali said roche originated project achieved target pathway engagement greater dose dependent reduction lysosomal biomarker bmp urine generally safe well tolerated dos tested prompting denali expand dnl phase b clinical trial study higher dos dnl dosed healthy volunteer phase trial parkinson patient phase b study ongoing though april group said dosing paused owing covid pandemic lrrk inhibitor developing parkinson dnl shelved since better pharmacokinetics crunch time new parkinson hope february lrrk complicated protein kinase complex many purported function despite denali statement role parkinson entirely clear dnl inhibits wild type lrrk well mutated form chance might unintended consequence proof whether actually improve symptom safe long term emerge couple year true earlier stage programme biogen apparently seen something lrrk inhibitor covered deal one appears preclinical crohn disease project dnl worth bn agreement cover candidate perhaps part lure denali transport vehicle tv technology well lrrk inhibitor biogen license entitles exclusive option two programme neurodegenerative disease use tv platform enables protein cross blood brain barrier including one amyloid beta separately right first negotiation two unnamed preclinical project use tv platform tv technology popular takeda took option three denali tv based preclinical programme including two alzheimer disease front equity takeda forge another neuroscience deal abbvie dip toe february even including potential tv technology deal involves paying huge amount early parkinson therapy one even reached phase heck bet company brought aducanumab way fda door biogen clearly nerve steel\n",
      "\n",
      "Keywords:\n",
      "lrrk 0.405\n",
      "denali 0.385\n",
      "parkinson 0.309\n",
      "dnl 0.283\n",
      "tv 0.243\n",
      "biogen 0.209\n",
      "lrrk inhibitor 0.173\n",
      "tv technology 0.13\n",
      "lysosomal 0.121\n",
      "biomarker 0.081\n",
      "parkinson patient 0.081\n",
      "well 0.081\n",
      "kinase 0.079\n",
      "disease 0.075\n",
      "phase 0.074\n",
      "upfront 0.074\n",
      "biomarker data 0.074\n",
      "preclinical 0.072\n",
      "mutation 0.071\n",
      "safe 0.069\n",
      "\n",
      "Abstract:\n",
      "small drug developer failed bring product market despite two decade trying novavax considered something wildcard among many pandemic vaccine effort data released last night nvx cov seem suggest company chance crossing finishing line absence big pharma partner mark novavax among already clinic though reality western vaccine major remain without covid project novavax clearly belief matter yesterday laid plan move phase iii september insisting would million dos ready go early couple billion end year helping company towards goal disclosure yesterday lower dose tested g worked well g dose mean manufactured batch go lot executive raised possibility testing even lower dos future trial nvx cov need adjuvant study tested two dos produced strong neutralising antibody cell response novavax released data pre print peer review result remains important step still released far seems competitive data seen moderna biontech pfizer astrazeneca notwithstanding almost impossible compare data released various player far scientific rigour well usual caveat cross trial comparison case researcher using different way measure antibody response remains unclear level might required confer immunity still novavax insisted strong relationship severity disease neutralising titre shown slide executive said compared favourably immune response elicited vaccine cell response considered important producing immunity novavax claimed strong response data showing cd helper cell response detail yet released whether cd killer cell response seen early data biontech pfizer moderna shown stimulation killer cell novavax keep investor waiting july safety performed well arguably project look benign moderna candidate prompted worrying level fever chill moderna covid vaccine show promise july pfizer biontech published data project end taken forward saying chosen candidate tolerable main drawback clinical data released far generated healthy individual young proving safety efficacy older patient weakened immune system le able tolerate side effect remains real hurdle covid vaccine project credit novavax said shortly starting patient study extend age range tested new data generated patient aged large phase iii trial begin september joining pivotal study astrazeneca moderna biontech pfizer already underway covid vaccine move pivotal development july bn warp speed funding several manufacturing partner already place novavax seems happy go alone lack track record probably put big pharma partner initially prove successful company surely need help distribution big vaccine player back race watching progress interest investor meanwhile novavax story since february helping company become best performing biotech stock year starting year stock trading per share market cap bn boosted another gain today soon become clear whether time novavax hit jackpot\n",
      "\n",
      "Keywords:\n",
      "novavax 0.424\n",
      "released 0.178\n",
      "vaccine 0.175\n",
      "cell response 0.174\n",
      "moderna 0.144\n",
      "response 0.129\n",
      "biontech 0.127\n",
      "biontech pfizer 0.112\n",
      "data released 0.111\n",
      "cell 0.107\n",
      "pharma partner 0.105\n",
      "big pharma partner 0.105\n",
      "data 0.1\n",
      "killer cell 0.095\n",
      "killer 0.095\n",
      "july 0.094\n",
      "pfizer 0.093\n",
      "moderna biontech 0.092\n",
      "immunity 0.092\n",
      "helping 0.092\n",
      "\n",
      "Abstract:\n",
      "liver toxicity looked killed cymabay seladelpar last year last month investigation cleared ppar agonist wrongdoing u fda allowed trial restart today company followed encouraging result phase iii trial primary biliary cholangitis stopped clinical hold spelled plan move another pivotal study early next year thus another former nash play pivot pbc genfit earlier year elafibranor another ppar agonist crashed phase iii genfit predictable liver disease failure set cirrhosis pivot may pbc rare disease market potential much smaller nash several company focused space competition hotting intercept already market ocaliva fda refused approve drug nash seems relying pbc sale foreseeable future autoimmune condition bile duct progressively destroyed leading liver cirrhosis ocaliva far perfect treatment option pbc however well black box warning liver failure cause severe pruritus patient according u label disease already cause around two third people suffer itching developer like cymabay genfit relatively low bar beat term safety clinical result suggest good chance perhaps efficacy well always caveat cross trial comparison least pruritus offer better option reported improvement patient itching score phase ii enhance trial cymabay detailed today seladelpar demonstrated significant improvement self reported pruritis scale higher dose tested executive said would probably taken phase iii suggested pruritus would made key secondary endpoint pivotal study goal getting label claim itch reduction would major point differentiation ocaliva biomarker measure seladelpar seems stack well primary endpoint used pbc traditionally composite three measure however impact alp considered important marker major point remember looking enhance trial result presented modified intent treat group trial stopped early due clinical hold many patient followed initially intended length time signal efficacy need repeated second phase iii although enthusiastic sellside analyst raised prospect filing back result subsequent trial becoming post marketing requirement seems highly unlikely cymabay executive rightly talked pointing absence month safety data drug already market said nash longer focus unless partner found another prudent move genfit saying want start pbc trial year cymabay need keep pace investor probably brace cash call story corrected make clear enhance phase iii trial\n",
      "\n",
      "Keywords:\n",
      "pbc 0.335\n",
      "cymabay 0.248\n",
      "genfit 0.18\n",
      "pruritus 0.157\n",
      "seladelpar 0.153\n",
      "nash 0.152\n",
      "enhance 0.149\n",
      "ocaliva 0.143\n",
      "liver 0.136\n",
      "enhance trial 0.122\n",
      "trial 0.116\n",
      "cirrhosis 0.112\n",
      "ppar agonist 0.105\n",
      "ppar 0.105\n",
      "itching 0.105\n",
      "clinical hold 0.105\n",
      "phase iii 0.104\n",
      "iii 0.1\n",
      "phase 0.096\n",
      "pivot 0.095\n",
      "\n",
      "Abstract:\n",
      "fear u project warp speed snubbed glaxosmithkline sanofi dispelled today company two world important vaccine maker revealed award bn development still unnamed covid product delivery initial million dos brings bn amount warp speed partnership u department health human service fda nih barda department defense committed towards vaccine coronavirus three project generated human data two yet even clinic change soon however glaxo sanofi project slated start clinical trial second half year timeline company updated today phase ii study begin september followed pivotal trial end possible u approval first half half bn award pegged delivery million dos thus paid development complete vaccine manufactured option u government buy another million dos later glaxo sanofi vaccine project yet named known based recombinant protein technology sanofi separate tie translate bio covering mrna vaccine expected enter phase study end year yet generate clinical data two major warp speed funding recipient johnson johnson adenovirus based project coded ad cov novavax nanoparticle vaccine nvx cov first human data latter due early august comprise one eagerly awaited event covid vaccine watcher johnson johnson meanwhile yesterday confirmed ad cov entered phase iia move phase iii september subject study comprise part pivotal effort see people enrolled trial six covid vaccine end year merck co separate global vaccine player merck co today provided information two vaccine developing coronavirus v recombinant vesicular stomatitis virus project collaboration iavi v based measles virus vector technology acquired along themis may clinic year seems themis project slightly ahead development though iavi asset beneficiary small barda award glaxo sanofi vaccine started relatively small grant u government namely april given budget project warp speed never disclosed neither number possible beneficiary award possible\n",
      "\n",
      "Keywords:\n",
      "vaccine 0.322\n",
      "award 0.224\n",
      "warp speed 0.216\n",
      "warp 0.216\n",
      "glaxo sanofi 0.168\n",
      "speed 0.162\n",
      "sanofi 0.151\n",
      "million dos 0.141\n",
      "johnson 0.136\n",
      "glaxo 0.132\n",
      "cov 0.128\n",
      "project warp speed 0.123\n",
      "project warp 0.123\n",
      "department 0.123\n",
      "project 0.122\n",
      "million 0.12\n",
      "themis 0.117\n",
      "iavi 0.117\n",
      "comprise 0.112\n",
      "ad cov 0.112\n",
      "\n",
      "Abstract:\n",
      "pricing biopharma rather opaque business covid pandemic public perception count lot perhaps mind astrazeneca today disclosed first time covid vaccine azd might cost dollar per dose revelation made group second quarter medium call morning threatens serious embarrassment two astra coronavirus vaccine rival pfizer suggested price vaccine moderna appears going higher still rumoured per dose per course mrna stressed moderna number official come anonymous source speaking uk financial time deflect attention moderna group whose covid vaccine effort attracted u taxpayer funding addition huge amount raised investor astra pfizer benefited project warp speed partnership u department health human service fda nih barda department defense tune bn nearly bn respectively important distinction pfizer get money vaccine successful funding essentially pre order wrapped agreement buy hundred million dos fda approval astra stressing pandemic unique global problem put duty biopharma strong implication come obligation price responsibly today call astra chief executive pascal soriot repeated group pledge supply adz cost long pandemic persisted pam cheng astra vice president operation fleshed promise stating cost good perspective able manufacture dollar per dose part pfizer recently announced cost bnt b potential covid vaccine joint development biontech covid vaccine move pivotal development july yesterday earnings call albert bourla pfizer chief executive said based volume people order order le price would higher order little bit lower important point group keeping eye margin want bnt b profitable manufacturing key element price equation whether assumes profit breakeven much vaccine cost make moderna pfizer mrna vaccine touted manufacturing advantage vaccine commercially available yet play astra today said fortunate azd traditional adenovirus vaccine made proven platform keeping cost implication price mr soriot appeared take swipe mrna vaccine stored much lower temperature azd vaccine work safe keep degree imagine practical distribute america africa said fierce pr battle biopharma role tackling coronavirus pandemic astra look moved noticeably ahead moderna story amended correct mistake regarding warp speed funding biontech pfizer\n",
      "\n",
      "Keywords:\n",
      "vaccine 0.377\n",
      "astra 0.237\n",
      "order 0.203\n",
      "cost 0.19\n",
      "pfizer 0.19\n",
      "per dose 0.182\n",
      "moderna 0.168\n",
      "covid vaccine 0.139\n",
      "per 0.135\n",
      "azd 0.129\n",
      "soriot 0.122\n",
      "department 0.122\n",
      "price 0.118\n",
      "funding 0.117\n",
      "covid 0.116\n",
      "warp speed 0.107\n",
      "warp 0.107\n",
      "mrna 0.104\n",
      "pandemic 0.104\n",
      "keeping 0.097\n",
      "\n",
      "Abstract:\n",
      "though august might normally classed quiet month sector time around hold valuable u approval decision five project due assessed blockbuster potential forecast bn according evaluatepharma consensus valuable novartis inclisiran pdufa date disclosed guided second half year project small interfering rna designed target pcsk lower ldl cholesterol inclisiran look effective marketed anti pcsk mabs amgen astellas repatha sanofi regeneron praluent mabs however proved disappointing commercially carried huge sale forecast since slashed inclisiran main advantage seems convenience injected twice yearly versus every two week monthly mabs still remains risky commercially key factor novartis price money another expected big money spinner due decision biomarin valrox haemophilia gene therapy ahead rival durability lingering red flag four year data showed treated patient clotting factor continued fade time valrox look approvable room improvement pfizer sangamo offering giroctocogene fitelparvovec produced encouraging albeit early result far prove durable biomarin fight hand three day later august fda discus roche risdiplam spinal muscular atrophy smn splicing modifier filed use infant type disease patient two year old le severe disease known type risdiplam shown encouraging efficacy clean safety profile oral agent threatens biogen spinraza delivered intrathecally sellside agrees risdiplam forecast look set overtake spinraza according evaluatepharma toxicity issue glaxosmithkline belantamab mafodotin anti bcma antibody drug conjugate received positive adcom vote multiple myeloma earlier month despite underwhelming efficacy serious ocular toxicity approved label include black box warning risk mitigation programme implemented whether patient willing accept side effect profile key forecast met another project adverse event implication gilead galapagos filgotinib filed use rheumatoid arthritis jak inhibitor called jyseleca received eu backing last week mg mg dos several question remain fda decision expected second half year black box warning likely thrombosis case abbvie rinvoq approved arthritis last year second worry fda take conservative approach approve lower dose adverse event appear dose dependent lastly potential warning risk testicular toxicity signal picked animal model specific case clinical trial two safety study called manta manta ray conducted expected read early next year stifel think unlikely fda need safety data approving filgotinib ra possibility agency add toxicity wording label study read leading slow early uptake study report fda seems largely track approval decision little sign covid pandemic abating real impact timeline become significant coming month go go pandemic loom fda timeline july table list first time supplementary fda approval due august consensus forecast evaluatepharma\n",
      "\n",
      "Keywords:\n",
      "risdiplam 0.173\n",
      "fda 0.151\n",
      "inclisiran 0.148\n",
      "mabs 0.12\n",
      "spinraza 0.115\n",
      "forecast 0.111\n",
      "toxicity 0.11\n",
      "warning risk 0.109\n",
      "manta 0.109\n",
      "august 0.107\n",
      "decision 0.107\n",
      "warning 0.105\n",
      "valrox 0.098\n",
      "pcsk 0.098\n",
      "second half year 0.092\n",
      "biomarin 0.088\n",
      "approval decision 0.085\n",
      "filgotinib 0.082\n",
      "box warning 0.081\n",
      "black box warning 0.081\n",
      "\n",
      "Abstract:\n",
      "failure spectrum poziotinib potentially pivotal study cohort december hope trial remaining arm low analysis second cohort yesterday yielded positive outcome sending company stock morning spectrum look set file latest data pending agreement u fda though niche poziotinib succeeded subset subset non small cell lung cancer poorly diagnosed even smaller one failed investor need remember threat takeda competing potentially efficacious project however spectrum bask glory multi cohort zenith trial poziotinib yielded independently adjudicated overall remission rate among second line later nsclc subject exon insertion zenith designed almost one arm registrational spectrum confirmed would request meeting fda discus filing benchmark spectrum set cohort uncontrolled trial lower bound confidence interval orr deemed part trial success zenith first cohort relapsed nsclc driven egfr exon insertion failed yielding orr call today spectrum confirmed analysis verified central review committee offer explanation disparate result beyond citing different receptor target raise fresh question poziotinib inhibitor taken forward nsclc niche spectrum initially looking breast cancer persuaded otherwise md anderson cancer moon shot programme preclinically identified poziotinib potent agent exon mutation first test spectrum shift november spectrum investor aware key competitor exon insertion niche takeda mobocertinib tak asco yielded orr month median duration response egfr exon insertion mutant nsclc cross trial basis data clearly beat zenith cohort unfortunately takeda yet generated result exon mutant comparison spectrum latest dataset possible niche spectrum poziotinib strategy simply need refining investor aware small niche takeda reckons egfr mutated nsclc tumour exon insertion spectrum say equates nsclc versus exon insertion thus space spectrum latest dataset open amount u eu patient year across therapy line separate problem exon mutation generally screened present whereas thanks drug like iressa tagrisso diagnosis specific type driver egfr mutation pretty standard spectrum hope clinician start testing based data generated without big partner drive effort wishful thinking spectrum surely need zenith cohort succeed show yesterday readout fluke\n",
      "\n",
      "Keywords:\n",
      "spectrum 0.551\n",
      "exon 0.298\n",
      "poziotinib 0.252\n",
      "insertion 0.252\n",
      "exon insertion 0.252\n",
      "zenith 0.21\n",
      "nsclc 0.161\n",
      "niche 0.148\n",
      "egfr 0.14\n",
      "cohort 0.129\n",
      "takeda 0.117\n",
      "latest dataset 0.088\n",
      "egfr exon insertion 0.084\n",
      "egfr exon 0.084\n",
      "exon mutation 0.078\n",
      "mutation 0.078\n",
      "orr 0.075\n",
      "yielded 0.074\n",
      "subset 0.073\n",
      "aware 0.073\n",
      "\n",
      "Abstract:\n",
      "going second antibody drug conjugate daiichi sankyo astrazeneca making abundantly clear expects technology bn front fee due handed d implies huge commercial success expected project remains phase limited proof concept stop astra handing even cash enhertu last year course anti adc progressed incredibly quickly approved backed blockbuster sellside forecast hope presumably repeat trick time partner dealing much le well known biological target trop rival already market competitor immunomedics approval anti trop adc trodelvy earlier year accelerated approval swiftly followed impressive readout confirmatory ascent trial cut risk progression impressive third line triple negative breast cancer tnbc setting immunomedics confirms approval within three month july important strategic difference daiichi focused initial development d non small cell lung cancer tnbc likely next focus new partner seem believe d safer offering stacking trop overexpressed variety cancer including pancreatic oesophageal tumour well lung breast however found epithelium normal tissue meaning potential toxicity big concern fact caused several previous project abandoned pfizer canned pf back example daiichi long touted structural difference d trodelvy stable drug linker lower drug antibody ratio mean le toxicity company argued although whether play whether come expensive efficacy remain important question answered little data compare two agent recent release daiichi asco orr heavily pretreated nsclc patient reported across three dos subject failed checkpoint blockade back immunomedics reported orr late line nsclc patient received immunotherapy neutropenia diarrhoea biggest concern trodelvy drug u label black box issue like enhertu d seems associated interstitial lung disease eight event reported asco stomatitis occurred another serious adverse event asco daiichi laid aggressive development plan d including starting tnbc trial year end astrazeneca board full speed ahead\n",
      "\n",
      "Keywords:\n",
      "daiichi 0.292\n",
      "trop 0.218\n",
      "trodelvy 0.202\n",
      "tnbc 0.202\n",
      "immunomedics 0.169\n",
      "asco 0.132\n",
      "nsclc patient 0.131\n",
      "enhertu 0.128\n",
      "adc 0.128\n",
      "lung 0.124\n",
      "reported 0.107\n",
      "nsclc 0.093\n",
      "breast 0.091\n",
      "orr 0.087\n",
      "cancer 0.085\n",
      "drug 0.077\n",
      "approval 0.077\n",
      "difference 0.076\n",
      "partner 0.074\n",
      "impressive 0.074\n",
      "\n",
      "Abstract:\n",
      "proof needed market taking donald trump effort address drug pricing seriously look today opening bell big pharma stock showed sign reaction u president attempt lower patient pocket cost four executive order announced friday arguably market reaction lack surprising scant detail around proposal unrealistic timeline left measure looking like last minute attempt president trump rally base drum support november election rather like serious policy closer look measure show hard mr trump achieve aim set access affordable lifesaving medication order would require community health clinic funded federal government provide insulin epipen cost would tie future funding clinic maintaining price level without mark discounted medicaid price surface hard see pharma objection measure industry fear centre policy expanded beyond low income family medicaid usually cover uninsured president trump targeting senior healthcare measure legislation would extended medicare encompass product beyond insulin epipen run objection pharma company well significant legislative hurdle drug import proposal likely controversial hardest implement thrust order relates insulin one area controversy around price gouging extended drug herein lie problem highly likely canadian government would unwilling see drug supply intended citizen cross border size canadian population mean realistic solution u issue pharma company would willing go court reference pricing would two front runner change current situation take year implement international reference pricing essence order tackle one mr trump biggest bugbear differential pricing different market level proposing benchmark pricing part b drug lowest price available economically comparable country problem constitutes comparable country often unpalatable decision mr trump initially leaving someone else pharma company tasked coming solution incredibly complex issue august order come force unlike measure outlined mr trump one unpopular within republican party member see price fixing another name hard implement eliminating kickback pbms middleman passing negotiated discount prescription drug patient logically winner concern rebate ended drug company rather lowering cost drug would keep saving first time mr trump wheeled policy previously quickly walked back projection showed might fact raise medicare premium senior bn year time caveat executive order passed law raise premium math still sorted reality policy seeing light day questionable sitting uncomfortably mr trump invited pharma executive white house tuesday discus new executive order promise slightly tougher much awkward meeting last time pharma boss gathered analyst pointed work many company done speed covid vaccine market mention president spending billion dollar taxpayer money aim give stronger position push back proposal option waiting thing pharma exec given mr trump falling rating covid crisis even mr trump win november exec unlikely sweating hard given difficulty politically legally logistically implementing measure loses democrat similar drug pricing ambition face many hurdle\n",
      "\n",
      "Keywords:\n",
      "mr trump 0.39\n",
      "trump 0.383\n",
      "order 0.266\n",
      "mr 0.198\n",
      "pricing 0.19\n",
      "policy 0.182\n",
      "pharma 0.148\n",
      "proposal 0.146\n",
      "executive order 0.146\n",
      "implement 0.137\n",
      "president 0.131\n",
      "measure 0.117\n",
      "insulin 0.117\n",
      "drug 0.104\n",
      "pharma company 0.096\n",
      "would 0.096\n",
      "reference 0.091\n",
      "epipen 0.091\n",
      "price 0.089\n",
      "drug pricing 0.087\n",
      "\n",
      "Abstract:\n",
      "took arbutus moderna almost hour comment publicly relevance thursday legal bust saw former prevail patent ruling threaten latter covid vaccine neither company look covered glory entry curevac fray complicates thing still arbutus admitted actually signed away much relevant right two year ago stock lost moderna meanwhile claimed tech fact covered arbutus patent case initiate legal action arbutus begin curevac clear german group revealed hand filing u sec proposed flotation document curevac spelled reliance lipid nanoparticle lnp technology developed acuitas private canadian company link alnylam way tie pay annual maintenance fee acuitas centre dispute moderna arbutus source lnps used biontech pfizer remarkable upshot three major mrna covid vaccine competitor might way rely lnp technology question longstanding aggression moderna say challenged three relevant arbutus patent response longstanding aggressive posture taken arbutus claim lnp technology advanced beyond arbutus patent describe perhaps implying largely engineered mrna approach past two year arbutus statement meanwhile come surprise investor paying close attention sake clarity arbutus might legal decision spell interest patent question u spun right lnp technology relate hepatitis b genevant venture vivek ramaswamy holding company roivant science covid vaccine battle got interesting july back one thinking covid arbutus key focus hepatitis b venture owned roivant arbutus investor get worse genevant subsequently issued convertible debt paid new equity arbutus shareholder significantly diluted arbutus say however entitled low single digit royalty sale product derived patent held genevant\n",
      "\n",
      "Keywords:\n",
      "arbutus 0.681\n",
      "lnp technology 0.22\n",
      "lnp 0.22\n",
      "patent 0.194\n",
      "legal 0.165\n",
      "genevant 0.165\n",
      "arbutus patent 0.165\n",
      "curevac 0.129\n",
      "moderna 0.122\n",
      "acuitas 0.11\n",
      "technology 0.104\n",
      "covid vaccine 0.095\n",
      "roivant 0.094\n",
      "covered 0.09\n",
      "covid 0.084\n",
      "hepatitis 0.081\n",
      "vaccine 0.079\n",
      "venture 0.076\n",
      "two year 0.064\n",
      "mrna 0.063\n",
      "\n",
      "Abstract:\n",
      "careful wish moderna fired first salvo arbutus two year ago seeking assert position lipid nanoparticle lnp technology event come worse yesterday u court deemed key arbutus patent stand sending tiny biotech stock remarkably moderna issued formal statement ruling presumably wanting give away anything possible implication lnp tech thought underlie mrna work including high profile covid vaccine project mrna moderna evidently want spell ruling concern third three arbutus patent moderna challenged inter partes review moderna prevailed first got mixed verdict second regarding third concerning u patent judge yesterday ruled moderna shown preponderance evidence claim patent unpatentable course appeal last two ruling virtually assured though moderna yet reveal hand stressed final outcome unlikely see moderna prevented marketing lnp based product worst moderna might agree pay arbutus royalty course long lnp tech arbutus claim indeed implicated moderna mrna work clinicaltrials gov entry moderna phase covid vaccine trial state mrna novel lnp encapsulated mrna based vaccine moreover infringement would depend mrna actually getting market based clinical data generated far moderna project lag biontech pfizer mrna rival bnt b novavax keep investor waiting july investor price extra risk yesterday moderna stock lost equivalent bn market cap complicated farrago came complicated markman advisor new york based patent consultancy pointed moderna initially licensed lnps acuitas small canadian firm acquired arbutus acuitas right sublicense became subject separate arbutus litigation settled february effect acuitas limited four specific viral target moderna thus appeared frozen started challenging validity arbutus lnp patent twist acuitas source lnps biontech pfizer use bnt b arrangement appears routed deal biontech genevant venture founded jointly april arbutus vivek ramaswamy holding company roivant science disparity arbutus moderna david versus goliath battle underestimated moderna bn market cap arbutus valuation stand puny even including yesterday surge u corporate law size financial firepower count lot nevertheless mark sudden turnaround arbutus fortune group formerly known tekmira best known hepatitis b failure stake second clinical stage covid vaccine\n",
      "\n",
      "Keywords:\n",
      "arbutus 0.52\n",
      "moderna 0.46\n",
      "lnp 0.294\n",
      "acuitas 0.196\n",
      "mrna 0.195\n",
      "patent 0.173\n",
      "ruling 0.134\n",
      "arbutus patent 0.098\n",
      "vaccine 0.094\n",
      "biontech 0.09\n",
      "covid vaccine 0.084\n",
      "complicated 0.084\n",
      "tech 0.076\n",
      "based 0.076\n",
      "yesterday 0.072\n",
      "bnt 0.07\n",
      "biontech pfizer 0.07\n",
      "bn market cap 0.067\n",
      "bn market 0.064\n",
      "covid 0.056\n",
      "\n",
      "Abstract:\n",
      "roche escaped hit top line covid pandemic one leading light coronavirus diagnostics effort medical device product drag found half year point unusual position medtech division better pharma revenue overall sfr bn bn missed analyst consensus expectation u stock traded morning today however full year guidance remains unchanged low mid single digit sale growth constant exchange rate roughly constant exchange rate group first half sale ticked thanks strong swiss franc underlying basis though total revenue sale drug fell owing decreased hospitalisation outpatient visit hit sale product including lucentis rituxan particular overall group profit sfr bn upside sale newer medicine including tecentriq hemlibra ocrevus perjeta company said sale rheumatoid arthritis drug actemra partly inclusion several country treatment guideline severe covid pneumonia though use case anti il mab relies theory proof increase sale drug cannot compensate however revenue bestseller falling biosimilar competition diagnostics side thing little better test sale fell overall routine testing disorder like cancer decreased molecular testing revenue jumped thanks largely cobas sars cov pcr test higher brake sale production capacity like covid test maker roche difficulty meeting demand situation likely continue month come even roche quadrupled test manufacturing capacity cobas assay roche flagship covid diagnostic mean one group far launched seven technology diagnose covid complication otherwise monitor patient known suspected disease antibody test appears one accurate available though link presence antibody protection reinfection remains unproven roche company secured u emergency authorisation test detect level il identify risk severe inflammatory response patient already diagnosed coronavirus may problem month swiss group lockdown restriction patient delayed appointment causing double digit decrease total revenue year year picture brightened somewhat june group saying strong recovery way even company full year outlook foresees possibility slight boost current status marked contrast company johnson johnson abbott asserted dismal second quarter would followed pretty spectacular comeback year end roche modest expectation probably stand better chance coming pas\n",
      "\n",
      "Keywords:\n",
      "sale 0.243\n",
      "test 0.209\n",
      "revenue 0.203\n",
      "roche 0.182\n",
      "covid 0.147\n",
      "constant 0.147\n",
      "decreased 0.132\n",
      "digit 0.12\n",
      "full year 0.118\n",
      "capacity 0.116\n",
      "exchange 0.114\n",
      "group 0.107\n",
      "diagnostics 0.105\n",
      "overall 0.105\n",
      "swiss 0.104\n",
      "il 0.098\n",
      "better 0.094\n",
      "thanks 0.092\n",
      "fell 0.091\n",
      "johnson 0.086\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Abstract:\n",
      "often cosy world patented drug development price war rare yet working similarly acting version biopharma expensive treatment launching discount precisely aim eqrx private biotech founded january yesterday company trained gun first target strategy pfizer cdk inhibitor ibrance breast cancer astrazeneca egfr targeting lung cancer drug tagrisso end eqrx licensed two early stage project mechanism g lerociclib jiangsu hansoh almonertinib respectively still leader probably panic yet take eqrx year develop asset fast follower plan depends stellar clinical data without big hitting sale machine behind eqrx little chance dislodging entrenched product even cut price approach lerociclib lerociclib deal cost eqrx signing give company right cdk inhibitor globally including japan excluding rest asia pacific region g earlier struck deal genor biopharma lerociclib one g two cdk inhibitor might first seem strange originator willing cut throat threat discounted pricing g positioned project trilaciclib niche make chemotherapy tolerable reducing myelosuppression face little immediate threat eqrx aim develop lerociclib cdk inhibitor traditional indication hormone receptor positive negative breast cancer three drug mechanism marketed today pfizer ibrance entrenched sale nearly bn last year ibrance current u list price around month though course excludes discounting cost patient depends insurance plan last year san antonio breast cancer symposium g presented phase ii data said lerociclib median progression free survival month consistent cdk inhibitor used combination fulvestrant breast cancer setting case eqrx second deal lung cancer space jiangsu hansoh almonertinib target downstream mutation entirely controlled astrazeneca tagrisso whose u wholesale acquisition price around month clinical evidence backing almonertinib fact drug already approved china trade name ameile green light came march backed single arm apollo trial result presented year virtual aacr meeting showed overall remission rate patient median progression free survival month grade rash qt interval prolongation beyond tagrisso industry pipeline plenty clinical project targeting downstream mutation initial egfr inhibitor therapy specifically mutation almonertinib face competition another third generation egfr inhibitor novartis egf though clovis rociletinib hanmi hm astellas asp pfizer pf discontinued front value jiangsu hansoh deal revealed eqrx say yet undisclosed project pipeline doubt series funding raised january give plenty firepower bring asset develop undercut competition\n",
      "\n",
      "Keywords:\n",
      "eqrx 0.443\n",
      "lerociclib 0.332\n",
      "cdk inhibitor 0.228\n",
      "cdk 0.222\n",
      "almonertinib 0.221\n",
      "jiangsu 0.155\n",
      "inhibitor 0.13\n",
      "breast cancer 0.124\n",
      "tagrisso 0.124\n",
      "ibrance 0.124\n",
      "egfr 0.124\n",
      "breast 0.123\n",
      "cancer 0.115\n",
      "egfr inhibitor 0.099\n",
      "free survival month 0.095\n",
      "mutation 0.091\n",
      "develop 0.09\n",
      "survival month 0.086\n",
      "median progression free 0.086\n",
      "median progression 0.086\n",
      "\n",
      "Abstract:\n",
      "generic competition blockbuster tecfidera possible next year fortune wedded controversial alzheimer antibody aducanumab biogen given investor plenty fret yesterday added another concern slipping news market close chief financial officer leaving today second quarter call call soon ex finance chief jeffrey capello present group brushed suggestion needed better deal maker still departure timing evening financials look strange stoke speculation biogen acquisition strategy instance one possibility mr capello leaving disagreement logic biogen left dependent aducanumab hold truth one logical assumption might biogen urgently start looking target biotech investor would welcome outcome though company starting shop acquisition time market time high would look strange hand perhaps biogen option stage maybe disagreement concerned whether biogen buy much spend scenario realistic true decision valuation affordability would certainly involve chief financial officer mr capello responsibility would logically limited financial matter seems odd chosen shoulder blame overall strategic shortcoming still departure second senior executive le year last october biogen head r michael ehlers left unexpectedly hypothetically head r would logical exec head finance carry development strategy failing binary outcome cannot denied aducanumab looming fda verdict one biggest binary outcome event recent year left biogen exposed especially true company recent u patent loss opened door generic version tecfidera seven year earlier expected today call biogen stressed appealing decision insisted remained well positioned irrespective final verdict analyst keen know aducanumab delay finally submitted fda month remarkably biogen would confirm whether applied breakthrough therapy designation used priority review voucher filing say fast track status expects hear priority review thus priority review granted investor way knowing whether based aducanumab merit merely due use voucher mr capello staying brief handover presenting account said enjoyed working biogen thanked given good wish management played question whether needed better deal maker though highlighted incoming finance chief mike mcdonnell extensive expertise value creating strategic financial consideration mr mcdonnell join iqvia company formed merger quintiles ims health perhaps coincidentally iqvia contractor biogen used run aducanumab pivotal trial confirmed today though said iqvia involved regulatory interaction mr capello time chief financial officer biogen stock lost probably matter much le fact share treading water year everything hinge aducanumab\n",
      "\n",
      "Keywords:\n",
      "biogen 0.439\n",
      "capello 0.279\n",
      "aducanumab 0.27\n",
      "mr capello 0.223\n",
      "financial 0.169\n",
      "financial officer 0.157\n",
      "chief financial officer 0.157\n",
      "chief financial 0.157\n",
      "finance 0.143\n",
      "mr 0.142\n",
      "chief 0.122\n",
      "priority review 0.118\n",
      "officer 0.111\n",
      "priority 0.109\n",
      "disagreement 0.099\n",
      "departure 0.099\n",
      "binary outcome 0.099\n",
      "left 0.097\n",
      "strange 0.095\n",
      "binary 0.095\n",
      "\n",
      "Abstract:\n",
      "number novel pivotal stage project big pharma pipeline noticeably dropped past couple year recent evaluate vantage analysis found big pharma sport smallest late stage pipeline decade june raise question happening developer investing success story pursuing called pipeline project approach seems partly true new crunch data suggests since clear rise average number indication novel product tested largely driven arrival immuno oncology huge brand extension programme conducted checkpoint inhibitor trend visible elsewhere chart show big pharma pipeline really started shrinking around time took trend simply feature fewer trial started world largest drug maker started phase iii trial new molecular entity nmes vantage calculation figure lower time though number novel project sitting developer phase iii pipeline dropped calculated using historical pipeline data evaluatepharma count conducted april every year analysis number average indication per nme vantage collected phase iii trial start project whether already marketed still r year big pharma company listed primary sponsor number separate indication product tested term trial initiated year found allowed average number indication per product calculated year across entirety big pharma phase iii clinical effort outcome average nme tested indication might seem like big rise absolute term equates increase look company level highlight two group indeed two product largely driven trend merck co keytruda bristol myers squibb opdivo put huge clinical programme astrazeneca imfinzi roche tecentriq trialled widely merck keytruda investment surely break record example phase iii trial started checkpoint inhibitor nine different tumour type pd l inhibitor entirely responsible tightening focus rise immunotherapy disease like rheumatoid arthritis crohn disease psoriasis seen drug tested numerous setting abbvie humira novartis cosentyx feature prominently realm result dominant company autoimmune focus upward trend chart analysis support theory phase iii pipeline shrinking attention directed fewer project whether strategy pay another question entirely course always winner loser merck left contender dust course suggest big pharma need beef late stage pipeline several large drug maker pressure diversify away hugely successful product sucked much energy abbvie example criticised reliance humira merck already close replicating scenario keytruda\n",
      "\n",
      "Keywords:\n",
      "pipeline 0.224\n",
      "big pharma 0.196\n",
      "trend 0.158\n",
      "indication 0.151\n",
      "pharma 0.148\n",
      "average 0.142\n",
      "big 0.135\n",
      "number 0.134\n",
      "phase iii 0.125\n",
      "rise 0.124\n",
      "started 0.123\n",
      "stage pipeline 0.122\n",
      "shrinking 0.122\n",
      "pharma pipeline 0.122\n",
      "number novel 0.122\n",
      "number indication 0.122\n",
      "late stage pipeline 0.122\n",
      "iii 0.12\n",
      "product 0.118\n",
      "tested 0.114\n",
      "\n",
      "Abstract:\n",
      "race develop vaccine covid moderna biontech pfizer rival project shown impressive ability generate neutralising antibody far little said ability stimulate cell today changed astrazeneca azd join leader first clinical data published lancet included finding ability generate cell response biontech pfizer preprint separate trial bnt b vaccine detailed perhaps impressive cell response far hypothesised prevent severe covid infection generate long lasting effect might necessary vaccine stimulate cellular well humoural antibody based immunity key part immune response ultimately lead destruction pathogen antibody astrazeneca today reported data part patient population want enrol astra oxford university trial far enrolled subject lancet paper key finding relate neutralising antibody level available showed detectable neutralising antibody response single azd dose became booster author wrote neutralising antibody key interfere virus ability infect cell cell response data meanwhile available subject response induced peaking day maintained two month injection astra said statement however lancet paper low detail revealed boost cellular response observed following second dose moreover nothing said whether cd helper cd killer cell response disappoint investor enthused uk press report friday stressed stimulation killer cell bnt b biontech pfizer bnt b biontech pfizer mrna moderna part biontech pfizer pre empted lancet publication publication another scientific paper pre print time relating german trial mrna vaccine project bnt b specifically highlighting effect cd cell trial enrolled subject across four g dose level tested cellular response company said mounted called functional cd cell response comparable memory response observed cmv ebv influenza virus cellular response covid receptor binding domain implying precise response antigen bnt b encodes dose response relationship author argued positive implying response mounted even low dose moderna mrna rival mrna shown effect cell study published nejm last week seen somewhat modest mrna encodes binding domain entire spike protein response said specific first bnt b study reported u trial evaluable volunteer shown strong neutralising antibody response nothing said cell covid vaccine remain hot spite inovio july doubt investor continue pick apart data coming day covid tectonic plate shifted biontech morning rose astra unmoved moderna lost\n",
      "\n",
      "Keywords:\n",
      "response 0.292\n",
      "cell 0.219\n",
      "bnt 0.209\n",
      "cell response 0.203\n",
      "neutralising antibody 0.189\n",
      "neutralising 0.186\n",
      "biontech 0.178\n",
      "biontech pfizer 0.174\n",
      "lancet 0.172\n",
      "cellular 0.162\n",
      "cellular response 0.156\n",
      "mrna 0.138\n",
      "antibody 0.134\n",
      "vaccine 0.116\n",
      "ability 0.113\n",
      "cd 0.11\n",
      "paper 0.11\n",
      "pfizer 0.109\n",
      "moderna 0.107\n",
      "stimulate 0.097\n",
      "\n",
      "Abstract:\n",
      "investor government itching analyse first clinical data astrazeneca oxford university covid vaccine today fact different uk company tiny biotech synairgen seized morning attention synairgen group focused respiratory disease whose key technological advance inhaled form interferon beta masterstroke begin study covid result small trial toplined today sent stock notwithstanding question company actually demonstrated even remarkably synairgen stand time higher start putting line one year best performing biotech even share price surge market cap still study synairgen inhaled interferon beta project coded sng two part made hospitalised patient home setting former generated market today deemed clinical win endpoint still synairgen disclosed little study primary endpoint absolute day improvement versus placebo eight point ordinal scale represents well death instead press released three apparently secondary efficacy measure developing severe disease recovery defined limitation activity evidence infection improvement breathlessness day backed p value point synairgen press release claim statistically significant medium call group accepted p value adjusted multiplicity analysis done revealed leaving open possibility lacked statistical significance moreover cited extremely wide confidence interval range suggesting high likelihood chance group evasive regard primary endpoint absolute improvement day chief executive richard marsden saying result hand professor tom wilkinson study lead investigator argued involved complicated statistical analysis performed analysis demonstrates clear treatment effect statistically significant stated management argued primary outcome captured measure improvement cited day absence primary efficacy analysis study important metric puzzling uk biotech win said perhaps given synairgen market cap borderline numerical benefit ultimately small trial called win every company working covid revealed clinical data multi billion dollar valuation raised red flag clear synairgen need trial sng money run today announcement certainly raise group profile interestingly study home part proved difficult enrol completion depend second wave covid uk believe happen said mr marsden synairgen university southampton spin earlier focused sng asthma copd greatest success tie astrazeneca perhaps covid data attract funding though likely come investor uk government far focused spending effort largely securing vaccine supply today uk government announced secured million dos biontech pfizer bnt delivery million dos valneva vla agreement supply uk million dos astrazeneca oxford university vaccine azd reportedly struck may whatever doubt might remain synairgen statistical rigor company co founder stephen holgate insisted feel confident real biological clinical signal within data\n",
      "\n",
      "Keywords:\n",
      "synairgen 0.539\n",
      "uk 0.188\n",
      "sng 0.173\n",
      "million dos 0.124\n",
      "interferon beta 0.108\n",
      "government 0.107\n",
      "million 0.106\n",
      "improvement 0.104\n",
      "covid 0.103\n",
      "marsden 0.103\n",
      "interferon 0.103\n",
      "astrazeneca oxford university 0.103\n",
      "astrazeneca oxford 0.103\n",
      "focused 0.099\n",
      "small trial 0.098\n",
      "university 0.096\n",
      "oxford university 0.095\n",
      "inhaled 0.092\n",
      "statistical 0.091\n",
      "today 0.088\n",
      "\n",
      "Abstract:\n",
      "path tackling alzheimer disease littered failure company generates even early hint promise reward high take tiny inmune bio whose share rocketed week phase ib data xpro tnf inhibitor said decrease neuroinflammation number developer lining alzheimer readout year numerous clinical catalyst horizon includes data big player like roche lilly well smaller group like biohaven cortexyme experience big swing share price result news ac immune week case point announcement group starting test high dose anti tau vaccine aci pushed stock higher history development space suggests little read move however investor would wise wait data assuming progress targeting tau one dominant mechanism found alzheimer pipeline alongside beta amyloid approach although doubt remain utility technique tau protein largely accumulates inside neuron best clear brain remains open question major test tau approach near however roche ac immune semorinemab yield data coming month primary completion date phase ii tauriel study june study prodromal mild subject test three active dos versus placebo month primary endpoint efficacy month wolfe research suggests trial large long enough potentially generate signal efficacy though might sufficiently powered hit significance minimum study need show reduction tau burden brain abbvie biogen shown tricky targeting tau development anti tau mabs abbv e gosuranemab respectively scrapped different tauopathy progressive supranuclear palsy owing lack efficacy development project alzheimer continues highlighting sizeable risk reward beta amyloid roche skin beta amyloid game early data next generation beta amyloid mab expected end year rg version gantenerumab formulated brain shuttle technology said increase antibody concentration brain trial healthy men primarily evaluating safety secondary measure include csf antibody concentration three five day dosing anti rg antibody two month data due open label portion scarlet road trial testing gantenerumab original form study chequered past terminated early owing lack interim efficacy prodromal patient initially given mg mg month post hoc analysis suggested trend towards benefit fast progressors study converted open label extension patient titrated mg roche hope dose high enough long enough efficacy signal might teased seen aducanumab biogen stack deck path forward clearer alzheimer december swiss group effectively testing theory pivotal graduate trial patient titrated mg data study expected earliest elsewhere beta amyloid front lilly donanemab target form protein aggregated amyloid plaque trailblazer alz study patient early disease report early next year mabs aside interim analysis cortexyme gain trial due fourth quarter futility test determine future group atuzaginstat taking completely different approach cracking alzheimer puzzle company hypothesised porphyromonas gingivalisin bacterium responsible gingivitis gum disease infect brain cause alzheimer hope atuzaginstat first class gingipain inhibitor neutralise gingipains brain protect neuron reduce inflammation preventing cognitive decline patient phase ii iii gain trial mild moderate alzheimer compare two dos atuzaginstat placebo interim analysis conducted approximately patient three study arm completed six month treatment cortexyme pass vital test topline result expected fourth quarter company weighty bn market cap rest entirely fate project result expected first quarter biohaven troriluzole another move away amyloid hypothesis troriluzole thought work reducing level glutamate synapsis studied protect ad trial evidence role glutamate alzheimer lundbeck namenda approved alzheimer target nmda glutamate receptor troriluzole passed first hurdle interim futility safety analysis patient completed week treatment project demonstrate numerically greater benefit placebo least one two prespecified criterion cognitive function measured ada cog mri assessed hippocampal volume project turbulent development history raise hope however february flunked pivotal study general anxiety disorder failing beat placebo feat repeated june phase ii iii trial obsessive compulsive disorder earlier failure spinocerebellar ataxia far biggest event horizon field however u review biogen aducanumab confirmation fda accepted filing consideration keenly awaited considering project questionable efficacy profile reassurance regulator willing look leniently alzheimer treatment give field much boost breakthrough data scarlet road trailblazer alz protect ad cdr sb clinical dementia rating scale sum box ada cog assessment scale cognitive subscale iadrs integrated alzheimer disease rating scale source evaluatepharma company statement clinicaltrials gov\n",
      "\n",
      "Keywords:\n",
      "alzheimer 0.327\n",
      "tau 0.264\n",
      "amyloid 0.235\n",
      "beta amyloid 0.196\n",
      "brain 0.186\n",
      "beta 0.136\n",
      "protect 0.106\n",
      "cognitive 0.103\n",
      "interim 0.097\n",
      "test 0.093\n",
      "study 0.085\n",
      "efficacy 0.085\n",
      "targeting tau 0.082\n",
      "owing lack 0.082\n",
      "month primary 0.082\n",
      "cog 0.082\n",
      "ada cog 0.082\n",
      "ac immune 0.082\n",
      "mg 0.081\n",
      "biogen 0.08\n",
      "\n",
      "Abstract:\n",
      "detailed data moderna covid vaccine finally seized upon market thirsty good news fight coronavirus result early contain promise healthy volunteer study showed neutralising antibody receiving two dos mrna downside adverse event profile suggests project might magic bullet many hoping fact effective covid vaccine might need dosed yearly regularly make moderna vaccine look even unpalatable otherwise healthy people might accept side effect like fever chill issue older sicker patient population need protection coronavirus potential issue appear concern investor moderna share price climbed morning giving company staggering bn market cap company certainly made enthusiasm desperation covid vaccine dribbling data phase niaid sponsored trial may bn public offering swiftly followed moderna reminds market biotech dual purpose may neutralising antibody time scant detail mrna ability elicit neutralising antibody thought indicator vaccine ability provide protection coronavirus blank filled yesterday publication full result study new england journal medicine promisingly mean level neutralising antibody similar seen patient recovering covid g dose relevant one moderna selected take phase iii\n",
      "\n",
      "Keywords:\n",
      "neutralising antibody 0.268\n",
      "neutralising 0.263\n",
      "moderna 0.238\n",
      "vaccine 0.206\n",
      "protection coronavirus 0.172\n",
      "covid vaccine 0.148\n",
      "antibody 0.135\n",
      "covid 0.131\n",
      "protection 0.127\n",
      "coronavirus 0.124\n",
      "healthy 0.11\n",
      "ability 0.1\n",
      "mrna 0.098\n",
      "level neutralising antibody 0.086\n",
      "level neutralising 0.086\n",
      "take phase 0.082\n",
      "study new 0.082\n",
      "staggering bn 0.082\n",
      "sponsored trial 0.082\n",
      "showed neutralising antibody 0.082\n",
      "\n",
      "Abstract:\n",
      "blueprint medicine disaster lead drug ayvakit company needed lifeline roche provided today licensing deal ret inhibitor pralsetinib allow blueprint become self sufficient set tasty battle roche lilly targeted cancer niche lilly ret inhibitor retevmo selpercatinib recently approved ret mutated non small cell lung thyroid cancer giving month head start pralsetinib roche claw back ground pralsetinib better safety profile possibility according data presented year asco meeting safety heart retevmo label detail side effect including qt prolongation haemorrhagic event hypersensitivity appear issue pralsetinib phase ii arrow study however like retevmo pralsetinib linked hypertension liver enzyme elevation might trickier differentiate drug efficacy least based evidence available far relies always inexact technique comparing two different trial full picture become clearer pralsetinib get approved project due decision u nsclc november blueprint filed thyroid cancer earlier month response rate thyroid tumour similar ranging retevmo pralsetinib roche obviously seen enough pay top dollar company shelling front due pay milestone price asset might driven bidding war blueprint executive said conference call today numerous party interested pralsetinib well cold hard cash factor helped roche seal deal diagnostic expertise testing key driving uptake ret inhibitor existing relationship two company early stage collaboration signed blueprint chief executive jeff albers added group wanted maintain independence something allowed latest deal however lack outright takeout seemed disappoint market blueprint stock trading flat morning initial surge company plan co commercialise pralsetinib u roche exclusively sell drug outside u blueprint due royalty high teen mid twenty agreement excludes china cstone pharmaceutical already right roche able opt second generation ret inhibitor designed combat target resistance roche second big targeted cancer bet acquiring ignyta bn ironically included ret inhibitor rxdx discontinued presumably hit braf playing catch war ret inhibitor lilly currently edge according evaluatepharma sellside consensus retevmo forecast sell bn versus pralsetinib however new big pharma entrant scene prompt change number look like two horse race time two ret inhibitor horizon one developed turning point therapeutic would hard time competing giant like roche lilly coming behind need find real differentiation big partner\n",
      "\n",
      "Keywords:\n",
      "pralsetinib 0.489\n",
      "ret 0.357\n",
      "ret inhibitor 0.326\n",
      "blueprint 0.272\n",
      "retevmo 0.245\n",
      "roche 0.173\n",
      "thyroid 0.129\n",
      "inhibitor 0.123\n",
      "thyroid cancer 0.098\n",
      "lilly 0.097\n",
      "roche lilly 0.093\n",
      "targeted cancer 0.089\n",
      "war 0.086\n",
      "cancer 0.073\n",
      "targeted 0.063\n",
      "sell 0.06\n",
      "pay 0.056\n",
      "deal 0.055\n",
      "due 0.053\n",
      "month response rate 0.047\n",
      "\n",
      "Abstract:\n",
      "coronavirus pandemic turning year unlike investor piled biopharma helping sector avoid spreading doom gloom one area helped surge sentiment however merger acquisition second quarter continued pattern first acquisition happening slightly reduced number evaluate vantage data show large deal combined value haemorrhaged worth asking whether covid induced apathy one hand spiralling asset price put aspect hold often said surge investor sentiment resulting valuation increase rarely coincide uptick big activity true pharma pipeline apparently forever need restocking acquirer need disciplined target price exceeds reasonable deal happen overall quarterly deal value trend past year lends support theory market cooled investor binge peaked reasonably healthy last year much nasdaq biotech index trod water however different story index today time high since january last time quarterly acquisition came lower bn recorded period ended second quarter might coincidental three year ago nasdaq biotech index standing year date biggest deal recent quarter unlikely linger memory novo nordisk bn takeout corvidia anti il antibody ziltivekimab gilead making bn move preclinical oncology player pionyr even le impressive might seem first sight corvidia deal worth signing gilead acquired stake pionyr front accordingly biggest second quarter takeout actual cash table portola alexion bought bn first quarter biggest takeover gilead bn buyout forty seven biopharma acquisition slow covid fault yet april vantage first quarter analysis latest data include minority majority stake purchase acquisition business unit option aggregated deal number concern deal dedicated drug maker included reverse merger adicet restorbio aduro chinook second quarter among straight takeout period least one tetraphase might play time yet la jolla increased bid twice two suitor total takeover slightly quarterly average since start difference reduction money spent effect might continue time yet\n",
      "\n",
      "Keywords:\n",
      "quarter 0.202\n",
      "deal 0.188\n",
      "acquisition 0.176\n",
      "quarterly 0.172\n",
      "second quarter 0.164\n",
      "index 0.148\n",
      "time yet 0.144\n",
      "nasdaq biotech index 0.137\n",
      "corvidia 0.137\n",
      "biotech index 0.137\n",
      "nasdaq biotech 0.132\n",
      "takeout 0.128\n",
      "sentiment 0.105\n",
      "merger 0.102\n",
      "bn 0.101\n",
      "gilead 0.099\n",
      "second 0.096\n",
      "biggest 0.092\n",
      "nasdaq 0.09\n",
      "surge 0.089\n",
      "\n",
      "Abstract:\n",
      "immunotherapy made inroad virtually every aspect oncology ovarian cancer look like might remain intractable roche tecentriq today became second anti pd l drug bavencio fail first line pivotal trial cancer type several similarly acting drug continue studied big phase iii trial various front line setting however including keytruda imfinzi opdivo roche failure raise important question market reshaped parp inhibitor role avastin ovarian cancer roche imagyn trial today failed meet primary endpoint progression free survival tested tecentriq plus avastin chemo versus avastin chemo alone roche attempting many case make avastin backbone immunotherapy combo ovarian failure spell bad news part avastin lifecycle management plan however use avastin ovarian cancer controversial backed pfs benefit chemo drug u label show statistically significant overall survival advantage avastin last year asco academic sponsored gog study showed overall survival benefit avastin versus chemo alone parp factor second point two parp inhibitor astrazeneca lynparza glaxosmithkline zejula shaken ovarian cancer market look like becoming standard care genetically defined patient subgroup lynparza nod confirms leg glaxo may immunotherapy company might relevant therefore focus pd l blockade part parp inhibition rather avastin combo indeed merck co keytruda astrazeneca imfinzi phase iii first line ovarian cancer trial include lynparza either part front line combo subsequent maintenance bristol myers squibb opdivo athena maintenance trial without clovis rival parp inhibitor rubraca unfortunately roche swiss group effort early small phase ii study measuring safety primary endpoint test tecentriq plus rubraca relapsed patient read year pivotal study yet initiated still tecentriq first pd l inhibitor failed ovarian cancer late last year pfizer merck kgaa bavencio flunked first line javelin ovarian trial chemo combo failed beat chemo alone term pfs interim analysis shortly afterwards company scrapped javelin ovarian parp study added pfizer parp inhibitor talzenna mix avastin chemo combo control reason given early discontinuation trial genetically unselected population bavencio failure javelin ovarian changing treatment landscape recent approval zejula maintenance setting earlier small uncontrolled trial called keynote showed modest orr benefit keytruda according asco second sixth line ovarian cancer merck co hope rest lynparza combo keylynk study yield data several year\n",
      "\n",
      "Keywords:\n",
      "ovarian 0.371\n",
      "avastin 0.343\n",
      "parp 0.26\n",
      "ovarian cancer 0.245\n",
      "chemo 0.197\n",
      "parp inhibitor 0.157\n",
      "javelin ovarian 0.147\n",
      "avastin chemo 0.147\n",
      "combo 0.138\n",
      "cancer 0.136\n",
      "lynparza 0.135\n",
      "javelin 0.121\n",
      "tecentriq 0.111\n",
      "chemo alone 0.107\n",
      "bavencio 0.107\n",
      "maintenance 0.097\n",
      "line 0.095\n",
      "roche 0.09\n",
      "immunotherapy 0.087\n",
      "zejula 0.083\n",
      "\n",
      "Abstract:\n",
      "locked barrier venture investor apparently private drug developer awash cash least second quarter saw record bn raised start ups though number deal done sits decade low fewer bigger investment model choice moment course huge pool capital available make trend obvious prime example investor right sana biotechnology well known executive team done focus cell genetic engineering company managed amass initial financing round sana disclosed final tranche funding june presumably busy securing spending cash since founding seattle based firm already staff boast several ex juno employee including one company founder han bishop coincidentally march saw another huge raise company juno link mr bishop board raised series c secretive lyell immunopharma whose chief executive rick klausner describes juno founder company say quest develop curative cell based immunotherapy recently struck deal glaxosmithkline invested start ups perhaps pandemic opposite effect venture world area like seen activity dim raise money certainly one philosophy investor keen see portfolio company strong possible case time get tougher stockpiling theme playing public market cash readily thrown biopharma company pandemic biotech float break record july important note analysis concern researching therapeutic excludes sector like medtech digital health last quarter saw notable jump number mega round six raised second quarter result average size financing half year stage around double raised year ago still sana lyell financing outlier dwarf round would otherwise topping table everest medicine series c example mabwell series notably company based china former strategy develop successful western drug market latter focus various antibody technology project bn raised far year way breaking annual record set sector year venture investor ploughed bn young drug developer expected figure ever broken certainly typical year\n",
      "\n",
      "Keywords:\n",
      "sana 0.224\n",
      "raised 0.193\n",
      "juno 0.191\n",
      "series 0.178\n",
      "round 0.171\n",
      "venture 0.153\n",
      "financing 0.152\n",
      "quarter saw 0.149\n",
      "lyell 0.149\n",
      "bishop 0.149\n",
      "founder 0.136\n",
      "bn raised 0.136\n",
      "venture investor 0.132\n",
      "start ups 0.121\n",
      "record 0.121\n",
      "company 0.109\n",
      "saw 0.107\n",
      "ups 0.107\n",
      "cash 0.105\n",
      "drug developer 0.093\n",
      "\n",
      "Abstract:\n",
      "pandemic fleeting affair far stock market concerned biopharma key role fighting covid prevent across board decline first quarter notable exception second quarter witnessed unmistakable return health revival mirror broader stock market recovery course evaluate vantage quarterly look sector share price show drug developer size posted strong gain past three month fact half year stage universe global stock grown value end remarkable considering much world still afflicted coronavirus outbreak analysis concern listed drug maker included evaluatepharma database across world cohort company micro cap market value le start year excluded subsectors like medtech diagnostics developer therapeutic included pinpoint sector winner loser performance universe tracked across year individually four market cap bucket set year end valuation threshold seen combined market cap group already greater start year real growth year new issue added allow like like comparison similarly firm float year included second quarter essentially complete reversal first cohort big pharma recovering lost valuation mid cap group stand however company put value second quarter big pharma remarkable surge considering relative size market cap involved largely driven strong performance several south korean company sit top end mid cap samsung biologics lg chem celltrion example another mid cap second quarter winner moderna added bn market cap period share price doubled rna researcher one biggest beneficiary interest covid research despite releasing little data date vaccine candidate regeneron rank among bn plus group another huge pandemic play valuation grew bn second quarter market cap bn group sitting record high course considering first quarter ended negative territory surprising many stock climbed trough look across first half year provides accurate picture performance company involved finding covid treatment still stand alongside regeneron moderna gilead vir inovio sitting huge gain well non pandemic reason include vertex whose share surged year giving market cap bn investor continue reward complete domination cystic fibrosis space eli lilly strong run recently boosted surprise clinical win breast cancer therapy verzenio always loser biotech market course despite recent rally around half stock universe water half year point among big cap merck pfizer feeling heat respectively year largely due concern replacing existing franchise biogen pressure mounting doubt approvability alzheimer antibody valuation trimmed bn year course always car crash found high risk sector amarin seen bn value erode surprise patent loss intercept seemingly fallen foul regulator refusing approve nash project share year dbv aimmune sage therapeutic list clinical commercial disappointment go usual period biotech space pandemic make future unpredictable usual least market turbulence\n",
      "\n",
      "Keywords:\n",
      "cap 0.296\n",
      "market 0.172\n",
      "market cap 0.172\n",
      "universe 0.168\n",
      "second quarter 0.168\n",
      "quarter 0.165\n",
      "mid cap 0.162\n",
      "half year 0.123\n",
      "bn 0.116\n",
      "cap group 0.112\n",
      "considering 0.109\n",
      "stock 0.108\n",
      "valuation 0.107\n",
      "across 0.104\n",
      "start year 0.104\n",
      "performance 0.104\n",
      "value 0.102\n",
      "half 0.102\n",
      "pandemic 0.101\n",
      "loser 0.098\n",
      "\n",
      "Abstract:\n",
      "turnaround go one kiadis experiencing extraordinary last november company knee scrapped lead project pivot natural killer cell technology acquired little earlier doctor ordered today sanofi stepped deal endorse approach true sanofi unusual cell therapy partner deal initially worth big pharma endorsement sniffed remarkably kiadis paid cash acquire tech project french group licensed even appeared analyst valuation still deal look like attempt turn sanofi cell therapy player rather focus use kiadis nk cell bearing particular antigen knock adjunct one drug anti cd mab sarclisa recently launched multiple myeloma problem sanofi identified cd well expressed target multiple myeloma cell present nk cell treating multiple myeloma patient anti cd mab thus risk inadvertently wiping nk cell make part immune response avoiding fratricide kiadis sanofi gained k nk allogeneic nk cell product cd knocked make cell resistant cd blockade prevent fratricide addition signing fee deal includes milestone royalty two undisclosed preclinical nk cell therapy kiadis acquired k nk along cytosen private nk cell company got share transaction april sanofi deal trigger payment cytosen vendor kiadis chief executive arthur lahr told evaluate vantage today cytosen unmodified nk therapy k nk k nk highlighted though preclinical data cd knock combined market leading anti cd mab genmab johnson johnson darzalex presented asco however idea avoiding cd based fratricide new kiadis rival fate therapeutic developing two cd knock nk cell project one ft begin clinical trial imminently two company approach differ cell sourced editing technology fate cited knock efficiency kiadis asco poster claimed mr lahr cited kiadis better nk profile approach activate expand nk cell really creates unique phenotype extremely potent persistent interestingly fate pursued licensing plan either cd knock out kiadis similarly keep option open k nk darzalex defend position mr lahr argued adding sanofi gain combination going motivated push product forward sarclisa dosed repeat infusion k nk adjunct given single course possibly three month interval mr lahr speculated bull case sarclisa combo result remission fewer relapse using darzalex alone might completely change landscape said mr lahr kiadis traded today though time preclinical nk cell player nkarta looking float valuation kiadis market cap show investor yet buy optimism\n",
      "\n",
      "Keywords:\n",
      "nk 0.523\n",
      "kiadis 0.473\n",
      "nk cell 0.284\n",
      "cell 0.227\n",
      "cd 0.208\n",
      "lahr 0.197\n",
      "mr lahr 0.158\n",
      "knock 0.134\n",
      "sanofi 0.127\n",
      "sarclisa 0.111\n",
      "fratricide 0.105\n",
      "darzalex 0.092\n",
      "cd mab 0.082\n",
      "anti cd mab 0.082\n",
      "mr 0.08\n",
      "fate 0.079\n",
      "myeloma 0.078\n",
      "multiple myeloma 0.078\n",
      "cell therapy 0.071\n",
      "avoiding 0.07\n",
      "\n",
      "Abstract:\n",
      "given depth panic sent stock market crashing late february strength speed recovery remarkable place evident biotech ipo statistic around show sign global pandemic course argued arrival covid spurred much demand seen recently young drug developer investor reminded sector worth chasing potential beneficiary outbreak biotech already run pandemic hit however far explanation sum raised second quarter record breaking bn according evaluate vantage analysis view sector concern company developing human therapeutic excluding medtech diagnostics digital health provides snapshot riskiest end healthcare flotation western exchange tracked pandemic cause ipo go hold march certain extent huge second quarter explained company gone month pushed back however result huge amount capital made available firm average amount raised ipo first half came second time following average raise total moved three figure analysis noted royalty pharma bn flotation included tally number new issue largely flat trend bigger individual offering apparent one way investor trying lessen risk funding end biopharma sector providing substantial sum considered likely succeed allowing one shot goal rather spreading money thinly clear huge demand floatation chart show average company received originally set raise second quarter investor largesse apparently level seen least five year premium discount calculated midpoint initial share price range proposed float price ipo look individual example illustrates enthusiasm second quarter largest ipo china u cell therapy researcher legend biotech amassed haul first setting raise forma therapeutic ended banking pricing offering higher first pitch selling two million share originally intended company offer real discount get away worst result price within initially proposed range sign support biopharma found brief look secondary market listed biopharma company apparently problem topping coffer chart show count f registration form document firm must submit sec selling new share pandemic making future unpredictable persuading company stock investor favouring company fortress balance sheet banker rbc capital market wrote recently help explain trend seen ipo secondary market however worth remembering much strength u centric one european ipo happened year belgium hyloris june though several continental firm took advantage nasdaq strength listed across atlantic given deep pool capital readily available easy see foreign issuer attracted u market\n",
      "\n",
      "Keywords:\n",
      "ipo 0.278\n",
      "second quarter 0.157\n",
      "capital 0.15\n",
      "strength 0.137\n",
      "firm 0.127\n",
      "originally 0.126\n",
      "average 0.12\n",
      "pandemic 0.117\n",
      "second 0.115\n",
      "discount 0.112\n",
      "quarter 0.11\n",
      "chart show 0.109\n",
      "sector 0.109\n",
      "raise 0.108\n",
      "proposed 0.102\n",
      "company 0.1\n",
      "individual 0.098\n",
      "flotation 0.096\n",
      "biopharma 0.095\n",
      "chart 0.092\n",
      "\n",
      "Abstract:\n",
      "doubt novavax credential one best performing stock inconsiderable matter bn cash injection u government operation warp speed assured biotech position investor darling share novavax started year early u trading today company beneficiary biggest sum pledged far operation warp speed white house backed covid vaccine development project trumping bn handed astrazeneca oxford university novavax form attracting called non dilutive funding secured source investor may company managed snag total coalition epidemic preparedness innovation largest award body paid date cepi money funded phase ii trial novavax recombinant nanoparticle vaccine nvx cov accompanying adjuvant almost certainly helped put company running inclusion operation warp speed roll dice bn used fund subject phase iii trial starting autumn year build manufacturing supply u government million dos early late say big gamble part u government understatement novavax never successfully brought vaccine market unlike others covid vaccine race company published human data candidate result cepi funded phase ii trial subject australia due month novavax promised immunogenicity data alongside safety result despite lack evidence linking presence neutralising antibody protection virus becoming important benchmark ranking rival vaccine approach biontech pfizer bnt b already set high bar others field mrna vaccine produced strong neutralising antibody level dosed subject according non peer reviewed preprint achieving level x higher patient recovered covid second bite cherry novavax nvx cov fails come near result biontech bn investment look like expensive folly part u government immediately clear whether funding tranched contingent certain milestone seems possible million dos delivered pivotal trial read time substantial proportion money presumably spent might end u government largesse towards novavax press statement company said today award allowed follow agreement u government additional production procurement support ows vaccine production goal u reach chequebook novavax deliver convincing data approaching readout something experience investing biotech u government know dead cert\n",
      "\n",
      "Keywords:\n",
      "novavax 0.425\n",
      "government 0.296\n",
      "vaccine 0.214\n",
      "warp speed 0.169\n",
      "warp 0.169\n",
      "operation 0.164\n",
      "speed 0.127\n",
      "award 0.117\n",
      "cepi 0.113\n",
      "nvx cov 0.107\n",
      "nvx 0.107\n",
      "neutralising antibody 0.1\n",
      "neutralising 0.098\n",
      "million dos 0.098\n",
      "funded 0.098\n",
      "cov 0.089\n",
      "production 0.087\n",
      "million 0.084\n",
      "funding 0.082\n",
      "biontech 0.078\n",
      "\n",
      "Abstract:\n",
      "topline data mid stage trial bellus chronic cough candidate blu gone way wanted group taking refuge subgroup analysis though time honoured technique trying salvage upside failed trial data dredge mollified investor bellus nursing loss far today p x receptor inhibitor failure unexpected merck p x inhibitor already succeeded phase iii bellus project regarded many safe bet binary outcome play always risky project development failure leaf bellus place turn relief trial bellus asset enrolled patient chronic refractory cough closed subject completed treatment bellus blamed early termination covid pandemic none four dos blu tested showed significant reduction awake cough frequency versus placebo dose response seen chronic cough hard condition treat phase ii highest dose merck co gefapixant significantly reduced awake cough frequency still would enough put merck asset ahead even without phase iii hit magnitude yet disclosed merck cough success highlight pipeline hope march still hoped bellus candidate coulf overtake gefapixant unpleasant side effect altering reducing patient ability taste blu appears better profile effect taste seen around patient versus nearly half merck phase ii trial blu better side effect profile believed related high selectivity p x receptor indeed dos tested relief achieved estimated receptor occupancy comparable greater gefapixant shionogi p x inhibitor however pointed call cross trial comparison suggest tighter molecule bind p x receptor worse efficacy bellus damage limitation strategy play claim success one prespecified subgroup subject coughing least time per hour median figure total population baseline strong cohort cough frequency reduced around versus placebo four dos tested bellus assigned p value reduction post hoc subgroup analysis failed trial statistical relevance bellus hope conduct phase iib trial enriched population high frequency coughers fourth quarter intends push forward itching phase ii trial chronic pruritus associated mild moderate atopic dermatitis planned second half two trial cost around respectively management said conference call company cash end last year phase ii trial shionogi p x inhibitor report year hence differing fortune gefapixant blu make result hard predict clear merck remains top pile chronic cough\n",
      "\n",
      "Keywords:\n",
      "bellus 0.465\n",
      "cough 0.349\n",
      "blu 0.225\n",
      "gefapixant 0.186\n",
      "chronic 0.152\n",
      "frequency 0.142\n",
      "cough frequency 0.14\n",
      "chronic cough 0.135\n",
      "merck 0.129\n",
      "trial 0.108\n",
      "subgroup 0.105\n",
      "four dos 0.102\n",
      "receptor 0.102\n",
      "shionogi 0.097\n",
      "failed trial 0.097\n",
      "phase 0.093\n",
      "trial bellus 0.093\n",
      "taste 0.093\n",
      "awake cough frequency 0.093\n",
      "awake cough 0.093\n",
      "\n",
      "Abstract:\n",
      "obseva trailed result second pivotal uterine fibroid study week ago failed include crucial data press release forcing investor wait conference call big reveal cynical tactic proved correct linzagolix profile versus competition look even questionable despite two ostensibly successful phase iii trial uterine fibroid primary secondary endpoint met executive afternoon continued insist project best class profile matter interpretation however plunge obseva stock morning suggests different conclusion possible obseva focused comparison absolute measure investor concerned placebo adjusted figure call afternoon executive insisted patient physician interested former relevance clinical practice look competing data abbvie myovant show obseva want spotlight fall comparison without head head data placebo controlled result typically provide cross trial analysis albeit normal caveat much higher placebo response recorded obseva trial executive claiming actually typical rate seen control arm rival study oriahnn abbvie however efficacy data investor worried primrose toplined last december bone density loss much greater trial elagolix relugolix abbvie myovant gnhr product time obseva management argued different demographic prohibition vitamin calcium use study blame primrose seems rule theory term patient characteristic primrose looked lot like elaris uf liberty trial elagolix relugolix yet bone mineral density loss still greater linzagolix level bone loss particularly concerning professor eugene mccloskey sheffield university said obseva call afternoon however remains seen regulator make signal least provide obseva rival stick beat linzagolix come persuading physician gnhr agonist pick worst force hand regulator already mindful safety setting abbvie snared first gnrh approval elagolix branded oriahnn fibroid last month fda insisted much stronger warning exclusion expected black box warning related clotting associated hormone add back therapy abt agent require expected however contraindicated group extended much woman increased risk blood clot including smoke high blood pressure safety aspect lead obseva seems turning key opportunity linzagolix investigated low dose option mg hormone add back many woman unwilling take hormone ameliorate menopause like side effect gnhr antagonism make linzagolix attractive option company maintains course proven linzagolix must first gain approval despite disappointment around data still widely expected game really begin reality obseva simply big enough compete investor certainly buying company market cap already tiny compared myovant considered strong contender relugolix today plunge take obseva valuation myovant sock orilissa june effort bring larger player way obseva probably enough cash see linzagolix across regulatory finish line unless partner deep well capital found argument around owns better drug might matter much\n",
      "\n",
      "Keywords:\n",
      "obseva 0.499\n",
      "linzagolix 0.308\n",
      "gnhr 0.16\n",
      "elagolix 0.16\n",
      "myovant 0.159\n",
      "primrose 0.142\n",
      "afternoon 0.132\n",
      "relugolix 0.122\n",
      "bone 0.122\n",
      "fibroid 0.117\n",
      "hormone 0.109\n",
      "abbvie 0.102\n",
      "oriahnn 0.1\n",
      "call afternoon 0.1\n",
      "density loss 0.095\n",
      "plunge 0.091\n",
      "hormone add back 0.091\n",
      "hormone add 0.091\n",
      "density 0.091\n",
      "add back 0.091\n",
      "\n",
      "Abstract:\n",
      "idorsia followed daridorexant first pivotal study success insomnia reported april claim hit project second pivotal trial closer reading result however reveals rather mixed dataset mg dose missed key secondary measure daytime functioning expected setback first pivotal study miss one two co primary endpoint failed show benefit idorsia must hope pooling result mg dose pass statistical regulatory muster earlier trial study toplined today measured similar efficacy metric enrolled around patient one key difference always apparent first tested mg mg second looked mg mg mg therefore seemed always dose idorsia banking mg representing something wild card however study mg aced primary secondary endpoint idorsia add insomnia pipeline success april trial readout show mg missing secondary daytime functioning endpoint first additionally hitting one primary sleep maintenance sleep onset lowest mg dose failed hit endpoint statistical significance though showed numerical benefit versus placebo analyst call idorsia stressed numerically result consistent across trial though reveal number scientific conference argument merely statistical powering defeated daridorexant aspect trial today group revealed statistical alpha split two primary analysis meaning p value better needed daridorexant meet either co primary endpoint sequential analysis secondary endpoint thus company pinning hope u fda accepting totality data backed yet undisclosed pooled analysis mg dose result study versus placebo u filing submitted end dose however group still spell dose want see approved hinting might file mg well mg let regulator decide tellingly continues cite daridorexant lack next morning residual hangover safety advantage even though mg dose shown statistical effect idsiq patient reported questionnaire safety key insomnia drug propensity cause sleepiness day daridorexant dual orexin receptor antagonist approved orexin antagonist merck co belsomra eisai dayvigo carry warning daytime impairment possible effect driving performance consideration perhaps caused idorsia put money daridorexant mg dose ironically however mg appears shown propensity adverse event mg mg least limited scope two pivotal study separate safety tolerability trial study yield result time fda filing review idorsia said given overall data positive perhaps leaving matter dos hand lenient regulator smart move\n",
      "\n",
      "Keywords:\n",
      "mg 0.463\n",
      "idorsia 0.319\n",
      "daridorexant 0.299\n",
      "mg dose 0.208\n",
      "dose 0.169\n",
      "insomnia 0.15\n",
      "daytime 0.142\n",
      "statistical 0.14\n",
      "mg mg 0.133\n",
      "endpoint 0.104\n",
      "orexin 0.1\n",
      "first pivotal study 0.1\n",
      "secondary 0.098\n",
      "sleep 0.091\n",
      "propensity 0.091\n",
      "pivotal study 0.086\n",
      "first pivotal 0.085\n",
      "primary 0.084\n",
      "study 0.08\n",
      "trial study 0.079\n",
      "\n",
      "Abstract:\n",
      "pursuit tomorrow medicine expensive undertaking company fall big pharma category evaluate vantage annual look r bill show ploughed research last year group ever total spending cohort climbed bn number adjusted inflation jump look like representing real increase roche stand company boosting r investment past couple year lilly remains committed term proportion sale put back lilly might one big spender real term huge sale ploughed back research remains sector generous investor company known action though struck biggest takeout history last year bn loxo oncology deal perhaps signal shift strategy big patent expiry hit company top line cause ratio fluctuate course astrazeneca example seen big jump sale r spend ratio past couple year blockbuster like nexium seroquel lost exclusivity real r bill remained largely real term however roche spends r big pharma group sale spend ratio might dipped notably last year bn invested drug development drug sale make one sector biggest spender merck co seems actively ploughing presumably huge investment keytruda must something sale r ratio surged since spend hit high decade bn abbvie doubled r spending since becoming standalone company bn year though proportion sale represents jump couple percentage point sanofi considered one sector laggard term r productivity sale spend ratio crept slightly decade real spend shifted little figure adjusted inflation arguably represents scaling back new chief executive paul hudson helm interesting see company pitch spend future\n",
      "\n",
      "Keywords:\n",
      "spend 0.286\n",
      "spend ratio 0.228\n",
      "sale spend ratio 0.228\n",
      "sale spend 0.228\n",
      "ratio 0.227\n",
      "sale 0.199\n",
      "real 0.159\n",
      "spender 0.142\n",
      "real term 0.142\n",
      "bill 0.142\n",
      "ploughed 0.135\n",
      "one sector 0.135\n",
      "jump 0.134\n",
      "year bn 0.13\n",
      "couple 0.126\n",
      "past couple year 0.113\n",
      "sector 0.113\n",
      "big 0.112\n",
      "term 0.11\n",
      "past couple 0.109\n",
      "\n",
      "Abstract:\n",
      "inovio attempt yesterday generate interest limited clinical dataset covid vaccine fell flat sending pandemic focused biotech stock competing approach better investor keenly awaiting imminent readout several vaccine player today instance first human data revealed biontech pfizer bnt b non peer reviewed preprint showing strong neutralising antibody level elicited subject dosed project shot across bow moderna may first dribble case report covid vaccine given human like moderna mrna bnt b mrna vaccine novel approach used separate sanofi translate bio project saw fee handed across last month biontech pfizer bnt project actually comprises four different approach b iteration nanoparticle formulated nucleoside modified encodes covid spike glycoprotein highlight today scientific paper preprint data neutralising antibody really important one interfere virus ability infect cell subject given single dos g g g showed neutralising antibody level x nearly twice seen panel serum recovered subject within day two low dos given second time within seven day level clocked x x convalescent serum course clear whether enough actually protect serious infection result strongly encouraging safety side fatigue headache common bnt b control additional nine subject got placebo two severe adverse event grade pyrexia sleep disturbance inovio moderna loss pfizer biontech traded morning respectively meanwhile moderna inovio lost another one day slumping moderna may said volunteer given mrna producing binding antibody though data neutralising antibody available eight subject said producing clearly market rewarded pfizer biontech complete dataset moderna might recover next catalyst publication mrna clinical data peer reviewed journal help investor decide whether effect real company cherrypicking data situation much worse inovio biotech famous jumping pandemic bandwagon bird flu swine flu ebola zika mers finally covid without yet bringing single vaccine market inovio said yesterday volunteer phase trial demonstrated overall immune response six week receiving two dos ino actually meant immediately clear little else disclosed importantly company failed say many patient produced neutralising antibody coronavirus earlier paper published lancet cansino adenovirus vaccine ad ncov disappointed volunteer given one three dos subject developed level neutralising antibody deemed sufficiently high end race investor plenty data look forward covid vaccine one thing three iteration bnt generate phase result imminently azd traditional viral vector based vaccine developed astrazeneca patient trial collaboration university oxford clinical data come investor looking level neutralising antibody least target level general rule higher better essential safety given covid vaccine would expected given broad patient population investor look absence inflammatory symptom examine disclosed adverse event closely addition humoural antibody based immunity might important show vaccine eliciting cell response might necessary prevent severe covid infection still much play especially given scope accelerated development view country might exit fully lockdown covid vaccine available said early winner loser emerged\n",
      "\n",
      "Keywords:\n",
      "neutralising antibody 0.265\n",
      "neutralising 0.26\n",
      "vaccine 0.255\n",
      "inovio 0.193\n",
      "bnt 0.174\n",
      "antibody 0.172\n",
      "moderna 0.161\n",
      "covid 0.148\n",
      "covid vaccine 0.139\n",
      "level 0.132\n",
      "given 0.124\n",
      "biontech 0.118\n",
      "mrna 0.11\n",
      "volunteer 0.101\n",
      "level neutralising antibody 0.097\n",
      "level neutralising 0.097\n",
      "iteration 0.097\n",
      "subject 0.095\n",
      "volunteer given 0.092\n",
      "dos 0.091\n",
      "\n",
      "Abstract:\n",
      "early approval ultragenyx dojolvi long chain fatty acid oxidation disorder yesterday take first market approval tally far well new arrival given greenlight halfway point last year however fda continues shift resource focus pandemic specific treatment approval goal timeline well knocked coming month impact pandemic already evident nabriva blamed travel restriction crl last month fda citing unresolved manufacturing issue european facility decision novartis new subcutaneous formulation ofatumumab delayed though specific reason given covid outbreak well played part despite advisory committee going virtual many postponed panel meeting discus glaxosmithkline belantamab mafodotin scheduled july anti bcma antibody drug conjugate produced underwhelming data relapsed refractory multiple myeloma falling short rival project pivotal dreamm study yielded orr including rate complete remission bluebird bristol karmma study ide cel yielded orr cr rate setting safety focus serious instance keratopathy toxicity involving change eye corneal epithelium reported another glaxo oncology effort approval pdufa date anti pd dostarlimab set second half year filing based phase ii garnet study woman advanced recurrent endometrial cancer microsatellite stable ms microsatellite instability high msi h tumour remission rate msi h patient impressive approved dostarlimab latecomer pd class fortunately endometrial cancer competitive tumour type merck keytruda pd endometrial cancer label tumour msi h mismatch repair deficient different population glaxo dostarlimab however keytruda approved msi h tumour irrespective tumour type competition ahead gilead galapagos filgotinib due decision rheumatoid arthritis month big question whether label get black box warning thrombosis similar seen older jak inhibitor xeljanz olumiant hope new generation jak would avoid however rinvoq abbvie rival project received black box approved arthritis last year filgotinib look slightly lower efficacy rinvoq better safety profile incidence deep vein thrombosis pulmonary embolism versus rinvoq though cross trial comparison come normal caveat another company hoping get handle competition jazz decision expected july narcolepsy project jzp product low sodium follow project xyrem xyrem big business jazz forecast set peak year bn fall entry generic sellside seem convinced jzp compete xyrem copycat forecast sit table list first time supplementary fda approval due july consensus forecast evaluatepharma\n",
      "\n",
      "Keywords:\n",
      "msi 0.238\n",
      "xyrem 0.187\n",
      "endometrial cancer 0.187\n",
      "endometrial 0.187\n",
      "tumour 0.144\n",
      "rinvoq 0.143\n",
      "microsatellite 0.125\n",
      "jzp 0.125\n",
      "jazz 0.114\n",
      "july 0.112\n",
      "rival project 0.11\n",
      "approval 0.105\n",
      "yielded orr 0.104\n",
      "thrombosis 0.104\n",
      "pd 0.097\n",
      "tumour type 0.091\n",
      "jak 0.089\n",
      "glaxo 0.089\n",
      "filgotinib 0.089\n",
      "decision 0.087\n",
      "\n",
      "Abstract:\n",
      "field beset failure akero therapeutic continued nash winning streak another set impressive data efruxifermin formerly known akr following earlier triumph mri result group yesterday delivered stellar biopsy data fgf stimulant notable efruxifermin performance fibrosis liver scarring associated nash prompting analyst describe result game changing secondary analysis phase iib balanced study responder treatment qualified end treatment biopsy showed improvement least one stage fibrosis without worsening nash symptom achieved two stage improvement fibrosis additionally responder achieved nash resolution worsening fibrosis result important study compared biopsy treated control subject considered robust measure mri scan result saw akero share open hitting record high since company floated june better rest fear covid pandemic would hit study disruption suitable responder treatment arm receiving biopsy perversely mean time biopsy pushed week meaning taken four week study end treatment effect might even greater biopsy conducted week akero showed satisfying dose related response mg arm study reporting improvement fibrosis patient showing nash resolution efruxifermin produced weight loss across treatment group importantly increase ldl something beset nash treatment prove drawback given cardiovascular profile many patient nash efruxifermin win fibrosis resolution set akero apart novo nordisk attempting extend use diabetes drug semaglutide nash recent trial glp agonist failed show significant benefit measure pulling ahead akero success even salient come hot heel several stumble field cymabay abandoned nash asset seladelpar adverse liver event genfit resolve trial elafibranor flopped back may earlier week intercept received u complete response letter lead asset obeticholic acid balanced trial lends strength fg stimulant mechanism studied ambrix bio novo nordisk morning trading bio share higher company due release topline data phase ib iia trial bio end year given strength efruxifermin data akero said would meet fda later year aim starting phase iib iii study first half using mg mg dos efruxifermin surface look efruxifermin addressing many metabolic imbalance nash field littered project failed translate early signal firmer evidence akero look like one stronger contender\n",
      "\n",
      "Keywords:\n",
      "efruxifermin 0.395\n",
      "nash 0.328\n",
      "akero 0.317\n",
      "biopsy 0.23\n",
      "fibrosis 0.207\n",
      "resolution 0.14\n",
      "responder 0.119\n",
      "responder treatment 0.106\n",
      "treatment 0.102\n",
      "field 0.099\n",
      "bio 0.098\n",
      "improvement fibrosis 0.097\n",
      "stimulant 0.093\n",
      "nash resolution 0.093\n",
      "balanced 0.09\n",
      "mri 0.086\n",
      "worsening 0.078\n",
      "phase iib 0.078\n",
      "iib 0.078\n",
      "mg 0.077\n",
      "\n",
      "Abstract:\n",
      "always going tough genmab seattle genetics tisotumab vedotin come close remission rate seen late line cervical cancer cohort earlier trial proved yesterday topline data innova study run specifically cancer showing modest response rate key question whether company done enough get tisotumab anti tissue factor antibody drug conjugate regulator data alone bull case tisotumab launched ovarian cancer next year representing genmab first self developed self marketed drug jefferies analyst one think innova result support u filing genmab first commercial launch note client morning forecast peak sale tisotumab half coming cervical cancer sellside consensus compiled evaluatepharma see though genmab earlier multi tumour trial gen shown tisotumab put third second line cervical cancer subject respectively remission benchmark set innova like oncology study salvage setting innov control cohort one trial found chemotherapy third line cervical cancer gave orr merck co keytruda approved second line pd l positive disease strength orr keynote study teasing benefit innova trial presented full year esmo meeting possible venue analyst doubt want dig baseline demographic patient received two prior systemic treatment precise benefit third line subject likeliest setting initial approval teased another consideration whether tisotumab toxicity overshadow quality whatever extra life project might bring innova least patient suffered alopecia nose bleeds nausea conjunctivitis fatigue dry eye company disclosed separate cervical cancer study innova test tisotumab combination avastin keytruda chemotherapy read time next year include front line subject collaboration genmab seattle date back year latter company acquired right opt tisotumab phase option giving seattle co development co promotion right exercised gen data came recently approved drug like tukysa padcev seattle slowly reducing dependence adcetris tisotumab important genmab alike\n",
      "\n",
      "Keywords:\n",
      "tisotumab 0.456\n",
      "innova 0.333\n",
      "genmab 0.265\n",
      "cervical cancer 0.231\n",
      "cervical 0.231\n",
      "line cervical cancer 0.158\n",
      "line cervical 0.158\n",
      "seattle 0.154\n",
      "cancer 0.144\n",
      "line 0.115\n",
      "line subject 0.095\n",
      "self 0.092\n",
      "gen 0.092\n",
      "third line 0.081\n",
      "third 0.078\n",
      "chemotherapy 0.069\n",
      "co 0.068\n",
      "second line 0.068\n",
      "orr 0.063\n",
      "keytruda 0.059\n",
      "\n",
      "Abstract:\n",
      "pivotal trial zynerba zygel reported topline data today every attempt treat fragile x syndrome failed sadly zynerba early trade remains true company hoped near miss primary endpoint connect fx trial might still good enough filing secondary measure hit cannabinoid gel actually missed primary mile hit precisely none secondary company claim might found way forward subgroup analysis even hit hardly emphatic connect fx designed show improvement placebo social avoidance subscale aberrant behaviour checklist abc primary outcome measure company telling evaluate vantage four month ago looking improvement percentage point placebo zynerba hope crack fragile x last march data actually show placebo adjusted benefit six point neither endpoint others hit statistical significance safety clean enough treatment related adverse event zygel cohort versus six placebo group common treatment related event application site pain seen zygel placebo subject respectively full methyl jacket company pinning hope path forward planned analysis patient study least methylation known full methylation gene associated fragile x fmr methylation epigenetic process whereby methyl group placed backbone dna full methylation fmr result decreased silenced transcription gene fragile x patient full methylation fmr severely ill zynerba say population made around participant connect fx zygel achieved p value social avoidance subscale despite main metric missed zynerba claimed statistically significant versus placebo none secondary showed nominal hit fully methylated subgroup challenged conference call provide mechanistic rationale zygel better performance fully methylated patient management said fmr gene function thing fall apart one thing endocannabinoid pathway plus side testing methylation fairly straightforward cost around company said confirmation nothing daunted group intends ask u fda soon possible whether submit connect fx dataset approval fully methylated patient alternative conducting trial specific population given connect fx took two year requirement would push timeline markedly zynerba around cash end june enough last second half next year planned recruit staff presumably sale people immediately connect fx readout happen potentially extending cash runway cash needed another trial necessary moreover trial population fully methylated around general fragile x population carry biomarker zygel approved subset without confirmatory trial potential market cut around u patient around zygel zynerba sole asset though developing gel indication fragile x far advanced one way another way ahead look rocky\n",
      "\n",
      "Keywords:\n",
      "zynerba 0.293\n",
      "zygel 0.293\n",
      "methylation 0.282\n",
      "fx 0.251\n",
      "fragile 0.251\n",
      "connect fx 0.251\n",
      "connect 0.251\n",
      "methylated 0.188\n",
      "fully methylated 0.188\n",
      "fmr 0.176\n",
      "full methylation 0.141\n",
      "fully 0.121\n",
      "placebo 0.101\n",
      "around 0.097\n",
      "social avoidance subscale 0.088\n",
      "social avoidance 0.088\n",
      "avoidance subscale 0.088\n",
      "hit 0.087\n",
      "social 0.084\n",
      "gel 0.084\n",
      "\n",
      "Abstract:\n",
      "six year ago result investigator sponsored study turned intercept midcap company overnight strength lead asset obeticholic acid nash today dream current iteration came sorry end u fda slapped project complete response letter effective refusal approve drug nash end week increasing doubt seen adcom first scheduled postponed twice analyst call today intercept slammed agency moving goalpost coming premature decision based incomplete data filing based interim readout pivotal regenerate trial submitted last september study shown complex histologic endpoint met positioned drug first reverse liver fibrosis nash intercept nash hope rest ocaliva borderline hit february concerning toxicity emerged including pruritus hepatobiliary event stop obeticholic acid approved ocaliva primary biliary cholangitis obviously cast long shadow nash given much broader potential indication intercept statement today setback say fda expressed concern activity based surrogate histopathologic endpoint might outweigh potential risk presumably reference toxicity emerged ocaliva use still entirely clear happened intercept said frustrating apparent context complete response letter especially group worked lockstep agency bring filing stage intercept appeared particularly annoyed adcom one initially scheduled first delayed covid pandemic postponed fda asked additional data intercept submitted within week june action date missed result commitment abandoned inexplicable fda abandoned commitment hold adcom intercept insisted company said awaiting instruction new date adcom instead agency issued crl rebuff apparently asks additional study data ongoing regenerate trial remarkably given intercept attacked fda action company say still hope agree regulator path forward admitted analyst clarity exactly agency looking still digesting impact beyond effect intercept crashed morning setback yet bad news nash space general seen numerous study failure company including gilead conatus may genfit long journey elafibranor ended pivotal study failure however one bright spot inventiva lanifibranor like elafibranor ppar agonist succeed mid stage trial month bull cling fact intercept licensed pan ppar agonist bezafibrate aralez last year though nash study yet provide handy pivot meantime intercept trading lowest point since explosion ocaliva long delay nash approvable\n",
      "\n",
      "Keywords:\n",
      "intercept 0.504\n",
      "nash 0.291\n",
      "ocaliva 0.183\n",
      "adcom 0.179\n",
      "agency 0.159\n",
      "study failure 0.112\n",
      "fda 0.11\n",
      "obeticholic acid 0.107\n",
      "obeticholic 0.107\n",
      "ppar agonist 0.1\n",
      "ppar 0.1\n",
      "scheduled 0.095\n",
      "postponed 0.095\n",
      "commitment 0.091\n",
      "elafibranor 0.088\n",
      "submitted 0.084\n",
      "abandoned 0.084\n",
      "acid 0.082\n",
      "study 0.081\n",
      "emerged 0.081\n",
      "\n",
      "Abstract:\n",
      "gilead never going please everyone price chose remdesivir covid antiviral far demonstrated marginal benefit number settled smaller expected company escape criticism remdesivir cost per vial gilead said morning patient expected receive five day treatment course equates investor least seem horrified company share around higher early trade helping patient discharged quickly remdesivir provide immediate net saving healthcare system gilead said robust phase iii data emerge far showed drug sliced four day recovery time average u would result saving around per patient company said price already provoked criticism many quarter study generated finding run niaid therefore effectively paid u taxpayer benefit lower price believe others concerned remdesivir yet show reduce risk patient dying mortality benefit recent analysis drug price watchdog icer found remdesivir cost effective slightly higher gilead price tag however calculation assumed two important factor firstly steroid dexamethasone incorporated standard care remdesivir show mortality benefit first look highly likely happen study found cheap steroid reduced death third sick patient however second far guaranteed niaid found numerically better survival day effect significant later cut data day released soon remdesivir delivers another perverse result june without mortality benefit remdesivir cost effectiveness benchmark fall icer concluded signal consistently fails emerge remdesivir study gilead find criticism price point harder shake still sellside analyst price model future sale graph evaluatepharma show current consensus comprises different number partly reflect differing opinion demand well price forecast predate dexamethasone finding svb leerink wrote morning price came slightly expectation although analyst still expect gilead make money remdesivir analyst suntrust robinson le convinced wondering company would recoup investment ringing bn year alone near term gilead investor want see cost covered sooner rather later given course pandemic progress potential treatment remain unknown mean pricing remdesivir high possible\n",
      "\n",
      "Keywords:\n",
      "remdesivir 0.488\n",
      "price 0.226\n",
      "gilead 0.207\n",
      "remdesivir cost 0.194\n",
      "mortality benefit 0.184\n",
      "criticism 0.171\n",
      "mortality 0.139\n",
      "cost 0.135\n",
      "icer 0.123\n",
      "benefit 0.122\n",
      "gilead said 0.114\n",
      "dexamethasone 0.111\n",
      "saving 0.105\n",
      "steroid 0.101\n",
      "day 0.1\n",
      "niaid 0.097\n",
      "found 0.088\n",
      "slightly 0.077\n",
      "patient 0.076\n",
      "emerge 0.073\n",
      "\n",
      "Abstract:\n",
      "final look next quarter clinical catalyst evaluate vantage analysed event due company whose market cap bn previously delved expected large drug maker small mid sized company smallest player look concentrate underserved indication amryt pharma epidermolysis bullosa rare inherited skin condition topline data expected iii ease study late third quarter early fourth project branded filsuvez following interim efficacy analysis continuing ease trial recommended increase patient reach statistical power april amryt closed recruitment short target owing ongoing covid pandemic claiming statistical impact patient recruitment would likely negligible investor want see company done enough primary measure proportion patient completely healed target wound day approaching readout ovid neptune study child aged angelman syndrome genetic disorder affect nervous system ov known gaboxadol gaba receptor agonist tested placebo phase ii star trial ovid claimed win called first prespecified efficacy endpoint cgi score ov failed show benefit huge list measure five seizure ov group although angelman patient often seizure none seen placebo cohort ov originated merck co lundbeck sedative development stopped owing toxicity lack efficacy lundbeck sold right ovid angelman project include roche ro due start phase gtx ultragenyx genetx phase ii according clinicaltrials gov cough cough relief trial bellus blu chronic cough set report soon study assessing project effect awake cough frequency versus placebo several time point day bellus reinvigorated merck co interest therapy area blu p xr antagonist mechanism action merck gefapixant phase ii showed placebo adjusted reduction baseline awake cough frequency highest dose tested mg twice daily however dose caused taste related side effect dropout gefapixant become first approved drug chronic cough already completed two phase iii study company yet release actual result saying mg twice daily dose met primary efficacy endpoint safety tolerability profile consistent phase ii blu said high degree selectivity p x receptor analyst think mean avoids taste side effect seen le selective antagonist following table note additional third quarter event smaller group odevixibat selective inhibitor ileal bile acid transporter mirium maralixibat ph pfic\n",
      "\n",
      "Keywords:\n",
      "cough 0.302\n",
      "ov 0.223\n",
      "angelman 0.176\n",
      "ovid 0.161\n",
      "blu 0.155\n",
      "taste 0.107\n",
      "gefapixant 0.107\n",
      "cough frequency 0.107\n",
      "bellus 0.107\n",
      "awake cough frequency 0.107\n",
      "awake cough 0.107\n",
      "awake 0.107\n",
      "chronic cough 0.104\n",
      "twice daily 0.101\n",
      "seizure 0.101\n",
      "mg twice daily 0.101\n",
      "mg twice 0.101\n",
      "selective 0.098\n",
      "efficacy endpoint 0.096\n",
      "lundbeck 0.093\n",
      "\n",
      "Abstract:\n",
      "problem top biotech takeout pick instead getting taken licensing deal market come like ton brick arcus found may yesterday uniqure turn partner uniqure chosen haemophilia b gene therapy major pharma company australia csl might resulted double whammy investor disappointment uniqure opened today still might csl blood disorder underestimated though deal quite backend loaded even front fee impressive considering gene therapy question etranacogene dezaparvovec generated data three subject uniqure continue running pivotal hope b study manufacturing reimbursed csl senior partner take production milestone due relating regulatory progress first commercial sale uniqure revealed analyst call last night real benefit kick later double digit sale royalty low twenty percent csl heavy lifting etranacogene dezaparvovec market setup make perfect sense csl huge presence blood therapeutic sourcing blood plasma selling intravenous immunoglobulin patent expired recombinant factor viii kogenate haemophilia australian stock exchange listed share near uninterrupted eight year climb thanks success hereditary angioedema drug haegarda said csl undoubtedly lower profile player like sanofi pfizer novo nordisk seen possible takeover suitor novo nordisk buy uniqure october neither experience trying sell gene therapy uniqure done little disabuse sellside takeover thesis accordingly today analyst disappointment palpable mizuho well fargo evercore isi downgraded stock latter admitting seen csl deal coming etranacogene dezaparvovec aim become first gene therapy haemophilia b ahead pfizer roche fidanacogene elaparvovec latter originated spark succumb takeover roche subsequent document revealed unnamed party b bid front collaboration spark haemophilia project might csl perhaps bidder wary buying uniqure concern patent backing etranacogene dezaparvovec based padua factor ix variant ip described spark somewhat confused uniqure switched padua variant first working wild type factor ix le impressive gene therapy coded amt latest data etranacogene dezaparvovec phase ii trial presented december ash conference factor ix activity three patient normal one year single administration gene therapy bleeding event reported pivotal hope b study read year licensed lead asset uniqure left early pipeline whose advanced gene therapy amt phase huntington disease haemophilia project amt discontinued uniqure revealed data regulatory feedback evolving competitive landscape perhaps discontinuation another reason morning investor disappointment\n",
      "\n",
      "Keywords:\n",
      "uniqure 0.426\n",
      "csl 0.397\n",
      "etranacogene dezaparvovec 0.248\n",
      "etranacogene 0.248\n",
      "dezaparvovec 0.248\n",
      "gene therapy 0.185\n",
      "haemophilia 0.174\n",
      "gene 0.165\n",
      "ix 0.139\n",
      "factor ix 0.139\n",
      "amt 0.127\n",
      "spark 0.116\n",
      "factor 0.101\n",
      "therapy 0.101\n",
      "pivotal hope 0.093\n",
      "disappointment 0.085\n",
      "variant 0.085\n",
      "blood 0.08\n",
      "takeover 0.078\n",
      "revealed 0.068\n",
      "\n",
      "Abstract:\n",
      "intriguing diabetes prevention signal reported cut farxiga heart failure study dapa hf annual diabetes association annual meeting month investigator found course study astrazeneca sglt inhibitor cut risk participant developing type diabetes almost third farxiga effectively already available setting recently granted heart failure indication limited diabetic cardiologist represent nascent market sglt inhibitor comment made ada suggest finding help drive sale farxiga new use data might spur endocrinologist consider using agent earlier diabetes management prevention diabetes resonates u whether endocrinologist cardiologist general physician said dr subodh verma cardiologist michael hospital toronto session discus dapa hf study really exciting new data diabetes prevention analysis pre specified study protocol finding considered exploratory dapa hf primarily heart failure trial recruited patient reduced ejection fraction hfref around half subject diabetes entered study split evenly active control cohort non diabetic dapagliflozin arm went develop type diabetes month versus placebo group equated risk reduction p limitation analysis dr silvio inzucchi lead investigator dapa hf professor medicine yale university school medicine pointed presentation ada include relatively short follow fact study designed pure diabetes reduction trial however said cohort patient without diabetes baseline farxiga minimal effect hba c body weight suggests sglt inhibition merely masking development diabetes dr inzucchi said concern raised wake diabetes prevention study glucose lowering agent mechanism behind wide benefit seen sglt inhibitor fully understood although agree many different pathway likely play dr jeffrey testani head heart failure research yale described sglt inhibitor smart diuretic predicted big uptake hfref setting pointing existing medication hard use required careful titration carried safety concern sglt big advantage easy use end day make people feel better said ada presentation pointed patient heart failure type diabetes bad prognosis another exploratory analysis dapa hf found patient develop diabetes trial experienced increase mortality sglt inhibitor promote loss salt glucose urine cascade physiological adaptation process providing preventative benefit speculated joris silon senior vice president astrazeneca cardiovascular renal metabolism unit get metabolic flexibility restores normal function body growing evidence astrazeneca unlikely start specific diabetes prevention study farxiga mr silon said seek diabetes prevention indication real world evidence might gathered add finding however might around corner dapa ckd study testing farxiga patient chronic kidney disease includes exploratory diabetes prevention analysis trial stopped early efficacy march credence study j j invokana drug approval diabetic ckd enrol non diabetic dapa hf big question whether non type ckd patient benefit extent diabetes mr silon said seen dapa ckd result hoped strong outcome stopped trial overwhelming success mean cardio renal protection whether type diabetic reducing risk end stage renal disease death ckd patient big win much way reducing heart failure hospitalisation death patient goal dapa hf second diabetes prevention signal considered icing cake drug class continues demonstrate benefit ever wider pool patient\n",
      "\n",
      "Keywords:\n",
      "diabetes 0.408\n",
      "dapa 0.274\n",
      "diabetes prevention 0.273\n",
      "dapa hf 0.225\n",
      "prevention 0.219\n",
      "hf 0.213\n",
      "sglt 0.203\n",
      "farxiga 0.171\n",
      "ckd 0.167\n",
      "heart failure 0.159\n",
      "sglt inhibitor 0.148\n",
      "diabetic 0.14\n",
      "heart 0.133\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "silon 0.117\n",
      "cardiologist 0.11\n",
      "ada 0.097\n",
      "dr 0.092\n",
      "failure 0.09\n",
      "study 0.084\n",
      "type 0.083\n",
      "\n",
      "Abstract:\n",
      "yesterday clinical trial success relugolix give myovant lead project second knockout hit endometriosis third possible indication albeit combination hormone replacement battle three gnrh antagonist relugolix chance catch abbvie orilissa launched first disappointed monotherapy investor might wondering trade news myovant stock closed yesterday giving bn market cap position sumitomo dainippon pharma intriguing japanese group last september paid roivant bn various subsidiary including myovant stake currently valued bn suggests myovant still account relatively small part valuation sumitomo struggling patent expiry clinical failure one solution sumitomo buy myovant gain full benefit relugolix doubt takeout thesis underpins much smaller company valuation bn clear much relugolix value market factor however sellside consensus amount product npv bn computed evaluatepharma analyst assign forecast revenue uterine fibroid endometriosis despite project scoring prostate cancer relugolix get hero welcome prostate cancer november myovant filed relugolix monotherapy prostate cancer back hero programme april differently dosed combo hormone replacement therapy hrt submitted uterine fibroid may data endometriosis therefore give asset third leg two near identical pivotal study run spirit spirit testing relugolix plus hrt latter read positively two month ago former success myovant celebrated yesterday spirit confirmed earlier positive data knockout result pain reduction relugolix plus hrt versus placebo term responder according patient daily assessment among period pain non menstrual pelvic pain amounting two co primary endpoint clean sweep seven key secondary measure uterine fibroid relugolix failed meet expectation relative abbvie similarly acting already approved orilissa endometriosis advantage cross trial basis efficacy line high orilissa dose without association hot flush bone density loss latter resulted orilissa high dose limited six month use suboptimal chronic condition suggested side effect profile contributed orilissa poor uptake evaluatepharma archive show sellside forecast fallen bn two year still one difference orilissa prescribed monotherapy without hrt abbvie imminently report data subject study comparing orilissa monotherapy versus orilissa plus hrt versus placebo hrt shown reduce bone loss orilissa label expanded neutralising relugolix threat third horse gnrh antagonist race obseva linzagolix however laggard associated bone loss whether given without hrt obseva valuation reflects fact linzagolix advanced indication uterine fibroid six month data primrose trial month update primrose expected imminently safety figure put myovant prove hard match\n",
      "\n",
      "Keywords:\n",
      "relugolix 0.368\n",
      "orilissa 0.34\n",
      "hrt 0.339\n",
      "myovant 0.288\n",
      "endometriosis 0.172\n",
      "plus hrt 0.145\n",
      "uterine fibroid 0.144\n",
      "uterine 0.144\n",
      "fibroid 0.141\n",
      "spirit 0.136\n",
      "sumitomo 0.12\n",
      "bone 0.11\n",
      "monotherapy 0.101\n",
      "prostate cancer 0.097\n",
      "prostate 0.094\n",
      "pain 0.093\n",
      "hormone replacement 0.091\n",
      "primrose 0.086\n",
      "hero 0.086\n",
      "bone loss 0.083\n",
      "\n",
      "Abstract:\n",
      "third quarter nearly upon u evaluate vantage looked important event approaching smaller player market cap bn bn filing biogen controversial alzheimer project dominated catalyst larger drug maker nearly half upcoming data reveals oncology related one event beigene sequoia trial brukinsa btk inhibitor treatment naive chronic small lymphocytic lymphoma expected data cohort one made subject without difficult treat p deletion brukinsa treanda plus rituxan primary endpoint progression free survival data released ash patient p deletion showed brukinsa monotherapy median follow month yielded overall response rate including complete remission rate patient experienced serious adverse event common neutropenia pneumonia hypertension one treatment related death brukinsa approved relapsed refractory mantle cell lymphoma cll bigger opportunity however market dominated abbvie j j btk inhibitor imbruvica leerink analyst reckon brukinsa confirm better safety imbruvica atrial fibrilliation major haemorrhage beigene start take market share notably alpine head head study imbruvica read next year time relapsed refractory cll sticking oncology turning point selective kinase inhibitor repotrectinib registrational phase ii study trident advanced solid tumour harbouring ro ntrk alk rearrangement including subject failed prior therapy third quarter see preliminary data patient across multiple cohort trial phase portion overall response rate tyrosine kinase inhibitor naive ro positive nsclc orr pretreated patient treatment needed patient failing front line drug like pfizer xalkori however repotrectinib exhibited worrying toxicity earlier data showing around half patient experienced dizziness case sudden death judged possibly related treatment therapy area elsewhere study test intra cellular caplyta adjunctive treatment depressive episode associated bipolar bipolar ii disorder patient enrolled taking mood stabiliser lithium valproate drug already one positive global trial study bag u trial study failed tested caplyta monotherapy failure said due high placebo response intra cellular hope file single positive trial possibly supportive data even latest study miss statistical significance idea still provide support caplyta approved schizophrenia bipolar bigger opportunity label permit adjunct use would limit market immunovant imvt anti fcrn mab tested myasthenia gravis igg driven autoimmune condition immunovant edge competitor project subcutaneous far group released data intravenous therapy immunovant phase ii ascend mg trial given patient weekly mg mg imvt versus placebo six week primary outcome measure includes safety change baseline igg level mg adl change symptom scale secondary endpoint competing trial shown placebo adjusted response rate mg adl argenx efgartigimod momentum nipocalimab subcutaneous version earlier development ucb version rozanolixizumab phase iii data due next year following table note additional third quarter event mid sized group evaluate vantage separately assessed expected catalyst larger drug maker analysis covering company market cap bn follow ln lifileucel zepzelca lurbinectedin\n",
      "\n",
      "Keywords:\n",
      "brukinsa 0.239\n",
      "caplyta 0.161\n",
      "immunovant 0.144\n",
      "bipolar 0.144\n",
      "imbruvica 0.129\n",
      "mg 0.123\n",
      "repotrectinib 0.101\n",
      "mg adl 0.101\n",
      "larger drug maker 0.101\n",
      "larger drug 0.101\n",
      "intra cellular 0.101\n",
      "deletion 0.101\n",
      "catalyst larger drug 0.101\n",
      "catalyst larger 0.101\n",
      "third quarter 0.098\n",
      "patient experienced 0.096\n",
      "intra 0.096\n",
      "patient 0.095\n",
      "igg 0.092\n",
      "adl 0.092\n",
      "\n",
      "Abstract:\n",
      "march covid vaccine deal sanofi translate bio included front fee eyebrow raised doubt sanofi commitment surely blown away today broad new transaction company saw senior partner hand across signing plus equity stake translate today tie broad focus developing mrna vaccine infectious disease including covid beyond deal effectively formalises update first collaboration company struck back translate nasdaq listed entity deal initial three year term included front focus mrna vaccine five undisclosed infectious disease pathogen march pact added one year timeline covid focus lead vaccine enter human trial fourth quarter closer tie sanofi seen enough focus earlier effort transaction tie closer still partner however little disclosed asset involved addition covid vaccine sanofi singled work influenza candidate preclinical trial saying enter clinic mid mrna vaccine work target another viral pathogen bacterial pathogen close play yesterday translate trading modest mid ipo price equity stake sanofi buying priced premium stock morning surged giving translate bn market cap might ask translation approach promising sanofi simply bought partner coronavirus new deal clearly broad largely undisclosed focus investor attention doubt continue fall effort tackle new coronavirus clinical trial covid vaccine might starting late year project fast tracked possible launch second half assuming positive data sanofi said today group highlighted translate established mrna manufacturing capacity supply million dos year various technology approach taken develop coronavirus vaccine mrna considered among promising sanofi said one advantage manufactured easily traditional egg based vaccine though course mrna vaccine yet reached market sanofi translate working together year find behind moderna whose covid mrna vaccine mrna brought huge amount funding already yielded anecdotal snippet clinical data moderna reminds market biotech dual purpose may company developing mrna vaccine covid include biontech pfizer whose four vaccine coded bnt entered volunteer study arcturus curevac german government recently bought stake sanofi today claimed translate large scale mrna manufacturing capacity perhaps time allow catch sector leader\n",
      "\n",
      "Keywords:\n",
      "vaccine 0.335\n",
      "translate 0.33\n",
      "mrna 0.307\n",
      "sanofi 0.265\n",
      "mrna vaccine 0.225\n",
      "pathogen 0.148\n",
      "covid 0.144\n",
      "focus 0.112\n",
      "sanofi translate 0.108\n",
      "sanofi said 0.108\n",
      "developing mrna vaccine 0.108\n",
      "tie 0.105\n",
      "developing mrna 0.103\n",
      "equity stake 0.098\n",
      "stake 0.098\n",
      "broad 0.097\n",
      "covid vaccine 0.093\n",
      "vaccine mrna 0.092\n",
      "manufacturing capacity 0.09\n",
      "infectious disease 0.09\n",
      "\n",
      "Abstract:\n",
      "pneumococcal vaccine hugely successful product global sale reached bn last year market controlled pfizer prevnar company might facing first real challenge coming year new project developed merck co v add two serotypes top prevnar strain streptococcus pneumoniae bacterium merck say associated serious invasive infection pfizer sitting still however vpnc valent project late stage development broader better one shot thinking pfizer claimed five additional serotypes vpnc provide coverage around strain adult strain infant v merck meanwhile going targeted approach noting broader important maintaining efficacy vital vaccination programme moved older prevnar valent product breakthrough infection seen certain serotypes perhaps company think effectively maintain durability tighter focus well v merck two project v developed target residual pneumococcal disease adult v described next generation paediatric vaccine latter yet clinic v arrived v project watch worth remembering merck already sell pneumovax valent vaccine uniquely polysaccharide vaccine therefore le immunogenic conjugate vaccine like prevnar v polysaccharide vaccine give shorter protection le useful infant older people weaker immune system pneumovax commercial potential limited little phase iii data released either v vpnc hard say yet strategy might successful need prove non inferiority prevnar well response new strain confer lasting protection march pfizer said vpnc shown non inferior prevnar pneumovax six seven serotypes included product adult one new seven serotypes missed non inferiority criterion small margin result two pivotal trial due coming month merck meanwhile huge phase iii programme way study go company revealed week v elicited immune response serotypes hiv positive patient although nothing said non inferiority readout expected year phase ii data healthy infant last year showed jab non inferior prevnar serotypes included vaccine produced immune response two additional strain merck one clear advantage ahead infant population childhood vaccine market make around pneumococcal vaccine sale pfizer begun pivotal development vpnc child announcing start two trial week company plan seek approval respective project end year adult however analyst believe merck around year ahead crucial infant setting assuming project convinces clinically substantial time advantage one merck highly motivated make\n",
      "\n",
      "Keywords:\n",
      "prevnar 0.386\n",
      "serotypes 0.361\n",
      "vpnc 0.275\n",
      "infant 0.258\n",
      "strain 0.235\n",
      "vaccine 0.222\n",
      "merck 0.196\n",
      "pneumococcal 0.155\n",
      "adult 0.142\n",
      "non inferiority 0.116\n",
      "pfizer 0.115\n",
      "inferiority 0.114\n",
      "non 0.112\n",
      "non inferior 0.094\n",
      "inferior 0.091\n",
      "immune 0.088\n",
      "project 0.077\n",
      "protection 0.076\n",
      "immune response 0.076\n",
      "broader 0.07\n",
      "\n",
      "Abstract:\n",
      "lockdown profoundly suppressed medtech dealmaking annihilated altogether invitae acquisition private cancer testing group archer dx yesterday front intended build company capable testing inherited cancer arise spontaneous mutation investor convinced pitch invitae stock closed adding bn company valuation archer recently filed float acquired mutation testing liquid biopsy group storming month buyout cap partnership deal astrazeneca bristol myers squibb delivers investor much preferred exit option invitae technology mainly focused testing germline mutation cause hereditary cancer cancer screen assay example examines gene ass healthy person risk developing inherited form cancer bought website sale invitae assay going gangbusters start year group track sell test versus prior guidance pandemic hit cancer testing longer priority mid march test sale halved prompting invitae suspend guidance covid reason invitae gave pulling back house development testing somatic spontaneous oncogenic mutation point early may company must least mulling archer dx acquisition target somatic mutation testing archer stock trade one big hope stratafide designed identify mutation fda approved targeted therapy though list exactly mutation detects appears available company intends seek fda approval product put stratafide running first pan solid tumour blood test mutation targeted various different therapy favourite win accolade however roche foundationone liquid filed fda december archer monitoring blood test subject deal bristol myers company evaluate use technique detecting minimum residual disease cancer cell remain treatment cause relapse clearance circulating tumour dna mean inform future therapy selection deal astra concern similar technology time focused aiding phase iii clinical trial pharma group immuno oncology programme invitae might viewed agreement validation archer tech case targeted cancer drug continuing reach market pace demand somatic mutation testing unlikely slacken archer describes genomic profiling recurrence monitoring market worth bn bn respectively term upfront part deal structured million share cash worth million share invitae common stock worth around friday closing price payable achievement milestone invitae arranged strategic financing help pay archer committed syndicate life science investor led perceptive advisor company conduct private placement supported existing investor company close time merger lastly invitae arranged credit facility leerink analyst described deal transformative stating invitae line annual revenue growth year come genetic testing becomes standard care though noted chunky sale multiple nine time archer estimated revenue deal positive medtech sector catastrophic effect covid business development cannot denied invitae archer merger th announced year evaluatemedtech data show\n",
      "\n",
      "Keywords:\n",
      "invitae 0.577\n",
      "archer 0.481\n",
      "mutation 0.238\n",
      "testing 0.193\n",
      "cancer 0.133\n",
      "deal 0.101\n",
      "liquid 0.09\n",
      "targeted 0.087\n",
      "arranged 0.086\n",
      "blood test 0.082\n",
      "test 0.081\n",
      "inherited 0.077\n",
      "guidance 0.075\n",
      "assay 0.073\n",
      "worth 0.066\n",
      "company 0.066\n",
      "monitoring 0.065\n",
      "merger 0.063\n",
      "million 0.059\n",
      "medtech 0.058\n",
      "\n",
      "Abstract:\n",
      "second quarter come close evaluate vantage delf non covid related catalyst due next quarter large drug maker one keenly awaited event clinical data filing biogen alzheimer project aducanumab biogen previously guided submission earlier year delay announced april saw share fall submission based emerge engage study whose reanalysis claimed teased efficacy signal dosing high enough long enough advisory committee doubt called scrutinise statistical rigour analysis aducanumab toxicity profile although first fda must accept filing last week biogen lost patent dispute mylan multiple sclerosis drug tecfidera making even reliant aducanumab company criticised thin pipeline expects readout mid stage parkinson candidate second half biib anti alpha synuclein mab phase ii spark study whose primary measure safety key secondary measure geared towards pharmacodynamic effect biib dopaminergic nerve well pharmacokinetics immunogenicity another anti alpha synuclein mab roche prothena prasinezumab previously reported mixed result ongoing phase ii pasadena study failed meet primary endpoint change md updrs week show sign efficacy secondary exploratory endpoint looking cognitive marker disease week blinded extension ongoing oncology test sanofi bn synthorx acquisition expected second half year data thor phase ii hammer trial non alpha il thor avoid triggering vascular leak syndrome serious side effect attached il therapy hammer study primarily look toxicity thor investigated single agent combination unspecified pd l agent solid tumour combination sanofi libtayo likely libtayo approved making late entrant competitive market combination thor differentiate combining il treatment pd l inhibition thought enhance cd cell response giving greater antitumour effect checkpoint blockade alone first line liver cancer astrazeneca himalaya trial expected report soon study test imfinzi monotherapy two combination anti ctla agent tremelimumab nexavar primary outcome overall survival earlier month first immunotherapy approved front line liver cancer setting roche tecentriq avastin combo backed imbrave study combination reduced risk death p cut risk disease worsening death p versus nexavar fibrosis bristol myers squibb turn nash fgf stimulant pegbelfermin phase iib falcon study report second half second longer term study primary completion date september falcon testing three dos week trial primary endpoint include stage improvement fibrosis without worsening nash nash improvement worsening fibrosis determined liver biopsy fibrosis activity score two primary measure phase iia study weekly pegbelfermin mg reduced hepatic fat fraction placebo adjusted percentage point p akero developing similar agent akr april reported impressive mri data relative reduction liver fat versus baseline three akr dos tested biopsy data pegged second quarter come day table show additional third quarter event large drug maker look catalyst smaller company published coming day\n",
      "\n",
      "Keywords:\n",
      "thor 0.215\n",
      "fibrosis 0.14\n",
      "liver 0.119\n",
      "worsening 0.119\n",
      "aducanumab 0.119\n",
      "combination 0.116\n",
      "alpha 0.115\n",
      "study 0.111\n",
      "primary 0.108\n",
      "hammer 0.107\n",
      "second 0.107\n",
      "biogen 0.104\n",
      "nexavar 0.102\n",
      "il 0.102\n",
      "nash 0.1\n",
      "synuclein 0.098\n",
      "study whose 0.098\n",
      "line liver cancer 0.098\n",
      "line liver 0.098\n",
      "biib 0.098\n",
      "\n",
      "Abstract:\n",
      "surely measure cancer vaccine abysmal track record mere overall response rate enough spotlight oncology conference step forward ro personalised neoantigen vaccine development roche biontech first human data unveiled year second virtual aacr meeting however despite highlighted pre meeting press conference result phase multi tumour study shown ro plus tecentriq modest activity heavily pretreated dose escalation patient population admitted dr juanita lopez royal marsden nh foundation trust investor come away wanting seen better dr lopez insisted trial least one important aspect saying thing excited managed show majority patient able elicit specific immune response typical immune response fail initiated evidenced immune cell seen within tumour trial tecentriq combo cohort neoantigen specific cell response induced vaccine observed subject ro monotherapy cohort detailed separate aacr presentation cell response observed peripheral blood patient sufficient however dr lopez accepted may sufficient ro monotherapy yielded one complete response evaluable subject combo tecentriq eight partial one complete remission evaluable patient one reason poor efficacy suggested dr lopez subject heavily pretreated median three prior therapy clear many subject might responded tecentriq alone dr lopez would indulge cross trial comparison patient entering combo cohort failed immunotherapy would say percentage nine responder dr lopez detail two remission one partial one complete initial dose escalation first checkpoint experienced pd l high second neither data presented tuesday ro known code rg bnt first project emerge deal roche biontech struck back course biontech floated able bask current bn valuation largely result effort develop mrna vaccine covid two clinical trial ro way phase dose escalation study unveiled aacr phase ii trial called imcode combination merck co keytruda front line melanoma started year ago company plan two randomised study resected lung colorectal tumour conceptually ro anything simple manufactured per patient basis patient tumour analysed sequenced identify neoantigens corresponding mrna generated encapsulated liposome injected aim eliciting immune response promising evidence mechanistic rationale approach shown unless cell response translate clinical remission cancer vaccine future\n",
      "\n",
      "Keywords:\n",
      "lopez 0.353\n",
      "ro 0.33\n",
      "dr lopez 0.295\n",
      "dr 0.207\n",
      "response 0.156\n",
      "one complete 0.151\n",
      "cell response 0.138\n",
      "tecentriq 0.134\n",
      "vaccine 0.132\n",
      "escalation 0.132\n",
      "dose escalation 0.132\n",
      "aacr 0.129\n",
      "immune 0.125\n",
      "immune response 0.122\n",
      "cancer vaccine 0.105\n",
      "tumour 0.101\n",
      "biontech 0.101\n",
      "patient 0.091\n",
      "cell 0.09\n",
      "remission 0.086\n",
      "\n",
      "Abstract:\n",
      "recent development update roche increasingly touted small molecule akt inhibitor ipatasertib underappreciated oncology asset basis first pivotal study yield result however uncertain big product ipatasertib become sellside consensus evaluatepharma show revenue bn roche aiming file project year prostate cancer two breast cancer setting prostate cancer study ipatential read today partial success claimed might lack relevance real world issue turn diagnosing patient presence genetic pten alteration ipatential shown ipatasertib benefit pten altered subject comer crux matter prostate cancer patient routinely screened pten mutation appear change hedged bet ipatential tested ipatasertib top standard care johnson johnson zytiga first line castrate resistant prostate cancer subject versus zytiga control primary efficacy measure progression free survival tested pten altered subject comer population study run basis result earlier phase ii go trial second line setting according data presented esmo gu symposium showed ipatasertib plus zytiga conferring large pfs benefit versus zytiga pten altered subject none non pten altered population mechanistically logical pten tumour suppressor major brake pi k akt survival pathway drive cancer since pi k akt ipatasertib inhibits stand reason project active subject lack pten brake activated pathway roche say pten alteration present castrate resistant prostate cancer designing ipatential seems hedging bet addition testing hypothesis pten altered subject hoping benefit might large enough drive pfs result comer proved case ipatential read positively pfs pten altered population true extent benefit plus numerically positive result comer well secondary overall survival endpoint yet revealed rescue study without backing however roche left trying change standard care make pten testing mandatory first line prostate cancer determine whether ipatasertib added zyitiga doctor happy prescribe zytiga xtandi without need testing case hard make addition prostate cancer roche ipatasertib filing plan includes first second line triple negative breast cancer front line hr positive negative breast cancer ipatunity pivotal trial setting read year noted recruited pten altered patient unless study back benefit comer swiss firm make case pten testing breast cancer otherwise ipatasertib end curate egg whose positive aspect fail redeem shortcoming\n",
      "\n",
      "Keywords:\n",
      "pten 0.525\n",
      "ipatasertib 0.321\n",
      "pten altered 0.263\n",
      "altered 0.25\n",
      "prostate cancer 0.188\n",
      "ipatential 0.188\n",
      "prostate 0.183\n",
      "zytiga 0.171\n",
      "cancer 0.167\n",
      "pten altered subject 0.15\n",
      "altered subject 0.15\n",
      "comer 0.124\n",
      "akt 0.107\n",
      "breast cancer 0.09\n",
      "breast 0.089\n",
      "pfs 0.078\n",
      "result comer 0.075\n",
      "pi akt 0.075\n",
      "subject 0.074\n",
      "roche 0.074\n",
      "\n",
      "Abstract:\n",
      "biomarin ahead rival valrox gene therapy haemophilia end might count much four year data released world federation hemophilia annual meeting showed treated patient clotting factor continuing fade time conference pfizer sangamo unveiled longest duration data seen far candidate sb maximum week follow still much learn project sign certainly encouraging patient experiencing bleeding event requiring factor viii infusion far partner presented update five subject received x vg kg dose therapy generically known giroctocogene fitelparvovec factor viii activity level measured chromogenic assay sustained median according press release data soon gauge durability response although notable pfizer sangamo generating level activity lower dose biomarin company valrox filed accelerated approval x vg kg first look result seven patient given dose four year ago presented wfh week showed another decline factor viii activity dropping median three year mark biomarin suffers minimal bleeding valrox readout may\n",
      "\n",
      "Keywords:\n",
      "viii 0.28\n",
      "factor viii 0.28\n",
      "valrox 0.252\n",
      "biomarin 0.225\n",
      "factor 0.213\n",
      "vg kg 0.179\n",
      "vg 0.179\n",
      "pfizer sangamo 0.179\n",
      "sangamo 0.163\n",
      "bleeding 0.153\n",
      "kg 0.15\n",
      "four year 0.147\n",
      "activity 0.137\n",
      "dose 0.111\n",
      "median 0.099\n",
      "week showed 0.093\n",
      "valrox gene therapy 0.093\n",
      "valrox gene 0.093\n",
      "therapy haemophilia 0.093\n",
      "suffers 0.093\n",
      "\n",
      "Abstract:\n",
      "place evidence covid new world order apparent biopharma smaller transaction getting away novo nordisk acquisition corvidia example however deal volume look set nose dive year pandemic come particularly bad time big pharma evaluate vantage analysis show number novel late stage asset sitting pipeline world biggest drug maker low decade decline last four year hoping form portfolio building struggle follow plan restriction global travel continue place chart show come novel project number fallen acquisition licensing compensatory uplift organic development analysis conducted using historical pipeline data evaluatepharma count conducted april every year collect every project enters phase iii phase transition month unlikely encompasses global pharmaceutical major april novel project sitting pipeline figure dropped month year one explanation streamlining portfolio happened several company new management glaxosmithkline sanofi example focus oncology many group another reason research team increasingly focusing brand extension rather new approval think huge number indication keytruda sold notably declining trend seen pipeline managed big drug maker chart includes company whose market cap averaged bn period includes acquired period rate seem fairly steady decade question suggesting late stage shrinkage big pharma phenomenon raise question whether analysis reflects deliberate focusing resource fact asset becoming harder acquire easy access financing allowing younger developer hold asset pushing valuation look transaction announced far year show already started slowly throw pandemic outlook deal making year pretty dire stephanie l ouzon partner head torreya europe global investment bank belief earlier stage deal favoured later stage transaction year type deal easier complete say seeing declining partnering licensing across industry continues active evan lippman takeda head corporate development valuation belief quick fix form mega merger table due current market uncertainty large acquisition happen might look different company mindful capital structure right might see structured deal rather outright use contingent value right say still believe old fashioned deal making might short term impact term covid remember company making long term bet say andy pasternak chief business officer horizon therapeutic perhaps longer term bet boost size late stage pipeline year time deal trend anything go big pharma phase iii portfolio set stay relatively small\n",
      "\n",
      "Keywords:\n",
      "deal 0.184\n",
      "pipeline 0.161\n",
      "portfolio 0.153\n",
      "novel project 0.141\n",
      "transaction 0.136\n",
      "late stage 0.136\n",
      "stage 0.133\n",
      "big pharma 0.113\n",
      "declining 0.112\n",
      "term 0.109\n",
      "novel 0.109\n",
      "global 0.107\n",
      "deal making 0.106\n",
      "acquisition 0.103\n",
      "focusing 0.102\n",
      "making 0.1\n",
      "sitting 0.099\n",
      "licensing 0.094\n",
      "decade 0.094\n",
      "conducted 0.094\n",
      "\n",
      "Abstract:\n",
      "despite striking trio deal last year neurocrine still thirst early stage asset yesterday deal takeda brought three clinical four preclinical neuroscience project bolstering pipeline already heavily reliant external innovation collaboration bold move neurocrine three named project novel mechanism tricky indication schizophrenia depression still marketed drug ingrezza still going strong company cash spend agreement cost front investor seemed like deal neurocrine stock closed yesterday company applauded reinvesting innovation takeda tie latest move overhaul began ingrezza failed tourette late wake flop group signed partnership voyager therapeutic develop cns gene therapy followed two deal xenon idorsia covering rare epilepsy project takeda motivation le clear particularly company emphasised neuroscience one core therapy area takeover shire yesterday call neurocrine chief executive kevin gorman stressed takeda licensed project still want involved added japanese company definitely getting cns term deal japanese company opt profit share asset asset basis takeda chooses opt earn clinical bn commercial milestone tak away neurocrine responsible development project tak advanced phase ii interact study currently recruiting top line data expected next year selective amino acid oxidase inhibitor tested adjunctive therapy negative symptom schizophrenia apathy blunted emotional response theory behind approach increasing nmda activity daao inhibitor address nmda receptor hypofunction linked schizophrenia drug approved specifically negative schizophrenia symptom daao inhibitor clinical trial according evaluatepharma taiwanese company syneurx naben sodium benzoate phase ii iii development conference call yesterday neurocrine exec described sodium benzoate much le potent inhibitor daao tak still project schizophrenia pipeline shooting goal leerink analyst noted tak tak meanwhile described phase ii ready former ampa potentiator development treatment resistant depression ampa long linked depression cns disorder however several project targeting ampa receptor discontinued due side effect neurocrine plan use pet ligand find therapeutic window tak look like particularly risky bet finally tak target g protein coupled receptor found habenula area brain involved reward system neurocrine planning evaluate project depressed patient anhedonia inability experience pleasure asset previously phase ii trial anhedonia schizophrenia neurocrine lofty goal world leading neuroscience company mr gorman said yesterday call group would continue invest area deal might card\n",
      "\n",
      "Keywords:\n",
      "neurocrine 0.477\n",
      "tak 0.31\n",
      "schizophrenia 0.281\n",
      "takeda 0.175\n",
      "daao 0.17\n",
      "ampa 0.17\n",
      "neuroscience 0.151\n",
      "depression 0.127\n",
      "cns 0.124\n",
      "deal 0.119\n",
      "ingrezza 0.106\n",
      "project 0.105\n",
      "yesterday 0.098\n",
      "nmda 0.097\n",
      "sodium 0.094\n",
      "area 0.09\n",
      "opt 0.084\n",
      "innovation 0.084\n",
      "receptor 0.08\n",
      "linked 0.078\n",
      "\n",
      "Abstract:\n",
      "last month looked like genfit finally killed hope ppar agonist nash inventiva breathed new life approach scoring result lanifibranor phase ii native trial tolerability long issue drug class finding therapeutic window lanifibranor yet prove difficult weight gain peripheral oedema rearing head native differently acting project making headway nash notably novo nordisk semaglutide meaning lanifibranor find tricky carve niche make market pan ppar positive inventiva stock much morning low base lanifibranor chance success looked slim earlier flop rare fibrotic disease systemic sclerosis well recent failure ppar agonist including genfit elafibranor cymabay seladelpar lanifibranor pan ppar agonist elafibranor hit ppar alpha delta seladelpar target delta subtype difference key lanifibranor efficacy provide boost intercept licensed pan ppar agonist bezafibrate aralez last year group might need new project pivot twice delayed nash candidate obeticholic acid get knocked back fda distinct possibility given mixed phase iii data still bezafibrate clinical trial nash inventiva say lanifibranor pan ppar agonist development liver disorder though selective project still play upcoming event fibroid data obseva inventiva turn nash march might explain inventiva appears taking time pushing phase iii chief executive fr ric cren refused give detail pivotal trial design despite pressed repeatedly conference call today saying would require lot thought deep dive native dataset go native taking higher mg dose lanifibranor forward seems like brainer one hit statistical significance primary endpoint native decrease two point steatosis activity fibrosis saf score worsening fibrosis six month therapy patient receiving mg lanifibranor achieved versus placebo group mg lanifibranor dose missed statistical significance inventiva exec said call possible dose show effect longer term use\n",
      "\n",
      "Keywords:\n",
      "lanifibranor 0.492\n",
      "ppar 0.31\n",
      "inventiva 0.295\n",
      "native 0.258\n",
      "ppar agonist 0.221\n",
      "pan ppar 0.207\n",
      "nash 0.16\n",
      "agonist 0.159\n",
      "pan 0.158\n",
      "pan ppar agonist 0.155\n",
      "mg lanifibranor 0.103\n",
      "bezafibrate 0.103\n",
      "seladelpar 0.086\n",
      "delta 0.081\n",
      "elafibranor 0.078\n",
      "genfit 0.076\n",
      "mg 0.076\n",
      "fibrosis 0.068\n",
      "statistical significance 0.064\n",
      "significance 0.059\n",
      "\n",
      "Abstract:\n",
      "bluebird accelerated filing plan place zynteglo approved sickle cell disease dataset remains strong give gene therapy chance compete traditional drug already market global blood oxbryta novartis adakveo bluebird need look shoulder weekend virtual european society hematology meeting saw rival presentation crispr therapeutic agio imara forma even glycomimetics bombed phase iii last year reckons might path forward though analyst seem unconvinced crispr vertex partnered gene therapy ctx perhaps intriguing given evaluatepharma sellside consensus already see generating nearly bn revenue even though data one treated subject available far eha updated patient said still free vaso occlusive crisis vocs nine month receiving infusion gene therapy subject enrolled study followed two year clearly still early day ctx reduction vocs half new primary endpoint proposed bluebird friday potentially registrational study zynteglo oral small molecule agio pursuing technically simpler approach oral small molecule mitapivat eha reported five eight evaluable sickle cell subject given mg twice daily achieved haemoglobin increase least g dl trial aim enrol subject dosing mg according amended protocol however agio fell friday one voc disclosed serious adverse event possibly related treatment despite leerink analyst say still hope drug mitapivat mechanism pyruvate kinase r activation lower vocs dosed chronically mechanism thought reduce haemoglobin polymerisation approach pursued forma therapeutic lead asset ft forma eha data early however detailing median mmhg reduction point sickling three subject hour single dose forma trial enrols healthy volunteer placebo cohort grade adverse event seen far mitapivat carry sellside forecast haemolytic anaemia according evaluatepharma consensus since forma private ft attract sellside forecast imara imr project licensed lundbeck pursuing yet another strategy sickle cell namely pde inhibition say prevents degradation cgmp leading reactivation fetal haemoglobin study evaluated subject safety yielded efficacy result show mean increase fetal haemoglobin baseline week high dose versus increase placebo low dose cohort imara want combine imr hydroxyurea used reduce frequency painful vocs said far combo shown drug drug interaction finally glycomimetics perhaps best remembered lead pfizer partnered sickle cell project rivipansel failing phase iii reset trial last year however revealed data reset update presented eha foundation sickle cell disease research meeting september describes post hoc analysis reset looking subject severe vocs requiring hospitalisation given rivipansel relatively early acute episode company claim show benefit rivipansel term time readiness discharge primary endpoint reset comer population full data interest stifel dismissive writing friday likely worth pursuing rivipansel\n",
      "\n",
      "Keywords:\n",
      "vocs 0.271\n",
      "forma 0.241\n",
      "rivipansel 0.216\n",
      "reset 0.203\n",
      "sickle cell 0.201\n",
      "sickle 0.201\n",
      "eha 0.185\n",
      "haemoglobin 0.173\n",
      "mitapivat 0.152\n",
      "imara 0.152\n",
      "agio 0.152\n",
      "subject 0.116\n",
      "pursuing 0.112\n",
      "bluebird 0.109\n",
      "cell 0.104\n",
      "zynteglo 0.101\n",
      "oral small molecule 0.096\n",
      "oral small 0.096\n",
      "friday 0.095\n",
      "ctx 0.092\n",
      "\n",
      "Abstract:\n",
      "perhaps truth behind report strategic covid vaccine deal trump administration german biotech company curevac resoundingly denied three month ago german government bought stake mrna researcher revealed today investment tied sort exclusive access supply arrangement curevac covid vaccine candidate company finance director pierre kemula told evaluate vantage however seems likely alarm highest level implication arrangement real otherwise helped persuade german government move covid appeared meeting government said support mr kemula said investment triggered covid related covid directly rule deal might involve access future example come figuring fund large expensive trial required test company vaccine candidate thoroughly however government remain large shareholder board seat say company strategic direction curevac mrna based vaccine candidate poised start trial healthy volunteer speculation company former chief executive talked exclusive supply agreement u sparked uproar germany back march upheaval company crisis crisis curevac denies everything march long term thinking investment made via country state owned development bank kreditanstalt f r wiederaufbau first germany partly driven realisation country healthcare sector need supporting shined brightly part economy mr kemula said money used support curevac research various disease area seems clear german government thinking long short term press release deal german minister acknowledges covid pandemic made securing medical supply chain national security issue deal say curevac valuation another question term put company worth bn sound low earlier financing said done bn valuation market cap mrna peer moderna biontech substantially higher mr kemula declined discus company might worth pointed lead project prostate cancer vaccine failed early event would certainly knock valuation although subsequent revival interest mrna would surely helped curevac recover since either way company majority shareholder serial german biotech investor dietmar hopp apparently support new financing stake diluted accordingly decade long generous backer country biotech scene mr hopp always exhibited ability look long term point view welcoming deep pocketed new partner party generous term pay dividend future\n",
      "\n",
      "Keywords:\n",
      "curevac 0.334\n",
      "german 0.267\n",
      "kemula 0.262\n",
      "government 0.203\n",
      "german government 0.168\n",
      "vaccine 0.146\n",
      "vaccine candidate 0.143\n",
      "covid 0.14\n",
      "mrna 0.139\n",
      "supply 0.136\n",
      "mr 0.133\n",
      "country 0.132\n",
      "term 0.119\n",
      "hopp 0.117\n",
      "company 0.115\n",
      "support 0.107\n",
      "germany 0.105\n",
      "generous 0.105\n",
      "exclusive 0.102\n",
      "arrangement 0.102\n",
      "\n",
      "Abstract:\n",
      "sickle cell disease key second pillar bluebird lentiglobin gene therapy u registration plan rather vague today company set sight accelerated filing backed crucial update hgb trial unveiled virtual european hematology association congress morning efficacy side data show lentiglobin curative potential larger patient cohort albeit still immature time point necessary subject enrolled however death one patient though deemed unrelated lentiglobin might remind gene therapy carry risk stifel analyst instance hailing update strongly supportive accelerated approval investor able shrug patient death bluebird along rest market come yesterday opened morning filing plan company today said lentiglobin would filed sickle cell disease second half based group c hgb trial phase iii hgb study serve confirm approval told analyst call another important change hgb formally test lentiglobin ability result least patient haemoglobin anti sickling hbat q form encoded gene therapy new primary endpoint approval reduction vaso occlusive crisis voc acute chest syndrome ac least year ash meeting nine group c patient least six month follow benefit seen mean reduction voc ac today eha update revealed mean reduction subject previous endpoint showing impressive efficacy patient least month follow hbat q comprises median haemoglobin five minimum month data available median bluebird said hgb group c comprises tweaked manufacturing process earlier shown give greater efficacy seen group b ash bluebird face lentiglobin reckoning december safety side bluebird already reported one case myelodysplasia earlier cohort blamed busulfan preconditioning regimen used today revealed patient death cardiac arrest sudden shortness breath around month getting lentiglobin deemed unlikely related lentiglobin subject history cardiac disease pulmonary hypertension venous thrombosis may cautious investor note whether death deemed related subjective decision study investigator perhaps importantly fda absolutely aware death time accelerated path discussed said bluebird chief medical officer dave davidson term durability effect agency apparently want see least month follow group c cohort fully enrolled follow range month median still time go explaining filing expected late according evaluatepharma consensus sellside expects lentiglobin selling bn coming sickle cell remainder already approved use zynteglo beta thalassaemia eha data give comfort forecast attainable though efficacy still need maintained longer patient without nasty adverse event surprise mounting competitive threat crispr vertex instance providing early evidence promise project ctx eha battle\n",
      "\n",
      "Keywords:\n",
      "lentiglobin 0.473\n",
      "hgb 0.263\n",
      "bluebird 0.226\n",
      "eha 0.144\n",
      "month follow 0.139\n",
      "death 0.131\n",
      "sickle cell 0.125\n",
      "sickle 0.125\n",
      "follow 0.116\n",
      "deemed 0.108\n",
      "voc 0.105\n",
      "least month 0.105\n",
      "ac 0.1\n",
      "least 0.1\n",
      "patient 0.099\n",
      "accelerated 0.099\n",
      "patient death 0.096\n",
      "sickle cell disease 0.093\n",
      "haemoglobin 0.09\n",
      "cell disease 0.09\n",
      "\n",
      "Abstract:\n",
      "private leo pharma managed keep tralokinumab somewhat wrap making unknown sanofi regeneron dominated dermatitis space result three pivotal study anti il mab toplined late last year lack actual data prompted suspicion le knockout proved efficacy data released though endpoint hit figure put tralo way behind competition indeed current clinical evidence pfizer jak inhibitor abrocitinib one beat ecztra trial comparing tralokinumbab placebo twin endpoint investigator global assessment iga score indicating clear almost clear skin easi representing reduction eczema area severity index least ecztra endpoint active treatment placebo administered alongside steroid result presented virtual annual meeting american academy dermatology comparing data different trial ideal variable design severity patient enrolled kim kj ller leo pharma executive vice president r pointed evaluate vantage nevertheless probably doctor payer magnitude placebo adjusted benefit endpoint suggests tralokinumab outplayed lilly lebrikizumab phase iii sanofi regeneron blockbuster dupixent dupixent became biggest selling eczema drug forecast remain position least sale forecast reach bn according sellside data compiled evaluatepharma despite shareholder rapturous response lebrikizumab phase iib data earlier year sellside appears consider product ran revenue forecast hovering fourth year market presumably reflects difficulty competing dupixent though clearly bother lilly acquired drug originator dermira bn earlier year lilly jump gun dermira deal january real threat obvious conclusion chart pfizer abrocitinib extremely well efficacy completely different mechanism agent inhibits jak tralo lebri hit il dupixent slightly different bind receptor il il moreover abrocitinib administered two mg pill taken together daily rather fortnightly subcutaneous jab like il targeting therapy abrocitinib achilles heel safety pivotal jade mono trial showed respective rate nausea headache mg dose sign increased risk thrombocytopenia lipid disorder fortunately pulmonary embolism deep vein thrombosis major cardiac event malignancy main concern jak class jade mono trial read three month point trial lasted four left unanswered question around toxicity longer term use pfizer deadly serious taking dupixent resorted high stake gamble head head trial toplining jade compare pfizer stated abrocitinib beat dupixent itching notably made claim co primary endpoint iga easi full data fda filing come year pfizer jak chance slicing chunk dupixent sale unlikely replace bestseller unless full jade compare data show surprise superiority claim leo pharma tralokinumab would appear le golden future mr kj ller say drug become second biologic treat adult moderate severe eczema first biologic available specifically neutralise il fair point since ahead lilly lebrikizumab suggests tralo offer treatment option patient whose disease uncontrolled cannot tolerate therapy suggesting post dupixent treatment favour clean safety profile little meaningful difference adverse event rate drug placebo pivotal ecztra trial come expense efficacy meaning struggle make mark dermatitis particularly offer convenience advantage market leader perhaps leo sale strategy allow make mab asset gain approval dream displacing dupixent even offering meaningful competition dissolved face ecztra data\n",
      "\n",
      "Keywords:\n",
      "dupixent 0.341\n",
      "abrocitinib 0.208\n",
      "ecztra 0.208\n",
      "leo 0.194\n",
      "il 0.185\n",
      "jade 0.171\n",
      "tralo 0.156\n",
      "tralokinumab 0.146\n",
      "leo pharma 0.146\n",
      "lebrikizumab 0.146\n",
      "jak 0.139\n",
      "eczema 0.139\n",
      "pfizer 0.108\n",
      "pfizer jak 0.097\n",
      "jade mono 0.097\n",
      "lilly 0.096\n",
      "mono 0.092\n",
      "easi 0.092\n",
      "iga 0.089\n",
      "jade compare 0.086\n",
      "\n",
      "Abstract:\n",
      "ucb bimekizumab already beaten humira stelara psoriasis need perform novartis cosentyx head head radiant study read shortly trial important validation since cosentyx anti il mab forecast market leader according evaluatepharma sellside consensus however abbvie anti il mab skyrizi viewed effective targeting il significantly improved treatment outcome skin disease leaving bimekizumab task taking market share tough one radiant enrolled patient moderate severe plaque psoriasis measure week pasi score primary endpoint bimekizumab phase iib able trial best week pasi response mg mg mg loading dose cosentyx shown peak effect week mg dose yielding pasi response erasure fixture phase iii study jefferies analyst expect bimekizumab numerically better superior cosentyx still place market given superiority humira stelara detailed data ready vivid study placebo stelara respectively released virtual aad meeting start friday co primary endpoint study pasi iga response defined clear almost clear week bimekizumab il il f inhibitor forecast sellside become ucb biggest growth driver sale seen reaching filing expected soon however psoriasis incredibly crowded space cosentyx skyrizi vying top spot head head trial run abbvie skyrizi showed pasi response week compared cosentyx one year pasi number skyrizi cosentyx jefferies analyst note bimekizumab greater potential psoriatic arthritis ankylosing spondylitis phase iii data due end next year study hidradenitis suppurativa recently started\n",
      "\n",
      "Keywords:\n",
      "bimekizumab 0.389\n",
      "cosentyx 0.363\n",
      "pasi 0.332\n",
      "skyrizi 0.221\n",
      "il 0.192\n",
      "stelara 0.182\n",
      "pasi response 0.182\n",
      "psoriasis 0.145\n",
      "head 0.122\n",
      "mg 0.118\n",
      "ucb 0.101\n",
      "il mab 0.101\n",
      "anti il mab 0.101\n",
      "jefferies analyst 0.099\n",
      "humira 0.099\n",
      "week 0.097\n",
      "anti il 0.093\n",
      "jefferies 0.091\n",
      "response 0.086\n",
      "mg mg 0.081\n",
      "\n",
      "Abstract:\n",
      "seasoned biotech investor yesterday broad alliance genmab abbvie rung old bell headline focus anti cd bispecific epcoritamab behind scene lie two project antigen familiar cd former perhaps famous target betalutin asset according whose fortune nordic nanovector stock waxed waned meanwhile used major focus several oxford biomedica approach brought crashing earth failure trovax pivotal trist study cd approach seen discontinuation expected genmab abbvie insist bispecifics duohexabody cd gen duobody cd x potentially best class genmab brings abbvie bispecific boost june gen bispecific mab virtue engaging two different epitope cd genmab say unique approach showing promise vitro dose escalation lymphoma study duobody cd x cell engaging bispecific ind submitted competition advanced industry work former antigen latter late norway nordic nanovector touched record valuation betalutin impressed late line lymphoma setting realisation work still early coupled delay caused stock drift since betalutin comprises unusual approach combining cd targeting radionuclide lutetium follow us lead radionuclide debiopharm naratuximab typical antibody drug conjugate acquired immunogen three year ago phase ii trial end imminently among disappointment another adc seattle genetics astellas canned despite showing promise heavily pretreated non hodgkin lymphoma still previous work cd prompt doubt target nothing compared tumour antigen discovered scientist cancer research uk back notorious casualty oxford biomedica trovax crashed phase iii year ago fair cancer vaccine failure might approach target oxford separately flirted mab adc even car format none making significant progress second big failure active biotech anti adc anyara whose phase ii iii renal cell carcinoma study blew anyara sound death knell targeted anticancers january remarkably active managed offload anyara neotx running phase trial combination imfinzi precedent targeting cd might great least genmab abbvie boast novel approach hitting old school antigen remains show worth clinic story updated include vaccitech vtp\n",
      "\n",
      "Keywords:\n",
      "cd 0.352\n",
      "genmab 0.248\n",
      "betalutin 0.2\n",
      "anyara 0.2\n",
      "genmab abbvie 0.187\n",
      "antigen 0.171\n",
      "adc 0.156\n",
      "bispecific 0.155\n",
      "approach 0.151\n",
      "oxford 0.134\n",
      "abbvie 0.128\n",
      "nordic 0.125\n",
      "duobody 0.125\n",
      "lymphoma 0.121\n",
      "showing promise 0.119\n",
      "engaging 0.119\n",
      "oxford biomedica 0.114\n",
      "biomedica 0.114\n",
      "gen 0.104\n",
      "old 0.087\n",
      "\n",
      "Abstract:\n",
      "genmab promising deal lead r project epcoritamab time today unveiled abbvie new partner cd targeting bispecific sits field roche regeneron ahead similar agent danish biotech always going need help competing abbvie big presence haematological cancer thanks imbruvica venclexta partnering certainly make sense deal term point promise seen bispecifics area front bn milestone genmab get keep healthy portion profit epcoritamab make market bispecific promise highly encouraging response rate regeneron regn roche mosunetuzumab across various lymphoma raised hope using bispecific hit cd might boost effectiveness well established mechanism hope agent might offer tolerable convenient option car later setting several cd bispecific project development roche regeneron considered front presented substantial datasets ash last year suggesting regn gained efficacy mosunetuzumab lost safety ash regeneron take bispecific baton run december huge player cd space rituxan gazyva roche ruled course race far genmab presented latest cut ongoing trial epcoritamab asco month appeared show competitive efficacy safety easily judged stage epcoritamab certainly hold much lower rate severe cytokine release albeit fewer patient far regeneron roche already started much larger phase ii programme respective candidate call investor afternoon genmab abbvie said keeping specific plan epcoritamab close chest acknowledged behind plan afoot catch insisted hinted huge pivotal programme card darzalex type development programme expected revealed involving multiple thousand patient combination imbruvica venclexta likely considering epcoritamab data patient published date might find talk premature broad deal involves two clinical stage bispecifics potentially four project road fee relate progress elsewhere big proportion linked epcoritamab however genmab jointly market abbvie u japan profit shared equally country elsewhere genmab receive royalty term broadly similar two bispecifics anti cd mab gen phase trial cell engager target expressed variety solid tumour ind latter filed call deal repeatedly described partnership transformational genmab executive although abbvie management probably hope pretty big thing company fired several blank oncology think rova veliparib share company opened almost today bn market cap genmab hardly described small biotech though valuation largely due substantial rally past month stock touched record high late may surged far year probably explains relatively muted response deal share trading higher news however clear abbvie motivated ambitious partner found\n",
      "\n",
      "Keywords:\n",
      "epcoritamab 0.412\n",
      "genmab 0.375\n",
      "bispecific 0.183\n",
      "abbvie 0.181\n",
      "regeneron 0.172\n",
      "cd 0.166\n",
      "bispecifics 0.128\n",
      "roche 0.116\n",
      "mosunetuzumab 0.112\n",
      "deal 0.11\n",
      "imbruvica 0.101\n",
      "venclexta 0.096\n",
      "regn 0.094\n",
      "profit 0.081\n",
      "programme 0.08\n",
      "elsewhere 0.078\n",
      "ash 0.076\n",
      "described 0.075\n",
      "substantial 0.069\n",
      "promise 0.064\n",
      "\n",
      "Abstract:\n",
      "confirmation keytruda first line bladder cancer study keynote bust open door merck kgaa pfizer bavencio carve presence cancer thanks bavencio unexpected success javelin bladder front line maintenance study profiled recent asco late breaker true keytruda still capture slice first line bladder cancer patient thanks combo astellas seattle genetics padcev shown stunning efficacy question whether widespread bavencio use early adjuvant setting effectively rule subsequent pd l blockade asco day ago professor thomas powles bart cancer centre said javelin bladder make first line maintenance bavencio new standard care bladder cancer trial bavencio given chemo progression patient still response stable disease something market would greatly expand available population happens would limit rival checkpoint blockade first line use chemo ineligible patient merck keytruda roche tecentriq approved second line leading anti pd l label importantly however would little rationale giving second anti pd l drug patient already treated first progressed javelin bladder control cohort subject progressed given pd l blockade bavencio number even presumably driven le scientific rationale lack option roche tecentriq used front line monotherapy patient ineligible chemo patient eligible non cisplatin chemo must least pd l expressers establishment bavencio maintenance make later use irrelevant would obviate need pd l testing maintenance javelin bladder disease control achieved initial chemotherapy provides time immune therapy effect professor powles told asco yesterday readout keynote valid question whether similar effect achieved simply combining checkpoint blockade front line chemo however study drawn blank keytruda chemo combo keytruda monotherapy cohort keynote earlier raised serious concern pd l low subject deriving greater survival benefit chemo alone keytruda alone still hope chemo combo show something positive least pd l high subject however though numerical survival benefit keytruda plus chemo chemo statistically insignificant true javelin bladder bavencio benefit driven pd l positive reduction risk death hazard ratio comer slightly le impressive shifting dynamic make second line immunotherapy irrelevant still worth considering much front line market company play flop keynote astrazeneca first line danube study failed show survival benefit imfinzi chemo despite looking pd l expressers bristol myers squibb checkmate trial ended mid recently upsized subject delayed merck co hope rest keytruda combination seattle astellas anti nectin drug padcev soon filed accelerated first line approval based impressive remission rate survival data ev study devil however detail efficacy pd l low subject compare javelin bladder much keytruda padcev combo overall benefit driven seattle drug remain open question\n",
      "\n",
      "Keywords:\n",
      "bladder 0.323\n",
      "chemo 0.284\n",
      "javelin bladder 0.269\n",
      "bavencio 0.262\n",
      "pd 0.238\n",
      "javelin 0.222\n",
      "keytruda 0.2\n",
      "line 0.174\n",
      "first line 0.124\n",
      "maintenance 0.118\n",
      "blockade 0.11\n",
      "bladder cancer 0.108\n",
      "keynote 0.105\n",
      "padcev 0.102\n",
      "front line 0.094\n",
      "survival benefit 0.091\n",
      "seattle 0.088\n",
      "combo 0.084\n",
      "line bladder cancer 0.084\n",
      "line bladder 0.084\n",
      "\n",
      "Abstract:\n",
      "genscript certainly timed flotation cell therapy business legend biotech perfection share listed nasdaq week impressive data lead car project j j partnered jnj unveiled asco presentation surely fanned investor interest ipo deliberately timed legend raised substantially initially intended hit market huge bn market cap evaluate vantage calculation make third biggest nasdaq flotation measure research stage drug developer market new issue booming helped course legend success surprising given new investor hold around third company based china u genscript biotech hong kong listed supplier biotech product service retains stake legend presumably big say spin future acted little deterrent legend ipo first setting raise soon hiked huge demand pushed final offer price way indicative range bringing haul two day since floating stock surged another perhaps remarkable aspect float hong kong listed genscript capitalised around bn meaning around two third valuation accounted stake hold legend vantage identified eight clinical stage company floated valuation bn look stand make encouraging reading legend new investor one trading higher still similar vantage analysis last october done covid opportunity lifted several name tell different story stage moderna vir trading ipo price bridgebio staying flat whether pandemic promise ever realised far certain wider stock market revival past month provided stock boost legend meanwhile highly reliant jnj confirming promise phase iii pivotal trial called cartitude started unlikely read car therapy one many project duelling highly competitive bcma targeting space early sign efficacy least encouraging asco j j see multiple myeloma response deepen may legend far silent partner project global development deal saw two group agreeing share cost profit equally except china transaction cost j j huge front legend lcar b already generated promising clinical data jnj j j incarnation yet enter clinic u pharma giant paid milestone since legend said use ipo proceeds fund clinical development launch jnj build manufacturing facility push forward pipeline project many still early fair assume company valuation largely based promise lead asset notably equity analyst covering j j yet append sale forecast jnj according evaluatepharma legend soon boast sellside following course market cap approaching bn seems inevitable pretty large number soon emerge\n",
      "\n",
      "Keywords:\n",
      "legend 0.596\n",
      "jnj 0.216\n",
      "genscript 0.163\n",
      "ipo 0.126\n",
      "new investor 0.109\n",
      "timed 0.103\n",
      "kong 0.103\n",
      "hong kong 0.103\n",
      "hong 0.103\n",
      "listed 0.096\n",
      "promise 0.089\n",
      "soon 0.077\n",
      "third 0.076\n",
      "flotation 0.076\n",
      "valuation 0.074\n",
      "market 0.072\n",
      "huge 0.071\n",
      "nasdaq 0.068\n",
      "stake 0.066\n",
      "vantage 0.065\n",
      "\n",
      "Abstract:\n",
      "soleno diazoxide choline breakthrough uncontrolled eating disorder prader willi however failure phase iii destiny pws study yesterday soleno slimmed losing half market cap morning group argues destiny pws might included subject true hyperphagia abnormal desire food inclusion criterion severe hyperphagia considered diazoxide effect say clearly market buy post hoc claim based cherrypicked patient disappointing state play disease already witnessed spectacular blow zafgen failure millendo livoletide pipeline asset meaningful sellside number phase ii april placebo response destiny pws enrolled subject blinded placebo controlled phase sought show superiority diazoxide basis hyperphagia score week subject diazoxide improved point unfortunately placebo point difference nowhere near statistical significance analyst call dr jennifer miller prader willi expert bemoaned fact caregiver parent totally familiar questionnaire whose basis subject enrolled destiny pws many knew child needed score qualify resulting enrolled despite actually hyperphagia suggested correct soleno picked subject baseline score basis said diazoxide showed effect versus placebo resulted nominal p value said analysis prespecified course p value statistically significant neither p value used back significant effect two three secondary endpoint p investigator assessed improvement p body fat reduction dxa scan especially convincing nominal p value measure called doubt perverse failure show benefit another secondary caregiver assessed improvement soleno argued significant reduction trunk fat mass favouring diazoxide explain measure backed patient subset destiny pws trial plus side diazoxide side effect profile looked good expected drug market since hypoglycaemia caused overproduction insulin soleno argument seem flimsy hardly blame group trying diazoxide pipeline asset future uncertain cannot raise money back soleno ended march bank based first quarter burn rate enough last end year realistically however diazoxide rationale prader willi action potassium channel interrupt synthesis appetite stimulating neuropeptide sellside consensus according evaluatepharma look dead water\n",
      "\n",
      "Keywords:\n",
      "diazoxide 0.475\n",
      "soleno 0.316\n",
      "pws 0.282\n",
      "destiny pws 0.282\n",
      "destiny 0.226\n",
      "hyperphagia 0.201\n",
      "willi 0.158\n",
      "prader willi 0.158\n",
      "prader 0.158\n",
      "caregiver 0.096\n",
      "pipeline asset 0.093\n",
      "nominal 0.093\n",
      "score 0.093\n",
      "value 0.092\n",
      "subject 0.086\n",
      "basis 0.085\n",
      "fat 0.084\n",
      "enrolled 0.082\n",
      "placebo 0.081\n",
      "effect 0.079\n",
      "\n",
      "Abstract:\n",
      "deal investor consider surely bizarre yet bombshell bloomberg astrazeneca approached gilead merger dropped yesterday causing widespread headscratching among analyst indeed subsequent report including bloomberg questioned company riding crest stock market wave fall prey one even better growth prospect still viewed certain angle deal make sense evaluate vantage look pro con gilead year date company typically fall prey takeover share longer reflect value within gilead stock market darling riding crest wave thanks effort tackle covid fresh thinking brought daniel day chief executive interested astra would approached gilead stock truly favour gilead past five year step back get full picture gilead actually peaked back hepatitis c mania since languished effort build oncology presence think zydelig kite pharma flopped management fearful risky indulged stock buyback revealed lack imagination exposed gilead vulnerability gilead bet unpromising approach astra boast impressively profitable cash generating business one best oncology pipeline industry want stake underwhelming asset like zydelig car therapy unproven promise filgotinib declining hepatitis c franchise gilead underappreciated hiv powerhouse though investor focused tigit cd novel approach might forget gilead established hiv business formidable gilead top three drug npv hiv antiviral biggest biktarvy sale forecast bn npv bn according evaluatepharma account gilead market cap combine remdesivir astra goal leading covid deal brainer buying gilead would constrain astra sale growth chart speak astra top line forecast grow year gilead stutter pedestrian combination two make sense would cut astra cagr buying gilead would bring astra significant new revenue le growth forecast absolute sale grab gilead acquisition biggest biopharma history allow astra instantly show bn prescription drug sale goal current sellside consensus say met deal value destroying astra strongly cash generating tune bn operating cash flow last year alone valid question whether money put better use buying pedestrian biopharma group notwithstanding vast profitability gilead established business near term share price reaction deal earnings accretive gilead bn cash balance sheet bn debt analyst opinion accretion dilution predicated much deal financed equity astra instead raise significant cash debt time interest rate historically low eps accretion question middle pandemic seems odd time mega merger notwithstanding recent cash inflow biotech equity raise huge uncertainty effect covid anyone guess economy might return normal deep recession biggest takeover biopharma history rather later asset price might crashed would take amazing amount certainty mention nerve steel uncertainty might create ideal buying opportunity throughout time astra chief executive pascal soriot shown independent thinker making big early bet novel science group investment moderna case point odds turning company formidable oncology player warren buffett said pay high price cheery consensus mr soriot wedded conventional wisdom course broader dimension deal one thing gilead takeover uk domiciled company might politically unacceptable remdesivir remains antiviral available treating covid certain astra made purported approach whether fact concerned full takeover joint venture collaboration say minority equity stake nevertheless market something new consider\n",
      "\n",
      "Keywords:\n",
      "gilead 0.437\n",
      "astra 0.335\n",
      "cash 0.142\n",
      "buying 0.138\n",
      "deal 0.131\n",
      "hiv 0.12\n",
      "takeover 0.113\n",
      "soriot 0.1\n",
      "formidable 0.1\n",
      "biopharma history 0.1\n",
      "zydelig 0.096\n",
      "pedestrian 0.096\n",
      "gilead stock 0.096\n",
      "bloomberg 0.096\n",
      "equity 0.092\n",
      "make sense 0.086\n",
      "growth 0.086\n",
      "bn 0.084\n",
      "debt 0.084\n",
      "riding 0.082\n",
      "\n",
      "Abstract:\n",
      "vaccine antiviral approach tackling covid pandemic time antibody take turn spotlight week lilly seized lead space starting first clinical trial antibody designed treat novel coronavirus ly cov derived deal abcellera target covid spike protein meaning unlike project aiming reduce infection complication take direct aim virus present clinical stage antibody covid retain monopoly long spike protein targeting approach similar several lilly competitor protein present virus surface virus us dock ace receptor target cell allowing internalised infect next project clinic mechanism come vir partnership glaxosmithkline far identified two lead mabs keenly awaited multi antibody cocktail regeneron project way astrazeneca studied patient within next month hope antibody prevent virus docking hit another part lead antibody mediated destruction last two noteworthy based part plasma derived patient recovered covid infection approach might surmised provide broader range target might provide efficient way targeting virus hitting spike protein spike protein used target industry vaccine approach seeking prime immune system indeed regeneron suggested regn cov prophylactic role biologicals already clinical development mabs cytokine gm csf angiopoietin considered aim treat effect covid cytokine elevation respiratory complication rather virus design though many project target common additional variability antibody structure instance based igg tie atreca beigene igm bioscience looking derived igm iga company argue binding domain hence greater binding power igg separate tie vir xencor look develop mabs engineered fc domain give extended half life similar thinking lie behind called darpins development molecular partner bispecific approach fusion protein instance si f development systimmune private u group focusing mabs bispecifics antibody dug conjugate combine two protein mimicking ace aiming take relevant binding site covid prevent interaction endogenous ace receptor many company making claim superiority respective approach course based animal vitro data comparison possible first clinical trial read lilly clinical study primarily testing safety pharmacokinetics pharmacodynamics design competitor trial watched interest article updated reflect celltrion choice ct p lead\n",
      "\n",
      "Keywords:\n",
      "protein 0.244\n",
      "virus 0.237\n",
      "spike protein 0.207\n",
      "antibody 0.2\n",
      "ace 0.182\n",
      "spike 0.18\n",
      "mabs 0.177\n",
      "approach 0.154\n",
      "covid 0.146\n",
      "binding 0.135\n",
      "derived 0.125\n",
      "target 0.122\n",
      "igm 0.116\n",
      "igg 0.116\n",
      "complication 0.109\n",
      "domain 0.104\n",
      "lead 0.102\n",
      "prevent 0.101\n",
      "clinical 0.096\n",
      "lilly 0.094\n",
      "\n",
      "Abstract:\n",
      "despite going virtual year biggest annual cancer conference asco still managed exert marked influence share price cell therapy company received biggest boost five developer notching substantial gain week abstract released topping table adaptimmune saw valuation double period predictable equity offering followed fundraisings cell therapy researcher adaptimmune allogene iovance completed impressive secondary bring respectively past week identify meeting biggest winner loser evaluate vantage analysed share price may close first big swathe data unveiled june day proceeding wrapped still worth noting three week stock market continued recover covid crash turnaround nasdaq biotechnology index particularly pronounced index vast majority drug developer included touched record high may cell therapy company stand analysis however perhaps investor getting concern sector progressing slowly despite huge amount money thrown already adaptimmune particular criticised apparent torpidity evidence tangible progress asco seemed allay concern company engineered cell receptor approach car player show allogene disclosed impressive response rate patient treated allo phase alpha study complete response belgian car rival celyad attracted attention new data cyad non gene edited allogeneic project two colorectal cancer patient achieved confirmed partial response evidence graft v host disease observed celyad made much relative safety approach myovant typically thought cancer play partly benefited setback competitor getting asco boost prostate cancer data relugolix gnrh antagonist primarily developed uterine fibroid trialled lupron hero study updated data showed relugolix achieving effective suppression testosterone older agent lower rate cardiovascular event result raise hope pending readout important secondary endpoint castration free survival hit data due third quarter bispecific developer particularly utilising ctla feature riser sweden alligator bioscience leading charge despite presenting poster concerned ator ctla ox bispecific stable disease best outcome patient albeit toxicity concern alphamab innovent cytomx project going ctla although first two got credit progress asco safety data presented cytomx bristol myers partnered project bm conference contained little concern cx partnered abbvie largely responsible cytomx decline project hit cd widely expressed target data phase study various solid tumour showed considerable injection site reaction anaemia trial continues update raised doubt whether therapeutic window found detail abbvie plan push forward keenly awaited second probody conjugate cytomx asco cx seems limited ocular toxicity red flag dose chosen push forward responsible one five partial response seen patient remainder achieved higher dos pursued another big asco loser arvinas whose stock slumped initial abstract drop full presentation arv company lead project purported work degrading androgen receptor studied prostate cancer two confirmed psa response subject underwhelmed overall overall however stock market reaction asco largely positive even big cap daiichi sankyo huge winner largely thanks well received data targeting antibody drug conjugate enhertu partner astrazeneca actually flat period although big pharma group get boost impressive adaura data tagrisso early stage lung cancer fellow japanese pharma eisai well possibly hope lenvima combination keytruda front line liver cancer vegfr kinase inhibitor eisai biggest selling product western big pharma fare well although course stock move much harder attribute single event still pfizer certainly hit failure pallas trial ibrance early stage breast cancer announced asco weekend roche merck co heavily invested closely watched anti tigit space although data probably early moving company share independent tigit player arcus another story however stock initially traded data fell back announcing deal gilead disappointing expecting takeout elsewhere gilead takeout cd player forty seven lot trillium stock surge since march asco disclosure another response trillium still wholly owned cd blocker tti heavily pretreated lymphoma patient gave share another boost new response partial joining previously disclosed confirmed response elsewhere worth mention turning point whose stock recovered remarkably since slumping close record low march share doubled since well received abstract ret inhibitor tpx seemingly providing lift new information concerned preclinical data although project already phase ii trial supportive sellside analyst duly described tpx potentially best class doubt mindful offering turning point launched shortly asco abstract released finally macrogenics failed build pre asco surge achieved earlier may disclosing much new data due presented conference hint efficacy pd lag bispecific mgd stood scrutiny detailed look b h targeting adc arguably live company pre conference tease still macrogenics stock still trading three time prior price scooping asco bounce seemed trick\n",
      "\n",
      "Keywords:\n",
      "asco 0.299\n",
      "cytomx 0.159\n",
      "adaptimmune 0.13\n",
      "cancer 0.129\n",
      "stock 0.128\n",
      "response 0.123\n",
      "data 0.12\n",
      "abstract 0.114\n",
      "although 0.103\n",
      "boost 0.103\n",
      "ctla 0.088\n",
      "partial 0.085\n",
      "cell therapy 0.084\n",
      "celyad 0.083\n",
      "allogene 0.083\n",
      "bispecific 0.081\n",
      "turning point 0.079\n",
      "cell therapy company 0.079\n",
      "confirmed 0.078\n",
      "conference 0.078\n",
      "\n",
      "Abstract:\n",
      "field year ago attracting deal worth hundred million dollar sting agonism come ignominious end seeing disappointing result aduro perhaps sting foremost exponent yesterday ran white flag reversed private biotech called chinook therapeutic perhaps strangest aspect deal aduro still two deal place sting novartis lilly separate anti cd tie merck co put legacy programme disposal focus turn instead chinook small pipeline kidney disease project advanced atrasentan version glaxosmithkline letairis resume phase iii development iga nephropathy second half atrasentan curious history first discontinued abbvie phase iii sonar study read positively according lancet paper chk investigational small molecule treating undisclosed ultra rare kidney disease preclinical development pipeline includes aduro anti april mab bion whose development multiple myeloma stopped phase iga nephropathy ownership combined company known chinook aduro securing relatively high stake largely account existing cash balance chinook separately raising put mix intent purpose reversal aduro chinook whose current management control combined business though aduro made much noise writing wall sting programme time december u sec filing quietly disclosed novartis removed pipeline adu lead asset firm groundbreaking sting deal deal catapulted sting spotlight novel immuno oncology pathway pre ipo sting give novartis stake aduro march follow lilly bought aduro sting antagonist approach bristol myers squibb paid sting player ifm therapeutic abbvie acquired mavupharma undisclosed amount well clinical data fired blank merck co house sting agonist mk stunned attendee esmo meeting response rate monotherapy adu disappointed asco last year based data novartis decided wind adu combo trial spartalizumab yervoy keytruda combo trial first line head neck cancer continues second half readout january aduro revealed restructuring laying workforce rest aduro novartis admitted sting dud leave numerous player abbvie instance mention specific mavupharma asset pipeline hand bristol still list sting pipeline bm opdivo yervoy combo trial slated end eisai e glaxosmithkline gsk spring bank sb synbio synb recently started phase paradoxical development given class underwhelmed still possible aduro chinook offload type asset start sufficient appetite risk investor perhaps expect massive windfall\n",
      "\n",
      "Keywords:\n",
      "sting 0.533\n",
      "aduro 0.509\n",
      "chinook 0.292\n",
      "novartis 0.125\n",
      "combo trial 0.122\n",
      "pipeline 0.111\n",
      "aduro chinook 0.097\n",
      "nephropathy 0.093\n",
      "deal 0.091\n",
      "iga 0.089\n",
      "abbvie 0.075\n",
      "kidney disease 0.074\n",
      "combo 0.073\n",
      "undisclosed 0.07\n",
      "yervoy 0.065\n",
      "kidney 0.065\n",
      "development 0.065\n",
      "stake 0.059\n",
      "second half 0.059\n",
      "perhaps 0.056\n",
      "\n",
      "Abstract:\n",
      "u fda approved four therapy early last month cancer indication one deciphera qinlock approved three month early gastrointestinal stromal tumour fourth line treatment day blueprint competing project ayvakit received complete response letter expected wake failure pivotal voyager study qinlock real potential lie earlier line therapy second line study readout next year ayvakit meanwhile look like limited niche group patient specific mutation already approved another early win bristol myers squibb opdivo yervoy chemo triplet front line lung cancer approval based checkmate la study came despite ongoing question around yervoy brings regimen given known toxicity earlier month opdivo plus yervoy approved pd l expressers merck co keytruda already used monotherapy patient keytruda chemo combo approved comer lastly two targeted therapy greenlit early eli lilly ret inhibitor retevmo novartis met inhibitor tabrecta however come safety warning retevmo lilly gained loxo acquisition approved advanced ret driven lung thyroid cancer label includes warning qtc prolongation hypersensitivity haemorrhagic event analyst noted toxicity reported blueprint rival ret inhibitor pralsetinib pralsetinib due hear u approval lung cancer november blueprint plan file thyroid cancer month novartis tabrecta meanwhile greenlit early metastatic nsclc met exon skipping label includes precaution interstitial lung disease pneumonitis occurred patient phase ii geometry mono study experiencing grade side effect restriction oncology aside abbvie oriahnn became first approved gnrh receptor antagonist uterine fibroid end may however strict language surrounding contraindication potentially limit oriahnn use indeed project gnrh class according svbleerink analyst advised using drug include woman increased risk blood clot smoke uncontrolled hypertension oriahnn label discloses two thrombotic event phase iii program discussed previously one thrombosis calf pulmonary embolism probable event caused hormone add back therapy abt needed counteract menopause like symptom associated gnrh inhibition abt carry risk advised patient high bmi diabetes cardiovascular disease nonetheless contraindication smoker oriahnn expected analyst thromboembolic signal disclosed competitor myovant obseva date myovant relugolix combination abt filed uterine fibroid week obseva developing low dose version antagonist linzagolix without abt obseva hope excluding abt open linzagolix first line treatment although project safety issue term bone mineral density loss\n",
      "\n",
      "Keywords:\n",
      "abt 0.281\n",
      "oriahnn 0.237\n",
      "ret 0.162\n",
      "approved 0.154\n",
      "obseva 0.148\n",
      "gnrh 0.141\n",
      "blueprint 0.141\n",
      "lung 0.128\n",
      "yervoy 0.119\n",
      "thyroid cancer 0.118\n",
      "retevmo 0.118\n",
      "pralsetinib 0.118\n",
      "ret inhibitor 0.113\n",
      "greenlit 0.113\n",
      "advised 0.113\n",
      "cancer 0.11\n",
      "thyroid 0.104\n",
      "linzagolix 0.104\n",
      "line 0.102\n",
      "early 0.097\n",
      "\n",
      "Abstract:\n",
      "today u approval roche tecentriq avastin combo backed overall survival imbrave trial mark first immunotherapy first line liver cancer boost roche avastin lifecycle strategy well enabling group leapfrog merck co bristol myers squibb whose keytruda opdivo carry liver cancer label second line setting bristol failed checkmate front line opdivo monotherapy study however roche lead might last long judging data presented asco weekend front line liver cancer competition around corner next threat come astrazeneca hope report finding first line himalaya study later year test imfinzi monotherapy two combination anti ctla agent tremelimumab nexavar primary outcome overall survival though clear statistical powering split across trial various cohort asco astra provided way handicapping himalaya courtesy phase ii trial called study enrolled mixture first second line subject though effectively control cohort provide backing sort imfinzi tremelimumab combo fact alone put study rare category trial tremelimumab flop cohort tested study two regimen combo well imfinzi tremelimumab monotherapies limited run period combo highlight best median overall survival month seen patient given imfinzi plus mg tremelimumab regimen tested one arm himalaya curiously tremelimumab monotherapy yielded second best mo figure month baseline characteristic imbalanced treme monotherapy subject second line versus combo presenter said study showed remission regardless subject pd l status part merck relying eisai lenvima half keytruda combination front line liver cancer pivotal leap study approach compared lenvima monotherapy read asco merck presented poster keynote small uncontrolled trial keytruda plus lenvima yielded month mo subject experienced disease remission though phase trial effectively represented front line setting subject received prior systemic therapy one caveat merck second line label backed accelerated approval look questionable last year failure confirmatory phase iii trial keynote roche therefore lot going avastin combo must make window opportunity\n",
      "\n",
      "Keywords:\n",
      "tremelimumab 0.312\n",
      "liver cancer 0.214\n",
      "line 0.21\n",
      "combo 0.183\n",
      "monotherapy 0.169\n",
      "line liver cancer 0.166\n",
      "line liver 0.166\n",
      "lenvima 0.166\n",
      "himalaya 0.166\n",
      "imfinzi 0.163\n",
      "second line 0.148\n",
      "avastin 0.137\n",
      "front line 0.136\n",
      "liver 0.135\n",
      "front line liver 0.115\n",
      "avastin combo 0.115\n",
      "overall survival 0.11\n",
      "asco 0.104\n",
      "merck 0.103\n",
      "second 0.101\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Abstract:\n",
      "gilead investor used group antiviral remdesivir generating confusing contradictory datasets proved today study moderately ill covid patient delivered supposed win five day course drug perversely day regimen show significant benefit extent matter separate point course remdesivir already available u emergency use authorisation measure tackle coronavirus pandemic borderline efficacy suggested latest dataset clearly come short expectation gilead sat share price gain year date opened moderate covid result came month gilead trial severely ill subject suggested five day course remdesivir might helpful day treatment big caveat study control cohort wind change gilead remdesivir april mix clearly negative remdesivir study china robust controlled design terminated early anecdotal data emergency access positive trial run niaid last far biggest remdesivir dataset perhaps limited adaptive design latest finding gilead study moderately ill patient add understanding probably remdesivir activity overall game changer trial compared remdesivir dosed five consecutive day consecutive day standard care measured efficacy day primary endpoint efficacy measure change least one point seven point scale signifies death represents discharge hospital gilead said across course study five day cohort increase chance day clinical improvement versus control yielded p value gilead say statistical bar set whether met day group showed increase hit statistical significance apart apparent paradox finding absolute number day lay bare remdesivir borderline efficacy day patient saw least one point improvement versus five day course still respectable standard care confounding factor clearly depth analysis possible data published peer reviewed publication possible confounding factor include baseline imbalance three cohort fact subject enrolled study point moderate trial actually enrolment target patient similarly gilead severe trial yielded data recruiting target covid subject u fda may decision grant remdesivir emergency use authorisation related five day course drug patient hospitalised severe covid euas equivalent fda approval withdrawn quickly perhaps fuelling morning gilead selloff said stage coronavirus pandemic drug even borderline efficacy might enough remdesivir likely still meet low bar\n",
      "\n",
      "Keywords:\n",
      "remdesivir 0.405\n",
      "day 0.291\n",
      "gilead 0.221\n",
      "five day 0.218\n",
      "five day course 0.215\n",
      "day course 0.215\n",
      "five 0.145\n",
      "borderline 0.142\n",
      "ill 0.128\n",
      "course 0.116\n",
      "improvement versus 0.107\n",
      "emergency 0.107\n",
      "least one point 0.102\n",
      "course remdesivir 0.102\n",
      "confounding factor 0.102\n",
      "point 0.099\n",
      "one point 0.095\n",
      "confounding 0.095\n",
      "efficacy 0.093\n",
      "clearly 0.089\n",
      "\n",
      "Abstract:\n",
      "enhertu associated big number bn astrazeneca paid daiichi sankyo secure right targeting agent billion sale sellside forecast example clinical realm asco year response rate reported three tumour impressively high analyst sale projection arguably swelled deal term competitive efficacy harder refute two physician discussing enhertu data virtual asco weekend acknowledged much however lung toxicity still leading patient death despite side effect well documented daiichi astra face challenge moving enhertu valuable earlier treatment setting surely required enhertu meet current forecast see global sale topping bn according evaluatepharma sellside consensus notable projection comprises different outlook minimum maximum forecast around higher lower bn average bank number low end range assume enhertu never move beyond last resort therapy certain disease least benefit obviously outweigh risk three study detailed asco concerned type patient heavily pretreated running option destiny crc example colorectal cancer patient received least four line prior therapy received destiny lung subject two prior treatment sixth lung result received perhaps effusive reception look waterfall plot response show almost patient responded objective remission rate hitting median progression free survival hitting month dr benjamin levy john hopkins reviewing trial asco described enhertu best drug mind evaluated mutated lung cancer\n",
      "\n",
      "Keywords:\n",
      "enhertu 0.466\n",
      "asco 0.214\n",
      "lung 0.201\n",
      "projection 0.17\n",
      "destiny 0.159\n",
      "daiichi 0.142\n",
      "received 0.142\n",
      "hitting 0.119\n",
      "prior 0.112\n",
      "forecast 0.108\n",
      "sale 0.098\n",
      "example 0.091\n",
      "realm 0.089\n",
      "comprises different 0.089\n",
      "patient 0.088\n",
      "two prior 0.085\n",
      "plot 0.085\n",
      "patient responded 0.085\n",
      "patient death 0.085\n",
      "john 0.085\n",
      "\n",
      "Abstract:\n",
      "ibrance big deal pfizer might never much bigger one great deal riding pallas study breast cancer blockbuster early disease finding interim analysis suggesting trial unlikely succeed knocked group badly pallas along another study called penelope b assessing ibrance utility adjuvant treatment alongside endocrine therapy january company said approval setting double number patient eligible treatment cdk inhibitor look doubtful pfizer stock early trading ibrance approved globally metastatic hr positive negative breast cancer sold bn pfizer last year group running pallas penelope b hope would allow drug approval earlier treatment sequence partly owing expectation sellside pencilled sale bn according evaluatepharma consensus pallas randomised nearly subject hr positive negative early breast cancer daily ibrance mg pill three week followed week treatment cycle continued two year addition standard adjuvant endocrine therapy endocrine therapy alone aim show significant improvement invasive disease free survival growth driver seems going happen implication ongoing penelope b setting slightly different population good even penelope b hit lesser prize patient population corresponding trial thought around strong g country pallas hit addressable g population would like patient crumb comfort fact expectation similar trial competing drug lilly monarche study verzenio novartis natalee trial kisquali earth shattering either real issue pallas failure mean pfizer growth expectation chief executive albert bourla insisted highly confident pfizer still deliver goal least revenue growth year need hit target pile even pressure group high profile project braftovi mektovi eczema asset abrocitinib abrocitinib acquitted well regeneron dupixent phase iii jade compare trial though jak without safety concern according evaluatepharma sellside consensus forecast stand long way behind billion expected ibrance pallas succeeded\n",
      "\n",
      "Keywords:\n",
      "pallas 0.426\n",
      "penelope 0.267\n",
      "ibrance 0.265\n",
      "endocrine therapy 0.2\n",
      "endocrine 0.183\n",
      "pfizer 0.149\n",
      "hr positive negative 0.122\n",
      "hr positive 0.122\n",
      "breast cancer 0.12\n",
      "breast 0.119\n",
      "abrocitinib 0.114\n",
      "growth 0.114\n",
      "positive negative 0.108\n",
      "hr 0.108\n",
      "expectation 0.105\n",
      "adjuvant 0.095\n",
      "population 0.09\n",
      "treatment 0.086\n",
      "hit 0.079\n",
      "negative 0.077\n",
      "\n",
      "Abstract:\n",
      "former celgene investor fret whether bristol myers squibb get ide cel approved time trigger contingent value right company takeover asco showed competition product would likely face market multiple myeloma space ide cel attempting break already look competitive bcma targeting car therapy show asco ide cel overshadowed johnson johnson jnj latter cartitude study last year yielded overall remission rate since thing got better today virtual asco presentation revealed headline efficacy number complete responder strong cartitude dataset asco abstract earlier data cut reported complete remission detailed last year ash meeting ash johnson johnson overshadows bluebird registrational reveal december deepening response seen highly promising cross trial basis look efficacious anti bcma car project relapsed refractory multiple myeloma jnj phase iii cartitude study course efficacy larger trial sort likely fall jnj bristol bluebird ide cel registrational karmma study highlighted asco showed deepening response overall remission rate rising two complete response versus revealed press release last december safety side two study still reporting one death due cytokine release one additional death due disease progression noted cartitude result aml said treatment unrelated since ide cel uncontrolled karmma trial registrational comparison sort made patient would likely fared end asco saw separate retrospective presentation cohort real world multiple myeloma patient said meet karmma eligibility criterion showed overall response various therapy asco saw long awaited update bristol second anti bcma car therapy orva cel used coded jcarh originated juno orva cel phase ii evolve trial evaluable subject said complete remission partial remission however two death look possibly treatment related one cardiac arrest withdrawal consent one due macrophage activation syndrome separate point still early judge long term durability many therapy though suffering relapse degree evolve responder far relapsed though eight low dose none far seen shorter follow high dose bristol might proceed two asset unclear though ide cel clearly important focus making orva cel possible back interestingly j j back sort form anti bcma bispecific duobody jnj little clinical data revealed far asco presentation show seven nine patient responding highest dose one death respiratory failure might reasonable expect bispecific mab match efficacy car long term threat come earlier use treatment priced car similar vein glaxosmithkline pinning hope anti bcma antibody drug conjugate belantamab example luck would bristol recently amended protocol evolve trial orva cel include cohort patient progressed prior bcma directed therapy\n",
      "\n",
      "Keywords:\n",
      "cel 0.351\n",
      "ide cel 0.223\n",
      "ide 0.223\n",
      "bcma 0.218\n",
      "asco 0.214\n",
      "orva cel 0.187\n",
      "orva 0.187\n",
      "cartitude 0.165\n",
      "anti bcma 0.152\n",
      "jnj 0.149\n",
      "car 0.136\n",
      "remission 0.122\n",
      "karmma 0.12\n",
      "bristol 0.105\n",
      "johnson 0.104\n",
      "registrational 0.1\n",
      "myeloma 0.099\n",
      "multiple myeloma 0.099\n",
      "asco showed 0.093\n",
      "death 0.093\n",
      "\n",
      "Abstract:\n",
      "half data available merck co keynote study keytruda seems premature say result change clinical practice yet researcher claiming late breaking asco presentation hail keytruda new standard care first line msi high mmrd colorectal cancer three year ago keytruda approved msi high mmrd cancer becoming first oncology drug secure tumour agnostic label though second line setting keynote toplined april co primary endpoint progression free overall survival said positive asco data alter situation however quantify extent benefit keytruda confers amount month median pfs versus month chemotherapy control unveiled asco late breaker reveals importantly subject derived especially strong pfs benefit resulting continued separation survival curve median reached accordingly reduction risk progression across subject p said keynote lead author dr thierry andr h pital saint antoine paris however nothing revealed keytruda effect keynote second co primary measure o presumably data insufficiently mature indeed widening pfs curve time show likely enough death derive much meaning o analysis study met one two primary endpoint definitively positive trial dr andr told asco press briefing past medical treatment shown difference term improvement pfs metastatic colorectal cancer keytruda new standard care patient cured metastatic disease bold statement backed fact astonishing keytruda recipient appear still free disease month another peculiar feature pfs curve cross early suggesting disease keytruda patient initially progress faster chemo though pseudoprogression keynote continue final analysis point o evaluated absence o data another key factor keytruda favour safety grade higher treatment related adverse event seen keytruda subject versus chemo control battleground msi miscrosatellite instability high mmrd mismatch repair deficient cancer turned something battleground merck bristol myers squibb shortly keytruda second line tumour agnostic approval opdivo monotherapy combined yervoy secured second line label specifically colorectal cancer msi high mmrd difference might slight msi high mmrd tumour mainly comprise colorectal cancer accounting early metastatic stage iv disease bristol running phase iii trial checkmate hw msi high mmrd colorectal cancer includes front line subject apart appear significant immediate challenger keytruda space last month merck said would move share keynote data regulator tends code filing whether u fda give green light without waiting o analysis main question\n",
      "\n",
      "Keywords:\n",
      "keytruda 0.289\n",
      "mmrd 0.273\n",
      "high mmrd 0.273\n",
      "msi 0.26\n",
      "msi high mmrd 0.228\n",
      "msi high 0.228\n",
      "keynote 0.171\n",
      "colorectal cancer 0.166\n",
      "colorectal 0.163\n",
      "pfs 0.159\n",
      "cancer 0.118\n",
      "curve 0.111\n",
      "asco 0.105\n",
      "metastatic 0.095\n",
      "high 0.094\n",
      "tumour agnostic 0.091\n",
      "mmrd colorectal cancer 0.091\n",
      "mmrd colorectal 0.091\n",
      "keytruda new standard 0.091\n",
      "keytruda new 0.091\n",
      "\n",
      "Abstract:\n",
      "half data available merck co keynote study keytruda seems premature say result change clinical practice yet researcher claiming late breaking asco presentation hail keytruda new standard care first line msi high mmrd colorectal cancer three year ago keytruda approved msi high mmrd cancer becoming first oncology drug secure tumour agnostic label though second line setting keynote toplined april co primary endpoint progression free overall survival said positive asco data alter situation however quantify extent benefit keytruda confers amount month median pfs versus month chemotherapy control unveiled asco late breaker reveals importantly subject derived especially strong pfs benefit resulting continued separation survival curve median reached accordingly reduction risk progression across subject p said keynote lead author dr thierry andr h pital saint antoine paris however nothing revealed keytruda effect keynote second co primary measure o presumably data insufficiently mature indeed widening pfs curve time show likely enough death derive much meaning o analysis study met one two primary endpoint definitively positive trial dr andr told asco press briefing past medical treatment shown difference term improvement pfs metastatic colorectal cancer keytruda new standard care patient cured metastatic disease bold statement backed fact astonishing keytruda recipient appear still free disease month another peculiar feature pfs curve cross early suggesting disease keytruda patient initially progress faster chemo though pseudoprogression keynote continue final analysis point o evaluated absence o data another key factor keytruda favour safety grade higher treatment related adverse event seen keytruda subject versus chemo control battleground msi miscrosatellite instability high mmrd mismatch repair deficient cancer turned something battleground merck bristol myers squibb shortly keytruda second line tumour agnostic approval opdivo monotherapy combined yervoy secured second line label specifically colorectal cancer msi high mmrd difference might slight msi high mmrd tumour mainly comprise colorectal cancer accounting early metastatic stage iv disease bristol running phase iii trial checkmate hw msi high mmrd colorectal cancer includes front line subject apart appear significant immediate challenger keytruda space last month merck said would move share keynote data regulator tends code filing whether u fda give green light without waiting o analysis main question\n",
      "\n",
      "Keywords:\n",
      "keytruda 0.289\n",
      "mmrd 0.273\n",
      "high mmrd 0.273\n",
      "msi 0.26\n",
      "msi high mmrd 0.228\n",
      "msi high 0.228\n",
      "keynote 0.171\n",
      "colorectal cancer 0.166\n",
      "colorectal 0.163\n",
      "pfs 0.159\n",
      "cancer 0.118\n",
      "curve 0.111\n",
      "asco 0.105\n",
      "metastatic 0.095\n",
      "high 0.094\n",
      "tumour agnostic 0.091\n",
      "mmrd colorectal cancer 0.091\n",
      "mmrd colorectal 0.091\n",
      "keytruda new standard 0.091\n",
      "keytruda new 0.091\n",
      "\n",
      "Abstract:\n",
      "fewer first time nine supplemental approval decision pending u fda june halfway point last year first market product approved number look little healthier even covid pandemic tally far first time approval june still come interesting outcome expected supplemental decision including use novartis subcutaneous formulation ofatumumab arzerra active ingredient multiple sclerosis pivotal study asclepios ii showed reduction annualised relapse rate versus sanofi aubagio relapsing m aubagio low bar beat roche blockbuster ocrevus anti cd mab like arzerra market relapsing progressive form m since bn forecast biggest seller relapsing m novartis project take third place sale bn according evaluatepharma sellside consensus reprieve mab intravenous version disappointed cll due decision epizyme oral ezh inhibitor tazverik follicular lymphoma much bigger opportunity indication drug approved epithelioid sarcoma phase ii study least third line subject objective response rate patient ezh mutation wild type ezh filing accepted without need companion diagnostic analyst think clinician may opt test ezh treatment leerink note tazverik much better tolerability profile convenient administration drug class p k inhibitor support full approval adaptive trial run combining tazverik revlimid plus rituxan pending judgement keytruda advanced cutaneous squamous cell carcinoma cscc based data keynote study showed objective response rate cscc aggressive tumour regeneron sanofi libtayo pd antibody currently approved basis orr first timer intercept nash project obeticholic acid available ocaliva primary biliary cholangitis panel pdufa date set june adcom postponed additional data request fda approval decision date likely missed second slip panel initially scheduled april delayed covid pandemic astrazeneca spinout viela bio first approved product next month anti cd mab inebilizumab filed neuromyelitis optica spectrum disorder nmosd rare autoimmune condition often lead irreversible blindness paralysis filing based pivotal n momentum trial inebilizumab reduced risk developing nmosd attack versus placebo aquaporin positive patient week treatment aquaporin antibody key biomarker disease viela bio close competition u market comprises around patient alexion soliris gained approval aquaporin positive nmosd last june follow ultomiris phase iii roche satralizumab filed last august decision project expected year though date given another eye drug abbvie abicipar review wet age related macular degeneration came abbvie acquisition allergan two phase iii trial cedar sequoia met primary endpoint showing non inferiority roche older amd therapy lucentis vision stability question vision loss evaluated well higher incidence intraocular inflammation abicipar third study maple used new formulation rate inflammation still well regeneron eylea eylea dominant drug wet amd competition become fiercer biosimilar version lucentis eylea hit market expected respectively table list rest first time approval due june consensus forecast evaluatepharma\n",
      "\n",
      "Keywords:\n",
      "ezh 0.239\n",
      "tazverik 0.179\n",
      "nmosd 0.179\n",
      "aquaporin 0.179\n",
      "eylea 0.153\n",
      "june 0.15\n",
      "relapsing 0.14\n",
      "decision 0.13\n",
      "first time 0.118\n",
      "approval 0.112\n",
      "viela 0.112\n",
      "time approval 0.112\n",
      "arzerra 0.112\n",
      "aubagio 0.106\n",
      "lucentis 0.102\n",
      "supplemental 0.099\n",
      "objective response rate 0.099\n",
      "objective response 0.093\n",
      "vision 0.085\n",
      "inflammation 0.085\n",
      "\n",
      "Abstract:\n",
      "adaura trial astrazeneca tagrisso egfr mutated lung cancer stopped two year early overwhelming efficacy last month promptly chosen top plenary presentation year asco full result show study tested tagrisso adjuvant treatment surgery generated reduction risk disease recurrence sellside analyst already added billion dollar drug sale forecast promise result another important early stage study horizon consensus rise aim adjuvant therapy prevent disease recurrence patient receive intervention question relatively long period certainly compared metastatic use adaura designed test three year treatment duration example partly explains win considered important financial analyst consensus sale jumped bn last month according evaluatepharma study focused big slice non small cell lung cancer population recruited subject stage ib ii iiia nsclc account around population presenting disease patient egfr mutation course tagrisso work however thought patient u europe around asia harbour genetic signal tumour stage removed surgery cancer tends recur adjuvant cisplatin based chemotherapy current standard care carry substantial toxicity although adaura stopped early completed enrolment patient followed least year tagrisso unequivocally demonstrated potential disease free survival two year tagrisso compared placebo look survival curve show decision stop early taken result presented full sunday asco virtual plenary session\n",
      "\n",
      "Keywords:\n",
      "tagrisso 0.344\n",
      "adaura 0.259\n",
      "adjuvant 0.185\n",
      "plenary 0.173\n",
      "recurrence 0.152\n",
      "egfr 0.137\n",
      "surgery 0.135\n",
      "stopped 0.126\n",
      "early 0.113\n",
      "disease 0.106\n",
      "lung cancer 0.104\n",
      "two year 0.1\n",
      "asco 0.099\n",
      "stage 0.098\n",
      "compared 0.097\n",
      "cancer 0.096\n",
      "last month 0.094\n",
      "lung 0.093\n",
      "test three 0.082\n",
      "subject stage 0.082\n",
      "\n",
      "Abstract:\n",
      "yesterday early u approval bristol myers squibb opdivo yervoy chemo triplet front line lung cancer brought second surprise trial based checkmate la kept wrap weekend asco conference drug updated prescribing information revealed label discloses obvious point interest like survival curve detailed adverse event data lay bare checkmate la design flaw triplet compared chemo alone prescribers way telling opdivo plus chemo without yervoy might stacked precisely yervoy brings table big part study discussion asco unfortunately way answering question accurately first line nsclc trial tested opdivo plus chemo part controversially overhauled checkmate study whose part separately backed month u approval opdivo plus yervoy pd l expressers bristol persistence pay relevance limited may final analysis checkmate part presented last year esmo immuno oncology congress revealed month median overall survival opdivo plus chemo versus chemo alone effect course lacked statistical significance meanwhile checkmate la opdivo yervoy chemo triplet yielded month median overall survival versus chemo alone giving highly statistically significant reduction risk death importantly varying baseline patient characteristic subtle difference chemo regiment direct comparison la part make particularly difficult cross trial analysis indeed chemo control cohort seem performed differently two study however right look like way splitting yervoy added benefit bald unsophisticated upshot overall survival term triplet beat chemo month whereas opdivo chemo doublet beat month worth continue unsatisfactory cross trial analysis net month gained adding yervoy worth part opdivo chemo recipient suffered treatment related grade adverse event point higher control corresponding number opdivo yervoy chemo triplet la course consideration purely theoretical doctor cannot prescribe first line nsclc patient opdivo plus chemo opdivo plus yervoy available long patient tumour show least pd l expression yesterday opdivo yervoy chemo triplet given comer still spanner work still come ema carrying review checkmate la ema earlier dismissed bristol attempt secure approval based checkmate causing filing withdrawn well slating earlier combo trial discern individual constituent contribution verdict la interesting relevant decision u whether prescribe bristol combo preference merck co keytruda available monotherapy pd l expressers chemo combo comer detract design shortcoming checkmate la\n",
      "\n",
      "Keywords:\n",
      "chemo 0.412\n",
      "opdivo 0.267\n",
      "yervoy 0.264\n",
      "la 0.263\n",
      "checkmate 0.2\n",
      "triplet 0.178\n",
      "opdivo plus 0.175\n",
      "checkmate la 0.174\n",
      "opdivo plus chemo 0.169\n",
      "yervoy chemo triplet 0.158\n",
      "opdivo yervoy chemo 0.158\n",
      "chemo triplet 0.158\n",
      "yervoy chemo 0.144\n",
      "opdivo yervoy 0.131\n",
      "plus chemo 0.125\n",
      "part 0.109\n",
      "plus 0.106\n",
      "chemo alone 0.092\n",
      "opdivo chemo 0.079\n",
      "cross trial analysis 0.079\n",
      "\n",
      "Abstract:\n",
      "investor catch scent buyout air collaboration agreement come bit disappointment arcus bioscience whose value tripled far year helped markedly rumour mid april gilead science considering purchasing stake company event gilead spending get stake around cancer focused biotech alongside year partnership co develop candidate arcus pipeline including anti pd anti tigit antibody biodollar value collaboration billion front portion reflecting disappointment given priced stock arcus trading morning conference call today group management emphasised advantage wide ranging collaboration single partner particularly strategic combination asset combination dear arcus heart checkpoint inhibitor zimberelimab studied combination tigit ab advanced solid tumour trial triplet two plus ab adenosine b receptor antagonist nsclc due yield interim data towards end year future combination gilead asset including obtained via acquisition forty seven march might end investigated yet unclear tigit spinner tigit inhibitor ab subject much excitement since roche made faith mechanism clear beginning year gilead might hankering project class chief executive daniel day came roche keen put gilead equal footing former company yearning might increased data roche anti tigit tiragolumab revealed asco abstract went live fortnight ago asco first line lung cancer focus may william grossman arcus chief medical officer said company excited roche data particularly signal seen pd l high population said support arcus strategy enrolling pd l positive nsclc patient triplet trial arc group bullish anti pd zimberelimab looking like commercial pd l agent whether look keytruda opdivo data generated u look indistinguishable said arcus chief executive terry rosen bold statement gilead agrees right opt project co developing co promoting arcus u gaining exclusive right territory gilead turn arcus free seek partner asset far zimberelimab agent arcus pipeline attracted forecast sellside set sell worldwide presumably combo use according consensus compiled evaluatepharma\n",
      "\n",
      "Keywords:\n",
      "arcus 0.503\n",
      "tigit 0.251\n",
      "gilead 0.202\n",
      "zimberelimab 0.19\n",
      "pd 0.163\n",
      "ab 0.158\n",
      "collaboration 0.118\n",
      "combination 0.109\n",
      "anti tigit 0.103\n",
      "roche 0.099\n",
      "anti 0.097\n",
      "triplet 0.095\n",
      "chief 0.089\n",
      "anti pd 0.084\n",
      "co 0.078\n",
      "nsclc 0.077\n",
      "disappointment 0.077\n",
      "stake 0.076\n",
      "asco 0.072\n",
      "asset 0.068\n",
      "\n",
      "Abstract:\n",
      "paul hudson sanofi chief executive signalling hunt new asset announcing sale french company stake u biotech regeneron lock share due expire end year however rise regeneron stock past month must presented opportunity good miss biggest public offering healthcare history sanofi plan sell million regeneron share netting bn based friday closing price regeneron separately repurchasing bn stock sanofi potentially leaving french firm share u biotech writing wall hint partner conscious uncoupling dotted throughout sanofi recent investor update december mr hudson said group would adjust portfolio divestments announced would restructuring year old deal regeneron pcsk drug praluent rheumatoid arthritis treatment kevzara partnership royalty based arrangement time mr hudson said new set saw sanofi gain sole global right kevzara ex u right praluent would free french drug maker joint decision making around drug part mr hudson go alone strategy sanofi seen end partnership including lexicon google company verily however complete break sanofi hanging stake regeneron allowing admittedly small share u group future success joint right dupixent mr hudson previously outlined belief dupixent achieve bn annual sale although consensus forecast evaluatepharma see drug hitting bn ploughing furrow sanofi clear plan set new course leadership english chief executive alongside deprioritising diabetes cardiovascular product mr hudson said group focus lucrative area oncology rare disease mr hudson already made good pledge bn purchase biotech group synthorx immuno oncology pipeline however expectation novel technology deal might offing sanofi seek catch rival oncology gene therapy rare disease rumour billion dollar proceeds used help sanofi regain control stake l oreal hold french pharma giant turn corporate musical chair l oreal turn might use money sale sanofi stock buy back nestle stake mr hudson made plain ultimate goal simplify expand sanofi proceeds regeneron sale unlikely hang around group bank account long\n",
      "\n",
      "Keywords:\n",
      "hudson 0.396\n",
      "mr hudson 0.374\n",
      "sanofi 0.331\n",
      "regeneron 0.229\n",
      "mr 0.214\n",
      "mr hudson said 0.168\n",
      "hudson said 0.168\n",
      "french 0.166\n",
      "stake 0.135\n",
      "said group 0.112\n",
      "proceeds 0.107\n",
      "praluent 0.099\n",
      "kevzara 0.096\n",
      "joint 0.087\n",
      "dupixent 0.087\n",
      "partnership 0.084\n",
      "oncology 0.079\n",
      "bn 0.079\n",
      "sale 0.078\n",
      "group 0.077\n",
      "\n",
      "Abstract:\n",
      "atara got bogged delay lead project tab cel transformation car company cell therapy approach progressive multiple sclerosis took something back seat work continues recent result backed selection dose enough efficacy take forward data presented virtual european academy neurology week late breaking abstract went live friday multiple sclerosis might secondary consideration investor lost faith atara stock run week last week ean abstract drop latest result relate ata allogeneic cell therapy atara pining multiple sclerosis hope group autologous m project ata deprioritised dose finding part ata phase trial yielded data first time high dose million cell month two six subject cohort showed clinical improvement defined expanded disability status scale eds unveiled ean poster reveals better transformational showing improvement suggests patient experiencing slowing disease especially important progressive m still relatively intractable though roche ocrevus making important inroad treatment halting disease transformational reversing disease even better aj joshi atara head clinical development told evaluate vantage across subject four cohort two deterioration eds score rest either improved stable atara told investor call today ata comprises donor cell sensitised epstein barr virus ebv antigen hla typed matched recipient atara argues recognise eliminate ebv infected b cell involvement ebv m put forward dr michael pender university queensland australia first clinical safety data ata released year ago last september ectrims meeting atara presented six month efficacy result first two cohort showing first hint activity ean finding updated showing one eds improvement five million cell cohort none subject given million cell cohort study million cell far two six subject showing eds improvement however six month yet confirmed month reading based modified score composite measure including eds atara decided take cohort dose next randomised placebo controlled stage study mr joshi said trial adaptive design retained possibility adding cohort dose subsequent data suggested benefit ready make switch toxicity signal said mr joshi next stage atara ata trial see initial subject recruited time next year month readout looking various measure addition eds including lumbar puncture data result ata study announced three participant experienced clinical improvement measured decreased eds score mr joshi stressed le robust investigator initiated trial comprised initial six month reading whether autologous therapy like ata future separate question allogeneic clearly way go large space like m said mr joshi updated version story first appeared friday\n",
      "\n",
      "Keywords:\n",
      "atara 0.417\n",
      "ata 0.371\n",
      "eds 0.325\n",
      "joshi 0.232\n",
      "mr joshi 0.185\n",
      "million cell 0.185\n",
      "cell 0.142\n",
      "ean 0.139\n",
      "ebv 0.13\n",
      "cohort 0.127\n",
      "million 0.114\n",
      "improvement 0.105\n",
      "six 0.101\n",
      "multiple sclerosis 0.095\n",
      "mr 0.094\n",
      "sclerosis 0.089\n",
      "showing 0.088\n",
      "cohort dose 0.087\n",
      "two six 0.083\n",
      "dose 0.082\n",
      "\n",
      "Abstract:\n",
      "belgian biotech argenx attracted pretty lofty expectation past two year happily investor bid company market cap similarly exuberant bn first set data lead project disappointed efgartigimod antibody fragment block fcrn improved symptom big proportion patient myasthenia gravis regulatory approval u sought later year rival nipping argenx heel shaping highly competitive space company look comfortably front adapt study tested efgartigimod placebo patient advanced myasthenia gravis mg neurological condition cause certain muscle weaken progressively primary endpoint percentage patient improved least two point mg adl symptom scale eight week significantly efgartigimod treated patient hit measure placebo group p almost subject met criterion active arm versus almost placebo cohort point difference likely provide yardstick sort project coming behind safety look hard beat argenx described efgartigimod similar placebo indeed common event headache stuffy nose nausea reported similar rate arm secondary endpoint almost unequivocally positive duration effect full week study missed statistical significance call afternoon company executive blamed use log rank test failure patient responding week week durability seems unlikely concern\n",
      "\n",
      "Keywords:\n",
      "efgartigimod 0.352\n",
      "argenx 0.255\n",
      "myasthenia gravis 0.184\n",
      "myasthenia 0.184\n",
      "gravis 0.184\n",
      "placebo 0.148\n",
      "almost 0.143\n",
      "improved 0.128\n",
      "week 0.124\n",
      "patient 0.114\n",
      "symptom 0.11\n",
      "mg adl 0.096\n",
      "call afternoon 0.096\n",
      "mg 0.094\n",
      "arm 0.094\n",
      "yardstick 0.092\n",
      "safety look 0.092\n",
      "point difference 0.092\n",
      "past two year 0.092\n",
      "nose 0.092\n",
      "\n",
      "Abstract:\n",
      "perhaps biggest question merck co entering covid vaccine race took long today u pharma giant announced raft coronavirus work including two vaccine one antiviral signalling intention tackling virus merck going hit ground running keep pace make headway crowded field already company clinic vaccine like moderna astrazeneca already announced human trial astra hoping start phase iii july however u pharma giant advantage rival manufacturing capacity group second biggest global vaccine maker glaxosmithkline effort clinic successful well equipped undertake rapid scale distribution potentially vaccinating billion people require speed current vaccine development mean merck unlikely first finish taking measured approach might achieve efficacious vaccine important covid become seasonal virus group appears keen come single dose vaccine potential advantage million billion people need protected first three separate announcement merck today said secured one vaccine candidate collaboration non profit group iavi work recombinant vsv technology choosing iavi make sense rvsv approach merck already used gain approval ebola zaire virus vaccine vaccine added roster come via acquisition private biotech company themis two company already relationship collaboration develop vaccine candidate using themis measles virus vector merck taking covid vaccine development using approach vaccine candidate start clinical trial later year merck leading regulatory filing step vaccine developer group secured funded barda collaboration iavi cover base merck announced collaboration ridgeback biotherapeutics develop oral antiviral eidd advanced merck new covid asset phase trial started early april result come summer sure closely watched project shown effect animal model sars mers merck finally moving rapidly progress surely compared big pharma group astrazenca teamed oxford university expects result study volunteer azd vaccine soon glaxo sanofi hope start human trial second half year aim working product end investor merck already warned group stand lose bn pharma revenue year covid pandemic hope group traditionally cautious approach yield better result rival eventually see tortoise beat hare\n",
      "\n",
      "Keywords:\n",
      "vaccine 0.45\n",
      "merck 0.292\n",
      "iavi 0.179\n",
      "virus 0.156\n",
      "collaboration 0.156\n",
      "vaccine candidate 0.147\n",
      "billion people 0.126\n",
      "group 0.121\n",
      "covid 0.12\n",
      "themis 0.119\n",
      "merck already 0.119\n",
      "human trial 0.119\n",
      "pharma 0.102\n",
      "approach 0.101\n",
      "already 0.099\n",
      "announced 0.098\n",
      "candidate 0.093\n",
      "vaccine development 0.091\n",
      "pharma giant 0.091\n",
      "secured 0.087\n",
      "\n",
      "Abstract:\n",
      "broad prostate cancer label surprising aspect week u approval lynparza close reading parp inhibitor pivotal profound study reveals question around treatment option control subject yet product new label largely gloss concern astrazeneca merck co drug approval week surprising mostly included use patient derived little benefit lynparza profound question whether prescribers happy simply follow lynparza label stand label allows lynparza used prostate cancer patient failed xtandi zytiga amounting best second line setting long carry hrr mutation hrr includes brca addition various mutation atm bard chek evaluate vantage argued approval hrr mutant controversial nejm paper discussing profound revealed benefit non brca hrr mutant particular atm positive prostate cancer borderline even nonexistent lynparza prostate cancer surprise may statement emailed vantage astra said individual gene analysis exploratory profound comparison may confounded multiple factor including lack stratification imbalance prognostic factor goal bring treatment many patient possible may derive benefit control question separate equally pressing issue concern profound control cohort lynparza label claim profound subject progressed xtandi zytiga randomised either lynparza control group physician choice xtandi zytiga obvious concern little evidence suggesting patient failed xtandi zytiga might later respond either drug best must assumed control subject failed xtandi got zytiga rather xtandi vice versa though neither nejm label spell adding concern clinicaltrials gov say profound actually allowed enrolment subject failed xtandi zytiga nejm reveals nearly fifth control arm patient study fact already failed one drug answering question rationale enrolling subject xtandi zytiga control arm astra said profound designed reflect real world clinical practice using xtandi zytiga comparator represents real world treatment sequencing failed option limited might well case patient already failed taxane however profound prior taxane use allowed mandated nejm paper point around profound enrolees failed taxane drug left considerable chunk taxane naive yet profound control arm would allowed option taxane mention drug like platinum agent instead would got drug little chance responding already failed overall retreatment xtandi zytiga taxane initial xtandi zytiga failure ideal astra said patient chemotherapy eg taxane platinum option fit choose go route dr vinay prasad haematologist oncologist oregon health science university school medicine frequent critic oncology study design strongly disagreed podcast slammed profound dr prasad called trial control arm deeply almost delinquently inappropriate bad medicine might well given control arm patient sugar pill neglected care vantage separately emailed statement london institute cancer research whose professor johann de bono cited lead author nejm paper quote attributed professor de bono lynparza approval described perfect example understanding genetics patient cancer used target disease achilles heel personalise treatment yesterday morning vantage put concern breadth approval profound control cohort institute cancer research time going press today yet receive reply\n",
      "\n",
      "Keywords:\n",
      "profound 0.419\n",
      "xtandi 0.319\n",
      "zytiga 0.31\n",
      "xtandi zytiga 0.29\n",
      "taxane 0.226\n",
      "lynparza 0.2\n",
      "control 0.176\n",
      "hrr 0.136\n",
      "failed xtandi 0.136\n",
      "nejm 0.132\n",
      "control arm 0.13\n",
      "failed 0.12\n",
      "profound control 0.109\n",
      "nejm paper 0.102\n",
      "failed xtandi zytiga 0.102\n",
      "prostate cancer 0.097\n",
      "prostate 0.094\n",
      "astra said 0.093\n",
      "cancer 0.088\n",
      "already failed 0.087\n",
      "\n",
      "Abstract:\n",
      "three day moderna generated investor frenzy dribbling report neutralising antibody eight volunteer given covid vaccine astrazeneca come swinging message big pharma group anything better astra today revealed help develop produce coronavirus vaccine secured bn u government double granted moderna development programme promise unveil data shortly study volunteer threaten upstage moderna effort far vaccine astra involved cov chimp adenovirus vector based project development uk university oxford astra joined effort last month scale distribution deal call project azd speedy work today development another example speed industry effort tackle new coronavirus azd clinical trial began last month yet expected yield result shortly though admittedly astra say whether data subject available still positive strong phase iii study planned manufacturing capacity secured enable shipping september part moderna unveiled positive though preliminary finding handful volunteer niaid trial mrna vaccine mrna moderna reminds market biotech dual purpose may biotech group starting phase ii volunteer imminently yet finalise design phase iii test subsequently moderna came fire piecemeal way revealed finding press release stat point impossible put company finding context verify claim mrna elicited neutralising antibody level equivalent convalescent serum given wide variability patient recovered covid scale project moderna year agreement lonza target eventual production billion dos year long dose g astra seems want least match saying first agreement least million dos concluded manufacturing capacity secured one billion dos far thorny issue hand however vague moderna claim company seems convinced many potentially efficacious product oxford vaccine meanwhile come fire lack activity rhesus monkey study astra keen reverse perception report first human data separate controversy moderna secured u government agency barda yet still able tap investor bn today astra revealed bn barda funding uk group come similar criticism moderna certainly valid ask u throwing taxpayer money hugely well financed sometimes profitable corporate entity astra hinted quid pro quo saying covid vaccine would widely accessible around world equitable manner neither moderna tackled directly thorny issue vaccine would priced whether soon would profitable\n",
      "\n",
      "Keywords:\n",
      "moderna 0.378\n",
      "astra 0.277\n",
      "vaccine 0.208\n",
      "volunteer 0.173\n",
      "secured 0.173\n",
      "vaccine would 0.118\n",
      "fire 0.118\n",
      "profitable 0.11\n",
      "mrna 0.106\n",
      "manufacturing capacity 0.104\n",
      "barda 0.104\n",
      "effort 0.103\n",
      "neutralising antibody 0.097\n",
      "finding 0.097\n",
      "neutralising 0.095\n",
      "capacity 0.093\n",
      "revealed 0.092\n",
      "oxford 0.089\n",
      "azd 0.088\n",
      "dos 0.088\n",
      "\n",
      "Abstract:\n",
      "filgotinib one safest jak inhibitor ulcerative colitis probably according result selection trial released late yesterday one effective much opinion confirmed share price slide galapagos stock morning jak inhibitor efficacy comparable filgotinib already market uc well abbvie rivoq much higher efficacy lower mg dose filgotinib failing hit primary endpoint leaf galapagos needing persuade regulator filgotinib reputation cleanest class worth reflecting prescribing label bragging right phase iib iii study enrolled adult moderate severe uc either previously taken biological biological naive initially randomised either placebo mg filgotinib daily mg daily week primary endpoint induction phase placebo compared remission responder randomised week maintenance filgotinib performance induction phase appears caused stock price movement mg dose failed beat placebo mg dose hit even performance higher dose slam dunk investor hoping week biological naive subject mg dose achieved placebo adjusted remission rate biological experienced patient achieved rate best filgotinib boast similar efficacy xeljanz caveat cross trial comparison withstanding worst filgotinib significantly lag abbvie rinvoq efficacy front three four bad abbvie jak october hindsight result released galapagos management tempted fate saying expecting filgotinib fall somewhere near placebo adjusted remission rate rinvoq miss measure compound concern filgotinib commercial potential uc even riding filgotinib much lauded safety profile cutting lot ice regulator selection trial project clean track record held similar bleeding herpes zoster infection gi issue across arm big question whether enough help avoid black box warning jak slapped many expecting gilead galapagos partner file u second half year however important manta manta ray study examining tescticular toxicity halted covid unclear regulator accept filing without safety data two study pertinent uc unlike arthritis disease tends affect younger patient take drug longer acing manta study would add valuable safety data speculated see product used earlier line disease giving competitive edge like xeljanz potentially boosting sale drug forecast generate revenue bn according sellside consensus figure evaluatepharma filgotinib might lost efficacy battle increasing uc sale still grasp\n",
      "\n",
      "Keywords:\n",
      "filgotinib 0.484\n",
      "uc 0.268\n",
      "biological 0.188\n",
      "mg 0.165\n",
      "jak 0.161\n",
      "manta 0.161\n",
      "mg dose 0.157\n",
      "galapagos 0.157\n",
      "placebo 0.108\n",
      "placebo mg 0.107\n",
      "dose 0.106\n",
      "xeljanz 0.103\n",
      "selection 0.099\n",
      "induction 0.099\n",
      "efficacy 0.097\n",
      "naive 0.092\n",
      "expecting 0.09\n",
      "remission 0.088\n",
      "abbvie 0.087\n",
      "rinvoq 0.086\n",
      "\n",
      "Abstract:\n",
      "company make big pharma reality vastly different size notably employee number starting abbvie bristol myers squibb mere staff member stats range johnson johnson year novartis came close matching u conglomerate sale alcon saw swiss firm become much smaller employer sale per employee generates different league table j j stand true company far best performer metric certainly worst astrazeneca win award fact sprawling company manages hold considerably smaller drugmakers course metric one many used compare company deemed peer group fact astrazeneca share price doubled last three year suggests investor unperturbed relative position analysis example fact sale per employee decade low decline metric astrazeneca occurred employee number climbing year peak sale dropped decade low wake series patent expiry still investor presumably hoping see company sale per employee increase coming year j j meanwhile managed improve sale per employee decade substantial top line growth even employee number risen currently sits range pfizer roche merck co eli lilly despite employing significantly people four time many case lilly remembered celgene acquisition yet properly reflected bristol myers performance measure company annual report record jump staff number biotech staff consolidated deal closed end november however bristol top line fully reflect takeover end year well propel bristol back realm abbvie second year row became big pharma company register sale per employee still argued abbvie actually like big biotech given reliance one biotechnology product relatively small top line sale employee number allergan acquisition yet reflected abbvie showing look big biotech company show sale per employee two firm dissimilar interesting biogen gilead generate pretty similar number company pressure boost top line biogen least improved sale per employee past year gilead heading firmly south huge hepatitis c franchise shrink sellside predicts gilead revenue trough year slowly climbing executive pressure make sure big biotech retains sort metric qualify growth stock however analysis show line big pharma big biotech many case blurring biogen big biotech company pay dividend example\n",
      "\n",
      "Keywords:\n",
      "employee 0.442\n",
      "sale per employee 0.329\n",
      "sale per 0.329\n",
      "per employee 0.329\n",
      "employee number 0.188\n",
      "big biotech 0.179\n",
      "per 0.171\n",
      "sale 0.154\n",
      "metric 0.132\n",
      "top line 0.13\n",
      "staff 0.113\n",
      "big 0.111\n",
      "biotech 0.104\n",
      "number 0.096\n",
      "company 0.092\n",
      "abbvie 0.09\n",
      "decade 0.088\n",
      "decade low 0.088\n",
      "top 0.087\n",
      "biogen 0.085\n",
      "\n",
      "Abstract:\n",
      "profound study presented last year esmo conference confirmed lynparza potential prostate cancer today formal approval setting nevertheless surprising breadth label allows treatment second line patient hrr mutation true profound showed astrazeneca merck co drug elicit huge progression free survival advantage hrr positive patient strongly driven brca mutation certain type hrr mutation atm benefit hard discern yet lynparza given patient battle parp inhibitor give lynparza dual advantage clovis rubraca lynparza used earlier five day ago u fda approved rubraca basis third line triton study clovis drug restricted brca mutated tumour primary endpoint beyond profound primary endpoint pfs patient brca atm mutation specific subtypes hrr met wide margin reduction risk progression p trial enrolled second line subject failed xtandi zytiga comparator zytiga xtandi profound enrolled wider group patient hrr mutation hrr mutant combined lynparza reduced risk progression problem largely benefit brca mutant driving overall result specifically single atm mutation instance median pfs increased negligible month hazard ratio meaning patient lynparza statistically likely progress control overall survival numerically favoured control atm mutant though survival curve crossed astra spokesperson earlier told evaluate vantage company filed broad hrr mutant label bring lynparza many patient possible interestingly full publication profound result nejm showed patient brca mutated cancer seemed derive marginal pfs benefit hand cdk mutation effect striking cdk gene strictly speaking function hrr pathway mutation affect hrr gene cdk mutation included broad hrr setting lynparza new prostate cancer label approval given lynparza advantage rubraca clovis second line prostate cancer trial triton read next attempted prostate cancer land grab front line setting lynparza propel study yield data next year testing zytiga combo versus zytiga alone crucial point propel enrols comer primary pfs endpoint applies intent treat population though subgroup analysis look specifically hrr mutant comer approach spokesperson said result phase ii trial showed lynparza zytiga combo extending pfs taxane progressed prostate cancer patient regardless hrr status either way earlier month losing ground glaxosmithkline zejula first line ovarian cancer maintenance lynparza found way save face\n",
      "\n",
      "Keywords:\n",
      "hrr 0.493\n",
      "lynparza 0.364\n",
      "mutation 0.217\n",
      "profound 0.195\n",
      "zytiga 0.187\n",
      "brca 0.176\n",
      "atm 0.156\n",
      "mutant 0.154\n",
      "prostate cancer 0.147\n",
      "prostate 0.143\n",
      "pfs 0.143\n",
      "hrr mutation 0.123\n",
      "hrr mutant 0.123\n",
      "rubraca 0.112\n",
      "cancer 0.107\n",
      "cdk 0.105\n",
      "clovis 0.103\n",
      "patient 0.087\n",
      "line 0.085\n",
      "patient brca 0.082\n",
      "\n",
      "Abstract:\n",
      "battle covid continues various clinical programme disrupted big data readout still play started pandemic hit evaluate vantage delf important event due next couple month major pharma player first novo nordisk semaglutide recently yielded encouraging mid stage result nash group hope add another string glp agonist bow time obesity data three late stage study step programme expected around middle year first look efficacy released last week impressive step study patient achieved total weight loss week comparison novo older glp agonist marketed obesity saxenda associated weight loss one company biggest hope increasing weight loss even amylin analogue phase ii dose ranging study expected report soon saxenda used active comparator according company combination semaglutide generate weight loss least early combination study report later year meanwhile bayer finerenone look entering narrowing opportunity diabetic kidney disease sglt inhibitor establishing beneficial class effect setting johnson johnson invokana first drug class win approval last year topline data finerenone first phase iii study due quarter second trial read early next year bayer hope finerenone reduce patient risk kidney failure cardiovascular death versus placebo result held invokana showed reduction risk end stage kidney disease reduction various cardiovascular event inflammatory disease ulcerative colitis roche dual action anti integrin antibody etrolizumab five phase iii trial etrolizumab pivotal programme need show differentiation competition takeda entyvio act one integrin etrolizumab placebo two study use humira control one remicade however pitted older anti tnf agent backward step newer mechanism expected dominate market coming year abbvie rinvoq jak inhibitor forecast lead market according evaluatepharma consensus phase iib iii study rinvoq showed statistically significant clinical remission per adapted mayo score highest dose versus placebo data two phase iii trial make rinvoq pivotal programme ulcerative colitis expected another jak inhibitor filgotinib gilead galapagos compete rinvoq topline data selection study due quarter rare disease sanofi hope defend place amicus pompe disease pivotal avalglucosidase alfa trial reading soon study treatment naive patient late onset disease pit avalglucosidase sanofi treatment myozyme lumizyme myozyme enzyme replacement therapy market since approved treatment rare disease forecast sale product reach bn according evaluatepharma sellside consensus forecast avalglucosidase alfa sit rise data impress myozyme approval based two small trial showed improvement ventilator free survival patient infantile onset disease versus untreated historical control competition horizon form amicus enzyme replacement therapy gaa rolling bla submission project late onset pompe disease begin second half phase iii data propel study needed support full approval expected next year gaa forecast table show additional second quarter event step programme step reported phase ii data nct\n",
      "\n",
      "Keywords:\n",
      "weight loss 0.173\n",
      "myozyme 0.157\n",
      "avalglucosidase 0.157\n",
      "step 0.151\n",
      "rinvoq 0.15\n",
      "finerenone 0.147\n",
      "etrolizumab 0.147\n",
      "weight 0.138\n",
      "disease 0.136\n",
      "study 0.113\n",
      "programme 0.11\n",
      "onset 0.11\n",
      "loss 0.11\n",
      "kidney 0.098\n",
      "integrin 0.098\n",
      "amicus 0.098\n",
      "alfa 0.098\n",
      "step programme 0.093\n",
      "saxenda 0.093\n",
      "enzyme replacement therapy 0.093\n",
      "\n",
      "Abstract:\n",
      "biotech exists develop new drug second equally important purpose raise money moreover money raised needed whenever possible case point moderna company whose valuation ballooned yesterday short bn back promising early covid vaccine data eight study volunteer though programme heavily financed u taxpayer moderna already bn bank equity raise bring bn swiftly followed course would unfair criticise management taking money investor throwing company indeed would strange biotech follow stock rise secondary offering involvement u government funding add uncomfortable dimension development though clear exactly much taxpayer provided far develop moderna covid vaccine mrna april contract u biomedical advanced research development authority fund advancement mrna fda licensure trial generated much excitement even sponsored company u niaid justified enthusiasm excitement justified possibly volunteer received mrna double g g dos single g dose according press release said seroconverted two week obviously promising mean subject producing binding antibody covid moreover first subject g g group producing level binding antibody equivalent higher seen blood people recovered covid however real test vaccine activity ability elicit neutralising antibody capable binding virus interfering ability infect cell data available eight subject g g group news good eight mrna elicited neutralising antibody grade adverse event grade toxicity amounted injection site redness g subject three event g however highest dose dropped moderna initial phase ii study test g g dos g commercial one yesterday phase ii plan changed g g big picture moderna seems left behind two covid vaccine rival sinovac university oxford astrazeneca generated controversy data preclinical main criticism moderna positive dataset extremely small cautious investor might fret company valuation price least mrna trial funded moderna remains relevant question u saw fit make significant award taxpayer money entity evidently already swimming cash one view might funding give u government part ownership resulting vaccine precedent set car therapy fanciful thinking perhaps tacit recognition fact historically vaccine development ended loss making value destroying industry moderna subsequent share price movement ability raise huge amount cash suggest always case\n",
      "\n",
      "Keywords:\n",
      "moderna 0.311\n",
      "vaccine 0.202\n",
      "mrna 0.2\n",
      "taxpayer 0.181\n",
      "binding 0.149\n",
      "money 0.142\n",
      "covid 0.134\n",
      "producing 0.128\n",
      "justified 0.128\n",
      "eight 0.127\n",
      "ability 0.123\n",
      "covid vaccine 0.121\n",
      "excitement 0.114\n",
      "antibody 0.111\n",
      "raise 0.11\n",
      "neutralising antibody 0.11\n",
      "neutralising 0.108\n",
      "volunteer 0.098\n",
      "moreover 0.094\n",
      "grade 0.094\n",
      "\n",
      "Abstract:\n",
      "glaxosmithkline majority owned specialist hiv company viiv healthcare struggling find response hiv powerhouse gilead whose product include biktarvy positive result hiv prophylaxis market come welcome victory today viiv said phase ii iii trial comparing monotherapy cabotegravir gilead market leading truvada known prep stopped early cabotegravir showed strong efficacy preventing new hiv infection patient hptn trial men sex men transgender woman compared daily oral truvada pill plus placebo injection two monthly cabotegravir injection three year participant study infection cabotegravir group versus truvada group represented incidence rate cabotegravir arm versus truvada arm making numerical reduction new infection rate non inferiority complex interesting note despite seeming strong showing cabotegravir claim non inferiority truvada original primary endpoint superiority truvada shifted non inferiority ensure datasets viiv submitted independent monitoring board complete impacted covid given bernstein forecasting pre exposure prophylaxis main engine near term growth hiv viiv disappointed denied chance prove superiority point analysis data ongoing however conference call today viiv keen point recommendation study monitoring board patient taking truvada trial offered cabotegravir prep market dominated truvada drug due lose patent protection september opening window host generic competitor gilead hoping shift patient second generation drug descovy given option lower cost alternative descovy marginal safety improvement truvada uptake forecast modest today data cabotegravir change market dynamic alongside strong showing today preventing new infection cabotegravir advantage dosed every two month improvement original monthly dosing previously tested provide valuable differentiator generic truvada patient struggle compliance daily pill remaining question however question people taking cabotegravir still managed become infected one theory individual lower body mass index eliminating drug body faster another hypothesis patient cabotegravir arm take oral dose five week study subject might failed comply whatever reason viiv examining data closely explanation body mass index impact drug effectiveness woman viiv running patient study woman africa hptn running month behind hptn looking clue around infection rate might wait covid almost certain impact data collection viiv scored important win hiv prevention interestingly monotherapy longitudinal study watched closely resistance issue\n",
      "\n",
      "Keywords:\n",
      "cabotegravir 0.477\n",
      "truvada 0.463\n",
      "viiv 0.371\n",
      "hiv 0.207\n",
      "hptn 0.139\n",
      "infection 0.124\n",
      "woman 0.101\n",
      "non inferiority 0.098\n",
      "inferiority 0.096\n",
      "body 0.092\n",
      "mass index 0.087\n",
      "infection rate 0.087\n",
      "body mass index 0.087\n",
      "body mass 0.087\n",
      "men 0.082\n",
      "monitoring board 0.076\n",
      "mass 0.074\n",
      "original 0.071\n",
      "monthly 0.071\n",
      "preventing 0.069\n",
      "\n",
      "Abstract:\n",
      "much lung cancer focus year virtual asco meeting non small cell histology roche tecentriq might challenged front line small cell disease ignored either one raise fresh concern deleterious effect inhibiting ctla courtesy data astrazeneca caspian trial despite several biotech continue investigate ctla albeit necessarily lung cancer early look asco abstract reveals still sclc merck co seems arguing keynote study keytruda positive though commercial potential likely zero keynote trial combining keytruda ctla inhibition chemo toplined january success progression free failure important overall survival endpoint merck said seemingly numerically positive reduction risk death meet statistical plan significance threshold disclose absolute time figure p value asco abstract however median o versus month p hazard ratio statistically non significant apparently merck assigned little alpha o analysis threshold significance set p abstract author add post hoc analysis yielded p value meet threshold elaborate conclude keytruda significantly prolonged o supporting benefit sclc ignoring intricacy statistical analysis month survival improvement seems offer little hope however underperforms even underwhelming two month benefit tecentriq approved impower study first line sclc battle roche astra imfinzi plus chemo combo approved march basis month o advantage one cohort caspian study second active cohort imfinzi chemo plus anti ctla mab tremelimumab doctor scrutinising asco subject actually worse chemo alone numerical term median o treme containing triplet versus month median pfs came month half month worse control fact rate adverse event leading discontinuation twice high triplet doublet control provides clue nevertheless research blocking ctla far dead innovent instance presenting data ctla mab ibi without pd mab sintilimab melanoma alligator xencor alphamab abstract ctla targeting bispecific antibody hint activity important patient already failed pd l blockade hope many datasets updated asco including cytomx alligator efficacy result abstract undisclosed virtual meeting late breaking abstract whose title known asco make public may still much play asco virtual conference take place may reading asco abstract dump trigger first move asco first line lung cancer focus asco early allogeneic car promise asco start take shape\n",
      "\n",
      "Keywords:\n",
      "asco 0.363\n",
      "ctla 0.273\n",
      "abstract 0.263\n",
      "sclc 0.164\n",
      "asco abstract 0.148\n",
      "chemo 0.141\n",
      "threshold 0.123\n",
      "lung cancer focus 0.115\n",
      "month 0.113\n",
      "ctla mab 0.109\n",
      "cancer focus 0.109\n",
      "alligator 0.109\n",
      "virtual 0.106\n",
      "caspian 0.105\n",
      "lung cancer 0.104\n",
      "versus month 0.094\n",
      "lung 0.093\n",
      "keytruda 0.091\n",
      "mab 0.088\n",
      "median 0.087\n",
      "\n",
      "Abstract:\n",
      "last night asco abstract dump revealed several result interest company pursuing first line non small cell lung cancer keenly awaited cityscape trial anti tigit mab tiragolumab instance show roche investing heavily project though real world relevance seems marginal roche important thing find way catching merck co keytruda similar consideration bristol myers squibb unveiled checkmate la study meant support approval opdivo plus yervoy chemo merck catching study stage iii nsclc show keytruda astrazeneca imfinzi sight tigit became closely watched immuno oncology target roche began wide ranging clinical programme tiragolumab year asco data supporting scant cityscape phase ii trial robust design tiragolumab plus tecentriq versus tecentriq alone good news roche addition tigit blockade pd l show additive effect term response rate median progression free survival bad strongly driven highest pd l expressers combo number look good tecentriq alone performs particularly badly first point particularly relevant pd l low subject efficacy pd l blockade need boosting yet tigit blockade appears add nothing providing clue cityscape enrolled pd l expressers roche phase iii tigit trial skyscraper enrols subject plus side tigit blockade appears add toxicity tecentriq plus tiragolumab combo look better keytruda already approved first line nsclc use arcus biotech tigit player traded strongly tandem roche tigit plan opened morning bristol case opdivo due double u fda verdict use st line nsclc first tomorrow yervoy combo based controversially overhauled checkmate trial august basis checkmate la study combining opdivo yervoy chemotherapy asco abstract reveals first efficacy data second trial since said succeeded last october improving overall survival indeed triple combo reduced risk death versus chemo alone p interim analysis reveals longer follow show improving picture median o versus month hazard ratio look promising approval like roche tigit hardly challenge keytruda whose chemo combo study keynote yielded reduction risk death versus chemo alone toxicity burden considerable checkmate la patient combo experienced grade toxicity versus control stage iii separate nsclc setting pre metastatic stage iii disease astra imfinzi carving niche thanks approval based pacific trial notwithstanding doubt benefit pd l non expressers threat checkpoint blocker looming asco reveals first data merck keynote trial keytruda regimen yielded remission rate six month o pacific imfinzi showed six month o orr important point keynote keytruda given chemoradiation whereas pacific enrolled subject already given chemoradiation progressed thus potential keytruda establish niche setting imfinzi approved keytruda already first line stage iii nsclc label courtesy keynote trial pd l patient candidate chemoradiation course keynote uncontrolled study cityscape checkmate la analysis comparison across different study possibly recruited differing patient population doubt data scrutinised asco being asco virtual conference take place may\n",
      "\n",
      "Keywords:\n",
      "tigit 0.312\n",
      "keytruda 0.185\n",
      "cityscape 0.174\n",
      "stage iii 0.166\n",
      "pd 0.157\n",
      "checkmate la 0.154\n",
      "asco 0.15\n",
      "tiragolumab 0.149\n",
      "la 0.145\n",
      "chemoradiation 0.14\n",
      "checkmate 0.138\n",
      "keynote 0.137\n",
      "nsclc 0.133\n",
      "combo 0.132\n",
      "tigit blockade 0.131\n",
      "roche 0.12\n",
      "pacific 0.119\n",
      "imfinzi 0.117\n",
      "blockade 0.114\n",
      "chemo 0.107\n",
      "\n",
      "Abstract:\n",
      "annual asco meeting prove volatile time drug stock despite cancer conference going virtual year still look likely deliver healthy flow market moving news abstract made public yesterday early beneficiary included allogene provided first look data shelf car project immunogen got boost encouraging result lead antibody drug conjugate downside however cytomx arvinas macrogenics fell heavily early trade pullback macrogenics almost inevitable company market cap tripled last week surprisingly detailed update trial would present macrogenics scoop asco bounce may later cut data due conference compared released abstract much remains learned two project feature remain early course toxicity particular key focus even dip morning macrogenics share remain two year high arvinas fell heavily data probably held mgc macrogenics anti b h bispecific prostate cancer arv mechanistically different described protein degrader androgen receptor psa response two patient seems underwhelming abstract detail two serious adverse event including case renal failure appears linked statin use drop morning cytomx look one biggest casualty company presentation three project asco disappointment around lack efficacy data highest profile one might playing part abstract bm ctla probody partnered bristol myers squibb contains toxicity data number project attempting improve known toxicity ctla inhibition show asco including bispecifics xencor alphamab share latter climbed hong kong today two cytomx abstract concern earlier stage wholly owned conjugate response rate appear underwhelming ocular toxicity confirmed signal watch cx company probody technology still largely unvalidated investor must hope full presentation reverse pre asco pessimism biggest pre asco bounce appears go allogene opened higher encouraging data lead car project allo lymphoma enjoying bounce immunogen present data antibody drug conjugate folate receptor alpha fr orr patient high fr expression look encouraging presentation attracting interest include amgen latest data kras project amg colorectal cancer orr look improved slightly presented esmo climbing although limited response tumour beyond colorectal lung cancer provide ammunition believe potential overblown elsewhere new data project recently acquired big pharma pull crowd gilead provide update magrolimab paid bn number point improvement update ash merck co provides first new data mk cost bn via peloton takeover hif inhibitor achieved response rate rare form renal cell carcinoma much headline grabbing data saved conference late breaking abstract text still wrap much still come asco investor plenty chew meantime look late breaker found asco start take shape asco virtual conference take place may\n",
      "\n",
      "Keywords:\n",
      "asco 0.302\n",
      "macrogenics 0.232\n",
      "abstract 0.229\n",
      "cytomx 0.16\n",
      "bounce 0.16\n",
      "data 0.136\n",
      "immunogen 0.117\n",
      "fr 0.117\n",
      "toxicity 0.112\n",
      "probody 0.111\n",
      "asco bounce 0.111\n",
      "allogene 0.111\n",
      "conjugate 0.108\n",
      "conference 0.104\n",
      "encouraging 0.104\n",
      "project 0.102\n",
      "update 0.1\n",
      "presentation 0.097\n",
      "look 0.093\n",
      "new data 0.091\n",
      "\n",
      "Abstract:\n",
      "one biggest question covid affecting work pharma company judging comment recent first quarter result industry biggest company answer much indeed many big pharma company taken surprisingly upbeat view pandemic first quarter notwithstanding decimation industry far merck co sole company deviating script cutting full year guidance hanging bn price expected reduction pharma sale much rest pharma buoyancy due short term boost top line wholesaler stockpiled product head future availability concern novartis bristol myers squibb glaxosmithkline lilly among reporting significantly increased first quarter demand bristol alone adding sale due covid related buying pattern must concerning pharma watcher future sale pattern settle beyond first quarter recent sale uplift bound unwind subsequent quarter would foolish expect volatility demand year go despite assurance company return normal second quarter doctor see one area demand already fallen physician hospital administered medicine merck full year pullback driven fact two third product physician administered patient concern going doctor office hospital compounded lockdown restriction case made travelling appointment highly risky impossible added hurdle doctor increasingly closing surgery reduce infection rate finding deployed front line work resulted falling injected infused medicine merck biggest seller keytruda hospital administered seven biggest selling product vaccine hence full year downgrade glaxo said seen decline shingrix prescription containment measure limited patient ability access vaccine adding meningitis portfolio hit delay child going back school sanofi reported falloff travel vaccine sale owing reduction global travel novartis said ophthalmology business affected unavailability doctor posing challenge delivering certain medicine hitting new launch equally hard sale team unable access physician promote product educate use new product initiation slowing bristol myers squibb said would hold launching new multiple sclerosis treatment zeposia despite receiving approval march zeposia would entering highly crowded market bristol hesitation presumably give product best start possible meanwhile industry smaller worse funded company luxury allowing delay face prospect much lower sale sale industry biggest new launch fare following quarter useful indicator sector health covid add new danger drug launch clinical holding pattern another albeit long term indicator sector health clinical trial mixed response among big pharma group came clinical trial update reporting continuation key study separate analysis evaluate vantage however showed past two month fold increase clinical trial suspension april alone suspension hit april running trial equate saving company gilead said r expense racked remdesivir offset pulling shutter clinical trial clinical trial life blood industry data move product clinic file launch new product eventually knock effect even difficulty big pharma company still expect return normal end year virus storing longer term headache industry might make achieving normality difficult delay treatment increase mortality rate clinical trial suspension hit industry longer term health additionally stalling licensing deal based positive data rise unemployment u industry biggest market leave million uninsured denting pharma sale certainty second wave covid later year gloom one striking theme first quarter call increasing use telemedicine digital health application glaxo said would see increase digital engagement novartis chief executive va narasimhan said digital technology really taken hold pharma ai effort taken scale choice right pharma division covid opening accelerating opportunity\n",
      "\n",
      "Keywords:\n",
      "industry 0.215\n",
      "pharma 0.204\n",
      "quarter 0.161\n",
      "sale 0.159\n",
      "product 0.156\n",
      "first quarter 0.155\n",
      "suspension 0.152\n",
      "industry biggest 0.152\n",
      "clinical trial 0.148\n",
      "pattern 0.144\n",
      "doctor 0.134\n",
      "biggest 0.129\n",
      "digital 0.121\n",
      "health 0.119\n",
      "full year 0.116\n",
      "launch 0.111\n",
      "administered 0.11\n",
      "pharma company 0.107\n",
      "clinical 0.106\n",
      "hospital 0.101\n",
      "\n",
      "Abstract:\n",
      "bristol myers squibb issued celgene holder contingent value right part takeout latter company approval ide cel seen one riskier condition shock u refusal file letter issued today suddenly throw ide cel approval spotlight course bristol partner bluebird putting brave face saying filing resubmitted end july four month setback second delay one cvr three element week raising serious question documentation bristol took celgene refusal file rtf letter sign mere administrative slip missing piece trifling data generally signifies filing incomplete submitted wrong format extent capable even reviewed hand fda said rtf allows sponsor informed filing deficiency soon possible allowing issue corrected sooner would case wait complete response letter bristol bluebird say problem ide cel filing lack detail primarily chemistry manufacturing control process used lentiviral vector manufacturing process however analyst call bristol said issue ability manufacture product filing responsibility bristol original submission made march time putting approval cvr specified deadline well within reach additional clinical non clinical data requested allowing quick resubmission plan however go unnoticed week ago second cvr three event approval decision juno derived liso cel end year slipped three month owing bristol submission new data fda deemed major amendment asset came bristol via celgene takeover liso cel acquired celgene juno obvious question whether problem emerging result numerous handover data possible personnel change curiously bluebird held separate analyst call today threw mix issue covid consideration timely review process however stressed expect second shoe drop uncertainty approval ide cel liso cel seen cvr riskiest element probably still case everything go without hitch liso cel approval still possible december deadline today rtf add ide cel uncertainty ide cel refiled july new issue arise filing accepted within day approval six month priority review happen february month spare clearly cvr still play holder contend growing list ifs\n",
      "\n",
      "Keywords:\n",
      "cel 0.408\n",
      "ide cel 0.259\n",
      "ide 0.259\n",
      "cvr 0.221\n",
      "bristol 0.195\n",
      "liso cel 0.192\n",
      "liso 0.192\n",
      "rtf 0.174\n",
      "filing 0.147\n",
      "celgene 0.13\n",
      "approval 0.128\n",
      "bluebird 0.117\n",
      "refusal file 0.109\n",
      "approval ide cel 0.109\n",
      "approval ide 0.109\n",
      "process 0.108\n",
      "letter 0.107\n",
      "refusal 0.103\n",
      "issue 0.099\n",
      "deadline 0.099\n",
      "\n",
      "Abstract:\n",
      "time biotech company mistakenly push pivotal development armed unconvincing phase ii data genfit one company yesterday reporting lead asset elafibranor crashed phase iii resolve study become latest reap frightful harvest fact writing wall elafibranor soon phase ii golden study failed five year ago serve lesson investor credulously poured cash genfit recently secondary nasdaq listing today investment tanked still fact elafibranor dead nash see project written much smaller though better defined indication exists primary biliary cholangitis pbc aka liver cirrhosis elafibranor already generated phase ii pbc data development continue genfit told analyst yesterday interestingly similar play developing cymabay last november discontinued rival nash asset seladelpar evidence interface hepatitis today cymabay climbed saying independent expert panel ruled evidence seladelpar induced liver injury basis want resume development fda agrees pbc look likely indication genfit failure evaluatepharma sellside consensus saw elafibranor generating sale nash pbc respectively third competitor intercept ocaliva approved pbc face fda adcom nash use june badly wrong thing gone badly wrong genfit nash question especially apt since company phase ii golden trial already failed show benefit elafibranor nash back genfit liver disease hail mary approach september error reading positive highly questionable post hoc analysis genfit argued suggested benefit severe nash subject new definition primary endpoint used assumption made basis positive phase iii hit would result rather week treatment yesterday genfit accepted pan phase iii resolve trial failed keenly awaited interim analysis primary key secondary endpoint drew blank notable despite several delay genfit still unable tease kind post hoc benefit nash resolution endpoint least suggests numerical benefit fibrosis improvement drawn complete blank genfit point subject missed biopsy automatically graded non responder however hope adjusting save resolve scuppered admitted percentage missing biopsy subject almost equal two cohort instead company said elafibranor efficacy line expectation placebo response significantly higher exactly excuse used five year ago golden failure genfit want take another look biopsy data possible variability however management accepts path forward elafibranor nash though want consult fda scrapping resolve trial entirely novo nordisk making concerted push nash biotech look increasingly unlikely play big role disease\n",
      "\n",
      "Keywords:\n",
      "genfit 0.424\n",
      "nash 0.324\n",
      "elafibranor 0.314\n",
      "pbc 0.238\n",
      "resolve 0.163\n",
      "golden 0.143\n",
      "biopsy 0.114\n",
      "badly wrong 0.104\n",
      "phase 0.096\n",
      "phase iii resolve 0.095\n",
      "iii resolve 0.095\n",
      "wrong 0.089\n",
      "five year ago 0.089\n",
      "liver 0.087\n",
      "seladelpar 0.087\n",
      "cymabay 0.085\n",
      "badly 0.085\n",
      "resolve trial 0.083\n",
      "want 0.081\n",
      "blank 0.08\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Abstract:\n",
      "first phase iii data roche ulcerative colitis programme etrolizumab come mid year five study run etrolizumab comfortably able demonstrate utility placebo controlled trial face tougher task come active control case remicade humira targeting integrins new mechanism gastrointestinal agent takeda entyvio alpha beta integrin antibody market ulcerative colitis crohn disease however etrolizumab novel target second integrin pivotal programme need show bestows important differentiation initial result one roche phase iii study hickory emerged tested etrolizumab versus placebo patient mild moderate ulcerative colitis failed respond anti tnf therapy open label induction cohort subject etrolizumab associated week clinical response patient patient improvement least one point baseline endoscopic score etrolizumab well tolerated frequency adverse event comparable placebo takeda entyvio approved ulcerative colitis based two integrated placebo controlled study total patient response rate week six versus placebo p week patient continued receive entyvio every eight week clinical remission versus switched placebo p reality however etrolizumab placebo notable roche pitted older anti tnf agent rather newer mechanism seen dominating market coming year either way analyst believe antibody good chance beating humira hibiscus study though showing superiority remicade gardenia tougher remicade ulcerative colitis trial total patient treated drug clinical response week eight versus placebo p week patient continued receive remicade every eight week clinical remission compared placebo p dual action anti integrin antibody etrolizumab target alpha beta alpha e beta integrins said work preventing inflammatory cell entering retained gut entyvio forecast market leader mechanism ulcerative colitis sale bn according evaluatepharma data despite absence confirmatory phase iii data sellside etrolizumab far behind sale pencilled year etrolizumab side convenience since administered monthly subcutaneous injection entyvio administered intravenously takeda developed subcutaneous version entyvio received crl december drug better luck europe approval last week roche hope file etrolizumab ulcerative colitis year company need make convenience argument succeed highly competitive market effective newer agent however approaching readout help determine project capable\n",
      "\n",
      "Keywords:\n",
      "etrolizumab 0.48\n",
      "entyvio 0.262\n",
      "ulcerative colitis 0.249\n",
      "ulcerative 0.249\n",
      "colitis 0.249\n",
      "remicade 0.175\n",
      "placebo 0.151\n",
      "week clinical 0.14\n",
      "integrin 0.131\n",
      "alpha beta 0.131\n",
      "week 0.112\n",
      "alpha 0.094\n",
      "week patient 0.087\n",
      "total patient 0.087\n",
      "takeda entyvio 0.087\n",
      "integrin antibody 0.087\n",
      "every eight week 0.087\n",
      "every eight 0.087\n",
      "clinical response 0.087\n",
      "takeda 0.087\n",
      "\n",
      "Abstract:\n",
      "comer label lynparza front line ovarian cancer always unlikely given result paola study presented esmo last year came pas last week fda restricted approval homologous recombination deficiency hrd positive patient still represents something broadening parp inhibitor label currently specifies use carrying brca mutation new indication specifies astrazeneca merck co drug must used roche avastin hrd positive patient combination examined paola undoubtedly confirms advantage glaxosmithkline whose zejula granted comer single agent label exact setting last week although certain complexity make future rivalry far straightforward substantial difference trial label expansion make figuring situation particularly difficult front line maintenance indication concerned cover woman responded first line platinum chemotherapy remains standard care case cured subsequent maintenance treatment brca positive disease lynparza established go maintenance therapy solo study paola prima trial zejula equivalent phase iii test run figure whether broader set patient might benefit parp inhibition used way answer yes although patient form hrd respond much strongly cross trial comparison show paola avastin plus lynparza v avastin prima zejula v placebo solo lynparza v placebo v hr v hr v hr v hr nr v hr v hr v hr v hr v hr n v hr v hr hazard ratio hrd negative group paola show fda declined give combination comer label important point however includes patient whose biomarker status unknown prima subject split hrd negative group one many caveat trying compare result study relative approval mean patient low tumour mutation burden choice physician becomes avastin monotherapy zejula clear cut decision however svb leerink analyst point month pfs achieved avastin monotherapy paola double zejula prima caveat cross trial comparison notwithstanding complicating issue fact hrd testing requires tumour biopsy well entrenched complex identifying brca mutation done simple blood test widely used diagnostic ovarian cancer lack access hrd testing benefit zejula particularly considering avastin usefulness ovarian cancer long debated extent antibody used disease varies widely geographically arrival avastin biosimilars presumably minimal marketing support roche must considered therefore easy see big push glaxosmithkline generate healthy uptick usage brca negative patient astrazeneca merck co standing course partner make convincing argument superior survival number several cohort detailed first time highly motivated rival arrived one straightforward message zejula used patient regardless whether biomarker test carried\n",
      "\n",
      "Keywords:\n",
      "hr hr 0.387\n",
      "hr 0.36\n",
      "hr hr hr 0.301\n",
      "hrd 0.268\n",
      "zejula 0.257\n",
      "paola 0.23\n",
      "avastin 0.212\n",
      "prima 0.161\n",
      "brca 0.138\n",
      "lynparza 0.119\n",
      "ovarian cancer 0.092\n",
      "ovarian 0.089\n",
      "label 0.086\n",
      "maintenance 0.085\n",
      "used 0.084\n",
      "solo 0.081\n",
      "hrd positive 0.081\n",
      "hrd negative 0.081\n",
      "comer 0.08\n",
      "comer label 0.077\n",
      "\n",
      "Abstract:\n",
      "quite leap faith investor backing oyster point flotation last october taking reformulation smoking cessation drug chantix backed mixed data would score pivotal study nasal spray treating dry eye disease today faith partly rewarded phase iii onset study new formulation company code oc yielding positive result le clear whether plus earlier equivocal data enough u approval though oyster point gunning second half filing jury still whether market rewarded faith oyster point stock doubled since ipo including surge friday one working day phase iii data revealed today press release elicited decline early trade burning however unusual trading oyster point today insisted oc efficacious dry eye treatment avoid burning stinging sometimes present approved eyedrop like allergan restasis novartis xiidra dry eye patient either drug back efficacy claim oyster point toplined phase iii onset study oc dos tested mg ml mg ml met primary endpoint relating sign disease high level statistical significance versus placebo however dry eye disease approval u fda normally requires symptom well sign improved data become le clear onset higher two dos beat placebo improving symptom p make perfect sense logical higher dose outperform lower one numerically oyster point problem phase ii onset study second two necessary pivotal trial showed benefit dry eye symptom mg ml mg ml oc dose nevertheless today oyster point determined would take mg ml dose regulator filing take form b submission pharmacokinetic data bridged generated chantix oc chantix smoking cessation drug developed pfizer contain active ingredient varenicline alpha beta nicotinic acetylcholine receptor agonist chantix hit association mental health issue although black box warning removed drug label discovery varenicline establish tear film homeostasis activating trigeminal parasympathetic pathway restasis xiidra act relatively late reduce inflammation oyster point argues gave rise oc course proving effect sign symptom dry eye disease easy task recently kala pharmaceutical found developing eysuvis run three study demonstrate benefit even needed sign symptom benefit demonstrated statistical significance twice persistence pay kala march however cut oyster point dataset oc mg ml filed shown benefit symptom one pivotal trial\n",
      "\n",
      "Keywords:\n",
      "oyster point 0.387\n",
      "oyster 0.387\n",
      "oc 0.301\n",
      "mg ml 0.258\n",
      "ml 0.241\n",
      "dry eye 0.207\n",
      "dry 0.201\n",
      "chantix 0.172\n",
      "eye 0.16\n",
      "symptom 0.137\n",
      "point 0.133\n",
      "onset study 0.129\n",
      "onset 0.121\n",
      "mg 0.118\n",
      "dry eye disease 0.115\n",
      "eye disease 0.103\n",
      "faith 0.098\n",
      "sign 0.081\n",
      "xiidra 0.08\n",
      "restasis 0.077\n",
      "\n",
      "Abstract:\n",
      "big pharma company including merck co eli lilly roche warned disruption clinical trial owing covid pandemic tended focus new patient start new analysis carried evaluate vantage paint somewhat starker picture particular past two month seen fold increase trial suspension irrespective reason given latest analysis find look every industry sponsored phase iii study listed clinicaltrials gov note every change made entry january end last month useful provides independent analysis current state play irrespective reason company give public pronouncement allows compared baseline number clinical study setback would expected occur outside covid lockdown thus average month around trial tend suspended reason world moving towards lockdown march saw jump study marked suspended snowballed trial suspended april figure differ vantage previous analysis carried last month looked trial marked suspended covid given reason identified study covid clinical damage start emerge april interestingly status change trial acute effect covid felt concern study suspension obvious impact trial termination instance neither study primary completion date appear affected trial completion date delayed march april respectively figure exactly line average across previous month however remembered many case primary completion date clinicaltrials gov mere estimate frequently odds reality possible effect expected completion date become apparent type analysis several month time industry sponsor come term fully precise impact measure taken combat spread covid\n",
      "\n",
      "Keywords:\n",
      "suspended 0.285\n",
      "completion date 0.227\n",
      "completion 0.212\n",
      "covid 0.178\n",
      "suspension 0.156\n",
      "marked suspended 0.156\n",
      "analysis carried 0.156\n",
      "date 0.154\n",
      "reason 0.148\n",
      "analysis 0.142\n",
      "trial 0.132\n",
      "month 0.131\n",
      "irrespective 0.127\n",
      "april 0.119\n",
      "primary completion date 0.117\n",
      "primary completion 0.117\n",
      "lockdown 0.113\n",
      "carried 0.113\n",
      "marked 0.112\n",
      "study 0.108\n",
      "\n",
      "Abstract:\n",
      "macrogenics yesterday managed achieve early asco bounce providing sneak peek data presented annual cancer conference week abstract due released early data three pipeline project piqued interest sending stock soaring huge two year high adding around company market cap quite rise update described directionally encouraging typically bullish sellside investor piled hope detail support reaction extra information emerge asco abstract due released may full detail conference start end month remembered impending update early take efficacy project one main asco presentation concern b h antibody drug conjugate mgc apparently showing promise prostate cancer reduction psa seen five seven patient metastatic castration resistant disease macrogenics disclosed yesterday company plan dose expansion cohort tumour equates response rate measure nearly good impressive result generated xtandi mcrpc one cut prevail trial found patient achieved psa decline although course subject number differ enormously b h highly expressed solid tumour particular prostate cancer ongoing phase trial conducted various tumour activity seen elsewhere macrogenics said second asco presentation note involve lag pd bispecific mgd yesterday company teased orr seen dozen patient positive tumour treated margetuximab macrogenics targeting antibody targeting pd previously managed achieve response rate company claimed adding development plus margetuximab would prioritised mdg large phase solid tumour study activity seen across several tumour type including anti pd therapy company said data asco shot slated asco discussed yesterday mgd bispecific hit pd ctla large phase basket study various advanced solid tumour dose escalation completed company disclosed evaluable patient treated mg kg four response seen albeit one unconfirmed four tumour type macrogenics expect take forward much higher dose important stifel analyst point far exceeds equivalent dos opdivo yervoy used according macrogenics dose limiting toxicity seen project safety profile described quite favourable notably astrazeneca put weight behind bispecific approach get combination data due emerge later year becomes important event astra turn bispecifics solve treme problem february dwindling hope potential margetuximab macrogenics advanced project beaten company stock since past month final look overall survival towards end year determine project future approaching regulatory review data data gastric cancer might salvage project objective response observed three four evaluable patient recruited first line mahogany trial company said yesterday plan seek accelerated approval initial single arm data though early hint yet prove misleading yesterday presentation designed prove macrogenics margetuximab certainly worked however share price gain prove durable hint clinical activity must prove robust\n",
      "\n",
      "Keywords:\n",
      "macrogenics 0.355\n",
      "margetuximab 0.223\n",
      "tumour 0.205\n",
      "asco 0.192\n",
      "yesterday 0.124\n",
      "prove 0.122\n",
      "solid tumour 0.118\n",
      "pd 0.115\n",
      "managed achieve 0.111\n",
      "abstract due 0.111\n",
      "solid 0.111\n",
      "seen 0.108\n",
      "psa 0.106\n",
      "mgd 0.106\n",
      "evaluable patient 0.106\n",
      "bispecific 0.104\n",
      "large phase 0.102\n",
      "asco presentation 0.098\n",
      "company 0.093\n",
      "presentation 0.092\n",
      "\n",
      "Abstract:\n",
      "encouraging mid stage result semaglutide nash big focus novo nordisk quarterly result today diabetes giant look gearing push phase iii despite glp agonist failing hit key secondary endpoint study looking fibrosis resolution novo seems believe semaglutide improve liver scarring longer period still convincing hit primary nash resolution endpoint set drug formidable competitor project nearing crucial readout genfit elafibranor particular elafibranor phase iii resolve trial due report coming week expected use proportion patient achieving nash resolution without worsening fibrosis week primary endpoint novo study detailed today semaglutide hit statistical significance dos tested placebo adjusted difference high group provides something bar beat novo study tested daily injection sema three different dos drug sold diabetes weekly injection branded ozempic formulated daily oral dosing sold trade name rybelsus\n",
      "\n",
      "Keywords:\n",
      "resolution 0.279\n",
      "novo 0.273\n",
      "semaglutide 0.257\n",
      "nash 0.196\n",
      "nash resolution 0.186\n",
      "elafibranor 0.158\n",
      "sold 0.149\n",
      "injection 0.138\n",
      "fibrosis 0.138\n",
      "hit 0.125\n",
      "diabetes 0.124\n",
      "daily 0.123\n",
      "endpoint 0.11\n",
      "formidable 0.105\n",
      "week primary endpoint 0.1\n",
      "sema 0.1\n",
      "genfit elafibranor 0.1\n",
      "competitor project 0.1\n",
      "dos 0.099\n",
      "tested 0.098\n",
      "\n",
      "Abstract:\n",
      "tg therapeutic yesterday claiming victory unity cll trial study standing among biotech curious confirmed unity cll suffered numerous delay focus changed initial failure despite apparently shown strong progression free survival benefit result position combo tg tested ublituximab plus umbralisib filed end chronic lymphocytic leukaemia cll project sale depend absolute benefit seen safety profile strong unity cll result first line versus relapsed refractory subject investor seeking answer question need wait full data presented medical meeting ash december look likely venue sellside consensus compiled evaluatepharma see two project generating combined bn revenue though includes ublituximab separate potential use multiple sclerosis high statistical significance however tg boast pfs benefit combo beat comparator cohort roche gazyva plus chlorambucil high degree statistical significance p though still undisclosed absolute result key tg closed yesterday valuation bn today took opportunity tap market tg separately hope complete u lymphoma filing umbralisib monotherapy mid unity cll however biggest mystery remains study shown benefit term objective response would nevertheless read positively pfs patient progression free logical expect responding tg readout suggests correlation two measure nevertheless michael wei tg chief executive insisted orr analysis failed insufficiently mature performed even today know orr benefit told evaluate vantage matter said cll different cancer chemo tended result high response limted pfs indeed relapsed cll trial ascend astrazeneca calquence showed strong pfs advantage rituxan plus zydelig bendamustine showed orr improvement alethia young analyst cantor fitzgerald said unity cll powered show improvement pfs goal combo reduce risk progression hr given interim result causing unity cll halted early efficacy actual hr even better neighbourhood wrote m young yesterday separate question ublituximab anti cd antibody umbralisib pi k delta inhibitor compete new regimen abbvie johnson johnson imbruvica roche abbvie venclexta first line cll venclexta plus gazyva cut risk progression versus gazyva plus chlorambucil imbruvica beat chlorambucil alone staggering hr importantly unity cll comprised first line well relapsed refractory subject ratio though tg insists pfs benefit observed across population precise contribution key datapoint watch determine drug potential label pi k first analyst call yesterday tg hailed combo first show benefit pi k delta inhibitor front line cll mechanism courtesy gilead ill fated zydelig become associated toxicity assuming tg safety data hold key selling point tg said unity cll springboard additional combination company pipeline includes btk inhibitor tg still investor would right remain cautious full data disclosed unity cll inability show remission rate benefit scuppered tg accelerated approval plan prompted change focus pfs pfs readout delayed twice forcing company add interim analysis tg shrug another delay history march analysis tg eleventh hour found something positive whether struck gold become clear full data known story updated add comment tg\n",
      "\n",
      "Keywords:\n",
      "tg 0.532\n",
      "cll 0.398\n",
      "unity cll 0.299\n",
      "unity 0.299\n",
      "pfs 0.195\n",
      "benefit 0.106\n",
      "umbralisib 0.1\n",
      "ublituximab 0.1\n",
      "chlorambucil 0.1\n",
      "gazyva 0.096\n",
      "pi 0.087\n",
      "hr 0.085\n",
      "plus 0.078\n",
      "progression 0.077\n",
      "combo 0.07\n",
      "relapsed 0.07\n",
      "full data 0.067\n",
      "zydelig 0.067\n",
      "pi delta inhibitor 0.064\n",
      "pi delta 0.064\n",
      "\n",
      "Abstract:\n",
      "unpredictable time appeal safe steady sale stream cannot denied despite alexion talk portfolio diversification strategic fit reliable le gobsmacking revenue recombinant clotting factor andexxa likely one major reason behind bn acquisition portola pharmaceutical andexxa approved factor xa inhibitor reversal agent forecast attain blockbuster status according consensus compiled evaluatepharma alexion relying geographical label expansion drug make portola acquisition work sale model underlying andexxa different followed alexion current product difficult adapt andexxa used reverse effect blood thinner patient suffer life threatening bleed kept stock hospital used emergency room probably patient lifetime alexion therapy generally intended chronic treatment rare disease thicker water speaking conference call today alexion management dismissed saying therapy fit critical care product soliris ultomiris used treat haemolytic uremic syndrome alexion established acute care hospital platform since hus patient tend present emergency room allowing rep offer andexxa er doctor trauma surgeon already business big plan expanding andexxa reach alexion reckons expand product europe wave one market including germany uk push country including france spain italy group say high rate factor xa inhibitor use april bm pfizer returned japanese right andexxa allowing alexion clear shot million factor xa inhibitor patient country company want obtain expanded approval andexxa currently used reverse effect xarelto eliquis potential used daiichi sankyo savaysa sanofi lovenox according alexion chief financial officer aradhana sarin casual observer might wonder portola pursuing opportunity company full year result january revealed disappointing sale andexxa point answer drug generated estimate range caused unprofitable company haemorrhage nearly half value portola stock trading high start year closed yesterday must made alexion cash offer per share look pretty appealing whether acceleration andexxa sale happen way alexion hope analyst stifel reserved judgement saying truly show story open question whether company able attract hospital administrator attention point availability andexxa new market new indication current pandemic\n",
      "\n",
      "Keywords:\n",
      "andexxa 0.606\n",
      "alexion 0.473\n",
      "portola 0.196\n",
      "factor 0.112\n",
      "used 0.108\n",
      "hospital 0.104\n",
      "emergency room 0.098\n",
      "room 0.082\n",
      "fit 0.082\n",
      "allowing 0.082\n",
      "reverse 0.076\n",
      "country 0.074\n",
      "sale 0.072\n",
      "emergency 0.068\n",
      "offer 0.061\n",
      "product 0.06\n",
      "saying 0.058\n",
      "inhibitor 0.055\n",
      "care 0.054\n",
      "current 0.053\n",
      "\n",
      "Abstract:\n",
      "clean clear consistent message akebia executive repeated today delivered positive top line data first pivotal trial vadadustat hard guess sentiment directed towards fibrogen criticised complexity opaqueness result rival anaemia pill roxadustat comparing two project tricky usual caveat trial different including choice control arm vadadustat success seem confirm oral hif ph inhibitor effective safe anaemia treatment assuming regulator agree fibrogen market next year akebia far behind first data come two phase iii trial conducted patient chronic kidney disease dialysis found project non inferior aranesp amgen blockbuster epo product efficacy crucially cardiovascular safety sd standard deviation hb haemoglobin criterion non inferiority g dl non inferiority margin fda ema source company statement full detail held back medical conference top line data show vadadustat comfortably cleared non inferiority margin set regulator whether vadadustat better roxadustat treating anaemia argument really need data disclosure assuming agent get market debate preoccupy marketing team year come importantly cardiovascular safety look clean notably fibrogen achieved hazard ratio mace analysis dialysis trial despite using epogen control arm call executive confirmed couple vital point mace event death occurred aranesp control arm hepatotoxicity concern raised case hy law seen liver safety signal rocked akebia couple year ago akebia play spot difference investor april company need repeat encouraging result pro tect trial two phase iii trial conducted kidney disease patient yet dialysis le sick population thought represent much bigger potential market result due around mid year\n",
      "\n",
      "Keywords:\n",
      "vadadustat 0.265\n",
      "akebia 0.265\n",
      "dialysis 0.191\n",
      "fibrogen 0.184\n",
      "anaemia 0.163\n",
      "control arm 0.16\n",
      "non inferiority 0.157\n",
      "inferiority 0.154\n",
      "top line data 0.139\n",
      "non inferiority margin 0.139\n",
      "inferiority margin 0.139\n",
      "aranesp 0.139\n",
      "mace 0.132\n",
      "line data 0.132\n",
      "trial conducted 0.127\n",
      "non 0.121\n",
      "roxadustat 0.119\n",
      "margin 0.116\n",
      "kidney disease 0.106\n",
      "two phase iii 0.103\n",
      "\n",
      "Abstract:\n",
      "newron pivotal star study testing sarizotan rett syndrome always high risk bet company lacked human data project starting trial star duly missed primary endpoint newron share tanked today company scrapped whole rett programme blow therapy area approved product candidate gw pharma acadia anavex next line like sarizotan focus treating symptom rather disorder underlying cause rett syndrome almost exclusively affect girl caused mutation x chromosome mecp gene encodes protein involved development central nervous system especially synaptic circuit maturation following apparently normal development first six month life patient experience decline hand use communication many recurrent seizure well variety motor problem including increased muscle tone abnormal movement behind sarizotan development pipeline anavex therapy anavex small molecule activator sigma receptor data six adult patient open label portion phase ii study showed improvement score rett syndrome behaviour questionnaire rsbq clinical global impression improvement cgi scale seven week data placebo controlled part trial patient ought provide compelling evidence expected second half year second phase ii study called avatar conducted australia report year phase ii iii paediatric excellence study due report clinic gw attention rett syndrome understandable company cannabinoid epidiolex already market rare childhood epilepsy condition dravet lennox gastaut filed tuberous sclerosis complex drug able reduce frequency seizure epilepsy condition sale forecast reach bn according consensus evaluatepharma tiny portion expected rett syndrome phase iii rett study arch recruiting patient aged two two dos epidiolex tested versus placebo week improvement rsbq cgi score primary endpoint study primary completion date august next year acadia trofinetide analogue neuropeptide igf company say reduce neuroinflammation support synaptic function phase iii lavender study week placebo controlled trial us rsbq cgi score primary endpoint trial started last november aimed recruit patient aged five march company announced new patient would enrolled due covid pandemic previously enrolled patient continue study although clear large cohort result expected next year disease modifying approach using gene therapy ultimate treatment goal retts still way sarepta therapeutic teamed stridebio end last year stride leading early r four cns target including one rett syndrome ind novartis gene therapy avxs gained avexis acquisition expected\n",
      "\n",
      "Keywords:\n",
      "rett 0.435\n",
      "rett syndrome 0.327\n",
      "syndrome 0.182\n",
      "cgi 0.155\n",
      "anavex 0.155\n",
      "newron 0.109\n",
      "score primary endpoint 0.104\n",
      "score primary 0.104\n",
      "study 0.1\n",
      "patient aged 0.096\n",
      "score 0.096\n",
      "seizure 0.093\n",
      "star 0.091\n",
      "epidiolex 0.091\n",
      "patient 0.09\n",
      "gw 0.089\n",
      "epilepsy 0.087\n",
      "gene 0.083\n",
      "portion 0.08\n",
      "aged 0.08\n",
      "\n",
      "Abstract:\n",
      "remdesivir gate gilead emergency use authorisation fda permitting commercial rollout antiviral covid instead company pledged donate entire supply million dos distributed u government gilead expected profit point however else explain share price surge year adding bn group market cap implies huge commercial opportunity awaits feel premature considering much remains unknown company earnings call last week executive said still unsure future commercial model remdesivir might look like big money stake remdesivir cost reach bn year gilead estimate sustainable economic model work achieves access affordability patient around world chief executive daniel day said rest assured understand responsibility unsurprisingly company talk price yet aside political sensitivity topic remdesivir real benefit far clear remdesivir result pile mean april cost watchdog icer stab topic however putting together model based cost recovery traditional cost effectiveness analysis concluded price per day dose would cover manufacturing cost although would require gilead write r investment price considered cost effective icer found assuming mortality benefit confirmed using quality adjusted life year threshold sellside published remdesivir model yet upper price seems higher many assuming consensus evaluatepharma provides insight however average derived wildly different number demonstrating lack clarity around opportunity gilead fiduciary duty shareholder mean executive focused recovering remdesivir cost risk might happen cannot ignored effective treatment might emerge vaccine lessen need remdesivir quickly expected course opportunity cost gilead focusing potentially profitable activity analyst baird noted commercial opportunity remains ambiguous sceptical substantially goodwill enterprise company considering bn sunk remdesivir year alone pretty big slice goodwill gilead applauded effort find treatment pandemic talking commercial model win fan call greater clarity investor soon grow louder\n",
      "\n",
      "Keywords:\n",
      "remdesivir 0.438\n",
      "cost 0.296\n",
      "gilead 0.227\n",
      "model 0.222\n",
      "commercial 0.194\n",
      "opportunity 0.143\n",
      "remdesivir cost 0.142\n",
      "price 0.137\n",
      "icer 0.135\n",
      "commercial opportunity 0.129\n",
      "clarity 0.129\n",
      "assuming 0.099\n",
      "executive 0.093\n",
      "considering 0.087\n",
      "effective 0.085\n",
      "watchdog icer 0.067\n",
      "unsure 0.067\n",
      "sunk 0.067\n",
      "price per 0.067\n",
      "political 0.067\n",
      "\n",
      "Abstract:\n",
      "approval decision oncology drug feature heavily may coming month two parp inhibitor take spotlight prostate cancer clovis rubraca due decision patient brca mutation may astrazeneca lynparza filed broader setting homologous recombination repair gene mutation second quarter date last week latest cut lynparza profound study found survival benefit patient brca atm gene mutation efficacy data released carrier mutation type question broad label fda might give drug lynparza filed earlier second line setting versus rubraca third little evidence support retreating patient parp inhibitor sale indication data evaluatepharma give astra therapy lead prostate cancer bn lynparza sale forecast versus rubraca another decision lynparza due second quarter ovarian cancer based result paola study investigator sponsored study tested anti vegf antibody avastin plus lynparza recruited patient regardless mutation status data released last year esmo showed progression free survival significantly extended although result clearly driven patient homologous recombinant deficiency hrd subgroup without evidence hrd hazard ratio dropped unimpressive big question whether paola allow lynparza gain approval treat front line ovarian cancer regardless hrd status though presumably label would restrict use avastin combination therapy astrazeneca contend gsk parp zejula single agent gained u approval day ago ovarian cancer regardless biomarker status zejula decision based prima study group described hrd proficient essentially negative hazard ratio reduction risk progression meanwhile bristol myers squibb find whether opdivo plus yervoy get green light first line lung cancer latest filing based pooled result part one checkmate trial bristol earlier controversially claimed progression free survival benefit patient high tumour mutation burden abandoning original statistical analysis plan creating whole new cohort patient filing plan abandoned bristol doubling chance first line nsclc pdufa set august based checkmate la study time concerning opdivo plus yervoy chemotherapy merck keytruda already market first line combination chemotherapy according consensus evaluatepharma keytruda forecast sit bn versus opdivo bn oncology aside astrazeneca sglt inhibitor farxiga already marketed type diabetes look set approved heart failure based dapa hf trial overall patient receiving farxiga plus standard care reduction primary endpoint cardiovascular death hospitalisation heart failure urgent heart failure visit versus receiving standard care alone difference highly statistically significant p value le astra chance get head start competition lilly boehringer sglt inhibitor jardiance biggest threat jardiance emperor reduced study analogous dapa hf primary completion date june jardiance set biggest class according evaluatepharma sellside consensus forecast sale year bn versus farxiga bn neither estimate includes heart failure presumably big upside drug make mark lastly abbvie orilissa already market management pain associated endometriosis decision due uterine fibroid approved gnrh antagonist would ahead competition myovant obseva cross trial comparison three put abbvie product top term placebo adjusted response rate\n",
      "\n",
      "Keywords:\n",
      "lynparza 0.248\n",
      "hrd 0.183\n",
      "mutation 0.169\n",
      "heart failure 0.14\n",
      "rubraca 0.132\n",
      "jardiance 0.123\n",
      "parp 0.117\n",
      "heart 0.117\n",
      "farxiga 0.112\n",
      "decision 0.112\n",
      "regardless 0.11\n",
      "ovarian cancer 0.11\n",
      "cancer 0.107\n",
      "ovarian 0.106\n",
      "patient brca 0.096\n",
      "ovarian cancer regardless 0.096\n",
      "based 0.093\n",
      "paola 0.091\n",
      "homologous 0.091\n",
      "status 0.091\n",
      "\n",
      "Abstract:\n",
      "matter ingenious approach taken developing covid vaccine major investment must made manufacturing yesterday uk university oxford initiative got astrazeneca board today moderna signed lonza manufacture highly touted mrna based approach effort come big pharma gradually taking lead bringing coronavirus vaccine market race includes johnson johnson tie sanofi glaxosmithkline pfizer backing biontech broad mrna effort numerous small biotech working vaccine struggle without similar big partner heavy lifting moderna case lonza committed year agreement large scale manufacture case coronavirus pandemic last long term call swiss group become involved additional moderna product future moderna covid effort focus mrna vaccine aiming raise immune response virus sars cov spike protein popular approach dosed first phase study subject march moderna point day target sequence selected show pace effort moved last month moderna fleshed development path filing u ind start phase ii current quarter secured funding u agency barda contribute setting u production yesterday university oxford effort develop coronavirus vaccine delivered using mrna chimp adenovirus vector got massive boost astrazeneca signed dotted line astrazeneca join covid vaccine push april one intriguing aspect today lonza deal anticipates ultimately approved vaccine dose g basis partner claim eventually able manufacture billion dos year interesting given moderna phase study test three dos g g g data yet made public phase ii plan evaluate g g either dose given twice day apart two subject cohort one aged either way dosing decision remain way moderna celebrate major manufacturing endorsement covid vaccine clinical development yet unpartnered biotech include inovio arcturus altimmune unless get big manufacturing partner board effort commercially amount little\n",
      "\n",
      "Keywords:\n",
      "moderna 0.323\n",
      "vaccine 0.28\n",
      "effort 0.242\n",
      "manufacture 0.209\n",
      "lonza 0.209\n",
      "mrna 0.166\n",
      "covid vaccine 0.126\n",
      "university oxford 0.122\n",
      "manufacturing 0.121\n",
      "coronavirus vaccine 0.116\n",
      "covid 0.111\n",
      "partner 0.106\n",
      "coronavirus 0.105\n",
      "signed 0.105\n",
      "oxford 0.105\n",
      "phase study 0.103\n",
      "board 0.1\n",
      "astrazeneca 0.088\n",
      "approach 0.088\n",
      "university 0.087\n",
      "\n",
      "Abstract:\n",
      "market desperate news progress coronavirus pandemic even highly equivocal result hailed triumph gilead rise yesterday plus another close dubious result niaid remdesivir trial much uncontrolled data company study antiviral taken face value together failed immature chinese remdesivir data gilead look gone two three bald view play latest result shortcoming niaid gilead data failure either detailed comparison finding show hint benefit enough struggling keep daily shifting drama three remdesivir datasets form chinese study rigorously blinded placebo controlled terminated prematurely gilead uncontrolled study niaid study double blind placebo controlled adaptive design extent undermines finding first report remdesivir activity covid revealed separately concerned compassionate use hospitalised subject paper published nejm april leak published stat internal meeting u hospital participating gilead study however neither amounted anything anecdotal case report little definite gleaned blinded dataset formal clinical trial data important niaid trial toplined yesterday showed remdesivir subject recovering faster placebo recipient said statistically significant confusingly however contradicts china trial showed difference time clinical improvement remdesivir placebo chinese study powered show versus day improvement terminated early wholly convincing reason failure numerically difference highly disappointing versus day crucial consideration comparing across trial recruitment criterion differ study concerned hospitalised subject niaid trial look like le severe overall something relatively better performance control arm seems bear gilead severe covid study unveiled yesterday muddies water since even control cohort wind change gilead remdesivir april nothing known whether subject baseline characteristic balanced across cohort either gilead niaid trial indeed hard secondary endpoint common three study mortality crucially none three able show statistically significant improvement though numerically subject remdesivir tend better chance survival rather tinkering trial design revealing gilead study added mechanically ventilated subject perhaps effect le severe patient insufficiently pronounced niaid primary endpoint changed improvement scale included death imply shenanigan one study open label deliberately adaptive design hint remdesivir might major impact preventing death people infected covid however fact card need spell disaster perhaps investor right looking home run stage pandemic country hospital risk overwhelmed patient number drug merely reduces severity disease make real difference remdesivir might capable\n",
      "\n",
      "Keywords:\n",
      "remdesivir 0.396\n",
      "niaid 0.303\n",
      "gilead 0.238\n",
      "niaid trial 0.173\n",
      "study 0.146\n",
      "chinese 0.119\n",
      "versus day 0.115\n",
      "subject 0.114\n",
      "improvement 0.112\n",
      "gilead study 0.11\n",
      "adaptive design 0.11\n",
      "chinese study 0.105\n",
      "remdesivir might 0.102\n",
      "le severe 0.102\n",
      "adaptive 0.102\n",
      "hospitalised 0.099\n",
      "trial 0.098\n",
      "terminated 0.092\n",
      "design 0.092\n",
      "severe 0.09\n",
      "\n",
      "Abstract:\n",
      "gilead antiviral remdesivir received attention potential treatment sufferer covid hard data true utility still collected two release today raise hope though caveat evidence needed remains first company said understands huge trial run national institute allergy infectious disease niaid met primary endpoint niaid provide detailed information upcoming briefing gilead said might immediately clear though speculated made u government daily coronavirus taskforce press briefing study seeking patient rigorous double blind placebo controlled test remdesivir trial recruited subject range severity although needed require supplemental oxygen mechanical ventilation patient went receive day course antiviral primary endpoint measured time recovery study expected report week however according entry clinicaltrials gov design allowed interim monitoring introduce new arm allow early stopping futility efficacy safety actual effect size remains crucial question well whether efficacy seen particular cohort patient severe patient likely see benefit analyst believe another glimmer second statement gilead concerned one company phase iii study severe patient past month massively upsized seeking patient recruitment criterion widened allow subject receiving mechanical ventilation study comparing five day course remdesivir placebo arm limit conclusion drawn first cut concerned patient concluded five day course might helpful longer treatment five day group mortality rate caveat comparing across trial notwithstanding seems better mortality rate seen placebo controlled china based study data released accident last week knocked confidence remdesivir though study never completed poor enrolment lancet released full data trial today wind changed today gilead jumping almost new information lot data still come remdesivir evercore isi analyst umer raffat summed many people probably thinking right remdesivir appears real drug covid although silver bullet said call investor today\n",
      "\n",
      "Keywords:\n",
      "remdesivir 0.29\n",
      "day course 0.211\n",
      "five day 0.172\n",
      "ventilation 0.141\n",
      "mechanical ventilation 0.141\n",
      "mechanical 0.141\n",
      "five day course 0.141\n",
      "gilead 0.129\n",
      "severe patient 0.124\n",
      "mortality rate 0.12\n",
      "briefing 0.117\n",
      "patient 0.116\n",
      "day 0.109\n",
      "niaid 0.106\n",
      "mortality 0.101\n",
      "comparing 0.101\n",
      "study 0.097\n",
      "seeking 0.095\n",
      "concerned 0.095\n",
      "five 0.095\n",
      "\n",
      "Abstract:\n",
      "abbvie humira best selling drug since look set retain crown couple year come keytruda annual sale merck co cancer drug overtake anti tnf antibody reach bn according new long term forecast evaluatepharma assuming number consensus sellside estimate come pas keytruda sell double drug year humira still make top selling drug although remarkably product cohort forecast register declining sale next six year number far set stone course coronavirus pandemic particular making short term sale forecast hard pin clear analyst projecting substantial growth group product already major blockbuster others however table identifies recently launched drug projected become substantial product newer therapy yet establish well struggle global lockdown notable list includes smaller company already considered higher risk proposition come launching drug like global blood alnylam closely scrutinised coming month stage covid crisis widely assumed longer term potential product remain intact however chance outlook shifting increase longer current disruption last\n",
      "\n",
      "Keywords:\n",
      "selling drug 0.21\n",
      "humira 0.187\n",
      "product 0.177\n",
      "drug 0.174\n",
      "selling 0.146\n",
      "substantial 0.134\n",
      "term 0.133\n",
      "forecast 0.133\n",
      "keytruda 0.122\n",
      "sale 0.121\n",
      "longer 0.118\n",
      "come 0.118\n",
      "global 0.117\n",
      "still make 0.109\n",
      "projected become 0.109\n",
      "number far 0.109\n",
      "identifies 0.109\n",
      "best selling drug 0.109\n",
      "anti tnf 0.109\n",
      "annual sale 0.109\n",
      "\n",
      "Abstract:\n",
      "haematological cancer originating cell relatively rare highly intractable private chinese group gracell look made breakthrough allogeneic car therapy antigen choice cd one fallen wayside antibody approach disappointed data presented aacr meeting today show five cell leukaemia subject treated gracell anti cd car gc went remission though one relapsed quickly rest remission remain deep first clinical data anti cd car interest private u group wugen following similar approach gracell data remarkable study healthy volunteer derived gc cell dosed fairly limited persistence nevertheless car cell expanded robustly within two week four five subject leading mrd negative stringent criterion complete remission three subject remained cr three six month later said gracell xinxin wang presenting data today fourth subject remains mrd negative month infusion meanwhile fifth patient went mrd positive cr two week leukaemia relapsed four week time point toxicity side five subject experienced serious cytokine release syndrome one grade though none neurotoxicity graft versus host disease study discussant dr yvonne chen university california los angeles put toxicity relatively high dos car cell used gracell said used enhanced lymphodepleting flu cy regimen ensure car cell engraftment one company china persongen known clinic cd directed cell therapy though unclear whether autologous allogeneic project u baylor college listed phase trial autologous anti cd car planned start another year relevant competitor gracell perhaps wugen venture backed company founded two year ago california still operating stealth mode group working allogeneic car licensed washington university coded wu cart like gc us crispr editing one problem using car target cell malignancy antigen choice definition present target cell well car cell thus car cell liable target destroy phenomenon known fratricide avoid gracell us crispr edit cd antigen gc however manufacturing straightforward crispr knockout separate step knocking car construct done using traditional lentivirus dr chen cautioned long term durability gc yet determined company studying gc cell though cell lymphoma another logical indication targeted group another approach treating cell lymphoma using car therapy taken autolus auto auto project separate gracell technology claim use one day manufacturing process bold claim remains proved company validation cd make others take note updater version story published earlier\n",
      "\n",
      "Keywords:\n",
      "gracell 0.388\n",
      "car 0.367\n",
      "gc 0.291\n",
      "cell 0.278\n",
      "car cell 0.23\n",
      "cd 0.191\n",
      "cd car 0.138\n",
      "anti cd car 0.138\n",
      "crispr 0.121\n",
      "allogeneic 0.111\n",
      "antigen 0.1\n",
      "auto 0.092\n",
      "allogeneic car 0.092\n",
      "anti cd 0.092\n",
      "target cell 0.088\n",
      "chen 0.088\n",
      "cell lymphoma 0.085\n",
      "autologous 0.083\n",
      "subject 0.079\n",
      "cr 0.079\n",
      "\n",
      "Abstract:\n",
      "take lot move needle big pharma company exactly bristol myers squibb achieved last year takeover celgene acquisition added bn top line propelled u company th fourth position sale ranking table though impending loss revlimid mean heady height short lived new consensus forecast evaluatepharma stretching show bristol slipping back eighth place year top table picture forecast remain coming year however roche easily retaining pole position roche clear lead somewhat surprising given biosimilars chipping away company suite antibody avastin herceptin rituxan combined sale huge blockbuster expected eroded bn sellside forecast growth new product including tecentriq ocrevus hemlibra compensate however fact projected annualised growth period put roche substantially ahead pack forecast naturally become le reliable course although consensus view constructed equity analyst model suggests another big shift big pharma sand threaten swiss company dominance chart shift month completion abbvie acquisition allergan create entity track take fourth position megadeal wrapped certainly question abbvie consider move declining humira sale blowing hole company top line year come standout number chart include rate astrazeneca projected topline growth year highly impressive considering largely organically driven due blockbuster oncology product tagrisso lynparza imfinzi calquence end scale cagr gilead barely projected grow revenue period company famously pressure strike deal steadfastly stuck bolt ons date like abbvie another contender making expansive move coronavirus pandemic making job forecasting particularly tough right covid seems clear roche lead pack\n",
      "\n",
      "Keywords:\n",
      "projected 0.221\n",
      "position 0.17\n",
      "growth 0.165\n",
      "pack 0.161\n",
      "roche 0.152\n",
      "forecast 0.149\n",
      "abbvie 0.148\n",
      "top 0.143\n",
      "top line 0.143\n",
      "move 0.131\n",
      "chart 0.129\n",
      "shift 0.128\n",
      "company 0.121\n",
      "blockbuster 0.116\n",
      "period 0.112\n",
      "fourth 0.109\n",
      "table 0.108\n",
      "big pharma 0.104\n",
      "sale 0.101\n",
      "acquisition 0.094\n",
      "\n",
      "Abstract:\n",
      "targeted oncology become watchword sky high valuation drug price nature project limit voyager trial example exposed extent utility blueprint ayvakit unfortunately much smaller company assumed blueprint share dropped early trade surprise failure late line gist study effectively limit drug tiny niche work gist abandoned executive said today admitted fda approval fourth line setting due next month unlikely happen voyager result show u regulator right cautious came reviewing ayvakit generically known avapritinib blueprint filed back navigator trial generated highly impressive overall response rate patient pdgfr exon mutation le convincing orr wider fourth line treatment setting fda split nda separate submission waiting voyager result make decision fourth line patient granting full approval tiny genetic subtype january blueprint beat deciphera punch january end voyager fail meet primary endpoint ayvakit actually performed worse bayer stivarga drug considered relatively easy bar beat\n",
      "\n",
      "Keywords:\n",
      "voyager 0.311\n",
      "blueprint 0.311\n",
      "fourth line 0.238\n",
      "ayvakit 0.238\n",
      "gist 0.178\n",
      "fourth 0.165\n",
      "limit 0.147\n",
      "tiny 0.142\n",
      "line 0.135\n",
      "beat 0.109\n",
      "january 0.106\n",
      "targeted oncology 0.093\n",
      "subtype 0.093\n",
      "share dropped 0.093\n",
      "pdgfr exon mutation 0.093\n",
      "pdgfr exon 0.093\n",
      "pdgfr 0.093\n",
      "month unlikely 0.093\n",
      "make decision 0.093\n",
      "avapritinib 0.093\n",
      "\n",
      "Abstract:\n",
      "verastem paid chugai roche pan raf inhibitor cki january clear promise project activity kras mutant cancer today data backing deal verastem time said seen revealed market promising result concerning cki combined fak inhibitor defactinib presented aacr meeting remission rate kras driven low grade serous ovarian cancer however toxicity worry verastem year date stock took pummelling crashing morning market open investigator sponsored dose escalation expansion trial attempted enrol subject two cohort dosing cki defactinib mg mg respectively dose limiting toxicity immediately ruled mg mg intermediate mg mg dose enrolled subject abandoned treatment beyond six month displayed chronic toxicity though institute cancer research professor udai banerji presenting data today insisted toxicity mostly grade reversible obvious consideration whether render verastem therapeutic window small especially true since response nsclc seem underwhelming kras competition result interest follower mirati whose bn valuation driven largely kras g c inhibitor mrtx toxicity aside data verastem asset demonstrate certain kras driven tumour targeted using approach target kras protein professor banerji trial concern various tumour type far treated subject impressive data concern partial remission four six subject kras positive low grade serous ovarian cancer two additional patient kras wild type serous ovarian cancer treated respond four responding subject one met criterion partial remission kras mutation varying type two g one g v one g three previously treated mek inhibitor relevant raf mek part pathway early uncontrolled study direct comparison impossible professor banerji said historical data suggested response rate femara mekinist cancer type interestingly defactinib well cki v big pharma castoff come pfizer deal worth front cash equity verastem play kras card january cancer far promising data mrtx amgen rival kras g c inhibitor amg come nsclc trial verastem combo aim recruit kras mutant nsclc subject far evaluable aacr heard one partial remission g v mutant subject however verastem said second g v nsclc patient went partial remission november data cutoff one nsclc subject continuing treatment rest one combo week study recruit colorectal cancer subject data presented aacr professor banerji said lowest mg mg dose one recommended study big question whether impairs verastem ability show efficacy anything beyond low grade serous ovarian cancer\n",
      "\n",
      "Keywords:\n",
      "verastem 0.366\n",
      "kras 0.361\n",
      "serous ovarian cancer 0.174\n",
      "serous ovarian 0.174\n",
      "serous 0.174\n",
      "cki 0.174\n",
      "banerji 0.174\n",
      "mg 0.159\n",
      "partial remission 0.139\n",
      "cancer 0.136\n",
      "professor banerji 0.131\n",
      "low grade serous 0.131\n",
      "grade serous ovarian 0.131\n",
      "grade serous 0.131\n",
      "professor 0.127\n",
      "ovarian cancer 0.124\n",
      "nsclc 0.124\n",
      "defactinib 0.122\n",
      "ovarian 0.12\n",
      "subject 0.12\n",
      "\n",
      "Abstract:\n",
      "rigorous study sanofi regeron repurposed rheumatoid arthritis drug kevzara found anti il antibody little use outside critically ill covid patient dashing hope big impact mechanism finding reminds investor danger jumping encouraging result small trial experimental intervention enthusiasm continues boost share price mesoblast notable beneficiary last day company australia listed share doubled data coronavirus subject treated allogeneic cell therapy evaluate vantage tracking notable covid announcement clear pandemic news flow showing sign slowing clinical data emerges biopharma myriad attempt identify potential treatment risk drug development must forgotten kevzara result show small study prompted chinese add roche actemra treatment guideline covid initiation bigger trial il antibody one theory driving work coronavirus infection prompt surge cytokine il blocker damp making sense covid treatment approach march seems utility lie critically ill patient meaning requiring mechanical ventilation high flow oxygenation sanofi regneron said today ongoing phase ii iii trial would continue subject interim analysis found little benefit le severe patient readout expected june plus phase iii critical patient cohort give clearer picture role last week announcement mesoblast hand show little clarity remestemcel l utility data gathered allogeneic cell therapy compassionate use programme u surface seems encouraging nine patient treated came ventilator impossible say whether remestemcel l anything lack control group one issue patient receiving several intervention mesoblast description moderate severe ards puzzling given ventilation tends reserved critical patient mention made randomised phase ii iii due start though company long history disappointing make many investor wary much data emerge covid pipeline far compassionate use programme mesoblast certainly alone benefiting press releasing early finding israeli microcap redhill biopharma trading higher morning saying sphingosine kinase inhibitor opaganib produced measurable improvement six subject treated pharming received boost last week reporting improvement five patient given ruconest failed respond standard care rigorously gathered result available right investor chasing pandemic play little else go worth remembering even best intention ind hand small company simply cash capacity run large confirmatory trial certainly short time frame bigger developer restrained astrazeneca example announced last week start patient study farxiga see diabetes medicine reduce risk complication death high risk covid patient smaller biotech really need industry academic partner help fund run bigger study necessary pharming example university hospital basel board run patient study ruconest covid mesoblast partnering arm nih u neither study seems started travail gilead remdesivir show even researched probably best funded project nothing certain rigorous data emerge\n",
      "\n",
      "Keywords:\n",
      "mesoblast 0.278\n",
      "covid 0.156\n",
      "patient 0.151\n",
      "ventilation 0.117\n",
      "ruconest 0.117\n",
      "remestemcel 0.117\n",
      "pharming 0.117\n",
      "il antibody 0.111\n",
      "critically ill 0.111\n",
      "critically 0.111\n",
      "compassionate use 0.111\n",
      "il 0.111\n",
      "bigger 0.108\n",
      "gathered 0.107\n",
      "compassionate 0.107\n",
      "allogeneic cell therapy 0.107\n",
      "allogeneic cell 0.107\n",
      "intervention 0.103\n",
      "last week 0.1\n",
      "subject treated 0.1\n",
      "\n",
      "Abstract:\n",
      "late yesterday non biotech investment world found industry specialist already know drug chance success hinge largely trial design data chinese trial gilead science remdesivir severe covid posted accident suggested study bust major repercussion jittery market trading gilead share briefly halted data emerged company closed yesterday important wider effect investor considered possibility remdesivir might fact quick easy cure allow swift resumption normal working life p closed yesterday reversing gain morning report summarises result patient severe disease terminated study stating gilead antiviral associated difference versus placebo time clinical improvement day mortality time negative result viral rna test drug actually numerically worse day death rate recipient dying versus placebo twice many remdesivir control patient discontinued treatment adverse event treatment group versus placebo data came marked contrast last week positive hint single site gilead trial severe covid patient prompted major stock rally hospital data leak set remdesivir expectation april hope keeping faith remdesivir argument muster drug favour gilead stated chinese trial early termination due low enrolment organiser intended recruit patient meant study underpowered draw statistically meaningful conclusion certainly underpowering accusation levelled gilead trial severe covid expanded repeatedly completed enrolment patient another difference chinese study gilead global study patient former sicker longer chinese trial recruited subject whose symptom appeared le day gilead specified four day confirmation presence coronavirus rna moreover gilead trial severe patient excluded subject mechanically ventilated extracorporeal membrane oxygenation least five day apply chinese study general rule antiviral work best given fast according umer raffat evercore isi timing treatment initiation important driver efficacy called day post symptom criterion chinese trial long window leerink analyst echoed saying plausible negative data due remdesivir administered late course illness ultimately finding like last week early incomplete yet subject peer review concrete conclusion remdesivir emerge full datasets large trial gilead pair major study run u national institute allergy infectious disease though latter scheduled report gilead analyst beginning consider much remdesivir might mean company consensus forecast compiled evaluatepharma put sale bn\n",
      "\n",
      "Keywords:\n",
      "remdesivir 0.336\n",
      "gilead 0.308\n",
      "chinese 0.252\n",
      "chinese trial 0.233\n",
      "gilead trial severe 0.196\n",
      "gilead trial 0.175\n",
      "severe 0.16\n",
      "severe covid 0.146\n",
      "day 0.142\n",
      "trial 0.116\n",
      "chinese study 0.112\n",
      "remdesivir might 0.108\n",
      "patient 0.101\n",
      "closed yesterday 0.1\n",
      "study 0.099\n",
      "versus placebo 0.09\n",
      "conclusion 0.086\n",
      "rna 0.084\n",
      "major 0.082\n",
      "antiviral 0.082\n",
      "\n",
      "Abstract:\n",
      "covid pandemic continues dominate headline cause delay clinical programme number important data readout expected soon small biotech company phase iii data chronic kidney disease patient due akebia vadadustat first result dialysis patient non dialysis data mid year japanese phase iii trial found vadadustat non inferior darbepoetin alfa one case fatal myocardial ischaemia considered possibly related project cardiac safety remains big question mark hif ph inhibitor fibrogen similarly acting asset roxadustat lingering safety question pdufa date set december akebia u partner vifor expected use priority review voucher vadadustat steal march competition blueprint ayvakit already approved treating gastrointestinal stromal tumour driven specific mutation niche population voyager study test head head stivarga patient previously treated gleevec one two tyrosine kinase inhibitor topline data supplement fourth line gist submission pdufa date next month well supporting expansion third line use blueprint ahead competitor deciphera august pdufa similarly acting ripretinib fourth line disease tg therapeutic unity cll study suffered number delay interim pfs readout expected trial pit ublituximab umbralisib tg anti cd antibody pi k delta inhibitor respectively roche gazyva plus chlorambucil notably study include roche abbvie highly efficacious newcomer venclexta might lack real world relevance earlier failure show orr benefit already made hitting pfs long shot readout genfit resolve trial elafibranor pushed back several time odds success nash trial low given elafibranor phase ii flop discontinuation cymabay similarly acting seladelpar february genfit said would sit blinded dataset second quarter incorporate latest fda insight might allow reduce endpoint tweaked last moment permissible unblinding evidence emerge would increase trial chance showing effect nash earlier month akero reported impressive result first cut mid stage nash trial pipeline lead akr share climbed relative reduction liver fat versus baseline three akr dos tested numerical dose response three hit statistical significance versus placebo recipient showed reduction biopsy data robust measure expected quarter mavacamten myokadia lead project small molecule reversibly bind myosin intended treatment hypertrophic cardiomyopathy inherited condition cause thickening cardiac muscle mavacamten showed promising result open label phase ii pioneer hcm trial patient obstructive form condition blood flow heart restricted marked reduction post exercise lvot gradient difference ventricular aortic pressure week versus baseline primary endpoint patient explorer hcm study placebo controlled combined primary endpoint clinical response improvement heart failure scale increase exercise capacity towards end last year kadmon reported positive interim analysis pivotal phase ii rockstar trial kd chronic graft v host disease two month project easily cleared objective response rate threshold unless result substantially deteriorate six month data released quarter unexpected safety issue rear head green light patient received least two prior line therapy look likely consensus forecast extra second quarter event please see table akebia vifor otsuka\n",
      "\n",
      "Keywords:\n",
      "vadadustat 0.155\n",
      "akebia 0.155\n",
      "similarly acting 0.124\n",
      "pdufa 0.112\n",
      "vifor 0.108\n",
      "acting 0.108\n",
      "tg 0.103\n",
      "mavacamten 0.103\n",
      "hcm 0.103\n",
      "exercise 0.103\n",
      "similarly 0.102\n",
      "nash 0.101\n",
      "readout expected 0.099\n",
      "dialysis 0.099\n",
      "nash trial 0.096\n",
      "versus baseline 0.093\n",
      "akr 0.093\n",
      "trial 0.092\n",
      "fourth line 0.088\n",
      "quarter 0.087\n",
      "\n",
      "Abstract:\n",
      "biopharma company laying pandemic repercussion clinical work week hard data impact emerging instance evaluate vantage uncovered commercially focused study suspended since march covid cited reason number medidata extracted active study paint even starker picture new patient start march dropped year year worsening slump first two week april first trial registry data pulled via evaluatepharma provide snapshot commercially focused study analysis excludes academic government backed work well experiencing even upheaval study uncovered extracting clinical trial entry updated since march examining marked suspended terminated withdrawn part sponsor provide reason changing recruitment status trial total blame covid vast majority suspended rather scrapped hope much clinical work resume however updating clinicaltrials gov voluntary seems probable analysis understates disruption much sensitive examination impact clinical study found number medidata technology company sell platform sponsor run trial figure extracted active study across global study site logical country hit hardest pandemic see biggest impact dramatic drop big centre research like u uk particularly alarming encouragement seen statistic china already recovering suggesting region follow analysis visit per study subject ongoing trial show impact stay home policy refocusing healthcare system course specific damage done loss data erosion integrity trial losing patient follow problem outside pandemic whether study survive severe disruption yet determined number show damage inflicted severe many region life long way returning normal\n",
      "\n",
      "Keywords:\n",
      "suspended 0.252\n",
      "impact 0.204\n",
      "study 0.191\n",
      "uncovered 0.162\n",
      "extracted 0.162\n",
      "clinical work 0.162\n",
      "disruption 0.15\n",
      "damage 0.15\n",
      "sponsor 0.143\n",
      "region 0.138\n",
      "march 0.124\n",
      "work 0.123\n",
      "commercially 0.12\n",
      "pandemic 0.118\n",
      "trial 0.117\n",
      "focused 0.113\n",
      "clinical 0.11\n",
      "follow 0.101\n",
      "number 0.101\n",
      "analysis 0.1\n",
      "\n",
      "Abstract:\n",
      "unveiling presentation title first instalment year aacr meeting revealed two surprise absence keenly awaited clinical data roche anti tigit mab tiragolumab presence trio study ox immuno oncology target earlier fallen favour latter feature first human data one glaxosmithkline major oncology hope bispecific alligator bioscience well early data moderna ox l producing mrna project plenty novel target whet investor appetite absence tigit major disappointment investor tigit focused biotech including arcus compugen iteos keenly awaiting early tiragolumab data evidence back roche decision launch phase ii iii programme comprises three skyscraper study subject tiragolumab nearest rival merck co subsequently put competitor mk four new trial however aacr nothing tiragolumab presentation obviously highlighting tigit targeting project story published roche told vantage tiragolumab data presentation planned aacr ii june instalment aacr started friday covid pandemic caused organiser turn meeting two virtual event first next monday tuesday feature clinical presentation aacr say wanted get timely manner meeting abstract title made available aacr ii separate three day virtual meeting june abstract go live may among novel approach featuring clinical presentation aacr anti lif mab northern biologics optioned celgene whose future bristol myers squibb uncertain anti cldn conjugate abbvie immutep soluble lag protein focus ox come surprise already written approach esmo meeting pfizer pf astrazeneca medi showed disappointing remission rate monotherapies among preclinical presentation serd theme get airing data astrazeneca roche kras via poster novartis shp inhibitor pair boehringer ingelheim asset targeting kras so kras data interest mirati slumped yesterday short report kerrisdale capital term share price appreciation aacr already produced one winner iovance multi billion dollar valuation put another april title til study revealed durable complete response nsclc inference least two cr trial recruited subject meant rate least however nothing known remission evaluated occurred durable indeed since single arm study combine tils opdivo il two chemotherapy seems difficult put benefit specifically iovance tils instead intriguing cell therapy presentation aacr might first human data gracell allogeneic anti cd car project gc little known gracell chinese company founded former chief executive controversial company cellular biomedicine group raised series b round claim one day car manufacturing process among technical question clear gc target cell leukaemia might avoid fratricide problem perhaps revealed next week aacr take place virtual format april full abstract text wil go live april\n",
      "\n",
      "Keywords:\n",
      "aacr 0.414\n",
      "tiragolumab 0.228\n",
      "presentation 0.205\n",
      "presentation aacr 0.171\n",
      "tigit 0.169\n",
      "ox 0.152\n",
      "title 0.141\n",
      "kras 0.118\n",
      "meeting 0.117\n",
      "instalment 0.106\n",
      "gracell 0.106\n",
      "gc 0.106\n",
      "clinical presentation 0.106\n",
      "abstract 0.104\n",
      "go live 0.101\n",
      "virtual 0.098\n",
      "tils 0.097\n",
      "iovance 0.094\n",
      "first human data 0.091\n",
      "durable 0.091\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Abstract:\n",
      "putting finerenone patient pivotal programme diabetic kidney disease looked like bold bet back bayer first started study five year later sglt inhibitor way establishing beneficial class effect setting risk move never pay even greater become clearer data start emerge two phase iii trial topline result first fidelio dkd due second quarter figaro dkd read early next year bayer trying show finerenone reduce patient risk kidney failure cardiovascular death study pit pill placebo result held invokana record invokana johnson johnson sglt inhibitor last year became first drug class win approval reduce risk end stage kidney disease cardiovascular event diabetic chronic kidney disease around diabetic develop nephropathy progressive destruction kidney patient high risk cardiac complication kidney failure difference study invokana approval credence finerenone programme complicates cross trial comparison certain data point used yardstick however particular invokana reduction risk end stage kidney disease reduction various cardiovascular event credence finding considered hugely important clear benefit shown invokana established type diabetes treatment proven cardiovascular benefit trial sglt inhibitor expected confirm finding class effect astrazeneca dapa ckd study farxiga lilly empa kidney trial jardiance due report later year respectively study recruiting diabetic non diabetic adding another dimension attempt ass commercial impact finerenone hope achieve finerenone mineralocorticoid receptor antagonist mra mechanism already used control high blood pressure dampen damaging inflammation fibrosis hallmark diabetic kidney disease safety concern mean existing mras used last resort pfizer inspra older spironolactone example bayer hoping show finerenone entirely different proposition project main differentiator include non steroidal greater selectivity mra receptor bayer reckons translate fewer androgen based side effect decreased risk hyperkalaemia high potassium rate side effect watched closely phase iii data assuming safety cleaner primary endpoint met unequivocally added complication two study different focus fidelio composite primary endpoint includes time onset kidney failure measure kidney function renal death key secondary endpoint another composite ass cardiovascular death event figaro switch around cardiac endpoint primary trial recruited largely patient population type diabetic kidney disease maximum dose blood pressure therapy patient already sglt medicine company annual result bayer executive said likely order typical market share sglt finerenone population bernstein analyst note patient background sglt inhibitor form important cohort one bayer likely tease future cut data first company need topline readout confirm finerenone even chance competing\n",
      "\n",
      "Keywords:\n",
      "kidney 0.359\n",
      "finerenone 0.357\n",
      "diabetic 0.239\n",
      "sglt 0.213\n",
      "kidney disease 0.205\n",
      "bayer 0.205\n",
      "invokana 0.204\n",
      "sglt inhibitor 0.145\n",
      "diabetic kidney disease 0.134\n",
      "diabetic kidney 0.134\n",
      "kidney failure 0.127\n",
      "cardiovascular 0.121\n",
      "risk 0.096\n",
      "stage kidney disease 0.089\n",
      "stage kidney 0.089\n",
      "end stage kidney 0.089\n",
      "risk end stage 0.085\n",
      "end stage 0.085\n",
      "credence 0.085\n",
      "disease 0.082\n",
      "\n",
      "Abstract:\n",
      "idorsia created wake johnson johnson takeover actelion licensed lead j j fate looked sealed instead taken idorsia set developing pipeline today reported positive pivotal study hit daridorexant separate lead asset daridorexant dual orexin receptor antagonist development insomnia look aced four primary endpoint first two phase iii trial dos tested data yet scrutinised detail look absence sleep inducing drug typical side effect give idorsia immunology cardiology pipeline added focus however analyst likely zero one key secondary endpoint namely patient daytime performance measured using idsiq patient reported questionnaire developed idorsia validated u fda according metric daridorexant mg mg hit statistical significance versus placebo important idorsia second pivotal trial test mg mg result consistent company might see benefit daytime performance second study nevertheless analyst call today executive said trial read marked first time insomnia product improved performance day addition improving sleep quality night daridorexant enables patient sleep faster sleep longer function better next day said idorsia chief executive jean paul clozel whether single trial backing one dose product sufficient make claim remain key focus market await full data readout second pivotal study due later year primary endpoint seems little doubt daridorexant efficacy dos beat placebo one three month sleep maintenance sleep onset perhaps even importantly adverse event looked balanced across three cohort numerically fall fainting placebo active drug none adverse event listed prevalent mg mg safety vital consideration insomnia drug propensity cause sleepiness day two orexin receptor antagonist approved merck co belsomra eisai dayvigo carry warning daytime impairment possible effect driving performance idorsia trading today clearly hope daridorexant revolutionise insomnia treatment sellside forecast see revenue present according evaluatepharma upgrade look likely full data retain lustre daridorexant development owes much persistence r mr clozel running actelion company developing earlier version orexin approach almorexant project pulled drug drug interaction actelion awakens research sleep medicine july today daridorexant data back decision press three year mr clozel got j j pay bn actelion idorsia asset midas touch deserted\n",
      "\n",
      "Keywords:\n",
      "daridorexant 0.419\n",
      "idorsia 0.383\n",
      "sleep 0.335\n",
      "insomnia 0.21\n",
      "actelion 0.199\n",
      "orexin 0.157\n",
      "mg 0.154\n",
      "daytime 0.15\n",
      "performance 0.123\n",
      "mg mg 0.105\n",
      "orexin receptor antagonist 0.105\n",
      "orexin receptor 0.105\n",
      "second pivotal 0.1\n",
      "receptor antagonist 0.082\n",
      "today 0.069\n",
      "full data 0.067\n",
      "drug 0.066\n",
      "antagonist 0.064\n",
      "day 0.061\n",
      "pivotal study 0.061\n",
      "\n",
      "Abstract:\n",
      "urogen first u approval week treatment rare form urothelial cancer executive forgiven feeling pang regret timing small developer face making debut incredibly tough market largely locked coronavirus pandemic urogen preparing virtual launch insists still carried successfully jelmyto arrive june company certainly alone braving uncertain territory evaluate vantage identified product launched past couple month sellside belief hold significant revenue potential sale risk none escape disruption though pandemic hurt launch others jelmyto example treat low grade upper tract urothelial cancer orphan disease afflicts patient year targeted marketing campaign specialist urogen doubt already sight probably still impact treatment cancer life threatening illness continuing throughout pandemic another advantage sort company focus however cancellation medical conference big blow hoping roll medicine captive physician audience treating rare disease certainly shield bluebird bio released beta thalassemia gene therapy germany january said earlier month expected first patient dosed later year warned pandemic would hinder ability launch european market feeling pain launch targeting primary care market thought particularly vulnerable global shutdown aside widespread disruption healthcare system sale team physically unable reach front line physician category biohaven look particularly exposed company launched migraine treatment nurtec odt march presumably marketing team grounded esperion cholesterol lowering drug nexletol arrived u pharmacy shelf end last month company resorted setting telephone line email address asking physician get touch question aimmune peanut allergy treatment another march debut hindrance uptake palforzia need administered office allergist like biohaven esperion aimmune due report first quarter earnings may point lockdown ramification launch revealed investor braced disappointing number hope result reflect delay rather permanent commercial setback big drug developer affected bristol myers squibb receiving approval new multiple sclerosis treatment zeposia march said would hold launch bristol motivation presumably give product entering highly competitive market best start possible smaller company however typically invested heavily ahead launch le willing able simply hit pause button closer eye cash flow difficult time note projected sale according evaluatepharma consensus urogen jelmyto fall outside threshold selected cut analysis depth look covid pandemic impacting biopharma medtech sector check free report\n",
      "\n",
      "Keywords:\n",
      "launch 0.275\n",
      "urogen 0.273\n",
      "pandemic 0.153\n",
      "debut 0.136\n",
      "physician 0.135\n",
      "feeling 0.131\n",
      "esperion 0.131\n",
      "aimmune 0.119\n",
      "disruption 0.117\n",
      "treatment 0.116\n",
      "urothelial cancer 0.112\n",
      "urothelial 0.112\n",
      "biohaven 0.112\n",
      "team 0.108\n",
      "marketing 0.106\n",
      "march 0.097\n",
      "launched 0.093\n",
      "cancer 0.08\n",
      "market 0.076\n",
      "hold 0.076\n",
      "\n",
      "Abstract:\n",
      "vir biotechnology setting go covid player work hepatitis b might getting much attention yesterday company launched bid join arrowhead dicerna race develop functional cure viral disease would expected given vir coronavirus work yesterday announcement first result trial vir elicited market reaction interest arrowhead well follower another rnai player hepatitis b arbutus last month crashed data read disappointing absolute result aside significant importance market pricing arbutus today capitalised whereas vir valuation stand bn six month group completed nasdaq ipo vir developing two approach hep b antibody vir yet enter clinic yesterday data related vir sirna partnered alnylam target conserved region hbv x gene vir similar aln hbv discontinued project contains added galnac moiety surface antigen like arbutus disappointing trial ab rival galnac delivered rnai vir study key efficacy measurement related reduction level hbsag surface antigen one four major hep b transcript virus believed use replicate rebound double vir dos mg given week mean hbsag level dose dependently reduced log versus broadly unchanged placebo cohort key metric cross trial comparison point four week first injection hbsag level fell log second metric relevant considering arbutus data march ab given single mg mg injection similar time point day mean hbsag reduction log respectively aside look broadly similar day data generated arrowhead johnson johnson jnj face arbutus result look broadly similar vir former share price lose firstly analyst hoped least log reduction mg result driven one outlier subject excluded mean reduction come short log secondly ab study raised safety concern four mg dose subject seeing liver enzyme increase though two grade rest unrelated however outlier subject considered fluke worry ab might dosed higher non starter adverse event go case vir vir said saw clinically significant liver enzyme elevation highlighted technology decreased propensity cause elevation relevance hbsag biomarker must considered hep b relatively intractable virus thinking achieve functional cure viral dna hbsag must suppressed prevent rebound infection virus persists reservoir cccdna alone thought capable reviving infection still minutia unlikely troubling vir investor given last week endorsement glaxosmithkline group chiefly covid player sustaining multi billion dollar valuation meanwhile arbutus already failed two previous hepatitis b project might yet strike three company coronavirus plan b\n",
      "\n",
      "Keywords:\n",
      "vir 0.507\n",
      "hbsag 0.277\n",
      "arbutus 0.268\n",
      "log 0.223\n",
      "ab 0.169\n",
      "hep 0.144\n",
      "mg 0.123\n",
      "broadly 0.121\n",
      "arrowhead 0.116\n",
      "hepatitis 0.112\n",
      "rebound 0.096\n",
      "broadly similar 0.096\n",
      "virus 0.094\n",
      "surface antigen 0.092\n",
      "functional cure 0.092\n",
      "reduction 0.087\n",
      "similar 0.087\n",
      "cure 0.087\n",
      "elevation 0.084\n",
      "outlier 0.08\n",
      "\n",
      "Abstract:\n",
      "sideways shift obesity logical move diabetes company particularly substantial glp agonist franchise proven metabolic impact novo nordisk biggest player led drive push drug weight loss space company ambition extend beyond mechanism coming month several mid stage project slated yield data variously promise suppress appetite increase energy expenditure novo belief combination approach ultimately needed match sort reduction achieved bariatric surgery biggest pending readout pivotal step programme semaglutide company newest glp agonist well form backbone treatment regimen phase ii trial suggest semaglutide produce double level weight loss seen liraglutide novo older glp agonist marketed obesity saxenda saxenda associated weight loss bariatric surgery shown help patient lose body weight three year despite bestowing appears marginal benefit saxenda launched share global obesity market end novo claim product generated revenue last year company aim double obesity sale target much easily hit semaglutide raise game data four late stage study step program expected around middle year novo indicated coronavirus pandemic changed timeline noting recently significant delay expected trial already close finalisation pivotal programme test weekly subcutaneous injection mg semaglutide previously phase ii study mg daily dose semaglutide produced weight loss one year effect show sign plateauing common adverse event dose related gastrointestinal symptom primarily nausea something watch higher dose used step program bernstein analyst written greater weight loss would ideal phase iii study assume novo use priority review voucher get semaglutide market soon possible saxenda patent expires semaglutide life expectation provide big improvement currently available therapy however novo ultimately want able offer result closer seen bariatric surgery despite successful result complex intervention carry risk tends restricted severly obese patient getting weight loss involve adding another mechanism although course prove monotherapy first one company biggest hope involves targeting amylin long acting human amylin analogue phase demonstrated around weight loss eight week phase ii dose ranging study expected report first half year saxenda used active comparator group little luck targeting amylin including amylin pharmaceutical pramlintide whose development obesity discontinued previously novo chief science officer mads krogsgaard thomsen told evaluate vantage novo made improvement help avoid nausea seen pramlintide real potential mechanism revealed trial combine semaglutide regimen generate weight loss least according mr thomsen phase combination study due report second half year semaglutide serve appetite suppressor novo two phase candidate la gdf pyy boosting energy expenditure side coin novo glp glucagon targeting doublet triplet add gip agonist come still early project entirely clear whether novo say much result ongoing trial probably considered material group whole progression larger study might best indication signal seen semaglutide different story course step readout one biggest event novo horizon sellside already high hope product projected become market leader obesity according evaluatepharma\n",
      "\n",
      "Keywords:\n",
      "novo 0.352\n",
      "semaglutide 0.341\n",
      "weight loss 0.295\n",
      "weight 0.266\n",
      "obesity 0.2\n",
      "saxenda 0.199\n",
      "loss 0.188\n",
      "amylin 0.159\n",
      "glp 0.128\n",
      "bariatric surgery 0.126\n",
      "bariatric 0.126\n",
      "step 0.103\n",
      "agonist 0.103\n",
      "glp agonist 0.102\n",
      "surgery 0.098\n",
      "thomsen 0.084\n",
      "targeting amylin 0.084\n",
      "pramlintide 0.084\n",
      "expenditure 0.084\n",
      "phase 0.077\n",
      "\n",
      "Abstract:\n",
      "given sheer enormity developing distributing vaccine coronavirus assistance big pharma existing expertise vast capacity always going required pull massive feat vaccinating world le clear new process partnership would required get goal yesterday saw update two approach herculean task johnson johnson laid accelerated development plan sars cov vaccine sanofi glaxosmithkline two world biggest vaccine maker announced collaboration put another vaccine clinic end year initially small biotech quick tout new potential vaccine pandemic handsomely rewarded market despite tangible evidence ability bring product market swiftly become clear even effort lab bear fruit one limiting factor would capability build repurpose manufacturing infrastructure deliver billion vaccine required working risk yesterday j j claimed potentially produce hundred million vaccine scaling billion sanofi glaxo forecast might able start human trial second half year aim working product end get point company taking massively risky approach abandoning usual linear method development simultaneously preparing increase manufacturing capacity alongside clinical trial expected cut usual year development time vaccine two three potential failure process significant reflects high stake manufacturing lead candidate two backup risk j j expects generate safety data lead candidate end year potentially leading emergency use vaccine early departure standard pharma model j j collaborating barda talk potential partner europe asia expand manufacturing capacity recognition global problem require global solution pooling manufacturing resource respectively biggest fourth biggest vaccine maker glaxo sanofi able help answer call huge manufacturing capability first harm company indemnify potential claim harm novel vaccine might new consideration pharma j j sanofi glaxo assured cutting corner come safety hard see limited testing group able carry ambitious developmental timeframes identify potential toxicity particularly product go million billion people company trying accelerate vaccine development consider alongside protecting people sars cov protect potential litigation deal waive liability well sought government previously seen swine flu outbreak particularly important company pursuing experimental rna based vaccine like pfizer biontech moderna already started dosing people lead candidate emerging covid pandemic old way working get industry need coronavirus alongside necessary multi pronged development approach account clinical failure need sharing manufacturing data expertise facility logistics increase coming week month\n",
      "\n",
      "Keywords:\n",
      "vaccine 0.392\n",
      "manufacturing 0.244\n",
      "potential 0.151\n",
      "capacity 0.142\n",
      "required 0.138\n",
      "glaxo 0.136\n",
      "sanofi 0.124\n",
      "billion 0.123\n",
      "sars cov 0.12\n",
      "alongside 0.12\n",
      "vaccine maker 0.111\n",
      "working 0.111\n",
      "able 0.109\n",
      "sars 0.108\n",
      "people 0.108\n",
      "development 0.106\n",
      "manufacturing capacity 0.105\n",
      "expertise 0.105\n",
      "capability 0.105\n",
      "usual 0.103\n",
      "\n",
      "Abstract:\n",
      "blackstone buy inclisiran set new valuation largely unproven rnai asset rank one biggest royalty monetisation deal recent year royalty monetisation mark new departure blackstone might hint state market private equity transaction blackstone bread butter deal struck yesterday alnylam broader strategic dimension stroke validated novartis controversial bn takeover inclisiran primary owner medicine company last november value acquisition already looked rich npv inclisiran medicine company asset calculated evaluatepharma sellside consensus number amounted around bn deal premium already takeover fuelled share price novartis bet bn rna interference november yesterday blackstone made novartis c suite look smart marking inclisiran value still making seem like swiss firm picked bargain alnylam due mid teen royalty medicine company novartis inclisiran sale analyst reckoned average royalty pure profit value endorsed novartis swiss firm purchase price bn yet blackstone deal alnylam call bn cash fee half royalty stream therefore make meaningful return blackstone betting entirety royalty worth well bn put different way blackstone must think inclisiran worth least novartis thought five month ago sellside might soon mark model according evaluatepharma consensus inclisiran sale peak nearly bn two year drug patent expires using cost capital assuming probability success interest net present value bn blackstone need worth break even course blackstone bet broader importance since give alnylam loan worth cardiometabolic project vutrisiran aln agt equity stake faith blackstone putting rnai technology yet reflected reality true inclisiran small interfering rna prevents production pcsk awaiting u approval produced stellar clinical data biggest test market precedent amgen astellas rapatha sanofi regeneron praluent mabs pcsk sobering drug carried massive sale expectation failed deliver forecast slashed one difference however repatha praluent injected every two week monthly inclisiran given twice yearly seem like much convenience blackstone put bn bet\n",
      "\n",
      "Keywords:\n",
      "blackstone 0.598\n",
      "inclisiran 0.392\n",
      "royalty 0.197\n",
      "alnylam 0.162\n",
      "novartis 0.156\n",
      "bn 0.128\n",
      "medicine company 0.121\n",
      "worth 0.099\n",
      "seem like 0.093\n",
      "swiss firm 0.09\n",
      "praluent 0.09\n",
      "value 0.088\n",
      "pcsk 0.087\n",
      "bet 0.084\n",
      "medicine 0.082\n",
      "deal 0.076\n",
      "rnai 0.074\n",
      "rna 0.07\n",
      "broader 0.069\n",
      "swiss 0.068\n",
      "\n",
      "Abstract:\n",
      "beginning year witnessed steady flow well received biotech ipo nine young drug developer managing get away covid infected market end march stream dried hiatus brief encouragingly two company keros therapeutic zentalis pharmaceutical managed float early april seems window entirely shut high risk investment one worst stock market crash history sure left mark however still harbouring hope public life proceed cautiously according data collected evaluatepharma nine drug developer floated first quarter raised bn total respectable haul looking back past year tally would presumably much higher pandemic called halt proceeding however analysis includes drug developer represents highest risk proposition attempting go public medtech diagnostic digital health company excluded flotation western exchange captured certainly evidence suggest pandemic curtailed shaping strong run new issue renaissance capital estimate company halted ipo plan march across sector healthcare currently supplying big proportion new issue seems likely drug developer make fair proportion number investor case accepted valuation placed front early part year another indication strength market chart examines difference initially proposed share price range price flotation went big uptick seen caveat first quarter cohort pretty small average boosted three company priced range upsized deal revolution medicine black diamond schr dinger focused targeted cancer therapy incredibly competitive space showing sign cooling imara raise huge haul rare disease specialist worth mentioning managed float march th market freefall true deal priced bottom range company previously upsized offer perhaps impressively stock held water since floating investor must consider keros zentalis pandemic proof got away successfully month market volatility far past upsized ipo trading substantially higher offer price former developing drug tgf beta target attracting much attention zentalis another targeted cancer drug play still hoping float still chance seems although whether worst anyone guess\n",
      "\n",
      "Keywords:\n",
      "zentalis 0.23\n",
      "upsized 0.21\n",
      "drug developer 0.192\n",
      "float 0.158\n",
      "developer 0.144\n",
      "range 0.142\n",
      "targeted cancer 0.14\n",
      "haul 0.14\n",
      "ipo 0.133\n",
      "new issue 0.125\n",
      "drug 0.116\n",
      "priced 0.113\n",
      "flotation 0.107\n",
      "worst 0.104\n",
      "march 0.103\n",
      "market 0.102\n",
      "targeted 0.099\n",
      "proportion 0.098\n",
      "pandemic 0.098\n",
      "first quarter 0.094\n",
      "\n",
      "Abstract:\n",
      "see new dedicated covid landing page latest story download free depth report covering pandemic gilead put covid subject remdesivir april interest testing remdesivir covid ramping gilead moved increase chance two study yield something positive look upcoming covid trial readout april industry sponsored clinical study new coronavirus proliferated design efficacy measure covid oil wheel business development april vir tie glaxo lead recent deal activity aiming treat new coronavirus fda authorises first covid antibody test april cellex win race get fda buy blood test pinpoint immunity long path effective coronavirus vaccine april biopharma develop vaccine covid property approach vantage take look joint maker report pandemic pain april sale implant set fall sharply non urgent procedure deferred covid threat business acquisition april key healthcare transaction struck covid pandemic hit yet formally completed scramble reinvent ventilator march smith group delay split partly focus ventilator production u fda grant emergency authorisation breathing device treat covid u authorisation arrives point care covid test march past week u fda granted emergency use authorisation seven vitro diagnostics covid infection bringing total biotech balancing act amid covid delay march vantage analysis suggests small biotech might seriously rethink r spending plan wake covid small company work covid antibody test march statement week public health england uk would soon start mass testing identify people covid infection recovered therefore immune thrown spotlight developer antibody based blood test making sense covid treatment approach march igm dan chen expert coronaviruses speaks value different way trying treat covid covid force lilly hit brake march lilly pause much research owing coronavirus pandemic vantage take look estimate cash committed ongoing clinical study clue lot pivotal readout threatened covid represent bn investment march last week vantage highlighted pivotal trial approaching readout face delay caused new coronavirus pandemic analysis seek put figure exactly much cash put work bn figure evaluatepharma vision estimate cost run study go go covid upstage u regulatory decision march vantage analysis fda decision expected next month ongoing covid pandemic affect clinical trial delay become reality covid risk spread march vantage analysis identifies pivotal trial risk like lexicon scored soloist study never completed genmark add value covid test authorisation march fate company obtained fda emergency use authorisation sequencing based test novel coronavirus diverged wildly judging share price performance trading period eua granted first clinical data show biopharma way covid march hint activity generated academic centre suggest antiviral antimalarial might play role covid hope replaces hype coronavirus stock march investor homing biopharma company able make real contribution coronavirus pandemic market frothiness far covid treatment plan slowly emerges march antiviral anti interleukin vaccine take centre stage clinical trial effort tackle coronavirus pandemic traditional high tech solution needed ventilator shortage march one thing certain ongoing covid pandemic hospital healthcare system need respirator crisis crisis curevac denies everything march covid vaccine exclusivity senior management storm engulfs curevac german mrna specialist insists conjecture coincidence two test nod fda relaxes rule still march thanks fda hologic labcorp managed arrest damage sustained yesterday bloodbath exchange share slightly agency granted emergency use authorisation covid diagnostics hunt covid vaccine march cepi asks bn fund development vaccine coronavirus moderna move clinic vantage take look previous pandemic development cost fda authorises covid test roche thermo fisher march race diagnostics company first get fda authorisation covid assay declared draw friday roche thermo fisher gaining emergency use authorisation respective test estimating cost covid antiviral development march money course object come funding development treatment covid much exactly talking tiziana take deep breath target covid march using drug cause exacerbate lung infection treat novel coronavirus go wrong covid vaccine gonna call march much world vaccine manufacturing capacity lie fairly small number company west least group world health organization would likely turn preventative treatment covid found group developed covid diagnostics change march fda loosening rule authorisation diagnostic test new coronavirus still way behind europe sale covid vaccine echo swine avian flu shot march vaccine maker managed respond pretty quickly previous viral outbreak swine flu avian flu specifically certain company still booking sale preventative shot evaluatepharma data show biopharma role tackling coronavirus march industry duty develop covid antiviral vaccine nature clinical trial mean lower profile measure must take precedence previous pandemic antiviral demand spike see biocryst jump aboard march covid outbreak highlighted need effective broad spectrum antiviral stockpiled time need look historic sale existing agent show use spiked previous outbreak coronavirus stock hype prof infectious february coronavirus focused investor willingly backed bona fide development egregious publicity stunt alike big cap join coronavirus scramble february longer small biotech taking aim coronavirus gilead science glaxosmithkline getting involved albeit via different route\n",
      "\n",
      "Keywords:\n",
      "covid 0.461\n",
      "march 0.324\n",
      "coronavirus 0.235\n",
      "authorisation 0.192\n",
      "vaccine 0.152\n",
      "test 0.143\n",
      "pandemic 0.135\n",
      "fda 0.119\n",
      "antiviral 0.116\n",
      "april 0.103\n",
      "emergency 0.095\n",
      "vantage take look 0.092\n",
      "vantage take 0.092\n",
      "march vantage analysis 0.092\n",
      "march vantage 0.092\n",
      "use authorisation 0.09\n",
      "emergency use authorisation 0.09\n",
      "new coronavirus 0.088\n",
      "take look 0.087\n",
      "covid test 0.087\n",
      "\n",
      "Abstract:\n",
      "clinical trial mothballed across biopharma industry company delaying launch new product covid bn arch venture partner raised two new fund anything go still substantial appetite private financing even high risk end biotech fact arch able amass huge war chest reflects belief biopharma eventually return semblance normality patient still require new innovative drug vantage latest analysis evaluatepharma data reflects venture seeming resilience coronavirus amount invested opening month year volume deal showing little retreat previous quarter noted analysis includes company developing human therapeutic providing look highest risk end biotech venture investing subsectors like medtech diagnostics excluded digital health industry seen huge inflow investment thanks covid pandemic current pace investment maintained rest total funding come around bn back level widely agreed outlier sum raised still high historically volume deal stayed pretty constant past seven quarter suggesting new normal emerging look like mega round remain much feature huge syndicate formed fund company far along development path possible concentrated venture cash ever fewer hand one fallout pandemic exacerbate trend vcs perhaps leaning towards safer play coming month annual biopharma venture investment investment bn financing count avg per financing round round q course point year everything speculative given yet see full fallout pandemic continue affect supply chain much biopharma interrupt hiring plan start ups almost certainly delay non covid related dealmaking shielding venture sector medium term fact good time allowed huge fund raised deployed within defined timeframes arch fundraising demonstrates limited partner supply capital fund still keen allocate cash asset class much depends long disruption continues something true pretty much sector usual turn book biggest financing quarter led uk company immunocore troubled biotech long looking money managed secure series b round although fact round took shine usual suspect oncology gene therapy company among five largest round kallyope focus small molecule drug targeting gut showed company lower profile therapy area rake substantial amount cash timing sutrovax series round end march might coincidental given time take put syndicate together alongside group primary focus pneumococcal infection cell free protein synthesis vaccine platform promise circumvent efficacy scaling issue traditional vaccine might provided additional attraction coronavirus time first quarter raise obvious alarm bell financing smaller company interesting watch venture chooses allocate money coming month\n",
      "\n",
      "Keywords:\n",
      "round 0.332\n",
      "venture 0.298\n",
      "financing 0.21\n",
      "arch 0.186\n",
      "fund 0.153\n",
      "investment 0.132\n",
      "series round 0.124\n",
      "syndicate 0.118\n",
      "fallout 0.118\n",
      "biopharma 0.115\n",
      "huge 0.108\n",
      "risk end 0.106\n",
      "usual 0.101\n",
      "quarter 0.099\n",
      "series 0.099\n",
      "reflects 0.099\n",
      "raised 0.097\n",
      "supply 0.092\n",
      "company 0.091\n",
      "volume 0.088\n",
      "\n",
      "Abstract:\n",
      "attention battle treat covid turn imminent readout remdesivir study china investor trying handicap chance gilead global trial reading little later worthwhile remembering clinical study recently got way treat case prevent new coronavirus analysis data evaluatepharma dedicated covid landing page reveals fewer trial seeking enrol nearly subject especially interesting commercial study endpoint group comprises trial project including course gilead two remdesivir study read may key consideration whether study blinded control case remdesivir one main point differentiating gilead chinese trial latter two test mild moderate severe covid subject quadruple blinded measure time clinical recovery versus placebo gilead meanwhile open label moderate disease trial versus standard care severe uncontrolled measure disease improvement day set trial use mg loading dose followed mg nine day though gilead test five day cohort one hand china trial open ended efficacy endpoint seems le strict gilead assuming effect within day though course former blinded design stringent another issue confounding comparison china group recruited subject within eight day symptom onset gilead specified four day pcr confirmation covid evercore isi say former source remdesivir gilead gilead stated visibility data among project investor keenly tracking malaria lupus drug plaquenil championed president donald trump since scrap data supporting largely anecdotal reassuring sanofi study ending late year quadruple blinded one measure tough endpoint cause mortality versus placebo two commercial vaccine trial present moderna cansino long path effective coronavirus vaccine april however soon joined vaccine johnson johnson uk university oxford latter consortium oxford biomedica joined today ultimately investor want share price reflect progress gilead valuation put nearly bn year date j j gained bn revealed lead covid vaccine candidate despite j j spelling profit basis work gilead unlikely able charge much remdesivir plaquenil patent said kudos company brings effective treatment market term publicity government recognition value\n",
      "\n",
      "Keywords:\n",
      "gilead 0.355\n",
      "remdesivir 0.242\n",
      "blinded 0.22\n",
      "day 0.163\n",
      "joined 0.141\n",
      "vaccine 0.135\n",
      "covid 0.134\n",
      "remdesivir study 0.134\n",
      "plaquenil 0.134\n",
      "china 0.123\n",
      "trial 0.119\n",
      "oxford 0.101\n",
      "study 0.097\n",
      "moderate 0.097\n",
      "measure 0.09\n",
      "nearly 0.087\n",
      "effective 0.084\n",
      "within 0.082\n",
      "treat 0.08\n",
      "johnson 0.078\n",
      "\n",
      "Abstract:\n",
      "flurry deal making towards end meant opening month year already unlikely see much among drug maker coronavirus arrived still first quarter number far desperately low suggesting real impact pandemic resulting global lockdown seen coming month gilead bn takeout forty seven early march rescued period obscurity investor must hope similar bolt deal continue happen year chance sizeable transaction getting ground surely close zero well straight company takeout analysis count minority majority stake purchase acquisition business unit reverse merger option aggregated deal number concern deal dedicated drug maker diagnostics medtech transaction excluded cover licensing transaction latest data evaluatepharma show volume transaction fell least four year low opening month similarly slow period reported recent year particularly following strong previous quarter final month certainly buoyant bn plus transaction announced big finish confirms takeover year remember january case pandemic probably really started hitting business europe u march mean second quarter number needed start properly assessing impact look money deployed transaction illustrates strength late spike particularly term whole company takeout show opening month far disastrous held activity past four year forty seven deal lilly move dermira next biggest transaction first quarter rest top five unit sale legacy business unlikely got biopharma investor heart pumping still happening horizon bought curzion front last week one assume negotiation case already started pre covid world hard imagine executive keen initiate complex takeover current climate future valuation hard pin even considering logistical challenge silver lining buyer suppressed valuation create opportunity perhaps provide sufficient motivation overcome barrier pandemic throwing hard know long disruption go many organisation pressing concern contend\n",
      "\n",
      "Keywords:\n",
      "transaction 0.333\n",
      "opening month 0.21\n",
      "opening 0.18\n",
      "deal 0.137\n",
      "takeout 0.131\n",
      "company takeout 0.12\n",
      "quarter 0.118\n",
      "business 0.111\n",
      "four year 0.11\n",
      "forty seven 0.109\n",
      "forty 0.109\n",
      "unit 0.107\n",
      "hard 0.104\n",
      "month 0.103\n",
      "drug maker 0.096\n",
      "pandemic 0.094\n",
      "first quarter 0.09\n",
      "maker 0.088\n",
      "period 0.085\n",
      "takeover 0.082\n",
      "\n",
      "Abstract:\n",
      "though seem like time vir biotechnology hardly timed flotation better infectious disease specialist ipo last october saw stock lose first day trading coronoavirus pandemic hit vir race flurry covid based development followed culminating yesterday injection glaxosmithkline seeing vir surge breach bn valuation several company benefited move covid thanks business development activity clinical trial initiation recent stock market gainer include mesoblast yesterday news u ind use remestemcel l acute respiratory distress cleared redhill boosted italian compassionate use designation yeliva adaptive biotechnology antibody deal amgen vir however covid journey began february discovery two antibody targeting virus spike protein next biotech signed deal wuxi alnylam expanded month later xencor nih biogen variously developing antibody rnai therapeutic vaccine thus glaxo deal announced yesterday came vir already signalled positioning go covid player uk company investment premium made vir stock already tripled year date deal immediate impact two lead mabs spike protein vir already identified vir vir partner plan take phase ii among industry coronavirus related business development activity two deal mark important theme use plasma patient covid recovered focus recent tie ups xbiotech biobridge amgen adaptive team seeking identify neutralising antibody immune system people raised covid view developing treatment ethris neurimmune pursuing conceptually similar practically much difficult approach seeking use information gleaned recovered patient develop mrna treatment would generate relevant antibody inhaled disappointment course good news multitude stock market announcement detailed covid threat business activity including delaying shareholder meeting pausing clinical trial covid force lilly hit brake march scientific conference turned virtual event include aacr acc isct asco easl meanwhile postponed august evaluate vantage identified several pending acquisition risked delayed pandemic covid threat business acquisition april however ucb purchase ra gilead takeover forty seven managed close coronavirus pandemic clearly major threat biotech represents sizeable opportunity\n",
      "\n",
      "Keywords:\n",
      "vir 0.438\n",
      "covid 0.233\n",
      "business 0.137\n",
      "threat business 0.136\n",
      "covid threat business 0.136\n",
      "covid threat 0.136\n",
      "antibody 0.134\n",
      "deal 0.127\n",
      "adaptive 0.12\n",
      "threat 0.114\n",
      "spike protein 0.111\n",
      "recovered 0.102\n",
      "biotechnology 0.102\n",
      "use 0.1\n",
      "stock 0.1\n",
      "spike 0.096\n",
      "activity 0.095\n",
      "business development 0.095\n",
      "identified 0.093\n",
      "seeking 0.092\n",
      "\n",
      "Abstract:\n",
      "even defensive pharmaceutical sector suffered widespread share price fall first quarter hundred billion wiped global valuation previous evaluate vantage analysis found covid infects global drug stock april look loss incurred regionally show u shielded certain extent several leading company leading charge find potential treatment europe hit hardest opening month italy spain became focus pandemic march japanese drugmakers escaping much either new project evaluate vantage started tracking stock market performance almost global drugmakers covered evaluatepharma universe excludes micro cap defined worth le includes dedicated drug maker company whose business primarily medtech diagnostics example excluded u contributes largest number drug maker universe company total therefore account biggest chunk market cap eroded first quarter huge proportion stock registering share price decline big proportion losing quarter value still u stock rose spectacularly vir biotechnology cytodyn topped table share price gain u across whole universe country contributed four biggest share price jump across universe forty seven inovio climbing strongly well term valuation huge market cap gain big u biotech regeneron bn gilead bn helped protect region sort loss seen elsewhere go without saying vast majority riser fuelled hope experimental covid treatment disparate country europe contribute drugmakers universe saw share price fall first quarter fall biggest hit region total market cap biontech german mrna player represents rare bright spot share price gain region impressive three month bn valuation boost topped european cohort france ab science spain pharmamar benefited coronavirus effort though small company japan chugai stand remarkable performance given company one country biggest pharma stock share price gain first quarter added equivalent bn market cap taking stock record high largely chugai exposure il approach discovered actemra roche owns company pay substantial royalty chugai sale antibody kyorin another big gainer company said mid april would launch test coronavirus take minute share small cap drug developer gained first quarter bright spot far common however drug index fared badly sector cold comfort executive investor hoping remainder year way\n",
      "\n",
      "Keywords:\n",
      "universe 0.284\n",
      "share price 0.21\n",
      "first quarter 0.184\n",
      "drugmakers 0.179\n",
      "cap 0.163\n",
      "share 0.163\n",
      "price 0.162\n",
      "chugai 0.158\n",
      "share price gain 0.146\n",
      "price gain 0.146\n",
      "quarter 0.143\n",
      "region 0.135\n",
      "stock 0.131\n",
      "gain 0.131\n",
      "country 0.128\n",
      "topped 0.119\n",
      "share price fall 0.119\n",
      "price fall 0.119\n",
      "market cap 0.116\n",
      "spain 0.114\n",
      "\n",
      "Abstract:\n",
      "coronoavirus pandemic swept globe early month stock market tumbled leaving industry untouched gain various drug developer working towards solution sheltered biopharma certain extent valuation across board still plummeted new project vantage started tracking stock market performance almost global drug maker covered evaluatepharma first cut dataset show big mid small cap company saw substantial market cap erosion first quarter adding huge bn loss valuation across universe still extent surge global biopharma stock enjoyed end last year forgotten three month period universe gained valuation lost first quarter driven run deal clinical win important new drug approval several came early global biopharma sector started pandemic high many company well funded selloff commenced three month earlier public drug developer investor would probably confronting period different frame mind illustration severity first quarter decline company universe registered share price drop three month losing quarter market value granular cut data biopharma sector split four cohort based year end market cap incorporate big pharma company big drug stock worth least bn mid cap capitalisation bn small cap sitting bn micro cap worth le excluded analysis universe cover dedicated drug maker company whose business primarily medtech diagnostics example excluded percentage wise small cap suffered first quarter cohort losing combined market cap higher risk company typically suffer downturn group provides impressive share price gain vir biotechnology advance sits top entire universe cytodyn gain far behind developer risen hope respective r project play role treating covid indeed pandemic responsible gain seen market cap group cohort large drug maker excluding big pharma escaped smallest market cap erosion largely thanks huge advance three company thought likely deliver covid therapeutic gilead regeneron japan chugai added bn market cap first quarter biggest gain seen across universe standing mid cap biontech moderna feature universe top share price gainer leading coronavirus vaccine player fact big pharma group logically defensive play pandemic punished heavily illustrates extent global stock market meltdown major index like dow jones industrial average ftse dropping around across first quarter perhaps actually got lightly major lilly ended quarter higher roche flat pfizer glaxosmithkline merck co biggest casualty registering decline respectively analysis market valuation gain loss directly attributable pandemic initiative check evaluate covid eventanalyzer\n",
      "\n",
      "Keywords:\n",
      "universe 0.358\n",
      "cap 0.294\n",
      "first quarter 0.198\n",
      "gain 0.177\n",
      "quarter 0.172\n",
      "market 0.157\n",
      "market cap 0.157\n",
      "small cap 0.131\n",
      "pandemic 0.115\n",
      "global 0.109\n",
      "across universe 0.107\n",
      "drug maker 0.105\n",
      "stock market 0.104\n",
      "extent 0.101\n",
      "biopharma 0.099\n",
      "stock 0.098\n",
      "mid cap 0.098\n",
      "erosion 0.098\n",
      "valuation 0.098\n",
      "three month 0.097\n",
      "\n",
      "Abstract:\n",
      "effort develop treatment covid continue probably possible declare pandemic truly effective vaccine exists numerous company active vantage analysis reveals nearly project special interest among mrna vaccine seized early lead courtesy moderna though johnson johnson promise develop adenovirus vector based approach non profit basis might promise however despite understandable enthusiasm road vaccine approved long treacherous need build sufficient manufacturing infrastructure one aspect slow process vaccine sufficient efficacy developed take find product right mix safety ability generate antibody offer sufficient protection recent article coalition epidemic preparedness innovation cepi nejm pointed industry ability respond quickly need pandemic flu vaccine said sars followed similar path additionally covid rna virus industry vaccine effort type pathogen notably rsv underwhelmed early attention might surprise coronavirus pandemic moderna mrna rather traditional vaccine approach seized early attention one key advantage rna dna vaccine use synthetic process require culture fermentation offering much faster manufacturing moderna claim mrna vaccine better mimicking natural infection highlight agility manufacturing system production phase ii trial begin month ultimately allow million dos made pfizer deal biontech hope enter clinic another mrna vaccine month told vantage working record pace development process generally take year working partner government agency find opportunity save time wherever unique antigen mechanistically prophylactic vaccine work exposing immune system antigen unique virus question seeking prime immune system quick generation large amount antibody event actual infection mrna vaccine instance comprises mrna code expression protein antigen different vaccine different property term whether generate humoral b cell antibody versus cellular effector cell immunity site elicited beyond modality vaccine approach us whether adjuvanting needed potentiate immune response key consideration clearly choice antigen far popular approach target epitope covid spike protein structure found surface virus ideally antibody raised bind virus immediately stop infection host cell vaccine target far undisclosed epitope protein cepi outlined carrying multiple activity simultaneously rather linearly curtail development time pandemic j j say accelerated timeline see lead vaccine ready emergency use would represent extraordinarily fast turnaround even vaccine sort might needed even sooner thus even suboptimal vaccine moderate efficacy merely reduce severity covid infection might viable way protecting people next winter approach think hard imagine fully returning pre covid life effective vaccine population infected therapy turn nearly severe case nothing annual flu say dan chen chief medical officer igm bioscience coronavirus expert virtue phd thesis require global government follow funding promise nejm paper author caution sars zika epidemic ended vaccine development complete point federal funding dried developer left nursing loss biopharma obviously want play role pandemic acutely aware often vaccine development represents economic black hole story corrects earlier mistake table\n",
      "\n",
      "Keywords:\n",
      "vaccine 0.521\n",
      "mrna 0.177\n",
      "mrna vaccine 0.145\n",
      "antigen 0.143\n",
      "virus 0.129\n",
      "infection 0.119\n",
      "sufficient 0.115\n",
      "pandemic 0.111\n",
      "approach 0.105\n",
      "process 0.103\n",
      "covid 0.099\n",
      "vaccine approach 0.099\n",
      "seized 0.095\n",
      "system 0.093\n",
      "epitope 0.092\n",
      "epidemic 0.092\n",
      "cepi 0.092\n",
      "sars 0.089\n",
      "immune 0.089\n",
      "moderna 0.086\n",
      "\n",
      "Abstract:\n",
      "even coronavirus pandemic directly blame today scrapping aurobindo buyout novartis generic brand might straw broke camel back many pending acquisition might face similar fate answer question vantage analysed open deal evaluatepharma identified healthcare related transaction dating back november announced yet completed clearly risk scrapped least delay renegotiation scenario investor must consider term value three pending transaction stand abbvie bn buyout allergan stryker bn bid wright medical ucb pending acquisition ra pharmaceutical worth bn first due close may abbvie agreed u ftc divest brazikumab astrazeneca zenpep viokace nestl completed time relies finalisation paperwork global lockdown cannot dismissed mere formality stryker wright deal shakier ground drawing attention ftc company looked like struggling meet second half completion date covid hit west ra takeover closed first quarter today ra remains listed nasdaq recent deal analysis gilead takeout forty seven thermo fisher qiagen necessarily threat since signed reality covid extent threat perhaps yet fully understood however typical pending transaction perhaps biggest worry pandemic lead lengthy delay end target business valuation departed reality existed time deal struck novartis aurobindo termination case point deal involving indian company paying u oral dermatology brand sandoz portfolio signed way back september month later ftc asked company information today deal terminated mutual agreement reason given ftc approval obtained within expected timeline implying longer realistic rely price agreed long ago covid cited prospect delaying completion even cannot helped amendment given break fee deal carry terminating mutual agreement blessing failing term pending transaction amended suit new reality without much negotiation legal expense interesting imaging group lantheus proposed takeover oncology company progenics deal struck last october february term amended give progenics holder greater share combined entity today covid lockdown caused investor vote transaction postponed two month june new reality shareholder awaiting takeover dividend contend\n",
      "\n",
      "Keywords:\n",
      "ftc 0.264\n",
      "pending 0.252\n",
      "transaction 0.224\n",
      "pending transaction 0.223\n",
      "deal 0.207\n",
      "ra 0.174\n",
      "reality 0.169\n",
      "pending acquisition 0.139\n",
      "new reality 0.139\n",
      "aurobindo 0.139\n",
      "brand 0.132\n",
      "deal struck 0.119\n",
      "takeover 0.117\n",
      "amended 0.116\n",
      "agreed 0.108\n",
      "covid 0.106\n",
      "lockdown 0.101\n",
      "signed 0.099\n",
      "agreement 0.095\n",
      "completion 0.094\n",
      "\n",
      "Abstract:\n",
      "perhaps nash data sector looking provided respite time covid derailing normal business activity akero company public market le year reported stellar result first cut mid stage nash trial pipeline lead akr group climbed yesterday close price nasdaq ipo last june success clearly interest developer asset use akr fgf stimulant mechanism including ambrx bio novo nordisk still scope covid disrupt akero party yesterday result related mri data including primary endpoint week change liver fat fraction versus placebo comparison biopsy treated control subject robust measure data might available seems air akero said subject amounting balanced study population eligible biopsy two day ago half collected paired biopsy data expected current quarter much covid interfere biopsy collection patient follow unclear akero said keenly awaited nash dataset remains interim result genfit resolve trial elafibranor several delay still due current quarter u adcom review intercept ocaliva meanwhile delayed june amid coronavirus pandemic impressive nevertheless non invasive mri data akero released yesterday look impressive relative reduction liver fat versus baseline three akr dos tested numerical dose response three hit statistical significance versus placebo recipient showed reduction evercore isi analyst wrote comfortably exceeded expectation mri reduction pointed competitor benchmark biopsy data akero shoot shown nash resolution one stage fibrosis improvement though course performance placebo cohort netted mri data alone position akr potential best class asset evercore said fgf stimulant project development include bristol myers squibb ambrx pegbelfermin bio bio yield mid stage nash data year covid pandemic permitting another important rival ngm biopharmaceuticals aldafermin fgf regulator last year showed relative fat content reduction phase ii however came cost significant jump patient ldl side effect watched akero say akr share nevertheless ngm february generated biopsy data showing aldafermin treated subject showing fibrosis improvement nash resolution versus placebo cohort shown fat reduction mri thus opportunity akero much better mri reduction crush opposition biopsy data covid scupper study course like akero ngm bio floated last year akero prof pick bunch amgen might come rue day sold akr mere\n",
      "\n",
      "Keywords:\n",
      "akero 0.424\n",
      "akr 0.254\n",
      "biopsy 0.252\n",
      "mri 0.241\n",
      "nash 0.184\n",
      "biopsy data 0.161\n",
      "fat 0.157\n",
      "ngm 0.148\n",
      "mri data 0.148\n",
      "fgf 0.136\n",
      "reduction 0.128\n",
      "bio 0.123\n",
      "data 0.105\n",
      "stage nash 0.099\n",
      "nash data 0.099\n",
      "mid stage nash 0.099\n",
      "fibrosis improvement 0.099\n",
      "data akero 0.099\n",
      "akero said 0.099\n",
      "covid 0.094\n",
      "\n",
      "Abstract:\n",
      "age old story love lost found lost case love really drug amarin vascepa crucial u patent invalidated yesterday company appeal tale still might twist plunge amarin stock today show investor lost interest rightfully executive gambled win rather settling two remaining generic challenger bet today seems woefully misjudged amarin alone expressing confidence prevailing lawsuit brought dr reddy hikma big majority analyst told investor company good chance winning sellside today swiftly moved slash price target single digit amarin share trading end last year morning opened hope takeout largely responsible driving company valuation reached bn peak party really interested decision hold today seem prescient intellectual property always thought vascepa achilles heel seems proven litigation risk still overhang amarin takeover thesis december district court decided although generic group would infringing amarin patent patent invalidated ground obviousness vascepa advanced fish oil product comprising pure eicosapentaenoic acid epa older drug like glaxosmithkline lovaza contain docosahexanoic acid dha ingredient long known raise ldl cholesterol therefore would obvious skilled artisan removing dha fish oil product solved ldl problem judge concluded retaining ability reduce triglyceride amarin seek injunction halt generic launch process believe stretch year immediate risk company injunction turned month stay long expired challenger anda filing u approval swiftly followed risk launch hikma today said evaluating option exactly course action dr reddy presumably another aspect consider teva might amarin settled israeli firm challenge back deal israeli firm agreed stay market august commercial launch another generic manufacturer certain circumstance bring date forward risk launch elsewhere surely one circumstance agreement pay amarin royalty early sale provides wafer thin silver lining cold comfort still three generic firm filed andas back notable tentative approval yet granted presumably complete response letter issued vascepa complex product approval anytime soon far guaranteed decision implication u sale leerink analyst estimate canada europe china combined represent least bn sale opportunity though drug launched first territory eu approval decision amarin intending find partner due later year clinical development still ongoing china potential delay generic approval cold comfort investor seen amarin transition stock market wildcard developer universally lauded lifesaving medicine mere month u always big prize sale start evaporating soon next year\n",
      "\n",
      "Keywords:\n",
      "amarin 0.517\n",
      "generic 0.24\n",
      "vascepa 0.192\n",
      "launch 0.129\n",
      "dha 0.112\n",
      "cold comfort 0.112\n",
      "lost 0.109\n",
      "firm 0.109\n",
      "oil product 0.108\n",
      "israeli 0.108\n",
      "fish oil product 0.108\n",
      "challenger 0.108\n",
      "patent 0.104\n",
      "approval 0.099\n",
      "fish oil 0.098\n",
      "comfort 0.098\n",
      "today 0.097\n",
      "oil 0.096\n",
      "fish 0.096\n",
      "stay 0.094\n",
      "\n",
      "Abstract:\n",
      "normal world posting positive pivotal data indication clearly separate competition would surefire way boost share price however normal time biohaven saw share slide yesterday reporting nurtec odt scored hit tricky migraine prevention setting uncertainty covid pandemic throwing made investor scrutinise company announcement closely normal despite showing significant difference placebo incidence monthly migraine day reduction nurtec odt mustered shy one day minimum analyst looking different three cgrp migraine drug already market prevention data key differentiator nurtec marking drug shown impact migraine treatment prevention alike asset one oral treatment something biohaven bound talk alongside prevention data company hope move quickly term regulatory submission said already working submission prevention setting fda ema filing expected mid year successful approval come next year haste wise given covid pandemic already started hit clinical trial timeline point disrupt function regulatory body new model sale army even without formal approval prevention doctor become aware new data pill approved february acute setting marketing commenced still four week first confirmed u covid case social distancing lockdown measure place almost certain blunt product prospect year current sale forecast sit year even covid unadjusted number might overly generous given acute cgrp market turned smaller expected part due availability cheap generic triptans issue around reimbursement initially saw company give away product sale failed ramp since even price concession patient access programme number player cgrp market proximity initial launch ensured payer benefited fierce competition maker existing headwind biohaven attempt launch environment sale force either lockdown prohibited visiting physician made even harder company relying virtual launch strategy seen use remote meeting technology provide education programme kols doctor company employing webinars accessing growing telemedicine market spread word alongside direct consumer tv social medium add constantly evolving time rest market watching see biohaven virtual approach prof model worth replicating\n",
      "\n",
      "Keywords:\n",
      "prevention 0.338\n",
      "biohaven 0.234\n",
      "migraine 0.225\n",
      "nurtec 0.225\n",
      "cgrp 0.187\n",
      "normal 0.145\n",
      "social 0.143\n",
      "prevention setting 0.137\n",
      "odt 0.125\n",
      "launch 0.123\n",
      "covid 0.114\n",
      "submission 0.111\n",
      "lockdown 0.109\n",
      "sale 0.105\n",
      "market 0.099\n",
      "doctor 0.099\n",
      "even 0.097\n",
      "alongside 0.095\n",
      "acute 0.095\n",
      "model 0.094\n",
      "\n",
      "Abstract:\n",
      "presentation vericiguat pivotal heart failure study victoria american college cardiology annual meeting weekend followed glowing endorsement two reviewing physician merck co bayer struggle translate acknowledgement broad commercial use true study first show benefit specific group sick patient already standard care novartis entresto becoming increasingly entrenched astrazeneca sglt inhibitor farxiga poised approval coming week vericuguat arrive competitive market certain cross trial comparison make flattering reading three pivotal trial agent paradigm hf dapa hf victoria recruited patient heart failure reduced ejection fraction hfref important differentiation victora enrolled worst prognosis however used primary endpoint composite cardiovascular death hospitalisation heart failure worsening allows comparison hazard ratio measure victoria look relatively weak measure cardiovascular death absolute mortality failed reach significance win primary endpoint driven hospitalisation number victoria trialists obviously anticipated comparison would made paper published circulation weekend time full result published new england journal medicine argued measure risk reduction standardised fixed time point made better comparison hazard ratio talk burden number event lowered absolute risk reduction matter term prevented event time lothar roessig head clinical development bayer cardio renal division told vantage comparison paint vericiguat much better light course presumably data bayer merck sale rep highlighting project win approval end day however merck bayer chose test vericiguat sick high risk population seems likely physician reserve drug category patient sglt inhibitor horizon prospect might different class diabetes drug mounting evidence utility heart failure well huge cardiovascular outcome study support safety weekend acc new analysis dapa hf presented demonstrated farxiga efficacy regardless background therapy regulatory approval emerge astrazeneca waste time trying establish drug new standard care hazard ratio doubt focus marketing message general sentiment gathered physician would continue start majority patient standard care regimen include entresto place angiotensin receptor blocker ace inhibitor sglt especially patient diabetes svb leerink analyst wrote today response victoria data still fact vericiguat likely kept option high risk patient underestimate need population hence recognition victoria study received another trial called vitality even sicker population due read shortly prove vericiguat worth sellside relatively modest expectation however sale seen reaching bn entresto forecast bring year according evaluatepharma merck paid bayer bn access project back along two cardiovascular asset probably hoping bigger thing\n",
      "\n",
      "Keywords:\n",
      "victoria 0.318\n",
      "vericiguat 0.265\n",
      "bayer 0.213\n",
      "heart failure 0.162\n",
      "entresto 0.148\n",
      "comparison 0.144\n",
      "hf 0.139\n",
      "heart 0.136\n",
      "sglt 0.133\n",
      "weekend 0.122\n",
      "cardiovascular 0.12\n",
      "hazard ratio 0.118\n",
      "hazard 0.118\n",
      "ratio 0.107\n",
      "physician 0.105\n",
      "dapa hf 0.098\n",
      "standard care 0.097\n",
      "sick 0.096\n",
      "merck 0.094\n",
      "dapa 0.093\n",
      "\n",
      "Abstract:\n",
      "admirable company like lundbeck recognised need restock drug development pipeline turned putting cash pile serious acquisition effort remedy problem unfortunately acquisition fired blank last week two asset danish group bought bombed mid stage trial tourette syndrome parkinson dyskinesia one bought drug approved migraine product vyepti end derailed covid pandemic vyepti one lundbeck important asset carrying npv bn calculated evaluatepharma consensus sellside analyst lundbeck acquired already awaiting registration part last september bn takeover alder lockdown drug administered doctor surgery surely struggle time essential activity lockdown owing coronavirus pandemic sellside consensus see vyepti selling year leerink already slashed respectively light covid clearly fault lundbeck company look exposed stock fallen five year low last week failure lu ag foliglurax exacerbated situation lu ag tourette disease acquired along originator abide therapeutic lundbeck bought last may friday danish group said lu ag flunked phase ii study failing beat placebo term primary measure yale global tic severity scale lundbeck say continue investigate lu ag cns disorder failure coming heel teva austedo leaf industry pipeline tourette barren otsuka abilify therapix thx practically remaining clinical project prexton write lundbeck parkinson setback meanwhile related foliglurax originated prexton company lundbeck paid acquire march though modest revenue forecast according evaluatepharma discontinuation caused lundbeck cut full year earnings guidance group wrote foliglurax balance sheet value foliglurax mglur modulator failed phase ii ambled study subject time significantly reduced versus placebo four week absolute reduction minute two dos came well short minute threshold separate phase ii trial attuned withdrawn business reason starting recruitment lundbeck profitable business firepower deal analyst see capable deepening pipeline though current environment anything conducive business development investor hope triple whammy bad luck group fortune change\n",
      "\n",
      "Keywords:\n",
      "lundbeck 0.472\n",
      "lu ag 0.254\n",
      "foliglurax 0.254\n",
      "lu 0.237\n",
      "ag 0.237\n",
      "vyepti 0.19\n",
      "tourette 0.178\n",
      "danish group 0.113\n",
      "bought 0.105\n",
      "minute 0.099\n",
      "danish 0.094\n",
      "parkinson 0.091\n",
      "business 0.089\n",
      "lockdown 0.086\n",
      "pipeline 0.081\n",
      "acquired 0.075\n",
      "last week 0.068\n",
      "group 0.065\n",
      "last 0.064\n",
      "phase ii 0.061\n",
      "\n",
      "Abstract:\n",
      "fund holding contingent value right bristol myers squibb issued celgene holder probably pressing thing worry present yesterday brought reminder u approval ozanimod mean one three condition necessary instrument pay met bluebird bio claiming ide cel filing remains track liso cel secured u priority review hitting jackpot might seem assured fact cvr still trade barely payout value risk covid pandemic derailing fda review process maybe however cvr trading depressed level ever since issued bristol completed celgene acquisition least partly account appalling track record previous security type another factor many fund holding cvr generalist nature earlier held celgene among big cap rather specific biopharma investment possible many unfamiliar nuance underpinning drug development regulatory process three horse accumulator cvrs issued part payment celgene holder got company buyout bristol tradeable security pay liso cel ozanimod called zeposia get u approval end year ide cel end march liso cel always looked like riskiest bet given last december final update pivotal trial even reported let alone filing made thing moved quickly project filed last year secured priority review february ash former celgene holder look anxiously contingent value december priority review seemed generous given two car treatment kymriah yescarta already available lymphoma indication sought may accolade resulted speedy fda action date august ide cel look target unmet need third fourth line multiple myeloma look virtually assured get priority review however trail liso cel development whether bristol bluebird would get filed schedule first half air given coronoavirus pandemic track yesterday however bluebird updated market saying plan submit bla remained track though would delay key project thus question liso cel ide cel alike whether u agency able complete site inspection necessary admin including holding advisory panel light covid lockdown fda yet carried inspection liso cel manufacturing plant bothell washington least three month cushion pdufa date cvr deadline one consideration seattle currently epicentre coronavirus pandemic ide cel summit new jersey manufacturing inspection important project must first filed march cvr deadline mean bla accepted late september priority review approval still card fda ability act depend state pandemic mid year guessed forgotten bristol party paying largely control timeline retains right buy back cvr time course suggestion game system sec prevent happening combined uncertainty weigh heavy beyond short term price fluctuation cvr look likely remain depressed\n",
      "\n",
      "Keywords:\n",
      "cel 0.39\n",
      "cvr 0.269\n",
      "liso cel 0.25\n",
      "liso 0.25\n",
      "ide cel 0.188\n",
      "ide 0.188\n",
      "priority review 0.177\n",
      "priority 0.164\n",
      "review 0.16\n",
      "inspection 0.142\n",
      "celgene 0.141\n",
      "celgene holder 0.135\n",
      "track 0.12\n",
      "holder 0.115\n",
      "holding 0.108\n",
      "bristol 0.106\n",
      "issued 0.103\n",
      "bluebird 0.101\n",
      "cvr deadline 0.094\n",
      "security 0.086\n",
      "\n",
      "Abstract:\n",
      "hit two suite phase iii trial merck co gefapixant become first drug approved chronic cough unpleasant side effect mean still chance tolerable therapy handful company work notably small developer bellus health bayer another interested party although immediately clear whether pharma major intention move larger study developer smaller company alongside bellus include nerre therapeutic shionogi cough pipeline share gefapixant mechanism according merck excessive activation p x receptor associated hyper sensitisation sensory neuron occurs airway lung triggered injury infection cause persistent frequent urge cough none p x antagonist development reached phase iii phase iia trial one bayer candidate bay hit primary endpoint july reducing hour cough count versus placebo bayer partner evotec said compound well tolerated trial bayer evotec p x inhibitor bay reached primary completion date last year data yet emerged still listed bayer pipeline perhaps german group trying decide one advance perhaps waiting see merck project looked like relief trial bellus blu assessing project effect awake cough frequency versus placebo several time point day scheduled conclude mid fortunately given potential covid pandemic delay ongoing trial patient enrolment complete clinical trial delay become reality covid risk spread march true two gefapixant phase iii trial merck must hope either avoid delay submit using data three study nerre ploughing lone furrow developing neurokinin receptor antagonist cough phase ii data show mechanism pursued anyone else phase iib volcano trial mg daily missed primary endpoint awake cough frequency three month nerre claimed predefined subgroup higher frequency coughers reduction cough frequency near significant still glaxo spinout planning phase iii study despite orvepitant tolerability described excellent though one long shot least nerre last raised vc funding favourite one way another merck favourite obtain first cough approval last week topline data gefapixant showed mg twice daily dose meeting primary efficacy endpoint statistically significant decrease average hourly cough frequency versus placebo week cough trial week cough mg twice daily missed trial merck released actual number cough said safety tolerability profile gefapixant consistent phase ii study problem since phase ii mg dose worked caused taste related side effect patient six patient mg group dropped study effect taste even full dataset cough merck say released upcoming medical meeting though presumably virtually show side effect similarly bothersome therapy still shot approval merck put prevalence chronic cough general adult population globally case treatable cause level unmet need persuade regulator lenient others daunted still find niche bellus one claim candidate little effect taste\n",
      "\n",
      "Keywords:\n",
      "cough 0.553\n",
      "gefapixant 0.197\n",
      "nerre 0.184\n",
      "bayer 0.165\n",
      "cough frequency 0.157\n",
      "bellus 0.157\n",
      "frequency 0.15\n",
      "merck 0.145\n",
      "trial merck 0.123\n",
      "taste 0.118\n",
      "mg 0.105\n",
      "phase 0.101\n",
      "effect 0.097\n",
      "trial 0.091\n",
      "effect taste 0.086\n",
      "favourite 0.082\n",
      "frequency versus placebo 0.079\n",
      "frequency versus 0.079\n",
      "cough frequency versus 0.079\n",
      "awake cough frequency 0.079\n",
      "\n",
      "Abstract:\n",
      "lilly galapagos already shown covid pandemic severely disrupting big clinical study nothing suggest small biotech hit least hard today bluebird bio ironwood myokardia warned investor delay digested new reality hard financial impact delay render clinical trial void mean entire cost wasted worst case scenario true one must considered however unlikely vantage identified biotech company exposed analysis considers company expected r expenditure calculated evaluatepharma consensus sellside forecast compare market capitalisation avoid extreme outlier minimum market cap specified according analysis company biggest projected r spend versus market cap mallinckrodt lexicon macrogenics course setting market cap denominator imperfect tool provides one measure company cash need versus capacity raise additional fund straitened time mallinckrodt probably bigger fish fry liability u opioid crisis bn gross debt balance sheet lower list clovis disproportionately large debt position carefully considering ability finance trial well amount already sunk study reading soon lexicon interesting case group last week halted two massive type diabetes study though new coronavirus pandemic one reason cited many group important consideration clinical trial delay become reality covid risk spread march source evaluatepharma sellside consensus company market cap tuesday cut third workforce january forecast might outdated includes front astellas today tide hope continued recede bluebird ironwood myokardia revealed delay caused spread covid addition filing delay bluebird said evaluating operating plan adjusting planned expense would update investor first quarter report ironwood hinted problem enrolled phase iii trial iw gastro oesophageal reflux disease saying site suspended recruitment citing general lower subject participation topline data longer expected year myokardia suspended study planned start second quarter condition change earlier provention bio iveric arrowhead moved pause study recruitment wake covid one bright spot sponsor cancer trial around seems especially strong effort delay given last remaining hope many participant oncology player list might le exposed ongoing trial delayed still salvaged either resumed later analysed real risk many written unethical simply cut funding end terminated prematurely expect operating priority changed biotech scramble evaluate much sunk r expenditure threat\n",
      "\n",
      "Keywords:\n",
      "delay 0.221\n",
      "ironwood 0.217\n",
      "myokardia 0.174\n",
      "bluebird 0.145\n",
      "expenditure 0.135\n",
      "market cap 0.131\n",
      "sunk 0.129\n",
      "suspended 0.124\n",
      "mallinckrodt 0.124\n",
      "lexicon 0.124\n",
      "cap 0.123\n",
      "debt 0.113\n",
      "operating 0.11\n",
      "exposed 0.108\n",
      "spread 0.103\n",
      "covid 0.103\n",
      "planned 0.097\n",
      "recruitment 0.094\n",
      "market 0.09\n",
      "trial 0.086\n",
      "\n",
      "Abstract:\n",
      "cash equity deal silence therapeutic signed astrazeneca today important endorsement group small interfering rna technology pushed silence stock added astra long running collaboration moderna plain uk giant see future rna based technology deal call delivering sirna molecule tissue liver tough prospect another question astra roped silence rather established rna interference player alnylam particularly since smaller company working mean delivering nucleic acid aspect crucial success project bn dream today deal see astra silence collaborate developing therapy cardiovascular renal metabolic respiratory disorder initial phase intended yield five target within three year astra forked cash equity investment option extend five target delivery sirna liver established approach silence achieves conjugating molecule galnac bind receptor hepatocytes pulling similar trick heart lung kidney likely require different delivery tech silence work lipid nanoparticles application colossal milestone silence stand gain deal term reflect difficulty kind development disease target silence line milestone plus tiered royalty giving potential total value excess bn actual cash company come fraction silence expect first fee identification first molecule go testing shift priority interim front cash sustain silence beyond management said conference call enable develop house candidate rejigged pipeline prioritise sln sirna apolipoprotein treatment cardiovascular disease yield topline human data around middle company say previous lead beta thalassaemia myelodysplastic syndrome project sln phase trial dosing expected conclude end month covid pandemic put paid group said recruitment paused silence intends develop new protocol broader population first data come year silence though alnylam bigger group proven tech onpattro lipid nanoparticle delivered transthyretin sirna launched treatment hereditary amyloidosis astra looking add sirna capability mrna based tech thanks tie moderna alnylam would logical place start perhaps alnylam interested astra deal wanted significantly front\n",
      "\n",
      "Keywords:\n",
      "silence 0.645\n",
      "sirna 0.269\n",
      "astra 0.189\n",
      "alnylam 0.18\n",
      "tech 0.132\n",
      "rna 0.116\n",
      "cash equity 0.113\n",
      "cash 0.106\n",
      "deal 0.106\n",
      "delivering 0.103\n",
      "molecule 0.1\n",
      "delivery 0.09\n",
      "lipid 0.083\n",
      "milestone 0.074\n",
      "established 0.072\n",
      "equity 0.069\n",
      "develop 0.065\n",
      "target 0.065\n",
      "liver 0.063\n",
      "moderna 0.062\n",
      "\n",
      "Abstract:\n",
      "numerous approach tackle covid clinical trial heading potential treatment differ biopharma make vantage asked dan chen someone especially well placed comment new coronavirus mr chen upbeat antiviral notwithstanding fact middling efficacy intrigued anti cytokine approach actemra say better understanding mechanism urgently needed antimalarial around president donald trump comment prompted recent surge interest seems le convinced biopharma investor familiar mr chen former head cancer immunotherapy roche genentech division chief medical officer igm bioscience outside oncology view covid heeded phd molecular virology focus coronavirus infection taking top antiviral like gilead remdesivir abbvie kaletra taisho avigan hold potential broad based first line attack entire class viral pathogen though efficacy fairly modest complete viral clearance need every therapeutic goal mr chen explains might enough take top viral infection something make difference someone flu like symptom versus needing respirator various antiviral class say blocking viral protease disappointed likely drug like kaletra whose lopinavir component protease inhibitor developed hiv covid keenly awaited catalyst rna polymerase inhibition remdesivir data chinese trial next month gilead study may blocking viral entry separate consideration however may need utilised earlier generally blocking viral replication say mr chen possible entry blocker include antibody spike protein blocker ace via receptor covid virus enters target cell tmprss calcium channel inhibitor early development treatment malaria lupus like plaquenil president trump three day ago suggested deployed quickly covid prompted highly equivocal academic trial france randomised chinese study showed benefit mr chen say sure whether give existing data credence hopeful modest amount activity anecdotal report lupus patient denied plaquenil hoarded coronavirus treatment pressing need evidence cytokine storm cytokine inhibitor idea gained traction roche actemra anti il rheumatoid arthritis drug added china emergency treatment guideline mabs il pathway rushed clinic include sanofi regeneron kevzara eusa pharma sylvant one theory driving coronavirus infection prompt surge cytokine akin seen response car therapy cause patient become extremely ill mr chen convinced think treating cytokine release syndrome suggested pushed back hard precise scientific communication il level covid infection multiple order magnitude lower see car mean il important might happening seriously ill covid patient il minor part cytokine secreted antiviral response creep driving macrophage dominance creating unfavourable environment cell mr chen concerned characterisation cytokine release syndrome see physician start use steroid appear help clinically slow clearance virus welcome access actemra time wait patient critically ill caution understanding yet timing treatment say unaware specific reason instance actemra differ biologically kevzara ultimately powerful way limit impact viral infection vaccine since highly specific molecular makeup virus take long time develop susceptible rendered useless virus mutates vaccine development need hurry say mr chen effective therapeutic foundation going get covid best prepared next potential pandemic\n",
      "\n",
      "Keywords:\n",
      "mr chen 0.375\n",
      "chen 0.36\n",
      "viral 0.214\n",
      "cytokine 0.211\n",
      "mr 0.191\n",
      "actemra 0.143\n",
      "blocking viral 0.141\n",
      "il 0.139\n",
      "covid 0.134\n",
      "infection 0.126\n",
      "antiviral 0.117\n",
      "virus 0.109\n",
      "say 0.106\n",
      "ill 0.105\n",
      "blocking 0.103\n",
      "kaletra 0.088\n",
      "coronavirus infection 0.088\n",
      "coronavirus 0.084\n",
      "someone 0.083\n",
      "say mr 0.083\n",
      "\n",
      "Abstract:\n",
      "coronavirus pandemic set back huge swathe clinical research week lilly became first pharma major outline strategy difficult time company delay new study start exception pause enrolment ongoing study lilly listed lead sponsor clinical study trial cost company around bn run according estimate evaluate omnium looking widely across sector reveals similar huge sum committed big pharma group massive investment far written longer take bring pandemic control bigger risk become potential loss research valuable new medicine biggest concern course delay arrival new treatment people need investor must cognisant financial impact larger developer capacity weather storm smaller firm find harder delay mean escalating cost longer wait sale level investment talking drug developer stock market listing named primary sponsor clinical study entry according clinicaltrials gov vantage analysis reveals study cost around bn run methodology analysis includes trial yet report excludes phase iv trial seems inevitable company follow lilly similar announcement weekend galapagos said paused enrolment across much filgotinib programme notably lilly featured dominantly previous vantage analysis specifically looked pivotal programme might threat company two huge phase iii project novel diabetes agent tirzepatide anti il mab mirikizumab clinical trial delay become reality covid risk spread march pausing enrolment necessary probably best hope many company preserve clinical work already completed speaking academic medical centre hospital u analyst bernstein wrote today would take really strong argument institution take new trial although continuing treatment already enrolled patient stopped taking new patient existing study oncology exception patient alternative view u course medical centre located europe many region seen week shutdown relatively upbeat assessment likely sound unimaginable true cost pandemic long way calculated money term beyond clear huge amount investment risk across entire biopharma sector evaluate omnium r cost model estimate cost individual clinical programme using real world data company disclosed product level spend clinical trial patient number combined create cost per patient benchmark technology therapy type utilising matching algorithm benchmark applied commercially relevant clinical trial estimate cost aggregated product estimate cost development product\n",
      "\n",
      "Keywords:\n",
      "cost 0.281\n",
      "estimate 0.15\n",
      "estimate cost 0.149\n",
      "clinical 0.143\n",
      "delay 0.13\n",
      "bn run 0.12\n",
      "lilly 0.118\n",
      "omnium 0.114\n",
      "evaluate omnium 0.114\n",
      "enrolment 0.107\n",
      "huge 0.104\n",
      "exception 0.097\n",
      "new 0.097\n",
      "investment 0.096\n",
      "around bn 0.095\n",
      "sponsor 0.093\n",
      "clinical study 0.093\n",
      "trial 0.088\n",
      "clinical trial 0.088\n",
      "centre 0.087\n",
      "\n",
      "Abstract:\n",
      "covid threw hand grenade global economy many investor looking bispecific antibody prove equal cell therapy still way promise apparently sufficient keep business development moving today cytomx struck cell engager alliance astellas fourth partner worth front considerable sum merely discovery tie another player pieris saw tectonic plate alliance servier shift focus two defined bispecific asset cytomx pieris presence bispecifics focus differs former active largely cell engaging mabs designed bring cell close contact antigen expressing tumour cell indeed focus astellas deal japanese group agreeing hand across signing might result biotech pushing instant cash given covid pandemic turned economy survival fittest cash king bn deal biodollar value sniffed either mizuho analyst called astellas endorsement validation probody approach commercial potential probody therapeutic designed remain dormant activated protease tumour microenvironment cytomx say perhaps best known probody bispecific ctla targeting bm phase ii cytomx deal bristol myers squibb addition bristol astellas cytomx signed deal abbvie amgen dual antigen approach pieris bispecific focus meanwhile molecule hit two distinct antigen servier bought concept back january tie worth front time centred around pr anti pd lag bispecific four undisclosed asset last september servier discontinued pr citing strategic reason deal extended additional year yesterday came news french firm decided focus interest two pieris asset pr pr former bispecific agonising bb antagonising pd l mechanism risk undesirably broad immune system activation pieris stress effect bb localised aiming give cell long lived phenotype mechanism pr disclosed neither deal remaining two molecule servier discontinuing reverting pieris ind pr filed shortly given coronavirus pandemic might enter clinic anyone guess\n",
      "\n",
      "Keywords:\n",
      "pieris 0.349\n",
      "pr 0.337\n",
      "cytomx 0.291\n",
      "servier 0.255\n",
      "bispecific 0.237\n",
      "probody 0.182\n",
      "astellas 0.18\n",
      "cell 0.156\n",
      "deal 0.143\n",
      "focus 0.133\n",
      "antigen 0.131\n",
      "worth front 0.127\n",
      "economy 0.121\n",
      "bb 0.112\n",
      "alliance 0.106\n",
      "tie 0.082\n",
      "molecule 0.075\n",
      "designed 0.07\n",
      "asset 0.068\n",
      "pd 0.066\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Abstract:\n",
      "regulatory delay growing ever likely threat coronavirus ramp globally u fda announced earlier month postponing certain manufacturing facility inspection advisory committee meeting cancelled drug approval surely next hit vantage took look u regulatory decision remaining month expected april bellwether future regulatory landscape closely watched include panel intercept nash project approval decision bristol multiple sclerosis asset ozanimod mizuho analyst note ozanimod manufacturing inspection probably occurred month ago review likely unaffected website new product named zeposia already live celgene holder eager hear decision ozanimod part contingent value right pay drug approved end fda told mizuho cder remains fully capable continue daily activity drug review business usual seems though presumably change condition worsen significantly u ema previously said committee meeting would held virtually end april fda said possible host meeting remotely several already postponed intercept ocaliva tentative panel date april timeline update would hit pdufa scheduled june beyond even delay second quarter approval date abbvie uterine fibroid treatment orilissa would still ahead gnrh antagonist competition myovant previously announced antagonist relugolix would submitted april obseva rival project linzagolix still phase iii acceleron reblozyl approval early april treat anaemia adult myelodysplastic syndrome md reblozyl gained approval beta thalassemia end last year md lucrative accounting nearly bn forecast according evaluatepharma sale indication data biggest financial impact delay would seen small company rely handful product revenue urogen biggest growth driver ugn low grade upper tract urothelial cancer decision due next month company hired sale force expected book revenue third quarter pushed back fda delay approval meanwhile astrazeneca several decision upcoming due month imfinzi looking add small cell lung cancer bow filed data caspian study showed success combination chemo result however unlikely challenge roche tecentriq company sglt inhibitor farxiga due decision second quarter heart failure reduced ejection fraction important step moving farxiga beyond diabetes without delay approval based dapa hf trial would keep farxiga ahead boehringer lilly rival project jardiance result latter emperor reduced trial expected later year uncertainty remains near term decision even surround due later fda need shift timeline company investor need prepared weather storm story updated statement fda\n",
      "\n",
      "Keywords:\n",
      "decision 0.209\n",
      "delay 0.175\n",
      "ozanimod 0.17\n",
      "april 0.163\n",
      "approval 0.151\n",
      "farxiga 0.15\n",
      "fda 0.144\n",
      "inspection 0.128\n",
      "reblozyl 0.122\n",
      "delay approval 0.122\n",
      "would 0.116\n",
      "rival project 0.113\n",
      "md 0.102\n",
      "mizuho 0.1\n",
      "committee 0.095\n",
      "regulatory 0.094\n",
      "due 0.092\n",
      "intercept 0.092\n",
      "month 0.09\n",
      "panel 0.088\n",
      "\n",
      "Abstract:\n",
      "molmed immatics signed merger agreement last week today curadev provided evidence covid pandemic put halt deal making indian group persuaded bayer become second big company license sting programme still perhaps deal owes something coronavirus fear rather agonist focus earlier activity sting pathway bayer deal concern sting antagonist potential among thing lung disease agonising sting pathway relevance oncology focus curadev tie takeda last year disappointed clear much work done since takeda curadev yet entered clinic sting deal recently notable abbvie buying mavupharma value disclosed abbvie hope turn around fortune sting july secrecy likely reflects fact recent sting tie ups included particularly high amount front cash little wonder disappointment advanced industry asset merck co mk monotherapy yielded remission phase cancer trial popped bubble approach better luck bayer hoping better luck sting antagonism area virtually industry involvement term today bayer curadev alliance disclosed beyond biodollar value likely owing early stage development bayer curadev say inhibiting sting modulate immune response associated various auto inflammatory disease including lung cardiovascular system agonist theory oncology meanwhile based finding sting played role priming cell thus stimulate immune response apart curadev according evaluatepharma sting antagonist development spring bank sb bristol myers squibb formerly ifm therapeutic project nimbus research stage late lilly paid aduro kick start deal investigating cgas sting inhibitor autoimmune inflammatory disease six agonist project still clinical trial investor written pathway might look bayer lilly endorsement sting antagonism breathe new life approach\n",
      "\n",
      "Keywords:\n",
      "sting 0.674\n",
      "curadev 0.364\n",
      "bayer 0.26\n",
      "better luck 0.114\n",
      "antagonism 0.114\n",
      "inflammatory disease 0.108\n",
      "deal 0.106\n",
      "agonist 0.105\n",
      "pathway 0.104\n",
      "luck 0.085\n",
      "immune response 0.084\n",
      "inflammatory 0.082\n",
      "takeda 0.075\n",
      "tie 0.073\n",
      "antagonist 0.069\n",
      "immune 0.065\n",
      "disclosed 0.065\n",
      "lung 0.061\n",
      "industry 0.06\n",
      "abbvie 0.058\n",
      "\n",
      "Abstract:\n",
      "knock effect covid spread far wide one aspect biopharma investor must consider risk ongoing trial might delayed even abandoned yesterday lexicon provided case point cancelling two zynquista study recently completed enrolment nearly type diabetic true coronavirus pandemic one reason cited likely lexicon largely wanted end uncertainty accept partner fund trial completion would found vantage identified pivotal study due end year subject might suffer similar fate among feature project pfizer clostridium difficile vaccine candidate pf whose clover study subject enrolled biggest analysis separate pf trial seeking recruit feature among top five study reading year yet enrol fully threat huge amount clinical work threat analysis sought identify biopharma advanced valuable crop r asset pinpoint study invested term time money vantage searched specifically pivotal stage project yet receive u approval trial primary completion date according clinicaltrials gov topline analysis reveals trial still recruiting another active fully enrolled comprising subject respectively remarkably look like least five near term blockbuster threat lilly tirzepatide reata bardoxolone immunomedics sacituzumab govitecan bristol myers squibb tyk inhibitor galapagos filgotinib exposure bristol especially striking four tyk study due completed year plus another four ozanimod latter project feature contingent value right issued celgene acquisition stat news pointed fda review delay mean cvr never pay numerous way covid situation hit clinical trial big risk patient lost follow early analysis possible would require protocol change database locked problem le severe actual analysis delayed cro already outside pivotal setting many first quarter expected clinical readout doubt provention bio iveric bio arrowhead three company recently said would pause study recruitment pending clinical readout make across line march lexicon case pointlessness scored soloist trial halted yesterday perhaps foregone conclusion zynquista awaiting approval type diabetes type setting scored soloist meant opened really big market however lexicon lost sanofi partner completing two trial relied finding new licensee something pandemic situation imposing severe restriction meeting movement people must seen impossible fortunate sponsor u fda taken lead problem trial delay spelling willingness consider protocol amendment design change alternative method study subject assessment small mercy something\n",
      "\n",
      "Keywords:\n",
      "lexicon 0.254\n",
      "feature 0.139\n",
      "soloist 0.139\n",
      "scored soloist 0.139\n",
      "trial 0.132\n",
      "study 0.128\n",
      "tyk 0.127\n",
      "analysis 0.126\n",
      "threat 0.117\n",
      "protocol 0.111\n",
      "pf 0.111\n",
      "study subject 0.108\n",
      "study due 0.103\n",
      "fully 0.095\n",
      "type 0.095\n",
      "completion 0.094\n",
      "clinical readout 0.094\n",
      "delayed 0.093\n",
      "consider 0.093\n",
      "situation 0.092\n",
      "\n",
      "Abstract:\n",
      "clinical development tackling covid pandemic moved pace first biopharma project recently entered trial already first clinical data albeit academic centre emerged true result concerning flu antiviral avigan anti hiv combination kaletra antimalarial plaquenil highly equivocal come range caveat represent first hint covid tackled dampen severity disease serve important guide industry already evident existing antiviral might form first line attack people infected covid even activity limited blunting course disease covid treatment plan slowly emerges march first clinical data gilead remdesivir due may keenly awaited interest grown around avigan taisho fujifilm drug available treating flu japan since added china emergency covid treatment programme yesterday chinese authority published first evidence avigan efficacy coronavirus face data positive avigan treated patient clearing virus four day versus day given lopinavir however subject enrolled randomised fashion got additional background therapy none seem severely ill setting front line treatment target intriguingly china claiming serious adverse event seen avigan known carry numerous toxicity indeed development outside japan largely discontinued like avigan remdesivir rna polymerase inhibitor read across gilead trial failure success yesterday first clinical data concerning abbvie anti hiv combo kaletra covid published nejm academic team several chinese centre author clear study failed showing benefit kaletra versus standard care time clinical improvement however evercore isi umer raffat disagreed pointing subject treatment initiated relatively quickly patient given kaletra within day symptom onset mortality versus standard care subset comprised subject set another benchmark remdesivir trial finally professor didier raoult ihu diterran e infection marseille reported data via youtube video covid subject given malaria drug plaquenil claimed six day subject tested positive covid versus separate group untreated patient caveat unpublished result trial without formal control cohort choloroquine non hydroxylated version plaquenil active ingredient separately subject covid prevention study uk university oxford trial initiation study listed past day include massachusetts general covid prevention trial using inhaled nitric oxide idea mooted mallinckrodt week ago private company pulmotect started prevention study using inhaled pul appears tlr agonist january pulmotect claimed seen positive preclinical signal roche moved begin phase iii study actemra covid patient cautioning little evidence backing il inhibition coronavirus sanofi regeneron separately begun trial similarly acting kevzara\n",
      "\n",
      "Keywords:\n",
      "avigan 0.34\n",
      "covid 0.25\n",
      "kaletra 0.238\n",
      "plaquenil 0.17\n",
      "first clinical data 0.139\n",
      "prevention 0.134\n",
      "first clinical 0.13\n",
      "remdesivir 0.123\n",
      "subject 0.117\n",
      "day 0.115\n",
      "prevention study 0.113\n",
      "versus standard care 0.109\n",
      "versus standard 0.109\n",
      "clinical data 0.105\n",
      "first 0.104\n",
      "inhaled 0.102\n",
      "covid treatment 0.102\n",
      "hiv 0.095\n",
      "japan 0.09\n",
      "clinical 0.089\n",
      "\n",
      "Abstract:\n",
      "company seal deal executive cannot shake hand maybe management team arya science immatics bumped elbow latter bought blank cheque company tuesday deal worth japanese group agc offer italy molmed presumably exec meet person given italy still locked may acquisition bid arranged somehow proving though covid pandemic deadening effect deal making annihilated altogether interesting aspect immatics molmed cell therapy player albeit different kind develop stark mission arya science acquisition corp set name suggests sole purpose effect merger similar combination one business controlled hedge fund perceptive advisor floated nasdaq october raising immatics receive cash arya trust account hold ipo proceeds plus interest deal close second quarter perceptive institutional investor including redmile wellington partner committed pipe funding arya say immatics cell receptor based candidate solid tumour hold kind disruptive potential investment vehicle looking immatics two main product class adoptive cell therapy use natural engineered cell cancer cell receptor bispecifics bind tumour specific peptide immunomodulating cell surface protein gaining access u capital market allow immatics advance project clinic group expects topline phase ii data three tcr project one bispecific end year going public represents long held goal immatics company already eyeing u exchange two year ago immatics soon become next listed cell therapy player july long term molmed take different route agc bid accepted becoming part much larger whole japan agc largest glass company world active field ceramic electronics chemical agc considers life science business strategic priority aim get unit sale bn buying molmed offering per molmed share premium allow acg move gene cell therapy get fast molmed withdrew zalmoxis designed reduce risk rejection imperfectly matched stem cell transplant sale europe confirmatory phase iii trial failed last summer next advanced product car project car v phase ii trial acute myeloid leukaemia multiple myeloma look unlikely yield data molmed another string bow appeal agc first company europe obtained gmp manufacturing authorisation cell gene therapy ex vivo offer group example produce strimvelis orchard therapeutic gene therapy immunodeficiency disorder ada scid closure odds since molmed largest shareholder fininvest holding company family former italian prime minister silvio berlusconi agreed tender stake hopefully buying specialised company agc know\n",
      "\n",
      "Keywords:\n",
      "molmed 0.418\n",
      "immatics 0.418\n",
      "agc 0.335\n",
      "arya 0.223\n",
      "cell 0.214\n",
      "cell therapy 0.134\n",
      "cell therapy player 0.099\n",
      "science 0.099\n",
      "therapy 0.097\n",
      "italy 0.095\n",
      "cell receptor 0.095\n",
      "therapy player 0.085\n",
      "kind 0.08\n",
      "gene 0.079\n",
      "deal 0.078\n",
      "company 0.076\n",
      "bid 0.075\n",
      "largest 0.073\n",
      "buying 0.072\n",
      "europe 0.068\n",
      "\n",
      "Abstract:\n",
      "two month ago coronavirus reality dawning press release far wide pointed repurposed drug promising pipeline candidate might prove helpful combating pandemic investor flocked stock regardless validity claim coronavirus stock hype prof infectious february week vantage taken another look covid related stock price move immediately clear dramatic share price gain longer feature le substantive pledge smaller company continue attract attention triple digit surge seen last month replaced huge valuation hike actually making progress biontech example one biggest share price gainer past two week boosted deal fosun pfizer experimental mrna vaccine bnt move clinic next month hope rna technology might yield vaccine much quickly traditional technique driving investor developer field moderna started dosing patient lead project seen one largest coronavirus related market cap gain biontech gain two week impressive given huge jump value company market cap sits bn climb registered stock must read context smaller valuation tiziana capitalised example synairgen seen market cap double past couple month uk respiratory researcher still worth biggest riser dwarfed stratospheric advance registered month ago novacyt co diagnostics surged respectively early february example firm come back bit since still sitting healthy gain year used opportunity raise money novacyt already supplying newly developed covid diagnostic public health england though progress made co diagnostics along cocrystal pharma tonix faller questionable public company always raise money course market turbulence doubt put paid group ambition tap market cash dire state global stock market throw gain made sharp relief tangible progress case rewarded real valuation surge table run january around time dawned west virus global problem remember however three company actually clinic even sitting billion dollar valuation hike much prove vir example announced series antibody collaboration revealingly even typically supportive sellside analyst questioned valuation jp morgan yesterday put underweight recommendation stock equivalent sell stock reached almost double bank price target perhaps hope hype driving gain certainly seems frothiness longer preserve small cap space\n",
      "\n",
      "Keywords:\n",
      "gain 0.229\n",
      "stock 0.179\n",
      "valuation 0.159\n",
      "novacyt 0.139\n",
      "example 0.137\n",
      "co diagnostics 0.132\n",
      "cap 0.127\n",
      "raise money 0.119\n",
      "progress 0.114\n",
      "registered 0.113\n",
      "market 0.111\n",
      "hype 0.111\n",
      "price 0.108\n",
      "month ago 0.106\n",
      "market cap 0.101\n",
      "driving 0.101\n",
      "coronavirus 0.1\n",
      "two week 0.098\n",
      "sitting 0.098\n",
      "month 0.097\n",
      "\n",
      "Abstract:\n",
      "two week left first quarter several major data readout slated period still outstanding coronavirus pandemic mean delay inevitable course provention bio iveric bio surely company pause clinical programme week still glimmer hope managed get study across finish line global lockdown commenced still report topline result vantage compiled list likely candidate though considering sort market reaction might expect positive data considering delaying fear muted response investor flip side take opportunity bury bad result clinical result due big cap arena includes roche pivotal mirros study likely show idasanutlin plus chemo beating cytarabine alone term overall survival aml swiss company hoping replicate success venclexta cancer type follow project antagonist mdm elsewhere first phase iii test lilly mirikizumab due read company invested lot money anti il mab seven pivotal study ongoing oasis study test mirikizumab versus novartis cosentyx psoriasis lilly project need shine looking smaller player phase ii path forward study ascendis hypoparathyroidism treatment transcon pth due report late last year despite recent market rout ascendis still sport bn market cap largely based hope lead project growth hormone deficiency second success would add another string bow biohaven targeting migraine prevention latest phase ii iii study oral rimegepant hope position drug convenient alternative approved injectable cgrp inhibitor meanwhile axsome ax stride trial treatment resistant depression end last year gemini study hit major depressive disorder causing axsome share rocket looking even smaller company akero taking nash fibroblast growth factor akr non invasive mri result expected first biopsy data due second quarter proqr exon skipping oligonucleotide qr report early data usher syndrome rare genetic disorder despite late stage study imminent reporting result cannot relied clinical work critical stage prospect sticking timeline look even bleaker\n",
      "\n",
      "Keywords:\n",
      "ascendis 0.15\n",
      "mirikizumab 0.142\n",
      "study 0.138\n",
      "axsome 0.132\n",
      "report 0.11\n",
      "due 0.108\n",
      "result 0.102\n",
      "bio 0.093\n",
      "considering 0.092\n",
      "growth 0.085\n",
      "still 0.082\n",
      "smaller 0.081\n",
      "disorder 0.079\n",
      "hope 0.078\n",
      "usher syndrome 0.075\n",
      "usher 0.075\n",
      "transcon pth 0.075\n",
      "transcon 0.075\n",
      "qr 0.075\n",
      "pth 0.075\n",
      "\n",
      "Abstract:\n",
      "easy dismiss many publicity seeking announcement related covid past two week beyond hype active progress made last several potential treatment led gilead remdesivir clinic mrna vaccine moderna week dosed first study subject first antibody therapeutic still planning stage interesting theory developing around il inhibition something resulted role proposed roche actemra sanofi regeneron kevzara excitement il already seen tiziana jump bandwagon tiziana take deep breath target covid march spurred addition actemra rheumatoid arthritis drug chinese guideline basis covid patient respond infection overproducing il two day ago sanofi regeneron said starting phase ii iii trial anti il mab kevzara clearly side effect drug kevzara acetmra carry black box warning risk serious infection patient pulmonary disease need closely monitored another emergency measure saw china add favipiravir covid treatment programme flu drug sold japan taisho fujifilm avigan discontinued virtually everywhere else toxicity profile likely limit use covid first line attack far antiviral go greatest hope west come gilead remdesivir two pivotal study read may one enrols moderately ill subject patient severe covid several intriguing study recently gone clinicaltrials gov registry neurorx plan test aviptadil largely discontinued antihypertensive covid related respiratory distress academic group studying chloroquine covid prevention cozaar soliris biocryst evaluating galidesvir evercore isi josh shimmer highlighted potential lopinavir rotinavir see sort antiviral first line attack new coronavirus amid hype however noteworthy johnson johnson moved issue statement cautioning evidence hiv antiviral prezista effect covid perhaps excitement reserved vaccine though work far relatively early vaccine development according trial registry company announcement one moderna mrna clinical study sponsored company niaid later line attack antibody none entered clinic yet regeneron thought analyst able move quickly area provided fertile ground deal making vir collaborating biogen lilly abcellera instance business development aplenty covid vaccine biontech recently tying pfizer fosun mrna project bnt german group standing around idly clinical trial pfizer deal begin next month\n",
      "\n",
      "Keywords:\n",
      "covid 0.261\n",
      "line attack 0.195\n",
      "kevzara 0.176\n",
      "il 0.173\n",
      "attack 0.157\n",
      "antiviral 0.137\n",
      "vaccine 0.131\n",
      "registry 0.13\n",
      "first line attack 0.13\n",
      "tiziana 0.125\n",
      "regeneron 0.12\n",
      "mrna 0.117\n",
      "excitement 0.111\n",
      "actemra 0.111\n",
      "hype 0.109\n",
      "gilead remdesivir 0.109\n",
      "sanofi regeneron 0.107\n",
      "announcement 0.095\n",
      "remdesivir 0.094\n",
      "discontinued 0.087\n",
      "\n",
      "Abstract:\n",
      "moderna yesterday began trial mrna vaccine stand one biotech taken real action covid drama come german mrna rival curevac started early month curevac trumpeted fact called discus development covid vaccine president donald trump member u coronavirus task force within day group embroiled international squabble vaccine one two chief executive departed exactly happened today press briefing curevac admitted convened struggling cope volume question received shed little light affair company effectively insisting management turnover pure coincidence exclusive central question precisely president trump proposed curevac regard developing mrna vaccine covid shortly white house talk took place report emerged curevac offered bn deal provide vaccine exclusively u elicited outrage german government official insisted germany sale today curevac denied whole affair know medium picked said supervisory board member friedrich von bohlen reject time offer trump government organisation right know bn offer exclusivity came unfortunately curevac quote senior german official including interior minister horst seehofer group primary investor dietmar hopp seem implicitly confirmed white house attempt court curevac offer exclusivity curevac today said mr hopp kind summarising integrating information heard information came even know said mr von bohlen curevac issued statement insisting covid vaccine focus product protect people worldwide yesterday tweeted outright denial still plot thickened march group announced chief executive daniel menichella suddenly replaced founder former chief ingmar hoerr mr menichella invited white house talk today mr von bohlen said company best interest mr hoerr step back ceo role given specific mrna knowledge company scientific founder dan sweet sport expertise said mr von bohlen adding mr manichella invited washington hour notice yesterday event took even bizarre twist five day named chief executive mr hoerr took temporary leave absence medical reason mr von bohlen explanation pure coincidence thing timeline told press briefing said estimate long mr hoerr might stressed contracted coronavirus curevac called situation unexpected probably understatement full truth whether battle waged germany u ownership unlikely emerge unless recording white house talk made public\n",
      "\n",
      "Keywords:\n",
      "curevac 0.383\n",
      "mr 0.243\n",
      "von bohlen 0.239\n",
      "bohlen 0.239\n",
      "von 0.223\n",
      "mr von bohlen 0.191\n",
      "mr von 0.191\n",
      "hoerr 0.191\n",
      "white house 0.17\n",
      "white 0.158\n",
      "white house talk 0.143\n",
      "mr hoerr 0.143\n",
      "house talk 0.143\n",
      "house 0.13\n",
      "vaccine 0.128\n",
      "said mr 0.118\n",
      "trump 0.102\n",
      "mrna 0.102\n",
      "german 0.097\n",
      "talk 0.092\n",
      "\n",
      "Abstract:\n",
      "novo nordisk strong position blood coagulation factor used treat haemophilia already challenged roche hugely successful hemlibra gene therapy horizon come internal setback trial company biggest pipeline hope area concizumab paused safety concern three patient suffered non fatal thrombotic event phase iii study started late last year novo said today unless way forward found danish pharma giant find without growth story area business turn prompt rethink company strategy sticking early stage collaboration last year example novo signed deal bluebird bio investigate use vivo genome editing aim making haemophilia therapy elicit genetic change directly patient work extremely early time novo said emerging project unlikely enter preclinical testing least three year novo go early leapfrog haemophilia gene therapy october gene therapy like biomarin uniqure reach market later year concizumab delay prof fatal novo start looking even behind vantage previously suggested making move one smaller gene therapy player smart novo nordisk buy uniqure october concizumab tissue factor pathway inhibitor mechanism act primary brake initiation blood coagulation thought modulate variety bleeding clotting disorder concizumab trialled haemophilia b prove useful patient without inhibitor autoantibody render first line coagulation factor unusable novo presented phase ii data thromboembolic event seen two phase iii programme started late last year alarming latest signal seen quickly larger trial test different dosing regime mid stage programme perhaps importantly patient given larger loading dose previously concizumab essentially novo response roche hemlibra bispecific mab way making bn sale third full year market hemlira used haemophilia given entrenched position always risk concizumab would consigned much smaller haemophilia b population forecast concizumab suggest analyst yet convinced evaluatepharma sellside consensus pencilled still novo long contended convenient administration give concizumab edge speaking vantage presenting phase ii data last year company head biopharma ludovic helfgott said project unsurpassed convenience describing best class device smallest needle low volume portability matter concizumab compete safety efficacy course delay clinical programme look like best case scenario novo serious growing haemophilia might need start considering plan b\n",
      "\n",
      "Keywords:\n",
      "concizumab 0.514\n",
      "novo 0.38\n",
      "haemophilia 0.281\n",
      "coagulation 0.171\n",
      "gene therapy 0.122\n",
      "gene 0.108\n",
      "year novo 0.102\n",
      "hemlibra 0.098\n",
      "uniqure 0.089\n",
      "late last year 0.089\n",
      "fatal 0.089\n",
      "factor 0.087\n",
      "late last 0.087\n",
      "last year 0.083\n",
      "therapy 0.083\n",
      "making 0.076\n",
      "programme 0.072\n",
      "phase ii data 0.072\n",
      "ii data 0.072\n",
      "novo nordisk 0.071\n",
      "\n",
      "Abstract:\n",
      "company institution around world race develop vaccine strain coronavirus sweeping around world cepi come forward estimate much money might take cross finish line bn profit foundation whose full name coalition epidemic preparedness innovation want fund extensive research programme aiming least three candidate submitted approval commercial developer typically reluctant discus development cost individual product call funding interesting put figure sort level investment might required back avian h n flu pandemic moment glaxosmithkline said spent bn developing vaccine establishing manufacturing likely big part cost estimate something cepi figure seem support developing vaccine avian swine h n flu costly global preoccupation evaluatepharma vision estimate spent trial various candidate entered clinic estimate includes study listed clinicaltrials gov real number higher still table single costly product actually made market several programme abandoned reaching regulator still available arepanrix withdrawn owing lack demand government cancelled large order threat swine flu receded total estimated trial cost since glaxosmithkline split spends vaccine r notable investment ticked higher late real term proportion total r spend much work avian swine flu product would going current pandemic uk pharma giant pledged contribute adjuvant platform technology cepi developer working coronavirus deal place china clovis biopharmaceuticals example length time traditional vaccine take develop mean many hoping alternative technology respond quickly glaxo hung around pandemic work company put first h n candidate clinic early became available little month later big hope rest moderna rna based approach according report moving clinic today luck early immunogenicity data emerge summer rna specialist accelerating work biontech said today planned start trial candidate next month furore another developer space germany curevac show progress approach monitored closely level company reportedly offered bn u president donald trump exclusive access successful vaccine evaluatepharma vision r cost model estimate cost individual clinical programme using real world data company disclosed product level spend clinical trial patient number combined create cost per patient benchmark technology therapy type utilising matching algorithm benchmark applied commercially relevant clinical trial estimate cost aggregated product estimate cost development product\n",
      "\n",
      "Keywords:\n",
      "estimate 0.245\n",
      "cost 0.233\n",
      "avian 0.168\n",
      "flu 0.162\n",
      "vaccine 0.16\n",
      "swine flu 0.153\n",
      "swine 0.153\n",
      "cepi 0.148\n",
      "estimate cost 0.14\n",
      "product 0.129\n",
      "candidate 0.11\n",
      "around world 0.102\n",
      "costly 0.099\n",
      "cost individual 0.096\n",
      "clinic 0.092\n",
      "evaluatepharma vision 0.091\n",
      "vision 0.085\n",
      "world 0.084\n",
      "spent 0.082\n",
      "individual 0.08\n",
      "\n",
      "Abstract:\n",
      "investing drug developer yet put project human testing always high risk business typically done private sphere away glare quarterly conference call demand quick demonstrable progress huge amount money available fledgling company past year pushed start ups hand public investor earlier earlier rubius one egregious example trend floating mid eye watering bn valuation despite little company formed around scientific hypothesis yesterday company confirmed becoming increasingly clear phenylketonuria pku project rtx bust failed generate meaningful signal efficacy first patient dosed event happened month later investor wanted first blood rubius approach big test october perhaps rtx always heading scrapheap even made way rubius would going stiff entrenched competition pku biomarin away rigour public life company would able progress project natural pace potentially different outcome pivot rubius claim platform genetically engineer red blood cell express therapeutic protein case cancer autoimmune condition stimulatory molecule cytokine antigen company pivot two area walked away work rare disease alongside abandoning pku project company rationale working chronic high dose therapy required rare disease space much costly developing treatment cancer little hope raising money selling share near future rubius need get bang buck left amount company say last cash directed two cancer project rtx start phase coming month follow asset unlikely enter clinic next year work autoimmune project loosely described stage rubius saying focusing cell mediated disease none project close demonstrating proof concept something company entire platform yet show leerink analyst generously wrote today preclinical oncology data far encouraging investor still little go except vague timeline progress rubius find held market cap much reflects company cash rubius currently look much appropriately valued preclinical company group yet prove even worth much money course next time public market confronted early stage idea perhaps investor think twice\n",
      "\n",
      "Keywords:\n",
      "rubius 0.539\n",
      "rtx 0.202\n",
      "pku 0.202\n",
      "company 0.141\n",
      "public 0.12\n",
      "away 0.12\n",
      "project 0.117\n",
      "progress 0.111\n",
      "pivot 0.105\n",
      "money 0.102\n",
      "platform 0.098\n",
      "autoimmune 0.098\n",
      "rare disease 0.091\n",
      "much 0.086\n",
      "little 0.084\n",
      "preclinical 0.08\n",
      "always 0.078\n",
      "blood 0.077\n",
      "investor 0.075\n",
      "cancer 0.075\n",
      "\n",
      "Abstract:\n",
      "welcome weekly roundup approaching clinical regulatory readout pivotal trial milestone pharmaceutical clinical product intranasal calcium channel blocker etripamil report end march node study patient paroxysmal supraventricular tachycardia psvt sudden unexpected episode rapid heart rate psvt typically life threatening episode last minute hour associated chest pain fatigue fainting according milestone patient psvt experience median four seven episode per year despite two third taking medication etripamil intended episodic use milestone note current option type treatment intravenous calcium channel blocker etripamil need play convenience card node adult patient randomised receive either mg etripamil self administered nasal spray placebo primary endpoint time conversion normal sinus rhythm single efficacy trial needed support nda submission two open label safety study node node needed support fda required safety database around unique psvt patient event safety study primary completion date next year dose ranging phase ii node study mg etripamil converted psvt patient normal sinus rhythm within minute versus placebo without drop blood pressure difference statistically significant etripamil sale forecast reach according evaluatepharma consensus npv company market cap milestone completed ipo last year share date company cash expected last third quarter next year take heart share transmedics lost quarter value since company floated last may group good news stem bleeding upcoming fda adcom supply bit uplift go well assuming called owing covid pandemic fda circulatory system device panel meet april discus approvability transmedics organ care system ocs heart device designed preserve donated heart outside body transplant patient keeping warm beating metabolically active state monitoring capability allow physician judge potentially suitable heart condition viability device development u lag european status significantly ocs heart originally ce marked september uk nice guideline state system extend preservation time compared cold storage heart donated brainstem death pivotal u based expand heart trial donor heart assessed using transmedics machine successfully transplanted giving utilisation rate transplanted patient day survival donor heart trial would suitable use preserved cold storage suggesting using ocs heart improve desperately limited supply donor heart version ocs designed preserve human lung transplant approved u two year ago transmedics developing version donor liver\n",
      "\n",
      "Keywords:\n",
      "heart 0.362\n",
      "etripamil 0.318\n",
      "psvt 0.265\n",
      "node 0.236\n",
      "transmedics 0.212\n",
      "ocs 0.212\n",
      "donor 0.175\n",
      "donor heart 0.159\n",
      "episode 0.136\n",
      "milestone 0.13\n",
      "device 0.127\n",
      "storage 0.099\n",
      "safety study 0.099\n",
      "rhythm 0.099\n",
      "needed support 0.099\n",
      "calcium channel 0.099\n",
      "transplant 0.09\n",
      "preserve 0.09\n",
      "calcium 0.09\n",
      "system 0.089\n",
      "\n",
      "Abstract:\n",
      "trial trial parp inhibitor proven highly effective cancer drug astrazeneca merck co lynparza leading pack drug failure late stage ovarian cancer study come surprise parps well established setting academic led gy trial tested lynparza plus cediranib vegfr inhibitor researcher time trying show combining mechanism open parp inhibition patient without homologous recombinant deficiency hrd theory well taken another knock hrd defective dna repair driven mutation brca form hrd seems increase patient susceptibility parp inhibition patient deemed hrd negative researcher trying reach example combining mechanism adding vegf blockade tested front line maintenance study paola astra merck presented esmo last year investigator sponsored study tested anti vegf antibody avastin plus lynparza recruited patient regardless mutation status progression free survival significantly extended although result clearly driven patient hrd subgroup without evidence hrd hazard ratio dropped unimpressive esmo lynparza push parps forward september happened nothing top line read known gy conclusion hard draw however high proportion patient hrd one explanation lack activity study recruited comer regardless patient mutation status nci sponsored trial tested lynparza plus cediranib patient relapsed platinum sensitive disease subject received one prior line therapy primary endpoint combination pitted platinum chemotherapy however trial contained lynparza arm disclosed trial meet primary endpoint intent treat itt population size miss remains crucial information performance lynparza arm course whether imbalance arm given parp inhibitor proven effectiveness hrd positive ovarian cancer good reason lynparza apparent impotence need found however conclusion cediranib adding nothing seems inescapable worst actually harm kinase inhibitor kicking around astra pipeline year filed ovarian cancer withdrawn back notoriously already crashed pivotal colorectal cancer study small academic trial combining lynparza ovarian cancer raised hope astra running concerto study read later year gy result prompt optimism concerto though course caveat cross trial comparison never forgotten still look ongoing study cediranib reveals little beyond academic work look like asset finally approaching end road astra merck meanwhile hear second quarter fda approval lynparza plus avastin maintenance treatment advanced ovarian cancer regardless biomarker status green light highly likely though question look set linger around whether patient really benefit combination mechanism\n",
      "\n",
      "Keywords:\n",
      "hrd 0.389\n",
      "lynparza 0.378\n",
      "cediranib 0.219\n",
      "ovarian cancer 0.195\n",
      "ovarian 0.189\n",
      "parp 0.166\n",
      "cancer 0.133\n",
      "regardless 0.117\n",
      "astra 0.114\n",
      "patient 0.108\n",
      "combining 0.105\n",
      "academic 0.104\n",
      "parp inhibition 0.097\n",
      "status 0.097\n",
      "tested 0.095\n",
      "trial tested 0.093\n",
      "plus 0.091\n",
      "mutation 0.09\n",
      "vegf 0.088\n",
      "parp inhibitor 0.088\n",
      "\n",
      "Abstract:\n",
      "lot time resource thrown developing treatment covid government around world pledging spend whatever take find treatment much initial expense fall biopharma company however estimate much investigation might cost vantage extracted estimate evaluatepharma vision looked historic precedent development vaccine antiviral previous pandemic phase iii trial gilead remdesivir likely expensive venture right u biotech indicated initial data emerge end march readout represents world nearest term chance finding treatment sometimes deadly respiratory symptom caused particular coronavirus according evaluatepharma vision r cost module trial probably cost gilead around run estimate phase iii trial run china included much lower figure reflect fact substantially cheaper run study region description cost calculated gilead afford course remdesivir prove effective commercial return likely huge notwithstanding company claiming effort rooted commercial roche booked cumulative sale bn tamiflu since launched annual sale peaked bn figure exclude sale booked company make previous vantage analysis looking historic sale flu antiviral show much drug brought developer previous pandemic antiviral demand spike see biocryst jump aboard march evaluatepharma vision r cost model estimate cost individual clinical programme using real world data company disclosed product level spend clinical trial patient number combined create cost per patient benchmark technology therapy type utilising matching algorithm benchmark applied commercially relevant clinical trial estimate cost aggregated product estimate cost development product\n",
      "\n",
      "Keywords:\n",
      "cost 0.316\n",
      "estimate 0.253\n",
      "estimate cost 0.168\n",
      "evaluatepharma vision 0.164\n",
      "vision 0.154\n",
      "antiviral 0.135\n",
      "previous pandemic 0.135\n",
      "historic 0.123\n",
      "vision cost 0.115\n",
      "evaluatepharma vision cost 0.115\n",
      "previous 0.112\n",
      "run 0.102\n",
      "world 0.101\n",
      "sale 0.094\n",
      "gilead 0.092\n",
      "remdesivir 0.092\n",
      "spend 0.09\n",
      "benchmark 0.09\n",
      "much 0.086\n",
      "product 0.078\n",
      "\n",
      "Abstract:\n",
      "article updated clarify mechanism eusa pharma sylvant addition last week roche anti il receptor antibody actemra chinese guideline treating patient covid prompted tiziana life science speed development similarly acting tzls use group stock london aim far today somewhat overenthusiastic one thing tzls still preclinical another approved anti il r mabs carry black box warning risk serious infection patient pulmonary disease planning give anti il r covid patient bold move actemra long approved rheumatoid arthritis reportedly used patient severe covid infection china lowering body temperature within one day one discharged hospital within fortnight approach seems prompted suggestion covid patient might respond infection overproducing inflammatory cytokine il phenomenon called cytokine storm actemra approved fda treat cytokine release syndrome caused car treatment rationale provided research published march indicating viral load associated elevated il level severely ill covid patient researcher wrote il considered therapeutic target critically ill patient excessive inflammatory response according wsj regeneron sanofi repurposing anti il r kevzara new virus partner intend start clinical trial mab widely approved rheumatoid arthritis cytokine release syndrome severe covid soon possible one approved product act pathway eusa pharma sylvant product chimeric monoclonal antibody bind il company state distinct different mechanism action anti il receptor antibody sylvant appear investigation coronavirus according label sylvant given patient severe infection tizzy advantage approved product opposed novel drug development gilead remdesivir used label relatively easily production distribution ramped relatively quickly getting away poor safety profile stopped tiziana course safety profile tzls like efficacy covid anything else unknown yet given human neither advantage approved product yet evidence dozen il r clinical preclinical development aimed covid perhaps group see nicely tiziana done market today might make announcement still giving untried drug severely ill patient many elderly comorbidities taking big risk would true even molecule belong class known potentially dangerous patient lung infection\n",
      "\n",
      "Keywords:\n",
      "il 0.353\n",
      "sylvant 0.223\n",
      "anti il 0.213\n",
      "tzls 0.179\n",
      "covid 0.17\n",
      "infection 0.16\n",
      "cytokine 0.153\n",
      "tiziana 0.153\n",
      "approved product 0.153\n",
      "approved 0.145\n",
      "covid patient 0.136\n",
      "actemra 0.136\n",
      "ill 0.133\n",
      "patient 0.131\n",
      "pharma sylvant 0.111\n",
      "il receptor 0.111\n",
      "eusa pharma sylvant 0.111\n",
      "eusa pharma 0.111\n",
      "eusa 0.111\n",
      "anti 0.107\n",
      "\n",
      "Abstract:\n",
      "pfizer chief executive albert bourla publicly eschewing big acquisition analyst attention turned identifying house asset world biggest pharma company turn nears next wave big patent expiry pfizer march investor day first decade hopefully provide answer meantime sellside already moved uncover hidden pipeline gem according evaluatepharma limited sellside forecast attached present presumably situation change end month perhaps intriguing aspect pfizer battle plan absence immuno oncology true important cancer readout coming concern small molecule drug ibrance braftovi mektovi instead immunology pipeline particular small molecule jak pathway take centre stage jak trade mizuho analyst recently highlighted upcoming readout validate four asset jak inhibitor abrocitinib anti jak tyk brepocitinib pf jak tec inhibitor pf tyk remarkably first significant revenue forecast attached sellside expecting generate big readout atopic dermatitis jade compare trial pitting project regeneron dupixent analyst seek guidance topline data timing key question whether pfizer drug unlike jak avoid lumbered boxed warning whether tested head head recently launched product like abbvie rinvoq mizuho reckons peak sale exceed bn brepocitinib recently hidden prospect consensus forecast yield proof concept data psoriatic arthritis psoriasis atopic dermatitis pf meanwhile readout vitiligo mizuho analyst seem focused phase ii iii alopecia trial though clear data due finally pf yield result year mid stage psoriasis study key consideration benefit term pasi response needed compete like skyrizi cosentyx injectable mabs oral agent like pf conceivably still competitive even le efficacious tyk class seen increased interest since bristol myers squibb vote confidence bm yield two crucial pivotal psoriasis readout year analyst keen see pfizer differentiate galapagos phase jak tyk inhibitor glpg recently discontinued owing undesirable pharmacokinetic profile focus small molecule tyrosine kinase inhibitor necessarily mean pfizer shying away novel technology indeed factor ix gene therapy pf key phase iii study group big oncology mover ibrance braftovi mektovi combo small molecule former penelope b trial positive breast cancer neoadjuvant chemo surgery latter anchor crc study first line colorectal cancer test asset blockbuster label expansion question data timing internal expectation interim data analysis along immunology portfolio doubt take much upcoming investor day\n",
      "\n",
      "Keywords:\n",
      "jak 0.297\n",
      "pf 0.283\n",
      "tyk 0.217\n",
      "small molecule 0.165\n",
      "pfizer 0.159\n",
      "psoriasis 0.142\n",
      "molecule 0.14\n",
      "mizuho 0.139\n",
      "readout 0.129\n",
      "brepocitinib 0.119\n",
      "mektovi 0.113\n",
      "immunology 0.113\n",
      "braftovi mektovi 0.113\n",
      "braftovi 0.113\n",
      "recently 0.112\n",
      "investor day 0.108\n",
      "hidden 0.105\n",
      "analyst 0.101\n",
      "attached 0.099\n",
      "mizuho analyst 0.097\n",
      "\n",
      "Abstract:\n",
      "latest analysis see covid daily update page number new covid case reported breached mark today world saw sharp increase case spain italy prompting italian government initiate complete lockdown country asia case china japan south korea continued slow country containment measure blunted impact virus europe italian case continued accelerate one largest daily jump since outbreak announced spain new case soared compared seven day average germany reported first two death new case hit france saw new case seven day average uk saw modest rise diagnosis seven day average u continued rollout testing kit saw u record highest daily count row turkey continued report known case despite proximity iran border australia canada saw significant rise new case versus seven day average\n",
      "\n",
      "Keywords:\n",
      "seven day average 0.349\n",
      "day average 0.349\n",
      "new case 0.326\n",
      "seven day 0.31\n",
      "case 0.29\n",
      "continued 0.227\n",
      "saw 0.195\n",
      "average 0.19\n",
      "seven 0.17\n",
      "spain 0.155\n",
      "italian 0.155\n",
      "daily 0.143\n",
      "new 0.132\n",
      "day 0.126\n",
      "country 0.117\n",
      "rise 0.111\n",
      "row 0.078\n",
      "page 0.078\n",
      "latest analysis 0.078\n",
      "kit 0.078\n",
      "\n",
      "Abstract:\n",
      "success kala pharmaceutical eysuvis third pivotal dry eye disease study tribute persistence smart trial design learning quickly previous failure pre empt regulatory request eysuvis therefore look highly approvable say easy part tricky meeting sellside expectation underpinning product within four year launch eysuvis second best selling dry eye medication evaluatepharma calculates eclipsed novartis xiidra perhaps recent product illustrates difficulty space better xiidra filed shire yielding mixed clinical result took fda year approve request data takeda bought shire swiftly offloaded xiidra novartis novartis see hidden value xiidra may last year sale totalled modest major obstacle meeting forecast recent availability generic version allergan restasis notwithstanding approved use dry eye sign versus xiidra sign symptom label still xiidra deal showed novartis still interested prescription ophthalmology drug alcon spinout kala investor hoping buyout company analyst call yesterday group somewhat unsubtly pointed novartis acquired xiidra bn good news kala yesterday success stride trial eysuvis virtually assured approved dry eye sign well symptom previous data put doubt stride eysuvis met co primary endpoint dry eye disease sign conjunctival hyperaemia symptom ocular discomfort severity stride hit former led u complete response letter requesting data stride kala made smart strategic decision file mixed data time hedging bet starting stride study kept four time daily two week dosing used stride subject increased powering focusing primary endpoint ocular discomfort kala said met comer high level statistical significance well predefined subgroup subject severe baseline discomfort main adverse effect watch seems intraocular pressure increase across three stride trial two subject mmhg increase versus none placebo cohort kala say eysuvis positioned treat dry eye disease flare targeting patient breakthrough flare restasis xiidra well patient taking either drug plan imminent filing resubmission u launch end want rep place sell product however whether latest data set kala takeover candidate highly relevant question many kala investor hope company never find complexity dry eye market first hand\n",
      "\n",
      "Keywords:\n",
      "xiidra 0.387\n",
      "kala 0.341\n",
      "dry eye 0.29\n",
      "stride 0.282\n",
      "dry 0.282\n",
      "eysuvis 0.256\n",
      "eye 0.224\n",
      "discomfort 0.145\n",
      "dry eye disease 0.138\n",
      "eye disease 0.124\n",
      "novartis 0.124\n",
      "sign 0.097\n",
      "flare 0.097\n",
      "stride trial 0.092\n",
      "restasis 0.092\n",
      "shire 0.088\n",
      "request 0.088\n",
      "ocular 0.085\n",
      "symptom 0.082\n",
      "smart 0.077\n",
      "\n",
      "Abstract:\n",
      "official bristol myers squibb abbvie empliciti used earlier multiple myeloma relapsed refractory disease immediate significance subject front line eloquent study almost nine year started today revealed dud reality course analyst already written empliciti multiple myeloma ran certainly drug failed miserably keep pace johnson johnson genmab rival darzalex today study failure lay bare divergence two product fortune show one mechanism action beat blocking cd darzalex pharmacology c empliciti neck neck rivalry become next big mechanism multiple myeloma today numerous industry project targeting cd anti c pipeline virtually bare empliciti failure move earlier treatment cascade nothing redress balance drug remains approved second line later multiple myeloma combination revlimid third line disease part pomalyst combo darzalex meanwhile established broad u label initially launched fourth line salvage setting monotherapy drug boast second third line use different combination fewer three different first line setting according evaluatepharma archived consensus empliciti near term revenue forecast peaked mid drug expected sell bn fact empliciti sold last year sellside consensus stand feeble respectively stark contrast darzalex whose sale rocketed nearly bn within four year launch forecast stand awesome bn evaluatepharma computes versus little bn thought capable selling within six year divergence fortune two drug launched roughly time largely j j ability expand darzalex multiple myeloma use ever earlier line therapy darzalex gone strength strength empliciti last major win eloquent study highlighted asco way back may secured second line label eloquent intended secure front line setting today bristol said failed extend progression free survival primary endpoint empliciti added top revlimid dexamethasone last week u fda approved second anti cd mab sanofi sarclisa isatuximab third line disease final irony consensus forecast sarclisa expected selling empliciti\n",
      "\n",
      "Keywords:\n",
      "empliciti 0.536\n",
      "darzalex 0.278\n",
      "myeloma 0.196\n",
      "multiple myeloma 0.196\n",
      "line 0.193\n",
      "eloquent 0.179\n",
      "multiple 0.144\n",
      "third line 0.121\n",
      "third line disease 0.111\n",
      "sarclisa 0.111\n",
      "divergence 0.111\n",
      "approved second 0.098\n",
      "neck 0.095\n",
      "cd 0.094\n",
      "line disease 0.093\n",
      "revlimid 0.091\n",
      "fortune 0.089\n",
      "bare 0.087\n",
      "third 0.078\n",
      "second 0.074\n",
      "\n",
      "Abstract:\n",
      "today failure astrazeneca danube study mark bladder cancer indication checkpoint blockade unlikely make major inroad underline huge potential seattle genetics antibody drug conjugate padcev one hottest asset watch cancer type particularly noteworthy astra done everything possible set positive result imfinzi yet despite front line study drew blank might bode well upcoming readout study merck co keytruda bristol myers squibb opdivo similar setting immediate beneficiary look seattle astellas padcev anti nectin drug already scored second line bladder cancer label accelerated approval keytruda combo study shown extraordinary potential front line setting pivotal study ev way checkpoint blockade astra danube result mark uncertainty five major anti pd l drug available second line failure roche confirmatory imvigor study raised concern accelerated approval tecentriq keytruda approved first line chemo ineligible patient roche drug additionally used eligible cisplatin long express pd l danube tested imfinzi monotherapy combination anti ctla mab tremelimumab compared standard platinum chemo expected read year ago primary endpoint looking o pfs combination cohort delayed astra made change increase chance success amendment focused trial primary endpoint o combo monotherapy arm alike latter relatively narrow cut pd l expression applied yet despite astra said survival benefit versus chemo seen uk group refocused danube o along two first line combo study neptune nsclc kestrel head neck cancer former already failed latter look likely need pointing danube setback mark yet another failure tremelimumab regimen astra stress two phase iii first line bladder cancer study way niagara test imfinzi plus chemo muscle invasive disease potomac combine imfinzi bcg non muscle invasive bladder cancer keytruda monotherapy january approved latter setting bcg unresponsive patient key two competitor front line study watch keynote test chemo combo checkmate combine opdivo chemo one cohort yervoy another whatever chance padcev important drug watch\n",
      "\n",
      "Keywords:\n",
      "danube 0.283\n",
      "chemo 0.22\n",
      "bladder cancer 0.204\n",
      "bladder 0.204\n",
      "astra 0.166\n",
      "line 0.165\n",
      "imfinzi 0.16\n",
      "padcev 0.145\n",
      "cancer 0.133\n",
      "keytruda 0.126\n",
      "study 0.123\n",
      "watch 0.121\n",
      "combo 0.12\n",
      "line bladder cancer 0.119\n",
      "line bladder 0.119\n",
      "front line study 0.119\n",
      "muscle invasive 0.113\n",
      "mark 0.108\n",
      "tremelimumab 0.102\n",
      "front line 0.1\n",
      "\n",
      "Abstract:\n",
      "welcome weekly roundup approaching clinical readout primrose study obseva uterine fibroid project linzagolix gnrh inhibitor report second quarter safety key earlier primrose trial efficacy result higher dose linzagolix combination hormone add back therapy abt put par abbvie orilissa ahead myovant relugolix cross trial caveat notwithstanding however loss bone mineral density higher competitor project combination abt according leerink analyst obseva reason bone loss smaller primrose since enrolled higher proportion black patient black woman tend higher average body mass index hypothesised inversely correlated bone loss analyst write patient primrose non caucasian meaning patient demographic aligned competitor trial obseva hope allow linzagolix produce comparable level bone loss another aspect look primrose result lower dose without abt abt needed counteract menopause like symptom associated gnrh inhibition side effect advised patient high bmi diabetes cardiovascular disease primrose showed placebo adjusted response rate low dose company called clinically relevant time saying open linzagolix first line treatment however tiny obseva catching linzagolix forecast sell according evaluatepharma consensus gnrh inhibitor myovant abbvie forecast reach respectively inventiva nash bash trial inventiva lanifibranor report biopsy data nash first half year last year project failed systemic sclerosis multi organ fibrostic disorder causing inventiva share price halve nash unlikely company saviour ppar agonist lanifibranor join like genfit elafibranor failed phase ii study readout genfit phase iii resolve trial delayed second quarter cymabay stopped development ppar agonist seladelpar nash interface hepatitis seen liver biopsy bull keen point difference project lanifibranor unlike ppars hit alpha delta form receptor gamma subunit inventiva nash trial native test mg mg lanifibranor per day week versus placebo enrolled patient primary measure improvement least two point steatosis activity fibrosis score lanifibranor sellside forecast assigned sale genfit elafibranor expected reach according evaluatepharma figure halved consensus forecast made year ago\n",
      "\n",
      "Keywords:\n",
      "primrose 0.314\n",
      "lanifibranor 0.261\n",
      "linzagolix 0.243\n",
      "inventiva 0.209\n",
      "abt 0.209\n",
      "obseva 0.183\n",
      "bone 0.179\n",
      "nash 0.171\n",
      "bone loss 0.151\n",
      "gnrh 0.131\n",
      "loss 0.123\n",
      "genfit 0.122\n",
      "gnrh inhibitor 0.11\n",
      "genfit elafibranor 0.105\n",
      "ppar agonist 0.094\n",
      "ppar 0.094\n",
      "higher 0.093\n",
      "myovant 0.087\n",
      "forecast 0.085\n",
      "elafibranor 0.083\n",
      "\n",
      "Abstract:\n",
      "group late stage developing therapy fragile x syndrome must somewhat daunting knowing every prior phase iii trial disorder met failure hand least mean competition zynerba cannabinoid project zygel succeed mean regulator might take lenient stance zynerba chief executive armando anido confident zygel pivotal trial hit belief approval might granted even barely missed primary endpoint hit secondary endpoint may still substantial opportunity fragile x fda anything currently available think would open conversation pathway fragile x tell vantage easy abc trial question connect fx last month hit enrolment target signing child aged three aim show improvement social avoidance subscale aberrant behaviour checklist abc standard measure use developmental disability clinical trial relies patient caregiver impression symptom topline result expected mid company definite idea magnitude benefit zygel need show anticipating placebo show improvement powered study patient able show improvement active arm mr anido say provided active arm percentage point clear placebo company ought able file data end year objective measure improvement biomarker fragile x mr anido say abc validated well recognised adding abilify risperdal used abc approval autism spectrum disorder safety bear watching september zynerba reported patient phase ii trial zygel different disorder developmental epileptic encephalopathy dee treatment emergent adverse event serious adverse event seen patient two lower respiratory tract infection status epilepticus possibly related treatment zynerba share slid mr anido said due misinterpretation primarily safety data point dee patient sick company plan speak fda coming month starting pivotal dee trial novel mechanistically zygel differs earlier failed fragile x project novartis afq seaside therapeutic stx rationale using cannabinoid come study knockout mouse reduced level endocannabinoids arachidonoylglycerol anandamide affect signalling neuronal plasticity mr anido say others tried either gaba ergic compound mglur compound work primarily affecting gaba system feel pretty good different probably make make difference mr anido say downside cannabinoids readily metabolised gastrointestinal side effect dosed orally zygel administered transdermally small amount gel applied patient upper arm twice day connect fx break fragile x tradition succeeding company intends price zygel around per year patient u alone penetration would make drug blockbuster fda clearance first genetic test fragile x expand enabling earlier diagnosis currently possible limiting propensity disorder misdiagnosed form autism evaluatepharma consensus sellside forecast see zygel worldwide revenue reaching zynerba launch drug alone home market seeking partner outside u another element hinge forthcoming readout\n",
      "\n",
      "Keywords:\n",
      "zygel 0.353\n",
      "fragile 0.308\n",
      "anido 0.297\n",
      "mr anido 0.248\n",
      "zynerba 0.22\n",
      "mr anido say 0.198\n",
      "anido say 0.198\n",
      "abc 0.185\n",
      "dee 0.149\n",
      "show improvement 0.132\n",
      "mr 0.126\n",
      "disorder 0.098\n",
      "improvement 0.089\n",
      "fx 0.088\n",
      "connect fx 0.088\n",
      "connect 0.088\n",
      "gaba 0.085\n",
      "cannabinoid 0.085\n",
      "developmental 0.082\n",
      "active arm 0.082\n",
      "\n",
      "Abstract:\n",
      "drug vaccine development long costly business frequently fails generate profit company involved widely appreciated within biopharma probably need repeating light call politically driven otherwise industry something coronavirus outbreak given harsh reality minor miracle gilead already managed initiate two pivotal study antiviral remdesivir numerous biotech diagnostic company getting covid act evaluatepharma show many case enthusiastic press release amount empty word vir epivax generex fall category biotech announcing signing deal aiming develop vaccine therapeutic targeting covid course signing deal actually developing something take lot longer least effort flagrant example jumping coronavirus bandwagon inovio instance week trumpeted fact accelerating timeline covid vaccine innovation pharmaceutical presented theoretical rationale backing one project evelo considering developing another asset adma biologics apparently relevant ip expected biotech fund raising seldom far behind especially purported news trigger share price spike coronavirus stock hype prof infectious february tonix co diagnostics instance week raised cash conjunction coronavirus related announcement yet pfizer perhaps present sober view monday world biggest drug company said screening antiviral pipeline possible hit identified would first need undergo toxicology testing pfizer calmly spelled meaning clinical trial start end doubt prominent vaccine developer like glaxosmithkline merck co sanofi case current situation unexpectedness mean little common say planning flu season case flu preparation made month advance identify relevant strain ensure sufficient manufacturing capacity infrastructure ship vaccine virulent strain differ markedly rarely enough time switch different vaccine within season situation like covid virus characterised manufacturing capacity place industry effectively standing start incidence rising exponentially present complexity completely different level say development effort slacken apart gilead remdesivir today clinicaltrials gov reveals covid study virtually sponsored chinese hospital testing everything antiviral vitamin traditional chinese medicine pharma designed fast response unit certainly charity time even treatment like remdesivir becomes commercially available covid either abated turned full pandemic right given report people south korea congregating hundred buy face mask instance le glamorous le important public education key\n",
      "\n",
      "Keywords:\n",
      "vaccine 0.219\n",
      "covid 0.175\n",
      "remdesivir 0.158\n",
      "antiviral 0.154\n",
      "season 0.153\n",
      "coronavirus 0.147\n",
      "strain 0.14\n",
      "instance 0.133\n",
      "manufacturing capacity 0.127\n",
      "signing 0.124\n",
      "capacity 0.115\n",
      "flu 0.111\n",
      "chinese 0.105\n",
      "situation 0.101\n",
      "case 0.091\n",
      "biotech 0.09\n",
      "within 0.089\n",
      "relevant 0.086\n",
      "manufacturing 0.084\n",
      "effort 0.084\n",
      "\n",
      "Abstract:\n",
      "glp agonist already enjoyed huge success type diabetes developer hope agent soon prove worth related condition novo nordisk much riding two sideways step mechanism obesity nash data setting due coming month liver disease nash proven cardiovascular benefit glp well certain beneficial effect thought bestow make drug ideal candidate novo running handful mid stage study semaglutide weekly agent test theory given nash huge focus many biopharma result wide interest partly glp thought likely form backbone future nash combination failure several novel mechanism underwhelming result deemed succeeded shown real impact one mechanism required speaking medium roundtable december novo chief executive lars fruergaard j rgensen echoed opinion adding various competitor approach fell wayside interest danish company work grew sense big appetite collaborating u weight lowering profile sema anti inflammatory property role play nash told journalist house business development focus additional mechanism u complimentary sema broader presence actively scouring researching see might danish company struck couple deal however seems earlier stage transaction rather move might help novo get market quickly likely emerge future mr j rgensen said novo looked whether collaborate take advanced project decided believe longer term play better play semaglutide said might disappoint shareholder company advanced nash asset genfit madrigal particular though surprisingly positive phase iii result change everything first though semaglutide need show worth weekly injected drug sold ozempic diabetes three trial one gilead collaboration testing various combination regimen first dataset arguably important emerge large three dose study novo running versus placebo due second quarter enrolled patient biopsy confirmed nash stage fibrosis test nash resolution without worsening fibrosis primary endpoint glp thought likely useful nash resolution improving fibrosis various study shown agent improve marker liver function beneficial effect liver inflammation steatosis tracked clinical study ass nash resolution phase ii study liraglutide novo daily glp victoza point semaglutide capable albeit small number patient nine patient resolution nash versus two placebo group two active arm registered progression fibrosis eight control showing benefit fibrosis would huge win novo analyst stifel commented recently semaglutide achieved perceived negative standalone nash company given drug already demonstrated positive benefit diabetes cardiovascular outcome course nash space reliably disappointed past couple year disease proven much tougher expected well known mechanism novo better chance many others make mark\n",
      "\n",
      "Keywords:\n",
      "nash 0.442\n",
      "novo 0.319\n",
      "semaglutide 0.223\n",
      "glp 0.209\n",
      "resolution 0.193\n",
      "fibrosis 0.179\n",
      "nash resolution 0.145\n",
      "mechanism 0.132\n",
      "thought likely 0.104\n",
      "sema 0.104\n",
      "danish company 0.104\n",
      "beneficial 0.1\n",
      "diabetes 0.097\n",
      "liver 0.091\n",
      "danish 0.087\n",
      "various 0.087\n",
      "thought 0.086\n",
      "play 0.077\n",
      "proven 0.075\n",
      "agent 0.074\n",
      "\n",
      "Abstract:\n",
      "roche decision start large pivotal programme tigit blocker tiragolumab rekindled enthusiasm mechanism notably sending arcus stock might overshadowed third tigit player private biotech iteos nevertheless boast surge interest behind scene iteos chief executive michel detheux come back investor conference new york tell vantage sensing momentum tigit become first next generation immunotherapy validated randomised phase ii clinical trial eye two presentation roche tiragolumab subject single agent cohort dose escalation study expected unveiled april aacr meeting followed result nsclc subject randomised receive monotherapy tecentriq combo expected asco presumably roche saw something extremely positive data warrant starting pivotal development roche next immuno oncology combo big bet tigit january even think swiss group betting tiragolumab catch merck co bristol myers squibb immuno oncology race part iteos taken anti tigit mab eos phase trial say mr detheux mostly solid tumour iteos reckons anti tigit monotherapy work pd l blockade failed registrational study include combination pd l standard care true put iteos behind roche arcus whose ab went phase ii last month make immune recent enthusiasm chief exec say roche showed hand january people would listen politely presented tigit asking eos even start translates partnering talk mr detheux iteos chief operating officer matthew call clear right vital iteos retain significant interest molecule company already raised strong negotiating position planning aggressive clinical strategy underappreciated make tigit mechanism exciting multi pronged effect something mr detheux say underappreciated differentiate multitude immuno oncology strategy fallen wayside fact tigit immune checkpoint whose blockade release immune system brake one aspect another present regulatory cell blockade aid treg depletion stopping binding one ligand cd might enhance positive co stimulatory signal another cd anti tigit mab like eos work antibody dependent cellular cytotoxicity key unblocking immune suppression say mr detheux whereas big player fighting combination pd l convinced multiple combination winning strategy one receptor inhibition iteos phase asset eos designed work high adenosine concentration tumour microenvironment data due aacr player including astrazeneca corvus arcus combining approach cd inhibition mr detheux reckons driven need lower adenosine concentration level relatively unsophisticated competitive antagonist work neither mince word come iteos competition tigit saying convinced arcus selected best antibody mereo etigilimab first class poorly potent merck mk shown remission monotherapy tigit blockade play tigit really hot right say mr call think going next pd\n",
      "\n",
      "Keywords:\n",
      "tigit 0.459\n",
      "iteos 0.38\n",
      "detheux 0.285\n",
      "mr detheux 0.237\n",
      "eos 0.19\n",
      "mr 0.145\n",
      "arcus 0.141\n",
      "say mr 0.127\n",
      "blockade 0.116\n",
      "tiragolumab 0.114\n",
      "anti tigit 0.108\n",
      "roche 0.105\n",
      "immune 0.101\n",
      "pd 0.092\n",
      "immuno oncology 0.091\n",
      "immuno 0.091\n",
      "say 0.09\n",
      "adenosine 0.084\n",
      "underappreciated 0.081\n",
      "work 0.079\n",
      "\n",
      "Abstract:\n",
      "end last year qiagen said longer interested buyout none offer received good enough thermo fisher scientific always favourite potential buyer must sweetened offer today said buying dutch diagnostics group bn including assumption bn net debt thermo fisher put effort straightening qiagen business catastrophic third quarter culminating resignation chief executive thermo fisher made success bn acquisition life technology might able repeat trick qiagen third quarter bad company swung net profit year earlier second quarter net loss forced admit defeat next generation sequencing tech genereader cancelling programme storm tossed qiagen plot course higher growth october infection information despite various woe qiagen reasonable underlying business sale forecast grow per year molecular diagnostics infectious disease particularly well detect viral bacterial nucleic acid blood sample company developed test kit new coronavirus trialled hospital china thermo fisher infectious disease assay microbiology testing segment forecast grow per year evaluatemedtech data show thermo fisher super excited getting hand qiagen bioinformatics technology executive said conference call today software applied thermo flagship iontorrent next generation sequencer line analysing interpreting vast amount data machine deliver help researcher healthcare worker make decision technology however might complementary another qiagen strength sample preparation market share thermo fisher another various regulatory body including u ftc uk competition market authority flexing muscle recently overlap attract attention thermo nuclear deal comfortably largest medtech acquisition announced far year record stand time even rumoured purchase livanova medtronic come thermo fisher paying around time qiagen estimated ebitda say move immediately accretive bottom line transaction funded combination cash new debt bridge financing per share came pretty much expected price buy qiagen november qiagen said november fielding offer share tracking stock duly tanked group said wanted remain independent well benefit might come complementary technology thermo expects wring saving deal third year close come cost synergy rest come form adjusted operating income benefit revenue synergy company say might sound optimistic thermo fisher met kind expectation life acquisition bn purchase electron microscopy specialist fei hit cost synergy target deal run antitrust problem work nicely thermo\n",
      "\n",
      "Keywords:\n",
      "thermo 0.5\n",
      "qiagen 0.434\n",
      "thermo fisher 0.333\n",
      "fisher 0.333\n",
      "synergy 0.13\n",
      "net 0.101\n",
      "forecast grow 0.087\n",
      "technology 0.086\n",
      "offer 0.081\n",
      "sample 0.08\n",
      "per year 0.08\n",
      "per 0.076\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "infectious disease 0.076\n",
      "debt 0.076\n",
      "grow 0.074\n",
      "next generation 0.073\n",
      "infectious 0.071\n",
      "acquisition 0.067\n",
      "said 0.065\n",
      "third 0.064\n",
      "\n",
      "Abstract:\n",
      "daniel day appointed chief executive gilead last year spoken judging company bn acquisition forty seven today message clear gilead want boost place oncology prepared pay top dollar immediate beneficiary though much lower base forty seven cd focused peer trillium stand since bloomberg thursday broke news forty seven acquired news le good cell therapy company iovance rumoured gilead crosshairs far left cold one surprising aspect forty seven buyout year ago targeting cd novel immuno oncology mechanism looked dead buried celgene terminated anti cd mab cc forty seven magrolimab stood pack posting highly promising myelodysplastic syndrome md data last year ash meeting indeed ash data seem triggered today buyout forty seven buck trend january analyst call today mr day said present meeting particularly impressed saw forty seven cash bn price valuing forty seven share remarkable bloomberg rumour prompted surge friday four month ago forty seven stock changing hand gilead management said bidding process forty seven competitive reveal detail said well size deal break fee would detailed regulatory filing interestingly given much work cd focused company like trillium surface oncology devoted tweaking antibody design deciding end cd pathway target gilead put forty seven strength optimised magrolimab dosing hitting ideal risk benefit profile mr day offered little insight made forty seven different cd player merely highlighting fact company mature dataset depending result md study getting way imminently magrolimab reach u market accelerated approval end said md gilead initially focus lymphoma provide separate development path especially combination car therapy yescarta gilead see kite cell therapy business bolstered disappoint betting gilead takeout iovance though course buyer come forward apart anything else iovance til technology face question patentability iovance bull focus execution february contrast targeting cd offer traditional antibody product approach forty seven mired patent litigation synthon settled hindsight look smart move\n",
      "\n",
      "Keywords:\n",
      "forty seven 0.471\n",
      "forty 0.471\n",
      "seven 0.333\n",
      "cd 0.194\n",
      "gilead 0.18\n",
      "iovance 0.173\n",
      "magrolimab 0.126\n",
      "md 0.117\n",
      "targeting cd 0.093\n",
      "bloomberg 0.093\n",
      "trillium 0.087\n",
      "oncology 0.069\n",
      "buyout 0.067\n",
      "ash 0.064\n",
      "cell therapy 0.063\n",
      "focused 0.06\n",
      "day 0.057\n",
      "said 0.056\n",
      "mr 0.053\n",
      "news 0.051\n",
      "\n",
      "Abstract:\n",
      "karyopharm bull believed fda approval xpovio last year boded well future label expansion congratulating morning share company surged open five year high news boston study second line multiple myeloma succeeded trial pitted combination xpovio velcade dexamethasone svd velcade dex alone vd detected significant extension progression free survival hazard ratio xpovio containing cohort importantly company said new safety signal svd arm imbalance death detail available cautious investor might choose wait full disclosure declare boston runaway success known toxicity profile xpovio includes high rate thrombocytopenia discontinuation phase ii storm trial much later line patient fatal adverse event rate record prevented fda granting approval last year albeit accelerated basis late line myeloma patient given high toxicity burden approval even refractory population thought given karyopharm rollercoaster end selinexor approval july conference call morning company executive said boston data would filed second quarter making approval much larger valuable setting possibility year multiple myeloma crowded space various treatment available patient relapse first line therapy typically revlimid top darzalex increasingly used use velcade come toxicity burden peripheral neuropathy thought declining second line setting favour kyprolis newer proteasome inhibitor lack relevance real world real problem xpovio despite ostensibly positive result despite karyopharm attempt clever trial design svd arm control tested weekly velcade dose label indication say proteasome inhibitor dosed twice week physician frequently reduce dosage avoid peripheral neuropathy steroid use lowered boston company belief prove svd regimen safer effective new option fact difference rate peripheral neuropathy prespecified secondary endpoint included statistical plan clear company gunning better tolerability label much depends full disclosure boston data trial prove pretty tricky interpret many way karyopharm would say today rate peripheral neuropathy significantly lower svd arm look trial used vd comparator arm similar setting provide benchmark sort investor added karyopharm valuation today bet xpovio chance label expansion given fda recent lenient record perhaps reasonable wager physician many option table might harder convince\n",
      "\n",
      "Keywords:\n",
      "xpovio 0.324\n",
      "svd 0.288\n",
      "karyopharm 0.27\n",
      "boston 0.27\n",
      "peripheral neuropathy 0.216\n",
      "neuropathy 0.216\n",
      "velcade 0.205\n",
      "peripheral 0.191\n",
      "svd arm 0.173\n",
      "myeloma 0.114\n",
      "proteasome inhibitor 0.108\n",
      "full disclosure 0.108\n",
      "arm 0.105\n",
      "toxicity burden 0.099\n",
      "line 0.093\n",
      "label expansion 0.092\n",
      "label 0.092\n",
      "approval 0.091\n",
      "disclosure 0.083\n",
      "burden 0.083\n",
      "\n",
      "Abstract:\n",
      "transformation zinc finger nuclease outdated ran gene editing technology least equal trendy crispr remarkable yesterday deal see biogen become latest buy technique leading exponent sangamo changed hand signing put neurology focused tie among industry biggest deal struck without single patient treated biogen already form given bn ionis preclinical cns tie sangamo received combined asset point partnered never seen human subject biogen sangamo long worked together struck one preclinical alliance focusing sickle cell disease beta thalassaemia cell therapy asset phase ii trial biogen spun bioverativ business owned sanofi sangamo tie pfizer covering haemophilia marked watershed zinc finger nuclease sangamo gene therapy get pfizer stamp approval may watershed sangamo marking start month period stock surged peak per share perhaps precedent make yesterday biogen deal seem le impressive equity element done per share sangamo fallen considerably march peak today share opened detract fact represents considerable bet biogen group focus initially fall three sangamo asset gain exclusive right st st anti tau synuclein gene therapy alzheimer parkinson disease respectively plus undisclosed cns asset overall cns focus alliance seems unusual given many preclinical deal attracted front cash centred oncology notably however perhaps valuable preclinical cns alliance featured biogen gave ionis cash bought amazing equity tie covering range disorder biogen growing dependence aducanumab focus cns increasing desire spend big business development understandable side equation le remarkable sangamo wake hype crispr gene editing looked like left behind outdated zinc finger technology used precisely technology bring cash without using treat single patient date two partnered gene therapy asset haemophilia beta thalassaemia sickle cell disease entered clinic third gilead zinc finger edited allogeneic anti cd car kite get year doubt biogen partnered project advanced quickly bet need clinical backing sooner rather later\n",
      "\n",
      "Keywords:\n",
      "sangamo 0.41\n",
      "biogen 0.318\n",
      "zinc finger 0.234\n",
      "zinc 0.219\n",
      "cns 0.213\n",
      "finger 0.2\n",
      "tie 0.142\n",
      "gene 0.138\n",
      "alliance 0.137\n",
      "preclinical 0.13\n",
      "partnered 0.117\n",
      "therapy asset 0.109\n",
      "outdated 0.109\n",
      "gene editing 0.1\n",
      "asset 0.098\n",
      "thalassaemia 0.097\n",
      "st 0.097\n",
      "sickle cell disease 0.097\n",
      "beta thalassaemia 0.097\n",
      "cell disease 0.094\n",
      "\n",
      "Abstract:\n",
      "welcome weekly roundup approaching clinical readout pharmacological product approved specifically prader willi syndrome genetic condition characterised insatiable hunger hyperphagia growth hormone attempt develop new prader willi medicine notably zafgen far met failure soleno therapeutic put topline phase iii data asset controlled release form diazoxide choline expected mid year diazoxide potassium channel activator first approved treatment hypoglycaemia caused overproduction insulin example patient islet cell malignancy rationale use prader willi according soleno open potassium channel particular type neuron hypothalamus interrupting synthesis appetite stimulating neuropeptide overproduced prader willi patient randomised destiny prader willi study testing daily dos mg patient condition aiming decrease hyperphagia related behaviour versus placebo uncontrolled stage phase ii trial diazoxide choline reduced hyperphagia versus baseline obese prader willi subject beating placebo clearly harder achieve safety soleno point decade data diazoxide use hypoglycaemia wholly clean drug label list sodium fluid retention frequent serious adverse reaction sellside forecast diazoxide choline leading market importantly though phase ii data phase ii iii zephyr trial millendo therapeutic livoletide due first half leerink analyst expect trial succeed moderate change hyperphagia safety concern add phase iii part zephyr hit data registrational meanwhile abandoned two previous hepatitis b project lack safety efficacy arbutus desperately need next wave contender shape first clinical data lead compound due coming week news might come fourth quarter earnings march ab project focus subcutaneously administered rnai therapeutic said target four major hepatitis b transcript virus us replicate rebound one called surface antigen hbsag developer trying show respective project suppress level biomarker arbutus running phase ia ii trial ab result single ascending dose seen initially data multiple ascending dos following second half first readout provide decent insight project might capable baird analyst reckon log decline hbsag would substantially derisk ab versus rnai approach second half readout manage show greater log decline ab would start look promising believe aside trial appears registered new zealand arbutus trailing rnai developer seeking find functional cure hepatitis b already secured big pharma partner arrowhead partnered johnson johnson roche signed dicerna last year well dispelling doubt earlier pipeline failure next update arbutus must show stay race much catching le spectacular data might struggle capture attention\n",
      "\n",
      "Keywords:\n",
      "willi 0.307\n",
      "prader willi 0.307\n",
      "prader 0.307\n",
      "diazoxide 0.256\n",
      "hyperphagia 0.194\n",
      "arbutus 0.18\n",
      "ab 0.17\n",
      "soleno 0.153\n",
      "diazoxide choline 0.153\n",
      "choline 0.153\n",
      "hepatitis 0.113\n",
      "rnai 0.111\n",
      "potassium channel 0.102\n",
      "potassium 0.097\n",
      "hypoglycaemia 0.097\n",
      "hbsag 0.093\n",
      "log 0.09\n",
      "channel 0.09\n",
      "ascending 0.09\n",
      "phase 0.08\n",
      "\n",
      "Abstract:\n",
      "every public health emergency present opportunity bioharma justify existence springing action develop vaccine diagnostics treatment time use mention disease way drive share price tap investor money regard current outbreak coronavirus covid stuck script several vaccine antiviral poised enter clinic every bona fide effort numerous hanger rough calculation vantage reveals outbreak helped several small midcap biotech put combined bn market valuation case several huge gainer fact little show beyond hype press release small cap jumping coronavirus bandwagon include faron aim immunotech novavax cerus immunoprecise antibody tonix vantage analysed stock market movement january february biopharma company made public announcement coronavirus though first covid case reported last december week january became apparent global health emergency offing perhaps prominent work develop treatment involves gilead rose yesterday starting phase iii covid trial nucleotide analogue remdesvir though iv route drug far optimal view baird brian skorney gilead far plausible coronavirus stock achieve anything besides overpriced follow offering financial bet even made back health crisis retail investor website recently ran article entitled initial coronoavirus trading plan seems distasteful still without hard cash little real work would likely get done treat emergency among biggest example hype stand novavax biotech burned bn investor cash marketed product show instead using press release like sars rsv bird flu prelude cash call yesterday announced plan develop covid vaccine faron surged mere mention failed lead traumakine interferon beta biological first line defence viral infection tonix yesterday trumpeted vaccine collaboration stock surged relevant period owing separate trial failure many stock cap movement exaggerated fact concern micro cap company taken together increase valuation considerable diagnostics predictably diagnostics group recorded largest share price gain novacyt co diagnostics dragging penny stock territory novacyt february launched world first ce marked test covid virus co diagnostics followed ce marked diagnostic week later today followed fund raising earlier pharmamar announced developing coronavirus test actuality three pipped roche full year result meeting january said already introduced commercial yet approved coronavirus assay elsewhere investor piling moderna though analyst remain sceptical whether mrna approach resist virus mutation vir biotechnology claim working anti covid mabs dismissed baird nowhere close effective therapeutic reality real progress virus much likely made big company academic centre established infectious disease expertise corporate world includes merck co notable developing ebola vaccine get market johnson johnson owns vaccine business crucell pharma giant sanofi glaxosmithkline company size use trader hoping ride speculative surge chasing corona trade remember small cap immune crashing back earth drama\n",
      "\n",
      "Keywords:\n",
      "diagnostics 0.215\n",
      "coronavirus 0.183\n",
      "vaccine 0.182\n",
      "covid 0.145\n",
      "novacyt 0.127\n",
      "health emergency 0.127\n",
      "emergency 0.126\n",
      "tonix 0.121\n",
      "co diagnostics 0.121\n",
      "baird 0.121\n",
      "virus 0.118\n",
      "stock 0.116\n",
      "cap 0.116\n",
      "health 0.112\n",
      "develop 0.11\n",
      "movement 0.106\n",
      "january 0.104\n",
      "small cap 0.103\n",
      "outbreak 0.101\n",
      "hype 0.101\n",
      "\n",
      "Abstract:\n",
      "one valuable u approval decision due march sits multiple sclerosis project ozanimod bristol myers gained celgene acquisition p modulator likely get green light commercial challenge await novartis rival p modulator gilenya already lost patent protection ozanimod shown similar efficacy relapsing remitting patient need compete safety gilenya come requirement cardiac monitoring liver warning ozanimod shown better side effect profile issue gilenya aside ozanimod struggle compete roche ocrevus expected become m market leader forecast sale bn relapsing remitting setting according evaluatepharma consensus anti cd mab shown impressive efficacy clean label representing high bar dravet zogenix fintepla awaiting decision dravet syndrome rare form childhood epilepsy regulator opinion safety tarred association although serious cardiovascular issue observed fintepla active ingredient fenfluramine one half fen phen obesity drug withdrawn link serious heart problem clinically fintepla edge rival gw pharma epidiolex dravet latter head start epidiolex approved dravet lennox gastaut syndrome another form childhood epilepsy back fintepla studied lennox gaustat syndrome recent result saw underperform epidiolex evercore isi analyst expect zogenix price fintepla largely smaller dravet population reducing competitive threat gw elsewhere decision biohaven zydis odt fast acting formulation oral cgrp rimegepant acute migraine expected end march allergan ubrelvy became first oral cgrp antagonist win approval end last year prior setback complete response letter intarcia itca back front regulator itca matchstick sized implant slowly release exenatide active ingredient glp receptor agonist diabetes drug bydureon itca manages reach market next challenge persuade patient physician benefit implant injectable glp option offer weekly dosing implant cannot claim cardiovascular benefit major drawback highly competitive space intelgenx long tortuous path approval first started rizaport seven year ago migraine project oral soluble film formulation triptan maxalt undergoing fourth review last crl due cmc issue company perform bioequivalence study priority review lastly vantage compiled list pending fda approval granted priority review speed regulator pushing type application mean high chance verdict come early notable project hoping speedy decision include risdiplam smn splicing modifier roche oral agent shown encouraging efficacy data clean safety profile spinal muscular atrophy threatens biogen spinraza incyte pemigatinib meanwhile showed impressive survival result last year esmo fgfr selected population bile duct cancer kinase inhibitor seeking approval tiny population whole cancer amount new case year worldwide fgfr drive\n",
      "\n",
      "Keywords:\n",
      "fintepla 0.241\n",
      "dravet 0.234\n",
      "ozanimod 0.193\n",
      "itca 0.175\n",
      "gilenya 0.175\n",
      "implant 0.164\n",
      "epidiolex 0.137\n",
      "oral 0.124\n",
      "remitting 0.104\n",
      "relapsing remitting 0.104\n",
      "shown 0.102\n",
      "decision 0.102\n",
      "oral cgrp 0.1\n",
      "childhood epilepsy 0.1\n",
      "zogenix 0.096\n",
      "modulator 0.096\n",
      "lennox 0.096\n",
      "review 0.092\n",
      "approval 0.092\n",
      "syndrome 0.091\n",
      "\n",
      "Abstract:\n",
      "stock close day market haemorrhage fair say done well iovance pulled trick yesterday meaning market valuation stand jaw dropping bn investor betting cell therapy player would better focus clinical execution economic potential vague takeover chatter especially given iovance said virtually nothing fourth quarter call day bloomberg claimed company held preliminary talk potential buyer eye instead fall viability iovance tumour infiltrating lymphocyte til approach whose lead exponent lifileucel yield potentially registrational clinical data imminently come fourth cohort c melanoma trial completed dosing last month baseline expectation set sitc meeting last november second cohort study showed overall remission rate among subject crowned year stock surged quite performance group previous incarnation lion biotechnology became embroiled litigation stock promotion scandal saw chief executive manish singh suspended sec however new name new leadership maria fardis became chief exec iovance look drawn line past nothing allay fear technology whose economic viability still far proven tils simply extracted person tumour expanded reinfused academic working procedure year importantly nci lab dr steven rosenberg reported striking remission using tils melanoma cancer known particularly immunogenic proof til approach lie generating efficacy additional tumour type though admittedly remission rate pd l refractory patient sniffed iovance shortly complete enrolment cervical cancer study til regimen code ln read year likely melanoma trial importantly unlike car cell product tils genetically modified patentable per se rather iovance relies ip covering method expanding tils novel process taking manufacturing several week day provide important barrier competitor entry patentability issue curbed enthusiasm achilles therapeutic using advanced variation til approach understood close filing ipo important considering likelihood iovance takeover especially close bn stifel analyst yesterday cautioned cell therapy acquisition difficult tuck gilead celgene found much kite juno respectively car therapy still struggling prove commercially fact tils look even le like drug product even like hospital procedure provide reality check\n",
      "\n",
      "Keywords:\n",
      "iovance 0.404\n",
      "tils 0.299\n",
      "til 0.239\n",
      "til approach 0.21\n",
      "melanoma 0.138\n",
      "melanoma trial 0.131\n",
      "economic 0.12\n",
      "procedure 0.115\n",
      "remission 0.103\n",
      "close 0.101\n",
      "tumour 0.09\n",
      "importantly 0.085\n",
      "cell therapy 0.084\n",
      "became 0.081\n",
      "cell 0.08\n",
      "approach 0.079\n",
      "especially 0.078\n",
      "remission rate 0.077\n",
      "car 0.076\n",
      "day 0.076\n",
      "\n",
      "Abstract:\n",
      "day market already trading jitter coronavirus american society retina specialist added gloom novartis investor note eye doctor warning worrying side effect seen swiss pharma giant new macular degeneration treatment beovu helped wipe bn company market cap yesterday today share futher late trading beovu seen one novartis important sale growth driver bn sale forecast make company sixth biggest product year according evaluatepharma much depends novartis ability grab share entrenched competitor eylea sold regeneron effort severely hampered safety concern worrying medical body alert several case dangerous form eye inflammation called vasculitis although seen beovu clinical programme occurrence appear confirm real issue product retinal vasculitis lead blindness although case reported asrs classified occlusive retinal vasculitis happens smaller retinal vessel become blocked even greater concern database advera health analytics specialises compiling curating u adverse event report show vasculitis seen three anti vegf eye product count two beovu eylea lucentis although immediately clear specific form vasculitis figure refer advera get data faers fda adverse event reporting system must read context vastly greater use eylea lucentis market much longer however advera calculates drug reporting odds ratio disproportionality measure adverse event currently sits beovu eylea lucentis mean vasculitis higher relative occurrence faers compared drug novartis hoping look vasculitis signal turn function heightened physician alertness using new drug beovu associated higher rate intraocular inflammation seen patient compared eylea contraindicated patient active intraocular inflammation moreover label note rate retinal artery occlusion throw another potentially serious side effect physician struggling find reason reach novartis product beovu usp le frequent dosing schedule naturally becomes irrelevant worse safety exactly beovu might associated inflammatory issue unknown antibody fragment molecule much smaller eylea lucentis autoantibody seen much frequently patient treated beovu persuade physician patient product worth trying novartis need quickly work identify people risk regeneron meanwhile got boost stock price yesterday one big cloud eylea horizon started look lot le threatening company still looming prospect lucentis biosimilars contend novartis setback provide great help try convince physician stick know article updated additional data advera health\n",
      "\n",
      "Keywords:\n",
      "beovu 0.467\n",
      "vasculitis 0.34\n",
      "eylea 0.31\n",
      "lucentis 0.222\n",
      "retinal 0.208\n",
      "eylea lucentis 0.208\n",
      "advera 0.194\n",
      "novartis 0.174\n",
      "physician 0.122\n",
      "inflammation 0.111\n",
      "intraocular inflammation 0.097\n",
      "eye 0.096\n",
      "seen 0.094\n",
      "product 0.093\n",
      "intraocular 0.092\n",
      "worrying 0.079\n",
      "reporting 0.073\n",
      "adverse event 0.072\n",
      "adverse 0.07\n",
      "although 0.069\n",
      "\n",
      "Abstract:\n",
      "developer vitro diagnostics seek formal fda approval assay witness rash homebrew test gone sale new coronavirus past week asuragen however like thing book fragile x syndrome diagnostic first test disorder gained fda authorisation advent proven fragile x test fda say accuracy test greater accelerate demand therapy already pressing since nothing yet approved specifically condition several project development three active trial one zynerba pharmaceutical zygel made phase iii u fda say fragile x syndrome common cause inherited intellectual disability asuragen blood test amplidex may used diagnose condition combination family history clinical sign symptom may used identify adult carry alteration gene associated fragile x fmr gene diagnostic measure number repeat cgg segment fmr us classify individual one four category normal intermediate premutation full mutation first two category concerning patient full mutation typically fragile x woman premutation increased risk child fragile x men premutation increased risk passing condition daughter delicate task phase ii iii data likely coming year indicate whether zygel becomes first therapeutic specifically approved fragile x connect fx study testing two weight based dos cannabinoid receptor agonist administered transdermal gel every hour versus placebo primary endpoint change score baseline week subscale aberrant behaviour checklist community fragile x factor structure parent caregiver reported behavioural outcome measure zygel open label phase ii fab c study hit primary endpoint reduction anxiety depression mood scale adam score baseline week patient average drop fab c showed improvement subscale used phase iii endpoint known whether similar showing phase iii good enough approval connect fx incorporates placebo group complicating matter connect fx yield convincing benefit approval come mid data another candidate come summer time phase ii rocket trial ov gaba receptor agonist licensed ovid therapeutic lundbeck assessing three administration regime adverse event rate three month main outcome phase ii study bpn men fragile x undertaken tetra therapeutic primary completion date december according clinicaltrials gov result yet emerged placebo controlled crossover study focus project safety raft secondary endpoint provide information efficacy trial report marinus pharmaceutical ganaxolone demonstrated proof concept fragile x appeared prior vantage analysis market novartis exit leaf fragile x pipeline even frail state may company developing project fragile x stating k might pursue future possible trigger might come ovid rocket trial hit reignites interest gaba modulators potential fragile x therapy difficulty treating fragile x pharmacologically minimised novartis roche failed recent year de novo clearance asuragen test raise stake providing ready population whichever project first gain approval race appears zynerba lose\n",
      "\n",
      "Keywords:\n",
      "fragile 0.624\n",
      "premutation 0.15\n",
      "asuragen 0.15\n",
      "zygel 0.134\n",
      "fx 0.134\n",
      "connect fx 0.134\n",
      "connect 0.134\n",
      "test 0.127\n",
      "fmr 0.094\n",
      "zynerba 0.089\n",
      "men 0.089\n",
      "fragile syndrome 0.089\n",
      "phase 0.086\n",
      "subscale 0.086\n",
      "ovid 0.086\n",
      "gaba 0.086\n",
      "baseline week 0.083\n",
      "rocket 0.08\n",
      "receptor agonist 0.08\n",
      "increased risk 0.08\n",
      "\n",
      "Abstract:\n",
      "esperion nasdaq flotation investor offered chance buy cholesterol lowering project treat intolerant statin need extra ldl lowering boost given time passed development u turn common biopharma surprising little message changed last friday fda approved project question bempedoic acid trademarked nexletol decision drug use combination ezetimibe due coming day anything another green light would huge surprise shifted year company focus relative affordability nexletol arrival pcsk particular mean post statin space become highly competitive esperion arguably little choice go hard price pill cost around per day company confirmed today equates around year comparison pcsk agent thought cost around annually relevant u patient pocket cost esperion claim substantially lower per day thanks access programme offer call today executive said plan sunset scheme see patient paying little three month supply race bottom ability esperion make money strategy major focus investor coming month much depend demand much money company need spend generate sale consensus number evaluatepharma sale year rising company starting turn profit similar cost lowering arrangement place pcsk course though seems unlikely developer antibody amgen sanofi regeneron willing come much lower aside fact company already slash price half drive demand drug potent cholesterol lowerers esperion strong convenience argument make nexletol day pill easy see regimen might appealing injected pcsk approval ezetimibe combination important take oral regimen closer pcsk term ldl lowering downside however esperion couple year wait know whether crucial cardiovascular claim grasp clear outcome testing nexletol versus placebo statin intolerant patient yield result least experion affordability convenience argument mean little trial fail yield convincing signal\n",
      "\n",
      "Keywords:\n",
      "esperion 0.382\n",
      "pcsk 0.298\n",
      "nexletol 0.279\n",
      "lowering 0.206\n",
      "statin 0.179\n",
      "cost 0.145\n",
      "convenience argument 0.139\n",
      "ldl lowering 0.132\n",
      "affordability 0.132\n",
      "per day 0.127\n",
      "cost around 0.127\n",
      "little 0.115\n",
      "day 0.108\n",
      "ldl 0.105\n",
      "cholesterol 0.105\n",
      "convenience 0.101\n",
      "argument 0.097\n",
      "pill 0.096\n",
      "demand 0.092\n",
      "regimen 0.088\n",
      "\n",
      "Abstract:\n",
      "welcome weekly roundup approaching clinical readout gilead galapagos gearing u regulatory action filgotinib rheumatoid arthritis later year meantime trial jak ulcerative colitis report second quarter see data phase iib iii selection study test mg mg filgotinib daily versus placebo adult treated biologicals week induction phase selected met response remission criterion week maintenance portion primary objective proportion participant achieving remission based component mayo clinic score filgotinib safety profile scrutinised owing thrombosis concern older jak question whether filgotinib differentiate competition abbvie rinvoq another jak inhibitor showed statistically significant clinical remission per adapted mayo score highest dose versus placebo full data well two phase iii trial make rinvoq pivotal programme uc expected jak autoimmune space rinvoq approved ra last year lead market according evaluatepharma sellside consensus uc expected make smaller portion rinvoq filgotinib sale ra abbvie marketing machine behind rinvoq expected take huge lead gilead galapagos uc sale versus filgotinib according evaluatepharma sale indication data u decision ra due h uc selection data due q uc extension study nct complete itch worth scratching meanwhile serlopitant source much woe menlo since company ipo two year ago menlo share since float owing serlopitant failure treat pruritus associated atopic dermatitis miss chronic cough trial data separate pruritus trial provide chance nk receptor antagonist redeem vital menlo another reason data two phase iii study serlopitant menlo licensed merck co ought appear march april trial assessing product therapy itching associated prurigo nodularis chronic skin disorder cause inflamed skin nodule arm leg trunk two phase iii study mti mti identical except conducted u europe respectively test mg serlopitant versus placebo total patient primary endpoint proportion patient showing improvement least four point worst itch numeric rating scale wi nrs week aim show treatment effect difference versus placebo analyst sentiment look positive investor consensus forecast pegged according evaluatepharma data hc wainwright point positive study completed ipo including post hoc analysis phase ii prurigo nodularis trial showed difference four point wi nrs responder rate treatment placebo p result upcoming phase iii trial key menlo merger foamix announced last november foamix menlo shareholder would approximately combined company respectively one serlopitant trial fail end may foamix shareholder ownership would increase rise study fail\n",
      "\n",
      "Keywords:\n",
      "menlo 0.334\n",
      "serlopitant 0.278\n",
      "uc 0.248\n",
      "filgotinib 0.224\n",
      "rinvoq 0.199\n",
      "foamix 0.167\n",
      "jak 0.149\n",
      "ra 0.13\n",
      "two phase iii 0.115\n",
      "two phase 0.109\n",
      "versus placebo 0.102\n",
      "placebo 0.1\n",
      "test mg 0.099\n",
      "mayo 0.099\n",
      "itch 0.099\n",
      "phase 0.095\n",
      "selection 0.092\n",
      "versus 0.091\n",
      "pruritus 0.089\n",
      "trial 0.088\n",
      "\n",
      "Abstract:\n",
      "bull bear continue argue principia multi cohort crossover multiple sclerosis dataset sar rival btk inhibitor making bold bet merck kgaa yesterday revealed design two pivotal study evobrutinib initiated last year would changed compare agent biogen avonex sanofi aubagio merck took decision seeing long term data phase ii study last year yielded controversial result trial suggest evobrutinib displace infusion become new oral standard care luciano rossetti merck head r told analyst call yesterday quite bullish view especially given little evidence exists back btk inhibition m approach relies theory disease involves b cell something separately spurred development roche blockbuster anti cd mab ocrevus higher bar heart lie merck view aubagio tougher comparator avonex beating former pivotal trial would help make best case evobrutinib especially would entail head head comparison two oral agent evobrutinib two pivotal trial evolution rms rms started enrolling planned relapsing m subject last august designed avonex comparator arm still stated clinicaltrials gov merck say site already enrolled willing change comparator drug aubagio site added said mr rossetti delay forecast pivotal data still possible fourth quarter merck claim confidence stem week cut phase ii evobrutinib trial whose primary week data published last year particular annualised relapse rate week two highest evobrutinib dos remain around week merck disclosed yesterday comparison two ocrevus extension study similar setting shown week relapse rate cross trial comparison lead merck believe evobrutinib become oral equal ocrevus two pivotal trial week annualised relapse rate primary endpoint inconceivable separate factor focused mr rossetti mind sanofi principia partner recently revealed pivotal study relapsing m would compare sar aubagio merck risked getting left behind german company yesterday denied consideration merck claimed evobrutinib brain penetrant admitted backed animal data central pillar principia bull case sar btk inhibitor property analyst previously called evobrutinib non brain penetrant despite merck bullishness middle highest evobrutinib dose met phase ii trial primary endpoint nejm revealed merck adjusted statistic multiplicity german merck watch evobrutinib benefit melt away june moreover btk inhibitor associated liver enzyme elevation clinicaltrials gov entry phase iii trial state evobrutinib twice daily suggesting merck taken project twice daily mg dose forward mg daily met phase ii primary endpoint though mg twice daily numerically better reducing relapse rate said done merck want take ocrevus pit evobrutinib directly roche drug aubagio comparator give sufficient power show superiority relatively small sample size argued mr rossetti cynic add suggesting similarity across trial safer demonstrating inferiority head head\n",
      "\n",
      "Keywords:\n",
      "evobrutinib 0.538\n",
      "merck 0.262\n",
      "aubagio 0.197\n",
      "rossetti 0.177\n",
      "relapse rate 0.157\n",
      "ocrevus 0.135\n",
      "comparator 0.135\n",
      "mr rossetti 0.133\n",
      "avonex 0.133\n",
      "btk 0.129\n",
      "relapse 0.12\n",
      "sar 0.113\n",
      "principia 0.11\n",
      "twice daily 0.106\n",
      "head 0.104\n",
      "two pivotal 0.099\n",
      "btk inhibitor 0.097\n",
      "daily 0.096\n",
      "pivotal 0.092\n",
      "met phase 0.083\n",
      "\n",
      "Abstract:\n",
      "common pitfall overzealous biotech company continue developing drug clinical readout suggests would wiser stop index pharmaceutical stockholm listed micro cap appears taken stage ulcerative colitis lead project cobitolimod six year ago cobitolimod crashed pivotal study index ploughed designing running new phase ii test yesterday yielded result best called equivocal index view new study confirms successful topline result support strategy going forward latest study conduct designed dose optimisation trial using slightly different endpoint failed phase iii test collect conduct toplined showing outstanding combination efficacy safety last august yesterday index revealed statistical analysis conduct tested four cobitolimod dos three higher one failed collect recruited ulcerative colitis specifically left side variety signifying relatively severe disease hopefully resulting uniform dataset collect make distinction seems double mg dose showed relevant activity joint highest tested low bar index revealed set remarkably low bar success conduct determining one sided p value would deemed statistically significant industry standard two sided p value roughly twice hard hit tougher threshold significance high dose cleared bar one sided p though apparently none three managed meet even low threshold used various undisclosed secondary endpoint said significant one sided p level given low goal impossible gauge clinical relevance low bar seen two sided p value high dose achieved scraping index said carry correction multiple analysis various dos arguing conduct exploratory study powered accordance regulatory guideline study even seem dose response relationship lowest dose performed numerically better joint highest four time mg instance unfortunately index available evidence taken together result conduct seems luck stock afternoon trading today cobitolimod oligonucleotide tlr according evaluatepharma advanced industry asset blocking target significant work gone tlrs toll like receptor without huge success company pursuing opposite mechanism agonising tlrs including tlr oncology use best conduct suggests even higher dos tested especially given said good safety undeterred index plan start enrolling subject new phase iii study double mg dose year chief executive peter zerhouni told vantage yet decided whether higher dose tested argued running yet another phase ii study instead would take almost long phase iii delay time market true without convincing efficacy signal caveat emptor applies\n",
      "\n",
      "Keywords:\n",
      "conduct 0.357\n",
      "index 0.307\n",
      "sided 0.279\n",
      "cobitolimod 0.239\n",
      "sided value 0.179\n",
      "dose 0.169\n",
      "one sided 0.168\n",
      "collect 0.168\n",
      "bar 0.151\n",
      "low bar 0.148\n",
      "low 0.126\n",
      "tested 0.104\n",
      "ulcerative colitis 0.091\n",
      "ulcerative 0.091\n",
      "colitis 0.091\n",
      "study 0.09\n",
      "joint 0.087\n",
      "high dose 0.084\n",
      "mg 0.082\n",
      "threshold 0.08\n",
      "\n",
      "Abstract:\n",
      "recent move sanofi roche advance respective selective oestrogen receptor degrader pivotal testing moved analyst take second look mechanism action perhaps boldest view articulated yesterday jefferies called least bn market opportunity quite turnaround mechanism action roche disastrous takeover seragon set make somewhat mediocre addition breast cancer armamentarium emboldened developer notion efficacious drug orally bioavailable real game changer selective oestrogen receptor degrader serd story actually begun fulvestrant astrazeneca faslodex launched whose sale breached bn mark last full year patent expired thought faslodex poor bioavailability intramuscular delivery held drug back spawning search effective oral negative er positive niche drug target breast cancer typically negative driven oestrogen receptor signalling faslodex second line label failure aromatase inhibitor theory binding oestrogen receptor change activity first generation selective oestrogen receptor modulators included tamoxifen blanket effect receptor signalling cue serds degrading receptor eliminate effect entirely structurally serds comprise molecular scaffold hit receptor ligand binding pocket plus long side chain known degron cause receptor degradation developer varying makeup pursuit ideal characteristic though course pivotal data ultimate test jefferies caution mechanism thrust spotlight recently sanofi new chief executive naming company offering sar one group top six growth driver sanofi new broom clean house december second line phase ii trial yield data end year allow filing roche meanwhile last month revealed rg entering phase iii study yet posted clinicaltrials gov swiss firm say test serd first line combination cdk inhibition two earlier generation serds roche acquired along seragon ditched time ago group reckons found secret sauce rg call best class oral asset improved efficacy vivo versus serds year early data come pfizer zentalis zn c g therapeutic rintodestrant according company potential best class serd start phase ii expansion study combination pfizer cdk inhibitor ibrance joker pack perhaps radius elacestrant entered phase iii emerald study showing impressive remission rate subject failed median three prior therapy however last november radius decided focus endocrine disease explore strategic option oncology emerald set complete enrolment later year company plan investment\n",
      "\n",
      "Keywords:\n",
      "oestrogen receptor 0.313\n",
      "oestrogen 0.278\n",
      "receptor 0.263\n",
      "serds 0.25\n",
      "selective oestrogen receptor 0.188\n",
      "selective oestrogen 0.188\n",
      "faslodex 0.188\n",
      "serd 0.176\n",
      "selective 0.146\n",
      "degrader 0.117\n",
      "sanofi new 0.111\n",
      "signalling 0.1\n",
      "cdk 0.1\n",
      "roche 0.092\n",
      "rg 0.089\n",
      "mechanism action 0.088\n",
      "jefferies 0.088\n",
      "best class 0.088\n",
      "sanofi 0.086\n",
      "mechanism 0.084\n",
      "\n",
      "Abstract:\n",
      "investor world largest medtech must hope medtronic disappointing third quarter result represent brief detainment doldrums trade wind pick group whole suite product launch lined ought boost sale later year early next factor including emergence new coronavirus delay one major new product increasing competition elsewhere becalmed company better expected earnings appease shareholder spooked revenue coming beneath projection share closed company diabetes unit grew slightly ahead expectation u business declined low double digit partly medtronic awaiting debut new product speaking earnings call outgoing chief executive omar ishrak said u filing minimed g next version medtronic artificial pancreas would occur march would push approval beyond end fiscal mid june end calendar earliest pivotal data system slated american diabetes association annual meeting june stifel analyst write crucial device meet criterion approval fully interoperable continuous glucose monitor icgm put equal footing like dexcom g approved g would medtronic fourth system classified fda artificial pancreas g g g device approved u market tandem diabetes care slim x big launch offing include spinal cord stimulation technology pain obtained via acquisition stimgenics january cobalt crome portfolio high powered implantable cardioverter defibrillator cardiac resynchronization therapy defibrillator case medtronic said customer holding buying new device new product launch contributing quarter softness valve pressure one main hit medtronic top line came u transcatheter aortic valve business sale grew market growth rate management suggested difficulty hiring training sale people quickly enough keep rapidly expanding market quite contrast performance edward lifesciences leader aortic space reporting fourth quarter result january said global aortic valve sale increased around underlying basis impressive strength u medtronic management least belief coronavirus imperilled operation china ought transient threat medtronic china based business make roughly global sale suffered postponed medical procedure shortage medical personnel company investor day june time led geoffrey martha currently president restorative therapy group hope put woe behind\n",
      "\n",
      "Keywords:\n",
      "medtronic 0.513\n",
      "valve 0.216\n",
      "aortic 0.202\n",
      "device 0.173\n",
      "new product 0.169\n",
      "grew 0.128\n",
      "artificial 0.123\n",
      "ought 0.119\n",
      "diabetes 0.119\n",
      "sale 0.118\n",
      "quarter result 0.115\n",
      "launch 0.111\n",
      "new 0.109\n",
      "june 0.108\n",
      "earnings 0.105\n",
      "product 0.104\n",
      "business 0.102\n",
      "quarter 0.081\n",
      "system 0.081\n",
      "china 0.079\n",
      "\n",
      "Abstract:\n",
      "introduction u breakthrough designation marked big jump accelerated approval latest data released fda show happened last year dip previous two year though seems unlikely biopharma company cooling fast market strategy regulatory pathway allows drug approved quickly based trial relying surrogate endpoint rather directly measuring clinical benefit ultimate aim get important new therapy patient quickly appears working although critic claim product real effectiveness established soon enough data released fda include first time supplementary approval cancer drug dominate particularly recent year keytruda example received approval based surrogate endpoint according regulator list four lung head neck melanoma setting converted full approval would expected chart show recent arrival converted full approval real concern lie product market time whose approval still backed insufficient evidence true case science probably moved particular drug longer used always case however raised significant concern regulator come pressure remove amag preterm birth treatment makena market example granted accelerated approval back notable keytruda failed liver gastric cancer trial last year though fda silent whether merck co accelerated approval rescinded withdrawal happen lilly pulled lartruvo last year confirmatory trial failed show benefit patient soft tissue sarcoma seem exception rather rule foot dragging little urgency detected industry part convert license full approval graph suggests although perhaps improvement decade ago far top left sits tykerb glaxosmithkline owned took eight year convert accelerated approval post menopausal breast cancer patient full licence mattered much mediocre effectiveness already sealed kinase inhibitor fate elderly accelerated approval yet converted commercially insignificant though many still actively marketed enzyme replacement therapy elaprase takeda acquired shire example lundbeck northera u sale product forecast reach respectively year benefit developer foot dragging plain see apparently patient physician must wait evidence medicine real value criticism fda chasing confirmatory study sufficient vigour look like fair rebuke case\n",
      "\n",
      "Keywords:\n",
      "approval 0.265\n",
      "accelerated approval 0.246\n",
      "accelerated 0.225\n",
      "converted 0.205\n",
      "full approval 0.184\n",
      "dragging 0.143\n",
      "foot 0.127\n",
      "full 0.123\n",
      "surrogate endpoint 0.123\n",
      "year though 0.12\n",
      "surrogate 0.11\n",
      "effectiveness 0.108\n",
      "fda 0.108\n",
      "example 0.106\n",
      "data released 0.101\n",
      "real 0.096\n",
      "confirmatory 0.095\n",
      "case 0.085\n",
      "last year 0.084\n",
      "product 0.083\n",
      "\n",
      "Abstract:\n",
      "decade drug development parkinson disease yielded little beyond levodopa used control movement disorder symptomatic condition therapy capable halting reversing patient neurodegeneration come light several mid stage trial set read year ought show new mechanism might stand chance halting progression parkinson chief among mechanism synuclein hypothesis imminent phase ii data rival inhibitor protein developed roche biogen ought show whether theory leg basis hypothesis several mutation synuclein protein cause autosomal dominant form parkinson others increase syn expression linked higher normal risk disorder spherical aggregated form protein lewy body hallmark parkinsonian neuropathology wage syn first data two part pasadena trial prothena anti syn mab prx licensed roche pasadena first part test high dose mg patient bodyweight kg mg weigh le low dose mg placebo end part one year patient placebo group randomised either high low dose prx another year primary endpoint change baseline patient score movement disorder society unified parkinson disease rating scale md updrs one year part one data come year prothena said last week phase ii spark trial biogen biib perhaps le useful proof syn concept spark similar size design pasadena testing three dos mab versus placebo interim readout one year endpoint look patient outcome instead primary measure rate adverse event secondary geared towards pharmacodynamic effect biib dopaminergic nerve well pharmacokinetics immunogenicity data safety possibly pharmacodynamics expected second half tiny phase ii trial even tinier extension study cerebral dopamine neurotrophic factor formulation development herantis pharma ought yield data year according finnish group cdnf protects neuron degeneration restores function already degenerating neuron function several way company contends one inhibiting formation synuclein oligomers play syn theory despite small size trial assessing whole suite endpoint initial trial primary endpoint extension according clinicaltrials gov value conclusion wrought small trial open question data expected first quarter swimming upstream data anavex anavex called blarcamesine expected mid year project sigma receptor ligand anavex say act upstream target activating neuroprotective signal help neuron return homeostasis company exploratory phase ii data suggesting project improve cognition alzheimer patient far human data parkinson phase ii parkinson trial ass effect two dos computer based cognition test well molecule safety versus placebo big cap pharma trying new attack sanofi gz aka venglustat development several rare disorder associated mutation glycosphingolipid metabolic pathway move pd trial enrolled parkinson disease patient mutation gba gene mutation one common genetic risk factor parkinson patient carry variant making common mutation synuclein gene patient gba mutation tend experience motor symptom deficit cognitive decline rapidly others move pd pretty solid endpoint change baseline md updrs part ii iii score two month one year almost unimaginably unlikely event move pd roche prothena pasadena trial hit sanofi project reach wider population following analysis exclude investigator initiated trial due report exclude gene therapy parkinson covered separately several novel mechanism evaluated phase study though naturally yield definitive conclusion disease modifying nature therapy two anti synuclein mabs phase takeda astrazeneca tak lundbeck lu af neither expected post data clinical benefit denali therapeutic two shot goal leucine rich repeat kinase inhibitor dnl dnl lrrk regulator lysosomal function impaired parkinson disease contributing formation lewy body neurodegeneration trial read month ago dnl meeting biomarker goal generally well tolerated lower dose tested dnl well tolerated dos trial met safety biomarker goal dnl phase b trial expanded study higher dos coming month denali intends choose either dnl dnl take phase ii iii trial parkinson fb target c abl south korean group st biotherapeutics claim play role driving synuclein pathogenesis parkinson compound thought first c abl inhibitor advance clinical trial single multiple ascending dose study report year trial pasadena move pd one watch since reveal effect differing mechanism development parkinson alzheimer plenty cns disorder extent difficulty showing definite effect disease progression matched vastness reward gained success difficulty reflected consensus forecast compiled evaluatepharma one project sale number attached prx forecast sell\n",
      "\n",
      "Keywords:\n",
      "parkinson 0.367\n",
      "dnl 0.259\n",
      "synuclein 0.202\n",
      "syn 0.197\n",
      "pasadena 0.185\n",
      "move pd 0.158\n",
      "trial 0.133\n",
      "mutation 0.13\n",
      "parkinson disease 0.12\n",
      "prx 0.118\n",
      "one year 0.111\n",
      "prothena 0.111\n",
      "anavex 0.105\n",
      "ought 0.098\n",
      "disorder 0.098\n",
      "neuron 0.092\n",
      "ii 0.088\n",
      "phase 0.087\n",
      "part 0.085\n",
      "one 0.081\n",
      "\n",
      "Abstract:\n",
      "result weekend asco genitourinary cancer symposium confirmed seattle genetics astellas padcev new force urothelial cancer well reminding mirati investor company entirely kras inhibition good news exelixis whose second attempt prostate cancer cabometyx boosted detail cosmic dataset seemed allay earlier fear patient death meanwhile merck co revealed nothing new hif inhibitor mk set expectation pivotal study way trial combine mk everolimus enrol kidney cancer subject failed pd vegf blockade corresponds population phase ii study whose highly positive result presented asco gu merck acquired mk along peloton therapeutic bn expectation high renal cancer though second line post vegf setting mirati multi kinase inhibitor sitravatinib yielded overall response rate subject received combination bristol myers squibb opdivo investigator initiated trial apparent improvement partial response rate seen esmo renal cancer expansion cohort phase trial subject received sitravatinib monotherapy another cross study basis beat rate opdivo showed checkmate trial back whose survival benefit opdivo monotherapy secured second line monotherapy label however combination keytruda bavencio lenvima set shake first line renal cancer meaning second line opportunity air perhaps explaining mirati primary sitravatinib focus nsclc according evaluatepharma asset sellside consensus revenue mirati investor mainly fixated kras inhibitor mrtx seattle meanwhile padcev represents new focus since scoring second line urothelial cancer label december first line setting combination keytruda look sight three cohort pivotal study ev patient got way last month asco gu update ev trial showed remission rate pd l high pd l low subject first time survival curve presented study inform expectation ev last week separate project tucatinib seattle acquired along cascadian therapeutic accepted u approval combination herceptin positive breast cancer august action date clear several misfire seattle story longer solely adcetris finally exelixis breathing easier result cosmic study presented asco gu last week abstract went live death dehydration year old subject study testing cabometyx plus tecentriq prostate cancer looked concerning asco gu revving peloton deal validation february however presentation explained even though death classified treatment related subject six month history failure thrive entering cosmic focus fell efficacy fact response seen pd l low well high patient story amended add astellas joint sponsor ev trial\n",
      "\n",
      "Keywords:\n",
      "asco gu 0.217\n",
      "gu 0.207\n",
      "cancer 0.201\n",
      "ev 0.192\n",
      "mirati 0.173\n",
      "sitravatinib 0.163\n",
      "cosmic 0.163\n",
      "asco 0.156\n",
      "seattle 0.151\n",
      "second line 0.132\n",
      "renal cancer 0.13\n",
      "mk 0.13\n",
      "line 0.113\n",
      "pd 0.112\n",
      "subject 0.107\n",
      "renal 0.104\n",
      "peloton 0.103\n",
      "subject received 0.099\n",
      "presented asco 0.096\n",
      "pd low 0.096\n",
      "\n",
      "Abstract:\n",
      "welcome weekly roundup approaching clinical readout data due second quarter see whether avadel ft take leading narcolepsy drug jazz pharmaceutical avadel project nightly formulation sodium oxybate ingredient jazz xyrem xyrem follow jzp jazz drug need taken twice nightly improvement administration alongside comparable efficacy safety give avadel boost avadel placebo controlled rest study enrolled narcolepsy patient aged older start g titration g given nightly continue use stimulant stable dos co primary endpoint measure change excessive daytime sleepiness cataplexy looking ft one xyrem trial patient taking g median reduction cataplexy attack baseline versus four placebo p another study patient taking g saw significant median reduction five point epworth sleepiness scale versus point placebo xyrem black box warning respiratory depression potential misuse mean restricted rem programme despite restriction xyrem market leader narcolepsy see generic competition sale forecast drop peak bn year according evaluatepharma consensus jazz low sodium follow project jzp pick slack sale forecast reach jzp filed last month shown comparable efficacy xyrem worryingly two patient jzp randomised withdrawal study serious adverse event deemed treatment related ft show safety advantage highly positive likely given essentially reformulation jazz product debatable ft developed abbreviated b pathway one phase iii study needed ultimately avadel need get place xyrem generic hit price ft accordingly axovant ups dose data axovant parkinson disease gene therapy axo lenti pd aim raise production dopamine expected month next axovant licensed axo lenti pd oxford biomedica therapy said tenfold potent oxford prosavin disappointed clinic six month result second cohort sunrise pd trial concern two patient dose x transducing unit threefold higher given first cohort encouraging albeit early data reported two patient cohort showed average point change baseline motor function assessed score month representing improvement earlier six month data showed average point change baseline improvement investor looking clear dose response second cohort term competition voyager vy aadc slightly ahead axovant project across three cohort vy aadc shown point change baseline score three year data phase ib study due later year voyager ongoing phase ii study restore patient according evaluatepharma sellside forecast sale axo lenti pd disparity analyst number wide\n",
      "\n",
      "Keywords:\n",
      "xyrem 0.373\n",
      "avadel 0.285\n",
      "jazz 0.243\n",
      "axovant 0.228\n",
      "ft 0.217\n",
      "jzp 0.213\n",
      "narcolepsy 0.16\n",
      "two patient 0.141\n",
      "change baseline 0.13\n",
      "baseline 0.112\n",
      "cohort 0.112\n",
      "pd 0.11\n",
      "sleepiness 0.101\n",
      "second cohort 0.101\n",
      "median reduction 0.101\n",
      "change 0.099\n",
      "point 0.098\n",
      "sodium 0.094\n",
      "patient taking 0.094\n",
      "patient 0.088\n",
      "\n",
      "Abstract:\n",
      "heavy toxicity burden ctla inhibitor like bristol myers squibb yervoy astrazeneca tremelimumab always major drawback still clear whether latter ever make market astra remains convinced mechanism hold much potential several tumour type today revealed plan large phase ii programme bispecific approach medi hit ctla pd designed target lymphocyte tumour bed express immune checkpoint jos baselga astra head oncology r told vantage early study shown bispecific achieving substantially higher inhibition ctla big reduction toxicity persuading company push astra figured optimal dose medi expanding ongoing phase trial preparing launch phase ii study according mr baselga moving ahead quickly indication ctla dependent renal cell carcinoma melanoma hepatocellular feel incredibly excited lung cancer hope launch aggressive programme said speaking vantage company released annual result today progress would make astra leading developer space west least alphamab oncology broad early mid stage clinical programme way kn although recruiting patient china australia xencor patient study candidate ongoing u astra burgeoning investment focus attention smaller player progress still mr baselga maintains medi advantage project thanks variability binding affinity different change binding affinity ctla upon binding pd bispecifics different giving two separate molecule say important toxicity seen agent like tremelimumab caused binding non tumour related ctla receptor preclinical study shown unlike lymphocyte periphery tumour infiltrating lymphocyte tils co express receptor tils might resistant single checkpoint blockade creating antibody bind well ctla alone requires pd preventing binding lymphocyte tumour preventing lot side effect seen ctla say judgement time course remains proven little clinical data available project mr baselga say astra hope present phase result coming month success would presumably help mitigate disappointment tremelimumab failed add anything imfinzi neptune study increasingly suspected dud tremelimumab deprioritisation laid bare february important readout project include bladder cancer study danube report coming month liver cancer study himalaya due report second half final survival readout poseidon due next year dave fredrickson head astra oncology unit said result three trial would help determine treme future seems medi company already pivot place story updated add macrogenics project\n",
      "\n",
      "Keywords:\n",
      "ctla 0.32\n",
      "baselga 0.252\n",
      "astra 0.229\n",
      "lymphocyte 0.224\n",
      "medi 0.208\n",
      "binding 0.208\n",
      "tremelimumab 0.202\n",
      "tumour 0.136\n",
      "affinity 0.118\n",
      "tils 0.108\n",
      "study shown 0.098\n",
      "mr 0.096\n",
      "study 0.095\n",
      "preventing 0.094\n",
      "express 0.094\n",
      "pd 0.091\n",
      "cancer study 0.089\n",
      "toxicity 0.085\n",
      "oncology 0.083\n",
      "programme 0.08\n",
      "\n",
      "Abstract:\n",
      "domination cancer research disease well appreciated new analysis deal money deployed show extent biopharma preoccupation almost half cash spent drug developer company acquisition licensing deal directed oncology past five year sum around bn total deployed according vantage analysis evaluatepharma data excludes deal targeting several therapy area like celgene real figure likely larger cardiovascular space seen second biggest spend though two substantial deal skew figure johnson johnson bn takeout actelion novartis recent move medicine company almost bn transaction left analysis pure therapy area play course removing increase cancer proportional take analysis constructed transaction clear primary therapy focus front fee paid used rather total deal value give complete look sector spending vantage counted licensing deal though disclosed front value assigned based therapy focus lead project important remember cancer cardiovascular field vast compared area like dermatology sensory organ expected attract larger sum money still working infectious disease example would argue distribution wealth always followed need dip sum spent oncology project surged last year deal making activity drug maker overall dimming since biotech boom previously described vantage licensing deal alike trend partly driven easy access financing lessened need smaller developer sell time however cancer share cash deployed hovered around chart show surging last year driven multi billion takeout array bn loxo bn arqule bn area stand include cardiovascular peak representing deal mentioned previously neurology seen big transaction area includes central nervous system related indication like psychiatry dementia peak driven novartis acquisition avexis similar story emerges looking count deal happening first proportional basis actual number outside ever dominant cancer space interesting see biopharma interest neurology remained constant around deal announced since notable considering exit several big pharma group space miscellaneous group seen emerging chart contains lot rare disease project easily fit traditional therapy area looking actual number deal dip activity across therapy area since evident field seem registered bigger underlying decline identified however infectious disease stand nine deal last year commercial difficulty antibiotic maker encountering perhaps one explanation whether huge investment cancer worth commercially driven commensurate improvement patient life question entirely course ability company charge premium price therapy big pull factor real progress made certain area field like immuno oncology advanced many hoped analysis suggest sector remains fully committed oncology though clear considerably le competitive sector found updated story corrected include several deal missing previous analysis\n",
      "\n",
      "Keywords:\n",
      "deal 0.314\n",
      "area 0.271\n",
      "therapy area 0.191\n",
      "deployed 0.154\n",
      "licensing deal 0.135\n",
      "cancer 0.133\n",
      "driven 0.131\n",
      "analysis 0.13\n",
      "therapy 0.13\n",
      "licensing 0.12\n",
      "sum 0.119\n",
      "transaction 0.116\n",
      "actual number 0.114\n",
      "field 0.113\n",
      "oncology 0.113\n",
      "neurology 0.106\n",
      "bn 0.101\n",
      "infectious disease 0.1\n",
      "dip 0.1\n",
      "cardiovascular 0.097\n",
      "\n",
      "Abstract:\n",
      "annual meeting american college cardiology held chicago towards end march see two presentation represent major catalyst one pharma medtech saturday march delegate get look full dataset victoria study vericiguat development merck co bayer heart failure trial toplined november guanylate cyclase agonist reducing risk heart failure hospitalisation cardiovascular death placebo patient chronic heart failure reduced ejection fraction patient study treated standard care includes novartis entresto extent improvement top critical evercore isi analyst write risk reduction considered meaningful possible lower cv benefit would considered success vericiguat markedly improve quality life project performance phase ii provide much benchmark predicting chance phase iii one thing endpoint completely different reduction nt probnp level surrogate cardiac stress another trial failed vericiguat made next stage development bayer felt enough dose response mace benefit hit another pivotal trial vitality harder treat heart failure population preserved ejection fraction would boost project bernstein analyst sceptical hit entresto several project failed data vitality imminent though late breaker slot acc heart failure tough market launch thanks conservative practice cost pressure slow pace guideline change least vericiguat added standard care much easier prospect replacing bernstein see global sale product peaking around bn partner getting half assigns probability success perfect spyral day later result u pivotal trial medtronic renal denervation product symplicity spyral presented highly positive justify group hefty investment moribund technology data first around patient spyral htn med study yielded surprise hit back revitalising interest technique corpse renal denervation start twitching august medtronic said would start pivotal trial spyral device mid however shift plan instead separate pivotal study started med trial would expanded recast registrational enrolment upped patient time cut primary efficacy endpoint ambulatory hour blood pressure change baseline altered three year three month full data study presented acc meeting interim cut revealed sham adjusted drop ambulatory blood pressure mmhg medtronic previously said hoped get least big reduction full data came drug therapy course initial treatment patient hypertension renal denervation used respond cannot tolerate various medication still enormous opportunity though medtronic putting renal denervation market somewhere neighbourhood bn according stifel analyst medtronic recently started patient pilot study dystal testing targeted procedural approach fewer radiofrequency ablation allow faster efficient procedure decision start study suggests medtronic optimistic med result though investor might wonder whether group getting ahead\n",
      "\n",
      "Keywords:\n",
      "medtronic 0.311\n",
      "spyral 0.233\n",
      "renal denervation 0.233\n",
      "denervation 0.233\n",
      "vericiguat 0.207\n",
      "heart failure 0.198\n",
      "med 0.175\n",
      "heart 0.166\n",
      "renal 0.139\n",
      "failure 0.112\n",
      "vitality 0.104\n",
      "ambulatory 0.104\n",
      "pressure 0.104\n",
      "entresto 0.096\n",
      "blood pressure 0.096\n",
      "acc 0.096\n",
      "pivotal trial 0.09\n",
      "ejection fraction 0.089\n",
      "ejection 0.089\n",
      "bernstein 0.089\n",
      "\n",
      "Abstract:\n",
      "mirikizumab would launched late late entrant crowded psoriasis market perhaps explains lilly simultaneously pushing ahead phase iii trial anti il mab ulcerative colitis crohn disease clinical programme phenomenally expensive project still somewhat radar evaluatepharma vision r cost model estimate total clinical development mirikizumab cost lilly bn including almost year insignificant investment become third il market psoriasis suggesting gi disorder might lilly see real opportunity still psoriasis market overlooked upcoming data phase iii trial give sense well mirikizumab might competition oasis study expected report spring enrolled nearly patient moderate severe plaque psoriasis pitting mirikizumab novartis cosentyx first phase iii study project indication evaluating active control primary endpoint assessed four month treatment percentage patient two point improvement baseline static physician global assessment pga proportion achieving pasi improvement baseline psoriasis area severity index cosentyx anti il forecast become psoriasis market leader according evaluatepharma sellside consensus abbvie skyrizi really one beat il antibody significantly improved treatment outcome skin disease skyrizi viewed effective pasi course tougher bar hit pasi mirikizumab aiming oasis oasis study completed last year us pasi co primary lilly yet report data trial lilly spokesperson told vantage oasis data released within next couple month another piece puzzle revelation three week ago skyrizi trounced cosentyx head head phase iii trial abbvie mab scored pasi rate four month compared cosentyx one year primary endpoint pasi difference starker skyrizi versus cosentyx skyrizi showed superiority cosentyx trial secondary endpoint including pasi pasi pga clear almost clear current consensus forecast mirikizumab peg sale would make ninth biggest psoriasis seller year lilly blockbuster anti il taltz number seven bigger opportunity developer hope il agent hold big potential autoimmune bowel disorder major clinical programme way first mirikizumab phase iii trial ulcerative colitis lucent yield data towards end year far ahead tremfya whose quasar phase ii iii uc study report late skyrizi however threat phase ii iii study abbvie product due conclude september neck neck lucent followed phase iii yield data skyrizi suggesting similar timeline mirikizumab stelara hit il well il approved condition last october back clinical remission rate unifi trial hope pure il best class proved psoriasis lucent skyrizi trial first big test hypothesis mirikizumab focus remains psoriasis market home six blockbuster already lilly must hoping timing advantage skyrizi challenge ulcerative colitis inconsiderable either evaluatepharma vision r cost model estimate cost individual clinical programme using real world data company disclosed product level spend clinical trial patient number combined create cost per patient benchmark technology therapy type utilising matching algorithm benchmark applied commercially relevant clinical trial estimate cost aggregated product estimate cost development product article updated include comment form lilly\n",
      "\n",
      "Keywords:\n",
      "mirikizumab 0.322\n",
      "skyrizi 0.309\n",
      "pasi 0.275\n",
      "psoriasis 0.269\n",
      "il 0.214\n",
      "cosentyx 0.193\n",
      "psoriasis market 0.161\n",
      "oasis 0.15\n",
      "lilly 0.149\n",
      "cost 0.137\n",
      "lucent 0.121\n",
      "iii 0.099\n",
      "estimate 0.094\n",
      "estimate cost 0.094\n",
      "ulcerative colitis 0.092\n",
      "ulcerative 0.092\n",
      "colitis 0.092\n",
      "anti il 0.086\n",
      "phase iii trial 0.08\n",
      "trial 0.079\n",
      "\n",
      "Abstract:\n",
      "last year merck co paid bn buy peloton therapeutic back data impressive came subject update first human study saturday give better idea whether money well spent venue presentation asco genitourinary cancer symposium start san francisco tomorrow continues presentation saturday radar clinical result cabometyx look reverse exelixis failure prostate cancer though investor look information treatment related death mentioned abstract exelixis cosmic trial combine cabometyx roche tecentriq asco gu abstract refers early data cut castration resistant prostate cancer subject progressed novel hormone therapy showed overall remission rate combo cosmic aim enrol patient across various cancer uncontrolled combo data available comparison tricky stifel analyst reckon remission rate merck keynote study keytruda plus lynparza provides benchmark sort investor want know cosmic show promise similar setting cosmic cabometyx failed prednisone exelixis wiped comet crash land september ask treatment related death dehydration year old cosmic subject riding peloton meanwhile asco gu abstract merck mk relate may cut already known time peloton bn takeout orr subject second line later renal cell carcinoma presentation saturday provide date dataset mk claimed first small molecule inhibitor hif another closely watched indication von hippel lindau disease according evaluatepharma sellside consensus mk yet included analyst model validation peloton takeover keenly awaited asco gu abstract caught analyst eye include update seattle genetics ev study padcev mirati sitravatinib plus opdivo combo advanced renal cancer latter yielded orr leerink said promising beat seen opdivo sitravatinib monotherapy another study mirati course bet kras inhibitor mrtx sitravatinib give sellside reason raise target price yet padcev seattle astellas anti nectin antibody drug conjugate secured accelerated u approval december anti pd l relapsed urothelial cancer basis ev trial ev front line study combination keytruda already impressed last year esmo meeting asco gu abstract relates june data cut orr esmo month median progression free survival since tecentriq plus chemo yielded month mpfs imvigor updated data presentation due friday make ev one highlight asco gu\n",
      "\n",
      "Keywords:\n",
      "cosmic 0.257\n",
      "asco gu 0.257\n",
      "gu 0.244\n",
      "gu abstract 0.22\n",
      "asco gu abstract 0.22\n",
      "peloton 0.195\n",
      "ev 0.181\n",
      "asco 0.177\n",
      "abstract 0.168\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "sitravatinib 0.154\n",
      "exelixis 0.128\n",
      "cabometyx 0.128\n",
      "saturday 0.123\n",
      "mk 0.123\n",
      "cancer 0.114\n",
      "presentation 0.113\n",
      "data cut 0.098\n",
      "treatment related death 0.091\n",
      "related death 0.091\n",
      "orr 0.088\n",
      "\n",
      "Abstract:\n",
      "sometimes thing go well biotech occasionally work brilliantly vtv therapeutic pivot type diabetes two year ago rewarded phase ii study win yesterday prompting share price surge luck would vtv second reason celebrate decision abandon alzheimer entirely played straight space novo nordisk recently drumming investor interest vtv still well high enjoyed piece place comeback comeback see vtv capitalise putative link alzheimer disease diabetes novo glp analogue diabetes victoza soon test imperial college elad trial whose readout due imminently novo nordisk quiet entry year alzheimer january heart hypothesis lie claim neurodegeneration linked low insulin insulin resistance however speculative might novo stock year date spike analyst put excitement elad readout elevage vtv evidence emerge first half next year phase ii elevage trial rage inhibitor azeliragon yield topline result elevage enrols subject mild alzheimer well impaired glucose tolerance vtv claim rage biology implicated diabetic complication well cognitive impairment started post hoc analysis phase iii steadfast trial azeliragon crashed alzheimer without diabetes meantime company investor celebrate yesterday win part two simpliciti study another pipeline asset oral glucokinase activator ttp type diabetes subject background insulin part one simpliciti patient read positively real test part two vtv appears hedged bet carrying two primary efficacy analysis le stringent excluded non complying patient increased bolus insulin showed point reduction week hba c versus placebo statistical significance p fact stringent assessment subject hit statistical significance vtv said p numerical hba c change disclosed patient daily time range important secondary endpoint improved versus placebo severe hypoglycaemia active cohort pivotal start vtv say second half move start pivotal ttp programme comprising two six month study estimated cost group bank september equity raise likely though say want talk others co development pure licensing given dearth novel type diabetes treatment patient basically rely insulin positive clinical result expected generate interest stark contrast type diabetes extremely crowded controlled big pharmaceutical company ttp development type disease de emphasised another move today look shrewd\n",
      "\n",
      "Keywords:\n",
      "vtv 0.505\n",
      "insulin 0.24\n",
      "diabetes 0.231\n",
      "alzheimer 0.186\n",
      "ttp 0.18\n",
      "elevage 0.18\n",
      "type diabetes 0.166\n",
      "novo 0.145\n",
      "type 0.128\n",
      "part two 0.112\n",
      "elad 0.112\n",
      "hba 0.107\n",
      "comeback 0.107\n",
      "celebrate 0.102\n",
      "stringent 0.096\n",
      "part 0.077\n",
      "well 0.075\n",
      "novo nordisk 0.074\n",
      "nordisk 0.074\n",
      "statistical significance 0.069\n",
      "\n",
      "Abstract:\n",
      "immuno oncology making inroad ever cancer type setting drug given surgery remain untapped opportunity judging recent comment however space roche making sizeable bet analyst naturally monitoring opportunity closely indeed nomura already called result roche impower trial testing adjuvant tecentriq versus best supportive care nsclc immuno oncology primary point coming year cautious forecast exist roche record major win chance broad success remain nebulous far anyway success proved elusive last month roche revealed imvigor testing adjuvant tecentriq high risk muscle invasive urothelial cancer failed extend disease free survival versus observation company earlier called bn opportunity continued confidence roche fourth quarter result presentation group worked hard stay positive expressed continued confidence future tecentriq neo adjuvant trial least including impower read true urothelial one cancer immunotherapy struggled generate unequivocally positive data tumour type judged merit earlier failure neoadjuvant triple negative breast cancer see tecentriq diverging merck co keytruda small neotripapdl trial read negatively december earlier separate neoadjuvant tnbc study imminent readout impassion enrolment increased rarely positive sign meanwhile keytruda scored positive hit keynote tnbc trial open evercore isi umer raffat reckons bn neoadjuvant adjuvant market merck yet disclose tnbc filing strategy keytruda bristol myers squibb opdivo boast adjuvant use label melanoma latter seriously lag race bristol making sizeable bet neo adjuvant setting instance checkmate trial neoadjuvant opdivo plus yervoy chemo nsclc yield pathological complete response data year checkmate testing adjuvant opdivo muscle invasive urothelial cancer read later closely watched given imvigor failure course tumour type different competing study slightly different design including different cut patient pd l status baseline instance imvigor used observation control checkmate give subject placebo subtle important difference roche impower read end primary endpoint disease free survival look subpopulation subject stage ii iiia nsclc assessed cut pd l expression across board comer intent treat analysis finally clear whether fda always insist hard survival data perioperative approval whether measure like pathological complete response suffice least initially investor know lot merck reveals keynote data impower read\n",
      "\n",
      "Keywords:\n",
      "adjuvant 0.291\n",
      "impower 0.205\n",
      "neoadjuvant 0.193\n",
      "testing adjuvant 0.186\n",
      "impower read 0.186\n",
      "imvigor 0.165\n",
      "tnbc 0.153\n",
      "tecentriq 0.141\n",
      "roche 0.137\n",
      "urothelial 0.136\n",
      "read 0.13\n",
      "roche impower 0.116\n",
      "pathological complete response 0.116\n",
      "neo adjuvant 0.116\n",
      "muscle invasive 0.11\n",
      "checkmate 0.11\n",
      "cancer 0.107\n",
      "nsclc 0.106\n",
      "pathological 0.106\n",
      "disease free survival 0.102\n",
      "\n",
      "Abstract:\n",
      "wonder whether biogen resurrection aducanumab stoked unrealistic hope alzheimer disease progress look lilly share opened morning failure dian tu study ambitious trial handicapped small sample size biogen share largely unmoved meanwhile positive signal dian tu would claimed major endorsement beta amyloid hypothesis aducanumab bull swiftly pointed trial design difference antibody involved might valid point yet another setback space emphasis precarious biogen position dian tu run washington university tested two failed anti amyloid beta antibody lilly solanezumab roche gantenerumab subject rare inherited form early onset dementia called autosomal dominant alzheimer disease adad individual display degeneration predictable age researcher hoped tease benefit small number subject another chance lilly roche take alzheimer january none seen least according primary endpoint study neither project showed significant slowing cognitive decline statement lilly roche said today press release confirmed small number patient received active agent randomised receive gantenerumab received solanezumab full data due presented medical conference april remain interest high dos tested dian tu helped rekindle hope echoing biogen case finding way forward aducanumab dose patient high enough long enough effect seen dian tu hiked dosage half way small sample size surely render positive signal emerge full result exploratory best analyst svb leerink week ago declared dian tu outcome would influence whether confidence beta amyloid target thus biogen antibody went today decided outcome limited impact aducanumab bank major supporter biogen stance aducanumab approvable three anti beta amyloid antibody work slightly differently targeting different epitope leerink pointed small number patient involved surely mean mechanistic conclusion hard draw still hard escape notion biogen putative progress aducanumab raised unrealistic hope next big test mechanism probably come roche gantenerumab due complete prodromal study later year biogen bull doubt ready reason fail\n",
      "\n",
      "Keywords:\n",
      "tu 0.317\n",
      "dian tu 0.317\n",
      "dian 0.317\n",
      "biogen 0.274\n",
      "aducanumab 0.234\n",
      "amyloid 0.172\n",
      "gantenerumab 0.151\n",
      "beta amyloid 0.151\n",
      "beta 0.14\n",
      "small number 0.124\n",
      "small sample 0.106\n",
      "sample size 0.106\n",
      "roche gantenerumab 0.106\n",
      "lilly roche 0.106\n",
      "alzheimer 0.105\n",
      "lilly 0.105\n",
      "small 0.104\n",
      "solanezumab 0.101\n",
      "unrealistic 0.093\n",
      "small number patient 0.093\n",
      "\n",
      "Abstract:\n",
      "zogenix claim yesterday succeeded lennox gastaut syndrome fenfluramine reformulation fintepla case putting brave face disappointing dataset technically positive fintepla result clearly underperformed gw pharma epidiolex childhood epilepsy indication market saw zogenix hype sending stock morning gw rose epidiolex clearer run lennox gastaut latest result force zogenix focus fintepla use dravet syndrome reduce threat epidiolex label fintepla epidiolex marketed dravet lennox gastaut fintepla u fda action date march former use evercore isi analyst cover gw said yesterday disappointing result would make zogenix price fintepla relatively high dravet smaller indication limiting label use seizure frequency led fintepla trial lennox gastaut subject read last night higher two fintepla dos mg kg day led reduction baseline frequency drop seizure yielding p value versus placebo control far good adjusting placebo reduction harsh reality epidiolex label reveals placebo adjusted difference study placebo performed far better zogenix trial mean fintepla simply lack real world clinical relevance zogenix argued key secondary measure favoured fintepla important aspect study dose response lower mg kg day beat placebo numerically missing statistical significance however best hint dose higher mg kg day rival epidiolex efficacy lennox gastaut hope higher dosing tempered fear fintepla active ingredient fenfluramine one half fen phen obesity drug withdrawn link serious heart problem indeed safety consideration still play fda considers fintepla dravet filing zogenix say serious cardiovascular issue observed none reported lennox gastaut trial common adverse event decreased appetite logical designed diet drug still go unnoticed full extent fen phen disastrous side effect profile emerged broad patient use weigh fda reviewer mind evaluate fintepla meantime project second leg cut\n",
      "\n",
      "Keywords:\n",
      "fintepla 0.531\n",
      "zogenix 0.286\n",
      "lennox gastaut 0.245\n",
      "lennox 0.245\n",
      "gastaut 0.245\n",
      "epidiolex 0.232\n",
      "dravet 0.159\n",
      "mg kg day 0.139\n",
      "kg day 0.139\n",
      "mg kg 0.119\n",
      "gw 0.113\n",
      "kg 0.106\n",
      "fenfluramine 0.093\n",
      "placebo 0.089\n",
      "phen 0.088\n",
      "fen phen 0.088\n",
      "fen 0.088\n",
      "seizure 0.079\n",
      "use 0.068\n",
      "mg 0.068\n",
      "\n",
      "Abstract:\n",
      "welcome weekly roundup approaching clinical readout building success venclexta acute myeloid leukaemia roche turning attention idasanutlin antagonist mdm first pivotal data mirros study idasanutlin top chemo relapsed refractory patient key success idasanutlin use combination venclexta result mirros patient trial expected current quarter study successful roche plan file later year mirros expected show idasanutlin beating cytarabine alone term overall survival phase ib trial heavily pretreated aml idasanutlin plus cytarabine showed composite complete response ccr rate patient given mg twice day dose tested mirros median duration response eight month one dose limiting toxicity myelosuppression monotherapy diarrhoea reported patient dose limiting patient given mg twice daily later idasanutlin improve venclexta bcl inhibitor expected lead aml market approved first line top chemo older patient induction chemotherapy cannot used inhibiting mdm idasanutlin activates tumour suppressor protein p turn promotes degradation mcl known resistance factor bcl inhibition phase ii study combination idasanutlin venclexta showed orr ccr rate unfit relapsed refractory aml study showed improved safety profile trial using higher dos roche looking first line use idasanutlin trial combination cytarabine daunorubicin started last year exon skipping rare genetic disorder usher syndrome caused mutation several gene patient hearing loss caused abnormality inner ear vision loss caused retinitis pigmentosa light sensing cell retina gradually deteriorate proqr exon skipping oligonucleotide qr qrx designed address usher syndrome type caused mutation exon ush gene skipping allow production shorter still functional form usherin protein crucial development supportive tissue inner ear retina qr phase ii trial stellar interim data emerge end next month study enrolled subject mutant exon receive single intravitreal injection qr whichever eye worse vision g g g evaluated six patient assigned cohort four receiving exon skipper two given sham injection study focused safety vision improvement measure secondary little development specifically rare condition trial highlighted usher syndrome coalition concern trial retinitis pigmentosa therapeutic might help alleviate usher symptom chance success hard estimate analyst evercore isi point sustained efficacy shown proqr lead project sepofarsen leber congenital amaurosis another form genetic blindness suggested partially derisks proqr technology hence qr evercore forecast sale judging evaluatepharma consensus rest sellside circumspect\n",
      "\n",
      "Keywords:\n",
      "idasanutlin 0.457\n",
      "usher 0.203\n",
      "qr 0.203\n",
      "mirros 0.203\n",
      "exon 0.19\n",
      "venclexta 0.165\n",
      "usher syndrome 0.152\n",
      "proqr 0.152\n",
      "cytarabine 0.152\n",
      "skipping 0.134\n",
      "aml 0.127\n",
      "vision 0.116\n",
      "caused 0.111\n",
      "given mg twice 0.101\n",
      "ear 0.101\n",
      "patient given mg 0.096\n",
      "caused mutation 0.096\n",
      "patient 0.096\n",
      "dose limiting 0.093\n",
      "exon skipping 0.09\n",
      "\n",
      "Abstract:\n",
      "positive clinical trial multiple sclerosis mechanism far failed deliver would normally hailed major medical advance case principia btk inhibitor sar however win mean clear cut sar mid stage study convoluted design detailed analysis needed tease real benefit right sanofi principia partner morning announced trial primary endpoint met providing detail nevertheless investor gone short principia today feeling increasingly uncomfortable principia short thesis centre shortcoming btk inhibition laid investment firm kerrisdale capital january even short interest stock creeping amounting almost outstanding capital middle last month today share premarket opening meaning short seller facing uninviting prospect deciding whether take loss hold disappointment line knowledge lift would ramp loss even multi cohort crossover study toplined today enrolled subject relapsing multiple sclerosis yet fewer eight cohort comprising four different dos given either placebo moreover primary endpoint relate relapse rate m progression number new gd enhancing hyperintense lesion investor ask basis trial complex design measuring mri surrogate endpoint said yielded positive result sanofi paid principia front two year ago sar coded prn today claimed compound become first disease modifying therapy address source m damage brain said trial showed dose response relationship would used determine phase iii dose like cd targeting approach roche ocrevus impressive example btk inhibition relies theory b cell involved m unfortunately virtually evidence exists back use btk inhibitor m sar one three agent development disease merck kgaa evobrutinib initially said succeeded phase ii subsequently fell foul statistical analysis rule associated liver enzyme elevation german merck watch evobrutinib benefit melt away june even evobrutinib sar managed yield clean phase ii win result might amounted much given placebo real world comparator ocrevus head head trial would clearly present much higher bar clear nevertheless sanofi highlighted sar brain penetration said four pivotal study would initiated course problem lie principia short seller might well right thinking sar dud time view proved right however rising share price meantime risk losing money continuing short principia take nerve steel\n",
      "\n",
      "Keywords:\n",
      "sar 0.38\n",
      "principia 0.367\n",
      "short 0.213\n",
      "btk 0.185\n",
      "evobrutinib 0.178\n",
      "principia short 0.119\n",
      "inhibitor sar 0.119\n",
      "btk inhibitor sar 0.119\n",
      "btk inhibition 0.113\n",
      "ocrevus 0.097\n",
      "seller 0.094\n",
      "btk inhibitor 0.093\n",
      "would 0.09\n",
      "brain 0.089\n",
      "sanofi 0.087\n",
      "multiple sclerosis 0.086\n",
      "capital 0.086\n",
      "right 0.082\n",
      "sclerosis 0.082\n",
      "nevertheless 0.08\n",
      "\n",
      "Abstract:\n",
      "productivity problem plagued big pharma beginning last decade apparently solved company least management team preoccupied focusing attention growth story astrazeneca enthusiastically selling non core asset couple year pfizer rejected piecemeal approach definitive move merging established drug division mylan today glaxosmithkline merck co unveiled respective plan rid slow growing product glaxo shed skin division glaxosmithkline split two division new uk group announced separation innovation mothership consumer health way back december today news added meat bone idea announcement one casualty split would prescription dermatology although dermatology big money spinner whole division generating sale move highlight group resolve slim something market understands get behind glaxo pressure year biggest shareholder argued company underperformance driven keeping slow growing dependable consumer health division roof dynamic riskier drug discovery arm restructuring consumer division almost complete following pfizer deal group taking back control bn joint venture novartis year focus turn new gsk biopharma company r approach focused science related immune system use genetics new technology glaxo forecasting annual saving following split come one time cost largely relating expense setting consumer healthcare standalone company today emma walmsey glaxo chief executive highlighted approval oncology hiv speciality respiratory medicine field group either lag much competition increasing exposure pricing pressure intense scrutiny strategy two standalone company continues shape launched two year move company might make immediately shore pipeline key growth merck separation involves spinning company woman health legacy biosimilars business new company focusing established group oncology vaccine animal health new business independently run listed take tried tested form tax free distribution new share existing holder much today fourth quarter call saw merck executive talk move way company become focused agile improve efficiency however one statistic say new company product account current group sale consume much larger share cost spin really come increasing investor exposure blockbuster keytruda franchise effectively selling merck pedestrian activity one bn dividend one hand understandable especially keytruda last year generated bn revenue outpacing revlimid world biggest selling cancer drug cause obvious concern much longer keytruda juggernaut keep growing current rate momentum maintained keytruda need show broad utility across cancer type well beyond nsclc likely adjuvant setting far drug approved adjuvant melanoma scored positive result adjuvant neoadjuvant triple negative breast cancer setting keynote study however leerink recently outlined several threat franchise including low cost rival china pricing pressure u election year competitor study due read pose threat including bristol myers squibb exelixis checkmate er full data ctla combo checkmate la astrazeneca poseidon recently read positively next really new trend big demergers horizon include move abbvie sealing deal buy allergan likely looking carve certain area even expect medical aesthetic business separated something allergan pressure undertake still sector exactly bereft big acquisition takeout allergan celgene last year following buyout shire party guaranteed make money whatever happens deal banker smart investor look benefit\n",
      "\n",
      "Keywords:\n",
      "division 0.291\n",
      "consumer 0.216\n",
      "glaxo 0.162\n",
      "new 0.147\n",
      "pressure 0.144\n",
      "health 0.133\n",
      "move 0.128\n",
      "growing 0.126\n",
      "split 0.122\n",
      "adjuvant 0.122\n",
      "keytruda 0.12\n",
      "allergan 0.12\n",
      "company 0.118\n",
      "standalone company 0.113\n",
      "selling 0.108\n",
      "standalone 0.103\n",
      "separation 0.1\n",
      "following 0.1\n",
      "dermatology 0.097\n",
      "merck 0.096\n",
      "\n",
      "Abstract:\n",
      "lilly confirmed last week huge hope experimental diabetes project tirzepatide patient cardiovascular outcome trial cvot start later year pitting dual gip glp agonist trulicity similarly acting agent company best selling drug executive wrong describe move bold though trulicity losing patent protection presumably feel risk worth taking new trial represents massive financial commitment evaluatepharma vision r cost model estimate trulicity cvot expensive ever run glp agonist tirzepatide though set new record trulicity rewind trial cost lilly almost bn run estimated glp agonist cvots rewind longest undertaken although almost patient enrolment similar outcome study conducted novo nordisk rybelsus victoza glaxosmithkline tanzeum shorter smaller cvots bring average table detail laid lilly last week indicate tirzepatide test cardiovascular safety come cheap called surpass cvot study recruit patient type diabetes confirmed atherosclerotic cardiovascular disease primary endpoint time first occurrence composite endpoint cv death myocardial infarction stroke ass non inferiority superiority tirzepatide versus trulicity lilly estimate study take four year complete trial alone double number patient company plan test tirzepatide however look clinical programme already running show company ambition project lie beyond diabetes impressive weight loss seen phase ii patient fuelling hope obesity mid stage programme underway nash thought hitting gip add effectiveness glp agonism though come cost tirzepatide weak spot likely tolerability high rate nausea vomiting diarrhoea reported earlier trial lilly belief managed dose titration long run proposed week highest dose tested limit project appeal surpass programme start read towards end year real potential tirzepatide hard estimate held sellside back consensus forecast indicate launch swift ramp sale bn surely represents best case scenario though committing billion project lilly must expecting nothing le evaluatepharma vision r cost model estimate cost individual clinical programme using real world data company disclosed product level spend clinical trial patient number combined create cost per patient benchmark technology therapy type utilising matching algorithm benchmark applied commercially relevant clinical trial estimate cost aggregated product estimate cost development product\n",
      "\n",
      "Keywords:\n",
      "tirzepatide 0.337\n",
      "trulicity 0.264\n",
      "cost 0.22\n",
      "estimate 0.198\n",
      "glp 0.161\n",
      "lilly 0.156\n",
      "estimate cost 0.132\n",
      "glp agonist 0.129\n",
      "indicate 0.1\n",
      "gip 0.1\n",
      "agonist 0.097\n",
      "programme 0.095\n",
      "vision cost model 0.093\n",
      "diabetes 0.093\n",
      "vision cost 0.09\n",
      "model estimate 0.09\n",
      "evaluatepharma vision cost 0.09\n",
      "cost model estimate 0.09\n",
      "cost model 0.09\n",
      "patient 0.087\n",
      "\n",
      "Abstract:\n",
      "first month saw u fda approve first peanut allergy treatment aimmune palforzia greenlit market closed friday company share opened today quickly retreated gain concern palforzia commercial opportunity treatment black box warning anaphylaxis restrictive risk mitigation programme based tolerising approach peanut delivery small amount peanut powder capsule patient question remain long term benefit versus peanut avoidance palforzia clinical program patient treatment greater epipen usage treatment consideration payer given come top k annual cost palforzia evaluatepharma consensus put sale bn forecast comprises different opinion stifel analyst among conservative believe palforzia become niche therapy competitor front dbv desensitisation patch viaskin peanut pdufa date august early positive decision fda last month included blueprint ayvakit month designated pdufa date ayvakit approved treating gastrointestinal stromal tumour driven pdgfr exon mutation including v mutation expanding ayvakit fourth line setting wait voyager study read due second quarter decision horizon tepezza expected march antibody became first approved treatment thyroid eye disease last month autoimmune condition lead eye bulging sometimes blindness disease occur present half people graf disease label language broader expected restriction around disease type severity topic heavily discussed unanimous ad com end last year treatment annual list price k horizon guided sale sale forecast reach according evaluatepharma consensus rest novo nordisk semaglutide two decision last month ozempic weekly version got cardiovascular risk reduction claim rybelsus oral daily version managed get pioneer data added label showed non inferiority placebo rybelsus wait data long term outcome study soul began earlier year decision biohaven zydis odt fast acting dissolving tablet formulation rimegepant acute treatment migraine still pending importantly result phase iii prevention study tablet formulation expected soon position rimegepant convenient alternative approved injectable cgrp inhibitor\n",
      "\n",
      "Keywords:\n",
      "palforzia 0.326\n",
      "peanut 0.286\n",
      "ayvakit 0.167\n",
      "treatment 0.155\n",
      "tablet formulation 0.13\n",
      "tablet 0.13\n",
      "decision 0.128\n",
      "rybelsus 0.121\n",
      "rimegepant 0.114\n",
      "last month 0.112\n",
      "pdufa date 0.1\n",
      "month 0.096\n",
      "pdufa 0.094\n",
      "formulation 0.094\n",
      "horizon 0.091\n",
      "eye 0.091\n",
      "wait 0.09\n",
      "version 0.085\n",
      "disease 0.084\n",
      "long term 0.084\n",
      "\n",
      "Abstract:\n",
      "week small cap biotech touting ware possible treatment new coronavirus emerging wuhan china established big cap group begun work gilead candidate remdesivir might realistic prospect certainly shareholder believe gilead stock early trade today far however remdesivir entered formal clinical trial ebola virus patient question remain fast trialled approved ncov randomised controlled trial coronavirus patient wuhan set despite need effective therapy u fda eagerness approve new product clean safety least hint efficacy crucial remdesivir already given ncov patient u compassionate ground patient recovered side effect though single case study needed nuc orbit far clinical data project limited trial two niaid sponsored study ebola virus patient particular interest phase ii iii palm study tested four drug different developer essentially kyboshed remdesivir development ebola independent data monitoring board concluded two drug worked better gilead molecule recommended study halted point patient treated remdesivir theoretically gilead still bolster approval case remdesivir ncov using safety data niaid ebola trial without blemish four serious adverse event palm judged potentially related trial drug two occurred patient treated remdesivir patient hypotension resulted halting loading dose remdesivir followed rapidly cardiac arrest noted however researcher stated adverse event palm readily distinguished underlying ebola infection vaccine collaboration getting action glaxosmithkline time directly collaboration coalition epidemic preparedness innovation cepi auspex researcher university queensland australia gain access glaxo pandemic vaccine adjuvant platform aid effort develop coronavirus vaccine cepi already working smaller biotech including curevac inovio moderna possible group sign partnership use glaxo adjuvant technology none vaccine project yet reached clinic though leaving gilead nuc potential coronavirus project least limited clinical data much evidence efficacy needed specific infection remdesivir safety slam dunk new trial wuhan conducted top speed regulator must certain robust rushing approve\n",
      "\n",
      "Keywords:\n",
      "remdesivir 0.431\n",
      "ebola 0.284\n",
      "ncov 0.199\n",
      "gilead 0.16\n",
      "coronavirus 0.134\n",
      "vaccine 0.133\n",
      "patient 0.132\n",
      "cepi 0.123\n",
      "niaid 0.105\n",
      "approve 0.105\n",
      "glaxo 0.1\n",
      "adjuvant 0.1\n",
      "patient treated 0.099\n",
      "researcher 0.097\n",
      "trial 0.088\n",
      "virus 0.087\n",
      "collaboration 0.087\n",
      "clinical data 0.082\n",
      "infection 0.08\n",
      "limited 0.078\n",
      "\n",
      "Abstract:\n",
      "alzheimer disease firmly back focus thanks biogen last year stunned field eking signal efficacy pivotal programme abandoned amyloid beta project aducanumab disclosure put spotlight another pending test amyloid beta hypothesis dian tu trial due yield result coming week study run washington university testing two failed anti amyloid beta antibody lilly solanezumab roche gantenerumab patient rare inherited form early onset dementia autosomal dominant alzheimer disease adad studied carrier gene associated adad almost certain display degeneration predictable age researcher believe creates unique opportunity test whether intervention delay slow course disease small around presymptomatic patient recruited dian tu relatively small number subject one main reason cited low hope success though study designer argue reliable disease progression model developed adad help detect change cognition fewer patient improve ability detect drug effect solanezumab gantenerumab pitted placebo change dian tu composite cognitive score primary endpoint measured annually four year composite score comprises four test researcher believe particularly suitable patient early stage disease numerous secondary endpoint assessed including biomarker information specific antibody gantenerumab group brain scan track deposit amyloid beta solanezumab arm ass amyloid beta level cerebrospinal fluid hope hit primary endpoint help validate predictive power biomarkers alzheimer study hope clear success low though notable dian tu testing high dos agent tracking patient long period biogen case finding way forward aducanumab rest exactly hypothesis dose patient high enough long enough effect seen molecule hypothesis read aducanumab naturally made dian tu fail biogen seems ready blame project tested rather underlying hypothesis result positive think would lend support amyloid hypothesis result negative want see evidence target engagement biological change brain make conclusion al sandrock biogen head r said investor call yesterday roche lilly substantially dialled development gantenerumab solanezumab roche annual result call yesterday dian tu trial even raised lilly presentation executive talked expectation chief science officer dan skovronsky highlighting small number subject aggressive nature form alzheimer still jp morgan lilly chief executive dave rick remarkably suggested solanezumab filed positive dian tu data fda make aducanumab yet revealed course biogen vague yesterday might submitted seems likely agency staff awaiting dian tu result interest\n",
      "\n",
      "Keywords:\n",
      "tu 0.355\n",
      "dian tu 0.355\n",
      "dian 0.355\n",
      "amyloid 0.217\n",
      "solanezumab 0.211\n",
      "amyloid beta 0.203\n",
      "gantenerumab 0.169\n",
      "hypothesis 0.164\n",
      "beta 0.147\n",
      "biogen 0.143\n",
      "adad 0.133\n",
      "aducanumab 0.131\n",
      "alzheimer 0.117\n",
      "solanezumab roche 0.089\n",
      "small number subject 0.089\n",
      "lilly 0.088\n",
      "number subject 0.084\n",
      "detect 0.084\n",
      "small number 0.069\n",
      "disease 0.068\n",
      "\n",
      "Abstract:\n",
      "paid careful attention roche full year financial presentation yesterday noticed company moving anti tigit antibody tiragolumab pivotal first line small cell lung cancer study combination tecentriq term roche ambition however tip iceberg speaking vantage yesterday swiss group revealed disclosed trial skyscraper one fewer eight pivotal tiragolumab study get way nothing else revealed competitive reason merck co rival tigit combo phase ii ido il tigit suddenly emerged industry next big immuno oncology bet course quest mechanism boost pd l blockade going year without much success yervoy still checkpoint blocker approved anti pd l drug incyte epacadostat nektar bempegaldesleukin mark ido il respectively two biggest disappointment search far earlier development targeting immune checkpoint tim lag ox failed deliver knockout data roche hope tiragolumab come anything lead renewed interest biotech including arcus beigene compugen early stage tigit blocker pipeline clear work tigit ramped behind scene recently two week ago without slightest fanfare merck co two begun keynote phase ii study company anti tigit project mk combination keytruda chemo first line nsclc merck reported partial response rate earlier keytruda combo study though mk monotherapy efficacy negligible sitc search immuno oncology combo continues november beyond data scarce oncomed merged mereo reported zero remission study etigilimab given lack published data immediately clear driven roche enthusiasm though group likely internal champion tigit genentech vice president oncology research ira mellman spoken tigit one several target capable synergising pd l blockade neither known sclc roche first targeted indication tecentriq secured first line sclc label back impower study threat atrazeneca imfinzi look like might amount much surprise tumour keytruda work january still numerous indication pursued perhaps sclc happens one start first roche revealed design skyscraper information available study registered clinicaltrials gov first subject dosed next week roche told vantage virtually every checkpoint blockade approach pd l underwhelmed clear company giving next generation mechanism yet next move merck others keenly awaited expanded version earlier story\n",
      "\n",
      "Keywords:\n",
      "tigit 0.418\n",
      "sclc 0.187\n",
      "roche 0.181\n",
      "tiragolumab 0.169\n",
      "pd 0.135\n",
      "blockade 0.129\n",
      "skyscraper 0.125\n",
      "checkpoint 0.124\n",
      "search 0.112\n",
      "merck 0.111\n",
      "anti tigit 0.107\n",
      "study 0.106\n",
      "pd blockade 0.105\n",
      "mk 0.105\n",
      "keytruda 0.104\n",
      "combo 0.099\n",
      "first 0.098\n",
      "first line 0.097\n",
      "blocker 0.097\n",
      "revealed 0.097\n",
      "\n",
      "Abstract:\n",
      "fda run early approval continued first month though time two horizon tepezza blueprint ayvakit received early nod latter gained green light patient gastrointestinal stromal tumour driven specific mutation bigger indication fourth line gist ayvakit february pdufa date however application supported result voyager study pitting ayvakit stivarga since data expected second quarter fda decision likely delayed esperion bempedoic acid another high profile project two pdufa decision next month one monotherapy fixed dose combination zetia cholesterol lowering pill used add statin good chance receiving regulatory approval thanks positive pivotal programme lack advisory committee good sign real question commercial opportunity lipid lowering market incredibly competitive bempedoic acid get important boost cardiovascular outcome study clear outcome prof successful trial primary completion date end head anti cgrp migraine market look like become even crowded next month regulatory decision eptinezumab prevention setting three product already market aimovig emgality ajovy administered subcutaneously month last given quarterly eptinezumab dosed every quarter via minute intravenous infusion lundbeck gained mab bn acquisition alder last september staying migraine biohaven zydis odt fast acting formulation oral cgrp rimegepant decision first quarter acute setting biohaven offering battle allergan ubrelvy became first approved oral cgrp antagonist end last year four asset due decision february rejected least durect painkiller posimir first rejected back finally got front fda advisory committee earlier month outcome meeting however far unanimous six six approval final pdufa date disclosed expected first half year another pain product baudax bio intravenous formulation meloxicam rejected twice agency oral version called mobic market since baudax say intravenous version act faster however recent complete response letter project successfully appealed specifically stated iv version delayed onset analgesia baudax spun recro pharma end agile contraceptive patch twirla two previous rejection first seven year ago nevertheless gained positive panel verdict last october caused group share rocket committee voted benefit project outweighed risk question remained twirla efficacy doubt raised whether project low dose therefore potentially safer contraceptive agile claimed acacia barhemsys indicated patient develop post operative nausea vomiting two prior rejection setback due deficiency contract manufacturer barhemsys active ingredient amisulpride company share dropped news second crl announced last may gaining ground since december acacia new supplier amisulpride priority pas lastly fda seemingly approval rally vantage looked upcoming decision priority review attached come early first zogenix fintepla dravet syndrome rare form epilepsy begin childhood gw pharma epidiolex gained approval indication april fda panel discus use intercept ocaliva nash decision pegged june\n",
      "\n",
      "Keywords:\n",
      "decision 0.19\n",
      "baudax 0.187\n",
      "rejected 0.154\n",
      "cgrp 0.146\n",
      "gained 0.145\n",
      "ayvakit 0.142\n",
      "intravenous 0.139\n",
      "committee 0.129\n",
      "pdufa 0.12\n",
      "bempedoic acid 0.111\n",
      "bempedoic 0.111\n",
      "fda 0.109\n",
      "version 0.108\n",
      "oral cgrp 0.106\n",
      "first 0.102\n",
      "oral 0.099\n",
      "approval 0.098\n",
      "rejection 0.095\n",
      "biohaven 0.091\n",
      "advisory committee 0.091\n",
      "\n",
      "Abstract:\n",
      "private company struggle raise cash float traditional way reverse merger provide alternative recent experience lumos pharma histogen respectively reversing newlink conatus show listed cash shell still found purpose obvious attraction reverse merger low cost relative ipo drawback fact cash shell rarely clean history carry nasty liability business valuing private entity regard lumos histogen raise eyebrow histogen instance valued deal reverse conatus announced yesterday despite fact far raised equity entity including lordship venture secure medical founder likely two key firstly deal stock transaction valuation purely nominal important effect determine ownership merged entity case conatus end owned current histogen holder secondly conatus laid low nash failure last year little remained third quarter cash balance negotiating position extremely weak investor likely written whatever put opportunity recoup loss would welcomed highly questionable similar argument made newlink trading peak though case group falling lumos highly questionable newlink defunct unlike conatus boast healthy cash balance end last september stock reversal lumos see private group investor get hand cash pile current newlink holder proposing give away equity interest yet argued lumos distressed entity group burned vc cash last raise lead asset lum picked ammonett pharma seems inactive little wonder opposition newlink deal evercel affiliate corona park investment partner countered cash offer per newlink share however newlink rejected likely reason counter offer undervalues newlink since amount cash would buy evercel newlink cash balance might net share merck co priority review voucher though newlink precise economic interest unclear entity like lumos attraction reversal include avoidance costly listing fee chart show reverse merger remain popular despite healthy ipo market risk include legacy liability fact reversal attract relatively little regulatory oversight resulting entity often criticised insufficiently scrutinised newlink problem fundamental investor really want place bet lum buy lumos outright using newlink cash hand rather throwing towel behoves newlink least consider evercel offer starting point negotiation\n",
      "\n",
      "Keywords:\n",
      "newlink 0.614\n",
      "lumos 0.33\n",
      "cash 0.228\n",
      "conatus 0.221\n",
      "entity 0.211\n",
      "histogen 0.189\n",
      "evercel 0.142\n",
      "reverse 0.13\n",
      "cash balance 0.121\n",
      "reverse merger 0.117\n",
      "reversal 0.117\n",
      "balance 0.098\n",
      "merger 0.093\n",
      "shell 0.084\n",
      "highly questionable 0.084\n",
      "liability 0.081\n",
      "attraction 0.081\n",
      "offer 0.079\n",
      "private 0.076\n",
      "holder 0.072\n",
      "\n",
      "Abstract:\n",
      "since taking rein pfizer beginning albert bourla overseen demergers company consumer healthcare division established medicine business yesterday annual result chief executive distanced pharma giant another old pfizer trope mr bourla ruled acquisition cost synergy main driver essentially suggests megamergers table past different pfizer deal constantly declining revenue even financial engineering said capital directed pipeline instead pledged spending bn share repurchase buyback planned year preserve firepower deal making investor expect evidence deployment coming month mr bourla said pfizer sight phase ii phase iii ready asset mitigate company next round painful patent expiry commence around apparent hoarding capital many suspecting company planning larger typical bolt deal though course close market project come cheap true far harder drive earnings growth via successful development valuable new drug using cash buy back stock exactly many large drug maker come rely form financial engineering disparaged mr bourla keep investor happy biotech big buck buyback begin burn november spending money wisely hard part drop pfizer share yesterday suggests shareholder entirely board mr bourla quickly come pressure revert former tactic business development fails pan mr bourla argues shedding legacy product left pfizer competitive growth profile among big pharma peer might true prospect largely driven drug already market yesterday annual result presentation talked pipeline progress expect year reality highlighted little speak company gene therapy project major interest though largely investor smaller player either competing collaborating pharma giant real doubt whether pfizer leading position candidate sellside yet pencil number revealing mr bourla directs firepower new project technology pledge put new gene therapy project clinic every year made yesterday though update limited vague timeline commitment new data pfizer duchenne muscular dystrophy therapy pf announced investor day march executive hinted advising interested party take front row seat company flagged abrocitinib according sellside consensus forecast pfizer biggest pipeline hope much depends approaching jade compare study pit project dupixent atopic dermatitis disappoints company need fresh blood laid bare absence sale forecast r project highlighted yesterday show much still prove important commercially speaking update year pfizer already marketed drug ibrance readout delayed slightly perhaps worry study double addressable patient blockbuster breast cancer pill anchor study meanwhile move pfizer newly acquired braftovi mektovi combination valuable front line setting certain colorectal cancer patient underline exactly cash earmarked year pfizer repositioned newly focused innovator readout flagged yesterday presumably represent biggest news existing pipeline capable generating next month mr bourla better get spending\n",
      "\n",
      "Keywords:\n",
      "mr bourla 0.389\n",
      "bourla 0.38\n",
      "pfizer 0.279\n",
      "mr 0.198\n",
      "spending 0.117\n",
      "yesterday 0.115\n",
      "financial engineering 0.104\n",
      "buyback 0.104\n",
      "gene therapy project 0.099\n",
      "pipeline 0.095\n",
      "year pfizer 0.095\n",
      "therapy project 0.095\n",
      "engineering 0.095\n",
      "annual result 0.095\n",
      "firepower 0.087\n",
      "newly 0.085\n",
      "project 0.077\n",
      "pharma giant 0.076\n",
      "capital 0.076\n",
      "giant 0.071\n",
      "\n",
      "Abstract:\n",
      "cash easy come young drug maker keep option open mean flog family silver keep light one explanation dip licensing deal last year certainly shortage motivated buyer finding echo decline company takeout presumably reason though analysis confirms asset price held last year notably average front fee paid phase ii asset surged almost five year high average skewed outlier course though jump phase ii seen median value revealing phase iii asset tend attract lower price earlier clinical stage hope hype apparently much effective tool drive price tag later stage data might inconveniently reveal true value asset chart look long term trend licensing deal drug maker excludes medtech diagnostic collaboration count transaction disclosed front fee analysis therefore understates real volume licensing deal happening though still reflect overall trend using deal front allows rigorous look trend biobuck total deal value cited rarely useful beyond headline fodder press release case go largely unpaid front fee represent real chunk cash changing hand analysis evaluatepharma data show sector paid bn initial payment deal last year figure five year low asset price hold seller need worry much dip activity financing environment tighten power quickly ebb across negotiating table\n",
      "\n",
      "Keywords:\n",
      "front fee 0.217\n",
      "licensing deal 0.2\n",
      "deal 0.199\n",
      "licensing 0.178\n",
      "fee 0.174\n",
      "trend 0.172\n",
      "deal last year 0.169\n",
      "deal last 0.162\n",
      "asset price 0.162\n",
      "asset 0.159\n",
      "dip 0.148\n",
      "front 0.144\n",
      "price 0.138\n",
      "five year 0.116\n",
      "drug maker 0.116\n",
      "value 0.116\n",
      "keep 0.11\n",
      "maker 0.106\n",
      "average 0.104\n",
      "last year 0.103\n",
      "\n",
      "Abstract:\n",
      "much analyst fear acceleron valuation running away reality group first drug reblozyl decent launch beta thalassaemia investor focus switched sotatercept promptly delivered win pulmonary arterial hypertension sent stock morning apparent mid stage study success mean acceleron second strategic pillar place pulmonary arterial hypertension pah feature entrenched player like johnson johnson united therapeutic acceleron claim group drug unlike sotatercept treat symptom disorder two week ago leerink analyst expressed concern acceleron share price run suggested market ignoring risk binary pah data readout today acknowledged latest data made whole new story doubled price target company takeout though leerink spell takeout thesis underlie acceleron bull case j j became big pah player bn takeover actelion united might need deal effort remain force pah firing blank united therapeutic fails expand beat april company product j j endothelin receptor antagonist tracleer opsumit prostacyclin agonist uptravi united numerous incarnation prostacyclin analogue treprostinil hold lion share pah market includes repurposed erectile dysfunction drug like pfizer revatio lilly united adcirca crucially basically act vasodilator relieve high blood pressure nothing underlying reason pah blood vessel wall thicken cause hypertension begin acceleron argues sotatercept block tgf beta superfamily pathway different acting rebalance bmpr signalling whose disruption claim promotes cell proliferation vascular remodelling pah yesterday result sotatercept pulsar trial back claim though company revealing numerical data sign good even though pulsar subject existing pah therapy sotatercept yielded statistically significant reduction week pulmonary vascular resistance versus placebo primary endpoint several secondary efficacy measure hit importantly study show significant toxicity issue sotatercept separate small phase ii pah study spectrum though described exploratory trial bottom line approval depend pivotal programme encompassing subject costly take several year complete business development come play though acceleron might want stay independent retain sotatercept value asset licensed celgene owned bristol myers squibb company stepped back development focus reblozyl retain royalty interest consideration course competitive nature selling pah drug industry project pipeline still pending full pulsar data readout increased interest sotatercept\n",
      "\n",
      "Keywords:\n",
      "pah 0.526\n",
      "sotatercept 0.394\n",
      "acceleron 0.328\n",
      "united 0.246\n",
      "pulsar 0.158\n",
      "hypertension 0.12\n",
      "pulmonary 0.113\n",
      "pulmonary arterial hypertension 0.098\n",
      "pulmonary arterial 0.098\n",
      "arterial hypertension 0.098\n",
      "reblozyl 0.094\n",
      "arterial 0.094\n",
      "vascular 0.09\n",
      "data readout 0.087\n",
      "retain 0.084\n",
      "claim 0.077\n",
      "though 0.074\n",
      "beta 0.065\n",
      "takeout 0.058\n",
      "blood 0.056\n",
      "\n",
      "Abstract:\n",
      "outcome study designed prove particular drug help patient live longer cheap undertaking therefore astrazeneca parthenon series involved six trial brilinta represented massive investment commitment big total parthenon cost likely reach bn according evaluatepharma vision r cost model figure include expense running odd study conducted product investigator sponsored vast majority astrazeneca involvement evaluatepharma estimate total clinical trial cost associated brilinta reach bn company risk sum reward owning life saving drug hard argue case spend worth plotting cumulative clinical trial cost sale suggests breakeven point brilinta however factor cost actually selling drug push profitability final twist arrival generic expected late brilinta long commercial disappointment largely bleeding risk parthenon programme arguably laid bare patient thales trial toplined today case point study recruited patient suffered minor acute ischaemic stroke high risk transient ischaemic attack astra said brilinta plus aspirin yielded statistically significant clinically meaningful reduction primary endpoint composite risk stroke death day came expense increased bleeding rate bedevilled project stroke notoriously tough setting substantial unmet need given brilinta bleeding risk hard handicap product chance approval without knowing magnitude benefit data remain wrap medical conference parthenon programme two study made drug label far two clear failure astra told vantage still talking regulator themis data showed clearest benefit prespecified subgroup patient astra head biopharmaceuticals r mene pangalos spoke vantage esc meeting last september themis trial remark summed crucial point brilinta bleeding risk different seen key finding population going see optimal benefit risk astrazeneca spent awful lot money finding population meantime prediction bn peak brilinta sale made astra fending pfizer looked increasingly unachievable even thales reveals unequivocal benefit expensive decision double brilinta trial look questionable evaluatepharma vision r cost model estimate cost individual clinical programme using real world data company disclosed product level spend clinical trial patient number combined create cost per patient benchmark technology therapy type utilising matching algorithm benchmark applied commercially relevant clinical trial estimate cost aggregated product estimate cost development product\n",
      "\n",
      "Keywords:\n",
      "brilinta 0.455\n",
      "cost 0.264\n",
      "parthenon 0.202\n",
      "bleeding 0.158\n",
      "bleeding risk 0.144\n",
      "risk 0.127\n",
      "estimate 0.127\n",
      "estimate cost 0.126\n",
      "stroke 0.121\n",
      "astra 0.112\n",
      "clinical trial cost 0.101\n",
      "clinical trial 0.099\n",
      "product 0.097\n",
      "themis 0.096\n",
      "vision cost model 0.089\n",
      "vision cost 0.087\n",
      "trial cost 0.087\n",
      "evaluatepharma vision cost 0.087\n",
      "cost model 0.087\n",
      "trial 0.085\n",
      "\n",
      "Abstract:\n",
      "secured u approval breast cancer four month early enhertu already showing promise elsewhere today topline data registrational study suggest astrazeneca daiichi sankyo anti antibody drug conjugate used late line gastric cancer targeting agent including roche kadcyla failed enhertu give analyst pleasant surprise especially inroad made earlier line therapy however sting tail enhertu toxicity especially interstitial lung disease emerged side effect watch enhertu destiny breast study secured approval last month subject suffered side effect leading four treatment related death sabcs astrazeneca daiichi join resistance december least interstitial lung disease related death seen among positive subject destiny gastric trial read today though toxicity related pneumonitis seen case mild one grade two grade event optimism said seems plenty room optimism especially destiny gastric enhertu improved overall survival well overall remission primary endpoint versus physician choice enter study subject positive failed least two treatment positive gastric cancer patient herceptin plus chemo first line standard care option limited relapse lilly cyramza instance second line label comer first line patient got chemo herceptin logically remains second line option however enhertu real triumph shown activity failure herceptin one assumption patient fails roche mab would longer respond another directed drug like destiny breast enhertu disproved theory astra daiichi argue enhertu high intensity payload cell membrane permeability might enable target tumour express relatively low level far theory playing moreover enhertu look especially promising light failure anti therapy recently roche kadcyla failed gatsby trial second line positive gastric cancer earlier novartis tykerb flunked tytan trial similar population asian subject roche perjeta studied front line neoadjuvant positive gastro oesophageal adenocarcinoma astra daiichi investor want know big opportunity become evaluatepharma sellside consensus see enhertu sale bn coming gastric cancer enhertu next gastric cancer test second line study ending october astra told vantage planning gastric cancer trial stressed educating doctor patient early identification intervention management interstitial lung disease pneumonitis front line label represents best case scenario surely require head head beat herceptin mention allaying fear lung disease\n",
      "\n",
      "Keywords:\n",
      "enhertu 0.447\n",
      "gastric 0.325\n",
      "gastric cancer 0.244\n",
      "herceptin 0.172\n",
      "line 0.169\n",
      "destiny 0.167\n",
      "lung disease 0.159\n",
      "daiichi 0.149\n",
      "interstitial lung disease 0.129\n",
      "interstitial lung 0.129\n",
      "interstitial 0.129\n",
      "cancer 0.127\n",
      "second line 0.119\n",
      "especially 0.116\n",
      "lung 0.105\n",
      "secured approval 0.098\n",
      "roche kadcyla 0.098\n",
      "kadcyla 0.093\n",
      "destiny breast 0.093\n",
      "astra daiichi 0.093\n",
      "\n",
      "Abstract:\n",
      "towards end last year several surprisingly speedy fda approval helped put wind biopharma sail look picture across whole confirms u drug regulator remains one sector best friend year agency approved novel medicine fifth year sale potential bn according vantage analysis evaluatepharma data neither number record far disappointing certainly fit within new regulatory normal developing past six year improve markedly last year average approval time breakthrough designation category give regulator best score since month mean even remarkable considering year btd first introduced three project used pathway average derived review project standard review came bang month median shown mean measure though analysis suggests fda struggle get priority review hit six month target aim past three year shown improvement least average priority review taking around eight month last year sense speed certainly emerged fda though two class made fastest approval decision since behind trikafta enhertu plenty quick review last year however drug approved le six month almost quarter submission vertex new cystic fibrosis triplet trikafta stand approved fastest last year projected become commercially successful sellside consensus sits bn u sale given extensive revenue company existing suite cystic fibrosis drug bring fair amount certainty attached figure astrazeneca daiichi sankyo enhertu scraped top accelerated approval late line breast cancer u sale bn estimated real commercial future antibody drug conjugate still hard determine big unknown toxicity profile influence use perhaps chance approval earlier line therapy chart look total commercial potential last year approval bn figure boosted arrival nine future blockbuster four predicted bringing bn u well trikafta includes two new arrival abbvie psoriasis antibody skyrizi jak inhibitor rinvoq ra pfizer amyloidosis treatment vyndaqel seen hugely successful future sale bn pencilled therapy trikafta treat rare disease prime example sort product biopharma chasing right small definable patient population big price tag accepted fda happy approve rare disease drug quickly reason believe biopharma turn away space anytime soon look internal disagreement agency around approval sarepta duchenne muscular dystrophy agent perhaps raise red flag little evidence internecine warfare broadly internal fda document reveal familiar story sarepta january big safety scare quickly change everything course thing stand expecting substantial regulatory landscape year\n",
      "\n",
      "Keywords:\n",
      "trikafta 0.246\n",
      "review 0.19\n",
      "approval 0.158\n",
      "last year 0.157\n",
      "fastest 0.134\n",
      "fda 0.126\n",
      "average 0.118\n",
      "bn 0.113\n",
      "sarepta 0.112\n",
      "enhertu 0.112\n",
      "cystic fibrosis 0.112\n",
      "cystic 0.112\n",
      "internal 0.109\n",
      "last 0.108\n",
      "arrival 0.103\n",
      "priority review 0.101\n",
      "future 0.096\n",
      "six 0.094\n",
      "month 0.094\n",
      "sale 0.094\n",
      "\n",
      "Abstract:\n",
      "largely derisked asset ipsen chief executive david meek described palovarotene time bn clementia acquisition today became abundantly clear rare bone disease project clementia brought nothing sort december safety concern prompted fda halt dosing child today ispen said almost entire palovarotene clinical programme paused futility analysis concluded phase iii trial heading towards failure mr meek problem departed wake regulatory hold last month leaving look like disastrous business development decision wake ipsen share dropped today three year low french company seen around half market cap erased since clementia buy announced last february equivalent loss around bn valuation urgent need refill pipeline prompted drugmaker strike several deal past year pursuing strategy apparently left investor cold doubt palovarotene existed moment clementia deal announced ipsen seemed disregarding numerous red flag included uncertain patent life project diminished economics royalty payable roche failure phase ii trial back ipsen look undone haste strike deal clementia banker apparently pitched deal perfectly rare disease play quick route market description tick box many deal hunter moment car crash palovarotene lead indication fibrodysplasia ossificans progressiva fop rare condition characterised abnormal growth bone muscle connective tissue known heterotopic ossification multiple osteochondroma development multiple benign bone tumour investigation fda approval come soon ipsen executive claimed time forecast peak sale fop alone ipsen take rare gamble clementia february wheel started come december fda told company stop dosing child age palovarotene treated patient displayed early growth plate closure essentially mean new bone stop produced child fully grown implication association therapy intended chronic dosing childhood obviously dire today news suggests phase iii fop trial going work anyway escalating situation full car crash ipsen apparently belief lost signal encouraging therapeutic activity observed preliminary post hoc analysis press release claimed independent data monitoring committee recommended study continued seems trial design blamed company scour data way forward flimsy basis hope even considering serious safety signal remains unaddressed palovarotene written investor seems likely ipsen soon concur\n",
      "\n",
      "Keywords:\n",
      "ipsen 0.433\n",
      "palovarotene 0.365\n",
      "clementia 0.365\n",
      "bone 0.185\n",
      "fop 0.183\n",
      "child 0.133\n",
      "rare 0.116\n",
      "deal 0.106\n",
      "strike 0.104\n",
      "dosing 0.101\n",
      "apparently 0.099\n",
      "crash 0.097\n",
      "stop 0.093\n",
      "moment 0.091\n",
      "wake 0.082\n",
      "prompted 0.077\n",
      "today 0.075\n",
      "claimed 0.068\n",
      "february 0.067\n",
      "car 0.066\n",
      "\n",
      "Abstract:\n",
      "welcome weekly roundup approaching clinical readout genmab nice royalty generator darzalex arzerra approved tepezza sell drug situation change anti tissue factor conjugate tisotumab vedotin middle year two study testing tisotumab cervical cancer read innova first line combo trial innova monotherapy test previously treated subject second vital pave way regulatory filing launch evaluatepharma sellside consensus computes forecast revenue tisotumab jefferies analyst cite potential peak sale half derived cervical cancer tisotumab curious history initially sole development genmab based antibody drug conjugate technology licensed seattle genetics seattle saw enough potential opt formal cost profit sharing deal innova test objective remission rate primary endpoint investor handicap result thanks earlier multi tumour trial called gen cervical cancer subject tisotumab achieved response eight confirmed including orr second line third line disease conjunctivitis frequent adverse event though rate grade paclitaxel platinum avastin front line cervical cancer standard numerous therapy used second line including topotecan abraxane chemos associated orr innov recruitment target surely struggle replicate orr gen second line cohort clearly however number well must hit genmab way market zogenix look second place quarter zogenix report phase iii data fintepla lennox gastaut syndrome severe form epilepsy begin childhood gw pharma epidiolex gained approval condition zogenix need better cannabidiol make late showing market epidiolex showed median placebo adjusted reduction baseline frequency drop seizure highest dose mg kg day zogenix trial primary endpoint testing two dos mg kg day mg kg day versus placebo patient background therapy anti epileptic earlier single arm study fintepla showed median reduction seizure frequency week versus baseline albeit subject best class fintepla need beat older anti epileptic approved lennox gastaut leerink analyst say need least range placebo adjusted improvement older drug come range side effect black box warning fintepla relatively clean safety profile across late stage trial another type intractable epilepsy called dravet syndrome filed serious cardiovascular issue observed crucial point fintepla active ingredient flenfluramine half fen phen diet pill found cause serious heart problem gw epidiolex shown elevation liver enzyme high dos said manageable epidiolex expected lead lennox gastaut market according evaluatepharma consensus forecast fintepla shot second place\n",
      "\n",
      "Keywords:\n",
      "fintepla 0.275\n",
      "tisotumab 0.237\n",
      "zogenix 0.183\n",
      "epidiolex 0.173\n",
      "cervical cancer 0.173\n",
      "cervical 0.173\n",
      "mg kg day 0.156\n",
      "kg day 0.156\n",
      "innova 0.156\n",
      "lennox gastaut 0.137\n",
      "lennox 0.137\n",
      "gastaut 0.137\n",
      "mg kg 0.133\n",
      "genmab 0.124\n",
      "kg 0.119\n",
      "line 0.108\n",
      "epileptic 0.104\n",
      "second 0.104\n",
      "showed median 0.099\n",
      "second line 0.095\n",
      "\n",
      "Abstract:\n",
      "among novel oncology mechanism let investor cd look particularly disappointing except one company forty seven today sits bn valuation thanks data presented ash last month suggesting lead asset magrolimab serious contender haematology true week unveiling magrolimab data colorectal cancer disappointed expectation solid tumour generally low armed post ash equity raise forty seven plan see magrolimab filed myelodysplastic syndrome next year would mark company distinct outlier cd inhibition celgene leader canned phase project prompting surface oncology currently ipo price change tack ditch work cd trillium kept faith share imploded eat competition find celgene discontinuation hard digest october ash winner magrolimab data ash marked forty seven transformation gain saw group become best performing stock conference period company tinkered antibody design fretted end cd pathway target forty seven success might something simple combining magrolimab chemotherapy azacytidine company argues combination synergistic ash data seemed back evaluable subject untreated intermediate high risk myelodysplastic syndrome md combo yielded overall response rate including complete remission similar population md patient roche abbvie blockbuster waiting venclexta combined azacytidine yielded orr cr rate second quarter forty seven plan start enhance phase iii md study versus azacytidine alone magrolimab showed striking data first line aml patient orr nine cr forty seven highlighted result aml subject tp mutation suggestive aggressive disease present aml case nine subject four complete three partial response aml intractable haematological tumour type seen entry several new drug possible forty seven target tp positive disease treatment specifically indicated plan enrol tp positive subject phase study inform potential registrational path asco gi result showed magrolimab promise haematology solid tumour much harder crack saturday asco gi conference see result erbitux combo colorectal cancer abstract paint gloomy picture two partial remission kras wild type disease among evaluable subject still analyst low expectation readout well separate bavencio combo ovarian cancer due presented asco sitc immuno oncology symposium february important separate pillar forty seven initial registrational strategy combining magrolimab rituxan lymphoma pivotal third line study begin current quarter initial data year end evaluatepharma sellside consensus see magrolimab generating revenue virtually lymphoma forecast derived ash data presentation seems likely md provide initial route market magrolimab forty seven hope found elusive secret sauce\n",
      "\n",
      "Keywords:\n",
      "magrolimab 0.419\n",
      "forty seven 0.325\n",
      "forty 0.325\n",
      "seven 0.23\n",
      "ash 0.19\n",
      "aml 0.163\n",
      "md 0.156\n",
      "cd 0.11\n",
      "haematology 0.093\n",
      "gi 0.093\n",
      "ash data 0.093\n",
      "evaluable subject 0.089\n",
      "asco 0.084\n",
      "myelodysplastic syndrome 0.084\n",
      "myelodysplastic 0.084\n",
      "subject 0.08\n",
      "cr 0.08\n",
      "initial 0.077\n",
      "combo 0.074\n",
      "evaluable 0.073\n",
      "\n",
      "Abstract:\n",
      "month since vantage last looked relative freshness pipeline biggest drug maker one striking observation lack progress made sanofi abbvie analysis measure proportion company sale coming product year old find sanofi remained steadfastly bottom table abbvie continues struggle overreliance humira u pharma company least point improving picture forecast sale suggest new launch start freshen abbvie portfolio coming year although number yet reflect inclusion allergan deal yet close much change predicted french firm however investor must hope sweeping strategy review announced new chief executive paul hudson signal turning big pharma tanker still sanofi abbvie alone bracket pfizer novo nordisk roche heavily reliant old drug last two least new product coming seen improving metric coming year although cannot said pfizer business development team sanofi pfizer surely pressure bring new source growth soon possible making prime candidate deal making year considering gilead considered dealmaker notable big biotech one youthful pipeline situation expected improve markedly pressure replace swiftly disappearing hugely cash generative hepatitis c franchise relatively young suite product bristol myers squibb scored highly youth front last year although impact celgene deal future profile remarkable almost inclusion revlimid join bristol ageing product opdivo eliquis company deal making day look far another company look need air freshener biogen though alzheimer candidate aducanumab change picture analysis seems explain keenness among japanese drug developer however rather looking absolute useful see shift time maturity product company portfolio standout performance look lilly astrazeneca five year ago lilly sale old product end figure dropped much turnaround driven strong performance diabetes drug trulicity raft mainly homegrown new launch including talz verzenio emgality turn astrazeneca continuing success oncology franchise boast blockbuster lynparza tagrisso increased sale contribution young product le last year among drug maker johnson johnson pipeline aged noticeably forecast suggest continue freshness index helpful revealing wisdom lack thereof trying buy new sale high spending sanofi recently shelled combined bn bioverativ ablynx apparently little show term fresher portfolio least novartis hand big spender pipeline projected get younger coming year future project based sellside forecast course subject change future deal making change picture investor hungry deal appear year jp morgan conference take comfort fact obvious need shore ageing pipeline many large developer freshness one way look clear remain table\n",
      "\n",
      "Keywords:\n",
      "year although 0.202\n",
      "product 0.182\n",
      "sanofi 0.166\n",
      "coming year 0.158\n",
      "coming 0.156\n",
      "pipeline 0.154\n",
      "deal making 0.152\n",
      "deal 0.151\n",
      "portfolio 0.147\n",
      "old 0.141\n",
      "abbvie 0.138\n",
      "new launch 0.135\n",
      "new 0.131\n",
      "picture 0.131\n",
      "making 0.128\n",
      "change 0.126\n",
      "inclusion 0.119\n",
      "sale 0.118\n",
      "improving 0.112\n",
      "franchise 0.103\n",
      "\n",
      "Abstract:\n",
      "scott gottlieb right move rebut claim u fda approving drug fast headed agency time standard allegedly falling however debacle approval sarepta vyondys revealed newly published document last night undoes much spirited defence vyondys unexpectedly greenlit december four month rejected via complete response letter u turn appears followed extensive internal fda disagreement reminiscent approval sarepta highly controversial duchenne muscular dystrophy drug exondys clinical data thing regulator reviewing vyondys filing go surrogate endpoint even barely supported efficacy drug like exondys received accelerated approval theoretically contingent confirmatory trial gottlieb legacy surge unproven treatment march course fda normally publish complete response letter crls drug question subsequently approved made public along relevant correspondence investor yesterday learned detail fda crl sarepta appeal final approval decision overturning initial ruling perhaps remarkable passage crl concerned vyondys exondys precedent set latter drug approval confirmation sarepta failure start confirmatory study back exondys accelerated approval concerning fda public agency wrote today exactly two year month exondys approval initiated required confirmatory trial despite poor precedent final approval vyondys came extracted sarepta following commitment concluded result confirmatory study support clinical benefit sarepta voluntarily withdraw vyondys market additionally two major sticking point crl preclinical kidney toxicity infection risk intravenous infusion port swiftly dismissed former addressed renal function monitoring latter need merely considered vyondys risk benefit balance approval summary state stein v unger v woodcock document reveals fda discord harking back review exondys vyondys crl issued dr elli unger director agency office drug evaluation approval rubbishing dr unger concern came relatively recently appointed director office new drug dr peter stein dr unger clashed dr janet woodcock fda drug review chief dr woodcock gone expert advice approve exondys dr unger time reported disagreed strongly filed formal dispute way decision reached dr unger office november restructured implying longer input ultimate vyondys approval power struggle aside influence duchenne patient group underappreciated extremely vocal exondys review might agency wanted avoid similarly damaging distraction second time fact remains despite fda insistence sarepta month started confirmatory exondys study case vyondys trial already way essence expected completion date may still commitment pull vyondys easily circumvented trial never allowed read never said failed story corrected reflect current status exondys confirmatory trial\n",
      "\n",
      "Keywords:\n",
      "vyondys 0.461\n",
      "exondys 0.448\n",
      "unger 0.269\n",
      "sarepta 0.245\n",
      "dr 0.21\n",
      "dr unger 0.179\n",
      "confirmatory 0.167\n",
      "approval 0.155\n",
      "woodcock 0.135\n",
      "crl 0.133\n",
      "fda 0.126\n",
      "office 0.12\n",
      "agency 0.114\n",
      "confirmatory trial 0.096\n",
      "drug 0.085\n",
      "approval sarepta 0.084\n",
      "confirmatory study 0.077\n",
      "review 0.071\n",
      "precedent 0.065\n",
      "duchenne 0.065\n",
      "\n",
      "Abstract:\n",
      "swift sometimes surprising decision u fda kept biopharma toe last year look like deliver fair share regulatory drama vantage annual analysis biggest approval horizon reveals several project potential delay controversy lofty expectation already building quarter table based evaluatepharma sellside consensus list top product approval year ranked projected sale seven forecast breach bn threshold time though course depends whether first pas regulatory muster biogen eisai controversial alzheimer disease project aducanumab top list global sale bn pencilled figure little dart throw dark however aside substantial uncertainty around whether regulator permit antibody market price might sold another important unknown second project roxadustat question hanging largely relating safety pivotal programme supporting novel anaemia pill hugely complex developer criticised way result presented fda verdict remains hard call though approval japan china contribute confidence advisory committee certain called though none announced yet chance delay might push roxadustat decision cannot ruled immunomedics meanwhile hope setback behind second verdict fda delivers antibody drug conjugate sacituzumab govitecan last year complete response letter considerable consensus sacituzumab boast boosted number emanating bullish investment bank even immunomedics get green light company work far project invite divided opinion includes aimmune peanut allergy therapy palforzia biohaven rimegepant migraine approval former seems fairly certain positive advisory committee commercial potential big question similar concern exist biohaven gearing enter highly competitive space biomarin meanwhile hope get first gene therapy haemophilia market valoctocogene roxaparvovec valrox lingering question durability project mean closely scrutinised application potential delay cannot dismissed hidden stumbling block never ruled course though review gilead galapagos rheumatoid arthritis project filgotinib bristol multiple sclerosis therapy ozanimod lilly targeted cancer treatment selpercatinib roche new option spinal muscular atrophy widely expected progress smoothly elsewhere list far complete overview next year regulatory action course another high profile decision involve esperion bempedoic acid february projected sale cardiovascular project fall outside top closely watched launch thanks earlier expected approval daiichi sankyo astrazeneca breast cancer therapy enhertu global blood therapeutic sickle cell treatment oxbryta reached market late last year look biggest expected arrival actually fared serf reminder unpredictable regulatory launch phase substantial setback last year top least though roxadustat palforzia failed reach market soon hoped consensus come considerably couple project however coincidence seen markedly product launched small developer reality market defeat enthusiasm eventually\n",
      "\n",
      "Keywords:\n",
      "roxadustat 0.169\n",
      "potential delay 0.132\n",
      "project 0.131\n",
      "top 0.13\n",
      "regulatory 0.129\n",
      "year look 0.125\n",
      "palforzia 0.125\n",
      "list 0.12\n",
      "sacituzumab 0.12\n",
      "meanwhile hope 0.12\n",
      "approval 0.11\n",
      "delay 0.107\n",
      "verdict 0.107\n",
      "biohaven 0.103\n",
      "advisory committee 0.103\n",
      "last year 0.102\n",
      "ruled 0.101\n",
      "projected 0.101\n",
      "though 0.099\n",
      "immunomedics 0.097\n",
      "\n",
      "Abstract:\n",
      "sometimes said enough succeed unless others fail case keytruda whose performance prompted yet analyst upgrade last year scored major victory rival opdivo saw biggest sign date abandoned sellside figure revealed vantage annual analysis bank upgrade downgrade derived evaluatepharma sellside based consensus forecast ranked find biggest move course show big adjustment diabetes drug changing guard hiv treatment sometimes overlooked still huge growth area gilead science thus gilead daily triplet biktarvy gained bn sellside consensus revenue partly expense group quad genvoya interestingly glaxosmithkline triplet triumeq made top downgrade perhaps analyst viewed company future lying increasingly monthly doublet meanwhile keytruda ability yield positive surprise well known drug added bn sale forecast year seeing consensus estimate climb bn striking example shifting sale outlook seen opdivo forecast upgraded bn saw consensus sale shrink made bristol myers squibb drug pharma harshly punished product last year lung cancer gave keytruda dominance renal cancer represented rare bright spot opdivo last year keynote readout keytruda plus inlyta look neutralised opdivo plus yervoy prompting soul searching among analyst away immuno oncology sellside anticipation ozempic cardiovascular risk reduction indication came month likely lie behind novo nordisk weekly diabetes drug third place upgrade jardiance ninth place upgrade outside top five pfizer amyloidosis drug vyndaqel blew expectation water first full quarter market earning upgrade side johnson johnson bayer anticoagulant xarelto failed key expansion study company protestation notwithstanding sellside started marking last year situation might helped publicity lawsuit settlement concerning drug bleeding risk copycat accounted many major forecast change including rituxan helped settlement pfizer allay threat biosimilars neulasta meanwhile downgraded ex u biosimilars started taking toll seeing post sale plummet three u version neutropenia drug approved u presidential election year upon u sellside pay close attention theme firm forecast\n",
      "\n",
      "Keywords:\n",
      "upgrade 0.383\n",
      "sellside 0.181\n",
      "opdivo 0.173\n",
      "keytruda 0.162\n",
      "forecast 0.148\n",
      "drug 0.135\n",
      "biosimilars 0.128\n",
      "sometimes 0.122\n",
      "diabetes drug 0.122\n",
      "consensus 0.121\n",
      "last year 0.119\n",
      "triplet 0.115\n",
      "sale 0.107\n",
      "seeing 0.104\n",
      "helped 0.097\n",
      "diabetes 0.09\n",
      "bn 0.086\n",
      "johnson 0.085\n",
      "last 0.082\n",
      "place 0.078\n",
      "\n",
      "Abstract:\n",
      "biogen aducanumab filing setting stage u fda showdown set year alzheimer disease danish diabetes specialist novo nordisk soon chance join party courtesy investigator sponsored study testing hypothesis neurodegeneration linked low insulin insulin resistance thus glp analogue diabetes drug like novo victoza improve cognitive function however outlandish sound novo share hit time high last week least one source put alzheimer wednesday danish newspaper b rsen floated idea victoza promise alzheimer lay behind spike citing analyst berenberg suggested positive data unleash hidden potential note bernstein following day asked alzheimer type diabetes posited role glp drug insulin signalling theory claim simply put diabetes associated dementia impaired insulin signalling suggested common mechanistic link correlation blood glucose level rate cognitive decline seen even without clinical diabetes suggested type diabetes almost double risk developing alzheimer associated accelerated cognitive decline people mild cognitive impairment others suggested insulin play role beyond glucose metabolism involved memory learning one paper describes function insulin receptor brain say defect receptor identified neuron alzheimer brain course correlation equal causation sceptical pharma sector remained sideline indeed striking number clinical trial testing hypothesis counted finger one hand none corporate pharma company sponsor change elad trial victoza run imperial college london generates promising data quarter enrolment target subject mild alzheimer dementia study far biggest date look diabetes drug cognitive impairment double blind placebo controlled design relatively long month treatment period primary endpoint measure rate glucose metabolism brain seeking stronger sign promise look secondary measure investigating various scale measuring cognition including ada cdr sum box adcs adl beyond vitro preclinical data little hard evidence suggest positive outcome clinical trial type approach generate data conducted university aarhus showed six month treatment victoza associated increase glucose metabolism versus placebo though effect statistically significant two academic study completed recently one victoza another astrazeneca bydureon data published beyond elad one trial ongoing u study non diabetic testing whether boehringer ingelheim lilly jardiance elevates level ketone body effect brain metabolism measured magnetic resonance clinical evidence backing aducanumab scant yet drug increasingly seen likely approval alzheimer year expect novo analyst seize hint victoza efficacy elad\n",
      "\n",
      "Keywords:\n",
      "victoza 0.292\n",
      "alzheimer 0.282\n",
      "insulin 0.273\n",
      "cognitive 0.222\n",
      "diabetes 0.219\n",
      "metabolism 0.188\n",
      "glucose 0.188\n",
      "glucose metabolism 0.171\n",
      "brain 0.16\n",
      "elad 0.16\n",
      "novo 0.138\n",
      "suggested 0.124\n",
      "cognitive impairment 0.106\n",
      "month treatment 0.101\n",
      "impairment 0.097\n",
      "correlation 0.097\n",
      "cognitive decline 0.097\n",
      "signalling 0.091\n",
      "dementia 0.087\n",
      "associated 0.086\n",
      "\n",
      "Abstract:\n",
      "welcome weekly roundup approaching clinical readout bayer merck co high stake decision advance heart failure project vericiguat phase iii paid late last year success victoria trial however increasingly competitive chronic hf space drug might need distinguish become commercially successful phase ii vitality hfpef trial taken significance despite vericiguat new found effectiveness add standard care one biggest issue finding place chronic hf treatment protocol look novartis entresto disappointing launch really took change treatment guideline victoria readout included topline result chronic hf reduced ejection fraction detailed number expected medical conference later year asset come reduction risk hf hospitalisation cardiovascular death top standard care suffer versus astrazeneca sglt farxiga performed strongly vitality hfpef come play subject trial vericiguat tested much tougher setting hf preserved ejection fraction hfpef market leader entresto failed significantly vitality hfpef patient reported quality life measure primary endpoint patient advanced stage disease often suffer severe limitation daily activity significant anxiety health making important measure effectiveness hope success vitality hfpef open new hfpef patient population quality life benefit help bypass physician conservatism drive patient demand factor led analyst leerink bernstein forecast peak sale bn considerably higher consensus akero bash nash nash tarred clinical setback stopped company looking new target akero one contender company akr belongs fibroblast growth factor class said regulate lipid energy metabolism non invasive mri result phase ii trial expected first quarter full biopsy data expected second akr analogue fgf phase ii balanced study testing weekly subcutaneous dos versus placebo week mg mg mg tested primary endpoint change baseline liver fat content measured mri pdff week secondary measure include biomarkers liver injury fibrosis study initially recruited patient stage fibrosis december week company said added subject stage fibrosis given mg akr placebo week akero licensed akr amgen june front amgen performed two phase trial type diabetes akr known amg showed activity lipoprotein reduction insulin sensitivity indicator study nash though liver specific endpoint study despite akr akero clinical candidate group managed raise ipo last year among top two company fgf candidate nash floated last year bio raised ngm biopharmaceuticals latter ngm shown fat reduction higher dose cost big jump ldl biopsy data due current quarter\n",
      "\n",
      "Keywords:\n",
      "hfpef 0.31\n",
      "akr 0.266\n",
      "vitality hfpef 0.221\n",
      "hf 0.216\n",
      "vitality 0.197\n",
      "akero 0.177\n",
      "chronic hf 0.166\n",
      "vericiguat 0.148\n",
      "nash 0.128\n",
      "ngm 0.103\n",
      "fibrosis 0.101\n",
      "mg 0.101\n",
      "victoria 0.098\n",
      "fgf 0.094\n",
      "chronic 0.093\n",
      "stage fibrosis 0.091\n",
      "quality life 0.091\n",
      "placebo week 0.091\n",
      "entresto 0.091\n",
      "liver 0.086\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Abstract:\n",
      "financing climate young drug maker cooled last year cash far scarce anything major concern heard private investor moment long term implication excess capital sign restraint however average financing size dipped peak remained record level frequency mega round amassed barely slowed point even pronounced concentration capital hand shrinking number start ups count round raised fell last year first time since least according evaluatepharma analysis look drug developer excluding medtech diagnostics genomics example represents look many would consider high risk end biopharma sector long equity investor industry display clear interest fledgling developer seems unlikely venture firm fret much apparent shrinking gene pool focusing capital reflects shift investment strategy widely embraced company builder describe allows start ups properly funded given best chance success evidence strategy working median time exit via measured date company foundation buyout dipped noticeably time ipo historically swift latter measure largely due receptive stock market course important swing factor venture industry year public world acceptance high risk offering term takeout private sphere wheel increasingly greased tranched deal structure separate analysis evaluatepharma data published vantage today find proportion private company takeout involved sort contingent value jumped almost substantially higher previous two year valuation testing many therapy field venture investor presumably little choice accept back end loaded term particularly target question relatively early separate analysis highlight another potential area concern venture sector number private takeout declined substantially past five year absolute term proportion deal true venture backed world substantially better funded making selling le necessity time public deal counted include relatively recently listed company venture backer retained interest time buyout synthorx example armo bioscience investor syndicate much larger takeout presumably benefit greater number investor past still viewed alongside declining number venture financing drop private transaction trend keep eye course flip side big positive venture field plentiful supply buyer partner portfolio company big pharma beyond depletion big biotech pipeline created another group cash rich acquirer recent year example apparently deep well limited partner investor venture fund keen inject huge amount cash access biopharma glut capital caused valuation reach eye watering proportion case surely raised unreasonable expectation many quarter whether declining number start ups matter question yet really answered concern clear business booming venture field prevailing mantra seems got spend depth look next year might hold biopharma download free preview\n",
      "\n",
      "Keywords:\n",
      "venture 0.411\n",
      "capital 0.174\n",
      "private 0.171\n",
      "start ups 0.146\n",
      "takeout 0.142\n",
      "ups 0.128\n",
      "substantially 0.127\n",
      "financing 0.122\n",
      "shrinking 0.12\n",
      "proportion 0.115\n",
      "separate analysis 0.114\n",
      "field 0.112\n",
      "dipped 0.109\n",
      "number 0.109\n",
      "investor 0.1\n",
      "declining 0.095\n",
      "term 0.093\n",
      "round 0.091\n",
      "funded 0.091\n",
      "example 0.088\n",
      "\n",
      "Abstract:\n",
      "significant doubt swirled around nektar therapeutic abuse proof painkiller oxycodegol long yesterday unequivocal u advisory panel vote approval analyst expected product yield significant revenue company distanced nektar stock fell morning therefore something mystery still hope adcom might sign sort unrealistic expectation exist current market perhaps share price fall suggests broad fear nektar technology evercore isi josh schimmer suggested note client yesterday nektar bouncing across scientific application pegylation tech wrote showed company jack trade master none including oxycodegol previous nektar project possibly current one filing pulled however lenient u fda late opportunity go advisor nektar quickly scrapped oxycodegol pulled filing said would save developing project cost group around total evaluatepharma vision estimate oxycodegol earlier known lab code nktr mu opioid receptor agonist designed give severe chronic low back pain relief without resulting cns mediated side effect like euphoria lead abuse addiction achieved pegylation altering project kinetics reduce entry cns however yesterday adcom decided potential abuse adequately addressed resulting concern product would marketed safer opioid whose full safety profile apparently characterised shortcut nektar taken develop oxycodegol already highlighted panel briefing document another factor made negative outcome foreseeable fda advice group run single efficacy trial yielding data beyond week thought trying get around shortcoming seeking relatively narrow label distance advisory panel postponed last august even nektar sought separate oxycodegol three month earlier transferred project legally separate though wholly owned entity inheris biopharma nektar hope attract fresh valuation may attempt minimise association u opioid crisis seen oncology company adcom result seen clearing event allows nektar formally discontinue oxycodegol project carried consensus sale forecast according evaluatepharma effort helped bristol myers squibb decision last week double il project bempegaldesleukin despite bubble asset deflating fast bristol moved add two registrational opdivo combo study bempegaldesleukin existing three trial rightly caused nektar stock pop today reaction might simply return normality oxycodegol death really surprised one\n",
      "\n",
      "Keywords:\n",
      "nektar 0.523\n",
      "oxycodegol 0.5\n",
      "abuse 0.175\n",
      "opioid 0.16\n",
      "adcom 0.134\n",
      "panel 0.12\n",
      "bempegaldesleukin 0.103\n",
      "advisory panel 0.095\n",
      "cns 0.091\n",
      "pulled 0.089\n",
      "project 0.087\n",
      "resulting 0.08\n",
      "advisory 0.08\n",
      "yesterday 0.065\n",
      "around 0.064\n",
      "current 0.06\n",
      "share price fall 0.058\n",
      "price fall 0.058\n",
      "separate 0.057\n",
      "vision estimate 0.056\n",
      "\n",
      "Abstract:\n",
      "always going hard live bumper ipo haul proved decent performance suffering comparison however worse much last year showing strong recovery last quarter october looked ipo window young drug maker might shutting western stock market contracted seven company listed third quarter prompting fear year would end huge note analysis look drug developer excluding sector like medtech genomics instead listing including four plus float helped finish flourish market bounced back health new biopharma issue raised total bn year far cry bn amassed comfortable beat bn chief among saviour fourth quarter phathom pharmaceutical raised making third biggest listing year phathom achievement impressive given upsized offering selling share initially intended company operates fashionable area gastrointestinal disease look trend investor sentiment show final quarter year traditionally tough period float last year exception average discount initially proposed price range least le severe final quarter fourth quarter figure however hide big difference like bio aprea therapeutic managed stick pre ipo price range car player cabaletta bio lower price say lot glut company space biontech galera therapeutic swallow significant discount make listing dream come true biontech failing raising initially targeted encouraging healthcare investor many last year sizeable biotech flotation trading water aprea tripled value example however venture investor story perhaps le encouraging chart look difference average share price achieved company private figure supplied u registration document price float suggests early investor able achieve valuation uplift ipo however one thing note many company listed immaturity pipeline meaning vast majority sale unlikely foreseeable future future funding requirement met follow offering signal much harder time market turn future hold year ipo market opaque normal u stock market keep climbing nasdaq hitting record intra day high week usually good looking float concern big correction due building u presidential election another confounding factor le clear another trump victory defeat mean healthcare stock ipo window open healthcare index moving upwards biotech making opportunity chinese company mab pencilled potential listing later week fare interesting insight investor appetite chinese healthcare stock following zai lab beigene u listing others ipo queue including arcutis black diamond therapeutic monitoring mab reception head market\n",
      "\n",
      "Keywords:\n",
      "ipo 0.277\n",
      "listing 0.241\n",
      "float 0.188\n",
      "healthcare 0.173\n",
      "quarter 0.164\n",
      "final quarter 0.137\n",
      "price 0.133\n",
      "price range 0.125\n",
      "company listed 0.125\n",
      "initially 0.112\n",
      "discount 0.111\n",
      "market 0.109\n",
      "stock 0.1\n",
      "future 0.098\n",
      "window 0.097\n",
      "investor 0.095\n",
      "chinese 0.094\n",
      "fourth quarter 0.093\n",
      "offering 0.09\n",
      "stock market 0.089\n",
      "\n",
      "Abstract:\n",
      "bristol myers squibb opdivo exelixis cabometyx bright future first line treatment kidney cancer two fought fiercely space outmanoeuvred merck co keytruda single study give second wind study checkmate er test combination opdivo cabometyx due completed month would huge surprise see trial fail given pfizer sutent low bar clear much relevant extent combination able extend survival sutent keynote keytruda plus inlyta reduced risk death versus sutent setting generating present look like strongest dataset front line comer setting moving quickly leadership renal cancer treatment changing fast cabometyx initially shown great first line promise monotherapy thanks cabosun study quickly outflanked bristol controversial checkmate trial opdivo plus yervoy many question answer esmo checkmate debacle september polemic patient subgroup quickly became irrelevant pfizer merck kgaa bavencio combination inlyta scored impressive comer benefit javelin renal trial soon afterwards merck co blew even data water keynote readout four regimen carry first line renal cancer label perhaps important aspect last two datasets showed clear promise combining checkpoint blockade vegf inhibition checkmate er play strength cabometyx like inlyta inhibitor several vegfr tyrosine kinase study undergone several change initially included additional opdivo yervoy cabometyx triplet removed two year ago citing need accelerate opdivo cabometyx doublet reflect changing clinical practice exelixis denied move due fear yervoy toxicity remaining two cohort slightly enlarged around subject improve powering delaying completion september month enrolment completed last april result due early first half chance success seem high investor hoping knockout result might disappointed one thing checkmate er primary efficacy measure progression free survival result toplined data underwhelm given strong overall survival benchmark set keynote subsequent effect o difficult parse given subject sutent control arm progress go receive immunotherapy derive benefit however javelin renal control cohort progressers got second line immunotherapy finally merck co still joker pack form clear keynote trial test eisai vegfr targeting drug lenvima without keytruda read later year seems exelixis bristol chance claw back lost ground tectonic plate continue shift\n",
      "\n",
      "Keywords:\n",
      "cabometyx 0.308\n",
      "sutent 0.234\n",
      "checkmate 0.195\n",
      "opdivo 0.174\n",
      "inlyta 0.163\n",
      "checkmate er 0.158\n",
      "renal 0.158\n",
      "keynote 0.154\n",
      "exelixis 0.154\n",
      "er 0.15\n",
      "yervoy 0.124\n",
      "vegfr 0.117\n",
      "opdivo cabometyx 0.112\n",
      "javelin 0.109\n",
      "line 0.106\n",
      "merck 0.104\n",
      "quickly 0.101\n",
      "renal cancer 0.098\n",
      "changing 0.098\n",
      "keytruda 0.098\n",
      "\n",
      "Abstract:\n",
      "uk verona pharma year shunned investor today made valiant attempt recovery chronic obstructive pulmonary disease study lead project ensifentrine succeeded boosting effect boehringer ingelheim spiriva initially sending verona stock surging albeit low base thus one half company strategy might place plan position ensifentrine add spiriva well top dual therapy stiolto however earlier study latter combo failed verona still lack licensing deal validate ensifentrine proved elusive one problem many company see respiratory space commoditised risky spend huge amount needed run necessary large scale pivotal study another possible doubt intellectual property ensifentrine around long original composition patent expires year licensing partner would take bullish view u eu patent protect pde inhibitor nebulised formulation claim exclusivity success however least verona one important clinical win belt study copd subject nebulised ensifentrine dose combined spiriva beat control arm spiriva alone term primary endpoint improvement fev four week importantly clear numerical dose response relationship spiriva adjusted fev benefit baseline increasing rising ensifentrine dose dose range mg four dos met statistical significance p verona stated spiriva control performing expected data build earlier study patient ensifentrine mg mg plus spiriva beat spiriva control term day fev elephant room however spiriva displaced boehringer efficacious combo stiolto comprises spiriva active ingredient combined laba olodaterol given top stiolto nebulised ensifentrine failed beat stiolto alone disappointment year ago exacerbated share price decline even today increase verona market cap stand uk company raised u secondary nasdaq listing stock still stand well much clinical mileage adding new drug top spiriva remains important unanswered question despite failed stiolto combo study speaking vantage today verona chief executive jan anders karlsson insisted ensifentrine active top spiriva laba added spiriva remained commonly used starting drug copd company hope data reinvigorate partnering interest clearly potential licensee gauge size opportunity interestingly pivotal programme somewhat agnostic background therapy mr karlsson said two identical phase iii study envisaged subject would background copd therapy remainder would bronchodilator may may spiriva later would pivotal triple combo trial considered cost two pivotal trial would verona told analyst call something look unsustainable group remains capitalised little decision market opportunity rest partner\n",
      "\n",
      "Keywords:\n",
      "spiriva 0.616\n",
      "ensifentrine 0.396\n",
      "verona 0.352\n",
      "stiolto 0.22\n",
      "fev 0.123\n",
      "copd 0.117\n",
      "combo 0.083\n",
      "top 0.081\n",
      "earlier study 0.073\n",
      "beat 0.069\n",
      "background 0.067\n",
      "study 0.066\n",
      "boehringer 0.065\n",
      "dose 0.062\n",
      "would 0.062\n",
      "pivotal 0.061\n",
      "mg 0.06\n",
      "control 0.058\n",
      "licensing 0.055\n",
      "failed 0.049\n",
      "\n",
      "Abstract:\n",
      "probably fair say biotech investor hungry deal start week jp morgan healthcare jamboree expecting something bigger lilly buyout dermira licensing deal incyte struck today morphosys tafasitamab still however much bullish follower want see latter deal sniffed represents joint fifth biggest single project licensing transaction front value recent time amazingly strong endorsement asset still lot left prove tafasitamab anti cd mab engineered fc fragment filed u part revlimid combination late line diffuse large b cell lymphoma launch use look likely setting might ultimately amount much spotlight fall tafasitamab december important front line dlbcl trial begun b mind bendamustine combo study rituxan however latter planned enrolment increased subject might cause concern magnitude expected clinical benefit said today incyte endorsement concern seen le relevant tie incyte morphosys co promote tafasitamab u sharing profit ex u incyte sole dlbcl right return royalty incyte fund development along similar line total cost u outside obvious reason incyte struck deal company need boost portfolio beyond jakafi bile duct cancer project pemigatinib underwhelmed le obvious factor pipeline includes pi k delta inhibitor incb parsaclisib toxicity plagued delta specific pi k inhibition shown gilead zydelig approved hardly used chronic lymphoblastic leukaemia incyte however see possible way forward saying want combine parsaclisib tafasitamab b cell malignancy sellside expects tafasitamab generate revenue according evaluatepharma consensus mizuho analyst morning said incyte project come cheap pipeline pressure incyte saw approvable oncology asset table likely realised pay\n",
      "\n",
      "Keywords:\n",
      "incyte 0.543\n",
      "tafasitamab 0.403\n",
      "dlbcl 0.134\n",
      "morphosys 0.129\n",
      "pi 0.118\n",
      "delta 0.11\n",
      "deal 0.105\n",
      "endorsement 0.104\n",
      "licensing 0.094\n",
      "obvious 0.092\n",
      "struck 0.091\n",
      "line 0.073\n",
      "want 0.073\n",
      "zydelig 0.067\n",
      "spotlight fall 0.067\n",
      "sellside expects 0.067\n",
      "obvious reason 0.067\n",
      "jakafi 0.067\n",
      "however much 0.067\n",
      "fund development 0.067\n",
      "\n",
      "Abstract:\n",
      "amarin hoped much better start week two potential rival astrazeneca epanova acasti capre look fallen wayside removing key threat fish oil based product vascepa competition frequently cited reason takeover bid company failed emerge one way read setback failure astrazeneca strength trial particular class effect fish oil ruled face value look positive amarin might necessarily good long term particularly mechanism responsible vascepa benefit remain unclear said many drug course including statin class proved potently lowering ldl reduce cardiovascular risk though precise mechanism benefit fully known statin became huge success commercially several slightly different compound showed thing giving physician confidence prescribe widely refute vascepa benefit convincing enough win product risk reduction claim u label last month amarin alone extolling type product benefit must argue sufficiently different others explain contrasting result vascepa advanced fish oil product comprised pure eicosapentaenoic acid epa epanova capre failed phase iii today contain docosahexanoic acid dha today development seems rule two competitor vascepa amarin really benefit need yield evidence never even bucket pure theorist advocate pure epa theory long argued case largely dha raise ldl cholesterol level muting beneficial effect epa astrazeneca detail data strength firm conclusion hard draw company said today study closed interim review saw little chance success strength recruited similar type patient vascepa successful outcome study reduce though subject trial around larger immediate question whether patient exposed sufficient level epa epanova contains almost half much vascepa implication failure acasti first phase iii study harder call share slumped early trade astrazeneca failure doubt adding reason investor flee morning canadian company stage proving capre ability lower triglyceride level trilogy study unfortunately demonstrated active control arm handful rogue site blamed unexpectedly high placebo response acasti presented collated chart fish oil study indeed suggest bad luck second near identical study trilogy read end february best case scenario seems substantial delay getting capre market\n",
      "\n",
      "Keywords:\n",
      "vascepa 0.354\n",
      "epa 0.236\n",
      "capre 0.236\n",
      "fish oil 0.207\n",
      "oil 0.202\n",
      "fish 0.202\n",
      "amarin 0.198\n",
      "epanova 0.186\n",
      "acasti 0.177\n",
      "pure 0.138\n",
      "strength 0.123\n",
      "trilogy 0.118\n",
      "dha 0.118\n",
      "benefit 0.117\n",
      "statin 0.106\n",
      "astrazeneca 0.1\n",
      "product 0.096\n",
      "ldl 0.093\n",
      "acid 0.086\n",
      "study 0.086\n",
      "\n",
      "Abstract:\n",
      "biopharma braced flood deal news next week lilly decided grab attention takeout dermira unveiling move today bn acquisition small fry big pharma group expectation high much bigger takeout unveiled jp morgan healthcare conference next week whether investor wildest dream fulfilled far certain course dermira deal end biggest disappointment palpable acquisition appears struck almost zero premium though biotech stock mysteriously climbed week doubled since beginning december leaky chinese wall obvious explanation though couple potential competitor lebrikizumab antibody developed autoimmune condition like atopic dermatitis fell wayside towards end november anaptysbio etokimab missed primary endpoint phase iib trial atopic dermatitis real boon dermira taken underwhelming result leo pharma tralokinumab private danish developer yet release actual data il targeting antibody low key statement widely interpreted mean result weak competitively speaking lebrikizumab target il look like hold space big beast sanofi regeneron dupixent dermira delivers dupixent march capping premium presumably lilly seen tralokinumab result project remains something wild card still contender hoping grab multi billion dollar sale dupixent generating jak class particular looking strong pfizer abrocitinib due release head head data v dupixent coming week autoimmune space lebrikizumab aiming already hugely competitive getting surely factor put lid dermira valuation running trial needed carve position expensive evaluatepharma vision r cost module estimate dupixent developer spend almost bn total drug clinical programme atopic dermatitis trial accounting around half well considering future expense lilly factor payment due roche dermira licensed lebrikizumab milestone still due include regulatory approval commercialisation sale related payment reach bn royalty range high single digit mid teen payment almirall bought right project europe last year provide income lilly course mean u company capture full economics region assuming lebrikizumab commercially successful perhaps remarkable fact deal relates huge sum money lebrikizumab associated far dermira paid roche far received almirall dwarfed bn cheque lilly write add development cost dermira must invested well going r bill roche must spent much clinical programme included four phase iii trial sunk cost matter little lilly course must seen potential make money clear space lot cash still need spent\n",
      "\n",
      "Keywords:\n",
      "dermira 0.401\n",
      "lebrikizumab 0.352\n",
      "dupixent 0.228\n",
      "lilly 0.174\n",
      "atopic dermatitis 0.14\n",
      "atopic 0.14\n",
      "dermatitis 0.137\n",
      "payment 0.134\n",
      "tralokinumab 0.117\n",
      "next week 0.1\n",
      "grab 0.1\n",
      "cost 0.092\n",
      "spent 0.087\n",
      "autoimmune 0.085\n",
      "must 0.083\n",
      "space 0.08\n",
      "week 0.075\n",
      "clinical programme 0.075\n",
      "il 0.074\n",
      "premium 0.073\n",
      "\n",
      "Abstract:\n",
      "welcome weekly roundup approaching clinical readout pfizer jak inhibitor abrocitinib need prove dermatitis stalwart dupixent phase iii jade compare trial data due shortly already known abrocitinib work atopic dermatitis since met key endpoint two phase iii trial safety profile need closely analysed jak inhibitor contend serious toxicity used rheumatoid arthritis abrocitinib said selective jak investigator believe reduces risk class related adverse event infection thromboembolic cardiovascular event abrocitinib previous atopic dermatitis study jade mono rate serious adverse event treated patient discontinuation range higher previously seen dupixent thromboembolic event pfizer jak seem tolerability issue judging rate nausea headache dupixent study frequent adverse event injection site reaction conjunctivitis term efficacy higher dose abrocitinib showed comparable result dupixent pivotal trial latest study jade compare abrocitinib pitted directly dupixent adult topical background therapy mg mg daily dos abrocitinib tested co primary endpoint investigator global assessment easi score week pfizer third quarter call management specifically pointed secondary endpoint pruritus reduction company expects abrocitinib outperform inhibits interleukin major itch mediator covered dupixent displacing dupixent tough given physician experience potential black box warning abrocitinib common jak pfizer side convenience abrocitinib oral dupixent subcutaneous term jak competition lilly olumiant abbvie rinvoq phase iii trial atopic dermatitis approved black box warning rheumatoid arthritis meanwhile dermira bought lilly lilly jump gun dermira deal jan myovant look spirit guidance myovant science phase iii endometriosis data due end second quarter scoring clinical win gnrh inhibitor relugolix hopefully show benefit approved market leader abbvie orilissa relugolix previously disappointed relative expectation cross trial comparison orilissa uterine fibroid current development trajectory even spirit spirit trial successful project hit market two half year orilissa strong data essential myovant stand chance taking market share pharma giant relugolix orilissa work blocking gonadotrophin hormone reducing pain associated endometriosis disorder tissue usually line wall uterus grow outside womb however orilissa used monotherapy spirit trial testing relugolix combination oestrogen add back therapy one biggest side effect gnrh antagonist bone loss limit duration treatment add back therapy thus extend treatment window chronic disease myovant supporter highlighted advantage orilissa alongside relugolix dosing convenience abbvie hobble advantage result patient trial comparing orlissa monotherapy combination hormone add back trial positive leerink analyst say label extension orilissa follow third quarter six month relugolix forecast endometriosis approval much stacked myovant surprising sale forecast relugolix endometriosis compared orilissa according evaluatepharma spirit data surprise myovant avoid ran indication\n",
      "\n",
      "Keywords:\n",
      "abrocitinib 0.372\n",
      "orilissa 0.29\n",
      "dupixent 0.271\n",
      "relugolix 0.247\n",
      "spirit 0.217\n",
      "myovant 0.207\n",
      "jak 0.187\n",
      "endometriosis 0.165\n",
      "dermatitis 0.135\n",
      "add back 0.119\n",
      "jade 0.115\n",
      "atopic dermatitis 0.104\n",
      "atopic 0.104\n",
      "pfizer jak 0.087\n",
      "thromboembolic 0.083\n",
      "trial 0.083\n",
      "event 0.081\n",
      "back therapy 0.079\n",
      "add back therapy 0.079\n",
      "pfizer 0.078\n",
      "\n",
      "Abstract:\n",
      "deciphera early ripretinib filing last month proved enough ward challenge blueprint medicine latter similarly super targeted small molecule cancer drug avapritinib yesterday scored u approval month valentine day action date chasing relatively rare cancer type gastrointestinal stromal tumour gist going different way blueprint starting precise biomarker driven strategy carving tiny niche deciphera initially pursuing fourth line comer label given small avapritinib initial patient population must precisely targeted blueprint approach overwhelming supporting data perhaps surprising fda acted alacrity drug branded ayvakit approved treating gist driven pdgfr exon mutation including v mutation kinase inhibitor avapritinib ripretinib inhibitor mutated kit pdgfr kinase often play role gist front line disease thought driven kit instance pdgfr involvement account common exon v substitution first line standard treatment gist novartis bcr abl tyrosine kinase inhibitor gleevec pfizer sutent bayer amgen stivarga used second third line respectively patient given avapritinib early first line long carry relevant pdgfr mutation blueprint supporting trial navigator showed overall remission rate gist subject exon mutation specifically v type pricing key initial market seems vanishingly small gleevec peak instance gist made annual revenue figure bn blueprint initially small genetically defined slice gist market blueprint deciphera clear expansion plan former case voyager study head head stivarga support avapritinib fourth line gist compass l future investigate drug sutent second line setting part deciphera filed ripretinib fourth line gist back invictus trial expected mid pdufa date second line study intrigue pit project versus sutent mastocytosis disease driven active mutant kit typically v important second indication project avapritinib disappointed fatal bleed taking shine data presented ash sellside consensus compiled evaluatepharma see gist contributing ripretinib revenue versus figure avapritinib however leerink analyst yesterday upgraded blueprint arguing avapritinib priced per patient per month generate peak global revenue bn kit mutant gist pdgfr mutated disease final scientific curiosity rival tyrosine kinase inhibitor work slightly differently avapritinib typical inhibitor mutant kit pdgfr kinase albeit optimised v loop mutant ripretinib meant bind kinase switch pocket preventing locked state reducing scope mutation based escape mechanism much difference make yet play blueprint early lead story updated correct expected pdufa date ripretinib\n",
      "\n",
      "Keywords:\n",
      "gist 0.427\n",
      "avapritinib 0.364\n",
      "blueprint 0.271\n",
      "ripretinib 0.255\n",
      "pdgfr 0.243\n",
      "kit 0.202\n",
      "kinase 0.165\n",
      "deciphera 0.155\n",
      "line 0.133\n",
      "mutant 0.128\n",
      "mutation 0.125\n",
      "sutent 0.121\n",
      "fourth line 0.104\n",
      "exon 0.096\n",
      "driven 0.093\n",
      "kinase inhibitor 0.089\n",
      "gleevec 0.085\n",
      "fourth line gist 0.081\n",
      "tyrosine kinase inhibitor 0.078\n",
      "stivarga 0.078\n",
      "\n",
      "Abstract:\n",
      "development end biopharma sector notoriously risky strong flow deal making crucial keep investor interested good year actually look like term number involved widely judged strong year huge sum committed bn type deal across year certainly stand topline number boosted two mega merger far end story saying nothing underlying transaction volume price paid paint detailed picture vantage crunched evaluatepharma data examine differed preceding year synopsis amount straight company takeout happening remained largely flat past three year though mid size deal rebounded highest level since meanwhile premium climbed highest point since least research stage company commanding particularly high price analysis focus activity company develop sell drug excludes medtech diagnostic group cro example first distribution deal price paid immediately noticeable takeover remain well volume biotech boom prompted something deal making frenzy drop inevitable artificially high level dearth medium sized deal particularly beloved investor cause concern flurry towards end put worry bed though many hope pace deal continues pick year least fall back table show deal bn range rebounded past couple year big pharma sweet spot fall somewhere although ideal bolt price differ company interesting volume sub takeout dipped somewhat trend explained climbing valuation private sphere larger bn deal always far whatever stage cycle sector sits suggests volume mid stage deal help set opinion quality year image plot frequency takeover struck bn striking observation dispersion deal year look substantially different\n",
      "\n",
      "Keywords:\n",
      "deal 0.359\n",
      "volume 0.247\n",
      "price 0.136\n",
      "deal making 0.131\n",
      "highest 0.107\n",
      "fall 0.104\n",
      "takeout 0.104\n",
      "paid 0.1\n",
      "stage 0.099\n",
      "bn 0.098\n",
      "takeover 0.098\n",
      "sector 0.092\n",
      "strong 0.089\n",
      "sweet spot 0.087\n",
      "end 0.086\n",
      "particularly 0.086\n",
      "past 0.086\n",
      "mid 0.083\n",
      "year look 0.083\n",
      "type deal 0.083\n",
      "\n",
      "Abstract:\n",
      "since floating nasdaq eight year ago verastem hardly stood still yesterday saw strategy take another twist bought hot competitive space kras inhibition licensing deal roche chugai unit measure excited market effort target kras mutated cancer driven mirati amgen verastem stock shot yesterday far good time chugai deal see clinical progress verastem remains micro cap biotech ragbag asset cast bigger company latest addition see verastem take global right chugai pan raf inhibitor ck return front backing deal ck ro already investigator sponsored clinical trial combination veastem clinical lead fak inhibitor defactinib however result revealed publicly verastem told vantage seen data would released year relying theory backing combo hint single agent activity course initial combo data belong academic sponsor uk institute cancer research yet clear verastem clinical effort might begin promise combination hopefully revealed uk study basket trial whose expansion phase includes strong cohort kras mutant nsclc subject meantime mirati amgen remain leader kras targeting triple meeting mirati avoids worst case scenario october monotherapy ck showed partial remission rate kras positive nsclc subgroup adenocarcinoma study shown defactinib meanwhile associated rate progression free survival week similar population say verastem citing previously published data ck one handful pan raf inhibitor include takeda tak basilea bal interestingly last year jazz paid struggling uk company redx right preclinical pan raf programme today redx named next clinical candidate rxc inhibitor rock mechanism kadmon kd advanced verastem chugai deal spell latest several since company floated point focusing targeting cancer stem cell defactinib came pfizer mere later failed generate meaningful single agent activity hence current combination focus verastem licensed pi k mtor inhibitor v bio discontinued duvelisib disappointing pi k inhibitor brought infinity deal front fee subsequently launched generates negligible sale backdrop paying chugai roche ck par course verastem ipo price investor remain sceptical whether company turn pharma castoffs gold story updated clarify verastem already seen institute cancer research combo data\n",
      "\n",
      "Keywords:\n",
      "verastem 0.562\n",
      "ck 0.243\n",
      "chugai 0.225\n",
      "kras 0.189\n",
      "raf 0.153\n",
      "pan raf 0.153\n",
      "defactinib 0.153\n",
      "mirati 0.122\n",
      "pan 0.117\n",
      "inhibitor 0.11\n",
      "redx 0.102\n",
      "raf inhibitor 0.102\n",
      "pan raf inhibitor 0.102\n",
      "combo data 0.102\n",
      "agent activity 0.102\n",
      "institute cancer research 0.097\n",
      "institute cancer 0.097\n",
      "deal 0.095\n",
      "cancer research 0.09\n",
      "uk 0.089\n",
      "\n",
      "Abstract:\n",
      "long wished pick company takeout end last year confirmed bumper period biopharma deal making evaluatepharma calculates global drug maker spent bn deal touch record breaking level whether spending spree continues year next big question many way rune read positively easy access financing example numerous large cash rich player pressure build portfolio investor hope jp morgan healthcare conference start next week confirms unsated appetite delivers deal table illustrates much firepower unleashed last year relative spending throughout decade though vast majority cash deployed went buying celgene bn allergan bn analysis includes deal developer human therapeutic excludes medtech company diagnostic player example another important point analysis incorporates various type deal well company takeout accounted around half transaction last year minority majority stake purchase acquisition business unit reverse merger option deal counted remembered looking total transaction volume declining since hitting peak currently sits low decade driven slump type deal straight company takeout remained largely flat past couple year fuller analysis transaction found make great year takeover january look trend detail past four year show total deal volume hovered around quarter since beginning recent takeover flurry aside seems like relatively slim picking investment banking sector earns valuable fee proposing administering type deal banker certainly take heart fourth quarter however bn cash committed huge sum considering largest deal bn novartis pledged medicine company big pick smaller transaction much loved stock picker really drove number gave sentiment towards sector big boost jp morgan conference favoured occasion unveiling major move disappointment palpable fail occur year however worth remembering flurry deal late last year came wake poor summer biopharma stock many fearing worst end decade perhaps helped deal get done concern future exacerbated approaching u presidential election uncertainty threat hold sector stock market might many reason cautious biopharma head company sitting newly inflated market cap must hope valuation deter buyer mood splash cash story amended state straight company takeout stayed flat last year rather rising previously stated\n",
      "\n",
      "Keywords:\n",
      "deal 0.285\n",
      "company takeout 0.207\n",
      "type deal 0.182\n",
      "transaction 0.165\n",
      "takeout 0.151\n",
      "decade 0.128\n",
      "last year 0.124\n",
      "straight company takeout 0.121\n",
      "straight company 0.121\n",
      "cash 0.12\n",
      "straight 0.112\n",
      "flurry 0.106\n",
      "morgan 0.104\n",
      "jp morgan 0.104\n",
      "jp 0.104\n",
      "sector 0.101\n",
      "flat 0.099\n",
      "spending 0.096\n",
      "pick 0.096\n",
      "company 0.093\n",
      "\n",
      "Abstract:\n",
      "running head head study expose risk answering question really want answered sometimes pay apellis found yesterday pegasus trial paroxysmal nocturnal haemoglobinuria apellis apl beat alexion soliris prompting initial share price surge subsequent pullback stock closed even predictable equity offering announced reveals doubt apl place market however space highly competitive alexion others bulking acquisition soliris might ultimately drug apl beat obvious threat alexion soliris follow ultomiris approved pnh subcutaneously delivered zilucoplan acquired ucb bn takeout ra achillion ach ach latter oral last october alexion hand none detract apellis immediate success look impressive given pegasus somewhat complicated design anaemic pnh subject first got three month soliris maintenance soliris plus apl combo one month run split two head head monotherapy cohort despite primary endpoint improvement haemoglobin level comfortably met starting baseline g dl subject apl saw average increase g dl week soliris g dl decline resulting difference statistically significant p apl carrying generic name pegcetacoplan inhibits complement c lie upstream c target soliris ultomiris rationale behind development lie fact pnh patient continue experience low haemoglobin level despite treatment c inhibitor however despite resounding primary endpoint win apellis appeared cautious analyst call yesterday saying needed talk regulator determining next step two obvious reason caution firstly apl side effect troubling apl subject injection site reaction diarrhoea versus respectively soliris though apl result le haemolysis soliris discontinuation apellis project higher secondly apl performance secondary measure somewhat patchy instance apl failed hit non inferiority versus soliris normalising lactate dehydrogenase level marker reduced haemolysis pnh though might patient censoring soliris cohort importantly however ultomiris boast non inferiority soliris measure come dosing advantage every eight week maintenance phase versus soliris every two week pegasus apl dosed every three day data good enough u filing apl potential hinge apellis ability break highly competitive market well label expansion sellside forecast low key evaluatepharma see consensus revenue versus bn bn soliris ultomiris respectively apellis investor point fact area ripe deal making alexion tie ups achillion synthimmune affibody ucb takeout ra demonstrate pegasus data put apellis acquisition frame company might worry selling apl cash injection strengthen hand negotiation\n",
      "\n",
      "Keywords:\n",
      "apl 0.564\n",
      "soliris 0.482\n",
      "apellis 0.322\n",
      "pnh 0.161\n",
      "pegasus 0.161\n",
      "alexion 0.157\n",
      "ultomiris 0.143\n",
      "dl 0.097\n",
      "head 0.076\n",
      "haemoglobin level 0.075\n",
      "alexion soliris 0.075\n",
      "every 0.075\n",
      "haemoglobin 0.065\n",
      "ucb 0.063\n",
      "ra 0.063\n",
      "highly competitive 0.059\n",
      "non inferiority 0.057\n",
      "inferiority 0.056\n",
      "maintenance 0.053\n",
      "versus 0.053\n",
      "\n",
      "Abstract:\n",
      "spectacular end year biotech stock helped generate several clear winner among world small drug maker across broad geographical spread best performing company really stand major region represented top five gainer go sector laggard failure disappointment brought company japan sumitomo dainippon nektar u irlab sweden third quarter global stock market rally helped many index exit year high prevailing story heading helped four drug maker vantage mid cap space market cap bn start double value last year daiichi sankyo represented huge bn appreciation value seattle genetics galapagos sino bio capitalised way bn true several gain accompanied clinical regulatory advance breast cancer progress boosted seattle daiichi example galapagos benefited huge collaboration gilead frothy market condition certainly detected towards end last year investor must consider whether rally continue opening week seen pullback understandable given certain global event approaching jp morgan healthcare conference start next week crucial help set tone notable even worst performer among mid cap avoided calamity previous year seen much severe decline category sumitomo lead laggard japanese group laid low early year failure stroke broad deal roivant yet reignite much investor excitement problem manufacturing site continue dog several indian generic maker aurobindo particular israeli giant teva continues struggle financial woe broad compression price generic market making life hard many player segment nektar hurt flagging confidence lead cytokine asset stand rare u faller typical u biotech notably benefited market rally company based america dominate list small cap riser frothy aspect market really seen kodiak arrowhead example long way go prove worth respective project though latter boosted dealmaking rnai space medicine company takeout novartis example deal gone stock sitting gain year target group removed ranking arqule synthorx whose takeout merck co sanofi respectively yet close stock faller usual populated company blighted clinical failure though several managing struggle novavax example pushing flu candidate failure rsv project caused stock crater earlier aptinyx trading cash failure pain asset four follow project mid stage trial sweden irlab astonishingly pulled right issue december fund development parkinson disease therapy irl failure caused company share plunge earlier year sign competitive nature duchenne muscular dystrophy space solid wave doldrums setback respective contender muscle wasting condition investor deserted solid year gene therapy hit clinical hold fell behind competitor wave crashed december abandoning exon skipping approach back disappointing data\n",
      "\n",
      "Keywords:\n",
      "failure 0.16\n",
      "rally 0.159\n",
      "market rally 0.13\n",
      "frothy 0.13\n",
      "example 0.128\n",
      "helped 0.123\n",
      "stock 0.119\n",
      "mid cap 0.119\n",
      "cap 0.118\n",
      "maker 0.117\n",
      "broad 0.117\n",
      "sumitomo 0.115\n",
      "laggard 0.115\n",
      "represented 0.108\n",
      "nektar 0.106\n",
      "several 0.105\n",
      "market 0.103\n",
      "benefited 0.103\n",
      "daiichi 0.099\n",
      "wave 0.098\n",
      "\n",
      "Abstract:\n",
      "keytruda domination anti pd l market sometimes seems comprehensive surprising see flunk clinical trial yesterday happened keynote study failing show overall survival benefit first line small cell lung cancer setback seems particularly galling two competitor desperate pursuit keytruda roche tecentriq astrazeneca imfinzi already succeeded tumour type disparity already seen one bank turn scientific paper answer citing retrospective analysis published jama leerink argued tumour characterised poor pd l expression le fit patient sclc one evidence pd l inhibitor like tecentriq imfinzi work better pd targeting drug like keytruda yesterday disclosure keytruda failed keynote earlier failure bristol myers squibb opdivo checkmate appear back hypothesis le sophisticated view hold pd drug overall better pd l though massively skewed timing study readout ecentriq already approved first line sclc basis impower trial last year imfinzi matched result caspian study world lung astra achievement sclc unlikely game changer september anti pd l drug showed month median overall survival yielding around reduction risk death versus chemo alone keynote absolute survival benefit disclosed merck said relative reduction risk death insufficient hit statistical significance statistical benefit progression free survival keynote co primary endpoint unlikely enough approval given availability tecentriq imfinzi caspian result merck stock morning irrespective first line failure keytruda retains third line sclc label backing remission rate seen keynote study front line development likely little relevance pharmamar zepsyre recently filed second line sclc licensed jazz hard gauge much keytruda lose sale evaluatepharma sale indication consensus forecast show revenue coming sclc clear much comprises first line use keytruda next significant test keynote readout first line triple negative breast cancer\n",
      "\n",
      "Keywords:\n",
      "sclc 0.363\n",
      "keynote 0.239\n",
      "keytruda 0.236\n",
      "pd 0.229\n",
      "line sclc 0.181\n",
      "line 0.176\n",
      "imfinzi 0.17\n",
      "first line 0.157\n",
      "survival 0.12\n",
      "tecentriq 0.116\n",
      "caspian 0.116\n",
      "pd drug 0.109\n",
      "reduction risk death 0.106\n",
      "risk death 0.099\n",
      "keynote study 0.096\n",
      "survival benefit 0.092\n",
      "reduction risk 0.088\n",
      "overall 0.086\n",
      "anti pd 0.084\n",
      "first 0.079\n",
      "\n",
      "Abstract:\n",
      "big cap biopharma landscape largely shaped u pre election fear tightening drug pricing however unrealistic scenario actually real gain big pharma investor made backing group based side atlantic said far disaster big cap stock u included celebrated healthy double digit share increase perhaps extraordinary turnaround effected lilly end third quarter stood year date following three month put fact u group enjoyed fourth quarter comeback thus index nasdaq biotech p pharma dow jones pharma biotech either flat anaemic single digit three month ago roared back end gain respectively september lilly stock red two thing happened first selpercatinib posted impressive result ret driven lung cancer setting stage possible launch year allaying fear company bn purchase loxo oncology priced biogen pulled alzheimer disease rabbit hat claiming aducanumab actually succeeded two pivotal trial vowing send regulator data look dubious u fda seen soft touch rekindled hope lilly amyloid beta mab solanezumab brought back dead overall however year belonged trio eu based big cap stock astrazeneca driven oncology drug tagrisso lynparza roche propelled ocrevus hemlibra novartis last remained aggressive asset buyer zolgensma look marketed product several false start mark gene therapy coming age debit side pfizer remained big pharma worst performing stock driven concern corporate strategy lowered full year forecast abbvie like lilly saw major fourth quarter recovery finishing standing end third quarter measure strong finish next worst performing big cap stock johnson johnson actually year eastern dominance among large biopharma company outside big cap sphere meanwhile based west continued dominate jiangsu hengrui position oncology seeing company emerge one china popular healthcare pick chugai majority owned roche reaping reward swiss group hemlibra success bottom table regeneron continued suffer imminent erosion eylea franchise gilead unable shake question lack business development nous worst performer stock category actually biogen given think aducanumab headed u approval year outcome might seem puzzling however biogen shock claim amyloid beta mab actually work stock trading year company flat performance represents erasing loss aducanumab initially occasioned whether turnaround viable rest lap fda one biggest upcoming event\n",
      "\n",
      "Keywords:\n",
      "big cap 0.261\n",
      "cap stock 0.21\n",
      "big cap stock 0.21\n",
      "actually 0.182\n",
      "stock 0.168\n",
      "cap 0.149\n",
      "aducanumab 0.145\n",
      "big 0.145\n",
      "worst 0.133\n",
      "end third quarter 0.131\n",
      "end third 0.131\n",
      "lilly 0.129\n",
      "biogen 0.127\n",
      "hemlibra 0.12\n",
      "amyloid beta 0.12\n",
      "driven 0.108\n",
      "amyloid 0.107\n",
      "pharma 0.106\n",
      "quarter 0.105\n",
      "flat 0.102\n",
      "\n",
      "Abstract:\n",
      "welcome weekly roundup approaching clinical readout july karopharm xpovio approved multiple myeloma basis phase ii storm trial tiny last chance setting karyopharm rollercoaster end selinexor approval july upcoming readout phase iii study boston earlier line treatment allow drug expansion much larger population boston testing xpo inhibitor adult relapsing remitting multiple myeloma received one two three prior regimen around patient u according leerink analyst population xpovio already approved patient refractory least two proteasome inhibitor least two immunomodulatory drug anti cd mab amount around boston enrolled subject pit xpovio plus velcade dexamethasone control group given latter two compound control patient cross xpovio combo arm objective disease progression confirmed primary endpoint progression free survival month toxicity major focus storm patient fatal adverse event approval came anyway since setting intractable earlier line therapy justification harder use boston hit leerink think add xpovio u sale sellside consensus compiled evaluatepharma forecast worldwide revenue xpovio though includes sale non hodgkin lymphoma soft tissue sarcoma risk boston show product safety profile markedly worse expected approval granted july withdrawn would highly unusual step fda particularly given recent positive inclination cannot ruled entirely worth meanwhile pfizer shortly find whether spent akcea ionis akcea angptl lrx worth proof concept phase ii trial subject type diabetes high triglyceride non alcoholic fatty liver disease soon yield data project ligand conjugated antisense oligonucleotide aim reduce production liver angiopoietin like protein angptl key regulator triglyceride cholesterol glucose energy metabolism elevated level protein associated increased risk heart attack thickening arterial wall multiple metabolic disorder phase ii study testing three subcutaneous dos akcea angptl lrx versus placebo primary endpoint percentage change fasting triglyceride baseline month six secondary endpoint including change liver fat phase ii study project demonstrated dose dependent reduction angptl highest dose concomitant decrease triglyceride reduction ldl cholesterol total cholesterol along positive safety profile including significant platelet count reduction pfizer bought right october ionis akcea ionis majority owned subsidiary shared front fee ionis received akcea stock increasing stake subsidiary company interested angptl regeneron evinacumab target protein phase iii study homozygous familial hypercholesterolemia showed reduction ldl cholesterol baseline versus placebo filing antibody expected mid arrowhead aro ang rnai therapy phase ii healthy volunteer data showing mean maximum reduction baseline triglyceride ldl c single dose data multi dose cohort patient non alcoholic fatty liver disease hyperlipidemia statin familial hypercholesterolemia severe hypertriglyceridemia expected year pivotal trial planned\n",
      "\n",
      "Keywords:\n",
      "xpovio 0.302\n",
      "angptl 0.269\n",
      "boston 0.252\n",
      "akcea 0.252\n",
      "triglyceride 0.215\n",
      "ionis 0.16\n",
      "cholesterol 0.151\n",
      "ldl 0.113\n",
      "liver 0.112\n",
      "reduction 0.109\n",
      "reduction ldl 0.101\n",
      "fatty liver disease 0.101\n",
      "fatty liver 0.101\n",
      "familial 0.096\n",
      "phase 0.092\n",
      "subsidiary 0.092\n",
      "fatty 0.092\n",
      "july 0.09\n",
      "phase ii 0.086\n",
      "ldl cholesterol 0.086\n",
      "\n",
      "Abstract:\n",
      "many time christmas new year represents dead period financial market mostly remain open stock moving event happen thus holiday period ended saw google health axsome therapeutic celebrate clinical trial win much worse fate awaited wave life science spectrum pharmaceutical found holiday period notwithstanding way bury negative clinical trial readout january september deepmind previously success using artificial intelligence analyse ophthalmological image incorporated google health resulting group published data showing using google health algorithm analyse mammogram good human analysis ai system used identify tumour mammogram woman known cancer status using standard u diagnostic criterion software significantly superior radiologist finding reducing false positive false negative using stringent uk diagnostic pathway mammogram assessed two radiologist reduction false positive negative respectively significant non inferiority much testing necessary incorporated clinical practice mammogram came hologic machine real world source would much diverse performance slip moreover since ai system intended learn improve time would crucial monitor system performance ensure get better least deteriorate december wound close axsome therapeutic phase iii momentum trial triptan nsaid combo ax hit two primary endpoint beating placebo alleviating migraine symptom two hour administration might well good enough approval unclear whether hit emphatic enough justify doctor using drug well co primary hit company said ax superior rizatriptan moseic meloxicam component drug measure total pain freedom hour post dose easier measure two hour cutoff particularly since momentum intended prove ax worth acute treatment separate published data merck co branded rizatriptan maxalt show rate pain freedom two hour much higher ax though might easier treat population axsome intends file ax second half next year meanwhile wave life science fell last chance ending year positive note evaporated result precision hd trial wve huntington disease second shoe drop december group canned development suvodirsen duchenne muscular dystrophy wave crash duchenne data disappoint december huntington setback especially damning throw question wave stereopure antisense oligonucleotide concept study theoretically succeeded showing reduction mutant huntingtin mhtt protein inferior greater mhtt knockdown roche ionis achieving rg wave remaining hope dial wve dose raising two concern firstly analysis us back dose response relationship precision hd look questionable secondly still remains risk dialling toxicity eliminating therapeutic window might exist december spectrum pharmaceutical looked good shot targeted approach hard treat lung cancer niche inhibitor poziotinib first test spectrum shift november unravelled boxing day spectrum crashed failure cohort zenith study previously treated nsclc patient egfr exon insertion mutation intent treat analysis showed objective response rate missing threshold success data cohort expected year december finally christmas acasti pharma delayed readout trilogy fish oil project capre meaning capre study yield data month acasti play catch amarin vascepa november might represent minor delay fearing hint greater problem shareholder sent company\n",
      "\n",
      "Keywords:\n",
      "ax 0.227\n",
      "mammogram 0.22\n",
      "wave 0.193\n",
      "spectrum 0.172\n",
      "two hour 0.155\n",
      "google 0.155\n",
      "false 0.155\n",
      "hour 0.15\n",
      "axsome 0.136\n",
      "december 0.13\n",
      "using 0.126\n",
      "rizatriptan 0.103\n",
      "pain freedom 0.103\n",
      "freedom 0.103\n",
      "wve 0.098\n",
      "wave life science 0.098\n",
      "wave life 0.098\n",
      "precision 0.098\n",
      "hd 0.098\n",
      "capre 0.098\n",
      "\n",
      "Abstract:\n",
      "quiet period christmas new year saw several development corporate regulatory front morphosys immunomedics beigene giving respective investor reason cheer holiday period got way astellas found time complete one acquisition qiagen investor meanwhile company might spoiled festive cheer december new year celebration get way pharming slipped news deal sobi covering ruconest scrapped pay sobi get right back sobi held ruconest right eu actually u trouble brewing complete response letter key label extension valeant held ruconest right u handed back pharming shoe drop pharming september better news morphosys met promise file tafasitamab relapsed refractory lymphoma end spotlight fall tafasitamab december shortly group started study target much larger first line opportunity immunomedics got june pdufa date long suffering sacituzumab govitecan triple negative breast cancer fda accepted filing resubmission following jan complete response letter u regulator wipe smile immunomedics face january december beigene tislelizumab approved china rd line classical hodgkin lymphoma becoming seventh anti pd l mab get nod country far behind competition yet secured u approval prevented drug attracting bn sale forecast according evaluatepharma higher merck kgaa pfizer bavencio december content bn purchase gene therapy player audentes early december astellas pharma boxing day picked another group hot technology time car front japanese group takeout xyphos bioscience much smaller audentes deal befits company project clinical development xyphos technology based engineering nkg receptor found mainly natural killer cell make inert activation come antibody designed bind receptor tumour antigen resulting immune cell bearing car like construct directed tumour xyphos call modular approach convertible car cell advanced candidate scheduled start first human study presumably triggering milestone payment deal interest especially celyad belgian group pursuing nkg based car approach december market close december qiagen took auction block diagnostics group tricky time towards end year said entertaining several buyout offer buy qiagen november say none bid good enough remain standalone business prompting share fall qiagen management intend get underperforming unprofitable business back foot unclear certainly qiagen lost cause top line forecast grow healthy annually take time effort turn ship around investor cannot blamed disappointed quick easy answer denied\n",
      "\n",
      "Keywords:\n",
      "qiagen 0.299\n",
      "december 0.223\n",
      "xyphos 0.201\n",
      "sobi 0.188\n",
      "ruconest 0.188\n",
      "pharming 0.188\n",
      "car 0.146\n",
      "immunomedics 0.139\n",
      "nkg 0.126\n",
      "tafasitamab 0.12\n",
      "morphosys 0.115\n",
      "audentes 0.115\n",
      "get 0.106\n",
      "beigene 0.098\n",
      "astellas 0.089\n",
      "group 0.087\n",
      "right 0.086\n",
      "complete 0.086\n",
      "response letter 0.084\n",
      "complete response letter 0.084\n",
      "\n",
      "Abstract:\n",
      "many european investor begin looking beyond advanced project like car therapy cell engaging antibody modality instead focus simple naked antibody tafasitamab anti cd mab engineered fc fragment represents morphosys attempt taking project way market asset hefty expectation behind evaluatepharma sellside consensus seeing sale track filed year lead indication diffuse large b cell lymphoma combination revlimid ongoing study key unlocking full potential study b mind compare morphosys project head head rituxan cohort getting bendamustine backbone november morphosys closed sellside celebrated fact b mind passed interim futility analysis rolling filing meanwhile rolling u bla initiated le important setting morphosys yet announce whether filing completed aim end basis filing l mind mind study former single arm trial testing tafasitamab plus revlimid latter separate test designed solely act l mind synthetic control use synthetic control unusual way getting around fact efficacy term morphosys currently armed single cohort trial regulator view awaited company argues worked hard ensure mind comprises comparable patient cohort simply way present l mind result light favourable tafasitamab possibly important point concern use revlimid combination drug revlimid main use multiple myeloma drug approved mantle cell lymphoma follicular lymphoma combination rituxan year mean standard care bottom line therefore tafasitamab secure initial approval basis l mind use might amount much term sale b mind important optimistic ever morphosys successfully win approval tafasitamab execute robust commercial launch proceed extend tafasitamab label additional indication gushed berenberg analyst recently however simple importantly performing futility analysis data monitoring board recommended enrolment b mind increased subject rarely good sign suggesting benefit marginal rendering trial underpowered original design moreover second change proposed b mind earlier year morphosys implemented additional biomarker based co primary analysis trial specific biomarker agreed regulator low baseline nk cell count peripheral blood interpreted sign tafasitamab struggling show effect comer population morphosys giving two shot goal perhaps resulted b mind lacking power analysis recruitment increased either way investor clear game plan tafasitamab much morphosys bn valuation riding\n",
      "\n",
      "Keywords:\n",
      "mind 0.492\n",
      "morphosys 0.423\n",
      "tafasitamab 0.392\n",
      "revlimid 0.168\n",
      "lymphoma 0.1\n",
      "synthetic 0.098\n",
      "futility analysis 0.094\n",
      "rolling 0.091\n",
      "cell lymphoma 0.091\n",
      "simple 0.088\n",
      "futility 0.088\n",
      "cell 0.084\n",
      "way 0.08\n",
      "rituxan 0.077\n",
      "use 0.076\n",
      "analysis 0.075\n",
      "filing 0.07\n",
      "biomarker 0.069\n",
      "combination 0.067\n",
      "cohort 0.065\n",
      "\n",
      "Abstract:\n",
      "christmas came early astrazeneca daiichi friday surprise approval company breast cancer drug enhertu antibody drug conjugate due decision april join impressive list quick decision u regulator including seattle padcev antibody drug conjugate bladder cancer vertex trikafta november alone saw five drug get approved early enhertu known generically trastuzumab deruxtecan granted accelerated approval showing response rate phase ii destiny breast trial striking efficacy heavily pretreated breast cancer patient drug however come black box warning interstitial lung disease label cite rate fatality pooled safety database patient question whether toxicity signal hold back use earlier stage patient ambitious sale forecast currently sit bn according evaluatepharma analyst said peak sale reach bn depend drug performance earlier setting phase iii trial currently underway including destiny breast herceptin chemotherapy progressed roche kadcyla ringing looking next year epizyme troubled epitheliod sarcoma drug tazemetostat likely get approved gaining universal endorsement advisory panel december drug plagued safety concern led previous clinical hold panel seemed put bed leerink analyst noting potential risk secondary malignancy appeared minimal concern panellist fda despite limited phase ii data showing relatively modest response rate epitheliod sarcoma panel considered proportion duration response clinically meaningful serious lack approved therapy play tazemetostat favour though confirmatory trial expected epizyme recently filed drug relapsed refractory follicular lymphoma larger opportunity another positive advisory committee came aimmune palfozia september although investor opinion mixed question remain long term benefit particularly versus peanut avoidance prospect palfozia hard call critical report cost watchdog icer concluded project likely expensive ramification drug commercial potential rimegepant odt biohaven fast acting oral dissolving tablet formulation known zydis odt due decision acute migraine come hot heel allergan offering ubrogepant due regulatory decision day zydis odt said start working minute traditional pill formulation known rimegepant filed decision due middle analyst placed bet biohaven project sale forecast reach rimegepant franchise versus ubrogepant supplemental approval due novo double whammy early next year decision cardiovascular risk reduction indication rybelsus ozempic based pooled data pioneer sustain study trial found respective reduction major adverse cardiovascular event product versus placebo pioneer showed non inferiority superiority sustain include prespecified superiority analysis hence pooling data therefore far clear whether either drug get cardiovascular go ahead novo might wait data bigger cardiovascular outcome trial patient soul study rybelsus began earlier year imfinzi move first line small cell lung cancer latest regulatory decision however unlikely unseat roche tecentriq go treatment imfinzi caspian trial showed month overall survival combined chemotherapy comparable tecentriq approved setting march meanwhile another competitor fast approaching data due day merck keytruda keynote study real threat tecentriq crown keytruda time high risk non muscle invasive bladder cancer unresponsive bacillus calmette guerin therapy panel december largely positive concern efficacy phase ii keynote study showed three month complete response rate median duration month one year initial responder remained responsive representing patient included efficacy analysis bar recommended international bladder cancer group merck currently running confirmatory trial called keynote given green light january keytruda would first pd l approved setting fda recent flurry early approval likely list see addition depth look expect next year check vantage preview free download\n",
      "\n",
      "Keywords:\n",
      "decision 0.164\n",
      "drug 0.139\n",
      "panel 0.138\n",
      "bladder cancer 0.129\n",
      "bladder 0.129\n",
      "rimegepant 0.126\n",
      "odt 0.126\n",
      "breast 0.119\n",
      "cancer 0.112\n",
      "cardiovascular 0.109\n",
      "due 0.109\n",
      "ubrogepant 0.101\n",
      "sustain 0.101\n",
      "epizyme 0.101\n",
      "pioneer 0.096\n",
      "get approved 0.096\n",
      "destiny breast 0.096\n",
      "approved setting 0.096\n",
      "keynote 0.094\n",
      "approved 0.093\n",
      "\n",
      "Abstract:\n",
      "sarepta bull proved right tune billion dollar morning deal roche pay front make equity investment exchange ex u right group microdystrophin gene therapy biggest single asset ex u license biopharma history conference call today sarepta management refused say whether swiss group advance peek data ongoing phase ii trial srp perhaps roche felt jump sarepta conducted bidding war duchenne muscular dystrophy project several company vying asset sale forecast reaching well billion sarepta reckons deal ultimately net bn fairly simple math contends based upfront cash bn milestone mid teen royalty net sale outside u roche side help push market reach say china roche investor might wonder whether company calculation add sum currently forecast srp put sale excess bn according consensus compiled evaluatepharma bn u far far drug shown promise four patient phase trial srp led microdystrophin expression level three month enrolment phase ii trial close completion blip safety caused brief alarm summer sarepta seems weathered squall fact srp safety look better rival duchenne gene therapy pfizer solid bioscience two six patient treated pfizer pf experienced toxicity one suffering acute kidney injury leading phase trial halted solid phase ii study sgt halted last month swathe adverse event another dystrophy catastrophe solid bioscience november current trial subsequent development remain sarepta control despite srp development cost shared equally manufacturing within sarepta purview group say expect meaningfully expand capacity couple year roche control pricing asset outside u obtaining reimbursement assuming make far doug ingram sarepta chief executive officer cautioned expectation licensing deal indeed business development effort despite vast newfound cash pile sarepta cheerleader hard satisfy justifiably far keenest wondering company bought\n",
      "\n",
      "Keywords:\n",
      "sarepta 0.5\n",
      "srp 0.333\n",
      "microdystrophin 0.133\n",
      "solid 0.132\n",
      "roche 0.131\n",
      "dystrophy 0.104\n",
      "duchenne 0.104\n",
      "halted 0.102\n",
      "ex 0.1\n",
      "net 0.098\n",
      "bioscience 0.097\n",
      "far 0.092\n",
      "phase 0.087\n",
      "phase trial 0.086\n",
      "billion 0.086\n",
      "outside 0.084\n",
      "say 0.081\n",
      "gene therapy 0.076\n",
      "deal 0.075\n",
      "bn 0.075\n",
      "\n",
      "Abstract:\n",
      "roche finally got bn acquisition spark therapeutic finishing line week without sell asset conclusion federal trade commission month investigation without condition tempt potential buyer gene therapy asset back market astellas pharma bn play audentes theapeutics earlier month showed definite interest pharma group wishing add new technology pipeline far year acquirer spent bn product holding promise one done treatment seeming willingness regulator approve novel gene therapy product helped drive interest spark deal done audentes taken board investor speculation inevitably turned might might next like rocket therapeutic regenexbio seeing share rise wake audentes deal analysis look public private gene therapy company might ripe due diligence luxury end come speculation gene therapy space number name regularly crop amicus therapeutic bluebird bio uniqure among uniqure example one promising haemophilia b gene therapy form amt despite tested handful patient company achieved market cap bn anyone wishing make move might want ahead readout pivotal hope b trial end next year uniqure price tag look little rich even acquisition premium added plenty lower profile affordable gene therapy company public private astellas deal show company gene therapy manufacturing capability expertise demand abeona therapeutic meiragtx homology medicine oxford biomedica boast technology platform capable pumping project one oldest among oxford biomedica uk firm finally seeing decade long focus gene therapy bear fruit pipeline six clinical product collaboration sanofi novartis group provide lentiviral vector manufacturing group uk listing explain low looking market cap despite planned ramp ups production capability ironically one oxford biomedica client fellow uk gene therapy group orchard therapeutic managed outpace supplier valuation front u listed company boast six clinical product licensed asset strimvelis better gene therapy devil know technology platform always welcome deal activity likely focus popular therapy area ophthalmology neurology rare disease meiragtx count among bigger ophthalmology player new york based biotech currently capitalised boast substantial aav vector platform six clinical stage gene therapy meiragtx ability pump pipeline product already attracted attention big pharma johnson johnson opting license three ophthalmology project one company actively courting interest abeona effectively hung sale sign september group looking lot cheaper following slide share fda put clinical hold moving lead product eb phase iii september house manufacturing facility four clinical project might blunt buyer concern comfortable risk voyager therapeutic represent good punt company hitched gene therapy wagon central nervous system two product clinic parkinson disease given issue drug based treatment neurological condition gene therapy might potential solution notwithstanding significant challenge remain disease involve multiple gene biology often well understood list far exhaustive show gene therapy company might break bank wanting grab slice action remember considerable risk remain space duration effect treatment remains unknown example reimbursement question linger phrase caveat emptor seems pertinent\n",
      "\n",
      "Keywords:\n",
      "gene therapy 0.38\n",
      "gene 0.362\n",
      "therapy 0.222\n",
      "meiragtx 0.153\n",
      "ophthalmology 0.136\n",
      "gene therapy company 0.136\n",
      "oxford biomedica 0.131\n",
      "biomedica 0.131\n",
      "audentes 0.131\n",
      "product 0.129\n",
      "therapeutic 0.122\n",
      "uniqure 0.119\n",
      "therapy company 0.116\n",
      "platform 0.104\n",
      "oxford 0.102\n",
      "boast 0.101\n",
      "wishing 0.095\n",
      "public private 0.095\n",
      "abeona 0.095\n",
      "might 0.084\n",
      "\n",
      "Abstract:\n",
      "welcome weekly roundup approaching clinical readout coming week tg therapeutic unveil survival data unity cll trial readout became harder handicap company controversially rowed back conducting overall response analysis last year time tg executive claimed data sufficiently mature take look orr though concern raised trial actually drawn blank dose reality tg therapeutic kick road september unity cll study pit ublituximab umbralisib tg two experimental project respectively anti cd antibody pi k delta inhibitor roche gazyva chemo chlorambucil patient treated untreated chronic lymphocytic leukaemia recruited progression free survival primary endpoint tg said result appear late early tg really failed see difference orr last year disappointment horizon survival tends closely correlated response gazyva label cite median pfs month versus month control orr front line patient around unity cll subject thought front line tg previously suggested median number beat month first line month relapsed cll concern include unique strategy testing two unproven agent together pivotal trial tg received fda blessing design rule possibility regulatory hold ups road result provide clear evidence efficacy toxicity closely watched front line refractory patient enrolled would seem potential tg seek relevance subgroup significance hit total trial population waiting long investor hoping water muddied risky business phase ii willow trial insmed in non cystic fibrosis bronchiectasis data expected coming quarter high risk high reward play project reversible inhibitor dipeptidyl peptidase fate agent reach clinic make comforting reading glaxosmithkline forced abandon development gsk first human study revealed unexpected toxicity epidermal desquamation skin peeling patient hand foot in avoided earlier trial phase showing good tolerability must still prove worth larger patient population bronchiectasis characterised pathological dilation airway diagnosed radiographically since condition clinical presentation vary widely heterogeneity main reason difficulty achieving endpoint clinical trial dpp catalysis activation neutrophil serine protease drive chronic inflammatory lung disease insmed licensed in astrazeneca front host milestone royalty payment willow testing small molecule daily pill either mg mg taken six month versus placebo primary endpoint time first pulmonary exacerbation company believed seeking delta treatment placebo arm insmed management acknowledged clear effectiveness signal may prove elusive owing differing sign symptom seen bronchiectasis data mixed little point company pursuing in given non cf bronchiectasis already overlap nontuberculous mycobacterial lung infection insmed still capture sizeable proportion patient marketed inhaled antibiotic arikayce possibly trickiness showing benefit disease forecast in modest according evaluatepharma consensus data trial hit expect increase sharply indeed insmed stock\n",
      "\n",
      "Keywords:\n",
      "tg 0.46\n",
      "insmed 0.287\n",
      "bronchiectasis 0.23\n",
      "cll 0.175\n",
      "unity cll 0.153\n",
      "unity 0.153\n",
      "tg therapeutic 0.102\n",
      "month versus 0.098\n",
      "gazyva 0.098\n",
      "orr 0.092\n",
      "trial 0.091\n",
      "front line 0.09\n",
      "front 0.087\n",
      "road 0.086\n",
      "delta 0.084\n",
      "survival 0.076\n",
      "patient 0.076\n",
      "month 0.075\n",
      "line 0.074\n",
      "closely 0.065\n",
      "\n",
      "Abstract:\n",
      "biopharma braced rocky ride rhetoric around drug pricing going increase u presidential election get closer keeping sector already unpopular voter spotlight political gridlock mean u lawmaker expected agree new measure time soon clear cost medicine remain live issue next year likely translate volatile time stock market ipo window expected completely close next year equity investor probably going receptive venture investor adopt prudent stance towards financing particularly start look like fund need last longer using depth analysis recent ipo venture financing activity well interview market participant vantage preview look activity heading next using evaluatepharma data report pinpoint sector biggest sale growth driver next year highlight company capturing growth certain mechanism action projected add billion dollar extra revenue surprisingly brake biopharma top line prize guessing cancer drug feature prominently report identifies highly valued r project clinical programme consuming huge amount money along biggest new medicine reach market analysis describe sector closely tracked asset reader take glimpse area investment vital intelligence company business development decision make investor back effort november market rally mean biotech sector heading towards triumphant finish whether maintained much longer dominant question investor mind download free copy report\n",
      "\n",
      "Keywords:\n",
      "sector 0.223\n",
      "heading 0.164\n",
      "report 0.155\n",
      "next year 0.149\n",
      "next 0.146\n",
      "venture 0.144\n",
      "financing 0.143\n",
      "towards 0.126\n",
      "ipo 0.122\n",
      "growth 0.12\n",
      "investor 0.117\n",
      "medicine 0.114\n",
      "going 0.112\n",
      "market 0.112\n",
      "longer 0.108\n",
      "market rally 0.105\n",
      "using 0.103\n",
      "volatile 0.1\n",
      "venture financing 0.1\n",
      "start look 0.1\n",
      "\n",
      "Abstract:\n",
      "recent flurry u clinical hold might excused thinking setback rise fact data past three year bear view show however alarming increase number hold imposed specifically gene therapy simply reflect increased work novel approach versus three year ago inescapable fact hold imposed gene therapy increased one four last year eight far includes repeat offender notably solid whose clinical hold sgt investor reminded week remarkably solid third clinical hold yesterday group played fact adverse event led resolved two earlier subject seeing microdystrophin expression potentially supportive therapeutic benefit duchenne muscular dystrophy however hold remains place analyst call solid would give guidance might lifted investor deal separate question far microdystrophin expression level sgt yielding lagged solid rival sarepta analysis past three year hold carried using evaluatepharma way database search disclosure made biopharma group press release quarterly report sec filing well reported story published vantage list might exhaustive though present accurate picture likely omits work way academia private company naturally lower disclosure burden traded public market risk search missed announcement specifically mention phrase clinical hold indeed listed biotech even disclosed information inexplicable decision given market sensitive nature setback possibility illustrated recent hold imposed regenxbio abeona marker therapeutic last involving gene therapy sat fda notification clinical hold week famously perhaps solid initially disclose clinical hold trying complete nasdaq flotation dmd day investor january company choosing reveal clinical hold quarterly sec filing respond fda imposition hold anything absolute number clinical hold place might higher\n",
      "\n",
      "Keywords:\n",
      "hold 0.487\n",
      "clinical hold 0.451\n",
      "solid 0.218\n",
      "clinical 0.158\n",
      "sgt 0.132\n",
      "microdystrophin expression 0.132\n",
      "microdystrophin 0.132\n",
      "three year 0.124\n",
      "past three year 0.12\n",
      "sec filing 0.116\n",
      "search 0.113\n",
      "gene therapy 0.112\n",
      "past three 0.107\n",
      "sec 0.105\n",
      "quarterly 0.105\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "disclosure 0.101\n",
      "gene 0.1\n",
      "expression 0.093\n",
      "fact 0.084\n",
      "increased 0.081\n",
      "\n",
      "Abstract:\n",
      "red hot therapy area nash mired clinical setback week added two disappointment today boehringer ingelheim canned one many deal space two day gilead revealed multi project atlas study failed true gilead setback great surprise separate positive development poxel today claimed early clinical nash win riskiest bet remains genfit whose future hang balance crucial pivotal study elafibranor due yield result early next year though genfit bullish retail follower remain convinced success resolve trial industry numerous nash failure contributed french group stock declining year date cymabay genfit band play november fear interaction latest boehringer aoc inhibitor bi german group today discontinued nash owing risk drug drug interaction decision taken spite ostensibly positive phase iia trial based assessment another recently completed phase study boehringer said group licensed bi pharmaxis front part push nash saw sign alliance yuhan dicerna mina unlikely boehringer enthusiasm space burn brightly year ago said gilead another company tried buy way nash latest quarterly update barely mentioned therapy area seems gilead new chief executive daniel day share commitment nash predecessor especially given year failure gilead ask inhibitor selonsertib sign atlas study likely fail fear confirmed monday gilead said none three combination tested atlas hit primary endpoint proportion patient achieving stage improvement fibrosis without worsening nash trial exploring combination selonsertib acc inhibitor firsocostat cilofexor fxr agonist echoing earlier finding promising reading emerged arm testing firsocostat plus cilofexor patient cohort demonstrated significant improvement various fibrosis measure liver function whether gilead considers signal strong enough justify work unclear safety something consider regimen caused rate mild moderate pruritus patient experienced big jump triglyceride level known issue acc inhibitor pfizer candidate class pf caused patient experience hypertriglyceridemia revealed aasld taking shine dramatic impact liver fat developer adding fenofibrates combination ameliorate target effect probably gilead focus turn last month company added vascepa plus firsocostat plus cilofexor arm separate phase ii study another cohort includes fenofibrate combination result due later early win backdrop positive development welcome one provided today french group poxel said pxl showed acceptable pharmacokinetic profile phase led decide week phase ii study biopsy proven nash start next year however pxl merely deuterium stabilised stereoisomer takeda ill fated diabetes treatment actos toxicity ppar agonist glitazone drug led contraindication poxel point dog study backing pxl improved safety actos detail interest genfit whose elafibranor ppar though targeting alpha delta subunit eliminates risk serious toxicity group fan argue either way debate settled imminent readout resolve last week yet another contender intercept revealed nash project ocaliva would likely face u advisory panel april delaying regulatory decision beyond march pdufa date priority review brought ocaliva widely expected receive grilling even chance nash drug seeing light day diminishing space hardly called dull\n",
      "\n",
      "Keywords:\n",
      "nash 0.36\n",
      "gilead 0.193\n",
      "boehringer 0.168\n",
      "firsocostat 0.158\n",
      "cilofexor 0.158\n",
      "genfit 0.156\n",
      "atlas 0.15\n",
      "selonsertib 0.105\n",
      "plus cilofexor 0.105\n",
      "firsocostat plus cilofexor 0.105\n",
      "firsocostat plus 0.105\n",
      "acc inhibitor 0.105\n",
      "bi 0.1\n",
      "french group 0.093\n",
      "acc 0.093\n",
      "combination 0.091\n",
      "ppar 0.09\n",
      "interaction 0.09\n",
      "study 0.085\n",
      "therapy area 0.084\n",
      "\n",
      "Abstract:\n",
      "glaxosmithkline failed secure late breaker belantamab mafodotin month ash conference investor today found likely reason data simply good enough result dreamm trial underwhelm versus earlier exploratory dreamm study fell well short rival multiple myeloma agent similar mechanism action inhibiting bcma antigen approach already hugely crowded yet undeterred glaxo today vowed complete regulatory filing belantamab belantamab antibody drug conjugate earlier yielded overall remission rate dreamm study subject failed least three prior line therapy ash saw multitude presentation rival bcma player yielding orr ash car bispecific antibody threat real december bad worse today however thing got even worse glaxo dreamm study belantamab filed yielded orr including rate complete remission group said bad enough serious instance keratopathy toxicity involving change eye corneal epithelium seen dreamm subject johnson johnson cartitude trial jnj instance detail keratopathy side effect gone badly wrong glaxo immediate finger blame pointed fact dreamm subject failed anti cd mab like darzalex represents particularly hard treat group today data suggest patient belantamab simply work well view confirmed thorough reading earlier dreamm data included darzalex progressed naive subject alike reveals important dichotomy previously treated cd mab orr belantamab yielded result illustrate glaxo j j orr result cartitude achieved despite fact study enrolees triple refractory meaning failed cd mab jnj car therapy look like efficacious anti bcma asset industry pipeline outside cell therapy direct threat glaxo bristol myers squibb anti bcma bispecific mab cc yielded orr study subject darzalex refractory making big surprise ash immediate competition glaxo come elsewhere bluebird bristol intend imminently file anti bcma car ide cel strength karmma study whose subject cd refractory evaluatepharma reveals bcma targeting industry project phase ii recent analysis bcma space bernstein identified car project six bispecifics two antibody drug conjugate two asset say glaxo work cut would putting mildly\n",
      "\n",
      "Keywords:\n",
      "dreamm 0.353\n",
      "bcma 0.301\n",
      "belantamab 0.284\n",
      "glaxo 0.277\n",
      "orr 0.157\n",
      "dreamm study 0.151\n",
      "ash 0.143\n",
      "darzalex 0.138\n",
      "anti bcma 0.135\n",
      "car 0.129\n",
      "cd 0.125\n",
      "yielded 0.124\n",
      "cd mab 0.122\n",
      "mab 0.112\n",
      "subject 0.109\n",
      "refractory 0.108\n",
      "cartitude 0.097\n",
      "yielded orr 0.092\n",
      "subject failed 0.088\n",
      "jnj 0.088\n",
      "\n",
      "Abstract:\n",
      "axsome already way one biopharma best performing biopharma stock year yesterday share price surge surely confirms company worth le start sport bn market value implying investor see blockbuster potential depression candidate ax certainly rare get two similarly positive outcome major depressive disorder disease foiled numerous project enthusiastic sellsiders describing ax potentially new standard care mdd however certain aspect axsome story worth remembering company valuation climb ever higher perhaps alarming investor concerned corporate governance issue axsome chief executive herriot tabuteau owns patent ax invented mr tabuteau assigned patent entity owns called antecip bioventures ii turn licensed axsome royalty arrangement fairly unusual company sec filing state cause conflict interest future dispute arise concern exist around nature ax proprietary formulation two generically available medicine buproprion active ingredient glaxosmithkline depression blockbuster wellbutrin cough medicine dextromethorphan axsome essentially pursuing old speciality pharma model largely eschewed high innovation combine two old well characterised generic drug try get market fast payer presumably opinion formulation whether blockbuster sale forecast really achieved sort product today aggressive reimbursement environment important question throw inevitably weaker patent position company protestation notwithstanding inconceivable ax disappoint commercially twin success regulatory risk seemingly minimal nowadays least axsome count friendly fda unless u agency dig hidden concern ax look reasonable chance reaching market yesterday company said placebo controlled gemini study succeeded significantly improving patient depressive symptom versus placebo hitting several secondary endpoint result remarkably similar phase ii ascend trial lit fire company stock january dextromethorphan ketamine like agent well hitting several target implicated neurological condition block nmda novel mechanism depression however like ketamine compound quick onset action buproprion come drug thought maintain dextromethorphan concentration providing complementary mechanism still notable axsome succeeded nmda targeting others failed year seen setback allergan rapastinel vistagen av alone ax similar mechanistically nuedexta avp two dextromethorphan combination developed avanir bought otsuka staggering bn neither project managed show effectiveness mdd argument ax presumably based belief dextromethorphan particular synergy buproprion avanir project combined quinidine act increase bioavailability dextromethorphan next big readout axsome trial called stride test ax treatment resistant depression versus bupropion extent real test matter debate company used questionable definition treatment resistance issue concern design study weed patient non responsive buproprion presumably flatter active cohort investor bought bull case far axsome long way go prove really worth nearly bn\n",
      "\n",
      "Keywords:\n",
      "axsome 0.417\n",
      "ax 0.417\n",
      "dextromethorphan 0.315\n",
      "buproprion 0.225\n",
      "depression 0.167\n",
      "mdd 0.105\n",
      "nmda 0.096\n",
      "blockbuster 0.095\n",
      "depressive 0.093\n",
      "patent 0.093\n",
      "owns 0.09\n",
      "presumably 0.081\n",
      "worth 0.077\n",
      "company 0.077\n",
      "succeeded 0.074\n",
      "old 0.073\n",
      "formulation 0.072\n",
      "hitting 0.067\n",
      "concern 0.066\n",
      "bought 0.062\n",
      "\n",
      "Abstract:\n",
      "today discontinuation novartis fevipiprant blow hole investment thesis behind gossamer bio like fevipiprant gossamer lead asset gb dp inhibitor targeting asthma issue fevipiprant failure severe asthma setting luster clinical programme measuring exacerbation one year gossamer argument fevipiprant october flop irrelevant come le sick patient market bought excuse causing group stock nearly double since surge today look foolhardy fevipiprant proxy gb evaluatepharma reveals litany dp inhibitor failed asthma discontinued including array arry boehringer bi novartis earlier qav astrazeneca azd coming today gossamer capitalised incredible bn morning stock tanked first fevipiprant first setback come pivotal zeal trial failed meet primary endpoint fev week subject moderate asthma today novartis said two remaining phase iii study severe uncontrolled asthma luster flopped measured exacerbation one year primary endpoint failure unequivocal neither mg mg fevipiprant dose worked despite data trial pooled swiss group said result contributed understanding dp pathway asthma ultimately support fevipiprant development indication gossamer gb expected sell according evaluatepharma sellside consensus bad news project phase ii leda trial moderate severe patient due read mid earlier study positive overall failed show dose response fevipiprant blow gossamer bull argued luster study would better indicate whether gb goer zeal thanks severe patient driving expected benefit leda today rhetoric change remain current one difference instance gossamer looking eosinophilic asthma whereas luster trial specified would include subset subject high eosinophil count gossamer primary endpoint composite including fev rescue medication use exacerbation indicate asthma worsening week else dp known crth prostaglandin receptor whose activation developer argue associated allergy inflammation clinical project still development targeting pathway include chiesi timapiprant acquired along atopix pulmagen teijin ptr idorsia act though last studied asthma nasal polyposis gossamer pulled highly successful nasdaq flotation february one reason investor stuck company october indicated zeal trial would likely fail today credibility suffered major sentiment knock back gossamer bull dp inhibitor developer alike would well take note\n",
      "\n",
      "Keywords:\n",
      "gossamer 0.482\n",
      "fevipiprant 0.434\n",
      "asthma 0.371\n",
      "dp 0.241\n",
      "luster 0.193\n",
      "gb 0.193\n",
      "exacerbation 0.129\n",
      "severe 0.094\n",
      "fev 0.09\n",
      "today 0.089\n",
      "indicate 0.086\n",
      "severe patient 0.08\n",
      "blow 0.08\n",
      "novartis 0.069\n",
      "one year 0.068\n",
      "moderate 0.062\n",
      "bull 0.062\n",
      "pathway 0.055\n",
      "would 0.054\n",
      "failed 0.053\n",
      "\n",
      "Abstract:\n",
      "welcome weekly roundup approaching clinical readout axsome sitting share price gain year making company worth impressive bn two catalyst due shortly company lead project ax shake thing data major depressive disorder mdd gemini study due year end result stride trial treatment resistant depression trd expected first quarter first gemini study test daily ax combination bupropion dextromethorphan versus placebo recruited mdd patient primary endpoint safety madrs clinician rated scale designed measure depression severity six week hope high given positive result earlier trial called ascend ax beat active control bupropion data sent axsome share stride meanwhile pit ax bupropion primary endpoint madrs six week aspect trial design raise question patient required inadequate response bupropion lead period since agent used active control trial design near certain way achieving zero response control group since bupropion ingredient ax non responsive bupropion seen detrimental treatment arm\n",
      "\n",
      "Keywords:\n",
      "bupropion 0.494\n",
      "ax 0.363\n",
      "mdd 0.165\n",
      "six week 0.157\n",
      "gemini study 0.157\n",
      "gemini 0.157\n",
      "axsome 0.145\n",
      "active control 0.145\n",
      "stride 0.137\n",
      "depression 0.131\n",
      "trial design 0.118\n",
      "control 0.117\n",
      "design 0.087\n",
      "active 0.085\n",
      "zero response 0.082\n",
      "dextromethorphan 0.082\n",
      "used active 0.078\n",
      "stride trial 0.078\n",
      "catalyst due 0.078\n",
      "six 0.077\n",
      "\n",
      "Abstract:\n",
      "roche tecentriq anti pd l antibody approval triple negative breast cancer extent checkpoint inhibitor play role disease remains unclear disappointing data small neoadjuvant trial underline fact tecentriq failed improve response rate chemotherapy announced today finding stand contrast keytruda success similar trial cross trial comparison always come caveat chemotherapy regimen differed case example investigator presenting result san antonio breast cancer symposium unsure patient responded differently two therapy tecentriq data come first look neotripapdl trial adding tecentriq neoadjuvant chemotherapy approximately six month resulted slightly higher rate pathologic complete response versus neoadjuvant chemo alone difference statistically significant academic study enrolled patient early high risk locally advanced inflammatory triple negative breast cancer chemo regimen trial carboplatin abraxane tecentriq already approved use abraxane patient locally advanced metastatic triple negative breast cancer similar keynote phase iii study neoadjuvant keytruda plus chemo followed adjuvant keytruda early triple negative disease merck checkpoint inhibitor yield significant improvement response chemo alone intriguingly keynote chemo arm responded higher rate neotripapdl control arm presenting neotripapdl data sabcs luca gianni fondazione michelangelo milan seemed suggest drug different pointed keytruda directed pd tecentriq bind receptor ligand end day interfere access pd pd l largely assumed mechanistically effect although subtle difference may subtle end day dr gianni said press conference worth noting chemo regimen different two trial keynote including another round chemotherapy post carboplatin abraxane presumably contributed higher response rate keynote control group well boosted response active arm pathologic complete response primary endpoint either trial merely considered surrogate long term outcome instead using event free survival main outcome measured five year neotripapdl full data due keynote event free survival measured approximately eight year clinicaltrials gov record say full data coming complicating picture still subgroup analysis keynote read positively merck blockbuster sabcs today among triple negative breast cancer patient whose cancer spread lymph node responded keytruda added chemo compared given chemo alone sellside see breast cancer much bigger opportunity keytruda tecentriq forecast sale indication bn former versus tecentriq however neoadjuvant use triple negative disease make fraction forecast perhaps important forthcoming readout keynote first line setting tecentriq first line breast cancer study impassion showed strong result pd l positive patient duly approved wider label eluded roche product esmo roche miss bullseye triple negative breast cancer october expected keytruda best tecentriq lastly impassion roche effort proving tecentriq worth neoadjuvant setting trial design different impassion focusing pathologic complete response comer pd l high patient without keynote focus event free survival trial chemo arm subtly different make hard certain two checkpoint inhibitor relative merit\n",
      "\n",
      "Keywords:\n",
      "tecentriq 0.277\n",
      "chemo 0.229\n",
      "triple negative 0.218\n",
      "keynote 0.208\n",
      "neoadjuvant 0.207\n",
      "breast cancer 0.198\n",
      "breast 0.196\n",
      "triple 0.177\n",
      "negative 0.168\n",
      "neotripapdl 0.166\n",
      "triple negative breast 0.156\n",
      "keytruda 0.153\n",
      "negative breast cancer 0.151\n",
      "negative breast 0.151\n",
      "cancer 0.138\n",
      "pd 0.128\n",
      "pathologic 0.124\n",
      "event free survival 0.124\n",
      "event free 0.124\n",
      "impassion 0.118\n",
      "\n",
      "Abstract:\n",
      "american society haematology conference final big medical meeting year data update help determine whether biopharma sector end year bang whimper former look likely thing currently stand ash saw notable progress reported closely watched field bispecifics targeted oncology handful deal related field announced period conference helping maintain biopharma rally started early october ash contain disappointment course though buoyant market condition helped contain loss extent meeting related stock sitting serious decline conference came close analysis track share price performance november ash abstract first released end conference december extensive period mean true ash effect hard quantify larger player though several smaller drug developer impact clear forty seven example ash abstract released struggling convince investor anti cd approach leg understandable given little progress elsewhere eat competition find celgene discontinuation hard digest october however data ongoing phase ib trial company lead project magrolimab showed startlingly good response patient untreated myeloid malignancy included patient myelodysplastic syndrome magrolimab plus azacitidine induced overall response rate half made complete response acute myeloid leukaemia patient orr reported cr number remain small however median duration response yet reached important future read still data compare favourably abbvie venclexta reported data ash similar patient pool orr cr rate generated md patient forty seven made share price jump raising almost see company fda hope file magrolimab approval takeout arqule btk inhibitor arq helped lift company working space deal confirmed potential seen btk inhibition arq data ash added flesh story non covalent project showed impressive response patient become resistant covalent btk inhibitor johnson johnson imbruvica astrazeneca calquence helping explain merck interest early data new version rocket gene therapy rare form anaemia rp l gave company share boost two treated patient showing sign engraftment company said major safety issue seen takeover gene therapy company audentes astellas given rocket lift along company like uniqure astellas spends bn bold move gene therapy december principia share hit high wake conference though uplift probably halo effect around btk inhibition company project prn reported incrementally interesting data immune thrombocytopenia ash well focus arqule takeout sanofi highlighted house btk project one six high priority programme added attention principia fate therapeutic provided update couple project ash weekend despite containing little clinical data gave stock uplift monday data presented conference generated excitement investor event company detailed evidence ft shelf nk cell therapy given two patient far working one patient aml progress simpler cell therapy approach overriding theme ash contrast complexity autologous car therapy made market progress bispecifics space example lifted small company like xencor leader regeneron roche advanced respectively period analysed going blueprint rare loser phase study kinase inhibitor avapritinib generated encouraging response mastocytosis patient safety remains sticking point fatal brain bleed one patient took lot shine data sangamo fell period question despite ash presentation encouraging update haemophilia gene therapy partnered pfizer five patient treated sb reported big increase clotting factor sustained far week post ash plunge coincided announcement result first three patient treated st ex vivo gene edited beta thalassemia project contained nothing dramatically worrying investor continue scratch head plunge sangamo share week finally precision bioscience remains period despite crashing monday stock climbed conference hope cd targeted allogeneic car project pbcar tested nine patient date presentation contained disappointing response rate early relapse summary detailed vantage coverage period including analysis intensely competitive bcma targeting space growing evidence bispecifics place haematological cancer next year\n",
      "\n",
      "Keywords:\n",
      "ash 0.355\n",
      "btk 0.178\n",
      "period 0.159\n",
      "patient 0.151\n",
      "conference 0.143\n",
      "magrolimab 0.118\n",
      "gene 0.116\n",
      "response 0.113\n",
      "reported 0.107\n",
      "gene therapy 0.104\n",
      "progress 0.1\n",
      "bispecifics 0.1\n",
      "therapy 0.099\n",
      "data 0.097\n",
      "company 0.095\n",
      "covalent 0.087\n",
      "btk inhibition 0.087\n",
      "arq 0.087\n",
      "plunge 0.084\n",
      "myeloid 0.084\n",
      "\n",
      "Abstract:\n",
      "trastuzumab deruxtecan antibody drug conjugate developed breast cancer astrazeneca daiichi forecast one biggest launch strength today data phase ii destiny breast trial unveiled san antonio breast cancer symposium suggest substantial expectation justified sting tail safety however result confirm adc cause serious toxicity patient study suffering interstitial lung disease four died complication death deemed treatment related impressive heavily pre treated patient responding therapy issue seems unlikely derail project approval chance impressive population median six prior line cancer therapy including roche adc kadcyla single arm study limitation data investigator noted result stand crowded field put context progression free survival month response rate roughly double triple typically seen study third later line population dr ian krop dana farber cancer institute said press conference overall survival reached earlier phase study trastuzumab deruxtecan managed objective response rate positive breast cancer patient previously treated average seven therapy including kadcyla time astra called achievement unprecedented larger trial largely replicated finding work astra daiichi lay plan better herceptin may current treatment sequence metastatic positive disease dominated three roche product first line treatment taxane plus herceptin plus perjeta second line treatment generally kadcyla consensus best therapy third line setting response rate trastuzumab deruxtecan destiny breast particularly notable among patient previously treated perjeta responded compared never received roche drug trastuzumab deruxtecan achilles heel side effect interstitial lung disease seen destiny breast patient slight improvement rate phase still drawback lead black box warning future label dr krop conceded rate interstitial lung disease higher seen study drug including herceptin kadcyla added investigator explain particularly since adcs supposed allow specific targeting tumour side effect require careful monitoring project due u decision bla third line breast cancer first quarter next year sellside already pencilled huge sale number make adc one sector valuable oncology asset currently development evaluatepharma consensus sale topping bn analyst mooted peak sale bn though relies trastuzumab deruxtecan proving worth earlier setting presumably kind revenue astra anticipating paid bn front license drug astra shake hand daiichi take roche march moreover plenty next gen following behind data seattle genetics tki tucatinib macrogenics margetuximab expected sabcs plenty others working better herceptin sitc preview pieris join quest better herceptin november one competing agent come close trastuzumab deruxtecan efficacy without safety signal expectation might reined project beat\n",
      "\n",
      "Keywords:\n",
      "trastuzumab deruxtecan 0.284\n",
      "trastuzumab 0.284\n",
      "deruxtecan 0.284\n",
      "herceptin 0.209\n",
      "breast 0.197\n",
      "kadcyla 0.18\n",
      "better herceptin 0.152\n",
      "destiny breast 0.135\n",
      "interstitial lung disease 0.125\n",
      "interstitial lung 0.125\n",
      "interstitial 0.125\n",
      "destiny 0.122\n",
      "adc 0.118\n",
      "lung disease 0.116\n",
      "breast cancer 0.113\n",
      "daiichi 0.109\n",
      "cancer 0.105\n",
      "astra 0.105\n",
      "line 0.098\n",
      "therapy including 0.095\n",
      "\n",
      "Abstract:\n",
      "diabetes cardiovascular haemophilia rare disease focus dupixent prevailing message root branch overhaul announced paul hudson sanofi new chief part french company first investor day leadership picked rein september mr hudson wasted time laying vision refocus sanofi operation hope achieving operating margin saving bn bn much saving come de prioritising certain activity including development work diabetes cardiovascular drawing line diabetes particular deciding launch efpeglenatide predicted vantage back september diabetes development road end sanofi september today mr hudson said sanofi would avoid situation group project late punchy number one central pillar sanofi growth dupixent hitting bn bn peak sale look ambitious especially analyst thought forecast peak sale bn mr hudson said given dupixent used adult atopic dermatitis year old scope significant growth even competition coming source including dermira reported impressive efficacy safety phase iia trial hanging hat big number mr hudson pressure deliver sanofi following industry trend focusing core area identified specialty care general medicine vaccine\n",
      "\n",
      "Keywords:\n",
      "hudson 0.372\n",
      "mr hudson 0.321\n",
      "sanofi 0.248\n",
      "diabetes 0.198\n",
      "dupixent 0.197\n",
      "mr 0.183\n",
      "mr hudson said 0.169\n",
      "hudson said 0.169\n",
      "diabetes cardiovascular 0.149\n",
      "saving 0.137\n",
      "bn bn 0.137\n",
      "september 0.126\n",
      "peak sale 0.121\n",
      "bn 0.118\n",
      "peak 0.1\n",
      "growth 0.096\n",
      "cardiovascular 0.091\n",
      "wasted 0.08\n",
      "sanofi new chief 0.08\n",
      "sanofi new 0.08\n",
      "\n",
      "Abstract:\n",
      "regeneron behind roche anti cd cd bispecific early data suggests might matter ash medical meeting saw highly encouraging response rate across various subtypes lymphoma regn though suspected tolerability main concern project cytokine release seen patient substantially higher proportion reported roche mosunetuzumab weekend including incidence serious event investigator disclosed one death due tumour lysis syndrome difference trial design patient population make valid comparison hard stage seems regn loses toxicity gain efficacy physician much comfortable dealing safety issue crowded space risk cytokine release mark regn troublesome option project already something reputation two patient died trial combined regn regeneron pd inhibitor libtayo xencor presented encouraging signal contender xmab manageable safety profile emerging project effectiveness look line mosunetuzumab result showed orr cr dlbcl patient treated although readout early early november safety data available nhl cll patient investigator reported rate cytokine release grade grade event occurred step dosing implemented dosing strategy look likely become widely established therapy dosing ongoing xmab data remain far end story table provides brief summary result seen cd cd bispecifics ash weekend roche gained prominent plenary presentation mosunetuzumab weekend dosed patient far swiss pharma giant detailed combination data second cd cd project rg biopharma watcher expect emerge efficacious agent different mosunetuzumab contains two cd binding domain yet clear whether roche bring project market clear bispecifics play role treatment haematological cancer distant future fit remains answered seems likely autologous car therapy increasingly consigned salvage setting shelf cell therapy yet show meantime however big company like roche regeneron look well set ride wave deep pocket count lot crowded market\n",
      "\n",
      "Keywords:\n",
      "cd 0.285\n",
      "mosunetuzumab 0.274\n",
      "regn 0.229\n",
      "cd cd 0.216\n",
      "cytokine release 0.169\n",
      "weekend 0.157\n",
      "cytokine 0.149\n",
      "roche 0.142\n",
      "xmab 0.137\n",
      "dosing 0.128\n",
      "regeneron 0.126\n",
      "release 0.12\n",
      "crowded 0.106\n",
      "bispecifics 0.105\n",
      "patient 0.102\n",
      "grade 0.097\n",
      "investigator 0.094\n",
      "ash 0.093\n",
      "project 0.089\n",
      "encouraging 0.085\n",
      "\n",
      "Abstract:\n",
      "time dust settle year ash might best remembered conference bispecific antibody threat car became real case point multiple myeloma targeting bcma long hotbed car activity duelling anti bcma car therapy continued battle ash yesterday regeneron became latest group suggest bispecific mab least good came day bristol myers squibb cell engager cc virtually unknown asset first knocked hole car approach cc data look even impressive ash abstract suggested particular highest cc dose mg appears active many anti bcma car t overall response rate rate complete remission true numerous caveat importantly mg dataset comprises nine subject clearly difference baseline patient characteristic comparing across multiple study cannot denied car competitor reckoned advanced car therapy space bluebird bristol ide cel yielded orr cr rate respectively highest dose pivotal karmma study patient characteristic cc population failed median five prior therapy triple refractory disease karmma subject failed least three therapy line triple refractory perhaps impressive aspect cc result none subject given highest dose progressed seven month responding vital consideration time patient relapse becoming big problem bcma targeted car car suddenly look vulnerable regeneron another beneficiary company yesterday reported first clinical data regn take anti bcma cell engager approach regn differs structurally cc latter two bcma binding domain instance principle behind ash poster yesterday revealed four response one complete first seven regn treated subject dose escalation still ongoing dose limiting toxicity yet reached remarkably population failed median seven line systemic therapy debit side one partial remitters relapsed seven week though three response ongoing one week counting comparison glaxosmithkline bcma targeting antibody drug conjugate belantamab mafodotin whose dreamm study yielded orr belantamab pivotal dreamm trial known read positively apparently submitted ash late breaker ultimately make year conference like car different cell engager like cc bind target antigen one end interacts cell thus bringing latter close proximity target tumour cell effect similar car approach achieved antibody possible convenience advantage immune system stimulating strategy safety important consideration cc trial one patient died cytokine release syndrome similar single death karmma cartitude study separate anti bcma car johnson johnson jnj investor want know weekend shift bcma tectonic plate might play virtue celgene acquisition bristol look pole position boasting cc addition several car asset prioritises cc ide cel obviously latter originator bluebird lose threat jnj cell therapy including poseida roche consistently refused buy car ground impractical expensive see major vindication saturday roche fired shot across bow shape mosunetuzumab bispecific mab showed activity patient relapsed car mean end cell therapy expectation reset\n",
      "\n",
      "Keywords:\n",
      "car 0.387\n",
      "cc 0.369\n",
      "bcma 0.31\n",
      "anti bcma 0.144\n",
      "ash 0.143\n",
      "cell 0.127\n",
      "engager 0.126\n",
      "cell engager 0.126\n",
      "bcma car 0.117\n",
      "anti bcma car 0.117\n",
      "karmma 0.114\n",
      "regn 0.106\n",
      "therapy 0.096\n",
      "seven 0.092\n",
      "failed median 0.088\n",
      "car approach 0.088\n",
      "triple refractory 0.084\n",
      "dose 0.084\n",
      "bispecific 0.082\n",
      "highest 0.082\n",
      "\n",
      "Abstract:\n",
      "today highly encouraging ash data arqule btk inhibitor arq must seen merck co group putting together bn takeover bid strength data even wondering whether arqule extracted even higher price held leaping merck embrace dreaming bigger premium remember btk inhibitor space incredibly competitive arqule data still early big pharma always get price asset right market get wrong arqule share anywhere near merck offering almost year longer term shareholder doubt delighted btk ftw data attracting attention ash today concern patient various b cell lymphoma phase dose escalation study still ongoing patient heavily pretreated failed chemotherapy anti cd antibody either imbruvica calquence despite response rate promising overall response rate eight nine achieved chronic lymphocytic leukaemia patient btk c mutation thought responsible driving resistance existing btk inhibitor activity mutant crucial arq leg represents major validation arq non covalent reversible btk inhibitor unlike j j imbruvica astrazeneca calquence thought differentiation help work others fail c usually develops resistance mutation treatment first generation btk like imbruvica calquence result patient le home run result impressive elsewhere orr achieved six subject richter transformation aggressive type lymphoma two additional partial response generated one follicular lymphoma one diffuse large b cell lymphoma competition earlier data trial presented european hematology association meeting summer suggested reversible btk inhibitor might one day used permanent blocker imbruvica calquence eha turnaround put arqule takeover frame june starting look like real possibility though even might merck behind long way go imbruvica forecast sale bn according evaluatepharma clear arq leading reversible btk inhibitor though lilly loxo far behind presentation ash detailed orr cll patient treated loxo orr c mutant latest data sunesis pharmaceutical rival asset vecabrutinib show three five patient treated mg achieved stable disease remission reported durability remains key test agent sign promising another non covalent btk inhibitor hand big pharma project pushed forward quickly\n",
      "\n",
      "Keywords:\n",
      "btk 0.419\n",
      "btk inhibitor 0.294\n",
      "arqule 0.237\n",
      "imbruvica 0.23\n",
      "arq 0.205\n",
      "calquence 0.19\n",
      "reversible btk inhibitor 0.173\n",
      "reversible btk 0.173\n",
      "imbruvica calquence 0.173\n",
      "reversible 0.154\n",
      "lymphoma 0.139\n",
      "inhibitor 0.135\n",
      "ash 0.104\n",
      "non covalent 0.102\n",
      "covalent 0.102\n",
      "cell lymphoma 0.095\n",
      "orr 0.092\n",
      "merck 0.091\n",
      "achieved 0.09\n",
      "loxo 0.09\n",
      "\n",
      "Abstract:\n",
      "sanofi setting stall immuno oncology decisive bn play u biotech synthorx next generation il project thor bold move given synthorx essentially preclinical data entice would suitor say volume plan paul hudson sanofi new chief executive french pharma group mr hudson place since september meet investor analyst tuesday lay plan future direction company many see moribund share remained pretty range bound past three year increased albeit late focus industry hottest therapy area bring much needed injection investor enthusiasm buying synthorx mr hudson bucking trend seen company wishing get hand il asset licensing bristol myers squibb paid bn nektar nktr bn whole company clinical asset three project development peptide technology look bad even premium friday closing price deal look even appealing sanofi appears chosen il project unshackled deal pharma company well non alpha il variant il validated mechanism action thanks nestle proleukin serious side effect attached stimulating variant il particular vascular leak syndrome severely curtained use il therapy hitting non alpha il however appears avoid triggering vascular leak syndrome thor yet report serious adverse event primate model demonstrated half life measured day putting one one together thor shown sign activity monotherapy preclinical data real promise analyst believe lie combination sanofi checkpoint inhibitor libtayo combining il treatment pd l inhibition thought enhance cd cell response giving greater anti tumour effect checkpoint blockade alone adding thor might help differentiate libtayo became sixth pd l market gained eu approval synthorx alone going non alpha il roche alkermes nektar advanced project pipeline question potency nektar nktr monotherapy analyst arguing read across combination alkermes alks reported toxicity issue short half life requires daily dosing leaving roche rg clinical asset watch rg non alpha il demonstrated clinical activity monotherapy shown favourable safety profile interesting thor stack competition caveat cross trial comparison notwithstanding project entered clinic patient phase ii hammer trial looking solid tumour monotherapy combination checkpoint inhibitor generate result second half alongside executive synthorx winner today deal investor put company seen payoff july ipo today takeover whether sanofi another winner remains seen thor one later entrant clinic much depend performs hammer read\n",
      "\n",
      "Keywords:\n",
      "il 0.358\n",
      "thor 0.308\n",
      "synthorx 0.22\n",
      "non alpha il 0.205\n",
      "non alpha 0.205\n",
      "alpha il 0.205\n",
      "alpha 0.147\n",
      "hudson 0.136\n",
      "sanofi 0.126\n",
      "nektar 0.125\n",
      "monotherapy 0.114\n",
      "hammer 0.103\n",
      "clinical asset 0.103\n",
      "vascular leak syndrome 0.098\n",
      "vascular leak 0.098\n",
      "mr hudson 0.098\n",
      "leak syndrome 0.098\n",
      "il project 0.098\n",
      "checkpoint 0.097\n",
      "vascular 0.094\n",
      "\n",
      "Abstract:\n",
      "since bristol myers squibb completed bn celgene takeover latter investor left holding unusual financial instrument contingent value right pay car therapy jcar must secure u approval yesterday unveiling data transcend nhl study ash pivotal best news came shape safety profile appears meaningfully better gilead yescarta novartis kymriah jcar efficacy worryingly low manufacturing success rate little pressure u fda bust gut get third car therapy line speed needed contingent value right cvr triggered three condition met one jcar liso cel must secure u approval lymphoma december yesterday bristol said based transcend nhl u bla filing would completed end true month turnaround filing impossible cvr holder continue fret whether fda actually deem transcend nhl data sufficiently robust given still said done single arm trial whose analysis paint jcar best possible light yesterday analysis first meaningful data cut transcend nhl year lymphoma study started juno taken celgene deemed pivotal hand bristol ash professor jeremy abramson massachusetts general hospital said transcend nhl subject suffered serious cytokine release syndrome neurotoxicity respectively given rate typical car therapy represents major argument favour jcar finding justify jcar extra manufacturing step yield product ratio cd cd cell meant result car therapy controllable therefore safer however make manufacturing complex expensive time cytokine release neurotoxicity becoming controllable thanks protocol suggesting use actemra steroid whether jcar offer real advantage clear news get worse efficacy side equation bristol project look better yescarta across variety metric including remission rate survival course real devil detail underlying patient characteristic question manufacturing success transcend nhl actually enrolled subject one reason actually ended getting jcar conformed manufacturing standard rather used denominator efficacy analysis flattering data presented ash issue soon hand fda doubt agency perform analysis kymriah decide number subject enrolled appropriate one use calculate efficacy meantime debate manufacturing failure rumble jcar manufactured specification transcend nhl subject died infused exclusion final dataset classified simply doubt celgene cvr holder hail yesterday data great success ask one key question absence overwhelmingly better efficacy two similar product already approved fda allow third onto market basis another uncontrolled single arm study\n",
      "\n",
      "Keywords:\n",
      "jcar 0.417\n",
      "transcend nhl 0.341\n",
      "transcend 0.341\n",
      "nhl 0.325\n",
      "manufacturing 0.161\n",
      "car therapy 0.136\n",
      "cvr 0.119\n",
      "car 0.114\n",
      "controllable 0.098\n",
      "ash 0.095\n",
      "kymriah 0.089\n",
      "bristol 0.088\n",
      "celgene 0.087\n",
      "yescarta 0.086\n",
      "secure approval 0.086\n",
      "efficacy 0.084\n",
      "actually 0.081\n",
      "holder 0.079\n",
      "single arm 0.078\n",
      "cytokine release 0.076\n",
      "\n",
      "Abstract:\n",
      "bluebird missing deadline getting registrational karmma dataset ash conference way left clear johnson johnson seize early spotlight today ash presentation first human data j j anti bcma car project jnj shown staggering remission rate bluebird bristol myers squibb unveil karmma data yesterday press release result certainly seem good enough secure approval ide cel bb late line multiple myeloma relapse remain elephant room care taken attempting cross study comparison owing differing patient characteristic karmma instance treated subject failed least three therapy line triple refractory key efficacy data overall response rate including complete remission look reasonable compared orr cr rate seen earlier study bb subject failed average seven prior therapy however worry relapse remission karmma lasted month average median progression free survival month backdrop threat j j jnj already highly competitive field suddenly become real ash today j j said cartitude trial jnj far treated subject triple refractory penta refractory patient responded jnj amazing showing complete remission better follower j j thus breathe sigh relief company licensed jnj bispecific car two different epitope bcma protein nanjing legend subsidiary china genscript biotech front legend data since drawn criticism ash legend mystery car raise question december cartitude presenting author dr deepu madduri mount sinai medical center suggested preferential expansion cd central memory cell one reason behind jnj impressive efficacy said real test durability early day subject progression free median six month follow go unnoticed cartitude karmma featured report patient death owing cytokine release syndrome might surprising given prevailing view car related side effect largely controllable interesting aside legend still running chinese study legend update result ash monday continues call project lcar b identical jnj though j j previously told vantage us different manufacturing scale process separate car asset multiple myeloma unveiled ash today another chinese group cellyan therapeutic target bcma cd yielded orr cr multiple myeloma subject failed two nine prior therapy response ongoing week said huazhong university science technology dr heng mei however given differing standard treatment prospective western partner project would well advised run confirmatory study u j j jnj contingent value leave bluebird bristol investor ide cel important consideration one three element contingent value right bristol issued bought celgene bluebird original partner cvr triggered among thing ide cel approved u march strength karmma certainly look achievable filing based dataset look likely go ahead imminently broader question big ide cel turn unfortunately bluebird karmma provides little solace potent though short lived therapy offer little hope expanding ide cel earlier line therapy bb bluebird played potentially improved version ide cel actually look little better according ash abstract attention turn bristol bispecific anti bcma mab cc whose first clinical data presented ash today impressed ide cel kicked bcma revolution multiple meyloma time year instalment ash might look remarkably vulnerable\n",
      "\n",
      "Keywords:\n",
      "jnj 0.272\n",
      "karmma 0.256\n",
      "ash 0.249\n",
      "ide cel 0.238\n",
      "ide 0.238\n",
      "cel 0.225\n",
      "legend 0.195\n",
      "bluebird 0.184\n",
      "bcma 0.167\n",
      "ash today 0.128\n",
      "car 0.125\n",
      "cartitude 0.113\n",
      "bb 0.113\n",
      "subject failed 0.102\n",
      "myeloma 0.091\n",
      "multiple myeloma 0.091\n",
      "remission 0.089\n",
      "multiple 0.088\n",
      "refractory 0.084\n",
      "triple refractory 0.081\n",
      "\n",
      "Abstract:\n",
      "scrapping resuscitating alzheimer project aducanumab biogen needed make strong case pushing attempt came yesterday medical conference ctad seems hugely complex presentation failed substantially shift opinion either medical financial community many firmly entrenched either way biogen insisted file approval next year setting fda make decision inevitably many disagree yesterday presentation made life easier regulator allowing company employee present data highly irregular medical conference real dissenting voice among reviewer biogen remained control message message clear aducanumab effective drug dosed high enough long enough represents real step forward alzheimer disease almost put moral obligation fda grant approval make running sort confirmatory trial incredibly hard physician patient believe interpretation enrolling trial subject might receive placebo becomes almost impossible biogen said preparing dose patient originally enrolled engage emerge study company presumably hope endeavour sufficient clear remaining question regulator may would deeply imperfect way rigorously examining aducanumab lot unanswered question well unseen data even one stand way biogen analysed result clinical relevance efficacy signal teased remains subject debate safety considered something must easily dismissed agent dosed chronically advisory committee hearing inevitably convened next year provide fda first thought hugely pivotal moment biopharma sector green light interpreted sarepta demise standard evidenced based medicine roadblock criticised delaying patient access potentially life changing therapy history suggests biogen prevail either way alzheimer set one big story\n",
      "\n",
      "Keywords:\n",
      "biogen 0.341\n",
      "aducanumab 0.195\n",
      "alzheimer 0.174\n",
      "inevitably 0.167\n",
      "medical 0.149\n",
      "either way 0.146\n",
      "medical conference 0.143\n",
      "message 0.137\n",
      "way 0.136\n",
      "either 0.135\n",
      "hugely 0.126\n",
      "dosed 0.103\n",
      "fda 0.099\n",
      "presentation 0.097\n",
      "life 0.096\n",
      "make 0.096\n",
      "regulator 0.089\n",
      "almost 0.087\n",
      "enough 0.085\n",
      "scrapping 0.084\n",
      "\n",
      "Abstract:\n",
      "welcome weekly roundup approaching clinical readout gilead focus nash turned combination approach ask inhibitor selonsertib flunked two phase iii trial used monotherapy data phase ii atlas trial test seven different combination selonsertib two gilead agent acc inhibitor firsocostat cilofexor fxr agonist due year end company noted third quarter result atlas allow u think pivot nash strategy moving forward given selonsertib essentially failed asset little expected arm contain project atlas recruited advanced patient many compensated cirrhosis stage fibrosis alongside safety trial evaluating proportion patient achieving least one point improvement fibrosis score without worsening nash week endpoint selonsertib missed monotherapy data proof concept trial hinted efficacy combo first batch released easl second came earlier year trial showed combination firsocostat plus cilofexor produced largest median decline liver fat fraction patient stage fibrosis treated week issue acc inhibitor firsocostat known increase triglyceride notably early month gilead added another arm proof concept study adding vascepa firsocostat plus cilofexor another new cohort includes fenofibrate generic lipid lowering drug combination study primary completion date may next year seems hint way gilead moving forward atlas patient taking anti hyperlipidaemics clarify firsocostat lipid impact expanded proof concept trial one watch gilead front runner nash failure selonsertib intercept fxr agonist ocaliva lead space pdufa march next year despite shown modest effect fibrosis readout due genfit phase iii resolve trial elafibranor going hunting huntington disease project developed roche ionis pharmaceutical pivotal phase iii trial due report fully possible group obtain accelerated fda approval rg next year based combination several trial one key readout contributing data small extension study due next month patient enrolled roche ionis placebo controlled phase ii trial followed another month open label basis data study expected used fda submission along interim biomarker data pivotal trial generation hd readout approach biggest huntington hope march rg known ionis httrx antisense agent block production mutant protein cause huntington achieving accelerated approval asset crucial roche ionis get drop rival wave life science takeda partner collaborating two antisense project one wve forecast launch half patient extension trial receive rg intrathecally month subject treated every two month study focused agent safety primary endpoint incidence treatment emergent adverse event secondary include concentration huntingtin protein cerebrospinal fluid assessment patient cognition earlier trial showed significant dose dependent reduction mutant huntingtin protein mean reduction around two highest dos mg mg definitive link reduction mutant huntingtin improvement symptom yet proven closest ionis come exploratory post hoc analysis phase ii trial suggested correlation extension confirm rg safety earlier study threw serious adverse event drug discontinuation longer period sign improving patient symptom would major bonus kind proof expected full pivotal readout two year hence indeed come\n",
      "\n",
      "Keywords:\n",
      "selonsertib 0.237\n",
      "firsocostat 0.237\n",
      "ionis 0.188\n",
      "atlas 0.18\n",
      "rg 0.145\n",
      "cilofexor 0.142\n",
      "trial 0.14\n",
      "roche ionis 0.135\n",
      "huntingtin 0.135\n",
      "proof 0.133\n",
      "huntington 0.13\n",
      "fibrosis 0.124\n",
      "nash 0.117\n",
      "proof concept 0.113\n",
      "gilead 0.108\n",
      "mutant 0.107\n",
      "extension 0.105\n",
      "readout 0.103\n",
      "concept 0.103\n",
      "combination 0.102\n",
      "\n",
      "Abstract:\n",
      "result pivotal aurora trial aurinia pharmaceutical voclosporin lupus nephritis quite hit slam dunk response level hoping benefit show good enough send share early trade leap much safety efficacy side effect profile look good relief imbalance death seen phase ii aurinia file calcineurin inhibitor u first six month launch group conduct alone pencilled aurora trial tested voclosporin versus placebo top standard care lupus nephritis mycophenolate initial treatment iv methylprednisolone followed oral steroid patient disease systemic lupus cause kidney inflammation enrolled analyst suggested best case scenario benefit control arm primary endpoint renal response defined using combination urinary protein creatinine ratio estimated glomerular filtration rate one year magnitude benefit fact comfortable statistically significant hit endpoint site specific aurinia claim clean sweep trial pre specified hierarchical secondary endpoint safety much improved phase ii aura lv trial study patient treatment arm control arm died death determined drug related hardly inspired confidence aurora data put lingering safety fear bed serious adverse event seen voclosporin patient numerically lower rate control arm mortality rate favoured drug one death voclosporin arm five control group reward aurinia reaped excluding certain site aurora worst mortality voclosporin group aura lv due poor access healthcare subset trial site ie southeast asia according leerink analyst full data released conference european lupus meeting march eular june possible venue partner wanted assuming data good enough approval great leap aurinia intends market drug u speaking conference call today chief executive peter greenleaf said early discus pricing though added lack innovation lupus nephritis give aurinia fair amount negotiating leeway payer country mr greenleaf reiterated company previous statement overture potential partner interested right europe asia latin america welcome pretty rare end phase iii result like asset already sold geography help capitalise company said today sit drug unencumbered major region aurinia boast bn market cap much better negotiating position\n",
      "\n",
      "Keywords:\n",
      "aurinia 0.457\n",
      "voclosporin 0.327\n",
      "lupus 0.262\n",
      "aurora 0.244\n",
      "arm 0.148\n",
      "control arm 0.14\n",
      "site 0.124\n",
      "leap 0.116\n",
      "control 0.115\n",
      "negotiating 0.112\n",
      "asia 0.102\n",
      "good enough 0.092\n",
      "death 0.091\n",
      "mortality 0.087\n",
      "good 0.086\n",
      "benefit 0.069\n",
      "rate 0.068\n",
      "safety 0.067\n",
      "trial 0.065\n",
      "endpoint 0.064\n",
      "\n",
      "Abstract:\n",
      "sage therapeutic well armed reason explain failure sage mountain study investor buying share highly valued company plunged open erasing cool bn market cap poor track record psychiatric project meant study major depressive disorder always high risk sage previous success tempted investor start believing secret sauce end company even blame stronger expected placebo response make finding even concerning future sage mountain failed trial incontrovertible despite claim contrary sage chief executive jeff jonas conference call morning primary endpoint reduction depression scale called ham day compared placebo missed dos tested patient treated sage responded remarkably similarly given placebo pill placebo response mountain dissimilar seen earlier phase ii study sage group deviated previous experience prompting company indulge data digging explain apparent misfiring lead asset first non compliant patient blamed sage mg group patient subject measurable drug concentration excluding primary analysis set resulted statistically significant readout time point sage said second explanation involved greater proportion mildly depressed patient mountain previous study excluding helped data set achieve statistical significance remove inconvenient patient group hey presto mg sage performance look markedly improved however failure primary endpoint make post hoc finding little exploratory conference call executive would commit running confirmatory study severe population though admitted done fairly quickly hardly build confidence company explanation derailing trial sage stance seems data along positive read post partum depression enough support filing sage breakthrough status company able conversation fda relatively quickly failed study mr jonas insisted call pretty clear data right direction clearly supportive true depression drug approved negative study pivotal data two study due next year fda good reason wait see sage prove activity without needing post hoc data scrub today news consensus among sellside launch sale surging bn estimate looking lot le secure\n",
      "\n",
      "Keywords:\n",
      "sage 0.732\n",
      "mountain 0.225\n",
      "depression 0.134\n",
      "study 0.104\n",
      "post 0.098\n",
      "previous 0.094\n",
      "placebo response 0.09\n",
      "placebo 0.086\n",
      "explanation 0.085\n",
      "excluding 0.085\n",
      "post hoc 0.083\n",
      "hoc 0.083\n",
      "explain 0.075\n",
      "data 0.072\n",
      "call 0.072\n",
      "conference call 0.069\n",
      "patient 0.066\n",
      "quickly 0.062\n",
      "company 0.059\n",
      "finding 0.058\n",
      "\n",
      "Abstract:\n",
      "look biogen pipeline lay bare challenge confronts company management full high risk neurological project financial community largely declined assign value aducanumab carry weight according sellside number least though current estimate alzheimer asset soon ripped presentation phase iii data two trial medical conference tomorrow promise huge event alzheimer field biogen desperately need defend commitment challenging disease area table show phase iii ii asset aducanumab attracting number notable size predicting success experimental neurological treatment notoriously hard couple project assigned value notable biib phase ii data released yesterday apparently devoid value agent shown utility lupus biib handicapped due novel mechanism action yet establish relevance disease antibody bind bdca receptor found plasmacytoid dendritic cell immune cell produce large amount type interferon key driver lupus plasmacytoid dendritic cell shown accumulate skin hoped biib particularly marked impact rash seen many lupus patient yesterday data trial called lilac appear support hypothesis though little information released virtually nothing said safety trial enrolled patient distinct lupus population two separate cohort first concerned patient various form lupus skin disease including cutaneous lupus discoid lupus reported significantly stronger response placebo patient skin activity score called clasi three dos tested worryingly middle one performing convincingly group included subject systemic lupus erythematosus patient registered statistically significant improvement joint pain placebo biogen yet announce plan biib seems unlikely sellside change view asset yet course big readout biogen aducanumab data two trial emerge engage unveiled clinical trial alzheimer disease ctad annual congress california tomorrow study failed futility analysis earlier year biogen published new analysis data october purported find benefit patient given high dose antibody tracked longer shock revelation see biogen erase aducanumab loss october far company provided little information new datasets given bn boost biogen market cap reversal bestowed tomorrow presentation crucial essentially company need explain exactly new analysis trusted specific question concern aducanumab seemed work better emerge engage whether different distribution patient genetic predisposition alzheimer played role physician investor keen see actual number far biogen revealed percentage change dementia rating scale cdr sb give idea absolute benefit must framed within closer look aducanumab safety profile brain swelling condition aria e seen patient worst case scenario biogen marginal benefit heavy toxicity burden fda would surely require another trial situation confirm finding physician another major group need convincing sign encouraging critical editorial written lancet nature author taking exception use post hoc analysis doubting validity efficacy signal biogen work cut tomorrow little else fall back another aducanumab disappointment far reaching repercussion company\n",
      "\n",
      "Keywords:\n",
      "lupus 0.369\n",
      "biogen 0.349\n",
      "aducanumab 0.279\n",
      "tomorrow 0.197\n",
      "biib 0.197\n",
      "alzheimer 0.143\n",
      "skin 0.126\n",
      "engage 0.103\n",
      "patient 0.102\n",
      "new analysis 0.099\n",
      "neurological 0.09\n",
      "two trial 0.088\n",
      "data two 0.082\n",
      "analysis 0.078\n",
      "value 0.07\n",
      "information 0.07\n",
      "trial 0.068\n",
      "physician 0.068\n",
      "little 0.067\n",
      "disease 0.066\n",
      "\n",
      "Abstract:\n",
      "astellas move audentes fourth acquisition gene therapy player year though bn price come premium audentes closing price yesterday fairly modest compared sum paid gene therapy developer deal good news biopharma sector head year unpredictability caused forthcoming presidential election making investor nervous point ongoing appetite japanese pharma audentes lead asset phase ii trial rare neuromuscular condition x linked myotubular myopathy extreme muscle weakness caused condition limit patient ability move eat breathe mortality rate around first month life patient die age occurs one live male birth patient mutated form gene myotubularin protein produce necessary normal development function skeletal muscle cell delivers functional copy gene using aav vector filing next year audentes released data seven patient treated far one received higher dose look likely filed regulator phase ii aspiro trial achieved significant durable reduction ventilator dependence considered correlate morbidity mortality xlmtm patient audentes said october currently tested pivotal expansion cohort confirm safety efficacy higher dose x vg kg audentes intended file bla mid european submission second half sale reach according evaluatepharma sellside consensus though figure highly risk adjusted antitrust deal look largely driven audentes lead asset audentes programme might pose bit risk acquisition audentes three preclinical stage oligonucleotides duchenne muscular dystrophy might overlap astellas duchenne candidate asp called oral small molecule phase astellas developing reldesemtiv called ck phase ii spinal muscular atrophy similarity roche spark deal still yet close owing ftc review bristol myers squibb getting celgene latter group sold psoriasis blockbuster otezla inconceivable astellas might attract attention antitrust regulator audentes pipeline however probably part appeal astellas probably interested audentes aav based technology platform house large scale gene therapy manufacturing capability kind thinking led thermo fisher scientific buy brammer bio earlier year investor clearly believe gene therapy based deal coming uniqure regenxbio trading respectively far today\n",
      "\n",
      "Keywords:\n",
      "audentes 0.62\n",
      "astellas 0.218\n",
      "gene 0.187\n",
      "gene therapy 0.14\n",
      "aav 0.117\n",
      "duchenne 0.096\n",
      "deal 0.092\n",
      "muscular 0.091\n",
      "higher dose 0.09\n",
      "muscle 0.088\n",
      "mortality 0.088\n",
      "lead asset 0.086\n",
      "therapy 0.077\n",
      "patient 0.073\n",
      "condition 0.068\n",
      "caused 0.068\n",
      "phase 0.065\n",
      "phase ii 0.064\n",
      "ii 0.063\n",
      "regulator 0.062\n",
      "\n",
      "Abstract:\n",
      "one predicted november would see wave early approval fda two sickle cell drug adakveo oxbryta btk inhibitor brukinsa rnai therapy givlaari month ahead schedule whether streak continues questionable december often quiet month interesting upcoming decision supplemental approval highly anticipated amarin vascepa purified fish oil product looking broader label mentioning cardiovascular risk reduction gaining unanimous vote fda advisory panel november broad label might get big question restriction secondary prevention setting namely patient established cardiovascular disease possible benefit seen primary prevention setting considered risk future cardiac problem much le pronounced consensus evaluatepharma show sale bn giving npv bn vascepa obtains cardiovascular risk reduction label analyst believe sale peak double figure another notable supplemental approval expected month lynparza maintenance setting pancreatic cancer result polo trial strongly favoured astrazeneca merck co parp progression free survival overshadowed absence overall survival benefit success seen pancreatic cancer current therapy involve toxic platinum chemotherapy regulator might look favourably lynparza offering meanwhile pfizer hope gain ground prostate cancer rival j j due approval decision xtandi metastatic hormone sensitive disease j j erleada approved september first timer allergans oral cgrp antagonist ubrogepant likely gain approval acute migraine setting end year product backed positive late stage trial clean safety profile ubrogepant allergan valuable pipeline project sale forecast reach according evaluatepharma consensus hot ubrogepant heel biohaven orally dissolving tablet formulation rimegepant known zydis odt pdufa date first quarter next year decision due shionogi gsk hiv doublet cabotegravir rilpivirine long acting injectable treatment dosed monthly concern drug resistance mean many remain convinced doublet strategy three drug regimen represent current standard care gilead oral daily triplet biktarvy dominates market forecast bn according evaluatepharma consensus enzyvant rvt one treatment severe immune deficiency result rare childhood disease complete digeorge anomaly regenerative therapy first approval vivek ramaswamy roivant stable company strategic alliance sumitomo dainippon includes enzyvant announced september le likely receive fda backing intra cellular lumateperone schizophrenia decision due three month delay previous pdufa date fda cancelled advisory meeting requested preclinical data address toxicity finding previous animal study phase iii result mixed\n",
      "\n",
      "Keywords:\n",
      "ubrogepant 0.195\n",
      "approval 0.131\n",
      "pancreatic cancer 0.13\n",
      "supplemental approval 0.124\n",
      "decision 0.121\n",
      "prevention setting 0.119\n",
      "cardiovascular risk reduction 0.119\n",
      "supplemental 0.115\n",
      "pancreatic 0.115\n",
      "cardiovascular risk 0.111\n",
      "decision due 0.109\n",
      "vascepa 0.106\n",
      "setting 0.106\n",
      "cardiovascular 0.105\n",
      "doublet 0.104\n",
      "risk reduction 0.1\n",
      "prevention 0.098\n",
      "fda 0.098\n",
      "lynparza 0.096\n",
      "pdufa date 0.095\n",
      "\n",
      "Abstract:\n",
      "welcome weekly roundup approaching clinical readout data due end year set kalvista therapeutic good christmas strong readout proof concept trial kvd diabetic molecular oedema dme tempt merck co opt big pharma company paid kalvista option kvd intravitreal injection based plasma kallikrein inhibition decision whether exercise option depends data patient trial merck took option earlier oral dme candidate based mechanism payment possible though would structured disclosed positive data would help validate novel approach treating eye disease sellside analyst covering kalvista largely held assigning project value study read kalvista advanced player space nearest rival asset oxurion bicycle therapeutic thr earlier year yielded reassuring data showing clean safety profile sign efficacy patient phase trial thr showed average letter increase best corrected visual acuity day single injection expectation kdv visual acuity gain modest given larger trial size observer looking three five letter improvement base case project safety profile huge bearing sentiment given excellent safety macular oedema product market vegf inhibitor like lucentis eylea commonly used dme kalvista focusing estimated dme patient respond adequately leerink estimated peak sale product target niche reach bn worldwide though kalvista others must first prove plasma kallikrein inhibition place sanofi fight meanwhile genmab darzalex race become first cd targeting multiple myeloma drug market sanofi giving fight french group filed antibody isatuximab earlier year shortly see result another pivotal study ikema seeking broaden addressable population ikema due yield data first quarter next year pit isatuximab combination kyprolis dexamethasone kyprolis dexamethasone alone subject treated one three prior line therapy progression fee survival primary endpoint setting broadly analogous darzalex approved use back castor study genmab drug given second line combination velcade dexamethasone genmab combo posted month median pfs versus month velcade dexamethasone alone hr p isatuximab first use expected third line combination pomalyst plus dexamethasone back icaria trial yielded positive data earlier year jefferies analyst expect approval second quarter u fda action date think sanofi asset mark great improvement darzalex indeed evaluatepharma sellside consensus see isatuximab posting revenue versus darzalex bn additional sanofi trial seek expand setting investor note early threat takeda molecular template tak mention genmab darzalex follow hexabody cd partnered johnson johnson\n",
      "\n",
      "Keywords:\n",
      "kalvista 0.361\n",
      "dexamethasone 0.241\n",
      "dme 0.24\n",
      "darzalex 0.234\n",
      "isatuximab 0.225\n",
      "genmab 0.179\n",
      "oedema 0.113\n",
      "sanofi 0.111\n",
      "earlier year 0.11\n",
      "velcade dexamethasone 0.107\n",
      "velcade 0.107\n",
      "line combination 0.103\n",
      "fight 0.096\n",
      "plasma 0.094\n",
      "molecular 0.094\n",
      "option 0.091\n",
      "estimated 0.084\n",
      "earlier 0.083\n",
      "positive data 0.082\n",
      "letter 0.074\n",
      "\n",
      "Abstract:\n",
      "earlier year spectrum ditched portfolio ageing marketed product focus developing two key pipeline asset next month see result trial show whether first poziotinib filed u approval poziotinib targeted highly intractable lung cancer niche exon mutation might equal prevalence alk amounting u patient appears advanced industry project development first cohort zenith trial sufficiently positive spectrum reckons used u filing zenith uncontrolled study split several cohort almost might registrational spectrum hope first comprises relapsed nsclc subject documented egfr exon insertion fortunately investor handicap result thanks single centre poziotinib study run earlier md anderson presented world lung conference last year evaluable egfr exon mutant subject spectrum asset yielded overall remission rate patient still therapy median seven month would clearly unrealistic robust potentially registrational trial show similar level efficacy earlier study set baseline expectation spectrum say remain blinded open label zenith study data hope present next month include remission safety durability serendipity md anderson even ran study shine light serendipitous nature spectrum came developing poziotinib setting poziotinib inhibitor spectrum licensed undisclosed amount south korean group hanmi spectrum initially developing breast cancer meantime md anderson cancer moon shot programme started looking exon mutation preclinically identified poziotinib seemingly potent agent basis hospital ran academic trial persuaded md anderson opportunity spectrum moved focus mutated lung rather breast cancer sellside forecast compiled evaluatepharma see spectrum drug generating impressive sale exon mutation thought particularly intractable owing steric hindrance competitor behind poziotinib development including takeda tak rain therapeutic tarloxotinib otsuka ta asco tepotinib capmatinib fight new lung cancer niche june mutation occur resistance pathway resulting various type targeted therapy hence multiple setting zenith however attention cohort\n",
      "\n",
      "Keywords:\n",
      "spectrum 0.461\n",
      "poziotinib 0.368\n",
      "md anderson 0.221\n",
      "zenith 0.21\n",
      "anderson 0.21\n",
      "exon 0.208\n",
      "md 0.176\n",
      "exon mutation 0.146\n",
      "mutation 0.13\n",
      "lung 0.119\n",
      "trial show 0.111\n",
      "lung cancer niche 0.105\n",
      "egfr exon 0.105\n",
      "cancer 0.102\n",
      "cancer niche 0.101\n",
      "ran 0.09\n",
      "intractable 0.09\n",
      "egfr 0.088\n",
      "developing 0.086\n",
      "registrational 0.079\n",
      "\n",
      "Abstract:\n",
      "short course hayfever vaccine space investable investor asit biotech allergy therapeutic rightly asking question week seen company set back yet quest develop treatment grass pollen allergy asit flunked second phase iii study gp asit despite earlier claiming grass pollen season strong mirroring failure allergy birch pollen project earlier year today allergy turned pivotal plan grass pollen product upside likely delaying launch allergy programme grass mata mpl already extensively delayed started phase iii imminently failure birch mata mpl birch pollen allergy earlier year apparently prompted soul searching allergy lesson bet study delayed march least allergy afford run new extended pivotal programme luck asit monday fell leaving market cap around cash convertible debt coming due next year even normally bullish analyst edison said see asit continue fund operation one problem still entirely clear type allergy study keep failing collapse asit first phase iii trial gp asit blamed subject variability poor pollen season second study execution flawless group said despite yielded result significant statistical term failing meet prespecified threshold clinical relevance moreover trial took place strong allergy season similarly allergy birch mata mpl flunked phase iii despite run one severest birch pollen season recent year like asit allergy unable explain failure nevertheless setback resulted allergy deciding today run pivotal trial grass mata mpl one two allergy season intended allow interim look data deciding whether continue confounding plan might make perfect sense caution called threatens introduce confounding factor already complex dataset variability patient centre already problem adding top variability two separate allergy season make trial write even study read positively launch delayed another month stifel analyst reckon timeframe investor note would put launch nearly year allergy clinical programme first delayed u hold lack progress build already poor precedent alk abell stallergenes developed promising sublingual vaccine failed sell strongly latter recently merged private uk company greer laboratory true acute end space peanut allergy company aimmune dbv better time tackling chronic seasonal disorder time running merck co instance threw towel hard see many investor would bother hand technology\n",
      "\n",
      "Keywords:\n",
      "allergy 0.534\n",
      "asit 0.337\n",
      "pollen 0.295\n",
      "season 0.237\n",
      "grass 0.211\n",
      "birch 0.211\n",
      "mpl 0.169\n",
      "mata mpl 0.169\n",
      "mata 0.169\n",
      "pollen season 0.126\n",
      "grass pollen 0.126\n",
      "birch pollen 0.126\n",
      "allergy season 0.126\n",
      "delayed 0.106\n",
      "variability 0.096\n",
      "deciding 0.07\n",
      "confounding 0.07\n",
      "launch 0.065\n",
      "flunked 0.061\n",
      "run 0.06\n",
      "\n",
      "Abstract:\n",
      "fair say topline data phase iii advocate trial avacopan come surprise sentiment turned complement factor c inhibitor failure inflarx similarly acting ifx hidradenitis suppurativa may investor feared class effect highly positive result advocate designed show noninferiority standard care avacopan found actually superior position project therapy choice rare disease anti neutrophil cytoplasmic antibody associated vasculitis analyst peg value market bn chemocentryx stock today giving company weighty bn valuation trial enrolled patient acute anca vasculitis condition overactivation complement pathway boost neutrophil activity causing inflammation destruction small blood vessel subject took either avacopan steroid prednisone current standard care plus either rituxan cyclophosphamide six month avacopan noninferior control remission rate assessed birmingham vasculitis activity score year however chemocentryx project statistically superior steroid cohort measure two measure co primary endpoint trial tested sequentially avacopan arm showed significant reduction glucocorticoid related toxicity might expected steroid sparing regimen significant improvement kidney function patient renal disease seen avacopan regimen chemocentryx said project better quality life measure said safety described anything better acceptable though numerically fewer subject serious adverse event avacopan group control approval application u europe come next year avacopan licensed vifor pharma outside u vifor sublicensed kissei japan weighing anca investor reaction data seems reflect expectation avacopan become new standard care initial treatment anca vasculitis remarkable turnaround since chemocentryx withdrew eu marketing application seeking early approval avacopan anca vasculitis june regulator might require study maintenance setting broadening label include use patient presumably open option avoid chronic high dose steroid lumbered today drug european composition matter patent expires u ip cover analyst forecasting peak sale early well blockbuster territory chemocentryx success lifted inflarx share investor latter clearly hoping advocate data provides positive read across phase ii anca vasculitis trial anti c asset ifx ifx project mid late stage development condition avacopan later stage development ifx though orally administered inflarx antibody intravenous even ifx match avacopan phase iii doubtful whether even make far given hidradenitis suppurativa debacle avacopan convenience give edge market\n",
      "\n",
      "Keywords:\n",
      "avacopan 0.62\n",
      "vasculitis 0.268\n",
      "ifx 0.238\n",
      "chemocentryx 0.238\n",
      "anca 0.238\n",
      "anca vasculitis 0.191\n",
      "inflarx 0.143\n",
      "steroid 0.139\n",
      "advocate 0.134\n",
      "vifor 0.089\n",
      "suppurativa 0.089\n",
      "hidradenitis suppurativa 0.089\n",
      "hidradenitis 0.089\n",
      "complement 0.085\n",
      "stage development 0.079\n",
      "standard care 0.077\n",
      "superior 0.074\n",
      "care 0.07\n",
      "standard 0.067\n",
      "application 0.064\n",
      "\n",
      "Abstract:\n",
      "surface might seem first mover advantage novartis early approval sickle cell treatment adakveo last week eliminated yesterday nod global blood therapeutic oxbryta voxelotor u regulator green lit daily pill three month early saying drug give additional hope people u live blood disorder question still remain around oxbryta impact long term outcome large number drug patient failed show benefit perhaps novartis much worry good good enough oxbryta approved basis increased haemoglobin response patient defined increase g dl following week treatment however patient hope trial took maximum g dose oxbryta met haemoglobin improvement threshold harder endpoint backed oxbryta effectiveness removed hope trial disappointing data early cut study included measure quality life rate vaso occlusive crisis seen risk company argued long term benefit increasing patient haemoglobin level thought include reduced risk stroke organ damage would enough win approval global blood launch bold bid early sickle cell approval june u regulator obviously convinced though global blood might find tougher audience come payer two drug better one industry bull might tempted argue given two drug different mechanism action used combination oxbryta improve haemoglobin level adakveo stop painful vaso occlusive crisis associated disorder gained approval last week sickle cell sufferer however go hospital emergency room vaso occlusive crisis oxbryta le clear benefit might make hard convince payer advantage combining two drug respective annual price tag adakveo oxbryta discount would cut oxbryta price year according global blood executive drug commercial potential seriously disappoint patient experience benefit real world sellside consensus revenue forecast collected agent approval sat bn oxbryta adakveo according evaluatepharma hanging achieving sale relies oxbryta staying market drug conditional approval succeed confirmatory trial even study measure surrogate endpoint transcranial doppler flow velocity indicates patient risk stroke according blood flow brain rather hard data stroke reduction argued fda given global blood easy ride given unmet need sickle cell perhaps understandable payer unlikely lenient however particularly competitor easily measured benefit available\n",
      "\n",
      "Keywords:\n",
      "oxbryta 0.506\n",
      "global blood 0.23\n",
      "blood 0.202\n",
      "adakveo 0.192\n",
      "haemoglobin 0.172\n",
      "sickle cell 0.16\n",
      "sickle 0.16\n",
      "two drug 0.144\n",
      "vaso occlusive crisis 0.138\n",
      "vaso occlusive 0.138\n",
      "vaso 0.138\n",
      "occlusive crisis 0.138\n",
      "occlusive 0.133\n",
      "global 0.128\n",
      "stroke 0.12\n",
      "payer 0.118\n",
      "crisis 0.113\n",
      "approval 0.101\n",
      "haemoglobin level 0.101\n",
      "risk stroke 0.096\n",
      "\n",
      "Abstract:\n",
      "genfit came close becoming biggest casualty yesterday discontinuation cymabay seladelpar little wonder french group moved morning issue statement protesting nash project elafibranor affected toxicity done seladelpar true cumulative year patient exposure elafibranor worrying finding toxicity worry efficacy safety genfit project major challenge today move continue pivotal resolve trial driven futility analysis rather genfit pointed routine safety review seventh analysis show toxicity signal resolve nash trial continue important interim readout first quarter genfit liver disease hail mary approach september luck cymabay yesterday canned nash asset seladelpar citing evidence interface hepatitis liver biopsy cymabay stock crashed surprising extent implies seladelpar much value begin reality asset already looked like dead duck flunked phase ii nash study june pivotal trial primary biliary cholangitis yesterday way ppar fallout net tightens around ppar agonist promising class metabolism drug disaster encompasses gamma specific asset glitazone diabetes drug like avandia contraindicated existence well glitazars act alpha gamma ppar subtypes discontinued owing toxicity cymabay seladelpar setback spell curtain delta specific ppars development another ppar delta agonist glaxosmithkline gw known scrapped year ago tumour seen rodent study big question genfit follower might mean elafibranor dual ppar agonist active alpha delta receptor genfit fell yesterday cymabay discontinuation announced recovered end day flat today group took unusual step directly naming competitor differentiate mechanistic specificity elafibranor trial elafibranor date issue interface hepatitis genfit stated prompting stock climb today focus genfit remains whether elafibranor efficacious question today safety clear answer given project mid stage golden study failure success phase iii look like long shot resolve fail genfit move press without confirmatory phase ii trial criticised interestingly two competing ppar delta specific industry asset remain early clinical trial abionyx cer reneo ren licensed vtv therapeutic though neither studied nash day might numbered\n",
      "\n",
      "Keywords:\n",
      "genfit 0.39\n",
      "ppar 0.301\n",
      "elafibranor 0.264\n",
      "seladelpar 0.244\n",
      "cymabay 0.238\n",
      "delta 0.183\n",
      "nash 0.182\n",
      "resolve 0.137\n",
      "toxicity 0.113\n",
      "interface hepatitis 0.112\n",
      "interface 0.112\n",
      "gamma 0.112\n",
      "cymabay seladelpar 0.112\n",
      "agonist 0.108\n",
      "specific 0.101\n",
      "ppar agonist 0.1\n",
      "yesterday 0.087\n",
      "hepatitis 0.087\n",
      "alpha 0.084\n",
      "asset 0.084\n",
      "\n",
      "Abstract:\n",
      "seems novartis cannot get enough commercially risky novel technology play year paying bn scandal prone avexis swiss group yesterday handed across bn medicine company lone asset rnai project inclisiran rather like avexis gene therapy zolgensma little clinical risk remains inclisiran however whether strong data translate anything close sellside commercial expectation lipid lowering product big unknown nevertheless biotech bull celebrate premium come top share price already boosted ongoing takeover rumour takeover speculation around medicine company prompted successive clinical success european society cardiology meeting inclisiran orion trial impressed showing reasonable safety promising ldl lowering activity resulting merck co mooted buyer week ago full data orion presented american heart association conference sparked share price spike novartis named leading acquirer aha medicine company reach star november clinical data made abundantly clear inclisiran target pcsk lower ldl cholesterol via rnai efficiently marketed anti pcsk mabs amgen repatha sanofi regeneron praluent problem however despite huge investment repatha praluent proved commercially disappointing sellside consensus drug compiled evaluatepharma nearly halved past month present inclisiran main advantage seems convenience small interfering rna given via twice yearly subcutaneous injection repatha praluent subcutaneously injected every two week monthly novartis insists inclisiran mega blockbuster potential major upcoming test breadth inclisiran reach patient cardiovascular outcome study orion expected read handy novartis hope sell drug using sale force currently responsible entresto heart failure drug approaching end patent life still commercially inclisiran remains risky evercore isi described medicine company takeover major execution story jefferies said inclisiran likely faced similar commercial problem repatha praluent notwithstanding convenient administration key part problem amgen sanofi effectively engaged price war bottom desperate bid get respective drug onto u formulary price cut would squeeze novartis opportunity even already medicine company said would price inclisiran discount repatha whether novartis u turn something look investor course highly encouraging novartis making bet risky technology approach company willingness undertake world first rnai therapy launch endorsement alnylam licensed inclisiran medicine company front alnylam rnai peer arrowhead morning opened respectively le positive outcome amarin nevertheless crept today despite proven fish oil based approach lipid lowering already market amarin remains bridesmaid bride\n",
      "\n",
      "Keywords:\n",
      "inclisiran 0.49\n",
      "medicine company 0.248\n",
      "repatha 0.237\n",
      "novartis 0.186\n",
      "praluent 0.184\n",
      "medicine 0.169\n",
      "rnai 0.151\n",
      "repatha praluent 0.148\n",
      "orion 0.148\n",
      "risky 0.115\n",
      "lowering 0.115\n",
      "commercially 0.102\n",
      "price 0.101\n",
      "avexis 0.095\n",
      "lipid lowering 0.092\n",
      "pcsk 0.089\n",
      "takeover 0.087\n",
      "amarin 0.083\n",
      "alnylam 0.083\n",
      "ldl 0.078\n",
      "\n",
      "Abstract:\n",
      "welcome weekly roundup approaching clinical readout pancreatic cancer marred clinical setback recent failure halozyme pegph many hope immuno oncology might start offer way forward step biolinerx tiny israeli biotech whose cxcr antagonist bl combined merck co keytruda chemotherapy phase ii combat keynote trial second line patient data due next month response rate revealed esmo io conference december abstract due december topline data important survival result emerge middle next year company hope show adding chemotherapy improve response rate generated dual combination bl keytruda tested earlier arm study generated disease control rate count response instance stable disease patient response seen however partial though many patient heavily pretreated five line prior therapy median overall survival month patient improved month patient considered second line finding prompted triple combo arm restricted second line population though small number involved absence control make next set data hard call regimen win approval second line pancreatic cancer setting onivyde fu leucovorin basis month overall survival versus month fu lv alone provides yardstick sort survival data still month biolinerx big improvement response rate dual therapy arm would lift hope triple combo fixxing pku homology meanwhile hope gene therapy offer new approach enzyme deficiency disease phenylketonuria pku condition sufferer unable break phenylalanine first clinical data hmi transfects patient functional copy phenylalanine hydroxylase gene due end year result three adult patient reported phase ii phenix study initial data expected patient dosed lowest level tested thought around x vg kg total subject recruited primary measure alongside safety drive phenylalanine level mol l patient enrolled study start level mol l analyst expect lowest dose show reduction phenylalanine reckon higher volume gene therapy required reach desired efficacy sign immune response monitored closely hmi us aav vector mitigate increase liver enzyme seen aav based gene therapy subject phenix trial prophylactically dosed steroid data provide first look homology technology since group completed ipo march position company biggest threat biomarin disease area homology share since float biomarin dominates pku two product market including enzyme replacement therapy palynziq gene therapy project bmn due start clinical testing next year meanwhile enthusiasm rubius rtx us red blood cell deliver missing therapeutic protein taken knock owing delay patient recruitment\n",
      "\n",
      "Keywords:\n",
      "phenylalanine 0.256\n",
      "pku 0.179\n",
      "homology 0.179\n",
      "gene 0.151\n",
      "second line 0.146\n",
      "patient 0.141\n",
      "gene therapy 0.136\n",
      "enzyme 0.13\n",
      "therapy 0.13\n",
      "response 0.127\n",
      "pancreatic cancer 0.12\n",
      "aav 0.114\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "survival 0.113\n",
      "triple combo 0.109\n",
      "pancreatic 0.105\n",
      "line 0.103\n",
      "month 0.1\n",
      "lowest 0.1\n",
      "response rate 0.097\n",
      "biomarin 0.091\n",
      "\n",
      "Abstract:\n",
      "david chang saw end goal early chief medical officer kite pharma company ever allogeneic cell therapy deal ucla secure supply pluripotent stem cell chief executive allogene repeated trick licensing notch therapeutic stem cell technology month speaking vantage week jefferies conference london mr chang said within month allogene creation recognised need secure cell supply course done kite allogeneic cell therapy company point start thinking renewable cell source state since approval kymriah yescarta development autologous cell therapy product stalled many investor see allogeneic shelf therapy breakthrough move needle however first generation allogeneic player hit production bottleneck struggled cell derived healthy donor tend heterogeneous variable quality needed goal produce reliable universal product single cell using induced pluripotent stem cell ipscs source however likened another player field fate therapeutic going monoclonal antibody principle starting single cell line idea virtually adult cell petri dish regressed ipsc phenotype using clever science reprogrammed defined mature cell infinitely expanded ipsc differentiated depends developer focus allogene clearly working cell whereas fate initially targeting nk cell therapeutic come degree difficulty mr chang argues differentiating ipscs nk cell possibly easy say allogene actively went source technology several potential partner though course ucla work longer available without going scientific minutia notch team underlying concept ucla say mr chang however notch approach serum free cell free system differentiate ipscs ucla technology pioneered dr gay crook known artificial thymic organoid us called feeder cell top desired ipsc derived cell differentiated said notch deal caused degree consternation allogene investor seeing demonstrating lack confidence cellectis donor derived approach mr chang say taken aback pushback stress transition autologous allogeneic bet single technology stepwise process nevertheless clear implication time cellectis current healthy donor cell source approach become obsolete though mr chang accepts science quite implement notch technology clinical programme say way see future whether five year line renewable cell source\n",
      "\n",
      "Keywords:\n",
      "cell 0.415\n",
      "chang 0.309\n",
      "notch 0.258\n",
      "mr chang 0.258\n",
      "allogene 0.229\n",
      "ucla 0.206\n",
      "allogeneic 0.184\n",
      "source 0.164\n",
      "ipscs 0.155\n",
      "ipsc 0.155\n",
      "cell source 0.155\n",
      "mr 0.131\n",
      "donor 0.128\n",
      "stem cell 0.124\n",
      "stem 0.115\n",
      "technology 0.114\n",
      "differentiated 0.097\n",
      "derived 0.095\n",
      "cell therapy 0.093\n",
      "allogeneic cell therapy 0.088\n",
      "\n",
      "Abstract:\n",
      "fda swift review givosiran second rnai based therapeutic win marketing approval speaks growing comfort technology across industry string hefty deal struck dicerna recently alnylam success getting project market rnai field making great progress givosiran sold givlaari approved two half month ahead pdufa date around five half month first submitted fda speed laudable novel technology rare disease space approval far quickest regulatory action seen analysis reveals number based date fda receives application recorded official approval decision letter company frequently cite timeline based acceptance nda boasting quick decision presumably method lead smaller number however acceptance nda left company announce inevitable gap disclosure make thorough analysis tricky detract alnylam achievement approved rare condition acute hepatic porphyria givlaari first therapy reduce frequency painful attack plague suffers condition exactly many patient still unknown hence use novel payment structure make givlaari list price per annum palatable alnylam worked harvard pilgrim include value based agreement industry first prevalence based agreement value based deal full price givlaari payable patient outcome real world similar achieved clinical trial payment metric becoming increasingly common arguably bold move given trial structured include patient thought likely benefit mark alnylam arrangement truly innovative prevalence based agreement designed stop cost ballooning payer event unexpectedly large patient number rebate triggered number diagnosed patient exceeds epidemiologic estimate ahp alnylam belief patient u europe qualify treatment ahp market proven hard size due difficulty diagnosis limited physician awareness disorder biopharma sector interest rare disease showing sign waning seems likely arrangement become common alnylam reckons givlaari sale reach around sellside slightly optimistic consensus currently sits peak sale reaching almost according evaluatepharma early comment financial analyst hint little change number though product fare coming year closely scrutinised\n",
      "\n",
      "Keywords:\n",
      "alnylam 0.339\n",
      "givlaari 0.338\n",
      "based agreement 0.228\n",
      "based 0.191\n",
      "agreement 0.146\n",
      "half month 0.142\n",
      "prevalence 0.135\n",
      "acceptance 0.135\n",
      "number 0.13\n",
      "nda 0.125\n",
      "arrangement 0.118\n",
      "payment 0.109\n",
      "rare 0.108\n",
      "rnai 0.103\n",
      "patient 0.1\n",
      "rare disease 0.096\n",
      "common 0.086\n",
      "fda 0.08\n",
      "condition 0.078\n",
      "industry 0.076\n",
      "\n",
      "Abstract:\n",
      "amarin vascepa virtually assured broader u label enjoyed far others hoping jump fish oil bandwagon next important clinical datapoint come small canadian biotech called acasti whose rival project capre yield phase iii result next month say amarin suddenly major competitor acasti trial narrow severe hypertriglyceridaemia setting acasti capitalised investment case point might positive data attract player keen get foothold space deal magnitude represent relatively small outlay bull might think cash rich partner finance large cardiovascular outcome study necessary broaden capre potential label bring line vascepa look set shortly enjoy said consideration one thing next year see readout large cardiovascular outcome trial astrazeneca epanova huge ramification player moreover vascepa set lose patent protection around time potential cardiovascular outcome trial capre would expected complete important remember competing omega project comprises vascepa pure form eicosapentaenoic acid epa competitor contain mixture epa docosahexanoic acid dha product lower triglyceride amarin argues containing dha raise ldl bad cholesterol something epa acasti different argument capre epa dha mixture sourced krill oil group claim yield phospholipid transport omega fatty acid efficiently fish oil derived epa dha must undergo additional digestion canadian company running two near identical pivotal trial trilogy screened subject obtain expected fasting triglyceride severe range namely mg dl aim show capre reducing baseline week statistical significance versus placebo bull want acasti repeat success capre scored five year ago trifecta phase ii placebo controlled study data cleanup complete trilogy expected read december trilogy toplined january full data including result key secondary exploratory endpoint like non hdl c ldl c vldl hdl c hba c expected scientific meeting starting next year basf ex pronova takeda glaxosmithkline u ex reliant amarin omega player show cardiovascular benefit company completed study expects reap reward amarin enters home stretch november debate around product component settled additional cardiovascular outcome study epanova strength trial read much earlier development matinas bio developing mat formulation dpa docosapentaenoic acid matinas describes potent le prevalent omega fatty acid year ago small open label head head trial suggested superiority versus vascepa lipid change phase ii enhance study versus amarin drug start next year broad setting remains rich small biotech compete shift severe hypertriglyceridaemia landscape provide impetus deal making\n",
      "\n",
      "Keywords:\n",
      "capre 0.297\n",
      "amarin 0.249\n",
      "epa 0.248\n",
      "acasti 0.248\n",
      "omega 0.223\n",
      "vascepa 0.212\n",
      "dha 0.198\n",
      "acid 0.181\n",
      "cardiovascular outcome 0.166\n",
      "trilogy 0.149\n",
      "cardiovascular 0.141\n",
      "oil 0.127\n",
      "outcome 0.107\n",
      "epanova 0.104\n",
      "outcome trial 0.095\n",
      "fatty 0.095\n",
      "cardiovascular outcome trial 0.095\n",
      "cardiovascular outcome study 0.092\n",
      "canadian 0.092\n",
      "next 0.09\n",
      "\n",
      "Abstract:\n",
      "first cholesterol lowering rna interference therapy look like way full data orion trial confirm medicine company inclisiran comparable lipid lowering efficacy similarly acting anti pcsk antibody repatha praluent company share surged early trade today record high rumour takeover approach novartis named leading contender medicine company file inclisiran fda year eu application follow couple month later group belief inclisiran represents vastly different value proposition antibody thanks convenient dosing whether doctor payer agree important question much depend price company chooses launch new data almost certainly good enough approval orion result presented american heart association meeting saturday inclisiran reduced ldl c placebo month better seen similar orion trial september esc medicine company impress inclisiran september placebo adjusted reduction ldl seen orion data pooled line data repatha praluent showed placebo adjusted ldl lowering medicine company looked ahead orion study vast cardiovascular outcome trial due report around five year time exploratory analysis pooled orion data showed risk reduction cardiovascular event using company projected five year relative risk reduction mace rate orion though slight imbalance cv death heart attack stroke orion might give pause expand reach aha data came orion study heterozygous familial hypercholesterolaemia presented yesterday showed ldl lowering month safety clean data slightly different population expand potential reach inclisiran conference call medicine company made much drug twice yearly administration comparing flu vaccine stating would solve problem dwindling adherence seen repatha praluent may pricing drug tricky line walk amgen regeneron sanofi difficulty setting acceptable price repatha praluent eventually forced settle le half wanted regeneron sanofi play follow leader praluent pricing february may decision someone else headache despite tripling group share price acquisition considered real possibility novartis management far refused comment rumoured candidacy buyer data like feasible big pharma group interest cardiovascular space taking serious look medicine company cheap apple pluck morning market cap shy bn notion inclisiran launch might depress valuation well give interested party pause\n",
      "\n",
      "Keywords:\n",
      "orion 0.443\n",
      "inclisiran 0.31\n",
      "medicine company 0.247\n",
      "praluent 0.228\n",
      "repatha praluent 0.197\n",
      "repatha 0.189\n",
      "medicine 0.168\n",
      "ldl 0.155\n",
      "lowering 0.153\n",
      "orion trial 0.103\n",
      "regeneron sanofi 0.098\n",
      "ldl lowering 0.098\n",
      "company 0.097\n",
      "data 0.088\n",
      "pooled 0.084\n",
      "pause 0.084\n",
      "cardiovascular 0.084\n",
      "risk reduction 0.079\n",
      "pricing 0.072\n",
      "placebo adjusted 0.07\n",
      "\n",
      "Abstract:\n",
      "myovant look like might able add second string bow lead asset relugolix apparent success hormone sensitive prostate cancer trial lead u filing perhaps helping sumitomo dainippon pharma justify recent purchase stake myovant much prostate cancer setting amount key question however thorough analysis hero study read today needed determine whether relugolix efficacy merely line leuprolide established androgen deprivation therapy stage prostate cancer relugolix potential lay mainly uterine fibroid phase iii win greeted concern prospect expensive launch myovant punished success may today myovant surged hope company change standard care androgen deprivation prostate cancer hero tested relugolix gnrh antagonist head head leuprolide lhrh agonist aim ultimately reduce testosterone production slow prostate cancer becomes castration resistant ever devil detail face relugolix simply demonstrated non inferiority leuprolide hero primary efficacy measure testosterone suppression castration level week showed response rate relugolix versus leuprolide according trial design met non inferiority threshold demonstrating non inferiority necessary eu approval myovant stressed relugolix efficacy well set threshold u approval lower bound confidence interval response rate must least met hero study myovant said relugolix showed superiority leuprolide five secondary endpoint high degree statistical significance key additional data point castration resistance free survival expected emerge hero third quarter next year however significant relevant measure might relugolix real benefit lie safety convenience leuprolide myovant make case doctor payer specifically nature mechanism action leuprolide cause initial increase testosterone worsen disease symptom clinical flare seen relugolix myovant said mean testosterone level returned normal within day treatment discontinuation hero moreover relugolix given orally lhrh agonist injected hormone allow myovant make case convenient therapy fit growing relevance oral drug like xtandi zytiga injected chemotherapy early treatment prostate cancer relugolix set filed next year focus switch myovant ability convince doctor turn away established therapy whether hero data enable relugolix priced significant premium leuprolide another consideration whether abbvie marketed gnrh antagonist orilissa tested prostate cancer\n",
      "\n",
      "Keywords:\n",
      "relugolix 0.463\n",
      "leuprolide 0.374\n",
      "myovant 0.348\n",
      "hero 0.291\n",
      "prostate cancer 0.219\n",
      "prostate 0.213\n",
      "testosterone 0.175\n",
      "castration 0.116\n",
      "cancer 0.114\n",
      "non inferiority 0.099\n",
      "inferiority 0.097\n",
      "prostate cancer relugolix 0.088\n",
      "cancer relugolix 0.088\n",
      "make case 0.08\n",
      "androgen 0.08\n",
      "gnrh antagonist 0.075\n",
      "injected 0.07\n",
      "gnrh 0.07\n",
      "hormone 0.064\n",
      "threshold 0.063\n",
      "\n",
      "Abstract:\n",
      "another day another deal dicerna yesterday unveiled substantial collaboration diabetes giant novo nordisk week ink dried hepatitis b pact roche big drug developer comfortable enough rna based technology start committing substantial amount money company research platform benefiting rna approach derisked large programme like medicine company inclisiran concern target toxicity great marcus schindler head novo drug discovery told vantage belief biggest challenge facing dicerna collaboration finding novel target relevant cardio metabolic condition focus extremely high confidence found target truly expressed hepatocytes dicerna able knock worried burden biology said novo increasing effort big data genomics bioinformatics find new target mr schindler said deal see liver cell target investigated disease nash diabetes obesity well rare condition term transaction include front fee dicerna equity investment novo struck substantial premium rnai specialist recent share price well three year help fund discovery development milestone due project taken forward dicerna technology generates therapy designed silence disease driving gene liver mr schindler said company technology highly tuned hepatocytes hoped see project minimal systemic exposure good tolerability emerging clinical work commence two three year deal certainly typical novo early stage though represents company first move rna danish company shown interest novel technology recently last year struck genome editing collaboration bluebird bio haemophilia mr schindler said novo remained interested adding novel treatment modality access dicerna platform bring ability address intracellular target particularly relevant many cardio metabolic condition company existing peptide platform largely focus extracellular secreted protein though argued technology sit completely different world still talking injectables field extremely well versed nucleotide chemistry far away peptide chemistry said give u lot tool address biological target relevance collaboration small step novo represents something much larger dicerna climbed news yesterday close four half year high deal fifth extensive date extra cash leaf company well financed around bank analyst reckon dicerna easily enough fund launch house rare disease project dcr phxc pivotal data emerge later next year sort validation long time coming dicerna floated even got project clinic promptly saw share price triple exuberance short lived however high risk rnai space taken year prove worth rnai still far mainstream course collaboration typically cautious developer like novo much move technology general direction\n",
      "\n",
      "Keywords:\n",
      "dicerna 0.426\n",
      "novo 0.294\n",
      "schindler 0.243\n",
      "collaboration 0.176\n",
      "technology 0.161\n",
      "target 0.153\n",
      "rnai 0.124\n",
      "platform 0.124\n",
      "rna 0.117\n",
      "hepatocytes 0.114\n",
      "chemistry 0.114\n",
      "peptide 0.108\n",
      "cardio 0.108\n",
      "substantial 0.099\n",
      "metabolic 0.095\n",
      "address 0.095\n",
      "condition 0.093\n",
      "mr 0.093\n",
      "discovery 0.092\n",
      "novel 0.088\n",
      "\n",
      "Abstract:\n",
      "vital robust phase ii result hand rolling dice ploughing pivotal development puretech health affiliate karuna probably enough today mid stage win schizophrenia psychosis caution warranted cns project often struggle replicate phase iii positive result seen earlier whether cns amount dressing bad data avert later disaster puretech found friday lead asset another affiliate restorbio bombed phase iii outcome highly predictable given phase ii data reported last year best mixed restorbio writing wall ever since company trumpeted success rtb phase ii trial aiming reduce incidence respiratory tract infection elderly patient fact data way analysed flawed vantage argued time restorbio clutch straw investor say fine july little wonder restorbio pushed phase iii regardless red flag later study blew face friday group crashed saying pivotal protector trial bust rtb development elderly people respiratory disease would halted numerically subject actually worse rtb placebo according protector primary endpoint group said wanted understand difference rtb activity observed protector compared prior phase ii study apparently forgetting phase ii nothing write home karuna win least better news karuna whose karxt today overcame first hurdle impressive result phase ii trial schizophrenia acute psychosis causing share rocket early trading company market cap bn patient study showed placebo adjusted point mean reduction total positive negative syndrome scale pan score week statistically significant result karuna noted antipsychotic historically approved five point minimum improvement treatment placebo similar rate weight gain somnolence issue often plagued older schizophrenia drug karuna project contains trospium chloride xanomeline latter active ingredient originated lilly showed placebo adjusted point total pan score change small schizophrenia trial however association cholinergic adverse event excessive sweating nausea vomiting diarrhoea necessitating co formulation trospium chloride muscarinic receptor antagonist mitigate side effect karuna phase iii real test lie often case larger cns trial effect size narrow improvement seen placebo patient karuna phase ii study average decrease point lower side typically seen control arm schizophrenia study company put design trial karuna expect start phase iii end next year early trial pain alzheimer disease psychosis due read second half puretech owns around karuna restorbio quite turnaround company fell friday today rise erased loss\n",
      "\n",
      "Keywords:\n",
      "karuna 0.515\n",
      "restorbio 0.268\n",
      "schizophrenia 0.236\n",
      "rtb 0.229\n",
      "phase 0.168\n",
      "phase ii 0.129\n",
      "ii 0.128\n",
      "cns 0.125\n",
      "often 0.11\n",
      "chloride 0.107\n",
      "affiliate 0.107\n",
      "placebo 0.103\n",
      "elderly 0.102\n",
      "friday 0.101\n",
      "showed placebo adjusted 0.098\n",
      "showed placebo 0.098\n",
      "phase iii 0.091\n",
      "iii 0.088\n",
      "pan 0.082\n",
      "trial 0.079\n",
      "\n",
      "Abstract:\n",
      "time six year ago heavily indebted amarin whose market cap crushed tiny waiting fda turn application market vascepa bigger patient population fast forward picture look different unanimous vote fda advisory panel yesterday almost guarantee broader label purified fish oil product big remaining question many patient regulator prepared include new indication decision due end year wait find soon use mineral oil placebo considered one big issue heading adcom event panellist judged unlikely influenced finding reduce study vascepa future hinge next week panel november main focus assembled expert instead whether vascepa new indication restricted secondary prevention setting meaning patient established cardiovascular disease le fifth subject recruited reduce fitted primary prevention description considered risk future cardiac problem benefit vascepa much le pronounced cohort fda reason err side caution even panel particularly concerned safety flag like atrial fibrillation bleeding panellist advocating encompassing label sellside analyst modelling revenue restricted population peak number sitting around bn implies net present value vascepa around bn according evaluatepharma npv analyzer pretty much amarin market cap today share company surged sevenfold since reduce surprised reading positively edged higher morning exactly vascepa bestows cardioprotective quality remains unanswered perhaps another reason fda might decide broad label amarin announced plan study drug primary prevention setting vascepa patent running around u probably little reason commercial company run trial small academic study presented late breaker american heart association annual meeting weekend make interesting reading however evaporate trial look vascepa ability stabilise artery plaque recruited statin treated patient atherosclerosis measuring change plaque volume subject treated vascepa placebo strong finding would add vascepa story provided biopharma watcher riveting ride past decade yet though certainly longer look like disaster movie indeed many hoping tale ultimate happy ending buyout\n",
      "\n",
      "Keywords:\n",
      "vascepa 0.536\n",
      "amarin 0.157\n",
      "prevention 0.148\n",
      "panel 0.136\n",
      "primary prevention 0.132\n",
      "panellist 0.125\n",
      "prevention setting 0.12\n",
      "plaque 0.12\n",
      "reduce 0.117\n",
      "new indication 0.116\n",
      "oil 0.107\n",
      "around bn 0.105\n",
      "restricted 0.103\n",
      "fda 0.099\n",
      "reason 0.094\n",
      "reading 0.089\n",
      "label 0.084\n",
      "recruited 0.082\n",
      "around 0.072\n",
      "treated 0.071\n",
      "\n",
      "Abstract:\n",
      "welcome weekly roundup approaching clinical readout investor interest wave life science centred around duchenne muscular dystrophy product suvodirsen lot riding outcome phase ii trial huntington disease asset wve wve positive result see takeda exercise option develop asset road far smooth earlier year wave share fell almost result two trial delayed slow patient enrolment data wve due end quarter wve result expected early next year trial primarily designed look safety tolerability measurement include change huntingtin htt protein secondary endpoint functional change measured unified huntington disease rating scale examined early sign disease modification although data available end year wave two antisense oligonucleotides bind htt mrna preventing production mutant protein lie behind huntington disease company alone tackling disorder roche ionis rg pivotal generation hd trial filed early project knock healthy mutant form htt gene alike wave hope leaving healthy htt alone might prove safer bet long term effect knocking expression wild type htt gene unknown antisense treatment might eventually come pressure uniqure find success huntington gene therapy amt due start phase ii trial early next year huntington market big enough multiple therapy wave want avoid delay second rather third market e sale subcutaneous key meanwhile argenx lead targeting neonatal fc receptor fcrn hanging thread company need show latest subcutaneous formulation efgartigimod deliver argenyx using iv form pivotal trial sc version must project gain ground chronic autoimmune disorder phase study sc efgartigimod due report end year project us halozyme enhanze technology need show non inferiority potentially interchangeability iv formulation primary endpoint igg level week treatment efgartigimod antibody fragment work binding fcrn control breakdown igg reducing level igg circulating body goal treatment igg mediated autoimmune disease like myasthenia gravis immune thrombocytopenia phase result define argenx commercial plan including potential bridging later stage iv study speed sc project clinical development argenx signed exclusive license halozyme back february upfront preventing competitor collaborating halozyme argenx sc form subject halozyme deal designed maintenance dosing competition fcrn space far behind argenx cannot afford slip ucb whole antibody rozanolixizumab delivered sc although infusion rather injection like efgartigimod rozanolixizumab phase iii trial myasthenia gravis phase ii result due ash primary immune thrombocytopenia efgartigimod npv bn according evaluatepharma nearly matching argenx bn market cap dutch biotech plenty cash ended third quarter bn bank recently topped equity raise brought alexion iv intravenous sc subcutaneous gmg generalized myasthenia gravis source evaluatepharma credit suisse clinicaltrials gov\n",
      "\n",
      "Keywords:\n",
      "sc 0.303\n",
      "htt 0.252\n",
      "argenx 0.25\n",
      "huntington 0.216\n",
      "efgartigimod 0.216\n",
      "halozyme 0.189\n",
      "wve 0.18\n",
      "wave 0.177\n",
      "igg 0.173\n",
      "iv 0.157\n",
      "myasthenia gravis 0.135\n",
      "myasthenia 0.135\n",
      "gravis 0.135\n",
      "huntington disease 0.129\n",
      "fcrn 0.129\n",
      "subcutaneous 0.105\n",
      "rozanolixizumab 0.09\n",
      "immune thrombocytopenia 0.09\n",
      "thrombocytopenia 0.083\n",
      "antisense 0.079\n",
      "\n",
      "Abstract:\n",
      "assembly bioscience recent share price jump data presented aasld meeting look short lived update ongoing mid stage trial abi h confirmed hepatitis b project impact various marker viral infection becoming increasingly clear far company still travel real measure abi h efficacy occur dosing withdrawn virally supressed patient assembly confirmed week phase study start next year conference call executive talked apparent superiority follow project abi h behind phase ib asset start look like horse back road ahead assembly look even longer assembly focus core modulation target virus replication machinery company alone roche ro johnson johnson jnj considered biggest competitor thought agent work way become vital component future combination hep b therapy j j already testing theory first data triple combo trial emerged aasld showing encouraging viral suppression using cocktail jnj closely watched rnai candidate licensed arrowhead jnj nucleoside inhibitor roche plan ro known rg immediately clear group presented phase data previous liver conference study started company would answer specific question asset roche certainly invested hepatitis b recently paid phase dicerna rna based therapy much read decision scrap push ahead core inhibitor smoke signal hepatitis b infection driven complex poorly understood biology still unclear biomarkers useful assessing patient long term response widely accepted effective hep b agent must show dramatic suppression viral dna rna surface antigen known hbsag hep b virus us fragment trigger rebound though ultimately life source believed cccdna minichromosome deposit liver cell researcher believe level viral dna rna hbsag suppressed long enough cccdna start decay functional cure achieved termed functional integrated viral dna likely remain host thought capable reviving infection however viral dna effectively suppressed existing nucleotide inhibitor decline viral rna hbsag particular considered crucial measure new therapy hbsag measure assembly disappointed update easl april study treatment naive subject given abi h patient registered decline hbsag greater log time update year aasld one patient passed threshold larger trial patient already suppressed nucleotide inhibitor result slightly encouraging seven showing greater log decrease hbsag company explanation largely rested mechanism core inhibitor work meaning measure take time drop\n",
      "\n",
      "Keywords:\n",
      "hbsag 0.301\n",
      "assembly 0.275\n",
      "viral 0.267\n",
      "abi 0.22\n",
      "viral dna 0.209\n",
      "dna 0.183\n",
      "hep 0.157\n",
      "rna 0.151\n",
      "aasld 0.15\n",
      "suppressed 0.145\n",
      "core 0.137\n",
      "jnj 0.131\n",
      "hepatitis 0.122\n",
      "viral dna rna 0.11\n",
      "dna rna 0.11\n",
      "core inhibitor 0.11\n",
      "greater log 0.104\n",
      "suppression 0.1\n",
      "nucleotide 0.1\n",
      "inhibitor 0.098\n",
      "\n",
      "Abstract:\n",
      "reporting detailed result tulip trial systemic lupus erythematosus sle astrazeneca confident anifrolumamb hit market early notwithstanding earlier phase iii failure fear group might need another confirmatory trial following tulip flop potentially pushing approval several year speaking vantage today richard marshall senior vice president late stage r astra brushed aside suggestion delay said uk group would move rapidly get anifrolumab front regulator patient soon possible achieving filing launch ambition depend u european regulator accepting data package includes positive readout phase ii muse trial sub analysis tulip full phase iii data tulip amended endpoint might play well limited treatment option lupus tulip already toplined positive yesterday revealed anifrolumab led patient showing reduced disease activity versus placebo arm judged bicla composite measure remembered tulip tulip initially similar trial design primary endpoint number patient achieving sle responder index score sri greater week versus standard care following tulip failure tulip unblinded astra changed primary endpoint latter bicla let flip remains debate industry two measure best reflects efficacy notoriously hard treat condition bicla requires partial improvement seen organ whereas sri measured complete response lupus symptom today mr marshall said bicla stringent measure captured totality disease measure anifrolumab shown compelling evidence efficacy disease activity consistently across three trial however keen point anifrolumab sri win muse trial measure validated regulator shown impact across measure said regulator prepared validate crux issue one important driver going unmet need mr marshall much aware stating anifrolumab represents new first class treatment disorder high disease burden historic precedent fda generous come disease alternative glaxosmithkline benlysta u approval basis unmet need despite one pivotal trial failing beat placebo next hurdle glaxosmithkline found regulatory success always add commercial win much made benlysta first new lupus treatment year launched sale never really lived initially lofty expectation recent increase mainly driven launch self injectable subcutaneous formulation launching benlysta sale finally forecast tip bn mark according evaluatepharma anifrolumab make past regulator priced competitively opportunity huge\n",
      "\n",
      "Keywords:\n",
      "tulip 0.546\n",
      "anifrolumab 0.364\n",
      "bicla 0.243\n",
      "lupus 0.194\n",
      "measure 0.146\n",
      "regulator 0.144\n",
      "unmet need 0.09\n",
      "unmet 0.09\n",
      "disease 0.087\n",
      "trial 0.084\n",
      "achieving 0.079\n",
      "following 0.067\n",
      "astra 0.063\n",
      "launch 0.062\n",
      "need 0.062\n",
      "mr 0.062\n",
      "initially 0.062\n",
      "endpoint 0.059\n",
      "glaxosmithkline 0.059\n",
      "win 0.057\n",
      "\n",
      "Abstract:\n",
      "usually impossible repeat positive phase ii result rigorous setting phase iii reata demonstrated cardinal study lead asset bardoxolone rare kidney disease alport syndrome said efficacy data undeniably still positive fact borne group move proceed regulatory filing say approval assured course key question whether latest result reignite concern hyperfiltration long held reata bear thesis thesis hold bardoxolone work overworking kidney causing hyperfiltration result strong initial benefit however wane eventually perhaps even lead speeding renal failure progression leerink analyst remaining bullish bardoxolone accepted detailed proteinuria data might needed disprove potential hyperfiltration bardoxolone expected sell bn according evaluatepharma sellside consensus resounding win subject open label phase ii portion cardinal reata appeared score resounding victory bardoxolone treatment caused estimated glomerular filtration rate egfr increase ml min baseline week remained ml min baseline four week washout time reata said hoping replicate kind benefit placebo controlled patient phase iii part cardinal specifying four week withdrawal analysis wanted see delta least ml min managed trump beating placebo time point high level statistical significance p value however achieved part placebo recipient experienced relatively large decline egfr indeed four week withdrawal stage subject bardoxolone actually saw egfr decline baseline almost ml min reata bear latch reata provided fuel fire pointing tolvaptan approved chronic kidney disease basis small egfr benefit placebo active placebo cohort experienced baseline decline argued analyst call today indicated mere slowing rather stopping egfr decline problem bearish reading phase iii cardinal data construed showing exactly thing four week withdrawal group showed egfr decline reata argued decline slight non significant versus baseline stressed analysis included subject including low dose patient discontinued might depressed absolute benefit proteinuria said albuminuria unchanged withdrawal increased week unchanged adjusted egfr fda care change albuminuria care change egfr told analyst reata stock initially fell premarket open impressive especially surge last month bardoxolone omaveloxolone bought back abbvie latter scored friedreich ataxia study considering threat fund raising remains risk u fda might ask longer term analysis cardinal allay risk hyperfiltration investor happy live\n",
      "\n",
      "Keywords:\n",
      "reata 0.36\n",
      "bardoxolone 0.331\n",
      "egfr 0.301\n",
      "cardinal 0.253\n",
      "ml min 0.202\n",
      "min 0.202\n",
      "hyperfiltration 0.202\n",
      "ml 0.189\n",
      "decline 0.173\n",
      "withdrawal 0.167\n",
      "four week withdrawal 0.152\n",
      "four week 0.145\n",
      "baseline 0.124\n",
      "kidney 0.095\n",
      "resounding 0.095\n",
      "week 0.091\n",
      "placebo 0.091\n",
      "unchanged 0.09\n",
      "benefit placebo 0.086\n",
      "thesis 0.075\n",
      "\n",
      "Abstract:\n",
      "nextcure found morning sitc give take away group stock surged abstract presentation immunotherapy conference unveiled full data presented saturday failed enthuse today reason resumed seat nextcure crashed better news meeting nektar pieris celyad investor nextcure debacle serve cautionary tale desperation single agent activity pd l refractory cancer considerable nextcure managed wipe almost gain made week ago enthusiasm prompted second partial remission nextcure nc anti siglec mab seen lung cancer cohort earlier partial response deepened became complete group trial treatment refractory solid tumour market keen additional sign activity emerge full sitc presentation instead became apparent many patient nc work trial given mab nsclc seven melanoma seven ovarian four breast three colorectal cancer subject without additional efficacy reported beyond two already known response thing got worse complete response come lowest mg nc dose raising question much higher dos appear relatively inactive nextcure failed back argument mab efficacy siglec biomarker data promising siglec expression would evaluated retrospectively phase ii dose expansion pieris hand disappoint delivered promise show first human response pr bb bispecific five evaluable positive subject got highest mg kg every two week dose two responded remission seen lower dos however pieris stressed efficacy linked biomarker evidence bb agonism early say whether pr turn cold tumour hot one responder failed treatment keytruda opdivo pd l positive biomarker data second provided pieris opened cautious morning meanwhile celyad protracted spell without meaningful data ended sitc company making case allogeneic cell therapy alloshrink trial cyad yielded two partial response relapsed colorectal cancer patient treated far respectable indication early efficacy cancer equally important allogeneic cell therapy fact graft versus host disease seen monitored closely cyad dose escalated data subject recruited expected first quarter next year like celyad autologous lead cyad cyad target nkg ligand behind cyad lie tcr inhibitory molecule concept silence endogenous cell receptor cause gvhd though fact might celyad brightest allogeneic hope earlier stage celyad asset use short hairpin rna technology knock cell receptor last quartet sitc relevant stock nektar morning though update troubled pivot study basically rehash data already seen asco main difference one previously pd l negative subject first line melanoma trial bempegaldesleukin plus opdivo classified pd l positive company argued remission already seen deepening indeed across pivot nine complete response started partial remission since opdivo plus yervoy already approved setting back similar orr data checkmate study nektar best bet present seems play bempegaldesleukin relatively cleaner safety\n",
      "\n",
      "Keywords:\n",
      "nextcure 0.294\n",
      "cyad 0.257\n",
      "celyad 0.245\n",
      "pieris 0.188\n",
      "sitc 0.172\n",
      "siglec 0.165\n",
      "nc 0.165\n",
      "partial 0.135\n",
      "nektar 0.126\n",
      "allogeneic 0.118\n",
      "response 0.109\n",
      "remission 0.107\n",
      "pd 0.106\n",
      "biomarker 0.103\n",
      "cancer 0.095\n",
      "cell receptor 0.094\n",
      "biomarker data 0.094\n",
      "allogeneic cell therapy 0.094\n",
      "allogeneic cell 0.094\n",
      "pr 0.091\n",
      "\n",
      "Abstract:\n",
      "trenchant doubter roxadustat today feeling comfortable future astrazeneca fibrogen new anaemia pill major presentation weekend threw substantial area concern regard roxadustat cardiac safety chance project reaching market look increased next hurdle regulatory u advisory panel meeting virtually assured discovery unappreciated finding large dataset never ruled final decision might made hard tell roxadustat partner conducted large complex clinical programme regulator want take time dig data regulatory uncertainty perhaps fibrogen share opened lower morning possibility fund raising back ostensibly positive data another sellside naturally came support project though often case situation company yet disclose probably important main thrust roxudustat programme prove project oral hif ph inhibitor safer erythropoiesis stimulating agent esas epos therapy widely used decade treat anaemia caused kidney disease black box warning increased risk cardiovascular issue restricted use need patient dependent dialysis example rarely given epo main aim term u trying remove boxed warning show compared epo increase cardiovascular risk compared background rate already patient john houghton astrazeneca global medicine leader told vantage believe result show\n",
      "\n",
      "Keywords:\n",
      "roxadustat 0.273\n",
      "epo 0.202\n",
      "fibrogen 0.187\n",
      "anaemia 0.165\n",
      "increased 0.13\n",
      "warning 0.129\n",
      "main 0.127\n",
      "compared 0.119\n",
      "cardiovascular 0.115\n",
      "large 0.109\n",
      "regulatory 0.104\n",
      "want take 0.101\n",
      "thrust 0.101\n",
      "project though 0.101\n",
      "ostensibly positive 0.101\n",
      "dig 0.101\n",
      "cardiac safety 0.101\n",
      "take time 0.097\n",
      "ph inhibitor 0.097\n",
      "ostensibly 0.097\n",
      "\n",
      "Abstract:\n",
      "welcome weekly roundup approaching clinical readout axsome due report data end year ax acute migraine patient inadequate response prior acute treatment acute migraine therapy dominated generic triptans ax combination rizatriptan cox nsaid meloxicam essentially designed better version older drug mean axsome aiming different slice market oral cgrp inhibitor example likely reserved patient respond triptans cannot take drug linked cardiovascular side effect ax us axsome moseic technology designed improve drug absorption leerink analyst say project find niche faster onset version established component help ax gain market share front line setting price hindrance ax might end cardiovascular warning label like triptans first project need win phase iii momentum trial patient study testing ax versus rizatriptan meloxicam alone placebo co primary endpoint freedom headache pain freedom bothersome migraine associated symptom two hour dosing ax compared placebo superiority ax rizatriptan meloxicam arm established based sustained freedom headache pain two hour dosing look historical data rizatriptan show axsome project might need achieve axsome recently started another acute migraine trial ax called intercept due read first quarter evaluate treatment ax soon migraine start rather waiting migraine reach moderate severe intensity typical migraine trial however according axsome momentum study required nda filing expected second half next year back stride meanwhile hit complete response letter august kala kpi need shine next phase iii trial stride data expected first quarter regulatory knockback hugely unexpected dry eye project kala branded eysuvis produced mixed result two previous trial stride missing one co primary endpoint ocular discomfort sole primary endpoint stride compare kpi placebo cohort dosed four time day two week approximately patient dry eye disease kala hope change inclusion exclusion criterion give stride better chance success company previously said patient stride variable level symptom baseline stride hit resubmission occur first half next year followed six month review according company next challenge would hitting sellside number sale forecast reach project npv bn according evaluatepharma consensus making kala valuable project asset however company market cap investor apparently share sellside enthusiasm\n",
      "\n",
      "Keywords:\n",
      "ax 0.439\n",
      "stride 0.291\n",
      "axsome 0.264\n",
      "migraine 0.262\n",
      "rizatriptan 0.199\n",
      "kala 0.176\n",
      "triptans 0.149\n",
      "freedom 0.149\n",
      "meloxicam 0.142\n",
      "acute migraine 0.136\n",
      "acute 0.126\n",
      "two hour 0.1\n",
      "half next year 0.085\n",
      "half next 0.085\n",
      "dry eye 0.085\n",
      "dry 0.083\n",
      "momentum 0.081\n",
      "headache 0.079\n",
      "project 0.074\n",
      "hour 0.072\n",
      "\n",
      "Abstract:\n",
      "sanofi already shaky ground dengue fever vaccine dengvaxia product look likely relegated sideline thanks impressive data pivotal tide trial takeda rival candidate tak dengvaxia approved u fda may child previously infected virus following concern safety dengue na subject notably well looking good overall population tak showed sign efficacy previously uninfected people help takeda project get broader label still finding dengue na seronegative population exploratory far takeda wait data confirm tak efficacy takeda vaccine showed much better performance strain virus others although data exploratory turning tide result first part patient tide study published yesterday nejm previously takeda said trial met primary endpoint serious safety concern study enrolled healthy child aged asia latin america received either two dos tak placebo three month apart primary endpoint prevention dengue caused four different serotypes virus known denv tak overall efficacy higher pooled efficacy rate seen across dengvaxia two phase iii trial figure dengvaxia skewed lack efficacy seronegative people excluding population dengvaxia efficacy according u label putting line tak however dengvaxia ineffective seronegative population actually harmful mass immunisation programme philippine uncovered link vaccine severe disease seen previously uninfected child went contract dengue sanofi dengue setback benefit takeda march tak edge safety analysis thrown nothing worry far secondary endpoint tide vaccine performance according baseline infection status part one study found efficacy around seronegative group exploratory finding present need confirmed second part trial involves another six month follow another secondary endpoint formally assessed part two tak performance different dengue serotypes exploratory analysis part one vaccine best strain known denv modest efficacy serotypes handful case infection denv serotype data inconclusive indication conclusive vaccine might effective denv strain people seronegative baseline picture soon become clearer takeda plan present data tak american society tropical medicine hygiene held maryland november including formal assessment secondary endpoint commercial prospect vaccine dengue endemic poorer country might another matter takeda prove tak worth seronegative subject vaccine presumably potential traveller dengue afflicted region would open broader market tak forecast bring according evaluatepharma sellside consensus making takeda valuable pipeline asset whether live expectation one unanswered question around vaccine evidence far better chance making mark dengvaxia\n",
      "\n",
      "Keywords:\n",
      "dengue 0.415\n",
      "tak 0.395\n",
      "dengvaxia 0.323\n",
      "seronegative 0.259\n",
      "takeda 0.257\n",
      "vaccine 0.185\n",
      "denv 0.184\n",
      "tide 0.164\n",
      "serotypes 0.129\n",
      "exploratory 0.12\n",
      "efficacy 0.119\n",
      "strain 0.118\n",
      "child 0.101\n",
      "part 0.099\n",
      "previously 0.094\n",
      "na 0.086\n",
      "virus 0.08\n",
      "part one 0.079\n",
      "population 0.078\n",
      "secondary endpoint 0.077\n",
      "\n",
      "Abstract:\n",
      "biotech follower yesterday unveiling presentation upcoming ash conference notable prompting deflation bubble around next generation btk inhibitor arqule sunesis fell heavily constellation unexpected winner early data bet inhibitor first line myelofibrosis course meeting year last big medical showdown crucial bigger company though might reflected stock movement instance liso cel registrational study hugely relevant contingent value right cvr payable bristol myers squibb takeout celgene one event cvr payout depends u approval liso cel jcar lymphoma end celgene vowed file car project fda end year ash allow investor first look transcend nhl study hinge year death prior infusion manufacturing failure excluded liso cel ash abstract reveals orr broadly line gilead novartis marketed car therapy yescarta kymriah car therapy available however key doubt whether fda even approve third without significantly stronger data key focus thus fall safety liso cel look good rate serious cytokine release syndrome instance four treatment related death doubt draw attention last significant update one bcma among celgene asset investor paying attention anti bcma bispecific cc might impressed first clinical data due ash meeting feature different bcma targeting asset crowding space already led discontinuation autolus auto instance closely watched glaxosmithkline belantamab mafodotin whose dreamm study submitted ash late breaker bluebird bcma presence centre underwhelming update bb lead asset ide cel bb form another part celgene cvr pivotal karmma study make ash expected instead unveiled press release transcend nhl orr mpfs mth mo mth manu failure treatment related death absence data sent two non covalent btk inhibitor player yesterday sunesis fell news vecabrutinib yet generate single remission investor must hope ash abstract placeholder data meeting arqule failed convince arq lilly provided first early sign activity redx originated loxo derived asset loxo closely watched ash relevant btk inhibitor actually astrazeneca calquence whose first line elevate tn trial mark serious challenge abbvie imbruvica first line cll away oncology bluebird feature courtesy lentiglobin data hgb sickle cell trial main point sanofi sangamo st look like threat least yet ash presentation another sickle cell challenger vertex crispr ctx present clinical data fate therapeutic stem cell derived nk cell therapy ft ft disappointment sending originator stock yesterday early winner ash constellation thinly traded biotech floated year ago lead asset cpi impressed ash abstract covering bet inhibitor detail combination incyte jakafi untreated myelofibrosis concern four subject given least four treatment cycle true four exceeded threshold spleen volume reduction total symptom score improvement day nextcure surged perhaps constellation stock increase another indication biotech investor thirst glimmer efficacy however early might ash conference take place orlando florida december\n",
      "\n",
      "Keywords:\n",
      "ash 0.39\n",
      "cel 0.189\n",
      "liso cel 0.177\n",
      "liso 0.177\n",
      "bcma 0.157\n",
      "ash abstract 0.138\n",
      "cvr 0.123\n",
      "celgene 0.12\n",
      "btk inhibitor 0.117\n",
      "btk 0.117\n",
      "transcend nhl 0.1\n",
      "transcend 0.1\n",
      "sunesis 0.1\n",
      "four treatment 0.1\n",
      "abstract 0.099\n",
      "nhl 0.096\n",
      "inhibitor 0.09\n",
      "asset 0.09\n",
      "treatment related death 0.089\n",
      "related death 0.089\n",
      "\n",
      "Abstract:\n",
      "past year tough supernus thing getting worse demise group biggest seller trokendi xr look approaching even quickly expected company need pipeline project step breach unfortunately supernus one hopeful adhd aggression candidate spn look like dead duck asset expected pick slack trokendi xr upcoming patent expiry bright spot horizon supernus might look externally growth investor seem convinced company chance getting current hole supernus stock already fallen since time last year far today double whammy disappointing trokendi third quarter sale news spn phase iii failure however company refuse rushed making deal conference call today chief executive jack khattar said supernus long looking business development opportunity found late stage asset would create value added group want end overpaying deal bargain cns sector far supernus well funded huge amount firepower cash equivalent end third quarter super still company might need something soon spn dopamine antagonist flunked first pivotal test p trial study patient aged adhd impulsive aggression meet primary endpoint average weekly frequency impulsive aggression episode versus placebo fell spn dosed mg mg respectively compared decline placebo arm supernus claimed statistically significant decrease episode higher dose spn time interim analysis citing p value versus placebo company blamed variability latter part trial primary endpoint miss unclear whether group use finding justify pressing ahead spn data second phase iii trial called p soon make picture clearer supernus stopped enrolment study early target result due end mr khattar said company would consider total data package making decision supernus need spn hit due file another non stimulant adhd candidate spn u month even approved commercial prospect far certain three four pivotal trial spn read positively project shown better lilly non stimulant adhd drug strattera lost patent protection find tough compete supernus struggle gain attention march talking intellectual property trokendi xr set lose exclusivity leaving supernus limited time find something plug gap group hope expand epilepsy therapy oxtellar xr bipolar disease codenamed spn escaping fact spn removed company pipeline look thin supernus last acquisition bet biscayne neurotherapeutics hardly game changer company need make decisive move\n",
      "\n",
      "Keywords:\n",
      "supernus 0.56\n",
      "spn 0.513\n",
      "trokendi 0.187\n",
      "adhd 0.187\n",
      "xr 0.175\n",
      "trokendi xr 0.14\n",
      "aggression 0.125\n",
      "episode 0.08\n",
      "stimulant 0.077\n",
      "company 0.073\n",
      "company need 0.067\n",
      "tough 0.066\n",
      "need 0.064\n",
      "third quarter 0.056\n",
      "patent 0.051\n",
      "placebo 0.05\n",
      "getting 0.049\n",
      "group 0.048\n",
      "look 0.046\n",
      "find 0.046\n"
     ]
    }
   ],
   "source": [
    "#### get top 20 keywords for each article and map to pageviews.\n",
    "allstories = nomedtech\n",
    "allstories = allstories.reset_index()\n",
    "allstories['dist'] = 397-allstories['index']\n",
    "keyword=[]\n",
    "keyvalue=[]\n",
    "articleurl=[]\n",
    "pageviews=[]\n",
    "from sklearn.feature_extraction.text import TfidfTransformer \n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "tfidf_transformer=TfidfTransformer(smooth_idf=True,use_idf=True)\n",
    "tfidf_transformer.fit(X)\n",
    "    \n",
    "    # Get feature names\n",
    "feature_names=cv.get_feature_names()\n",
    " \n",
    "# Fetch document for which keywords needs to be extracted\n",
    "\n",
    "\n",
    "for x in allstories.itertuples():\n",
    "    doc=corpus[ds_count-int(x.dist)]\n",
    "     \n",
    "    # Generate tf-idf for the given document\n",
    "    tf_idf_vector=tfidf_transformer.transform(cv.transform([doc]))\n",
    "    \n",
    "    \n",
    "    # Sort tf_idf in descending order\n",
    "    from scipy.sparse import coo_matrix\n",
    "    def sort_coo(coo_matrix):\n",
    "        tuples = zip(coo_matrix.col, coo_matrix.data)\n",
    "        return sorted(tuples, key=lambda x: (x[1], x[0]), reverse=True)\n",
    "     \n",
    "    def extract_topn_from_vector(feature_names, sorted_items, topn=25):\n",
    "        \n",
    "        # Use only topn items from vector\n",
    "        sorted_items = sorted_items[:topn]\n",
    "        score_vals = []\n",
    "        feature_vals = []\n",
    "        \n",
    "        # Word index and corresponding tf-idf score\n",
    "        for idx, score in sorted_items:\n",
    "            \n",
    "            # Keep track of feature name and its corresponding score\n",
    "            score_vals.append(round(score, 3))\n",
    "            feature_vals.append(feature_names[idx])\n",
    "     \n",
    "        # Create tuples of feature,score\n",
    "        # Results = zip(feature_vals,score_vals)\n",
    "        results= {}\n",
    "        for idx in range(len(feature_vals)):\n",
    "            results[feature_vals[idx]]=score_vals[idx]\n",
    "        return results\n",
    "    \n",
    "    # Sort the tf-idf vectors by descending order of scores\n",
    "    sorted_items=sort_coo(tf_idf_vector.tocoo())\n",
    "    \n",
    "    # Extract only the top n; n here is 25\n",
    "    keywords=extract_topn_from_vector(feature_names,sorted_items,20)\n",
    "     \n",
    "    # Print the results, save as CSV\n",
    "    print(\"\\nAbstract:\")\n",
    "    print(doc)\n",
    "    print(\"\\nKeywords:\")\n",
    "    for k in keywords:\n",
    "        print(k,keywords[k])\n",
    "        keyword.append(k)\n",
    "        keyvalue.append(keywords[k])\n",
    "        articleurl.append(x.URL)\n",
    "        pageviews.append(x.Pageviews)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "              word  value                                                url  \\\n",
      "0        stage one  0.322  https://www.evaluate.com/vantage/articles/news...   \n",
      "1            stage  0.297  https://www.evaluate.com/vantage/articles/news...   \n",
      "2        stage two  0.258  https://www.evaluate.com/vantage/articles/news...   \n",
      "3          aptinyx  0.241  https://www.evaluate.com/vantage/articles/news...   \n",
      "4     significance  0.206  https://www.evaluate.com/vantage/articles/news...   \n",
      "...            ...    ...                                                ...   \n",
      "7935       placebo  0.050  https://www.evaluate.com/vantage/articles/news...   \n",
      "7936       getting  0.049  https://www.evaluate.com/vantage/articles/news...   \n",
      "7937         group  0.048  https://www.evaluate.com/vantage/articles/news...   \n",
      "7938          look  0.046  https://www.evaluate.com/vantage/articles/news...   \n",
      "7939          find  0.046  https://www.evaluate.com/vantage/articles/news...   \n",
      "\n",
      "      pageviews  \n",
      "0           281  \n",
      "1           281  \n",
      "2           281  \n",
      "3           281  \n",
      "4           281  \n",
      "...         ...  \n",
      "7935        981  \n",
      "7936        981  \n",
      "7937        981  \n",
      "7938        981  \n",
      "7939        981  \n",
      "\n",
      "[7940 rows x 4 columns]\n",
      "          word    pageviews  value\n",
      "0         aacr  4298.500000      2\n",
      "1        aasld   941.500000      2\n",
      "2         aatd   880.000000      1\n",
      "3          aav   766.000000      2\n",
      "4           ab   780.750000      4\n",
      "...        ...          ...    ...\n",
      "4095   zydelig  1191.666667      3\n",
      "4096     zygel   560.333333      3\n",
      "4097   zynerba   560.333333      3\n",
      "4098  zynteglo   901.000000      1\n",
      "4099    zytiga  1150.666667      3\n",
      "\n",
      "[4100 rows x 3 columns]\n"
     ]
    }
   ],
   "source": [
    "#joing the lists\n",
    "\n",
    "combdata = pd.DataFrame(list(zip(keyword, keyvalue, articleurl,pageviews)), \n",
    "               columns =['word', 'value','url','pageviews'])\n",
    "combdata.to_csv('top20keywords.csv')\n",
    "print(combdata)\n",
    "pvmeans = combdata.groupby('word')['pageviews'].mean().reset_index()\n",
    "pvcount = combdata.groupby('word')['value'].count().reset_index()\n",
    "pvalldata = pvmeans.merge(pvcount,on='word')\n",
    "pvalldata.to_csv('avgpageviewkeywords.csv')\n",
    "print(pvalldata)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
